<SEC-DOCUMENT>0001628280-18-003726.txt : 20180328
<SEC-HEADER>0001628280-18-003726.hdr.sgml : 20180328
<ACCEPTANCE-DATETIME>20180328163209
ACCESSION NUMBER:		0001628280-18-003726
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180328
DATE AS OF CHANGE:		20180328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Menlo Therapeutics Inc.
		CENTRAL INDEX KEY:			0001566044
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				453757789
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38356
		FILM NUMBER:		18719216

	BUSINESS ADDRESS:	
		STREET 1:		200 CARDINAL WAY, 2ND FLOOR
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		650-486-1416

	MAIL ADDRESS:	
		STREET 1:		200 CARDINAL WAY, 2ND FLOOR
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Menlo Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170728

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tigercat Pharma, Inc.
		DATE OF NAME CHANGE:	20130104
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mnlo12311710-k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s39B6C8E19A57549B96BFD40568CEA8FA"></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">FORM 10-K</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">&#9746;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">OR</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">FOR THE TRANSITION PERIOD FROM ___ TO ___.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Commission file number </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">001-38356</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">MENLO THERAPEUTICS INC.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">45-3757789</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(State or other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(I.R.S. Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">200 Cardinal Way, 2</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#32;Floor</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Redwood City, California 94063</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">(Address of principal executive offices including zip code)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">650-486-1416</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Title of each class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Name of each exchange on which registered</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Common Stock, $0.0001 par value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">The NASDAQ Global Select Market</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Securities registered pursuant to Section 12(g) of the Act: None</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Yes&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#9744;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#9746;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Yes&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#9744;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#9746;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Yes&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#9746;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#9744;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Yes&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#9746;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#9744;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&#167;229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#9746;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act (Check one):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:21%;"></td><td style="width:4%;"></td><td style="width:47%;"></td><td style="width:24%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Large accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#9744; </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#9744;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#9746;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Smaller reporting company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#9744;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">Emerging growth</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#9746;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#9746;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Indicate by check mark whether the registrant is a shell company (as defined in 12b-2 of the Act).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Yes&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#9744;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#9746;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The registrant was not a public company as of the last business day of its most recently completed second fiscal quarter, and therefore cannot calculate the aggregate market value of its voting and non-voting common equity held by non-affiliates as of such date. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of February&#160;28, 2018, there were 22,977,998 shares of the registrant&#8217;s Common Stock outstanding. </font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="sFDB0268F8A7C5BA1996D1B928F4E1F53"></a></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:85%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s05aa292c55834de39a0dabfa80721c59"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Part I</font></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s70A2736BB05850E2947DAC388FCE800E"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 1.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s70A2736BB05850E2947DAC388FCE800E"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Business</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s70A2736BB05850E2947DAC388FCE800E">1</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s42EE65B3F60C5B5EA07B81A8DAFA9E3D"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 1A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s42EE65B3F60C5B5EA07B81A8DAFA9E3D"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s42EE65B3F60C5B5EA07B81A8DAFA9E3D">30</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sad6b9d2b97a44f2b95e7be4f7e73b398"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 1B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sad6b9d2b97a44f2b95e7be4f7e73b398"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sad6b9d2b97a44f2b95e7be4f7e73b398">67</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s00cc96d1140b46c4a9f33afd0374b017"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 2.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s00cc96d1140b46c4a9f33afd0374b017"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Properties</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s00cc96d1140b46c4a9f33afd0374b017">68</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s6dbf1f3bf3f14a8a86e9779a59ba98e2"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 3.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s6dbf1f3bf3f14a8a86e9779a59ba98e2"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s6dbf1f3bf3f14a8a86e9779a59ba98e2">69</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s80cc13a04b3c4d7eaebcae28eb903ee3"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 4.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s80cc13a04b3c4d7eaebcae28eb903ee3"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s80cc13a04b3c4d7eaebcae28eb903ee3">70</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sdc06fa56f6124c4db00a7b856d2761ff"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Part II</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sc4f00a3495df4cadb8f088d10a61b2c4"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 5.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sc4f00a3495df4cadb8f088d10a61b2c4"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sc4f00a3495df4cadb8f088d10a61b2c4">71</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s993D660BB53D501282F43702A818CACD"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 6.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s993D660BB53D501282F43702A818CACD"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s993D660BB53D501282F43702A818CACD">73</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sB78767A093FD5372B11F8E664F2DF4A3"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 7.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sB78767A093FD5372B11F8E664F2DF4A3"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sB78767A093FD5372B11F8E664F2DF4A3">75</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s6e6b628a36e544b4b600cbee85dc396d"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 7A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s6e6b628a36e544b4b600cbee85dc396d"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Quantitative and Qualitative Disclosure About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s6e6b628a36e544b4b600cbee85dc396d">89</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s1A62084FD5A9549BA358324F892FBD85"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 8.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s1A62084FD5A9549BA358324F892FBD85"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s1A62084FD5A9549BA358324F892FBD85">90</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s616adf60600d4a14a38228c5b456d56f"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 9.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s616adf60600d4a14a38228c5b456d56f"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s616adf60600d4a14a38228c5b456d56f">116</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sc216b2e3caf94cca89b62ceddc65dcd3"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 9A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sc216b2e3caf94cca89b62ceddc65dcd3"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sc216b2e3caf94cca89b62ceddc65dcd3">117</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s4f30c20a6421476eaeaf09dccc76c121"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 9B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s4f30c20a6421476eaeaf09dccc76c121"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s4f30c20a6421476eaeaf09dccc76c121">118</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s2a8159d6328c457293ae0e3ac3f6860b"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Part III</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s6b56c5a68c564ca1971592cd5673a20b"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 10.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s6b56c5a68c564ca1971592cd5673a20b"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s6b56c5a68c564ca1971592cd5673a20b">119</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s8FBFC44B270A59069B686D053D06A6DA"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 11.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s8FBFC44B270A59069B686D053D06A6DA"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Executive Compensation</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s8FBFC44B270A59069B686D053D06A6DA">124</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sfba4e6e2619643399cfbffddfd8f2eab"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 12.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sfba4e6e2619643399cfbffddfd8f2eab"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sfba4e6e2619643399cfbffddfd8f2eab">132</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s441532c6419948ccbea091879a5ea9cf"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 13.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s441532c6419948ccbea091879a5ea9cf"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Certain Relationships and Related Transactions and Director Independence</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s441532c6419948ccbea091879a5ea9cf">135</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s38c71ed005c04965a26be26792ed57c3"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 14.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s38c71ed005c04965a26be26792ed57c3"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s38c71ed005c04965a26be26792ed57c3">138</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sccb79c034c7148d596f9939b169c2ff4"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Part IV</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s735D6C38FAA35889A4476785E1A54C82"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Item 15.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s735D6C38FAA35889A4476785E1A54C82"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Exhibits, Financial Statement Schedules</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#s735D6C38FAA35889A4476785E1A54C82">138</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sB5F0F198126A5B2E9D899CDBED4D3C3B"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">SIGNATURES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9pt;" href="#sB5F0F198126A5B2E9D899CDBED4D3C3B">141</a></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">i</font></div></div><hr style="page-break-after:always"><div><a name="s05aa292c55834de39a0dabfa80721c59"></a></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><a name="s70A2736BB05850E2947DAC388FCE800E"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical facts contained in this Annual Report on Form 10-K are statements that could be deemed forward-looking statements reflecting the current beliefs and expectations of management with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These statements are often identified by the use of words such as </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">and similar expressions or variations. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about:</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our clinical and regulatory development plans for serlopitant, including the timing of the commencement of, and receipt of results from, our ongoing Phase 2 and planned Phase 3 clinical trials and the timing of our submission of an NDA to the FDA for serlopitant;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our expectations regarding the potential market size and size of the potential patient populations for serlopitant, if approved or cleared for commercial use;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the timing of commencement of future non-clinical studies and clinical trials;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to successfully complete clinical trials;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our intentions and our ability to establish collaborations or obtain additional funding;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our use of net proceeds from our initial public offering;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the timing or likelihood of regulatory filings and approvals or clearances for our product candidates;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our commercialization, marketing and manufacturing capabilities ad expectations;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our intentions with respect to the commercialization of serlopitant or any other candidates;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the pricing and reimbursement of serlopitant, if approved;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates, including the projected terms of patent protection;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to attract and retain key scientific or management personnel;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the impact of laws and regulations;</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our financial performance; and</font></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:42px;"><font style="padding-bottom:12px;padding-top:0px;text-align:left;font-family:Trade Gothic,sans-serif;font-size:9.5pt;padding-right:53px;">&#8226;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">developments and projections relating to our competitors and our industry, including competing drugs and therapies.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We caution you that the foregoing list may not contain all of the forward-looking statements made in this Annual Report on Form 10-K.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Annual Report on Form 10-K. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">1. Business.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Overview </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We are a late&#8209;stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. There are currently no therapies approved in the United States that are primarily intended to reduce the pruritus associated with these conditions. We are concurrently evaluating the use of serlopitant for the treatment of refractory chronic cough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause. There are currently no drugs specifically approved for refractory chronic cough in the United States. These indications each represent a significant patient need. We believe that serlopitant, a highly selective, once&#8209;daily, oral small molecule inhibitor of the neurokinin 1 receptor, or NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R, has the potential to significantly alleviate pruritus and refractory chronic cough symptoms. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have initiated a broad clinical development program for serlopitant as a once&#8209;daily oral tablet treatment for pruritus associated with multiple underlying chronic dermatologic conditions and for the treatment of refractory chronic cough. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We expect data from our ongoing Phase 2 clinical trial in pruritus associated with atopic dermatitis in April 2018, from our ongoing Phase 2 clinical trial in refractory chronic cough in the fourth quarter of 2018 and from our ongoing Phase 2 clinical trial in pruritus associated with psoriasis by late 2018 or early 2019. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We plan to initiate two Phase 3 clinical trials in pruritus associated with prurigo nodularis in the second quarter of 2018, with results expected in the first half of 2020. If these and future clinical trials are successful, we could potentially submit a New Drug Application, or NDA, for up to three indications in 2020: pruritus associated with atopic dermatitis, psoriasis and prurigo nodularis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have completed two double&#8209;blind Phase 2 clinical trials in over 380 patients with pruritus and observed clinically relevant and statistically significant improvements in pruritus in patients treated with serlopitant compared to patients treated with placebo. The first Phase&#160;2 clinical trial, conducted in 257 patients with chronic pruritus, met its primary and multiple secondary efficacy endpoints of pruritus reduction for patients treated at our two highest doses (5 mg and 1 mg daily) compared with those receiving placebo. The second Phase 2 clinical trial, conducted in 127 patients with prurigo nodularis, a severely pruritic skin condition with lesions, also met its primary and multiple secondary efficacy endpoints demonstrating significant pruritus reduction. Serlopitant has been dosed in more than 1,000 individuals and has been shown to be well tolerated, including when administered to patients in a clinical trial for up to one year.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">More than 35 million patients in the United States are affected by atopic dermatitis, psoriasis, or prurigo nodularis. Pruritus is the primary complaint among such patients, often significantly impacting their quality of life. Current therapies, however, do not adequately control pruritus in many of these patients. Accordingly, there is a significant opportunity for a once&#8209;daily oral tablet therapy for pruritus associated with these disease conditions. We believe that serlopitant, if approved, may be adopted by physicians as an oral anti&#8209;pruritic therapy either as an adjunct to topical or systemic treatments or as a monotherapy in patients for whom management of pruritus is the primary patient need. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">More than 10 million patients in the United States suffer from refractory chronic cough, for which no drugs have been specifically approved in the United States. Many patients report that their condition is frequently disabling and has a marked effect on their quality of life. Similar to pruritus, treatment options for refractory chronic cough are limited and may have inadequate benefit for many patients.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have exclusive, royalty&#8209;free development and commercialization rights to serlopitant in all markets other than Japan, where we have licensed serlopitant to Japan Tobbacco Inc. and Torii Pharmaceutical Co. Ltd, together referred to as JT Torii, for development and commercialization. In the United States, serlopitant has composition of matter patent protection into 2025, which may be extended for up to five years, issued methods of use patent protection for pruritus applications into 2033, and a filed patent application for use in cough.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Members of our management team have extensive experience in product development, having held drug development, commercial and leadership roles at numerous biopharmaceutical and dermatology products companies, including Genentech/Roche, Gilead Sciences, Millennium Pharmaceuticals (acquired by Takeda), Relypsa (acquired by Galenica), Anacor Pharmaceuticals (acquired by Pfizer), Medicis Pharmaceutical (acquired </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">by Valeant), Connetics Corporation (acquired by Stiefel, now a division of GSK), BioForm Medical (acquired by Merz) and Merz Aesthetics. At their prior companies, our management team members have been involved in product development or commercialization of many successful dermatology products.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Our Strategy</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of serlopitant. The key elements of our strategy are to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Obtain regulatory approval for serlopitant for the treatment of pruritus associated with multiple highly pruritic dermatologic conditions. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We plan to focus on the near term development and potential regulatory approval and commercialization of serlopitant for the treatment of pruritus associated with multiple dermatologic conditions. Following our discussions with the U.S. Food and Drug Administration, or FDA, and European regulatory agencies, we are advancing into Phase 3 clinical trials for the treatment of pruritus associated with prurigo nodularis. We have also commenced Phase 2 clinical trials for the treatment of pruritus associated with atopic dermatitis and psoriasis. If the results of these trials are promising, we intend to rapidly advance into Phase 3 clinical trials, for these indications, with the goal of seeking regulatory approval in the United States and Europe.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Build a specialty sales organization to commercialize and market serlopitant in the United States, if approved. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If approved by the FDA for pruritus associated with our target dermatologic conditions, we intend to commercialize serlopitant by developing our own sales organization targeting a subset of the 10,000 to 12,000 dermatologists in the United States. If approved for pruritus associated with atopic dermatitis, we anticipate that we may need to expand this sales organization to reach high prescribing pediatricians and primary care physicians. Outside the United States, we intend to establish commercialization strategies for serlopitant as we approach possible commercial approval in each market, which may include collaborations with other companies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Develop serlopitant to treat refractory chronic cough. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We believe that the mechanistic overlap of the NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R pathway in the pathology of pruritus and cough supports the development of serlopitant as a potentially efficacious therapy for patients suffering from refractory chronic cough. Our program builds upon data from several proof of concept studies with other NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists. We are evaluating the efficacy and safety of serlopitant in our ongoing Phase 2 clinical trial for refractory chronic cough.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;font-weight:bold;">Leverage our development and commercial infrastructure to expand our pipeline over time</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;">.&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may elect in the future to pursue additional indications for serlopitant or in&#8209;license or acquire drug candidates or commercial products that leverage our development or commercial capabilities.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Our Serlopitant Development Programs</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We are developing serlopitant for the treatment of pruritus associated with atopic dermatitis, psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for the treatment of refractory chronic cough. Our development pipeline is summarized in the figure below: </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="pipelineimage.jpg" alt="pipelineimage.jpg" style="height:260px;width:473px;"></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our collaborator in Japan, JT Torii, is also conducting a clinical development program for serlopitant in pruritus indications and is conducting a Phase 2 clinical trial. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Clinical Need in Pruritus and Cough</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Chronic Pruritus Overview</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Chronic pruritus, defined as itching lasting longer than six weeks, can be as burdensome as chronic pain in negatively impacting a patient&#8217;s quality of life. The urge to scratch can be unbearable, and the act of scratching can remove layers of skin and break the skin barrier leading to bleeding, scarring and greatly increasing the risk of infection. Similar to chronic pain, severe chronic pruritus causes a number of physical and psychological issues that substantially impact patients&#8217; day&#8209;to&#8209;day well&#8209;being. Pruritus can lead to trouble sleeping, resulting in loss of work productivity and increased anxiety and depression as patients struggle to maintain self&#8209;control.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Chronic pruritus is a hallmark of many dermatologic and systemic diseases, such as atopic dermatitis, psoriasis and prurigo nodularis, and is the predominant reason that patients with these diseases experience so much discomfort. In a recent report published in the Journal of the American Academy of Dermatology, up to 26% of the worldwide population suffers from chronic pruritus at some point in their lives.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Despite its prevalence, chronic pruritus is not well addressed by current therapies. Skin diseases such as atopic dermatitis, psoriasis and prurigo nodularis are commonly treated with a multi&#8209;prong therapeutic approach. Skin barrier restoration and maintenance through application of topical moisturizers and treatment of skin lesions locally through the use of topical corticosteroids or other topical anti&#8209;inflammatory agents are the predominant first&#8209;line therapies for many pruritic skin diseases. Phototherapy and systemic immunomodulators including biologics are frequently used for more severe disease. These therapies may reduce pruritus to some degree in addition to their effects on skin health and inflammation. Yet many patients with atopic dermatitis, psoriasis, or prurigo nodularis still report high levels of pruritus despite active topical or systemic therapy. This significant medical need is reflected by the widespread use of therapies intended to address pruritus specifically, such as oral antihistamines, despite evidence demonstrating their relative lack of efficacy, as well as concerns regarding their safety and tolerability, such as sedative effects of antihistamines.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The itch&#8209;scratch cycle can also undermine progress in treating skin lesions if pruritus is not addressed adequately. In any skin disease, but especially in atopic dermatitis, repeated itching and scratching can lead to secondary cutaneous infections. In psoriasis patients, scratching can lead to the development of new psoriatic lesions. Similarly, prurigo nodularis is characterized by excoriations, crusting and sometimes ulceration of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">lesions due to the incessant scratching provoked by chronic pruritus. We believe that the pruritus associated with multiple distinct diseases, such as atopic dermatitis, psoriasis and prurigo nodularis, involves activation of a common neuronal pathway for itch signaling, enabling a drug that is effective in reducing pruritus associated with one disease to have efficacy in reducing pruritus in others.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Atopic Dermatitis Overview</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">There are an estimated 26 million people in the United States who </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;">have</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">atopic dermatitis</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;">, a</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">chronic, inflammatory skin disease that is most commonly first diagnosed in childhood.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Atopic dermatitis is characterized by skin barrier disruption and immune dysregulation. Patients with atopic dermatitis may have chronically inflamed skin lesions and often have persistent pruritus. Physicians and patients report pruritus as the primary patient complaint associated with this disease.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Of the total population of atopic dermatitis patients in the United States, an estimated 37% of those are actually diagnosed with the disease, and of those diagnosed, an</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;">estimated 45&#8209;50% of these patients are actively being treated by a physician.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Creams and ointments and topical corticosteroids or other topical or systemic anti&#8209;inflammatory agents are routinely used to manage skin health and to reduce skin inflammation in patients with atopic dermatitis. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;">In our market research, dermatologists report that up to 30% of</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the patients they treat for atopic dermatitis have inadequately controlled pruritus.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Psoriasis Overview</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;">According to the World Health Organization, psoriasis, a common chronic autoimmune disorder of the skin, causing redness, irritation and scaly lesions, affects up to five percent of the world&#8217;s population. Approximately 12 million people in the United States</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">have psoriasis; of these, an estimated 7.5 million have been diagnosed with the skin disease and an estimated 50&#8209;60% of diagnosed patients are actively being treated. Of those patients in active treatment, an estimated 50-60% </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;">of these patients have moderate to severe pruritus. In a recent survey of 5,604 psoriasis patients, over 90% reported pruritus as a significantly bothersome symptom.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The severity of the pruritus in psoriasis patients does not always correlate with the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">severity and number of skin lesions</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, suggesting that pruritus and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">skin inflammatory disease </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">may be somewhat independent of each other in </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">patients with </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">psoriasis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Mild to moderate psoriasis is typically treated with topical therapies such as corticosteroids or vitamin D analogs. Moderate to severe psoriasis may be treated with topical therapies, systemic immunosuppressive or immunomodulatory drugs, or phototherapy. While all of these therapies can help reduce the skin irritation and plaques in patients with psoriasis, and may also reduce pruritus to some degree, they may not adequately resolve the pruritus associated with psoriasis.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prurigo Nodularis Overview</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We estimate that there are approximately 350,000 </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">people with </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">prurigo nodularis in the United States. Prurigo nodularis is a chronic skin disorder affecting primarily older adults and is characterized by multiple, firm, itchy nodules typically found on a patient&#8217;s arms, legs and trunk. Prurigo nodularis results from a vicious cycle of repeated itching and scratching leading to formation of raised, inflamed skin nodules that can develop sores or become hard and crusty. The itching sensation in prurigo nodularis is extreme and often leads to scratching to the point of bleeding or pain. Prurigo nodularis may be associated with a variety of dermatologic and systemic diseases such as atopic dermatitis, psoriasis, diabetes, chronic renal failure and HIV infection.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">No treatment for prurigo nodularis has been approved in the United States or Europe. A high priority in any treatment for prurigo nodularis is to identify and address any underlying cause of itching. However, specific trigger factors for the development of prurigo nodularis in an individual patient may be difficult to identify. Treatment of prurigo nodularis typically involves a multifaceted approach to treat the lesions and reduce itch. Therapies may include corticosteroids and other immunosuppressive or anti&#8209;inflammatory treatments, phototherapy and agents such as gabapentin and Lyrica (pregabalin). Prurigo nodularis is often treatment resistant with high recurrence rates.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Refractory Chronic Cough Overview</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Cough is a symptom of many underlying conditions such as respiratory infections, inflammatory conditions such as asthma, irritants such as smoke, and diseases that limit lung function. While cough from acute conditions usually resolves, it has been estimated that over 10% of adults have, or have had, chronic cough, a cough that </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">persists for greater than eight weeks, at some point in their lives. The most prevalent underlying conditions associated with chronic cough are asthma, gastroesophageal reflux disease, or upper respiratory infections. Approximately 40% of patients with chronic cough are diagnosed with refractory chronic cough, a chronic cough that persists despite treatment of any identified underlying cause. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Current treatment options for refractory chronic cough have demonstrated limited efficacy. The two most common antitussive drugs are codeine and dextromethorphan, neither of which appears to be efficacious in recently conducted trials. Furthermore, concerns about the safety and abuse liability of narcotics such as codeine have restricted their use.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Our Solution: Serlopitant</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We are developing serlopitant, a small molecule, highly selective NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonist, as a once&#8209;daily oral tablet therapy to reduce pruritus in patients with atopic dermatitis, psoriasis or prurigo nodularis, and to reduce cough frequency in patients with refractory chronic cough.&#160;We believe serlopitant has the potential to be a safe and efficacious treatment for pruritus and/or cough based on the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Two multicenter randomized Phase 2 clinical trials have demonstrated a statistically significant reduction of pruritus</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.&#160; Both of our completed double&#8209;blind Phase 2 clinical trials met their primary efficacy analyses and multiple secondary efficacy endpoints, demonstrating greater reduction of pruritus in patients treated with serlopitant compared with the patients treated with placebo.&#160;In addition, several proof&#8209;of&#8209;concept preclinical studies and clinical trials with other NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists have shown the benefit of NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R inhibition in pruritus and cough.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Serlopitant has been dosed in more than 1,000 individuals and has been shown to be well-tolerated, including when administered to patients in a clinical trial for up to one year.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;Serlopitant has been studied in multiple completed Phase 1 and Phase 2 clinical trials, including the two Phase 2 clinical trials conducted by us for pruritus and two Phase 2 clinical trials conducted by Merck for other indications.&#160;In several of these clinical trials, much higher doses than our current target therapeutic dose have been used (in one study 50 mg was used for up to 28 days), and approximately 40 patients have been treated for up to one year at a dose comparable to our target therapeutic dose.&#160; We believe this safety experience supports development of serlopitant for chronic dosing.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Serlopitant, if approved, could fit easily into the current treatment regimen for our target indications.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160; Serlopitant, if approved, would be a once&#8209;daily oral tablet therapy and could be used as an adjunct to standard of care topical or systemic treatments for pruritic dermatologic conditions. The drug interaction profile of serlopitant supports its use with a wide range of standard of care therapies, and the simple once&#8209;daily oral dosing regimen can be added to current therapy to manage pruritus. Serlopitant may also be used </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">as a monotherapy for patients for whom management of the pruritus or refractory chronic cough symptoms is the primary patient need. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Background on Substance P and NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">-R</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Serlopitant is a small molecule, highly selective NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonist. Two critical mediators of the urge to scratch and the urge to cough are Substance P, or SP, and its receptor, the neurokinin&#8209;1 receptor, or NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R. SP is a naturally occurring peptide in the tachykinin neuropeptide family. Tachykinins have a broad range of functions in the nervous and immune systems. SP binding of NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R has been shown to be a key mediator of sensory nerve signaling, including the itch&#8209;scratch reflex, the cough reflex and the vomiting reflex. Accordingly, the biological bases of our pruritus and cough programs are similar and have been shown to involve SP and NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R in the signaling process. The following figure illustrates the role of NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R in itch and cough signaling:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="chronicitchcougha02.jpg" alt="chronicitchcougha02.jpg" style="height:381px;width:624px;"></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">SP administration and NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R inhibition have been validated in multiple animal models of human disease, which indicate potential therapeutic development paths in pruritus, cough and vomiting.&#160;Based upon the animal models of vomiting, NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists have been successfully developed and commercialized as treatments for chemotherapy induced nausea and vomiting. In pruritus animal studies, SP injection can stimulate scratching and NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R inhibition can stop scratching. Similarly, a study of canine cough has demonstrated that an NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonist can reduce cough frequency.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Proof of concept trials have been conducted in patients with pruritus with Emend (aprepitant), a commercially available NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonist. In an open label pruritus trial published in 2010, 20 patients with chronic pruritus refractory to other therapies were treated with aprepitant and 80% of these patients had significant alleviation of their pruritus after one week of treatment. Subsequent reports of aprepitant in other indications associated with pruritus such as</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;prurigo nodularis, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">cutaneous T&#8209;cell lymphoma and drug&#8209;induced pruritus have also suggested efficacy at reducing pruritus associated with these disease conditions.&#160; Recently published or presented case studies and small proof of concept trials in patients with chronic cough have demonstrated the ability of NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists to reduce cough frequency.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our work builds upon the successful demonstration of activity in animal models and human proof of concept studies in pruritus and cough. We have leveraged the experience with NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists to advance serlopitant quickly into Phase 2 studies in indications that present a significant opportunity and a strong basis for use of NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonism.&#160; Serlopitant has been designed to overcome many of the limitations of previous generation NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists, such as aprepitant. Aprepitant is only approved for short term use associated with chemotherapy&#8209;induced nausea and vomiting. Compared to aprepitant, serlopitant has a longer half&#8209;life, fewer potential drug&#8209;drug interactions, a more linear pharmacokinetic profile and was well tolerated when administered to patients in a clinical trial for up to one year.&#160; </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Serlopitant Clinical Trials</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We are conducting a clinical development program in patients with pruritus associated with atopic dermatitis, psoriasis and prurigo nodularis, and in patients with refractory chronic cough. A Phase 2 clinical trial in pruritus associated with atopic dermatitis (484 patients) has completed enrollment with results expected in April 2018. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Phase 2 clinical trials in refractory chronic cough (170 patients) and pruritus associated with psoriasis (200 patients) are underway with results expected in the fourth quarter of 2018 and in late 2018 or early 2019, respectively.  </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In the second quarter of 2018, we plan to initiate our Phase 3 clinical trials in pruritus associated with prurigo nodularis.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Chronic Pruritus Completed Phase 2 Clinical Trial</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Trial Design</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We completed a Phase 2 clinical trial in December 2014 to evaluate the safety and efficacy of serlopitant in patients with chronic pruritus. The study was a multicenter, randomized, double&#8209;blind, placebo&#8209;controlled trial in 257 adult patients (18 to 65 years of age) with pruritus for more than six weeks that were non&#8209;responsive or inadequately responsive to topical steroids or antihistamines, and who had a baseline visual analog scale, or VAS of at least 70 mm. To report itch severity on the VAS, patients place a mark on a 100 mm line corresponding to the degree of severity of their pruritus. The distance from the origin of the line is measured to indicate pruritus severity, where 0 mm represents no itch and 100 mm represents the worst itch imaginable. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Patients underwent a screening period of up to two weeks. Eligible patients were randomized to one of four treatment groups (placebo or serlopitant 0.25 mg, 1 mg or 5 mg tablets), and began a six&#8209;week treatment period, followed by a four&#8209;week follow&#8209;up period. At baseline, patients received a loading dose of three tablets. Thereafter, patients took one tablet every day at bedtime for six weeks. A total of 257 patients were randomized into one of the four groups (64 received a placebo, 64 received 0.25 mg serlopitant, 65 received 1 mg serlopitant and 64 received 5 mg serlopitant). The mean age was 43.7 years, and 60.7% of the patients were female. Demographics were generally balanced across treatment groups.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The primary efficacy analysis compared the percent change from baseline in itch VAS score in each serlopitant treatment group with the placebo group. An important secondary efficacy endpoint was percent change from baseline in itch on the Numeric Rating Scale, or NRS, an 11&#8209;point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Other secondary efficacy endpoints included assessments of sleep and quality of life. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Efficacy Results</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The study met its primary and multiple secondary efficacy endpoints of pruritus reduction for patients treated at our two highest doses (5&#160;mg and 1&#160;mg daily). </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">At week six, for the primary efficacy analysis, the serlopitant 5&#160;mg group and serlopitant 1&#160;mg group showed an improvement in pruritus of 42.5% and 41.4% from baseline, respectively, measured by the itch VAS. Each represents a statistically greater improvement compared with the placebo group improvement of 28.3% (5&#160;mg, p = 0.013; 1&#160;mg, p = 0.022).</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">P&#8209;value is a conventional statistical method for measuring the statistical significance of clinical results. A p&#8209;value of less than 0.05 is generally considered to represent statistical significance, meaning that there is a less than five percent likelihood that the observed results occurred by chance.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The figure below shows the weekly itch VAS percentage change from baseline assessment for all four groups in this chronic pruritus Phase 2 clinical trial:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="tcp101vaschange.jpg" alt="tcp101vaschange.jpg" style="height:400px;width:504px;"></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Serlopitant at 5 mg and 1 mg also demonstrated superior efficacy over placebo for the secondary efficacy endpoint of percent change from baseline in itch NRS. At week six, the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">serlopitant 5 mg group and serlopitant 1 mg group showed an improvement in pruritus of 39.0% and 39.4% from baseline, respectively, measured by the itch NRS score. Each represents a statistically greater improvement compared with the placebo group improvement of 28.7% (5 mg, p = 0.038; 1 mg, p = 0.031). </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">After the completion of the trial, we conducted additional (post&#8209;hoc) analyses to look at patients with at least 40 mm of improvement on the itch VAS or a 4&#8209;point improvement on itch NRS scores. These analyses were conducted to help us plan and power future clinical trials based upon our interactions with the FDA. In this analysis of itch VAS responders, 52.8% of patients receiving 5 mg serlopitant had at least a 40 mm improvement in itch VAS compared with 25.9% of patients in the placebo group showing similar improvement (p=0.004). 46.2% of patients receiving 5 mg serlopitant had at least a 4&#8209;point improvement on the itch NRS as compared to 22.6% of patients in the placebo group (p = 0.011).</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table summarizes VAS and NRS efficacy outcomes at week six in the chronic itch Phase 2 clinical trial</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:20%;"></td><td style="width:11%;"></td><td style="width:11%;"></td><td style="width:12%;"></td><td style="width:11%;"></td><td style="width:12%;"></td><td style="width:11%;"></td><td style="width:12%;"></td></tr><tr><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Endpoint</font></div></td><td rowspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Placebo</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Serlopitant 0.25 mg</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Serlopitant 1 mg</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Serlopitant 5 mg</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p&#8209;value*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p-value*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p-value*</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Mean Percent Change from Baseline Analyses</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">VAS % change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">-28.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">-34.1%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p = 0.309</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">-41.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p = 0.022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">-42.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p = 0.013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">NRS % change</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">-28.7%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">-35.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p = 0.153</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">-39.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p = 0.031</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">-39.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p = 0.038</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Responder Rate Analyses</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">VAS &#8805; 40mm</font></div><div style="padding-left:12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">responder rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">25.9%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">42.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p = 0.068</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">38.2%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p = 0.171</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">52.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p = 0.004</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">NRS &#8805; 4-point</font></div><div style="padding-left:12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">responder rate</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">22.6%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">38.5%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p = 0.078</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">32.7%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p = 0.242</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px dotted #acacac;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">46.2%</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">p = 0.011</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">All p-values compare treatment group versus placebo group.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Safety Results</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Serlopitant was well tolerated in this study. No serious adverse events, or SAEs, were assessed as definitely, probably, or possibly related to serlopitant. The most common treatment emergent adverse event, or TEAEs, in the serlopitant groups were diarrhea (6.2%, 1 mg group), upper respiratory tract infection (4.7%, 0.25 mg group), somnolence (4.7%, 5 mg group), nasopharyngitis (4.6%, 1 mg group), headache (4.6%, 1 mg group), urinary tract infection (3.1%, 5 mg group), dry mouth (3.1%, 1 mg group), nausea (3.1%, 1 mg group), arthralgia (3.1%, 0.25 mg group), musculoskeletal pain (3.1%, 1 mg group), and pruritus (3.1%, 0.25 and 1 mg groups). The most common TEAEs in the placebo group were headache (6.3%), nasopharyngitis (3.2%), upper respiratory tract infection (3.2%), urinary tract infection (3.2%) and asthma (3.2%).</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prurigo Nodularis Completed Phase 2 Clinical Trial</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Trial Design</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We completed a Phase 2 clinical trial in June 2016 to evaluate the safety and efficacy of serlopitant in patients with prurigo nodularis. The study was a multicenter, randomized, double&#8209;blind, placebo&#8209;controlled study in 127 adult patients (18 to 80 years of age) who had prurigo nodularis for more than six weeks, whose pruritus was nonresponsive or inadequately responsive to topical steroids or </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">antihistamine </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">and who had a baseline VAS pruritus score of at least 70 mm. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Patients underwent a screening period of up to four weeks. Eligible patients were randomized to either the serlopitant 5 mg group or the placebo group, and began an eight&#8209;week treatment period, followed by a two&#8209;week follow&#8209;up period. At baseline, patients received a loading dose of three tablets. Thereafter, patients took one tablet every day at bedtime for eight weeks. A total of 127 randomized patients received study drug in one of the two arms (63 received placebo, 64 received 5 mg serlopitant). The mean age was 57.6 years, and 52.8% of the patients were female. Demographics were generally balanced across the two treatment arms.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The primary efficacy analysis was the change in average itch VAS from baseline in patients in the serlopitant treatment group compared with placebo. The week four and eight tests were considered primary; hence, there were two primary comparisons, one for each visit. Secondary efficacy analyses included additional itch assessments such as the worst itch VAS and average and worst itch NRS, quality of life measures and assessments of prurigo nodularis lesion severity. Safety endpoints included TEAEs, laboratory values, vital signs and electrocardiogram findings.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Efficacy Results</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The study met its primary and multiple secondary efficacy endpoints of pruritus reduction in patients in the serlopitant treatment group </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">compared with placebo</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. For the primary efficacy analysis defined as change from baseline in average itch VAS at weeks four and eight, a serlopitant dose of 5 mg given once a day led to a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">superior change from baseline in average itch VAS than placebo. At week four, the serlopitant 5 mg group showed a 25 mm improvement from baseline in average itch VAS compared to a 15 mm improvement from baseline in the placebo group (p = 0.025), and at week eight, the serlopitant 5 mg group showed an improvement of 36 mm from baseline in average itch VAS compared with an improvement of 19 mm for the placebo group (p = 0.001). Patients receiving 5 mg serlopitant had a statistically significant reduction in the average itch VAS score for pruritus compared to the placebo group at every measured time point.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The figure below shows comparative reduction in pruritus between the serlopitant treatment group and the placebo group in this Phase 2 clinical trial of pruritus associated with prurigo nodularis:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="image001a07new002.jpg" alt="image001a07new002.jpg" style="height:493px;width:624px;"></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The figure below shows the distribution of average itch VAS percentage change from baseline at week 8 using a cumulative distribution function, or CDF, which shows a continuous plot of the change from baseline on the X-axis and the percentage of patients experiencing that change on the Y-axis. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The leftward shift of the curve for the serlopitant-treated patients indicates that these subjects were more likely than placebo-treated subjects to have any given degree of reduction in average VAS score.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;"><img src="distributionfunctia.jpg" alt="distributionfunctia.jpg" style="height:294px;width:624px;"></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Serlopitant also demonstrated superior efficacy over placebo in multiple additional predefined measures of itch VAS and NRS change from baseline. The chart below summarizes the VAS and NRS in this study. After the study was completed, we conducted post&#8209;hoc analyses of responder rates using a responder definition of 40 mm VAS improvement or a 4&#8209;point NRS improvement. These responder analyses were conducted for the purposes of planning our Phase 3 clinical trials and are consistent with the 4&#8209;point improvement responder definition we have set as the primary efficacy analysis for our planned Phase 3 clinical trials in pruritus associated with prurigo nodularis. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table summarizes VAS and NRS efficacy outcomes at week eight in the prurigo nodularis Phase 2 clinical trial:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:43%;"></td><td style="width:14%;"></td><td style="width:19%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;font-weight:bold;">Endpoint</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;font-weight:bold;">Placebo</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;font-weight:bold;">Serlopitant 5 mg</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;font-weight:bold;">Treatment Effect Difference (p-value)</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;font-style:italic;">Mean Change from Baseline Analyses</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">Average-itch VAS change from baseline</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">-19 mm</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">-36 mm</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">17 mm (p = 0.001)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">Worst-itch VAS change from baseline </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">-20 mm</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">-36 mm</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">16 mm (p = 0.002)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">Average-itch NRS change from baseline</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">-2.4 points</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">-3.7 points</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">1.4 points (p = 0.007)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">Worst-itch NRS change from baseline </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">-2.3 points</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">-3.3 points</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">1.0 points (p = 0.056)</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;font-style:italic;">Responder Rate Analyses</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">Average-itch VAS &#8805; 40 mm responder rate</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">25.0%</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">54.4%</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">29.4% (p = 0.002)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">Worst-itch VAS &#8805; 40 mm responder rate</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">17.4%</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">47.4%</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">30.0% (p = 0.001)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">Average-itch NRS &#8805; 4-point responder rate</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">28.2%</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">51.2%</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">23.0% (p = 0.034)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">Worst-itch NRS &#8805; 4-point responder rate</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">25.6%</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">46.5%</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;">20.9% (p = 0.050)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Several additional measures of pruritus </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">and prurigo nodularis severity rec</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">orded in the study as exploratory or secondary measures also indicated greater improvement in serlopitant-treated patients compared with the placebo-treated patients. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Safety Results</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Serlopitant was well tolerated in this study. Two patients had SAEs that were assessed as possibly related to serlopitant (depression and dizziness/vertigo). The most common TEAEs in the serlopitant group were nasopharyngitis (17.2%), diarrhea (10.9%), fatigue (9.4%), dizziness (7.8%), headache (6.3%), peripheral edema (6.3%), pruritus (4.7%), hypertension (4.7%), vomiting (3.1%), bronchitis (3.1%) and cough (3.1%). The most common TEAEs in the placebo group were pruritus (11.1%), fatigue (6.3%), headache (6.3%), urinary tract infection (6.3%), diarrhea (4.8%), nasopharyngitis (3.2%), nausea (3.2%), upper abdominal pain (3.2%), asymptomatic bacteriuria (3.2%), bradycardia (3.2%), eczema (3.2%), insomnia (3.2%) and oral herpes (3.2%). </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prurigo Nodularis Planned Phase 3 Clinical Trials</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We intend to initiate two multicenter, placebo&#8209;controlled, double&#8209;blind Phase 3 clinical trials of serlopitant </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">for the treatment of pruritus associated </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">with prurigo nodularis in </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the second quarter of 2018</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. These trials are intended to evaluate if treatment with 5 mg serlopitant daily for eight weeks can reduce pruritus associated with prurigo nodularis compared with placebo. We expect to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">enroll 200 patients in each study and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">conduct one trial in the United States and one trial in Europe, with approximately 50 sites in each study. The trials will enroll patients with a worst&#8209;itch NRS score, or WI&#8209;NRS, of at least seven at screening. The primary efficacy analysis for both of these trials is a four&#8209;point responder rate in the WI&#8209;NRS at eight weeks. Secondary efficacy endpoints will include WI&#8209;NRS at four weeks, change in WI&#8209;NRS from baseline to day seven and day three, change in number of night time scratching events from baseline to week eight and changes in a measure of scratching behavior. Results from both trials are expected in the first half of 2020. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In parallel with the two Phase 3 efficacy and safety trials in prurigo nodularis, we have initiated an open label long&#8209;term safety trial in which patients will receive treatment doses of 5 mg serlopitant for one year.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Atopic Dermatitis Ongoing Phase 2 Clinical Trial </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In December 2016, we commenced a multicenter, placebo&#8209;controlled double&#8209;blind Phase 2 clinical trial of serlopitant for the treatment of pruritus associated with atopic dermatitis. The trial is being conducted at more than 50 sites in the United States and enrolled 484 patients age 13 or over who have a past or present diagnosis of atopic dermatitis, have pruritus for at least six weeks and a screening WI&#8209;NRS pruritus score of at least seven. Patients were randomized into one of three arms: daily doses of 1&#160;mg serlopitant, 5&#160;mg serlopitant or placebo. The trial includes a six&#8209;week treatment period and four&#8209;week follow up period. This trial is intended to evaluate if treatment with either 5 mg or 1 mg serlopitant daily for six weeks can reduce pruritus associated with atopic dermatitis compared with placebo. The primary efficacy analysis will compare serlopitant versus placebo changes on WI&#8209;NRS at week six. The trial is fully enrolled, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">and the patient treatment and follow-up periods have recently been completed.  </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We expect data from this trial to be available in April of 2018. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Psoriasis Ongoing Phase 2 Clinical Trial </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In October 2017, we commenced a multicenter, placebo&#8209;controlled double&#8209;blind Phase 2 clinical trial of serlopitant as a treatment for pruritus associated with psoriasis. This trial is being conducted at approximately 40 sites in the United States and is expected to enroll approximately 200 patients between the ages of 18 and 80 who have had plaque&#8209;type psoriasis for at least 6 months, a maximum psoriasis body surface area of 10% have pruritus for at least four weeks and a screening WI&#8209;NRS pruritus score of at least seven. The trial includes an eight&#8209;week treatment period and two&#8209;week follow up period. This trial is intended to evaluate if treatment with 5&#160;mg serlopitant daily for eight weeks can reduce pruritus associated with psoriasis as compared with placebo. The primary efficacy analysis will compare serlopitant versus placebo changes on WI&#8209;NRS at week eight. We enrolled the first patients in the trial in November 2017 and we expect data from this trial to be available in late 2018 or early 2019. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Cough Ongoing Phase 2 Clinical Trial</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In October 2017, we commenced a multicenter, placebo&#8209;controlled double&#8209;blind Phase 2 clinical trial of serlopitant in patients with refractory chronic cough. This trial is being conducted at approximately 40 sites in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the United States and the United Kingdom and is expected to enroll approximately 170 patients between the ages of 18 and 80 who have had treatment refractory chronic cough or unexplained cough for at least one year. This trial includes a twelve&#8209;week treatment period and four&#8209;week follow&#8209;up period. This trial is intended to evaluate if treatment with 5&#160;mg serlopitant daily for 12&#160;weeks can reduce cough frequency in patients with refractory chronic cough as compared with placebo. We </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">enrolled the first patients in the trial in October 2017, and we </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">expect data from this trial to be available in the fourth quarter of 2018.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Clinical Studies</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition to our efficacy and safety studies noted above, we have in the past and will in the future conduct additional studies required for regulatory review of serlopitant.  These include pharmacokinetics studies, safety studies, and other studies as needed to support our applications for regulatory approval in the United States and Europe. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">An investigator at Stanford University has recently completed an independent investigator-sponsored 14-patient exploratory study of serlopitant as a treatment to reduce pruritus associated with Epidermolysis Bullosa, or EB, a rare, severe skin condition occurring primarily in children and young adults. We expect the EB study results to be presented at a scientific conference in the second quarter of 2018.&#160;</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Safety</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Serlopitant has been dosed in more than 1,000 individuals across multiple completed Phase 1 and Phase 2 clinical trials. Single doses up to 400 mg and doses up to 50 mg a day for four weeks have been administered. Doses of 4 mg (in a liquid filled capsule, which provides comparable exposure to our current 5 mg tablet) a day for up to one year have been administered. The safety profile to date indicates that serlopitant is well tolerated. Across all completed Phase 2 studies, including the trials conducted by Merck, no SAEs to date have been assessed as probably or definitely related to serlopitant, and only four patients have experienced SAEs that were assessed as possibly related to serlopitant. The most commonly reported treatment&#8209;emergent adverse events across all completed Phase 2 studies were nasopharyngitis (6.4%, as compared to 3.8% for patients treated with placebo), urinary tract infection (6.0%, as compared to 3.1% for patients treated with placebo), diarrhea (6.0%, as compared to 5.0% for patients treated with placebo) and headache (5.6%, as compared to 7.5% for patients treated with placebo). </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The non-clinical safety profile of serlopitant has been well characterized. The safety of serlopitant was evaluated in genetic toxicity, acute toxicity, repeated dose oral toxicity studies up to nine months in duration, two&#8209;year oral carcinogenicity studies, developmental toxicity studies, fertility and reproduction studies and local tolerability (dermal and ocular) studies.&#160; Serlopitant was neither mutagenic nor genotoxic in </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">in vitro</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">in vivo</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;assays. Additional non&#8209;clinical studies are planned to support NDA submission and pediatric development, including a pre and post&#8209;natal development study and a juvenile toxicology study. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Regulatory Pathway</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have completed an end&#8209;of&#8209;Phase 2 review process with the FDA for pruritus associated with prurigo nodularis and have presented the FDA with the design, the target population, key endpoint measures, and other clinical trial design elements of our planned Phase 3 clinical trials in pruritus associated with prurigo nodularis. We have also completed a CMC end&#8209;of&#8209;Phase 2 review with the FDA, which provided clear guidance on the work remaining to support the CMC information to be presented in the NDA, all of which is consistent with our ongoing and planned activities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Scientific advice meetings have been completed with regulatory authorities in three European countries and such meetings have provided clear guidance with respect to the regulatory path supporting submission of an MAA for pruritus associated with prurigo nodularis and our broader pruritus program.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We anticipate that development of serlopitant for use in pediatric patients will be a required element of our development program for some of our target indications. We are developing a pediatric plan for review with regulatory authorities in Europe and the United States.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Prior to the start of our Phase 2 study in pruritus associated with atopic dermatitis, we discussed this trial design with the FDA and received confirmation that we can pursue such a pruritus indication with helpful </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">feedback regarding primary efficacy analysis considerations, statistical considerations and other key elements of the development program for pruritus associated with atopic dermatitis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">From the multiple discussions we have had with the FDA and the European regulatory authorities, we believe that our serlopitant development program can be directed to the specific indications of pruritus associated with each of&#160;atopic dermatitis, psoriasis, and prurigo nodularis. If our ongoing and future clinical trials are successful, we could potentially submit an NDA for pruritus associated with up to three indications in 2020: pruritus associated with atopic dermatitis, psoriasis, and prurigo nodularis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have received clearance from the FDA of an investigational new drug application (&#8220;IND&#8221;) to conduct our Phase 2 clinical trial in refractory chronic cough.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;We enrolled the first patient in the clinical trial in October 2017.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Competition</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The biopharmaceutical industry is intensely competitive and is subject to rapid and significant change. We face competition from other pharmaceutical and biotechnology companies, research institutions and other organizations. We consider our primary competitors to be those companies that are developing drugs specifically to treat pruritus associated with a variety of underlying dermatologic or systemic conditions, companies that are developing drugs specifically to treat chronic cough, companies that are developing and marketing other NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists for pruritus or other conditions, that, when approved, could be used off&#8209;label to treat pruritus or cough, and companies that currently market or are developing treatments intended directly to treat the underlying disease condition in atopic dermatitis, psoriasis, or prurigo nodularis that have also been shown to have anti&#8209;pruritic effects. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We are aware of other companies targeting pruritus or chronic cough as the primary outcome measure in clinical studies of drugs. There are multiple companies developing products at varying stages of development specifically intended to treat pruritus including: Vanda Pharmaceuticals, Trevi Therapeutics, Galderma, Sienna Biopharmaceuticals, Tioga, Nerre Therapeutics, Opko Health and Cara Therapeutics. In addition, Merck, GlaxoSmithKline and Nerre Therapeutics are developing therapeutic treatments for chronic cough. Of these companies, Vanda, Opko and Nerre are developing NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists for indications t</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">hat may compete directly with serlopitant.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;Other companies, including Tesaro and Merck, are also marketing or developing NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists for other indications and could compete with serlopitant.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">License and Collaboration Agreements</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">JT Torii Agreements </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In August 2016, we entered into an exclusive royalty&#8209;bearing license and collaboration agreement with JT Torii, for the development and commercialization of products containing serlopitant in Japan for the treatment of diseases and conditions other than nausea and vomiting. JT Torii currently markets Remitch in Japan for pruritus in patients on dialysis. Under our agreement, we received an upfront, non&#8209;refundable payment of $11.0 million. In addition, we are entitled to receive aggregate payments of up to $28.0 million upon the achievement of specified development and regulatory milestones, and $15.0 million upon the achievement of a commercial milestone, as well as tiered royalties from the mid-single digits </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">up to the mid-teens </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">on sales of licensed products in Japan. We are primarily responsible for prosecuting, maintaining and enforcing licensed patent rights in Japan. The agreement contains customary representations, warranties, and indemnities, and terminates on a product&#8209;by&#8209;product basis upon the later of the last to expire patent covering a licensed product under the agreement or 10 years after the first commercial sale of such product, after which the licenses granted with respect to such product become perpetual, irrevocable and non&#8209;exclusive. The currently issued patents covering a licensed product under the agreement is expected to expire in 2025. Currently issued patents are expected to expire between 2034 and 2038. JT Torii may terminate the agreement without cause at any time upon advance written notice to us. We may terminate the agreement if JT Torii or its affiliates challenges the validity, enforceability, or scope of any licensed patents anywhere in the world. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Either party may terminate the Collaboration Agreement for the other party&#8217;s material breach or for certain bankruptcy or insolvency related events. We have also entered into a Supply Agreement and a Services Agreement with JT Torii pursuant to which they reimburse us for certain supplies, services and expenses. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In September 2017, we entered into a services agreement with JT Torii to provide research and development services, including regulatory, chemistry and manufacturing support and related materials. We have no obligation to provide services unless requested by JT Torii and agreed to by us. We are eligible to receive reimbursement of estimated costs incurred and payment for research services performed directly by us at agreed upon rates.&#160;The services agreement terminates upon the termination of the Collaboration Agreement or by mutual agreement of the parties.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Merck License</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In December 2012, we entered into a license agreement with Merck for exclusive worldwide royalty&#8209;free rights for the development and commercialization of serlopitant and two other NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists in all human diseases, disorders or conditions, except for the treatment or prevention of nausea or vomiting. We paid Merck an upfront licensing fee of $1.0 million and issued to Merck an aggregate of 1,243,168 shares of our common stock. In addition, we have agreed to make aggregate payments of up to $25.0 million upon the achievement of specified development and regulatory milestones for serlopitant. Furthermore, if we choose to pursue the development of any other products pursuant to this agreement, we may owe up to an aggregate of $50.0 million of additional payments upon the achievement of specified development and regulatory milestones.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;In the near term, upon dosing our first patient in our Phase 3 clinical trial for serlopitant for the treatment of pruritus associated with prurigo nodularis, we will be obligated to make a milestone payment of $3.0 million to Merck. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We are responsible for the prosecution and enforcement of patents licensed under the agreement. The agreement contains customary representations, warranties, and indemnities, and terminates on the date of achievement of all of milestones set forth in the agreement, after which our licenses become fully paid and perpetual. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Each party may also terminate the agreement for material breach by the other party or for certain bankruptcy or insolvency related events, and we may terminate the agreement without cause at any time upon advance written notice to Merck.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Manufacturing</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We currently contract with third parties for the manufacture of serlopitant drug substance and drug product for clinical trials and intend to continue doing so in the future. We require all of our contract manufacturing organizations, or CMOs, to conduct manufacturing activities in compliance with current good manufacturing practice, or cGMP, requirements. We have assembled a team of experienced employees and consultants to provide the necessary technical, quality and regulatory oversight over our CMOs. We rely solely on these third&#8209;party manufacturers for scale&#8209;up and process development work and to produce sufficient quantities of serlopitant for use in clinical and non-clinical studies. We currently have development contracts and quality agreements with two CMOs</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">for the manufacturing of serlopitant drug substance and drug product. We anticipate that these CMOs will have capacity to support commercial scale production, but we do not have any formal agreements at this time with either of these CMOs to cover commercial production. We also may elect to pursue additional CMOs for manufacturing supplies of regulatory starting materials in the future. We currently have no plans to establish our own manufacturing capabilities and plan to continue to rely on third&#8209;party manufacturers for any future trials and commercialization of serlopitant, if approved.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Commercial Operations </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We currently have no marketing and sales organization. If approved by the FDA for pruritus associated with our target dermatologic conditions, we intend to market and commercialize serlopitant by developing our own sales organization targeting a subset of the 10,000 to 12,000 dermatologists in the United States. If approved for pruritus associated with atopic dermatitis, we anticipate that we may need to expand this sales organization to reach high prescribing pediatricians and primary care physicians. If approved by the FDA for refractory chronic cough, we believe we can establish a direct sales organization targeting the approximately 10,000 pulmonologists and allergists in the United States. Outside the United States, we intend to establish commercialization strategies for serlopitant as we approach possible commercial approval in each market, which may include collaborations with other companies.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Intellectual Property </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our drug candidates, manufacturing and process discoveries, and other know&#8209;how, to operate without infringing the proprietary rights of others, and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing U.S. and foreign patent applications related to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also rely on trade secrets, know&#8209;how, continuing technological innovation and potential in&#8209;licensing opportunities to develop and maintain our proprietary position.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">With regard to serlopitant, we intend to pursue composition&#8209;of&#8209;matter patents, where possible, and dosage and formulation patents, as well as method&#8209;of&#8209;use patents on novel indications for known compounds.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December 2017, we own, co&#8209;own, or have an exclusive license to 11 issued U.S. patents and 51 issued foreign patents, which include granted European patent rights that have been validated in various EU member states, and 5 pending U.S. patent applications and 19 pending foreign patent applications.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The patent portfolio for serlopitant is directed to cover compositions of matter and methods of treatment. This patent portfolio includes issued U.S. patents, pending U.S. patent applications and corresponding foreign national and regional counterpart patents and patent applications. The issued composition of matter patent (U.S. Patent No. 7,217,731), is exclusively licensed from Merck and if the appropriate maintenance fees are paid, is expected to expire in 2025. We own or co&#8209;own the patents and patent applications relating to the use of serlopitant. The issued methods of use patents (U.S. Patent Nos. 8,906,951; 9,198,898; 9,381,188; 9,474,741; 9,486,439, 9,737,507 and 9,737,508), if the appropriate maintenance fees are paid, are expected to expire in 2033. Additional patent term may be awarded for one of the serlopitant U.S. patents as a result of the patent term extension provision of the Hatch&#8209;Waxman Amendments of 1984, or the Hatch&#8209;Waxman Act. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The term of composition of matter patents and patent applications, if issued, relating to serlopitant in other jurisdictions (some of the major jurisdictions include Australia, Canada, China, Denmark, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands, Norway, Spain, Sweden, Switzerland, Taiwan, United Kingdom and India) and methods of use patents and patent applications, if issued, relating to serlopitant (some of the major jurisdictions include Australia, Brazil, Canada, China, Europe, India, Indonesia, Israel, Japan, Korea and Mexico), if the appropriate maintenance, renewal, annuity and other government fees are paid, are expected to expire between 2025 and 2034. These patents and patent applications (if applicable), depending on the national laws, may benefit from extension of patent term in individual countries if regulatory approval of serlopitant is obtained in those countries. In the European Union member countries, for example, a supplementary protection certificate, if obtained, provides a maximum five years of market exclusivity. Likewise, in Japan, the term of a patent may be extended by a maximum of five years in certain circumstances.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Additional U.S. and PCT patent applications relating to serlopitant are pending. Patents resulting from these applications, if issued, and if the appropriate maintenance, renewal, annuity, and other government fees are paid, are expected to expire between 2037 and 2038.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We also protect our proprietary technology and processes, in part, by confidentiality and invention assignment agreements with our employees, consultants, scientific advisors and other contractors. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees, consultants, scientific advisors or other contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know&#8209;how and inventions.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our commercial success will also depend in part on not infringing the proprietary rights of third parties. It is uncertain whether the issuance of any third&#8209;party patent would require us to alter our development or commercial strategies, alter our drugs or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the United States Patent and Trademark Office, or USPTO, to determine priority of invention.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Government Regulation </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">marketing and distribution of drugs, such as serlopitant. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post&#8209;approval monitoring and reporting, sampling and export and import of our product candidate. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Government Regulation of Drug Products </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">completion of non-clinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin in the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">performance of adequate and well&#8209;controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug product for each indication;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">submission to the FDA of an NDA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">satisfactory completion of an FDA advisory committee meeting, if applicable;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">satisfactory completion of FDA audits of clinical trial sites and the sponsor&#8217;s clinical trial records to assure compliance with GCPs and the integrity of the clinical data; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">payment of user fees and securing FDA approval of the NDA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">compliance with any post&#8209;approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post&#8209;approval studies.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Non-clinical Studies</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Non-clinical studies include laboratory evaluation of product chemistry and formulation, as well as animal studies to assess safety, toxicity and efficacy. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The conduct of the non-clinical tests must comply with federal regulations and requirements, including GLPs. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">An IND sponsor must submit the results of the non-clinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some non-clinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Clinical Trials</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Clinical trials involve the administration of the investigational new drug to human patients under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research patients provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the protocol for any clinical trial including informed consent information before the study commences at that institution. Information about most clinical trials must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in some cases for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Phase 1: The drug is initially introduced into healthy human patients or patients with the target disease or condition and tested for safety, dosage tolerance, pharmacokinetics, absorption, metabolism, distribution, excretion, side effects and, if possible, to gain an early indication of its effectiveness.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well&#8209;controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk&#8209;benefit profile of the product, and to provide adequate information for the labeling of the product. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate efficacy of the drug.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. The FDA or the sponsor may suspend or terminate a clinical trial at any time </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">or the FDA may impose other sanctions</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Marketing Approval</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Assuming successful completion of the required clinical testing, the results of the non-clinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that the NDA is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in&#8209;depth substantive review. The FDA has agreed to certain performance goals in the review of NDAs. Most applications for standard review drug products are reviewed within ten to twelve months; most NDAs for priority review drugs are reviewed in six to eight months. The review process for both standard and priority review </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">may be extended by FDA for three additional months to consider certain late&#8209;submitted information, or information intended to clarify information already provided in the submission. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In accordance with the Pediatric Research and Equity Act, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The FDA also may require submission of a REMS plan </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">if it determines that a REMS is necessary </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The FDA may refer an application for a novel drug, or a drug that presents difficult questions of safety or efficacy, to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites and the sponsor to assure compliance with GCP requirements and the integrity of the clinical data submitted in an NDA.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA will issue an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or non-clinical testing in a resubmission to the NDA in order for the FDA to reconsider the application. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">FDA has committed to reviewing such submissions in two or six months depending on the type of information included in the resubmission. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post&#8209;approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post&#8209;marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Special FDA Expedited Review and Approval Programs</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The FDA has various programs, including fast track designation, breakthrough therapy designation, accelerated approval, and priority review, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under the fast track program, the sponsor of a new drug candidate may request that FDA designate the drug candidate for a specific indication as a fast track drug concurrent with, or after, the filing of the IND for the drug candidate. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Fast track designation provides opportunities for frequent interactions with the FDA review team to expedite development and review of the product. FDA may initiate review of sections of a fast track drug&#8217;s NDA before the application is complete. This rolling review is available if the applicant provides, and FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, FDA&#8217;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, a sponsor can request breakthrough therapy designation for a drug if it is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are eligible for intensive guidance from FDA on an efficient drug development program, organizational commitment to the development and review of the product including involvement of senior managers, and, like fast track products, are also eligible for rolling review of the NDA. Both fast track and breakthrough therapy products are also eligible for accelerated approval and/or priority review, if relevant criteria are met.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under the FDA&#8217;s accelerated approval regulations, the FDA may approve a drug for a serious or life&#8209;threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug candidate approved on this basis is subject to rigorous post&#8209;marketing compliance requirements, including the completion of Phase 4 or post&#8209;approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post&#8209;approval studies, or confirm a clinical benefit during post&#8209;marketing studies, will allow FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated approval regulations are subject to prior review by FDA.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Once an NDA is submitted for a product intended to treat a serious condition, the FDA may assign a priority review designation if FDA determines that the product, if approved, would provide a significant improvement in safety or effectiveness. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the current PDUFA agreement, these six and ten month review periods are measured from the 60-day filing date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review from the date of submission. Most products that are eligible for fast track breakthrough therapy designation are also likely to be considered appropriate to receive a priority review.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, the manufacturer of an investigational drug for a serious or life&#8209;threatening disease is required to make available, such as by posting on its website, its policy on responding to requests for expanded access. Furthermore, fast track designation, breakthrough therapy designation, accelerated approval and priority review do not change the standards for approval and may not ultimately expedite the development or approval process.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Post-Approval Requirements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, substantial annual user fee requirements for any marketed products. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">These fees are typically increased annually.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The FDA may impose a number of post&#8209;approval requirements as a condition of approval of an NDA. For example, the FDA may require post&#8209;marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third&#8209;party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Once an approval or clearance of a drug is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post&#8209;market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">fines, warning letters or clinical holds on post&#8209;approval clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">product seizure or detention, or refusal to permit the import or export of products; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">injunctions or the imposition of civil or criminal penalties.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off&#8209;label uses, and a company that is found to have improperly promoted off&#8209;label uses may be subject to significant liability.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">The Hatch-Waxman Act</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Section 505 of the FDCA describes three types of applications that may be submitted to request marketing authorization for a new drug. A 505(b)(1) NDA is an application that contains full reports of investigations of safety and effectiveness. The Hatch&#8209;Waxman Act created two additional marketing pathways under Sections 505(j) and 505(b)(2) of the FDCA. Section 505(j) establishes an abbreviated approval process for generic versions of approved drug products through the submission of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the branded reference drug and has been shown to be bioequivalent to the branded reference drug. ANDA applicants are required to conduct bioequivalence testing to confirm chemical and therapeutic equivalence to the branded reference drug. Generic versions of drugs can often be substituted by pharmacists under prescriptions written for the branded reference drug.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">A 505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant. This alternate regulatory pathway enables the applicant to rely, in part, on the FDA&#8217;s findings of safety and efficacy for an existing product, or published literature, in support of its application. The FDA may then approve the new product candidate for all or some of the labeled indications for which the branded reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Hatch&#8209;Waxman Act establishes periods of regulatory exclusivity for certain approved drug products. The holder of an NDA may obtain five years of exclusivity upon approval of a new drug containing a new chemical entity, or NCE, that has not been previously approved by the FDA. During the five year exclusivity period, the FDA cannot accept for filing or approve any ANDA seeking approval of a generic version of that drug or any 505(b)(2) NDA for the same active moiety and that relies on the FDA&#8217;s findings regarding that drug, except that FDA may accept an application for filing (but still may not approve it) after four years if the follow&#8209;on applicant makes a paragraph IV certification, as described below. The Hatch&#8209;Waxman Act also provides three years of marketing exclusivity to the holder of an NDA for a particular condition of approval, or change to a marketed product, such as a new formulation or new indication for a previously approved product, if one or more new clinical studies (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. This three&#8209;year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDA for drugs that include the innovation that required the new clinical data.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA, in the opinion of the applicant and to the best of its knowledge (1) that relevant patent information on the referenced drug product has not been submitted to the FDA; (2) that the relevant patent has expired; (3) the date on which the relevant patent expires; or (4) that such patent is invalid, unenforceable or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a paragraph IV certification. If the NDA holder or patent owner(s) files a patent infringement action against the ANDA or 505(b)(2) applicant within 45 days of receipt of the paragraph IV certification, the FDA may not approve the ANDA or 505(b)(2) application until the earlier of (i) 30 months from the receipt of the notice of the paragraph IV certification (generally referred to as the 30 month stay), (ii) the expiration date of the patent(s) listed in the Orange Book for the reference drug product, (iii) the date the court enters a final order or judgment that the patent(s) are invalid, unenforceable and/or not infringed or (iv) such shorter or longer period as may be ordered by a court. Where the ANDA or 505(b)(2) applicant files an application with a paragraph IV certification within the fifth year of the five&#8209;year NCE exclusivity period enjoyed by the NDA holder for the reference branded product, and where patent litigation is brought within 45 days of receipt of notice of the paragraph IV certification, the 30&#8209;month stay will be extended by the amount of time such that 7.5 years will elapse from the date of approval of the original NDA to the expiration of the stay. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes, whether the reference product enjoys NCE exclusivity, and the reference drug sponsor&#8217;s decision to initiate patent litigation. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">However, an ANDA applicant may be able to submit a section viii statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method&#8209;of&#8209;use rather than certify to a listed method&#8209;of&#8209;use patent. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Regulation Outside the United States</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In the European Economic Area, or EEA, which is composed of the 28 Member States of the European Union plus Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">There are two types of MAs:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products and medicinal products that contain a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto&#8209;immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. Under the Centralized Procedure the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP). Accelerated evaluation might be granted by the CHMP in exceptional cases, when the authorization of a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. Under the accelerated procedure the standard 210 days review period is reduced to 150 days.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Prior to obtaining an MA in the EEA, applicants have to demonstrate compliance with all measures included in a Paediatric Investigation Plan, or PIP, approved by the EEA regulatory agency, covering all subsets of the pediatric population, unless the EEA regulatory agency has granted (1) a product&#8209;specific waiver, (2) a class waiver or (3) a deferral for one or more of the measures included in the PIP.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In the EEA, upon receiving an MA, new chemical entities generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the EEA from referencing the innovator&#8217;s data to assess a generic application. During the additional two&#8209;year period of market exclusivity, a generic marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic product can be marketed until the expiration of the market exclusivity. However, there is no guarantee that a product will be considered by the EEA regulatory agencies to be a new chemical entity, and products may not qualify for data exclusivity.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Healthcare Laws</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition to FDA restrictions on the marketing of pharmaceutical products, other foreign, federal and state healthcare regulatory laws restrict business practices in the pharmaceutical industry. These laws include, but are not limited to, federal and state anti&#8209;kickback, false claims, data privacy and security, and physician payment and drug pricing transparency laws.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The U.S. federal Anti&#8209;Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti&#8209;Kickback Statute has been interpreted to apply to arrangements between pharmaceutical and medical device manufacturers on the one hand and prescribers, purchasers, formulary managers and beneficiaries on the other hand. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not meet the requirements of a statutory or regulatory exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the U.S. federal Anti&#8209;Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case&#8209;by&#8209;case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Moreover, a claim including items or services resulting from a violation of the U.S. federal Anti&#8209;Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. The majority of states also have anti&#8209;kickback </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">laws, which establish similar prohibitions and in some cases may apply to items or services reimbursed by any third&#8209;party payor, including commercial insurers.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The federal false claims and civil monetary penalties laws, including the civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Actions under the civil False Claims Act may be brought by the Attorney General or as a </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">qui tam</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;action by a private individual in the name of the government. Violations of the civil False Claims Act can result in very significant monetary penalties and treble damages. Several pharmaceutical, medical device and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved (e.g., or off&#8209;label) uses. In addition, the civil monetary penalties statute imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Many states also have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Violations of fraud and abuse laws, including federal and state anti&#8209;kickback and false claims laws, may be punishable by criminal and civil sanctions, including fines and civil monetary penalties, the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid), disgorgement and corporate integrity agreements, which impose, among other things, rigorous operational and monitoring requirements on companies. Similar sanctions and penalties, as well as imprisonment, also can be imposed upon executive officers and employees of such companies. Given the significant size of actual and potential settlements, it is expected that the government authorities will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third&#8209;party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti&#8209;Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and certain other healthcare providers. The Affordable Care Act imposed, among other things, new annual reporting requirements through the Physician Payments Sunshine Act for covered manufacturers for certain payments and &#8220;transfers of value&#8221; provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties. Covered manufacturers must submit reports by the 90</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;day of each subsequent calendar year </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">and the reported information is publically made available on a searchable website</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. In addition, certain states require implementation of compliance programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices and/or require the tracking and reporting of marketing expenditures and pricing information as well as gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Clinical Health Act, or HITECH, and their respective implementing regulations, including the Final HIPAA Omnibus Rule published on January 25, 2013, impose specified requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates. Among other things, HITECH made HIPAA&#8217;s security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating compliance efforts.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Similar foreign laws and regulations, which may include, for instance, applicable post&#8209;marketing requirements, anti&#8209;fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals, may apply to us to the extent that any of our product candidates, once approved, are sold in a country other than the United States.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Coverage and Reimbursement</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical product for which we obtain regulatory approval. In the United States and markets in other countries, patients who are prescribed drugs generally rely on third&#8209;party payors to reimburse all or part of the associated healthcare costs. Providers and patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. If approved, sales of serlopitant will depend, in part, on the availability of coverage and adequate reimbursement from third&#8209;party payors. Third&#8209;party payors include government authorities, managed care plans, private health insurers and other organizations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In the United States, the process for determining whether a third&#8209;party payor will provide coverage for a pharmaceutical product typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. With respect to drugs, third&#8209;party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA&#8209;approved products for a particular indication, or place products at certain formulary levels that result in lower reimbursement levels and higher cost&#8209;sharing obligation imposed on patients. A decision by a third&#8209;party payor not to cover a product could reduce physician utilization of a product. Moreover, a third&#8209;party payor&#8217;s decision to provide coverage for a pharmaceutical product does not imply that an adequate reimbursement rate will be approved. Adequate third&#8209;party reimbursement may not be available to enable a manufacturer to maintain price levels sufficient to realize an appropriate return on its investment in product development. Additionally, coverage and reimbursement for products can differ significantly from payor to payor. One third&#8209;party payor&#8217;s decision to cover a particular medical product does not ensure that other payors will also provide coverage for the medical product, or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process usually requires manufacturers to provide scientific and clinical support for the use of their products to each payor separately and is a time&#8209;consuming process.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In the European Union, governments influence the price of products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription products, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross border imports from low&#8209;priced markets exert a commercial pressure on pricing within a country.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of pharmaceutical products have been a focus in this effort. Third&#8209;party payors are increasingly </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost&#8209;effectiveness of pharmaceutical products, in addition to questioning safety and efficacy. If third&#8209;party payors do not consider a product to be cost&#8209;effective compared to other available therapies, they may not cover that product after FDA approval or, if they do, the level of payment may not be sufficient to allow a manufacturer to sell its product at a profit. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Healthcare Reform and Other Potential Changes to Healthcare Laws</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, in December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and devices and to spur innovation, but its ultimate implementation is unclear. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, in August 2017, the FDA Reauthorization Act was signed into law, which reauthorized the FDA&#8217;s user fee programs and included additional drug and device provisions that build on the Cures Act. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third&#8209;party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other healthcare funding, and applying new payment methodologies. For example, in March 2010, the Affordable Care Act was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers&#8217; outpatient drugs coverage under Medicare Part D; subjected drug manufacturers to new annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs; imposed a new federal excise tax on the sale of certain medical devices; created a new Patient Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; created the Independent Payment Advisory Board, which, once empaneled, will have authority to recommend certain changes to the Medicare program that could result in reduced payments for prescription drugs; and established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. The Trump administration and members of the U.S. Congress have indicated that they may continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the Affordable Care Act. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Most recently, the Tax Cuts and Jobs Acts was enacted, which, among other things, removes penalties for not complying with the individual mandate to carry health insurance. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">It is uncertain the extent to which any such changes may impact our business or financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, we cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance and review and approval of marketing applications. Notably, on January 30, 2017, President Trump issued an Executive Order, applicable to all executive agencies, including the FDA, that requires that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the &#8220;two&#8209;for&#8209;one&#8221; provisions. This Executive Order includes a budget neutrality provision that requires the total incremental cost of all new regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the Executive Order requires </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">agencies to identify regulations to offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new regulation or repealed regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within the Office of Management and Budget, or OMB, on February 2, 2017, the administration indicates that the &#8220;two&#8209;for&#8209;one&#8221; provisions may apply not only to agency regulations, but also to significant agency guidance documents. In addition, on February 24, 2017, President Trump issued an executive order directing each affected agency to designate an agency official as a &#8220;Regulatory Reform Officer&#8221; and establish a &#8220;Regulatory Reform Task Force&#8221; to implement the two&#8209;for&#8209;one provisions and other previously issued executive orders relating to the review of federal regulations, however it is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act to reduce healthcare expenditures. These changes include the Budget Control Act of 2011, which led to aggregate reductions of Medicare payments to providers of 2% per fiscal year and that will remain in effect through 2025 unless additional action is taken by Congress; the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years; and the Medicare Access and CHIP Reauthorization Act of 2015, which ended the use of the statutory formula for Medicare payment adjustments to physicians, and provided for a 0.5% annual increase in payment rates under the Medicare Physician Fee Schedule through 2019, but no annual update from 2020 through 2025. More recently, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Employees</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December 31, 2017, we had 32 employees. Within our workforce, 23 employees are engaged in research and development and the remaining 9 in general management and administration, including finance and facilities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We believe that we maintain good relations with our employees.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">29</font></div></div><hr style="page-break-after:always"><div><a name="s42EE65B3F60C5B5EA07B81A8DAFA9E3D"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">1B. Risk Factors.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Our business is subject to various risks and uncertainties, including those described below, that we believe apply to our business and the industry in which we operate. You should carefully consider these risks, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to Our Financial Position and Capital Needs&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We have a limited operating history, have incurred significant losses since our inception, and anticipate that we will continue to incur losses for the foreseeable future. We have only one product candidate in clinical trials and no commercial sales, which, together with our limited operating history, makes it difficult to assess our future viability.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We are a late&#8209;stage biopharmaceutical company with a limited operating history. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have focused principally on developing serlopitant, which is our only product in development. We are not profitable and have incurred losses in each year since our inception in 2011. We have only a limited operating history upon which stockholders can evaluate our business and prospects. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. We have not generated any revenue from product sales to date. We continue to incur significant research and development and other expenses related to our ongoing operations. Our net loss for the years ended December&#160;31, 2017 and 2016 was approximately $29.1 million and $14.1 million, respectively. As of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, we had an accumulated deficit of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$59.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. We expect to continue to incur losses for at least the next few years, and we anticipate these losses will increase as we continue our development, seek regulatory approval of, and, if approved, begin to commercialize serlopitant. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We will require substantial additional financing, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have devoted substantially all of our financial resources and efforts to the development of serlopitant as a once&#8209;daily, oral tablet treatment of pruritus associated with underlying dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis, and for the treatment of chronic refractory cough. As of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, we had capital resources consisting of cash, cash equivalents and investments of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$62.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In January 2018, we completed our initial public offering, or IPO, which increased our cash resources by approximately $125.5 million. We expect to incur substantial expenditures in the foreseeable future as we advance serlopitant through clinical development, the regulatory approval process and, if approved, commercial launch activities. Specifically, in the near term, we expect to incur substantial expenses relating to our ongoing Phase 2 and planned Phase 3 clinical trials, the development and validation of our commercial manufacturing process for serlopitant, and other development activities including potentially commencing Phase 3 clinical trials for pruritus associated with atopic dermatitis and psoriasis, and for refractory chronic cough. In addition, we expect to pay a $3.0 million milestone payment to Merck upon the initiation of our Phase 3 clinical trials for pruritus associated with prurigo nodularis. Furthermore, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We also expect to incur expenses related to the recruitment and retention of personnel, working capital and other general corporate purposes. We may incur additional expenses in connection with expanding our pipeline, including by pursuing additional indications for serlopitant or the in&#8209;license or acquisition of additional drug candidates or commercial products.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We believe that our existing cash, cash equivalents and investments will be sufficient to fund our planned operations through at least the next 12 months. However, because the outcome of any clinical trial or regulatory approval process is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development, regulatory approval process and commercialization of serlopitant. Our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity, debt financings or other sources, such as strategic collaborations. Such financing may result in dilution to stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our future funding requirements will depend on many factors, including, but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the time and cost necessary to complete our ongoing Phase 2 clinical trials for pruritus associated with atopic dermatitis and psoriasis and for refractory chronic cough, our planned Phase 3 clinical trials for pruritus associated with prurigo nodularis as well as any additional current and planned clinical trials of serlopitant;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the number, size and type of any additional clinical trials or studies we may choose to initiate or that we may be required to complete prior to obtaining regulatory approval of serlopitant;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the timing of, and costs involved in, seeking and obtaining approvals from the FDA and comparable foreign regulatory authorities, including the potential by the FDA or comparable regulatory authorities to require that we perform more studies than those that we currently expect, and the costs of post&#8209;marketing studies that could be required by regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to receive payments under our collaboration with JT Torii, and the timing of receipt of any such payments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the timing of the milestone payments we must make to Merck;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the costs of preparing to manufacture serlopitant on a commercial scale;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to successfully commercialize serlopitant;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the manufacturing, selling and marketing costs associated with serlopitant, including the cost and timing of forming and expanding our sales organization and marketing capabilities;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the amount of sales and other revenues from serlopitant, including the sales price and the availability of adequate third&#8209;party reimbursement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the degree and rate of market acceptance of any products launched by us or our partners;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the cash requirements of any future acquisitions or discovery of product candidates;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the progress, timing, scope and costs of our non&#8209;clinical studies and clinical trials, including the ability to enroll patients in a timely manner in potential future clinical trials;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the time and cost necessary to respond to technological and market developments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our need and ability to hire additional personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the emergence of competing technologies or other adverse market developments.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">clinical trials or other development activities for serlopitant or any future product candidate; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize serlopitant or any future product candidate.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to Our Business</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We are substantially dependent on the success of our sole product candidate, serlopitant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">To date, we have invested substantially all of our efforts and financial resources in the development of serlopitant, which is currently our sole product candidate in development. Our prospects, including our ability to finance our operations and generate revenue from product sales, will currently depend entirely on the successful development and commercialization of serlopitant. The clinical and commercial success of serlopitant will depend on a number of factors, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the timely completion of and results from our three ongoing Phase 2 clinical trials of serlopitant for the treatment of pruritus associated with atopic dermatitis and psoriasis, and for refractory chronic cough;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the initiation of and results from our planned Phase 3 clinical trials of serlopitant for the treatment of pruritus associated with prurigo nodularis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the initiation of and results from any Phase 3 clinical trials, if conducted, in pruritus associated with atopic dermatitis, pruritus associated with psoriasis, or refractory chronic cough; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">whether the FDA disagrees with the number, design, size, conduct, or implementation of our planned and future clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to demonstrate serlopitant&#8217;s safety and efficacy to treat pruritus associated with atopic dermatitis, with psoriasis or with prurigo nodularis or to treat refractory chronic cough to the satisfaction of the FDA or foreign regulatory authorities;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the timely completion and results of any additional clinical trials and non&#8209;clinical studies conducted to support the filing for regulatory approvals of serlopitant; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">whether we are required by the FDA or foreign regulatory authorities to conduct additional clinical trials prior to approval to market serlopitant for any indication;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to execute on our clinical trial plans and monitor the conduct of the studies by the contract research organizations, or CROs, and medical institutions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the prevalence, frequency and severity of adverse side effects of serlopitant;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the timely receipt of necessary marketing approvals from the FDA and foreign regulatory authorities to treat pruritus associated with atopic dermatitis, psoriasis or prurigo nodularis, or to treat refractory chronic cough;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to raise sufficient additional capital to fund development, manufacturing and commercialization activities for serlopitant;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to successfully commercialize serlopitant, if approved for marketing and sale by the FDA or foreign regulatory authorities, whether alone or in collaboration with others;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the ability of our third&#8209;party manufacturers to manufacture quantities of serlopitant using commercially sufficient processes at a scale sufficient to meet anticipated demand and at a cost appropriate for our commercialization;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the ability of our third&#8209;party manufacturers to comply with current good manufacturing practices, or cGMP;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">achieving and maintaining compliance with all regulatory requirements applicable to serlopitant;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our success in educating physicians and patients about the benefits, administration and use of serlopitant;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the willingness of physicians and patients to utilize or adopt serlopitant;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to obtain and sustain an adequate level of reimbursement for serlopitant by third&#8209;party payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the effectiveness of our own, our current collaborator&#8217;s, or any future strategic collaborators&#8217; marketing, sales and distribution strategy and operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to enforce our intellectual property rights in and to serlopitant;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to avoid&#160;third&#8209;party&#160;patent interference or patent infringement claims; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">a continued acceptable safety profile of serlopitant following approval; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">emerging safety signals from other drugs generally perceived to be in the same drug class as serlopitant, including NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">-R antagonists.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Many of these factors are beyond our control. Accordingly, we cannot be certain that we will ever be able to generate revenue through the sale of serlopitant. If we are not successful in commercializing serlopitant, or are significantly delayed in doing so, our business will be materially harmed.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of serlopitant.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">To gain approval to market a drug product, we must provide the FDA and foreign regulatory authorities with non&#8209;clinical, clinical, and chemistry, manufacturing, and controls, or CMC, data that adequately demonstrates the safety and efficacy of the product for the intended indication applied for in the NDA or other respective regulatory filing. Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical trials. Further, although members of our management team have conducted clinical trials and obtained marketing approvals for product candidates in the past while employed at other companies, we as a company have not done so. As a result, such activities may require more time and cost than we anticipate.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our business currently depends entirely on the successful development, regulatory approval and commercialization of serlopitant following completion of all required non&#8209;clinical and clinical trials, and generation of adequate CMC data. We plan to initiate two multi-center placebo-controlled double blind Phase 3 clinical trials of serlopitant for the treatment of pruritus associated with prurigo nodularis in the second quarter of 2018. We also met with the FDA prior to the start of our Phase 2 clinical trial in pruritus associated with atopic dermatitis to discuss clinical trial design elements, primary endpoint measures, statistical considerations and other key elements of the development program. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We anticipate that development of serlopitant for use in pediatric patients will be a required element of our development program for some of our target indications. We are developing a pediatric plan for review with regulatory authorities in Europe and the United States. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In September 2017, the FDA authorized us to proceed with our Phase 2 clinical trial in refractory chronic cough under a separate IND for this indication.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We enrolled the first patients in the trial in October 2017 and we expect data from this trial to be available in the fourth quarter of 2018.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may experience numerous unforeseen events during or as a result of our non&#8209;clinical studies and clinical trials that could delay or prevent our ability to receive marketing approval or commercialize serlopitant, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the number of subjects required for clinical trials of serlopitant may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for post&#8209;treatment follow&#8209;up at a higher rate than we anticipate;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">serlopitant may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate the trials;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our third&#8209;party contractors and clinical trial sites may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical trials for various reasons, including noncompliance with regulatory requirements or a finding that the trial subjects are being exposed to unacceptable risks;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the supply or quality of serlopitant or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the institutional review boards of the institutions in which such trials are being conducted, by the data safety monitoring board for such trial or by the FDA or other regulatory authorities. Authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using serlopitant, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of serlopitant, the commercial prospects of serlopitant will be harmed, and our ability to generate product revenues from serlopitant will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our development of serlopitant and its approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of serlopitant. If we are required to conduct additional clinical trials or other testing of serlopitant beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of serlopitant candidates or other testing, if the results of these trials or tests are not favorable or if there are safety concerns, we may:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">be delayed in obtaining marketing approval for serlopitant;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">not obtain marketing approval at all;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">obtain approval for indications or patient populations that are not as broad as intended or desired;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">be subject to additional post&#8209;marketing testing requirements; or&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">have the drug removed from the market after obtaining marketing approval.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Success in non-clinical testing and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be certain that any of our current Phase 2 clinical trials, planned Phase&#160;3 clinical trials or any other clinical trials that we may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market serlopitant in any indication.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The primary efficacy analysis in our completed Phase 2 clinical trials of pruritus was a statistically significant change in itch VAS from baseline compared to placebo measured at week six or eight. Based upon our interactions with the FDA, we will use a different efficacy analysis for our planned Phase 3 clinical trials, a 4&#8209;point responder rate on the worst&#8209;itch numeric rating scale, or WI&#8209;NRS. We analyzed 4&#8209;point responders in our Phase 2 clinical trials after the completion of the study. The analyses of the percentage of patients with at least a 40 mm response on the visual analogue scale, or VAS, or a 4&#8209;point response on WI&#8209;NRS, were not pre&#8209;specified in our initial completed Phase 2 clinical trials&#8217; statistical analysis plans, and are thus considered post&#8209;hoc analyses. For these and other reasons, our Phase 2 clinical trials may not predict serlopitant&#8217;s ability to demonstrate a statistically significant reduction in pruritus using this measure in Phase 3 clinical trials. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">It is also possible that the FDA or other regulatory agencies may require additional endpoints that are not currently included in our serlopitant clinical trials. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In our completed Phase 2 clinical trial of serlopitant for pruritus associated with prurigo nodularis, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">concomitant medications for treatment of pruritus other than loratadine or cetirizine were excluded</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. In our planned Phase 3 clinical trials for pruritus associated with prurigo nodularis, patients will be permitted to take certain additional medications that were not permitted in the Phase 2 clinical trial. The efficacy or safety of serlopitant when used with other agents in the Phase 3 clinical trials may differ from the Phase 2 clinical trial as a result of these additional medications. Phase 3 clinical trials with larger numbers of patients or longer durations of therapy may also reveal safety concerns that were not identified in earlier smaller or shorter trials.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Other companies in the biopharmaceutical industry have frequently suffered significant setbacks in later clinical trials, even after achieving promising results in earlier non&#8209;clinical studies or clinical trials.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Use of patient-reported outcome assessments, or PROs, in our clinical trials may delay or impair the development of serlopitant and/or adversely impact our clinical trials.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Due to the difficulty of objectively measuring pruritus,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;the assessment of pruritus in clinical trials typically involves the use of PROs</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">For example, our clinical trials evaluating serlopitant in pruritus indications have used both the VAS and NRS scales, which require patients to evaluate their pruritus according to a numerical scale with the lowest number representing no itch and the highest number representing the worst itch imaginable. PROs have an important role in the development and regulatory approval of treatments for pruritus such as serlopitant. PROs involve patients&#8217; subjective assessments of efficacy, and this subjectivity can increase the uncertainty of clinical trial outcomes assessing pruritus. Such assessments can be influenced by factors outside of the patient&#8217;s control, and can vary widely from day to day for a particular patient, and from patient to patient and site to site within a clinical trial. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The variability of PRO measures for itch and the high placebo response rates could adversely impact our serlopitant development program. In addition, PROs for itch assessment have historically been observed to have high placebo group response rates, including in some of our trials. For example, in our Phase 2 clinical trial in patients with chronic pruritus, patients receiving placebo reported a greater than 25% decrease from baseline in itch VAS scores. Variability in the placebo group response has adversely impacted clinical results of other therapies being tested for itch reduction, and could adversely impact our clinical trial results. The variability of a PRO measure may be greater than some measures used for clinical trial assessments, and that variability can complicate clinical trial design, adversely impact the ability of a study to show a statistically significant improvement, and generally adversely impact a clinical development program by introducing additional uncertainties. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">It is also possible that the FDA may require changes in the PRO we are currently using or may indicate that the PRO we are using is not acceptable for demonstrating efficacy in pruritus reduction, potentially delaying clinical development of serlopitant, increasing our costs and making additional clinical trials necessary.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If we experience delays or difficulties in the enrollment of subjects in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Successful and timely completion of clinical trials will require that we enroll a sufficient number of subjects. Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population and the ability of clinical sites to successfully recruit subjects to participate in clinical trials. Trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. For example, we previously initiated a clinical trial of serlopitant to treat pruritus following burn injury but discontinued the trial due to lack of timely enrollment. Enrollment can also be affected by seasonality and other factors. We may not be able to initiate or continue clinical trials for our drug candidates if we are unable to locate and enroll a sufficient number of eligible subjects to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. In particular, among our target indications, prurigo nodularis is a relatively rare condition, and we are in discussions regarding the specific population of prurigo nodularis patients that we may enroll in our Phase 3 clinical trials. It is possible that the specific requirements by the FDA for our patients to be included in these trials may make the trials more difficult to conduct or may significantly extend the time required for enrollment of these trials.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We cannot predict how successful we will be at enrolling subjects in future clinical trials. Subject enrollment is affected by other factors including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the eligibility criteria for the trial in question;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the prevalence and incidence of the conditions being studied in the clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the perceived risks and benefits of serlopitant;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or therapeutic biologics that may be approved for the indications we are investigating;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the efforts to facilitate timely enrollment in clinical trials;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">competition for patients from other clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the success of any advertising campaigns conducted to recruit subjects to enroll in clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the willingness of potential clinical trial subjects to provide informed consent to participate in the trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the patient referral practices of physicians;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the ability to monitor subjects adequately during and after treatment; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the proximity and availability of clinical trial sites for prospective subjects.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our inability to enroll a sufficient number of subjects for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our drug candidates or delays in regulatory filings and progression, which would cause the value of our company to decline and limit our ability to obtain additional financing. Furthermore, we rely on and expect to continue to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and we will have limited influence over their performance.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We rely on third parties to conduct our non-clinical studies and our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize serlopitant or any future product candidates.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We do not have the ability to independently conduct non&#8209;clinical studies and clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, collaborative partners and other third parties, such as CROs, to conduct non&#8209;clinical studies and clinical trials on our drug candidates. The third parties with whom we contract for execution of our non&#8209;clinical studies and clinical trials play a significant role in the conduct of these </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">studies and trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we have limited ability to control the amount or timing of resources that they devote to our programs. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Although we rely on third parties to conduct our non&#8209;clinical studies and clinical trials, we remain responsible for ensuring that each of our non&#8209;clinical studies and clinical trials is conducted in&#160;accordance with its investigational plan and protocol. Moreover, the FDA and foreign regulatory authorities require us to comply with regulations and standards, including some regulations commonly referred to as good clinical practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial subjects are adequately informed of the potential risks of participating in clinical trials.&#160;In the past, we have experienced an issue of non&#8209;compliance with dosing among several patients at one of the clinical sites in one of our trials. We determined through analysis of the results of the trial and a comprehensive third&#8209;party audit that this single&#8209;site issue did not affect the results of that clinical trial.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, the execution of non&#8209;clinical studies and clinical trials, and the subsequent compilation and analysis of the data produced, requires coordination among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. Moreover, these third parties may also have relationships with other commercial entities, some of which may compete with us. Under certain circumstances, these third parties may terminate their agreements with us upon as little as 30&#160;days&#8217; prior written notice. Some of these agreements may also be terminated by such third parties under certain other circumstances, including our insolvency. If the third parties conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed or terminated or may need to be repeated. If any of the foregoing were to occur, we may not be able to obtain regulatory approval for or commercialize the product candidate being tested in such trials.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We rely completely on&#160;third-party&#160;suppliers to manufacture serlopitant, and we intend to continue to rely on third parties to produce non-clinical, clinical and commercial supplies of serlopitant.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We currently contract with one third party for the manufacture of serlopitant drug substance and another third party for serlopitant drug products for clinical trials, and we do not plan to acquire the infrastructure or internal capability to produce our non&#8209;clinical, clinical and commercial supplies of serlopitant. We anticipate that these third parties will have capacity to support commercial scale, but we do not have any formal agreements at this time to cover commercial production of serlopitant. We may engage additional contract manufacturers for production of supplies of precursor materials used to synthesize serlopitant drug substance and to assist in the manufacture of the drug product. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In order for us to obtain approval of serlopitant or any future product candidates, our contract manufacturers must, pursuant to inspections that will be conducted after we submit our NDA or relevant foreign regulatory submission, maintain a compliance status acceptable to the FDA and other comparable foreign regulatory agencies. We do not directly control the manufacturing of serlopitant, and we are completely dependent on our contract manufacturers for compliance with the cGMP requirements for manufacture of both active drug substances and finished drug products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or foreign regulatory agencies, we will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no direct control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. Furthermore, all of our contract manufacturers are engaged with other companies to supply or manufacture materials or products for such companies, which exposes our manufacturers to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may generally affect the regulatory clearance of our contract manufacturers&#8217; facilities. If the FDA or a comparable foreign regulatory agency does not approve these facilities for the manufacture of our product candidates, or if it withdraws its </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">approval in the future, we may need to find alternative manufacturing facilities, which would negatively impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We and our&#160;third&#8209;party&#160;suppliers continue to refine and improve the manufacturing process, certain aspects of which are complex and unique, and we may encounter difficulties with new or existing processes, particularly as we seek to significantly increase our capacity to commercialize serlopitant. Our reliance on contract manufacturers also exposes us to the possibility that they, or third parties with access to their facilities, will have access to and may appropriate our trade secrets or other proprietary information.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As drug candidates are developed through non&#8209;clinical studies to late&#8209;stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, methods of making drug formulations, and drug formulations, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our drug candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our drug candidates and jeopardize our ability to commence sales and generate revenue.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Key manufacturing steps and materials used in our drug substance and in our drug product are provided by limited numbers of suppliers, and supply shortages or loss of these suppliers could result in interruptions in supply or increased costs.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Certain manufacturing steps and materials used in our serlopitant drug substance and in our serlopitant drug product are currently performed by or purchased from a single outside source. The reliance on a sole or limited number of suppliers could result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">delays associated with redesigning or revalidating a drug product or manufacturing process due to a failure to obtain a single source material from an existing validated supplier;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">an inability to obtain an adequate supply of required materials; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reduced control over pricing, quality and delivery time.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have supply agreements in place for certain starting materials of our drug substance and drug products, but do not have in place long term supply agreements. Therefore, the supply of a particular starting material could be terminated at any time without penalty to the supplier. In addition, we may not be able to procure required starting materials from third&#8209;party suppliers at a quantity, quality and cost acceptable to us. Any interruption in the supply of single source starting material could cause us to seek alternative sources of supply or manufacture these materials internally. Furthermore, in some cases, we are relying on our third&#8209;party collaborators to procure supply of necessary materials. If the supply of any materials for our drug product is interrupted, materials from alternative suppliers may not be available in sufficient volumes or at acceptable quality levels, or at acceptable cost within required timeframes, if at all, to meet our needs or those of our third&#8209;party collaborators. This could delay our ability to complete clinical trials and obtain approval for commercialization and marketing of our product candidates, causing us to incur additional costs, delay new product introductions, or lose sales, and could harm our reputation.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Investigator sponsored trials of serlopitant may produce results and safety signals that are beyond our control and impact our development and commercialization of serlopitant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Serlopitant has been evaluated in a 14&#8209;patient exploratory investigator sponsored study at Stanford University as a potential treatment to reduce pruritus associated with epidermolysis bullosa, a rare primarily pediatric skin condition. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may in the future choose to permit other investigators to evaluate serlopitant or future product candidates in other investigator sponsored studies. These studies have the potential to result in serious adverse events or the identification of other undesirable side effects, or unexpected characteristics of serlopitant or other product candidates, which could adversely impact our development programs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell serlopitant, if approved, or any future product candidates or generate product revenue.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We currently do not have a sales organization. In order to commercialize serlopitant, if approved, we must build our marketing, sales, distribution, managerial and other non&#8209;technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If serlopitant receives regulatory approval, we expect to establish a specialty sales organization with technical expertise and supporting distribution capabilities to commercialize it to dermatologists and possibly also to pediatricians and primary care physicians or to pulmonologists and allergists, which will be expensive and time consuming. We have no prior experience in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, provide adequate training to sales and marketing personnel, gain access to physicians or persuade adequate numbers of physicians to prescribe serlopitant, if approved, or any future drugs, and effectively manage a geographically dispersed sales and marketing team. Our efforts to commercialize serlopitant on our own may also be impacted by the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines, and any unforeseen costs and expenses associated with creating an independent sales and marketing organization. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales organization and distribution systems or in lieu of our own sales organization and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize serlopitant. If we are not successful in commercializing serlopitant or any future product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we would incur significant additional losses.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If we breach our license agreement for serlopitant, we could lose the ability to continue the development and commercialization of our product. Merck also retains rights to serlopitant in specific fields.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In December 2012, we entered into a license agreement with Merck to obtain exclusive worldwide rights to research, develop, manufacture, market and sell serlopitant, other than for the treatment or prevention of nausea and vomiting. This agreement requires us to use commercially reasonable efforts to develop and commercialize serlopitant, make timely milestone payments, provide certain information regarding our activities with respect to such products, maintain the confidentiality of information we receive from Merck and indemnify Merck with respect to our development and commercialization activities under the terms of the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If we fail to meet these obligations, Merck has the right to terminate our exclusive license and upon the effective date of such termination, has the right to re&#8209;obtain the licensed technology as well as aspects of any intellectual property controlled by us and developed during the period the agreement was in force that relate to the licensed technology. This means that Merck could effectively take control of the development and commercialization of serlopitant after an uncured, material breach of our license agreement by us. This would also be the case if we voluntarily terminate the agreement. While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under the patents licensed to us, we may not be able to do so in a timely manner, at an acceptable cost or at all. Any uncured, material breach under the license could result in our loss of exclusive rights and may lead to a complete termination of our product development and any commercialization efforts for serlopitant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Merck could also develop serlopitant for treatment of nausea or vomiting, or license these rights to a third party. Development of serlopitant in other fields could increase the possibility of identification of adverse safety results that impact our development of serlopitant for pruritus associated with dermatologic conditions and refractory chronic cough. In addition, if approved, commercialization of serlopitant in other fields could result in an increased threat of off&#8209;label use to compete with the sale of serlopitant to treat these indications.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We depend on our collaborative relationship with JT Torii for the development and commercialization of serlopitant in Japan. The collaboration relationship with JT Torii or any other collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize serlopitant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have a license and collaboration agreement with JT Torii under which we have granted JT Torii the rights to develop and commercialize products containing serlopitant in Japan in exchange for an up&#8209;front payment and potential future development, regulatory and commercial milestone payments and royalties based on future sales of licensed product in Japan.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may seek additional collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization of serlopitant. We may enter into these arrangements on a selective basis depending on the merits of retaining commercialization rights ourselves compared to entering into selective collaboration arrangements with leading pharmaceutical or biotechnology companies for serlopitant internationally and possibly also in the United States. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our ability to generate revenues from our collaboration arrangement with JT Torii will depend on JT Torii&#8217;s ability to successfully perform the functions assigned to it in the arrangement, and accordingly, any failure by JT Torii to develop and commercialize serlopitant could adversely affect our cash flows. Similarly, the success of future collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">When entering collaboration arrangements, such as that with JT Torii, we are subject to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial or abandon products, repeat or conduct new clinical trials, require a new formulation of products for clinical testing, may decide not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to their acquisition of competitive products or their internal development of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">any safety issues or adverse side effects that result from trials conducted by a collaborator will adversely impact our ability to obtain regulatory approval for serlopitant or any other product we may develop in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">any failure by a collaborator to demonstrate efficacy of serlopitant, or any potential future product candidate, in its clinical trials could decrease the perceived likelihood of success for our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters may lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">collaboration arrangements are complex and time consuming to negotiate, document and implement, and we may not be successful in our efforts to establish and implement collaborations or other alternative arrangements should we so chose to enter into such arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party and any such termination or expiration would adversely affect us financially and could harm our business reputation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">collaboration agreements may be terminated and, if terminated, may result in delays or the need for a new collaborator or additional capital to pursue further development or commercialization of serlopitant or other future product candidates in certain markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">terms of any collaborations or other arrangements that we may establish may not be favorable to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">we will face, to the extent that we decide to enter into collaboration agreements, significant competition in seeking appropriate collaborators;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party and any such termination or expiration could adversely affect us financially and could harm our business reputation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">collaborators may own or co&#8209;own intellectual property covering products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">disputes may arise with respect to the ownership of any intellectual property developed pursuant to our collaborations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">collaborators&#8217; sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">adverse regulatory determinations or other legal action may interfere with the ability of a collaborator to conduct clinical trials or other development activity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">one or more collaborator may be subject to regulatory or legal action resulting from the failure to meet healthcare industry compliance requirements in the conduct of clinical trials or the promotion and sale of products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">collaboration arrangements could be adversely impacted by changes in collaborators&#8217; key management personnel and other personnel that are administering collaboration agreements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Additionally, JT Torii will be conducting clinical trials of serlopitant under our collaboration agreement. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If serious adverse events or other undesirable side effects, or unexpected characteristics of serlopitant, are observed in these trials, it may adversely affect or delay our clinical development of serlopitant, and the occurrence of these events would have a material adverse effect on our business.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The biopharmaceutical industry is intensely competitive and is subject to rapid and significant change. We face competition from other pharmaceutical and biotechnology companies, research institutions, and other organizations, particularly companies that develop and market pharmaceutical products for dermatologic and respiratory conditions. Our commercial potential may be limited by other companies that develop and sell other novel products that are effective for our target indications, or that may be more effective, safer or cost less than serlopitant. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Although there are currently no approved drugs specifically indicated for pruritus associated with atopic dermatitis, psoriasis or prurigo nodularis, either in the United States or in Europe, we may face competition from</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;those companies that are developing drugs specifically to treat pruritus associated with a variety of underlying dermatologic or systemic conditions, companies that are developing drugs specifically to treat chronic cough, companies that are developing and marketing other NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists for pruritus or other conditions, that, when approved, could be used off&#8209;label to treat pruritus or cough, and companies that currently market or are developing treatments intended directly to treat the underlying disease condition in atopic dermatitis, psoriasis, or prurigo nodularis that have also been shown to have anti&#8209;pruritic effects.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We are aware of other companies targeting pruritus or chronic cough as the primary outcome measure in United States clinical studies of drugs. There are multiple companies developing products at varying stages of development specifically intended to treat pruritus including: Vanda Pharmaceuticals, Trevi Therapeutics, Galderma, Sienna Biopharmaceuticals, Tioga</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, Nerre Therapeutics, Opko Health,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and Cara Therapeutics. In addition, Merck, GlaxoSmithKline, and Nerre Therapeutics are developing therapeutic treatments for chronic cough. Of these companies, Vanda Opko and Nerre are developing NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists for indications t</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">hat may compete directly with serlopitant.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;Other companies, including Tesaro and Merck, are also marketing or developing NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists for other indications and could compete with serlopitant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Even if serlopitant receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If serlopitant receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third&#8209;party payors and others in the medical community. If serlopitant does not achieve an adequate level of acceptance, we may not generate significant revenue and we may not become profitable. The degree of market acceptance of serlopitant, if approved for commercial sale, will depend on a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">its efficacy, safety and potential advantages compared to alternative treatments;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to offer serlopitant for sale at competitive prices;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the convenience and ease of administration compared to alternative treatments;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the willingness of the target patient population to try new treatments and of physicians to prescribe these treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the risk that a competitor product may treat both the underlying condition and the associated pruritus;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to hire and retain a sales force in the United States;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to attract and retain potential commercialization collaborators in markets outside of the United States if we choose to do so;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the strength of our marketing and distribution support;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the availability of third&#8209;party coverage and adequate reimbursement;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the willingness of patients to pay out of pocket for serlopitant to the extent it is not reimbursed by third&#8209;party payors;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the prevalence and severity of any side effects; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">any restrictions on the use of serlopitant together with other medications.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If coverage and adequate reimbursement from third-party payors are not available, it may make it difficult for us to sell serlopitant profitably.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our ability to commercialize serlopitant successfully will depend in part on the extent to which governmental authorities, private health insurers and other third&#8209;party payors establish adequate coverage and reimbursement for it. Patients who are prescribed treatments for their conditions and providers furnishing such services generally rely on third&#8209;party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of serlopitant.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Significant uncertainty exists as to the coverage and reimbursement status of newly approved products. A trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third&#8209;party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. Third&#8209;party payors also are increasingly challenging the effectiveness of and prices charged </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">for medical products and services, including requiring companies to demonstrate the comparative effectiveness of a new therapy against other types of therapies that are available. The clinical trials we have conducted and plan to conduct on serlopitant test serlopitant&#8217;s performance against a placebo. Third&#8209;party payors may request additional trials to demonstrate comparative effectiveness. Such trials would be expensive and time consuming, and the results are uncertain. As a result of these cost containment measures, coverage and reimbursement may not be available for serlopitant when it is approved for commercialization, and, even if available, the level of reimbursement may not be sufficient enough for successful commercialization of serlopitant or may significantly limit our revenue or profits, if any.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In the United States, private third&#8209;party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. However, no uniform policy requirement for coverage and reimbursement for products exists among third&#8209;party payors and coverage and reimbursement can differ significantly from payor to payor. Each plan determines whether or not it will provide coverage, what amount it will pay, and with respect to pharmaceutical products, on what tier of its formulary such product will be placed. The position of a prescription drug on a formulary generally determines the&#160;co&#8209;payment&#160;that a patient will need to make to obtain the product and can strongly influence the adoption of a product by patients and physicians. Each plan may separately require us to provide scientific and clinical support for the use of our products and, as a result, the coverage determination process is often a time&#8209;consuming and costly process with no assurance that coverage and adequate reimbursement will be applied consistently or obtained at all. Our inability to obtain coverage and adequate reimbursement promptly from both government&#8209;funded and private payors for any approved products that we develop could significantly harm our operating results, our ability to raise capital needed to commercialize our product candidates and our overall financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Serlopitant may cause undesirable side effects or have other properties that could delay or prevent its regulatory approval or result in significant negative consequences following marketing approval, if any. The number of patients exposed to serlopitant treatment and the average exposure time in the clinical development program may be inadequate to detect rare adverse events that may only be detected once serlopitant is administered to more patients and for greater periods of time.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Undesirable side effects caused by serlopitant could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Serlopitant has been dosed in more than 1,000 individuals across multiple completed Phase 1 and Phase 2 clinical trials and has been shown to be well&#8209;tolerated, including when administered to patients in a clinical trial for up to one year, and in shorter trials at much higher doses than our current planned therapeutic dose. However, patients may experience adverse reactions when using serlopitant. In our clinical trials, the most commonly reported treatment&#8209;emergent adverse events across all completed Phase 2 studies were nasopharyngitis, urinary tract infection, diarrhea and headache. Although we have not seen any evidence of these reactions causing a safety concern in our clinical&#160;programs, it is possible that the FDA may ask for additional data regarding any adverse events seen in our trials. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Results of our future trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval for our product candidate for any or all targeted indications. The drug&#8209;related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Additionally, clinical trials by their nature utilize a sample of the potential patient population. However, with a limited number of subjects and limited duration of exposure, we cannot be fully assured that rare and severe side effects of serlopitant may only be uncovered with a significantly larger number of patients exposed to the drug. If one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">regulatory authorities may withdraw approvals of such product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">regulatory authorities may require additional warnings on the label;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">we could be sued and held liable for harm caused to patients; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our reputation may suffer.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We must successfully manage multiple complex clinical trials simultaneously while growing our business.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We currently have three ongoing Phase 2 clinical trials of serlopitant and we plan to initiate two Phase 3 clinical trials in the second quarter of 2018. If the results of our Phase 2 clinical trials are promising, we plan to rapidly advance serlopitant into Phase 3 clinical trials in up to two additional dermatologic conditions and refractory chronic cough. As of December 31, 2017, we had 32 employees. In order to manage our operations, clinical trials, regulatory filings, manufacturing and supply activities, marketing and commercialization activities for serlopitant or any future product candidates, we will need to continue to expand our managerial, operational, finance, systems, facilities and other resources. To effectively execute our strategy we must:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">manage all of our clinical trials, which are being conducted at multiple trial sites globally through multiple third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">manage our internal development efforts effectively while carrying out our contractual obligations to third parties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">expand our general and administrative and sales and marketing organizations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">identify, recruit, retain, incentivize and integrate additional employees;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">continue to improve our operational, legal, financial and management controls, reporting systems and procedures.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Inability to effectively expand or manage our personnel and other resources, and complexities or unforeseen expenses or setbacks associated with managing our clinical trials and other activities, could delay or prevent completion of our planned clinical trials, the commercialization of serlopitant or any future product candidates, or the successful expansion of our product pipeline. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We are highly dependent on the services of our senior management and our ability to attract and retain qualified personnel.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified personnel. In particular, we are highly dependent upon our experienced senior management, including Steven Basta, Chief Executive Officer, Paul Kwon, M.D., Chief Medical Officer and Kristine Ball, Senior Vice President, Corporate Strategy and Chief Financial Officer. The loss of services of any of these individuals could materially adversely impact our ability to sustain or grow our operations. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Although we have not historically experienced unique difficulties attracting and retaining qualified employees, we could experience such problems in the future. For example, competition for qualified personnel in the biotechnology and pharmaceuticals field is intense due to the limited number of individuals who possess the skills and experience required by our industry. In addition to the competition for personnel, the San Francisco Bay Area in particular is characterized by a high cost of living. We will need to hire additional personnel as we expand our clinical development and commercial activities, and we may be required to expend significant financial resources in our employee recruitment and retention efforts. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output or other proprietary knowledge. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We may not be successful in our efforts to obtain regulatory approval of serlopitant in multiple indications concurrently or at all. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">One element of our strategy is to seek approval for and commercialize serlopitant for pruritus associated with multiple dermatologic conditions. If our planned Phase 3 clinical trials of serlopitant for pruritus associated with prurigo nodularis and any Phase 3 clinical trials we may initiate for pruritus associated with atopic dermatitis and psoriasis following the completion of our Phase 2 clinical trials for such indications, are successfully completed, and such clinical trials demonstrate efficacy and safety of the same dosage form and route of administration of serlopitant in more than one indication at approximately the same time, we may seek FDA approval concurrently for the treatment of pruritus in multiple indications. There can be no assurance that we will successfully initiate any Phase 3 clinical trials for pruritus associated with atopic dermatitis and psoriasis, or that any of the Phase 3 clinical trials that we do initiate will be completed in time to permit this, or that the FDA will review or approve multiple indications simultaneously. It is possible that our strategy of pursuing multiple indications may distribute our activities in a manner that is less advantageous than a strategy that may focus on fewer indications or a single indication. It is possible that the data from trials in multiple indications could adversely affect the regulatory review of serlopitant as compared with review for a single indication. The FDA may not accept our submission in a single NDA application and we may not be able to seek approval of multiple indications for review at the same time, which could increase the time and expense required to obtain approval of multiple indications and delay the launch of one or more of our planned indications.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We may have chosen indications for serlopitant development that are more difficult or have less commercial potential than other possible indications.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Because we have limited financial and management resources, we are focusing on development programs for specific indications. As such, we are currently primarily focused on the development of serlopitant for the treatment of pruritus associated with several dermatologic conditions and refractory chronic cough. As a result, we may forego or delay pursuit of opportunities in other indications, or with other drug candidates that we may identify or that may be available, that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on profitable market opportunities. Our spending on current and future development programs and drug candidates for specific indications may not yield any commercially viable indication. If we do not accurately evaluate the commercial potential or target market for a particular indication for serlopitant, or for any other drug candidate, we may relinquish valuable rights to that drug candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If we seek and obtain approval to commercialize serlopitant outside of the United States, a variety of risks associated with international operations could materially adversely affect our business.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If serlopitant is approved for commercialization outside the United States, we may choose to commercialize it ourselves or enter into agreement with third parties to do so. For example, our agreement with JT Torii gives them rights to commercialize serlopitant in Japan. If we chose to commercialize internationally, we expect that we will be subject to additional risks, including:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">different regulatory requirements for drug approvals in foreign countries;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">differing United States and foreign drug import and export rules;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">different protection for intellectual property rights in foreign countries;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">unexpected changes in tariffs, trade barriers and regulatory requirements;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">different reimbursement systems, and different competitive drugs indicated to treat pruritus and refractory chronic cough;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;&#160;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">foreign taxes, including withholding of payroll taxes;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">workforce uncertainty in countries where labor unrest is more common than in the United States;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">potential liability resulting from development work conducted by these distributors; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of serlopitant or any future product candidates that we may develop.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We face an inherent risk of product liability exposure related to the testing of serlopitant in human clinical trials and will face an even greater risk if we sell commercially any drugs that we may develop. If we cannot successfully defend ourselves against claims that serlopitant causes injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">delays in clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">decreased demand for serlopitant, if approved for marketing;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">injury to our reputation and significant negative media attention;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">withdrawal of clinical trial participants;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">significant costs to defend the related litigation;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">substantial monetary awards paid to trial participants or patients;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">loss of revenue;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reduced resources of our management to pursue our business strategy; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the inability to commercialize any drugs that we may develop.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We currently hold $7.0&#160;million in product liability insurance coverage in the aggregate, with a per incident limit of $7.0&#160;million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our drug candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our research and development activities and our third&#8209;party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product and product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean&#8209;up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third&#8209;party manufacturers for handling and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Significant disruptions of information technology systems or breaches of data security could materially adversely affect our business, results of operations and financial condition.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third&#8209;party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber&#8209;attacks or cyber&#8209;intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The risk of a security breach or disruption, particularly through cyber&#8209;attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Moreover, if a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws, if applicable, including the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Clinical Health Act of 2009, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our corporate headquarters and other facilities are located in the San Francisco Bay Area, which in the past has experienced severe earthquakes. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business&#160;for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to Our Intellectual Property&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We may become subject to claims alleging infringement of third parties&#8217; patents or proprietary rights and/or claims seeking to invalidate our patents, which would be costly, time consuming and, if successfully asserted against us, delay or prevent the development and commercialization of serlopitant or any future product candidates.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">There have been many lawsuits and other proceedings asserting patents and other intellectual property rights in the pharmaceutical and biotechnology industries. We cannot assure you that serlopitant or any future product candidates will not infringe existing or future third&#8209;party patents. Because patent applications can take many years to issue and may be confidential for 18&#160;months or more after filing, there may be applications now pending of which we are unaware and which may later result in issued patents that we may infringe by commercializing serlopitant or future product candidates. Moreover, we may face claims from non&#8209;practicing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect. We may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of serlopitant.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may be subject to third&#8209;party claims in the future against us or our collaborators that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing a third&#8209;party&#8217;s patents. We may be required to indemnify future collaborators against such claims. If a patent&#160;infringement suit were brought against us or our collaborators, we or they could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we or our collaborators may choose to seek, or be required to seek, a license from the third&#8209;party and would most likely be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we or our collaborators were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or forced to redesign it, or to cease some aspect of our business operations if, as a result of actual or threatened patent infringement claims, we or our collaborators are unable to enter into licenses on acceptable terms. Even if we are successful in defending against such claims, such litigation can be expensive and time consuming to litigate and would divert management&#8217;s attention from our core business. Any of these events could harm our business significantly.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition to infringement claims against us, if third parties prepare and file patent applications in the United States that also claim technology similar or identical to ours, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office, or the USPTO, to determine which party is entitled to a patent on the disputed invention. We may also become involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology. Since patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If our intellectual property related to serlopitant or any future product candidates is not adequate, we may not be able to compete effectively in our market.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to serlopitant and our development programs. Patents covering the composition of matter for serlopitant will expire in 2025, subject to potential extensions, where available, including, potential extension of up to five years in the United States. Patents and patent applications, if issued, covering methods&#8209;of&#8209;use for serlopitant to treat pruritus will expire in 2033 in the United States and 2034 in foreign countries. We have filed a U.S. patent application covering methods&#8209;of&#8209;use of serlopitant to treat refractory chronic cough, but there can be no assurance that such patent will issue. The expiration of our patents will limit our ability to profit from the commercialization of serlopitant. Furthermore, any disclosure to or misappropriation by third parties of our confidential or proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own, co&#8209;own, or license may fail to result in issued patents in the United States or in foreign countries. Even if patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the USPTO may be subject to third&#8209;party challenges such as (without limitation) re&#8209;examination proceedings, post&#8209;grant review, or </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">inter partes</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;review, and patents granted by the European Patent Office may be opposed by any person within nine months from the publication of the grant. Similar proceedings are available in other jurisdictions, and in some jurisdictions third parties can raise questions of validity with a patent office even before a patent has granted. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. For example, a third&#8209;party may develop a competitive product that provides therapeutic benefits similar to serlopitant but has a sufficiently different composition to fall outside the scope of our patent protection. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to serlopitant or any future product candidates is successfully challenged, then our ability to commercialize serlopitant or any future product candidates could be negatively affected, and we may face unexpected competition that could have a material adverse impact on our business. Further, if we encounter delays&#160;in our clinical trials, the period of time during which we could market serlopitant or any future product candidates under patent protection would be reduced.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Even where laws provide protection, costly and time&#8209;consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. If we or one of our future collaborators were to initiate legal proceedings against a third party to enforce a patent covering serlopitant or one of our future products, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non&#8209;enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability against our intellectual property related to serlopitant, we would lose at least part, and perhaps all, of the patent protection on serlopitant. Such a loss of patent protection would have a material adverse impact on our business. Moreover, our competitors could counterclaim that we infringe their intellectual property, and some of our competitors have substantially greater intellectual property portfolios than we do.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We also rely on trade secret protection and confidentiality agreements to protect proprietary know&#8209;how that may not be patentable, processes for which patents may be difficult to obtain and/or enforce and any other elements of our product development processes that involve proprietary know&#8209;how, information or technology that is not covered by patents. Although we require all of our employees to assign their inventions to us, and endeavor to execute confidentiality agreements with all of our employees, consultants, advisors and any third parties who have access to our proprietary know&#8209;how, information or technology, we cannot be certain that we have executed such agreements with all parties who may have helped to develop our intellectual property or who had access to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our proprietary information, nor can we be certain that our agreements will not be breached. We cannot guarantee that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide&#8209;ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The USPTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. Noncompliance with these requirements can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We have not yet registered trademarks for a commercial trade name for serlopitant in the United States or elsewhere and failure to secure such registrations could adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have not yet registered trademarks for a commercial trade name for serlopitant in the United States or elsewhere. During trademark registration proceedings, our trademark application may be rejected. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties can oppose pending trademark applications and seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use with our product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We may not be able to enforce our intellectual property rights throughout the world.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market serlopitant or any future products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain and enforce adequate intellectual property protection for our technology.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If we are unable to protect the confidentiality of our proprietary information and know&#8209;how, the value of our technology and products could be adversely affected.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may not be able to protect our proprietary information and technology adequately. Although we use reasonable efforts to protect our proprietary information, technology, and&#160;know&#8209;how,&#160;our employees, consultants, contractors and outside scientific advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third party illegally obtained and is using any of our proprietary information, technology or&#160;know&#8209;how&#160;is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect proprietary information, technology and know&#8209;how. We rely, in part, on&#160;non&#8209;disclosure&#160;and confidentiality agreements with our employees, consultants and other parties to protect our proprietary information, technology and know&#8209;how. These agreements may be breached and we may not have adequate remedies for any breach. Moreover, others may independently develop similar or equivalent proprietary information, and third parties may otherwise gain access to our proprietary knowledge.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self&#8209;executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to Government Regulation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">The regulatory approval process is lengthy, time-consuming, and highly uncertain, and we may experience significant delays and may not obtain regulatory approval for the commercialization of serlopitant or any future product candidates.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, which regulations differ from country to country. We currently have no products approved for sale, and we may never obtain regulatory approval to commercialize serlopitant. Neither we nor any current or future collaborator is permitted to market serlopitant or any future product candidate in the United States or in any foreign countries until we or they receive approval of an NDA from the FDA or marketing </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">authorization from the applicable regulatory authorities of such jurisdictions. We have not submitted an application or obtained marketing approval for serlopitant anywhere in the world. Obtaining regulatory approval of an NDA can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and other applicable United States and foreign regulatory requirements may subject us to administrative or judicially imposed sanctions or other actions, including:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">warning or untitled letters;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">civil and criminal penalties;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">injunctions;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">withdrawal of regulatory approval of products;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">product seizure or detention;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">product recalls;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">total or partial suspension of production; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">refusal to approve pending NDAs or supplements to approved NDAs.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Prior to obtaining approval to commercialize a drug candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well&#8209;controlled clinical trials, and to the satisfaction of the FDA or other foreign regulatory agencies, that such drug candidate is safe and effective for its intended uses. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The number of non-clinical studies and clinical trials that will be required for FDA approval varies depending on many factors, including the drug candidate, the disease or condition that the drug candidate is designed to address, and results of non-clinical studies and clinical trials of the drug candidate. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Even if we believe the non&#8209;clinical or clinical data for our drug candidates is promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering drug candidates to humans may produce undesirable side effects, which could interrupt, delay or halt&#160;clinical trials and result in the FDA or other regulatory authorities denying approval of a drug candidate for any or all targeted indications.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Regulatory approval of an NDA is not guaranteed, and the approval process is expensive and may take several years. The FDA also has substantial discretion in the approval process and we may encounter matters with the FDA that requires us to expend additional time and resources and delay or prevent the approval of our product candidates. For example, the FDA may require us to conduct additional studies or trials for serlopitant either prior to or post&#8209;approval, such as additional drug&#8209;drug interaction studies or safety or efficacy studies or trials, or it may object to elements of our clinical development program such as the number of subjects in our current clinical trials from the United States. The FDA can delay, limit or deny approval of a drug candidate for many reasons, including, but not limited to, the following:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">a drug candidate may not be deemed safe or effective;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">FDA officials may not find the data from non&#8209;clinical studies and clinical trials sufficient;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the FDA might not approve our third&#8209;party manufacturers&#8217; processes or may find objectionable conditions at our third&#8209;party manufacturers&#8217; facilities that must be corrected before our drug candidate can be approved; or&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the FDA may change its approval policies or adopt new regulations.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If serlopitant or any future product candidate fails to demonstrate safety and efficacy in clinical trials or does not gain regulatory approval, our business and results of operations will be materially and adversely harmed. Additionally, if the FDA requires that we conduct additional clinical studies, places limitations on serlopitant in our label, delays approval to market serlopitant or limits the use of serlopitant, our business and results of operations may be harmed.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Even if we receive regulatory approval of serlopitant or any future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Any regulatory approvals or other marketing authorizations we obtain for serlopitant or any future product candidates may be subject to limitations on the indicated uses for which the product may be marketed or the conditions of approval or marketing authorization, or contain requirements for potentially costly post&#8209;market testing and surveillance to monitor the safety and efficacy of the product candidate. In addition, if the FDA or a comparable foreign regulatory authority authorizes our product candidates for marketing, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and record keeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post&#8209;marketing information and reports, registration, as well as continued compliance with cGMPs, and GCP requirements for any clinical trials that we conduct post&#8209;approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third&#8209;party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">restrictions on the marketing or manufacturing of our product, withdrawal of the product from the market, or product recalls;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">fines, warning or untitled letters or holds on clinical trials;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">refusal by the FDA to accept new marketing applications or supplements, approve or otherwise authorize for marketing pending applications or supplements to applications filed by us or current or future collaborators or suspension or revocation of approvals or other marketing authorizations;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">product seizure or detention, or refusal to permit the import or export of our product; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">injunctions or the imposition of civil or criminal penalties.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, in December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and devices and to spur innovation, but its ultimate implementation is unclear. In addition, in August 2017, the FDA Reauthorization Act was signed into law, which reauthorized the FDA&#8217;s user fee programs and included additional drug and device provisions that build on the Cures Act. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">may not obtain marketing approval or </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third&#8209;party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other healthcare funding, and applying new payment methodologies. For example, in March 2010, the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers&#8217; outpatient drugs coverage under Medicare Part D; subjected drug manufacturers to new annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs; imposed a new federal excise tax on the sale of certain medical devices; created a new Patient Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; created the Independent Payment Advisory Board, which, once empaneled, will have authority to recommend certain changes to the Medicare program that </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">could result in reduced payments for prescription drugs; and established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. The Trump administration and members of the U.S. Congress have indicated that they may continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the Affordable Care Act. Most recently, the Tax Cuts and Jobs Acts was enacted, which, among other things, removes penalties for not complying with the individual mandate to carry health insurance. It is uncertain the extent to which any such changes may impact our business or financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, we cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. Notably, on January&#160;30, 2017, President Trump issued an Executive Order, applicable to all executive agencies, including the FDA, that requires that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the &#8220;two&#8209;for&#8209;one&#8221; provisions. This Executive Order includes a budget neutrality provision that requires the total incremental cost of all new&#160;regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the Executive Order requires agencies to identify regulations to offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new regulation or repealed regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within the Office of Management and Budget, or OMB, on February&#160;2, 2017, the administration indicates that the &#8220;two&#8209;for&#8209;one&#8221; provisions may apply not only to agency regulations, but also to significant agency guidance documents. In addition, on February&#160;24, 2017, President Trump issued an executive order directing each affected agency to designate an agency official as a &#8220;Regulatory Reform Officer&#8221; and establish a &#8220;Regulatory Reform Task Force&#8221; to implement the&#160;two&#8209;for&#8209;one provisions and other previously issued executive orders relating to the review of federal regulations, and on September 8, 2017, the FDA published notices in the Federal Register soliciting broad public comment to identify regulations that could be modified in compliance with these Executive Orders. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We expect that any regulatory approval to market serlopitant in the United States will be limited by indication. If we fail to comply or are found to be in violation of FDA and other regulations restricting the promotion of serlopitant for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If our clinical trials are successful, we intend to seek approval to market serlopitant for the treatment of pruritus associated with specified dermatologic conditions, as well as for refractory chronic cough. We do not have plans to seek approval of serlopitant for any other indication at this time, including for the treatment of pruritus associated with any dermatologic condition other than atopic dermatitis, psoriasis or prurigo nodularis. If we obtain regulatory approval to market serlopitant with an indication statement for the treatment of one or more of these indications, we will likely be prohibited from marketing serlopitant using any promotional claims relating to treatment of pruritus generally. Marketing of serlopitant may also be limited by regulatory authorities based on use as a monotherapy or adjuvant, concomitant medications, severity of pruritus and other factors.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA and other government agencies. While serlopitant is being studied in pruritus associated with each of atopic dermatitis, psoriasis and prurigo nodularis, as well as refractory chronic cough, serlopitant may not be promoted for uses that are not approved in the labeling by the FDA or EMA. Physicians may nevertheless prescribe serlopitant off&#8209;label to their patients in a manner that is inconsistent with the approved label. We intend to implement compliance and training programs designed to ensure that our sales </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">and marketing practices comply with applicable regulations. Notwithstanding these programs, the FDA or other government agencies may allege or find that our practices constitute prohibited promotion of serlopitant for unapproved uses. We also cannot be sure that our employees will comply with company policies and applicable regulations regarding the promotion of products for unapproved uses.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In recent years, a significant number of pharmaceutical and biotechnology companies have been the target of inquiries and investigations by various federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for unapproved uses and other sales practices, including the Department of Justice and various U.S. Attorneys&#8217; Offices, the Office of Inspector General of the Department of Health and Human Services, the FDA, the Federal Trade Commission and various state Attorneys General offices. These investigations have alleged violations of various federal and state laws and regulations, including claims asserting antitrust violations, violations of the Federal Food, Drug and Cosmetic Act, the False Claims Act, the Prescription Drug Marketing Act, anti&#8209;kickback laws and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. Many of these investigations originate as &#8220;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">qui tam</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8221; actions under the False Claims Act. Under the False Claims Act, any individual can bring a claim on behalf of the government alleging that a person or entity has&#160;presented a false claim, or caused a false claim to be submitted, to the government for payment. The person bringing a </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">qui tam</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;suit is entitled to a share of any recovery or settlement. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Qui tam</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;suits, also commonly referred to as &#8220;whistleblower suits,&#8221; are often brought by current or former employees. In a </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">qui tam</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;suit, the government must decide whether to intervene and prosecute the case. If it declines, the individual may pursue the case alone.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">qui tam</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;suit and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If approved, serlopitant or any future products may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so we could be subject to sanctions that would materially harm our business.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If we are successful in commercializing serlopitant or any other products, FDA and foreign regulatory agency regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed time frame. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If third-party manufacturers fail to comply with manufacturing regulations, our financial results and financial condition will be adversely affected.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Before our contract manufacturers can begin commercial manufacture of serlopitant, the process and systems used in the manufacture of serlopitant must be approved and each facility must have a compliance status that is acceptable to the FDA and other regulatory authorities. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, pharmaceutical manufacturing facilities are continuously subject to inspection by the FDA and foreign regulatory authorities, before and after product approval. Due to the complexity of the processes used to manufacture pharmaceutical products and product candidates, any potential third&#8209;party manufacturer may be unable to continue to pass or initially pass federal, state or international regulatory inspections in a cost&#8209;effective manner.&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Furthermore, although we do not have day&#8209;to&#8209;day control over the operations of our contract manufacturers, we are responsible for ensuring compliance with applicable laws and regulations, including cGMPs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If a third&#8209;party manufacturer with whom we contract is unable to comply with </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">applicable laws and regulations, including cGMP</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">s, serlopitant may not be approved, or we may be subject to fines, unanticipated compliance expenses, recall or seizure of our products, total or partial suspension of production and/or enforcement actions, including injunctions, and criminal or civil prosecution. These possible sanctions would adversely affect our financial results and financial condition.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our failure to obtain regulatory approvals for serlopitant in foreign jurisdictions would prevent us from marketing our products internationally.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In order to market any product in the European Economic Area, or EEA (which is composed of the 28 Member States of the European Union plus Norway, Iceland and Liechtenstein), and many other foreign jurisdictions, separate regulatory approvals are required. In the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. Before granting the MA, the European Medicines Agency, or EMA, or the competent authorities of the Member States of the EEA make an assessment of the risk&#8209;benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file we may not receive necessary approvals to commercialize our products in any market.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We may be subject to healthcare laws and regulations relating to our business, and could face substantial penalties if we are determined not to have fully complied with such laws, which would have an adverse impact on our business.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third&#8209;party payors, customers and patients, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our products for which we obtain marketing approval. Such laws include:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the U.S. federal Anti&#8209;Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a U.S. healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the U.S. federal Anti&#8209;Kickback Statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti&#8209;Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. government;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;padding-top:0px;text-align:left;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Anti&#8209;Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations, which also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the U.S. Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and requires&#160;applicable manufacturers and group purchasing organizations to report annually to the government ownership and investment interests held by the physicians described above and their immediate family members;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">analogous state and&#160;non&#8209;U.S.&#160;laws and regulations, such as state anti&#8209;kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by&#160;non&#8209;governmental&#160;third&#8209;party payors, including private insurers; state laws that require pharmaceutical and device companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; and state and&#160;non&#8209;U.S.&#160;laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities may conclude that our business practices, including our consulting and advisory board arrangements with physicians and other healthcare providers, some of whom receive stock options as compensation for services provided, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of these or any other health regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Defending against any such actions can be costly, time&#8209;consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In the United States and some&#160;non&#8209;U.S.&#160;jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">post&#8209;approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">For example, in March 2010, the Affordable Care Act was enacted in the United States to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The law has continued the downward pressure on the pricing of medical items and services, especially under the Medicare&#160;program, and increased the industry&#8217;s regulatory burdens and operating costs. Among the provisions of the Affordable Care Act of importance to our potential product candidates are the following:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">an annual, nondeductible fee payable by any entity that manufactures or imports specified branded prescription drugs and biologic agents;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50%&#160;point&#8209;of&#8209;sale&#160;discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">extension of manufacturers&#8217; Medicaid rebate liability to individuals enrolled in Medicaid managed care organizations;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">expansion of eligibility criteria for Medicaid programs in certain states;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">a new Patient&#8209;Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">an independent payment advisory board that will submit recommendations to Congress to reduce Medicare spending if projected Medicare spending exceeds a specified growth rate.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. The new Presidential Administration and U.S. Congress will likely continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the Affordable Care Act. It is uncertain the extent to which any such changes may impact our business or financial condition.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. These changes include the Budget Control Act of 2011, which, among other things, resulted in reductions to Medicare payments to providers of 2% per fiscal year and will remain in effect through 2025; the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years; and the Medicare Access and CHIP Reauthorization Act of 2015, which, among other things, ended the use of the sustainable growth rate formula and provides for a 0.5% update to physician payment rates for each calendar year through 2019, after which there will be a 0% </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">annual update each year through 2025. More recently, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product and medical device pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, in October 2017, California passed a new law, to become effective in January 2019, which will require transparency from biopharmaceutical companies regarding price increases for prescription drugs. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and medical devices to purchase and which suppliers will be included in their prescription drug and other healthcare programs.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We expect that the Affordable Care Act, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we receive for any approved or cleared product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to new requirements or policies, or if we are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We face regulation and potential liability related to privacy, data protection and information security which may require significant resources and may adversely affect our business, operations and financial performance.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The regulatory environment surrounding privacy, data protection and information security is increasingly demanding. We are subject to numerous U.S. federal and state laws and non-U.S. regulations governing the protection of personal and confidential information of our clinical subjects, clinical investigators, employees and vendors/business contacts, including in relation to medical records, credit card data and financial information. Failure to comply with these data protection laws and regulations could result in government enforcement actions and create liability for us (which could include civil and/or criminal penalties), private litigation and/or adverse publicity that could negatively affect our operating results and business.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">For example, HIPAA, as amended by HITECH, and their respective implementing regulations, impose specific requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates. Among other things, HITECH made HIPAA&#8217;s security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating compliance efforts.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Also, the European Parliament has adopted the General Data Protection Regulation (&#8220;GDPR&#8221;), which will become effective on May 25, 2018. This regulation replaces the EU's 1995 data protection directive and shall be the single EU standard across all member states. The GDPR takes a broad view of the types of information that are deemed covered as personal identification information and contains provisions that require businesses to protect such personal data and the privacy of EU citizens for transactions that occur within EU member states. The GDPR also regulates the exportation of personal data outside of the EU. Non-compliance with the GDPR could result in significant penalties. Many companies, including our company, are assessing the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">requirements of the GDPR against current business practices and preparing for compliance with this regulation once it becomes effective.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Risks Related to Our Common Stock and Our Status as a Public Company</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">An active public market for our common stock may not be sustained. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We completed our IPO in January 2018. Prior to that offering, there has been no public market for our common stock, and an active trading market for our shares may not be sustained. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Further, certain of our existing institutional investors, including investors affiliated with certain of our directors, purchased an aggregate of 1,684,118 shares of common stock in our IPO. Accordingly, fewer shares may be actively traded in the public market because these stockholders will be restricted from selling the shares by restrictions under applicable securities laws, which would reduce the liquidity of the market for our common stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The lack of an active market may impair our ability to raise capital and may impair our ability to acquire other businesses, applications or technologies using our shares as consideration.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">The trading price of the shares of our common stock is volatile, and stockholders could incur substantial losses. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our stock price is volatile. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, stockholders may not be able to sell their common stock at or above the price paid for the shares. The market price for our common stock may be influenced by many factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">announcement of clinical trial results, including the anticipated announcement of results from our Phase 2 trial of serlopitant for the treatment of pruritus associated with atopic dermatitis in April 2018, or any additional results we announce;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the commencement or enrollment of our ongoing and planned clinical trials of serlopitant or any future clinical trials we may conduct, or changes in the development status of serlopitant; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">announcements of clinical trials results by competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">adverse results from, delays in or termination of clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">any delay in our regulatory filings for serlopitant or any other drug candidate and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">adverse regulatory decisions, including failure to receive regulatory approval of our drug candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">unanticipated serious safety concerns related to the use of serlopitant or any other drug candidate; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">changes in financial estimates by us or by any securities analysts who might cover our stock; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">future capital raising transactions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">conditions or trends in our industry; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">changes in the market valuations of similar companies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the biopharmaceutical industry; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">announcements by us or our competitors of significant acquisitions, strategic partnerships or divestitures; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">announcements of investigations or regulatory scrutiny of our operations or lawsuits filed against us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">investors&#8217; general perception of our company and our business; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">recruitment or departure of key personnel; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">overall performance of the equity markets; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">trading volume of our common stock; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">significant lawsuits, including patent or stockholder litigation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">general political and economic conditions; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">other events or factors, many of which are beyond our control. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, in the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#8217;s attention and resources from our business. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The trading market for our common stock may be influenced by the research and reports that equity research analysts publish about us and our business. Prior to our IPO, there had not been a public market for our common stock and we did not have research coverage by equity research analysts.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We do not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline. If our operating results fail to meet the forecast of analysts, our stock price will likely decline.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may from time to time issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market after the lock-up and other legal restrictions on resale lapse in connection with our IPO, the market price of our common stock could decline significantly. The lock-up agreements pertaining to that offering will expire July 23, 2018. As of February 28, 2018, there were approximately 23.0 million shares of our common stock outstanding. After the lock-up agreements expire, as of February 28, 2018, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">up to approximately 14.9 million additional shares of common stock will be eligible for sale in the public market, approximately 11.0 million of which shares are held by current directors, executive officers and other affiliates and may be subject to Rule 144 under the Securities Act.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, as of February 28, 2018, approximately 5.5 million shares of common stock are either subject to outstanding options or reserved for future issuance under our equity incentive plans are eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the lock-up agreements and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The holders of approximately 12.6 million shares of our common stock, or approximately 54.7% of our total outstanding common stock as of February 28, 2018, are entitled to rights with respect to the registration of their shares under the Securities Act, subject to vesting schedules and to the lock-up agreements described above. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">a classified board of directors with three&#8209;year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the ability of our board of directors to alter our bylaws without obtaining stockholder approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the required approval of at least 66 2/3% of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the requirement that a special meeting of stockholders may be called only by the chief executive officer or the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We are also subject to the anti&#8209;takeover provisions contained in Section&#160;203 of the Delaware General Corporation Law. Under Section&#160;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third&#8209;party claims against us and may reduce the amount of money available to us.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, as permitted by Section&#160;145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws, any action to interpret, apply, enforce, or determine the validity of our certificate of incorporation or bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We do not currently intend to pay dividends on our common stock, and, consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation in the price of our common stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, stockholders are not likely to receive any dividends on their common stock for the foreseeable future. Since we do not intend to pay dividends, stockholders&#8217; ability to receive a return on their investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of February 28, 2018, our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates will, in the aggregate, beneficially own 63.4% of our outstanding common stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As a result, these persons, acting together, would be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors, any merger, consolidation, sale of all or substantially all of our assets, or other significant corporate transactions. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that certain stockholders may believe are in their best interest.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We are an &#8220;emerging growth company&#8221; and, as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">not being required to hold a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of our IPO, (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non&#8209;affiliates exceeds $700&#160;million as of the prior June&#160;30th, and (2)&#160;the date on which we have issued more than $1.0&#160;billion in non&#8209;convertible debt during the prior three&#8209;year period. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under Section&#160;107(b) of the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, the Sarbanes&#8209;Oxley Act and the rules and regulations of Nasdaq. The Sarbanes&#8209;Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. Commencing with our fiscal year ending December&#160;31, 2018, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting in our Form&#160;10&#8209;K filing for that year, as required by Section&#160;404 of the Sarbanes&#8209;Oxley Act. This will require that we incur substantial additional professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. We have never been required to test our internal control within a specified period, and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We may identify weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If we are not able to comply with the requirements of Section&#160;404 of the Sarbanes&#8209;Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the Securities and Exchange Commission, or SEC, or other regulatory authorities. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">We have broad discretion to determine how to use the funds raised in our IPO of our common stock, and may invest or spend the proceeds in ways with which stockholders do not agree and in ways that may not increase the value of their investment.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our management has broad discretion over the use of proceeds from our IPO. Our stockholders may not agree with our decisions, and our use of the proceeds may not yield any return on their investment. We expect to use the net proceeds to us from that offering, together with our existing cash and cash equivalents: (i) to complete our ongoing Phase&#160;2 clinical trials of serlopitant for prutitus associated with atopic dermatitis and psoriasis, and for refractory chronic cough; (ii) to significantly advance our planned Phase 3 development of serlopitant for pruritus associated with prurigo nodularis; (iii) to supply serlopitant for our clinical trials and for the development and validation of our commercial manufacturing process for serlopitant in preparation for our NDA and Marketing Authorization Application, or MAA submissions; (iv) for a $3.0 million milestone payment to Merck, associated with initiating a Phase 3 clinical trial; and (v) the remainder for personnel expenses, other development activities, including potentially commencing Phase 3 clinical trials for pruritus associated with atopic dermatitis and psoriasis, and for refractory chronic cough, working capital and other general corporate purposes, including the costs of operating as a new public company. Our failure to effectively apply the net proceeds from our IPO could compromise our ability to pursue our growth strategy and we might not be able to yield a significant return, if any, on our investment of these net proceeds. Our stockholders will not have the opportunity to influence our decisions on how to use our net proceeds from that offering.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We might not be able to utilize a significant portion of our net operating loss carryforwards and research and development tax credit carryforwards. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December 31, 2017, we had federal and state net operating loss carryforwards of $44.3 million and $15.0&#160;million, respectively. These carryforwards will begin to expire in 2031 for federal and state purposes, if not utilized before they expire. As of December 31, 2017, we had federal and state research and development tax credit carryforwards of $2.1 million and $0.9 million, respectively. The federal credits begin to expire in 2031 and the California research credits have no expiration dates. These net operating loss and tax credit carryforwards could expire unused and be unavailable if we do not generate sufficient taxable income prior to their expiration. In addition, under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percentage point change, by value, in its equity ownership over a three&#8209;year period, the corporation&#8217;s ability to use its pre&#8209;change net operating loss carryforwards and other pre&#8209;change tax attributes to offset its post&#8209;change income or tax liability may be limited. We have not determined if we have experienced Section&#160;382 ownership changes in the past and if a portion of our net operating loss and tax credit carryforwards are subject to an annual limitation under Sections&#160;382 or 383. In addition, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, including our IPO, some of which may be outside of our control. As a result, even if we earn net taxable income, our ability to use our net operating loss and tax credit carryforwards may be materially limited, which could harm our future operating results by effectively increasing our future tax obligations. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">We will incur increased costs and demands upon management as a result of being a new public company. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As a new public company listed in the United States, we will incur significant additional legal, accounting and other costs. These additional costs could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and the Nasdaq Stock Market, LLC, may increase legal and financial compliance costs and make some activities more time&#8209;consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue&#8209;generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">66</font></div></div><hr style="page-break-after:always"><div><a name="sad6b9d2b97a44f2b95e7be4f7e73b398"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Item 1B. Unresolved Staff Comments.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">None.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">67</font></div></div><hr style="page-break-after:always"><div><a name="s00cc96d1140b46c4a9f33afd0374b017"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Item 2. Properties.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We lease our principal facilities, which consist of approximately 14,000 square feet of office space located in Redwood City, California under a lease that expires in March 2020. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We believe that our existing facilities are adequate for our current needs; however, we may require additional space and facilities as our business expands.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">68</font></div></div><hr style="page-break-after:always"><div><a name="s6dbf1f3bf3f14a8a86e9779a59ba98e2"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Item 3. Legal Proceedings.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We are not currently a party to any material legal proceedings</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">69</font></div></div><hr style="page-break-after:always"><div><a name="s80cc13a04b3c4d7eaebcae28eb903ee3"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Item 4. Mine Safety Disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Not applicable.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">70</font></div></div><hr style="page-break-after:always"><div><a name="sdc06fa56f6124c4db00a7b856d2761ff"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><a name="sc4f00a3495df4cadb8f088d10a61b2c4"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our common stock has been listed on The Nasdaq Global Select Market under the symbol &#8220;MNLO&#8221; since January 24, 2018. Prior to that date, there was no public trading market for our common stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Market Information </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our common stock has been listed on the Nasdaq Global Select market under the symbol &#8220;MNLO&#8221; since our IPO on January 25, 2017. Prior to that date, there was no public trading market for our common stock. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As a result, we have not set forth quarterly information with respect to the high and low sale prices for our common stock for the two most recent fiscal years. From January 25, 2018, our first day of trading on the Nasdaq Global Select Market, to February 28, 2018, the high and low prices for our common stock were $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">39.86</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and $20.50, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Holders of Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of February 28, 2018, there were approximately 26 holders of record of our common stock. This number does not include beneficial owners whose shares are held by nominees in street name.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Dividend Policy</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Recent Sales of Unregistered Securities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following list sets forth information as to all securities we have sold since January 1, 2015, which were not registered under the Securities Act.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:8%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In November 2015, we issued an aggregate of 14,106,583 shares of our Series B Preferred Stock at a price per share of $3.19 in cash.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:8%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In July 2017, we issued an aggregate of 11,854,463 shares of our Series C convertible preferred stock at a price per share of $4.26 in cash.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:8%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We sold an aggregate of 348,295 shares of common stock to employees and directors for cash and other consideration in the aggregate amount of approximately $136,496 upon the exercise of stock options and stock awards.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:8%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">4.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We granted stock options and stock awards to employees, directors and consultants covering an aggregate of 2,856,972 shares of common stock, at a weighted-average exercise price of $3.13 per share.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We claimed exemption from registration under the Securities Act for the sale and issuance of securities in the transactions described in paragraphs (1) and (2) by virtue of Section 4(a)(2) and/or Regulation D promulgated thereunder as transactions not involving any public offering. All of the purchasers of unregistered securities for which we relied on Section 4(a)(2) and/or Regulation D represented that they were accredited investors as defined under the Securities Act. We claimed such exemption on the basis that (a) the purchasers in each case represented that they intended to acquire the securities for investment only and not with a view to the distribution thereof and that they either received adequate information about the registrant or had access, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">through employment or other relationships, to such information and (b) appropriate legends were affixed to the stock certificates issued in such transactions.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We claimed exemption from registration under the Securities Act for the sales and issuances of securities in the transactions described in paragraphs (3) and (4) above under Section 4(a)(2) of the Securities Act in that such sales and issuances did not involve a public offering or under Rule 701 promulgated under the Securities Act, in that they were offered and sold either pursuant to written compensatory plans or pursuant to a written contract relating to compensation, as provided by Rule 701.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Use of Proceeds</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In January 2018, we completed our IPO and issued 8,050,000 shares of our common stock, including the underwriter&#8217;s exercise of their over-allotment option, at an initial offering price to the public of $17.00. We received net proceeds from the IPO of approximately $125.5 million, after deducting underwriting discounts and commissions of approximately $9.6 million and estimated offering costs of approximately $1.5 million. None of the expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to their associates, or to our affiliates. The underwriters were </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Jefferies LLC, Piper Jaffray &amp; Co., Guggenheim Securities LLC</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and JMP Securities LLC. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Shares of our common stock began trading on the Nasdaq Global Select Market on January 25, 2018. The shares were registered under the Securities Act on registration statement on Form S-1 (Registration No.&#160;333-222324), which was declared effective by the SEC on January 24, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We expect to use the proceeds from the IPO to fund our activities related to seeking U.S. regulatory approval, and for working capital and general corporate purposes. There has been no material change in the planned use of proceeds from our IPO as described in our prospectus dated January 24, 2018, filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Stock Performance Graph</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have elected not to include a performance graph in this Annual Report on Form 10-K because the period between the date that our common stock began trading on the Nasdaq Global Select Market and the end of our most recently completed fiscal year is 30 days or less.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We did not purchase any of our registered equity securities during the period covered by this Annual Report on&#160;Form&#160;10-K.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">72</font></div></div><hr style="page-break-after:always"><div><a name="s993D660BB53D501282F43702A818CACD"></a></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Item 6. Selected Financial Data.</font></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following selected financial data is qualified in its entirety by, and should be read in conjunction with the financial statements and the notes thereto included in Part&#160;II, Item&#160;8 and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in Part II, Item&#160;7 of this Report. The selected statements of income data for each of the three years in the period ended December&#160;31, 2017, and the balance sheet data as of December&#160;31, 2017, 2016 and 2015 have been derived from our audited financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:5px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:5px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:5px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(in thousands, except share and per share numbers)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Statements of Operations Data:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Collaboration and license revenue   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">4,582</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Operating expenses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research and development   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">29,007</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,255</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,921</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:32px;text-indent:-16px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">General and administrative   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">5,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,751</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total operating expenses   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">34,175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">15,006</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Loss from operations   </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(29,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(14,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:5px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:5px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Interest income and other expenses, net   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">517</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net loss attributable to common stockholders </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(29,076</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(14,068</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4,608</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net loss attributable to common stockholder per share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(5.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2.82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(0.97</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Weighted-average number of common shares used to compute basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">5,108,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4,987,133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4,735,148</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">73</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:12px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:9px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(in&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Balance Sheet Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Cash, cash equivalents and investments   </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">62,479</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">41,328</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">43,808</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Working capital   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">56,044</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">27,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">43,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total assets   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">66,867</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">42,053</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">43,885</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Convertible preferred stock   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">109,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">59,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">59,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accumulated deficit   </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(59,191</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(30,115</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(16,047</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total stockholders&#8217; deficit   </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(57,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(29,441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(15,953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">74</font></div></div><hr style="page-break-after:always"><div><a name="sB78767A093FD5372B11F8E664F2DF4A3"></a></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><a name="sC73630FC1AA652F2B40CFE0A2C24F910"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We are a late&#8209;stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for the treatment of refractory chronic cough.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R, has the potential to significantly alleviate pruritus and refractory chronic cough symptoms.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Since commencing operations in 2011, we have devoted substantially all of our efforts and financial resources to the clinical development of serlopitant. We have not generated any revenue from product sales and, as a result, we have never been profitable and have incurred net losses in each year since commencement of our operations. As of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, we had an accumulated deficit of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$59.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, primarily as a result of research and development and general and administrative expenses. We incurred net losses of approximately $29.1 million, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$14.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and $4.6 million in the years ended December&#160;31, 2017, 2016 and 2015, respectively. We do not expect to generate product revenue unless and until we obtain marketing approval for and commercialize serlopitant for the treatment of pruritus associated with one or more dermatologic conditions or for refractory chronic cough, and we can provide no assurance that we will ever generate significant revenue or profits.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have financed our operations primarily through private placements of convertible preferred stock, from which we have received net proceeds of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$109.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;through </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, including gross proceeds of $50.5 million from the sale of Series C convertible preferred stock in July 2017, and from an upfront, non&#8209;refundable payment of $11.0 million and a milestone payment of $2.0 million under our August 2016 license and collaboration agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd., together referred to as JT Torii, which we refer to as the Collaboration Agreement. As of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, our cash and cash equivalents and investments totaled </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$62.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. I</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">n January 2018, we completed our initial public offering. We sold 8,050,000 shares of our common stock and received cash proceeds of approximately $125.5 million, net of underwriting commissions and related expenses. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We believe that our existing cash, cash equivalents and investments will be sufficient to fund our planned operations for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. See &#8220;&#8212; Liquidity and Capital Resources.&#8221;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We expect to incur substantial expenditures in the foreseeable future as we advance serlopitant through clinical development, the regulatory approval process and, if approved, commercial launch activities. Specifically, in the near term, we expect to incur substantial expenses relating to our ongoing Phase 2 and planned Phase 3 clinical trials, the development and validation of our commercial manufacturing process for serlopitant, and other development activities including potentially commencing Phase 3 clinical trials for pruritus associated with atopic dermatitis and psoriasis, and for refractory chronic cough. In addition, we expect to pay a $3.0 million milestone payment to Merck upon the initiation of our Phase 3 clinical trials for pruritus associated with prurigo nodularis. Furthermore, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from sales of serlopitant, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back, or discontinue the development and commercialization of serlopitant for one or more indications or delay our efforts to expand our product pipeline. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">75</font></div></div><hr style="page-break-after:always"><div><a name="sD961DCFA8A265A4082537818A29D7CDD"></a></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Components of Operating Results</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have not generated any revenue from the sale of products since our inception and do not expect to generate any revenue from the sale of products in the near future.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Collaboration and License Revenue</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We recognize revenue pursuant to the Collaboration Agreement and our services agreement with JT Torii in connection with the clinical development and commercialization of products covered by the collaboration, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">including non-refundable upfront license fees, contingent consideration payments based on the achievement of defined collaboration milestones and royalties on sales of commercialized products. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under the Collaboration Agreement, we granted to JT Torii the right to develop and commercialize products containing serlopitant in Japan, for the treatment of diseases and conditions other than nausea or vomiting. In exchange, JT Torii paid us an upfront, non&#8209;refundable payment of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$11.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;in August 2016. In addition, we are entitled to receive aggregate payments of up to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$28.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;upon the achievement of specified development and regulatory milestones, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$15.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;upon the achievement of a commercial milestone, as well as tiered royalties from the mid-single digits up to the mid&#8209;teens on sales of licensed products in Japan.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Revenue from the upfront payment is being amortized over the period of performance of the Collaboration Agreement, the period which we expect to provide research and development services to JT Torii. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During the fourth quarter of 2017, the Company achieved a substantive milestone related to the validation of the manufacturing process under the Collaboration Agreement, and recognized revenues of $2.0 million.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On September 1, 2017, we entered into a new services agreement with JT Torii to provide research and development services, including regulatory, chemistry and manufacturing support and related materials, that is distinct from the original Collaboration Agreement. We evaluated the new services agreement and determined that the research and materials delivered to JT Torii represent a separate contractual arrangement that provides standalone value to JT Torii. The fees received under the services agreement are recognized as and when such services are performed by us and JT Torii consumes the benefits of those services.  We have no obligation to provide services unless requested by JT Torii and agreed to by us. We are eligible to receive reimbursement of estimated costs incurred, and payment for research services performed directly by us, at agreed upon rates.  </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Operating Expenses </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Substantially all of our research and development expenses consist of expenses incurred in connection with the development of serlopitant. These expenses include certain payroll and personnel expenses including stock&#8209;based compensation, consulting costs, contract manufacturing costs and fees paid to clinical research organizations or CROs to conduct certain research and development activities on our behalf. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We do not allocate our costs by each indication for which we are developing serlopitant, as a significant amount of our development activities broadly support all indications.&#160; In addition, several of our departments support our serlopitant drug candidate development program and we do not identify internal costs for each potential indication.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;We do not separately track costs incurred in connection with our agreements with JT Torii, which are also included in research and development expenses. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as an expense as the goods are delivered or the related services are performed.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We expense both internal and external research and development expenses as they are incurred. We are focusing substantially all of our resources and development efforts on the development of serlopitant. We expect our research and development expenses to increase during the next few years as we seek to complete our clinical program, pursue regulatory approval of serlopitant in the United States and prepare for a possible commercial launch of serlopitant. Predicting the timing or the final cost to complete our clinical program or validation of our commercial manufacturing and supply processes is difficult and delays may occur because of many factors, including factors outside of our control. For example, if the U.S. Food and Drug Administration or FDA, or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">76</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict when or if serlopitant will receive regulatory approval in the United States with any certainty.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">General and administrative expenses consist principally of personnel&#8209;related costs, including stock&#8209;based compensation, for personnel in executive, finance, business and corporate development, and other administrative functions, professional fees for legal, consulting, accounting services, rent and other general operating expenses not otherwise classified as research and development expenses.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We anticipate that our general and administrative expenses will increase as a result of increased personnel costs, including stock&#8209;based compensation, expanded infrastructure and higher consulting, legal and accounting services associated with maintaining compliance with stock exchange listing and SEC requirements, investor relations costs and director and officer insurance premiums associated with being a public company.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Interest Income and Other Expense, Net</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Interest income consists primarily of interest earned on our investments in corporate notes and government agency notes.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">77</font></div></div><hr style="page-break-after:always"><div><a name="sD97D9C613E495DE389BC7304D7162CF0"></a></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of the Years Ended December 31, 2017 and 2016</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table summarizes our results of operations for the periods indicated (in thousands):</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Increase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Collaboration and license revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">4,582</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">580</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">29,007</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">11,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">17,752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">158</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">5,168</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">3,751</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,417</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">38</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(29,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(14,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(15,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">106</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Interest income and other expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">517</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">253</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">96</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(29,076</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(14,068</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(15,008</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">107</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Collaboration and License Revenue</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Collaboration and license revenue of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$4.6 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;for the year ended December 31, 2017 was primarily due to the allocation of revenue we recognized during the period from the initial upfront payment of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$11.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;under the Collaboration Agreement with JT Torii we entered into in August 2016, as well as $2.0 million in milestone revenue and additional revenue from JT Torii for development support services recognized by us during the period. We had collaboration and license revenue of $0.7 million for the year ended December 31, 2016 related to the Collaboration Agreement.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During the year ended December 31, 2017, research and development expenses increased </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$17.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, or </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">158%</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;as compared to 2016. The increase was primarily due to an increase in clinical trial expenses of $10.9 million, an increase in personnel expenses of $2.3 million as a result of an increase in our employee headcount, as well as an increase of $2.0&#160;million in consulting expenses. For the periods presented, substantially all of our research and development expenses related to our development activity for serlopitant. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During the year ended December 31, 2017, general and administrative expenses increased </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, or </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">38</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">% as compared to 2016. The increase was primarily due to an increase in personnel expenses of $0.8 million as a result of an increase in our employee headcount, as well as an increase of $0.6 million in consulting expenses. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Interest Income and Other Expense, Net</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Interest income and other expense, net was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;for the years ended December 31, 2017 and 2016, respectively, which is related to interest earned on our outstanding investment balances. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">78</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of the Years Ended December&#160;31, 2016 and 2015</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table summarizes our results of operations for the periods indicated (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended <br>December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Increase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"><br></font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#160;% change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Collaboration and license revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,334</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">285</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,751</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,064</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">122</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(14,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(9,724</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">211</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Interest income and other expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">264</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(14,068</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4,608</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(9,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">205</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Not meaningful.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Collaboration and License Revenue</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Collaboration and license revenue of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.7 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;for the year ended December&#160;31, 2016 was entirely due to the allocation of revenue we recognized during the period from the initial upfront payment of $11.0 million under the Collaboration Agreement with JT Torii we entered into in August 2016. We had no collaboration and license revenue for the year ended </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During the year ended December 31, 2016, research and development expenses increased </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$8.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, or </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">285%</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;as compared to 2015. The increase was primarily due to a $5.2 million increase in clinical trial costs, an increase of $1.5 million in personnel expenses </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">as a result of an increase in our employee headcount</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, and a $1.2 million increase in consulting expenses and professional fees. For the years ended December&#160;31, 2016 and 2015, substantially all of our research and development expenses related to our </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">development activity for</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;serlopitant.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During the year ended December 31, 2016, general and administrative expenses increased </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$2.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, or </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">122%</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;as compared to 2015. The increase was primarily due to an increase in personnel expenses of $1.0&#160;million and an increase in consulting expenses and professional fees of $0.9 million incurred as we expanded our operations.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Interest Income and Other Expense, Net</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Interest income </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">and other expense, net</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;for the year ended December&#160;31, 2016, which related to interest earned on our outstanding investment balances. We had no interest income and other expense, net for the year ended </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div><a name="sA47171E4F67D5B2EAB65E5071C4E5A43"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Through December 31, 2017, we have financed our operations primarily through private placements of convertible preferred stock and from payments under the Collaboration Agreement. We received net proceeds of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$109.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;from the sale and issuance of preferred stock through </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, including </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$50.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;received from the sale of our Series C convertible preferred stock in July 2017, net of offering costs. In August 2016, we received an upfront, non-refundable payment of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$11.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;from JT Torii in connection with the entry into the Collaboration Agreement. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, we had cash, cash equivalents and </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">investments of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$62.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;Our cash, cash equivalents and investments are held in money market accounts and investments in corporate notes and government notes.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In January 2018, we completed our initial public offering. We sold 8,050,000 shares of our common stock and received cash proceeds of approximately $125.5 million, net of underwriting commissions and related expenses.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We expect to incur substantial expenditures in the foreseeable future as we advance serlopitant through clinical development, the regulatory approval process and, if approved, commercial launch activities. Specifically, in the near term, we expect to incur substantial expenses relating to our ongoing Phase 2 and planned Phase 3 clinical trials, the development and validation of our commercial manufacturing process for serlopitant, and other development activities including potentially commencing Phase 3 clinical trials for pruritus associated with atopic dermatitis and psoriasis and for refractory chronic cough. In addition, we expect to pay a $3.0 million milestone payment to Merck upon the initiation of our Phase 3 clinical trials for pruritus associated with prurigo nodularis. Furthermore, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We will continue to require additional capital to develop our product candidate and fund operations for the foreseeable future. We may seek to raise capital through private or public equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. We anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the time and cost necessary to complete our ongoing Phase 2 clinical trials for pruritus associated with atopic dermatitis and psoriasis and for refractory chronic cough, our planned Phase 3 clinical trials for pruritus associated with prurigo nodularis as well as any additional current and planned clinical trials of serlopitant;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the number, size and type of any additional clinical trials or studies we may choose to initiate or that we may be required to complete prior to obtaining regulatory approval of serlopitant;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the timing of, and costs involved in, seeking and obtaining approvals from the FDA and comparable foreign regulatory authorities, including the potential by the FDA or comparable regulatory authorities to require that we perform more studies than those that we current expect</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, and the costs of post&#8209;marketing studies that could be required by regulatory authorities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to receive payments under our collaboration with JT Torii, and the timing of receipt of any such payments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the timing of the milestone payments we must make to Merck;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the costs of preparing to manufacture serlopitant on a commercial scale;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to successfully commercialize serlopitant;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the manufacturing, selling and marketing costs associated with serlopitant, including the cost and timing of forming and expanding our sales organization and marketing capabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the degree and rate of market acceptance of any products launched by us or our partners;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the cash requirements of any future acquisitions or discovery of product candidates;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the progress, timing, scope and costs of our non-clinical studies and clinical trials, including the ability to enroll patients in a timely manner for potential future clinical trials;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our need and ability to hire additional personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the emergence of competing technologies or other adverse market developments.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others, rights to serlopitant in certain territories or indications that we would prefer to develop and commercialize ourselves. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">See &#8220;Risk Factors&#8221; for additional risks associated with our substantial capital requirements.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Summary Statement of Cash Flows </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table sets forth the primary sources and uses of cash for each of the periods presented below (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year&#160;Ended <br>December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net cash (used in) provided by:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(28,247</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2,291</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4,183</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(15,065</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(37,490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">49,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">47,718</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Net increase (decrease) in cash</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">6,179</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">(39,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">43,535</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Cash Used In Operating Activities </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Cash used in operating activities for the year ended December&#160;31, 2017 was $28.2 million, primarily due to the net loss of $29.1 million, offset by stock based compensation of $1.5 million and changes in operating assets and liabilities, including an increase in prepaid and other assets of $1.8 million, a decrease in deferred revenue of $1.8 million and an increase in accounts payable and accrued liabilities of $3.6 million.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Cash used in operating activities in 2016 was primarily due an increase of $10.3 million in deferred revenue associated with the upfront cash payment received in August 2016 in connection with the Collaboration Agreement, non&#8209;cash stock&#8209;based compensation expense of $0.6 million, offset by use of funds in our operations that resulted in a net loss of $14.1 million, as well as changes in other operating assets and liabilities, including an increase of $0.6 million in prepaid expenses and an increase in accounts payable and accrued liabilities of $1.4 million. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Cash used in operating activities was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$4.2&#160;million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;for the year ended </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and was primarily due to the use of funds in our operations related to the development of serlopitant and the resulting net loss of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$4.6&#160;million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, offset by a decrease in accrued expenses of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.3&#160;million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Cash Used in Investing Activities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Cash used in investing activities for the year ended December&#160;31, 2017 represented purchases of investments of $64.1&#160;million, offset by proceeds received from maturities and sales of investments of $49.1&#160;million. Cash </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">81</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">used in investing activities for the year ended </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;represented purchases of investments of $55.3&#160;million, offset by proceeds received from maturities and sales of investments of $17.9&#160;million. We had no cash used in investing activities for the year ended </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;">Cash Provided by Financing Activities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During the year ended December 31, 2017 cash provided by financing activities was $50.4 million, consisting primarily of net proceeds from the sale of Series C convertible preferred stock. Cash provided by financing activities was $0 for the year ended December 31, 2016.  Cash provided by financing activities was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$47.7&#160;million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;for the year ended December&#160;31, 2015 consisted primarily of net proceeds from the issuance of Series A and Series B convertible preferred stock.</font></div><div><a name="s70D64FEF2F4D597FAE9A085E0F8203AF"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Contractual Obligations and Commitments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table summarizes our contractual obligations as of December&#160;31, 2017 (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Payments due by period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Less&#160;than <br>1&#160;year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">1&#160;to&#160;3 <br>years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">3&#160;to&#160;5 <br>years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">More than&#160;5 <br>years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Lease obligations, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">848</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In December 2012, we entered into an exclusive worldwide royalty&#8209;free license agreement with Merck for exclusive worldwide rights for the development and commercialization of serlopitant and two other NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists in all human diseases, disorders or conditions, except for the treatment and prevention of nausea or vomiting. We have agreed to make aggregate payments of up to $25.0 million dollars upon the achievement of specified development and regulatory milestones for serlopitant. However, because the achievement of these milestones is not fixed and determinable, such commitments have not been included on our balance sheet or in the Contractual Obligations and Commitments table above. In the near term, upon dosing our first patient in our Phase 3 clinical trials for serlopitant </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">for the treatment of pruritus associated with prurigo nodularis</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, we will be obligated to make a milestone payment of $3.0 million to Merck pursuant to our license agreement, which we anticipate paying from our existing cash resources. For additional information regarding future payments to third parties, including milestone and royalty payments to Merck, please see &#8220;Business&#8212;License and Collaboration Agreements.&#8221;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We enter into contracts in the normal course of business with CROs for clinical trials, non&#8209;clinical studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice, and therefore we believe that our non&#8209;cancelable obligations under these agreements are not material.</font></div><div><a name="sF76F0F48936A52568A65433878877FDA"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Critical Accounting Policies, Significant Judgments and Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">While our significant accounting policies are described in the Notes to our financial statements, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">82</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">To date, our clinical drug candidate, serlopitant, has not been approved for sale by the FDA and we have not generated any revenue from the sale of products. We generate revenue pursuant to the Collaboration Agreement and our services agreement with JT Torii in connection with the clinical development and commercialization of products covered by these agreements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On August 10, 2016, we entered into the Collaboration Agreement with JT Torii. Under the Collaboration Agreement, we granted to JT Torii the rights to develop and commercialize products containing serlopitant in Japan, for the treatment of diseases and conditions other than nausea or vomiting. In exchange, JT Torii paid us an upfront, non&#8209;refundable payment of $11.0 million. In addition, we are entitled to receive aggregate payments of up to $28.0 million upon the achievement of specified development and regulatory milestones, and $15.0 million upon the achievement of a commercial milestone, as well as tiered royalties from the mid-single digits up to the mid&#8209;teens on sales of licensed products in Japan. Our performance obligations under the license agreement include the transfer of intellectual property rights in the form of licenses, obligations to participate on certain development and/or commercialization committees with the collaboration partners and supply manufactured drug product for clinical trials. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We recognize revenue pursuant to the Collaboration Agreement in connection with the clinical development and commercialization of products covered by the collaboration, including non-refundable upfront license fees, contingent consideration payments based on the achievement of defined collaboration objectives and royalties on sales of commercialized products. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Revenue from our Collaboration Agreement is recognized when (i) persuasive evidence of an arrangement exists; (ii) transfer of technology has been completed, services have been performed or products have been delivered; (iii) the fee is fixed and determinable, and (iv) collection is reasonably assured.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">For revenue agreements with multiple elements such as the Collaboration Agreement, we evaluate the agreements in accordance with ASC 605-25 </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue Recognition - Multiple Element Arrangements</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;to identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria including whether the deliverable has standalone value. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Upfront payments for licenses are evaluated to determine if the licensee can obtain standalone value from the license separate from the value of the research and development services and other deliverables in the arrangement to be provided by us. The assessment of multiple-element arrangements also requires judgment in order to determine the allocation of revenue to each deliverable and the appropriate period of time over which the revenue should be recognized. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under the Collaboration Agreement, we have determined that the license does not have standalone value separate from the research and development services because </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">JT Torii cannot resell such license on a standalone basis or use the license with its available resources to obtain any economic value without our participation. T</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">he license and the services are combined as one unit of accounting and upfront payments are recorded initially as deferred revenue in the balance sheet. Revenue is then recognized on a straight-line basis over an estimated performance period that is consistent with the term of performance obligations, unless we determine there is a discernible pattern of performance other than straight-line, in which case we use a proportionate performance method to recognize the revenue over the estimated performance period. We are recognizing the upfront fee on a straight-line basis over the initial period of performance of six years, which represents the estimated development period in the territories based on the initial development plan managed by the joint steering committee. The term of the agreement is through the expiration of the patents associated with serlopitant. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We periodically review our estimated periods of performance based on the progress under each arrangement and account for the impact of any changes in estimated periods of performance on a prospective basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">At the inception of each agreement that includes milestone payments, including the Collaboration Agreement, we evaluate whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. We evaluate factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone, and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non&#8209;refundable payments that are contingent upon achievement of a substantive milestone are recognized in their entirety in the period in which the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">83</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">milestone is achieved, assuming all other revenue recognition criteria are met. Other contingent payments in which a portion of the milestone consideration is refundable or adjusts based on future performance or non&#8209;performance (e.g., through a penalty or clawback provision) are not considered to relate solely to past performance, and therefore, not considered substantive. Amounts that are not recognized as revenue due to the uncertainty as to whether they will be retained or because they are expected to be refunded are recorded as a liability. We recognize non&#8209;substantive milestone payments over the remaining estimated period of performance once the milestone is achieved. Contingent payments associated with the achievement of specific objectives in certain contracts that are not considered substantive because we do not contribute effort to the achievement of such milestones are recognized as revenue upon achievement of the objective, as long as there are no undelivered elements remaining and no continuing performance obligations by us, assuming all other revenue recognition criteria are met. We are</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;entitled to receive aggregate payments of up to $28.0 million upon the achievement of specified development and regulatory milestones, and $15.0 million upon the achievement of a commercial milestone. Certain of the milestones related to preparation of an IND for submission to regulatory authorities in the territory are considered substantive given that they are triggered by our performance relative to the achievement of pre-specified, &#8220;at risk&#8221; milestone events, such as the initiation or successful completion of regulatory development phases. All other milestones are considered non-substantive because the milestone is dependent upon the performance of the collaboration partner rather than us.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On September 1, 2017, the Company entered into a separate services agreement with JT Torii to provide research and development services, including regulatory, chemistry and manufacturing support and related materials that is distinct from the original Collaboration Agreement. The Company evaluated the new services agreement and determined that the research and materials delivered to JT Torii represents a separate earnings process that provides standalone value to JT Torii. The fees received under the services agreement will be recognized as and when such services are performed by the Company and JT Torii consumes the benefits of those services. The Company has no obligation to provide services unless requested by JT Torii and agreed to by us. The Company is eligible to receive reimbursement of estimated costs incurred and payment for research services performed directly by the Company at agreed upon rates. During the year ended December 31, 2017, the Company recognized revenue of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and recorded expenses of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;as research and development expense in the statement of operations related to the new services agreement. The services agreement terminates upon the termination of the Collaboration Agreement or by mutual agreement of the parties.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as an expense as the goods are delivered or the related services are performed.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We estimate non&#8209;clinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage non&#8209;clinical studies and clinical trials on our behalf. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation Expense </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company measures and recognizes compensation expense for all stock&#8209;based awards made to employees, directors and non&#8209;employees, based on estimated fair values recognized using the straight&#8209;line method over the requisite service period.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The fair value of options to purchase common stock granted to employees is estimated on the grant date using the Black&#8209;Scholes option valuation model. The calculation of stock&#8209;based compensation expense requires that the Company make certain assumptions and judgments about a number of complex and subjective variables used in the Black&#8209;Scholes model, including the expected term, expected volatility of the underlying common stock, risk&#8209;free interest rate, as well as estimating future forfeitures of unvested stock options. To the extent actual forfeiture results differ from the estimates, the difference will be recorded as a cumulative adjustment in the period the estimates are revised.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">84</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company accounts for common stock warrants and options issued to non&#8209;employees under Accounting Standards Codification (&#8220;ASC&#8221;) 505&#8209;50 Equity&#8209;Equity based payments to Non&#8209;Employees, using the Black&#8209;Scholes option valuation model as they are earned. The fair value of such non&#8209;employee awards is remeasured over the vesting period.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Common Stock Valuations</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Prior to our initial public offering, we were required to periodically estimate the fair value of our common stock when issuing stock options and computing our estimated stock-based compensation expense. The fair value of our common stock was determined on a periodic basis by our board of directors, with the assistance of an independent third-party valuation expert. The assumptions underlying these valuations represented management&#8217;s best estimates, which involved inherent uncertainties and the application of significant levels of management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation could be materially different. In determining the fair value of our common stock, our board of directors considered valuation methods intended to comply with Section&#160;409A of the Internal Revenue Code that create a presumption that the resulting valuation is reasonable for federal tax purposes.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The fair value of the common stock underlying our stock options was estimated at each grant date by our board of directors. Our board of directors intended all options granted to be exercisable at a price per share not less than the estimated per share fair value of our common stock underlying those options on the date of grant. The valuations of our common stock were determined in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We provide for income taxes under the asset and liability method. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards, and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We record a valuation allowance to reduce our deferred tax assets to reflect the net amount that we believe is more likely than not to be realized. Realization of our deferred tax assets is dependent on the generation of future taxable income, the amount and timing of which are uncertain. The valuation allowance requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Based upon the weight of available evidence at December 31, 2017, we continue to maintain a full valuation allowance against all of our deferred tax assets after management considered all available evidence both positive and negative, including but not limited to our historical operating results, income or loss in recent periods, cumulative income in recent years, forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We account for uncertain tax positions in accordance with ASC 740&#8209;10, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Accounting for Uncertainty in Income Taxes</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We recognize the tax effects of an uncertain tax position only if it is more likely than not to be sustained based solely on its technical merits as of the reporting date and only in an amount more likely than not to be sustained upon review by the tax authorities. evaluate uncertain tax positions on a quarterly basis and adjust the liability for changes in facts and circumstances, such as new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, significant amendment to an existing tax law, or resolution of an examination. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the income tax provision in the period in which such determination is made. The resolution of our uncertain income tax positions is dependent on uncontrollable factors such as law changes, new case law, and the willingness of the income tax authorities to settle, including the timing thereof and other factors. Although we do not anticipate significant changes to our uncertain income tax positions in the next twelve months, items outside of our control could cause our uncertain income tax positions to change in the future, which would be recorded in our consolidated statements of operations. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">85</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (&#8220;Tax Act&#8221;) that instituted fundamental changes to the taxation of multinational corporations. The Tax Act includes changes to the taxation of foreign earnings by implementing a dividend exemption system, expansion of the current anti-deferral rules, a minimum tax on low-taxed foreign earnings and new measures to deter base erosion. The Tax Act also includes a permanent reduction in the corporate tax rate to 21%, repeal of the corporate alternative minimum tax, expensing of capital investment, and limitation of the deduction for interest expense. Furthermore, as part of the transition to the new tax system, a one-time transition tax is imposed on a U.S. shareholder&#8217;s historical undistributed earnings of foreign affiliates. Although the Tax Act is generally effective January 1, 2018, GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date, which was December 22, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As a result of the impacts of the Tax Act, the SEC provided guidance that allows the Company to record provisional amounts for those impacts, with the requirement that the accounting be completed in a period not to exceed one year from the date of enactment. As of December 31, 2017, the Company has not completed the accounting for the tax effects of the Tax Act. Therefore, we have recorded provisional amounts for the effects of the Tax Act. The primary impact of the Tax Act relates to the re-measurement of deferred tax assets and liabilities resulting from the change in the corporate tax rate (&#8220;Corporate Tax Rate Change&#8221;). The Company is evaluating other accounting policies with respect to other provisions of the Tax Act.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December&#160;31, 2017 our total deferred tax assets were $15.0&#160;million. Due to our lack of earnings history and uncertainties surrounding our ability to generate future taxable income, the net deferred tax assets have been fully offset by a valuation allowance. The deferred tax assets were primarily comprised of federal and state tax net operating losses, or NOLs. Utilization of NOLs may be limited by the &#8220;ownership change&#8221; rules, as defined in Section&#160;382 of the Code. Similar rules may apply under state tax laws. Our ability to use our remaining NOLs may be further limited if we experience an ownership change in connection with future offerings, future offerings or as a result of future changes in our stock ownership.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Investment Securities </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have an investment policy which limits us to investing in highly rated corporate and government notes, and no individual investment may comprise more than 5% of the total portfolio.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We classify our investment securities as available&#8209;for&#8209;sale. Those investments with maturities less than 12&#160;months at the date of purchase are considered short&#8209;term investments. Those investments with maturities greater than 12&#160;months at the date of purchase are considered long&#8209;term investments. Our investment securities classified as available&#8209;for&#8209;sale are recorded at fair value based upon quoted market prices at period end. Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of comprehensive income or loss. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight&#8209;line interest method. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We determine the fair value of our assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:48px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:48px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">86</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:48px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div><a name="sFE31149EDAD85F0A979FFC62CB926F97"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Since our inception, we have not engaged in any off&#8209;balance sheet arrangements, as defined in the rules and regulations of the SEC. See Note 5 of our audited financial statements included in this </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Annual Report on Form 10-K</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, Commitments and Contingencies, regarding our guarantees and indemnifications.</font></div><div><a name="s17CB8A08DD795CEF8F51F19EF7AEFE8C"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">From 2011 through 2016, we have operated with significant consulting and management services provided by Velocity Pharmaceutical Development, LLC, or VPD. Development services fees paid to VPD under a development services agreement (the &#8220;Development Services Agreement&#8221;) were $1.0 million and $0.8 million for the years ended December 31, 2016 and 2015, respectively. We also reimbursed VPD for consulting, travel and other expenses incurred on our behalf. As of December 31, 2017 and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, we had no outstanding liabilities to VPD.  Several managing directors of VPD have served as officers and directors of the Company. David Collier, M.D., a former member of our board of directors, is the Chief Executive Officer of VPD, and Xiaoming Zhang, Ph.D., our Senior Vice President, Non&#8209;Clinical and Pharmaceutical Development, was a Venture Partner of VPD. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><a name="sA8EA4D076D7F565189FB8623AC52B0E1"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Indemnification</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As permitted under Delaware law and in accordance with our bylaws, we are required to indemnify our officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. We are also party to indemnification agreements with our directors. We believe the fair value of the indemnification rights and agreements is minimal. Accordingly, we have not recorded any liabilities for these indemnification rights and agreements as of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div><a name="s59CC98B64F195CFF82336AC175C2A737"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">JOBS Act Accounting Election</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are choosing to &#8220;opt out&#8221; of this provision and, as a result, we will comply with new or revised accounting standards as required when they are adopted. This decision to opt out of the extended transition period under the JOBS Act is irrevocable.</font></div><div><a name="sC3989016EB63514AB53DC8F1BBD5FFB3"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Recently Issued and Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In November 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016&#8209;18,&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. The update requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016&#8209;18 is effective for public entities for annual periods beginning after December 15, 2017, and interim periods within those annual periods. We are currently evaluating the effects, if any, that the adoption of this guidance will have on our financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In March 2016, the FASB issued ASU 2016&#8209;09, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Improvements to Employee Share&#8209;Based Payment Accounting </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">as part of its simplification initiative, which involves several aspects of accounting for share&#8209;based payment transactions, including the income tax effects, statutory withholding requirements, forfeitures and classification on the statement of cash flows. The standard is effective for companies for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years with early adoption permitted. We adopted this standard as of January 1, 2017, and there was no impact to our financial statements as a result of the adoption.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In February 2016, the FASB issued ASU 2016&#8209;02, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Leases </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">87</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight&#8209;line basis over the term of the lease, respectively. A lessee is also required to record a right&#8209;of&#8209;use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases today. ASC 842 supersedes the previous leases standard, ASC 840 </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Leases</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. The standard is effective on January 1, 2019, with early adoption permitted. We are currently evaluating the effects, if any, that the adoption of this guidance will have on our financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In January 2016, the FASB issued ASU 2016&#8209;01, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. ASU 2016&#8209;01 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. We are currently evaluating the effects, if any, that the adoption of this guidance will have on our financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In November 2015, the FASB issued ASU 2015&#8209;17, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;to simplify the presentation of deferred income taxes. The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. We elected to early adopt ASU 2015&#8209;17 as of the beginning of our fourth quarter ended December&#160;31, 2015 on a prospective basis. There was no impact to the balance sheet amounts as a result of early adoption.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In August 2014, the FASB issued ASU 2014&#8209;15 related to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Presentation of Financial Statements</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;&#8209; </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Going Concern (Subtopic 205&#8209;40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">This update provides guidance about management&#8217;s responsibilities in evaluating an entity&#8217;s going concern uncertainties, and about the timing and content of related footnote disclosures. Under this amended guidance, an entity&#8217;s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. This update is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. We adopted this standard in 2016 and there was no impact on the financial position, results of operations or related financial statement disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In May 2014, the FASB issued ASU No. 2014&#8209;09, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, which supersedes the revenue recognition requirements in ASC 605, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue Recognition</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, FASB issued ASU No. 2015&#8209;14, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, which effectively delayed the adoption date by one year, to an effective date for public entities for annual and interim periods beginning after December 15, 2017. In March, April and May 2016, the FASB issued additional updates to the new revenue standard relating to reporting revenue on a gross versus net basis, identifying performance obligations and licensing arrangements, and narrow&#8209;scope improvements and practical expedients, respectively. The effective date of this additional update is the same as that of ASU 2014&#8209;09. The guidance permits the use of either a retrospective or cumulative effect transition method. We have not yet selected a transition method. We are still finalizing the analysis to quantify the adoption impact of the provisions of the new standard, but we do not currently expect to have a material impact on the financial position or results of operations. Based on the evaluation of our current collaboration agreement and associated revenue streams, most of the revenue will be recorded consistently under both the current and the new standard. The FASB has issued, and may issue in the future, interpretive guidance which may cause our evaluation to change. We believe we are following an appropriate timeline to allow for proper recognition, presentation and disclosure upon adoption effective the beginning of fiscal year 2018.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on results of operations, financial condition, or cash flows.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">88</font></div></div><hr style="page-break-after:always"><div><a name="s6e6b628a36e544b4b600cbee85dc396d"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Item 7A.     Quantitative and Qualitative Disclosures about Market Risk.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates or exchange rates. As of December 31, 2017, we had cash, cash equivalents and investments of $62.5 million, consisting of interest&#8209;bearing money market accounts and investments in corporate notes and government securities, which would be affected by changes in the general level of United States interest rates. However, due to the short&#8209;term maturities and the low&#8209;risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash, cash equivalents and investments.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We do not believe that inflation, interest rate changes, or exchange rate fluctuations had a significant impact on our results of operations for any periods presented herein.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">89</font></div></div><hr style="page-break-after:always"><div><a name="s1A62084FD5A9549BA358324F892FBD85"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Index to Financial Statements </font></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Menlo Therapeutics Inc. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:93%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sC0AC387B1DCF59A49BB9386035F080EC"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sC0AC387B1DCF59A49BB9386035F080EC">91</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Balance Sheets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s115E60672ED55D79B94FD13902080698">92</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Statements of Operations and Comprehensive Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s62A237B458AC53A8BC4CEA496584B18D">93</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sAB827FBD68935B4E8F591F8BCFBE24D5">94</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#s133B0547B0E0522AB3EF867C7C529BD0">95</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sF664605C277E5E38B5DEB828943FDB49"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Notes to Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><a style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;" href="#sF664605C277E5E38B5DEB828943FDB49">96</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">90</font></div></div><hr style="page-break-after:always"><div><a name="sC0AC387B1DCF59A49BB9386035F080EC"></a></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">To the Board of Directors and Stockholders of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Menlo Therapeutics Inc.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Opinion on the Financial Statements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have audited the accompanying balance sheets of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Menlo Therapeutics Inc. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(&#8220;Company&#8221;) as of December 31, 2017 and 2016, and the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; deficit, and cash flows for each of the three years in the period ended December 31, 2017, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017, in conformity with accounting principles generally accepted in the United States of America. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Basis for Opinion</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">/s/ Mayer Hoffman McCann P.C.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have served as the Company's auditor since 2016.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">San Diego, California</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">March 28, 2018</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">91</font></div></div><hr style="page-break-after:always"><div><a name="s115E60672ED55D79B94FD13902080698"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Menlo Therapeutics&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Balance Sheets</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">10,206</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4,027</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Short&#8209;term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">49,295</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">26,881</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">786</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">632</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">63,861</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">31,540</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Long&#8209;term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,978</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10,420</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Prepaid and other long&#8209;term assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">66</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">66,867</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">42,053</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,559</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Deferred revenue, current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">7,817</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,903</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Deferred revenue, long&#8209;term</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,735</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,531</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Other non&#8209;current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,574</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">12,491</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Commitments and contingencies (see Note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series A convertible preferred stock, $0.001 par value, 14,300 shares authorized at December 31, 2017 and 2016; 14,300 shares issued and outstanding at December 31, 2017 and 2016; Liquidation value of $14,300 as of December 31, 2017 and 2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,183</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,183</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series B convertible preferred stock, $0.001 par value, 14,106,583 shares authorized at December 31, 2017 and 2016; 14,106,583 shares issued and outstanding at December 31, 2017 and 2016; Liquidation value of $45,000 as of December 31, 2017 and 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">44,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">44,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series C convertible preferred stock, $0.001 par value, 14,201,878 and 0 shares authorized at December 31, 2017 and 2016, respectively; 11,854,463 and 0 shares issued and outstanding at December 31, 2017 and 2016, respectively; Liquidation value of $50,500 and $0 as of December 31, 2017 and 2016, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">50,324</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stockholders&#8217; deficit:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-18px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Common stock, $0.0001 par value, 55,000,000 and 36,500,000 shares authorized at December 31, 2017 and 2016, respectively; 5,298,593 and 5,280,058 shares issued and outstanding at December 31, 2017 and 2016, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Additional paid&#8209;in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(51</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(59,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(30,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total stockholders&#8217; deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(57,034</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(29,441</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">66,867</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">42,053</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">92</font></div></div><hr style="page-break-after:always"><div><a name="s62A237B458AC53A8BC4CEA496584B18D"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Menlo Therapeutics&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Statements of Operations and Comprehensive Loss</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Collaboration and license revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">4,582</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">674</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">29,007</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,255</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,921</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">5,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,751</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,687</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">34,175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">15,006</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4,608</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(29,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(14,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Interest income and other expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">517</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(29,076</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(14,068</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Other comprehensive loss:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Unrealized loss on available&#8209;for&#8209;sale securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(29,101</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(14,094</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4,608</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net loss attributable to common stockholder per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(5.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2.82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(0.97</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Weighted&#8209;average number of common shares used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">5,108,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4,987,133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4,735,148</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></div><hr style="page-break-after:always"><div><a name="sAB827FBD68935B4E8F591F8BCFBE24D5"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Menlo Therapeutics&#160;Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except share data)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="44"></td></tr><tr><td style="width:13%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Series A Convertible</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Series B Convertible</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Series C Convertible</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Preferred Stock</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Paid-in</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Comprehensive</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Stockholders&#8217;</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Deficit</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Balance at January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">11,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">11,383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">4,962,653</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(11,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(11,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Issuance of Series A convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">2,800</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">2,800</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Issuance of Series B convertible preferred stock, net of issuance costs of $179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">14,106,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">44,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Exercise of unvested stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">317,405</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">(4,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">(4,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Balance at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">14,183</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">14,106,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">44,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">5,280,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(16,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(15,953</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Vesting of early exercised stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Unrealized loss on available-for-sale securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">(26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">(26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">(14,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">(14,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Balance at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">14,300</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">14,183</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">14,106,583</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">44,820</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">5,280,058</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">699</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(30,115</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(29,441</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Issuance of Series C convertible preferred stock, net of issuance costs of $173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">11,854,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">50,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Issuance of common stock on exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">18,535</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">34</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">34</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Vesting of early exercised stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">1,452</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">1,452</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Unrealized loss on available-for-sale securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">(25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">(25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">(29,076</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">(29,076</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">14,300</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">14.183</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">14,106,583</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">44,820</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">11,854,463</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">50,324</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">5,298,593</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">2,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(59,191</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">(57,034</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:7pt;font-weight:bold;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">94</font></div></div><hr style="page-break-after:always"><div><a name="s133B0547B0E0522AB3EF867C7C529BD0"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Menlo Therapeutics Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Statements of Cash Flows (in thousands</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">Operating activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(29,076</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(14,068</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(4,608</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Unrealized loss on available&#8209;for&#8209;sale investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Amortization of premium on investment securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">66</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">158</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Stock&#8209;based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">1,452</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Gain on disposal of equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Change in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(1,790</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(555</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Prepaid and other long&#8209;term assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">620</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">889</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">2,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">346</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(1,796</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">10,327</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">36</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Other non&#8209;current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Net cash used in operating activities </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">(28,247</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">(2,291</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">(4,183</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">Investing activities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Purchase of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Purchase of investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(64,148</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(55,309</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Proceeds from sales of investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">3,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Proceeds from maturities of investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">43,110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">14,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">(15,065</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">(37,490</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">Financing activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Proceeds from issuance of convertible preferred stock, net of issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">50,324</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">47,620</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Proceeds from the exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(867</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">49,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">47,718</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Net increase (decrease) in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">6,179</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(39,781</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">43,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Cash and cash equivalents at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">4,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">43,808</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">273</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Cash and cash equivalents at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">10,206</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">4,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">43,808</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">Noncash financing activities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Deferred financing costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">316</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">95</font></div></div><hr style="page-break-after:always"><div><a name="sF664605C277E5E38B5DEB828943FDB49"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Menlo Therapeutics Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Notes to Financial Statements</font></div><div><a name="s48FD895542925740A649F3342634AB17"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Formation and Business of the Company</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Menlo Therapeutics Inc., or the &#8220;Company&#8221;, is a late&#8209;stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The Company is concurrently evaluating the use of serlopitant for the treatment of refractory chronic cough, a cough that persists for at least eight weeks despite treatment of any identified underlying cause. The Company believes that its product candidate, serlopitant, a highly selective once&#8209;daily, oral small molecule inhibitor of the neurokinin 1 receptor, or NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R, has the potential to significantly alleviate itch and cough symptoms. Pruritus associated with atopic dermatitis, psoriasis and prurigo nodularis, as well as refractory chronic cough, each represents a significant patient need.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company was incorporated in Delaware in October 2011. Since commencing operations, the Company has devoted substantially all of its resources to developing its product candidate, including conducting clinical trials and providing general and administrative support for these operations.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Initial Public Offering</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In January 2018, the Company completed its initial public offering (&#8220;IPO&#8221;) of shares of its common stock, pursuant to which the Company issued </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,050,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares of common stock, which includes </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,050,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares issued pursuant to the over-allotment option granted to its underwriters, and received net proceeds of approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$125.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, after deducting underwriting discounts, commissions and offering expenses. In connection with the completion of the Company's IPO, all shares of convertible preferred stock converted into </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9,629,405</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares of common stock.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Since inception, the Company has incurred losses and negative cash flows from operations. For the year ended December 31, 2017, the Company incurred a net loss of $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">29.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and used </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$28.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;of cash in operations. As of December&#160;31, 2017, the Company had cash, cash equivalents and investments of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$62.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and an accumulated deficit of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$59.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company&#8217;s research and development activities. Management plans to finance operations through equity or debt financing arrangements, and/or third&#8209;party collaboration funding. There can be no assurances that, in the event that the Company requires additional financing, such financing will be available on terms which are favorable to the Company, or at all. If the Company is unable to raise additional funding to meet its working capital needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company believes that its existing cash, cash equivalents and investments as of December&#160;31, 2017 together with funds available from the January 2018 IPO, will provide sufficient funds to enable it to meet its obligations for at least the next twelve months.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">96</font></div></div><hr style="page-break-after:always"><div><a name="s759D7FA6137F5CFDA83F60E229456AA2"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Significant Accounting Policies</font></div></td></tr></table><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Reverse Stock Split</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On January 8, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2018, the Company effected a reverse split of shares of the Company&#8217;s common stock at a ratio of 1-for-</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2.6975</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;pursuant to an amendment to the amended and restated certificate of incorporation approved by the Company&#8217;s board of directors and stockholders. The par value and the authorized</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">shares of the common stock were not adjusted as a result of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse split for all periods presented, and the conversion ratio of the preferred stock was adjusted accordingly. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Segments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company operates in </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">one</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long&#8209;lived assets are maintained in the United States of America. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Preparation of financial statements in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, stock&#8209;based compensation expense, the resolution of uncertain tax positions and valuation allowance, recovery of long&#8209;lived assets and accruals for research and development costs. Management bases its estimates on historical experience on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Risk and Uncertainties</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s potential drug candidate, uncertainty of market acceptance of the Company&#8217;s product candidate, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company&#8217;s product candidate requires clearances from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the product candidate will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to complete clinical studies and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. The Company limits its credit risk associated with cash and cash equivalents by placing its investments with an institution it believes is highly creditworthy and with highly rated money market funds. As of December&#160;31, 2017 and 2016, cash and cash equivalents consisted of bank deposits, cash and investments in money market funds. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">97</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Investment Securities </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company classifies its investment securities as available&#8209;for&#8209;sale. Those investments with maturities less than 12&#160;months at the date of purchase are considered short&#8209;term investments. Those investments with maturities greater than 12&#160;months at the date of purchase are considered long&#8209;term investments. The Company&#8217;s investment securities classified as available&#8209;for&#8209;sale are recorded at fair value based upon quoted market prices at period end. Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of comprehensive income or loss. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight&#8209;line interest method. Dividend and</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Property and Equipment, Net</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Property and equipment are stated at cost and depreciated using the straight&#8209;line method over the estimated useful lives of the assets, generally between </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">three</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">five</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;years. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The carrying amounts of the Company&#8217;s financial instruments, which include cash, accounts payable and accrued liabilities and other current liabilities, and deferred revenue approximate their fair values due to their short maturities. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and investments. As of December&#160;31, 2017 and 2016, the majority of our cash, cash equivalents and investments are held by </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">one</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;U.S. financial institution in excess of federally insured limits. We invest cash in excess of our current needs in United States Treasury and government agency securities, highly&#8209;rated short or medium&#8209;term debt securities and money market funds and, by policy, diversify our investments to limit the amount of credit exposure. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company has an investment policy which limits the Company to investing in highly rated corporate and government notes, and no individual investment may comprise more than </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5%</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;of the total portfolio.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">accounts for income taxes under the asset and liability method which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company&#8217;s assets and liabilities and their financial statement reported amounts. Management makes estimates, assumptions and judgments to determine the Company&#8217;s provision for income taxes and also for deferred tax assets and liabilities, and any valuation allowances recorded against the Company&#8217;s deferred tax assets. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and to the extent the Company believes that recovery is not more likely than not, the Company must establish a valuation allowance.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">has adopted ASC 740-10, Accounting for Uncertainty in Income Taxes, that prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&#8217;s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research and development costs are expensed as incurred. Substantially all of our research and development expenses consist of expenses incurred in connection with the development of serlopitant. These expenses </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">98</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">include certain payroll and personnel expenses including stock&#8209;based compensation expense, consulting costs, contract manufacturing costs, and fees paid to clinical research organizations, or CROs, to conduct research and development. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as an expense as the goods are delivered or the related services are performed. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company estimates non&#8209;clinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage non&#8209;clinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Patent Costs</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company has no historical data to support a probable future economic benefit for the arising patent applications, filing and prosecution costs. Therefore, patent costs are expensed as incurred.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company recognizes rent expense on a straight&#8209;line basis over the non&#8209;cancellable term of the operating lease.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company measures and recognizes compensation expense for all stock&#8209;based awards made to employees, directors and non&#8209;employees, based on estimated fair values recognized using the straight&#8209;line method over the requisite service period.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The fair value of options to purchase common stock granted to employees is estimated on the grant date using the Black&#8209;Scholes option valuation model. The calculation of stock&#8209;based compensation expense requires that the Company make certain assumptions and judgments about a number of complex and subjective variables used in the Black&#8209;Scholes model, including the expected term, expected volatility of the underlying common stock, risk&#8209;free interest rate, as well as estimating future forfeitures of unvested stock options. To the extent actual forfeiture results differ from the estimates, the difference will be recorded as a cumulative adjustment in the period the estimates are revised. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company accounts for options issued to non&#8209;employees using the Black&#8209;Scholes option valuation model and is measured and recognized as the stock options are earned.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Convertible Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company recorded the convertible preferred stock at fair value on the dates of issuance, net of issuance costs. The convertible preferred stock is recorded outside of stockholders&#8217; equity because, in the event of certain deemed liquidation events considered not solely within the Company&#8217;s control, such as a merger, acquisition and sale of all or substantially all of the Company&#8217;s assets, the convertible preferred stock will become redeemable at the option of the holders. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">All outstanding convertible preferred stock converted into common stock in January 2018 upon the effectiveness of the IPO.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Comprehensive income (loss) is defined as the change in equity of the Company during a period from transactions and other events and circumstances excluding transactions resulting from investments and distributions to owners. Comprehensive loss consists of the net loss and changes in accumulated other comprehensive income, which are comprised of unrealized gains (losses) on available&#8209;for&#8209;sale investments.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">To date, the Company&#8217;s clinical drug candidates have not been approved for sale by the FDA and the Company has not generated any revenue from product sales. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">99</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On August 10, 2016, the Company entered into a license and collaboration agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd., together referred to as &#8220;JT Torii&#8221;, which is referred to as the &#8220;Collaboration Agreement&#8221;. Under the Collaboration Agreement, the Company granted to JT Torii the rights to develop and commercialize products containing serlopitant in Japan for the treatment of diseases and conditions other than nausea or vomiting. In exchange, JT Torii paid an upfront, non&#8209;refundable payment of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$11.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. In addition, the Company is entitled to receive aggregate payments of up to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$28.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;upon the achievement of specified development and regulatory milestones, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$15.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;upon the achievement of a commercial milestone, as well as tiered royalties from the mid-single digits up to the mid&#8209;teens on sales of licensed products in Japan. The Company&#8217;s performance obligations under the license agreement includes the transfer of intellectual property rights in the form of licenses, obligations to participate on certain development and/or commercialization committees with the collaboration partners and supply manufactured drug product for clinical trials. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company recognizes revenue pursuant to the Collaboration Agreement in connection with the clinical development and commercialization of products covered by the collaboration, including non-refundable upfront license fees, contingent consideration payments based on the achievement of defined collaboration objectives and royalties on sales of commercialized products. To date, the Company has not generated or recognized revenue from sales of its product candidates.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Revenue from the Collaboration Agreement is recognized when </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">persuasive evidence of an arrangement exists, </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">transfer of technology has been completed, services have been performed or products have been delivered, </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the fee is fixed and determinable, and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">collection is reasonably assured. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company evaluates revenue agreements with multiple&#8209;elements in accordance with ASC 605-25 </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue Recognition - Multiple Element Arrangements</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting based on the achievement of certain criteria including whether the deliverable has stand&#8209;alone value. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Upfront payments for licenses are evaluated to determine if the licensee can obtain standalone value from the license separate from the value of the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">obligations to participate on certain development and/or commercialization committees with the collaboration partners and supply manufactured drug product for clinical trials</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;in the arrangement to be provided by the Company. The Company is reimbursed by JT Torii for the non-commercial supplies of serlopitant at the same rate as charged by the third party manufacturer, which does not include a significant and incremental discount to JT Torii. The assessment of multiple-element arrangements also requires judgment in order to determine the allocation of revenue to each deliverable and the appropriate period of time over which the revenue should be recognized. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under the Collaboration Agreement, the Company has determined that the license does not have standalone value separate from the research and development services because </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">JT Torii cannot resell such license on a standalone basis or use the license with its available resources to obtain any economic value without the Company&#8217;s participation. T</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">he license and the services are combined as one unit of accounting and upfront payments are recorded initially as deferred revenue in the balance sheet. Revenue is then recognized on a straight-line basis over an estimated performance period that is consistent with the term of performance obligations, unless the Company determines there is a discernible pattern of performance other than straight-line, in which case the Company uses a proportionate performance method to recognize the revenue over the estimated performance period. The Company is recognizing the upfront fee on a straight-line basis over the initial period of performance of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">six</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;years, which represents the estimated development period in the territories based on the initial development plan managed by the joint steering committee. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The term of the agreement is through the expiration of the patents associated with serlopitant.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">100</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any changes in estimated periods of performance on a prospective basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">At the inception of each agreement that includes milestone payments, including the Collaboration Agreement, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non&#8209;refundable payments that are contingent upon achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved, assuming all other revenue recognition criteria are met. Other contingent payments in which a portion of the milestone consideration is refundable or adjusts based on future performance or non&#8209;performance (e.g., through a penalty or claw&#8209;back provision) are not considered to relate solely to past performance, and therefore, not considered substantive. Amounts that are not recognized as revenue due to the uncertainty as to whether they will be retained or because they are expected to be refunded are recorded as a liability. The Company recognizes non&#8209;substantive milestone payments over the remaining estimated period of performance once the milestone is achieved. Contingent payments associated with the achievement of specific objectives in certain contracts that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are recognized as revenue upon achievement of the objective, as long as there are no undelivered elements remaining and no continuing performance obligations by the Company, assuming all other revenue recognition criteria are met. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under the Collaboration Agreement, the Company is entitled to receive aggregate payments of up to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$28.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;upon the achievement of specified development and regulatory milestones, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$15.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;upon the achievement of a commercial milestone. Two of the milestones, which amount to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;each, relate to the preparation of an IND for submission to regulatory authorities in the territory are considered substantive given that they are triggered by the Company&#8217;s performance relative to the achievement of pre-specified, &#8220;at risk&#8221; milestone events, including the submission of all completed clinical trials data packages and the validation of the manufacturing process. All other milestones, which amount to an aggregate of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$24.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, are considered non-substantive because the milestone is dependent upon the performance of the collaboration partner rather than the Company. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#8217;s balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, current portion. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Expenses related to the collaboration agreement are recorded as a component of research and development in the statement of operations as incurred, and to date have been immaterial.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During the fourth quarter of 2017, the Company achieved a substantive milestone related to the validation of the manufacturing process under the Collaboration Agreement, and recognized revenues of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$2.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On September 1, 2017, the Company entered into a separate services agreement with JT Torii to provide research and development services, including regulatory, chemistry and manufacturing support and related materials that is distinct from the original Collaboration Agreement. The Company evaluated the new services agreement and determined that the research and materials delivered to JT Torii represents a separate earnings process that provides standalone value to JT Torii. The fees received under the services agreement will be recognized as and when such services are performed by the Company and JT Torii consumes the benefits of those services. The Company has no obligation to provide services unless requested by JT Torii and agreed to by us. The Company is eligible to receive reimbursement of estimated costs incurred and payment for research services performed directly by the Company at agreed upon rates. During the year ended December 31, 2017, the Company recognized revenue of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and recorded expenses of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;as research and development expense in the statement of operations related to the new services agreement. The services agreement terminates upon the termination of the Collaboration Agreement or by mutual agreement of the parties.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">101</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Net Loss per Share of Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted&#8209;average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted&#8209;average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock and common stock options are considered to be potentially dilutive securities. Because the Company has reported a net loss for the years ended December&#160;31, 2017, 2016 and 2015, diluted net loss per common share is the same as basic net loss per common share for those periods. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In November 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016&#8209;18,&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. The update requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016&#8209;18 is effective for public entities for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In March 2016, the FASB issued ASU 2016&#8209;09, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Improvements to Employee Share&#8209;Based Payment Accounting</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;as part of its simplification initiative, which involves several aspects of accounting for share&#8209;based payment transactions, including the income tax effects, statutory withholding requirements, forfeitures and classification on the statement of cash flows. The standard is effective for companies for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years with early adoption permitted. The Company adopted this standard as of January 1, 2017, and there was no impact to the Company&#8217;s financial statements as a result of the adoption. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In February 2016, the FASB issued ASU 2016&#8209;02, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Leases</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;(ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight&#8209;line basis over the term of the lease, respectively. A lessee is also required to record a right&#8209;of&#8209;use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASC 842 supersedes the previous leases standard, ASC 840 </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Leases</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In January 2016, the FASB issued ASU 2016&#8209;01, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. ASU 2016&#8209;01 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In November 2015, the FASB issued ASU 2015&#8209;17, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;to simplify the presentation of deferred income taxes. The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. We have elected to early adopt ASU 2015&#8209;17 as of the beginning of our fourth quarter ended December&#160;31, 2015 on a prospective basis. There was no impact to the balance sheet amounts as a result of early adoption.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In August 2014, the FASB issued ASU 2014&#8209;15 related to Presentation of Financial Statements &#8209; </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Going Concern (Subtopic 205&#8209;40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. This update provides guidance about management&#8217;s responsibilities in evaluating an entity&#8217;s going concern uncertainties, and about the timing and content of related footnote disclosures. Under this amended guidance, an entity&#8217;s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">102</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">after the date that the financial statements are issued. This update is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company adopted this standard in 2016 and there was no impact on the financial position, results of operations or related financial statement disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In May 2014, the FASB issued ASU No. 2014&#8209;09, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, which supersedes the revenue recognition requirements in ASC 605, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue Recognition</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, FASB issued ASU No. 2015&#8209;14, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, which effectively delayed the adoption date by one year, to an effective date for public entities for annual and interim periods beginning after December 15, 2017. In March, April and May 2016, the FASB issued additional updates to the new revenue standard relating to reporting revenue on a gross versus net basis, identifying performance obligations and licensing arrangements, and narrow&#8209;scope improvements and practical expedients, respectively. The effective date of this additional update is the same as that of ASU 2014&#8209;09. The guidance permits the use of either a retrospective or cumulative effect transition method. The Company has not yet selected a transition method. The Company is still finalizing the analysis to quantify the adoption impact of the provisions of the new standard, but it does not currently expect to have a material impact on the financial position or results of operations. Based on the evaluation of its current collaboration agreement and associated revenue streams, most of the revenue will be recorded consistently under both the current and the new standard. The FASB has issued, and may issue in the future, interpretive guidance which may cause the Company&#8217;s evaluation to change. The Company believes it is following an appropriate timeline to allow for proper recognition, presentation and disclosure upon adoption effective the beginning of fiscal year 2018. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">There are no other recently issued accounting standards that apply to the Company or that are expected to have a material impact on results of operations, financial condition, or cash flows.</font></div><div><a name="s56E81E58C1695FB7ADCD7F6E32D6AF4D"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The fair value of our financial instruments reflects the amounts that we estimate we would receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose and recognize the fair value of our assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 1 &#8209; Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date;</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 2 &#8209; Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active;</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 3 &#8209; Inputs that are unobservable.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During the years presented, the Company has not changed the manner in which it values assets and liabilities that are measured at fair value using Level 3 inputs. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the years ended December 31, 2017 and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">103</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows (in thousands): </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,685</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,685</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Corporate notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">46,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">40,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Government notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,175</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,175</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">60,958</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">19,963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">40,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,808</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,808</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Corporate notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">26,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">7,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">18,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Government notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,193</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,193</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">41,109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">22,226</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">18,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company uses a market approach for determining the fair value of all its Level&#160;1 and Level&#160;2 money market funds and marketable securities. To value its money market funds, the Company values the funds at $1 stable net asset value, which is the market pricing convention for identical assets that the Company has the ability to access.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The investments are classified as available&#8209;for&#8209;sale securities. At December 31, 2017 and 2016, the balance in the Company&#8217;s accumulated other comprehensive income was comprised solely of activity related to the Company&#8217;s available&#8209;for&#8209;sale securities. There were no realized gains or losses recognized on the sale or maturity of available&#8209;for&#8209;sale securities for the years ended December 31, 2017 and 2016 and as a result, the Company did not reclassify any amounts out of accumulated other comprehensive income for the year. The Company has a limited number of available&#8209;for&#8209;sale securities in insignificant loss positions as of December 31, 2017 and 2016, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized cost for the investment at maturity. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">104</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table summarizes the available&#8209;for&#8209;sale securities (in thousands): </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Corporate notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">46,133</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">46,098</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Government notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">61,009</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">60,958</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,808</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,808</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Corporate notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">26,134</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">26,108</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Government notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">41,135</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">41,109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><a name="sD04C0322E7F05F1C89E619BCC58B0DA4"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Balance Sheets Components</font></div></td></tr></table><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Accrued Expenses and Other Current Liabilities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accrued personnel expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">273</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accrued clinical and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">245</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,559</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><a name="s4F491F2F5DDD5DA5846F899943575769"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Commitments and Contingencies </font></div></td></tr></table><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Legal Matters</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company&#8217;s industry is characterized by frequent claims and litigation, including claims regarding intellectual property. As a result, the Company may be subject to various legal proceedings from time to time. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Management is not aware of any pending or threatened litigation.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">105</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">License Agreement</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In December 2012, the Company entered into an exclusive worldwide royalty free license agreement with Merck Sharp &amp; Dohme Corp., or &#8220;Merck&#8221; for exclusive worldwide rights for the development and commercialization of serlopitant and two other NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists in all human diseases, disorders or conditions, except for the treatment and prevention of nausea or vomiting. The Company paid Merck an upfront non&#8209;refundable, non&#8209;creditable licensing fee of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;dollars and issued to Merck shares of its common stock. In addition, the Company has agreed to make aggregate payments of up to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$25.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;dollars upon the achievement of specified development and regulatory milestones.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Future milestone payments are considered to be contingent consideration and will be accrued when the applicable milestone is achieved. Through December 31, 2017, no milestones have been achieved under the license agreement. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company conducts its operations using leased office facilities. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In September 2017, the Company entered into a lease agreement.&#160;The </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">30</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;month lease, beginning on October 1, 2017, provides approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;square feet of office space in Redwood City, California.&#160;Base annual rent is approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$55,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;per month, with annual increases.  The Company recognizes rent expense on a straight&#8209;line basis over the respective lease period.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Rent expense for the years ended December 31, 2017, 2016 and 2015 was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$400,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$208,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$7,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December&#160;31, 2017, total future minimum lease payments under our operating leases are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51020408163265%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">Year ending December 31:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">675</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total future minimum lease payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,504</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Indemnification</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As permitted under Delaware law and in accordance with the Company&#8217;s bylaws, the Company is required to indemnify its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of December 31, 2017.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">From time to time, we may have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</font></div><div><a name="sCFE3ABD568D75E6A842BD09BD53DD0A2"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Convertible Preferred Stock</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December 31, 2017, the Company&#8217;s Certificate of Incorporation, as amended, authorized the Company to issue up to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">28,322,761</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares of convertible preferred stock, par value of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.001</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, of which </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;were designated Series A convertible preferred stock and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,106,583</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;are designated Series B convertible preferred stock, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,201,878</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares are designated Series C convertible preferred stock. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In July 2017, the Company issued </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,854,463</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares of Series C convertible preferred stock to investors at </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$4.26</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;per share with gross proceeds of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$50.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In January 2018, the Company completed its initial public offering (&#8220;IPO&#8221;) of shares of its common stock, pursuant to which the Company issued </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,050,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares of common stock, which includes </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,050,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares issued pursuant to the over-allotment option granted to its underwriters, and received net proceeds of approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$125.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, after deducting underwriting discounts, commissions and offering expenses. In </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">106</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">connection with the completion of the Company's IPO, all shares of convertible preferred stock converted into </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9,629,405</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares of common stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company had outstanding convertible preferred stock as of the times set forth below as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares Issued and Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Aggregate Liquidation Preference</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,106,583</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,106,583</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">45,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,201,878</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,854,463</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">50,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">28,322,761</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">25,975,346</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">109,800</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares Issued and Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Aggregate Liquidation Preference</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,106,583</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,106,583</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">45,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,120,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,120,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">59,300</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Significant terms of the Series A, B and C convertible preferred stock as of December 31, 2017 (collectively, the &#8220;Preferred Stock&#8221;) are as follows:</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Liquidation Preference</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In the event of any liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, the holders of the then outstanding shares of Series A convertible stock and Series B convertible preferred stock and Series C convertible preferred stock are first entitled to receive the amount of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$3.19</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$4.26</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;per share, respectively plus all declared but unpaid dividends for such shares, prior and in preference to any distribution of any assets of the Company to the holders of the common stock. If, upon the occurrence of such event, the proceeds distributed among the holders of the Series A, B and C convertible preferred stock are insufficient to permit the full payment of the aforesaid preferential amounts to each holder the convertible preferred stock, then the entire proceeds legally available for distribution to the convertible preferred stock shall be distributed ratably among the holders of the Series A, B and C convertible preferred stock in proportion to the full preferential amount that each such holder of convertible preferred stock is otherwise entitled to receive.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Upon completion of the distributions required by the above&#8209;mentioned liquidation preferences, any remaining proceeds shall be distributed among the holders of Series B and C convertible preferred stock and common stock pro rata based on the number of shares of common stock held by each, assuming full conversion of the Series B and C convertible preferred stock to common stock at the then&#8209;effective conversion price for such shares.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Dividends</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The holders of shares of Series A, B and C convertible preferred stock are entitled to receive non&#8209;cumulative </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">107</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">dividends, out of any assets legally available, prior and in preference to any declaration or payment of any dividend on the common stock, at the applicable dividend rate of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$80.00</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;per annum for each share of Series A convertible preferred stock, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.2552</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;per annum for each share of Series B convertible preferred </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">stock and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.3408</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;per share per annum for each share of Series C convertible preferred stock</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, all subject to adjustment from time to time for recapitalizations, payable when and if declared by the Company&#8217;s board of directors. The Company has never declared any dividends on its convertible preferred stock.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Voting</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The holder of each share of Series B and C convertible preferred stock are entitled to one vote for each share of common stock into which such preferred stock could then be converted and, with respect to such vote, such holder has full voting rights and powers equal to the voting rights and powers of the holders of common stock and is entitled to notice of any stockholders&#8217; meeting in accordance with the Company&#8217;s bylaws. The holders of shares of Series A convertible preferred stock do not have a right to vote, other than as required by Delaware law and for certain directors, as set forth below.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The holders of shares of Series A convertible preferred stock are entitled to elect </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">two</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;of the Company&#8217;s directors. The holders of Series B convertible preferred stock are entitled to elect </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">two</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;of the Company&#8217;s directors. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The holders of Series C convertible preferred stock are entitled to elect </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">one</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;of the Company&#8217;s directors. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The holders of outstanding common stock are entitled to elect </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">three</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;of the Company&#8217;s directors. The holders of convertible preferred stock and common stock, voting together as a single class, and not as separate series, and on an as converted basis, are entitled to elect any remaining directors of the Company, subject to the approval of the then serving members of the Company&#8217;s directors.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Conversion</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The holder of each share of convertible preferred stock has the option to convert each share of convertible preferred stock into such number of fully paid and nonassessable shares of common stock as is determined by dividing the applicable original issue price for such series by the applicable conversion price for such series in effect on the date the certificate is surrendered for conversion. Each share of convertible preferred stock shall automatically be converted into shares of common stock at the conversion rate at the time in effect for such series of convertible preferred stock immediately prior to the earlier of (i) sale of the Company&#8217;s common stock in a firm commitment underwritten public offering pursuant to a registration statement under the Securities Act of 1933, as amended, with gross proceeds of not less than </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$40.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;in the aggregate and an offering price to the public of no less than </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$17.21</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;per share, or (ii) upon the receipt by the Corporation of a written request or agreement of the holders of a majority of the outstanding Series A, B and C convertible preferred stock, voting together as a single class and on an as converted basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The conversion price of the convertible preferred stock was initially set at an amount equal to the issue price. The Series B and C convertible preferred stock conversion price is subject to adjustment for stock dividends, stock splits, re&#8209;capitalization and upon the occurrence of certain triggering events related to anti&#8209;dilution protection rights. In the event that a future preferred stock financing should occur at a price lower than the last preferred financing round, the conversion ratios of the existing preferred stock are changed to protect the ownership position of existing investors.</font></div><div><a name="sBB61D080D67F516894BA4BA3A647FC1A"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December 31, 2017, the Company&#8217;s Certificate of Incorporation, as amended, authorizes the Company to issue </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">55,000,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.0001</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;par value common stock. Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the board of directors, subject to the prior rights of holders of all classes of preferred stock outstanding. The Company has never declared any dividends on common stock. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, there were&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">12,548,103</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;shares of common stock reserved&#160;available&#160;for issuance.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">108</font></div></div><hr style="page-break-after:always"><div><a name="sB0B82C3B163A58AC9C7C0109C9554A2F"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under the Company&#8217;s 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;), the Company may grant options to purchase common stock, restricted stock awards, or directly issue shares of common stock to employees, directors and consultants of the Company. During 2015, the Company&#8217;s board of directors and stockholders approved an increase to the shares available under the 2011 Plan to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,086,600</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During 2017, the Company&#8217;s board of directors and stockholders approved an increase to the shares available under the 2011 Plan to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,339,724</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, there were&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">411,772</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;shares of common stock available&#160;for issuance under the 2011 Plan. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Options may be granted at an exercise price per share of not less than </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">100%</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;of the fair market value at the date of grant. If an incentive stock option is granted to a stockholder holding </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10%</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;of the Company&#8217;s outstanding capitalization, then the purchase or exercise price per share must not be less than </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">110%</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;of the fair market value per share of common stock on the grant date. Options granted are exercisable over a maximum term of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10 years</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;from the date of grant and generally vest over a period of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">four years</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total stock&#8209;based compensation expense for employees and non&#8209;employees recognized in the statements of operations was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">660</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">316</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">64</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total stock&#8209;based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">1,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">573</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">At December 31, 2017, there was approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$7.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;of unamortized compensation expense, which was expected to be recognized over a weighted average period of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2.9</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;years.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">2011 Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The table below summarizes stock option and restricted award activity under the 2011 Plan:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Number of Shares Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Weighted- Average Remaining Contractual Term (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Balances at January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">317,405</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">0.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Exercised </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(317,405</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">0.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Balances at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,485,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Balances at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,485,132</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.99</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9.32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,805</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,040,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Exercised </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(18,535</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Balances at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,506,926</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">8.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">24,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Includes early exercise of </font><font style="font-family:Trade Gothic;font-size:9.5pt;">317,405</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;options during the year ended </font><font style="font-family:Trade Gothic;font-size:9.5pt;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, of which </font><font style="font-family:Trade Gothic;font-size:9.5pt;">138,864</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic;font-size:9.5pt;">218,216</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;remain unvested as of December 31, 2017 and </font><font style="font-family:Trade Gothic;font-size:9.5pt;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">109</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Upon vesting of restricted shares and exercise of options, the Company issues common stock from its authorized shares. During the years ended December 31, 2017, 2016 and 2015, the Company received </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$34,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$98,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;upon the exercise of stock options, respectively. There were </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">139,636</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">222,077</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares of early exercised restricted shares which have not vested at December 31, 2017 and 2016, respectively. As of December 31, 2017 and 2016, the Company had recorded a liability of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$43,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$68,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively for the early exercise of stock options, recorded as other current liabilities and other non&#8209;current liabilities. When options are subject to the Company&#8217;s repurchase right, the Company may buy back any unvested shares at their original exercise price in the event of an employee&#8217;s termination prior to full vesting.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The aggregate grant date fair value of employee options vesting during the years ended December 31, 2017, 2016 and 2015 was approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$539,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$182,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively. The aggregate intrinsic value of shares exercised during the year ended December 31, 2017 and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$209,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">zero</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The weighted average grant date fair value of stock options granted was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$5.56</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1.79</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.15</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;per share during the years ended December 31, 2017, 2016, and 2015, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">There were </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">no</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares exercised in the year ended </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Stock Awards Granted to Employees and Directors</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock&#8209;based compensation expense is based on the grant date fair value. The Company recognizes compensation expense for all stock&#8209;based options and restricted awards on a straight&#8209;line basis over the requisite service period of the awards, which is generally the option vesting term of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">four</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;years. Stock&#8209; based compensation expense related to awards granted to employees and directors for the years ended December 31, 2017, 2016 and 2015 was approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$791,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$314,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;an </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option valuation model. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. Industry peers consist of several public companies in the biotechnology industry with comparable characteristics, including clinical trials progress and therapeutic indications.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The expected term of the options is based on the average period the stock options are expected to remain outstanding. As the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior, the expected term is calculated as the midpoint between the weighted-average vesting term and the contractual expiration period also known as the simplified method. The risk-free rate is based on U.S. Treasury zero coupon issues with remaining terms consistent with the expected terms of the stock options, as determined at the time of grant. To date, the Company has not declared or paid any cash dividends and does not have any plans to do so in the future. Therefore, the Company used an expected divided yield of zero.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition to the assumptions used in the Black&#8209;Scholes valuation model, the Company must also estimate a forfeiture rate to calculate the stock&#8209;based compensation for its equity awards. The Company will continue to use judgment in evaluating the assumptions related to the Company&#8217;s stock&#8209;based compensation on a prospective basis. As the Company continues to accumulate additional data, it may have refinements to its estimates, which could materially impact the Company&#8217;s future stock&#8209;based compensation expense. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">110</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following assumptions were used to calculate the fair value of awards granted to employees and directors during the years indicated:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:57%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">6.0 - 6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4.6 - 6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">3.1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">75% - 100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">68% - 74%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">74%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Risk&#8209;free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">1.9% - 2.3%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.3% - 2.1%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.0%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Dividend yield</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Stock-Based Compensation for Non-employees</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock&#8209;based compensation expense related to stock awards granted to non&#8209;employees is recognized as the awards vest. The Company believes that the fair value of the stock&#8209;based awards granted is more reliably measurable than the fair value of the services received. The fair value of stock awards granted is calculated using the Black&#8209;Scholes option valuation model. Stock&#8209; based compensation expense related to awards granted to non&#8209;employees for the years ended December 31, 2017, 2016 and 2015 was approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$661,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$259,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$64,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The fair values of common stock awards granted to non&#8209;employees were calculated using the following assumptions for the periods presented:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:57%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">8.3 - 10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9.3 - 10.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.0 - 1.8</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">74% - 100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">84% - 86%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">62% - 74%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Risk&#8209;free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">2.1% - 2.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.6% - 2.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">0.5% - 0.7%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Dividend yield</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">111</font></div></div><hr style="page-break-after:always"><div><a name="s37B4920BFD685EA8BF1794B306C9D5C4"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Net Loss per Share Attributable to Common Stockholders</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net loss attributable to common stockholders, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(29,076</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(14,068</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Weighted&#8209;average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,285,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,280,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,060,918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Less: weighted&#8209;average common shares subject to repurchase</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(177,421</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(292,925</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(325,770</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Weighted&#8209;average common shares used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,108,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4,987,133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4,735,148</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net loss per share attributable to common stockholders:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(5.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2.82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(0.97</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:60%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Convertible preferred stock issuable upon conversion to common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9,629,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,234,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,234,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Outstanding common stock subject to repurchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">139,636</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">222,077</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;">324,355</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,506,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,485,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock options available for issuance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">411,772</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">198,978</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,684,110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">12,687,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">7,140,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">7,243,265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><a name="sEA1193D01AB45791AAFE9F738DAED5B7"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Income Taxes</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company did not record a provision or benefit for income taxes during the years ended December 31, 2017, 2016 and 2015.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following is a reconciliation of the statutory federal income tax rate to the Company&#8217;s effective tax rate:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">112</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:624px;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:244px;"></td><td style="width:107px;"></td><td style="width:15px;"></td><td style="width:5px;"></td><td style="width:107px;"></td><td style="width:15px;"></td><td style="width:5px;"></td><td style="width:108px;"></td><td style="width:15px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Statutory Rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">State Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Permanent Differences</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">General Business Credits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Change in Valuation Allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(36</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Tax Reform - Tax Rate Change</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Deferred Tax Assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">NOLs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10,458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Depreciation and Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">226</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">328</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">362</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock&#8209;Based Compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research &amp; Development Credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,063</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">586</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">233</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Deferred Revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Other Accruals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">235</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">98</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total Deferred Tax Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Valuation Allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(14,993</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(11,631</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(6,621</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net Deferred Tax Assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-top:0px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-top:0px;text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-top:0px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-top:0px;text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-top:0px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-top:0px;text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The net change in the total valuation allowance for the years ended December 31, 2017, 2016 and 2015 was an increase of approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$3.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$5.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1.9 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December 31, 2017 and 2016, the Company had net operating loss carryforwards for federal income tax purposes of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$44.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$28.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively which expire beginning in the year 2031 and federal research and development tax credits of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$2.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively which expire beginning in the year 2031.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December 31, 2017 and 2016, the Company had net operating loss carryforwards for state income tax purposes of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$15.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$15.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively which expire beginning in the year 2031 and state research and development tax credits of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.9 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively which do not expire. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Federal and state tax laws impose substantial restrictions on the utilization of the net operating loss and credit carryforwards in the event of an ownership change as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&#8217;s ability to utilize these carryforwards may be limited as a result of such ownership change. Such a limitation could result in the expiration of carryforwards before they are utilized.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">113</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company has adopted ASC 740-10, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Accounting for Uncertainty in Income Taxes</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, that prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&#8217;s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction of the provision for income taxes in the period that such determination is made. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December 31, 2017 the Company had  </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">no</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;accrued interest and penalties related to uncertain tax positions.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company filed US and California tax returns with varying statues of limitations. The federal and California tax years from 2011 to 2017 remain open to examination due to the carryover of unused net operating losses and tax credits. The Company does not expect any material changes to the estimated amount of liability associated with its uncertain tax positions within the next 12 months.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Uncertain Tax Positions</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table summarizes the activity related to unrecognized tax benefits (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">For the year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Tax Benefits:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Unrecognized Benefit &#8209; beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">229</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">73</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Gross Increases(Decreases) &#8209; prior period tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Gross Increases(Decreases) &#8209; current period tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">515</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">136</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total Unrecognized Benefit &#8209; end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Tax Reform</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 34% to 21% (the &#8220;Rate Reduction&#8221;) effective for tax years beginning after December 31, 2017. The Company reduced deferred tax assets at December 31, 2017 for the effect of the Rate Reduction. The Rate Reduction did not impact the Company's provision for income taxes for 2017 due to the full valuation allowance on deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. The Company determined that </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$7.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;of the reduction in deferred tax assets resulting from Rate Reduction was both provisional and a reasonable estimate at December 31, 2017. Additionally, the Company is still in the process of analyzing certain provisions of the Act including the application of new executive compensation limitation provisions under Internal Revenue Section 162(m). These items are subject to revisions from further analysis of the Tax Act and interpretation of any additional guidance issued by the U.S. Treasury Department, IRS, FASB, and other standard-setting and regulatory bodies.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><a name="s6A02E0988CED521FAEBC5BDA28BBA536"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">From 2011 through 2016, the Company has operated with significant consulting and management services provided by Velocity Pharmaceutical Development, LLC (&#8220;VPD&#8221;). Development services fees paid to VPD under </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">114</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the Development Services Agreement were </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;for the years ended December 31, 2016 and 2015, respectively. The Company also reimbursed VPD for consulting, travel and other expenses incurred on our behalf. As of December 31, 2017 and 2016, the Company did not have any outstanding liabilities to VPD. Several managing directors of VPD have served as officers and directors of the Company. David Collier, M.D., a former member of the Company&#8217;s board of directors, is the Chief Executive Officer of VPD, and Xiaoming Zhang, Ph.D., our Senior Vice President, Non&#8209;Clinical and Pharmaceutical Development, is a Venture Partner of VPD.</font></div><div><a name="s5CC27F1DDFFE50D0B7A5A1A3CC482A2E"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Subsequent Events</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On January 8, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2018, the Company effected a reverse split of shares of the Company&#8217;s common stock at a ratio of 1-for-</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2.6975</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;pursuant to an amendment to the amended and restated certificate of incorporation approved by the Company&#8217;s board of directors and stockholders. The par value and the authorized</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">shares of the common stock were not adjusted as a result of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse split for all periods presented, and the conversion ratio of the preferred stock was adjusted accordingly. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company adopted a 2018 Omnibus Incentive Plan, or 2018 Plan, effective on January 23, 2018. The 2018 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights and other stock and cash-based awards (including annual cash incentives and long-term cash incentives). The Company has reserved for issuance pursuant to awards under the 2018 Plan, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,000,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company adopted a 2018 Employee Stock Purchase Plan, or ESPP, effective on January 23, 2018. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The ESPP will enable eligible employees of the Company and designated affiliates to purchase shares of common stock at a discount following its effectiveness. The Company has reserved </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">325,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares of common stock for issuance under the ESPP.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In January 2018, the Company completed its initial public offering (&#8220;IPO&#8221;) of shares of its common stock, pursuant to which the Company issued </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,050,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares of common stock and received net proceeds of approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$125.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, after deducting underwriting discounts, commissions and offering expenses. In connection with the completion of the Company's IPO, all shares of convertible preferred stock converted into </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9,629,405</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;shares of common stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">115</font></div></div><hr style="page-break-after:always"><div><a name="sfe941ec1c0e544c09349cc7bdf02332a"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">13. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Selected Unaudited Quarterly Financial Data</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following tables show a summary of the Company&#8217;s unaudited quarterly financial data for each of the four quarters of 2017 and 2016 (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:0%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:0%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:0%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:0%;"></td><td style="width:1%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="30" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">June 30,</font></div><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#160;2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Collaboration and service revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">2,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">909</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">12,252</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">9,244</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">6,675</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">6,004</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(9,277</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(8,172</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(6,153</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(5,474</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Basic and diluted net loss per common share (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(1.59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(1.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:0%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:0%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:0%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:0%;"></td><td style="width:1%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="30" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">June 30,</font></div><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#160;2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Collaboration and service revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">5,374</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">3,699</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">3,636</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">2,297</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(4,836</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(3,398</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(3,562</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(2,272</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Basic and diluted net loss per common share (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(0.96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(0.68</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(0.72</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(0.43</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Basic and diluted net loss per common share are computed independently for each of the quarters presented. Therefore, the sum of quarterly basic and diluted per share information may not equal annual basic and diluted net loss per common share.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><a name="s616adf60600d4a14a38228c5b456d56f"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Item 9.&#160; Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">None.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">116</font></div></div><hr style="page-break-after:always"><div><a name="sc216b2e3caf94cca89b62ceddc65dcd3"></a></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Item&#160;9A.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2017, the end of the period covered by this Annual Report on Form 10-K. Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">This Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of the Company&#8217;s independent registered public accounting firm due to a transition period established by the rules of the SEC for newly public companies.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:justify;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, because we are an &#8220;emerging growth company&#8221; under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting for so long as we are an emerging growth company.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">There was no change in our internal control over financial reporting</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;(as defined in Rules 13a-15(d) and 15d-15(d) of the Exchange Act) </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">that occurred during the most recent fiscal quarter covered by this Annual Report on Form 10-K that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">117</font></div></div><hr style="page-break-after:always"><div><a name="s4f30c20a6421476eaeaf09dccc76c121"></a></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Item 9B.&#160; Other Information.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">None</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">118</font></div></div><hr style="page-break-after:always"><div><a name="s2a8159d6328c457293ae0e3ac3f6860b"></a></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><a name="s6b56c5a68c564ca1971592cd5673a20b"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Item 10. Directors, Executive Officers and Corporate Governance. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Executive Officers and Directors</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table sets forth information regarding our executive officers, directors and key employees as of December 31, 2017:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Age</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Position(s)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Executive Officers and Employee Directors</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Steven Basta</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">52</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">President, Chief Executive Officer and Director</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Kristine Ball</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Senior Vice President, Corporate Strategy and Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Paul Kwon, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">47</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Chief Medical Officer</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Key Employees</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Mary Spellman, M.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Senior Vice President, Clinical Development</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Danine Summers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">60</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Senior Vice President, Medical Affairs</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Xiaoming Zhang, Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Senior Vice President, Non&#8209;Clinical and Pharmaceutical Development</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Non-Employee Directors</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Paul Berns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">51</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Director</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Albert Cha, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Director</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Ted Ebel</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">48</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Director</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">David McGirr</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Director</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Aaron Royston, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">33</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Director</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Scott Whitcup, M.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Director</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Executive Officers and Employee Directors </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Steven Basta</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">has served as our President and Chief Executive Officer and member of our board of directors since September 2015. From October 2011 until August 2015, Mr.&#160;Basta served as Chief Executive Officer of AlterG, a privately held medical device company. From November 2002 to February 2010, Mr.&#160;Basta served as Chief Executive Officer of BioForm Medical, a publicly listed medical aesthetics company acquired by Merz, and from February 2010 to September 2011 served as Chief Executive Officer of Merz Aesthetics, the successor to BioForm Medical. Mr. Basta served on the board of Carbylan, Inc. from September 2009 to November 2016. Mr. Basta served on the board of RF Surgical, Inc. (acquired by Medtronic) from December 2013 to August 2015. Mr.&#160;Basta received a B.A. from The Johns Hopkins University and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University. We believe Mr.&#160;Basta is qualified to serve as our President and Chief Executive Officer and on our board of directors because of his extensive experience in leadership and management roles at various life sciences companies.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Kristine Ball </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">has served as our Senior Vice President, Corporate Strategy and Chief Financial Officer since September 2017. From November 2012 through October 2016, Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc., a publicly&#8209;listed pharmaceutical company acquired by Galenica. Prior to </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">119</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Relypsa, Ms.&#160;Ball was an independent consultant from June 2011 to October 2012, advising start&#8209;up life science companies on various strategic and operational business matters. Prior to being a consultant, Ms.&#160;Ball was Senior Vice President of Finance and Administration and Chief Financial Officer of KAI Pharmaceuticals, Inc. (acquired by Amgen), a drug discovery company, from February 2005 to January 2011, where she was responsible for finance, administration and strategic planning and was involved in a venture capital financing, pharmaceutical partnerships and, as a consultant, KAI&#8217;s acquisition. Prior to KAI, Ms.&#160;Ball served as Vice President of Finance at Exelixis, Inc., a biotechnology company, from 2000 to 2005, where she was involved in four acquisitions and Exelixis&#8217; initial public offering and other financings. Prior to Exelixis, Ms.&#160;Ball was a senior manager in Ernst&#160;&amp; Young&#8217;s life sciences audit practice. Ms. Ball is currently a board member of a privately-held company, Forty Seven (since February 2018). Ms.&#160;Ball holds a B.S. from Babson College and is a certified public accountant. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Paul Kwon, M.D.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;has served as our Chief Medical Officer since January 2016. Dr. Kwon previously served as Chief Medical Officer at Nora Therapeutics, a biotechnology company focused on developing therapeutics to address significant unmet needs in reproductive medicine from November 2010 to November 2015. Prior to joining Nora Therapeutics, Dr. Kwon held numerous positions at Genentech, where he was most recently head of the non&#8209;oncology early clinical development group. Dr. Kwon was in clinical practice as a dermatologist from 2001 to 2003 and from 2009 to 2010 with the Permanente Medical Group in Northern California, where he served as a consultant for the Permanente Technology Group. Dr. Kwon served as Assistant Clinical Professor of Dermatology at the University of California at San Francisco from 2004 to 2014. Dr. Kwon earned his B.A. in Human Biology from Stanford University and an M.D. from the University of California at San Francisco. He is a diplomate of the American Board of Dermatology and a fellow of the American Academy of Dermatology. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Key Employees</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Mary Spellman, M.D.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;has served as our Senior Vice President, Clinical Development since August 2017. Previously, Dr. Spellman was an independent consultant providing executive level medical, safety and development services to multiple life sciences companies, primarily supporting novel dermatology therapy and clinical development programs from August 2012 to August 2017. Prior to establishing her consulting practice, Dr. Spellman was Chief Medical Officer and Senior Vice President, Development at Revance Therapeutics, as well as Senior Director, Medical Research, Immunology at Biogen Idec, and Vice President, Dermatology Research at Connetics Corporation. Dr. Spellman is a board&#8209;certified dermatologist with over 30 years of clinical experience, including 20 years in the biopharmaceutical industry. Dr. Spellman received a BS, Honors in Biology from Loyola University of Chicago and earned her M.D. from the Medical College of Wisconsin. Sh</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">e is a diplomate of the American Board of Dermatology and a fellow of the American Academy of Dermatology.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Danine Summers</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;has served as our Senior Vice President, Medical Affairs since March 2017. Previously, from March 2013 to February 2017, Ms. Summers was Senior Vice President, Medical Affairs at Anacor Pharmaceuticals, where she participated in preparing the organization for two product launches, with responsibility for technology platform and clinical data communication and key opinion leader relationships. From February 2007 to December 2012, Ms. Summers was the Vice President, Medical Affairs for Medicis Pharmaceutical, where she led the organization&#8217;s medical information management, publications, educational grants, investigator&#8209;initiated study grants and health economics outcomes research. Ms. Summers has 35 years of experience in the pharmaceutical industry, the last 20 in dermatology specifically. Ms. Summers received a B.A. from San Jose State University and an M.B.A. in Marketing from Golden Gate University.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Xiaoming Zhang, Ph.D. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">has served as our Senior Vice President, Non&#8209;Clinical and Pharmaceutical Development since November 2015. Previously, Dr. Zhang was a Venture Partner at Velocity Pharmaceutical Development, where he provided non&#8209;clinical and CMC&#8209;related expertise to several project&#8209;focused companies. In 2010, Dr. Zhang co&#8209;founded Theron Pharmaceuticals, a clinical&#8209;stage company developing a bronchodilator for the treatment of chronic obstructive pulmonary disease and uncontrolled asthma. Prior to Theron, Dr. Zhang was Senior Director of Chemistry at CoMentis, Inc. where he led the research effort targeting Alzheimer&#8217;s disease and cognitive deficit associated with schizophrenia. Dr. Zhang previously served in scientific or program leadership roles at Millennium Pharmaceuticals, Portola Pharmaceuticals and Roche. Dr. Zhang received a B.S. from Donghua University, Shanghai and a Ph.D. from the University of Maryland, College Park, in the field of synthetic organic chemistry and pursued postdoctoral research at the University of California, Berkeley.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">120</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Non-Employee Directors</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Paul Berns</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;has served as a member of our board of directors since November 2017.  Mr. Berns has been a consultant to the pharmaceutical industry since July 2016, as well as from August 2012 to March 2014 and from July 2005 to March 2006. From March 2014 to June 2016, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Mr. Berns served as President and Chief Executive Officer at Anacor Pharmaceuticals, Inc. a biopharmaceutical company, which was acquired by Pfizer Inc. in 2016. Previously, Mr. Berns served as President and Chief Executive Officer of Allos Therapeutics,&#160;Inc., a biopharmaceutical company, from March 2006 to September 2012, when it was acquired by Spectrum Pharmaceuticals,&#160;Inc. Mr. Berns was President and Chief Executive Officer of Bone Care International,&#160;Inc., a specialty pharmaceutical company, from June 2002 to July 2005, when it was acquired by Genzyme Corporation. Prior to that, Mr. Berns was Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories from 2001 to 2002, and from 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll, when it was acquired by Abbott Laboratories in 2001. Earlier in his career, Mr.&#160;Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company from 1990 to 2000. Mr. Berns is currently a board member of the privately held company, MC2 Therapeutics (since May 2017), and the publicly held company, Jazz Pharmaceuticals,&#160;PLC (since April 2010). Mr. Berns previously served on the boards of Anacor Pharmaceuticals, Inc. (from June 2012 to June 2016), XenoPort,&#160;Inc. (from November 2005 to May 2016), Allos Therapeutics, Inc. (from March 2006 to September 2012) and Bone Care International, Inc. (from June 2002 to July 2005). Mr.&#160;Berns received his B.S. in Economics from the University of Wisconsin. We believe that Mr. Berns is qualified to serve on our board of directors because of his extensive experience in the biopharmaceutical industry and his service as a director of a number of public pharmaceutical companies.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Albert Cha, M.D., Ph.D.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;has served as a member of our board of directors since November 2015. In 2000, Dr. Cha joined Vivo Capital, a healthcare investment firm, where he has served in various positions, and he currently serves as a Managing Partner. Dr. Cha currently serves as a member of the boards of directors of several publicly and privately held biotechnology and medical device companies, including the following publicly listed companies: Ascendis Pharma A/S (since November 2014), Biohaven Pharmaceutical Holding Co. Ltd. (since February 2017) and KalVista Pharmaceuticals (since 2007). Dr. Cha was a board member of AirXpanders, Inc. from January 2012 to July 2016, a board member of Aclaris Therapeutics from August 2012 to August 2016, and a board member of Sierra Oncology, Inc. from August 2014 to June 2016.  Dr. Cha holds B.S. and M.S. degrees in Electrical Engineering from Stanford University and an M.D. degree and Ph.D. degree in Neuroscience from the University of California at Los Angeles. We believe that Dr. Cha&#8217;s substantial experience with companies in the healthcare sector and his financial and business experience qualify him to serve as a director of our Company.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Ted Ebel </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">has served as a member of our board of directors since March 2014. Mr. Ebel has served as Chief Business Officer at Colorescience since March 2013. Prior to that, he was Senior Vice President of Corporate Development for SkinMedica, Inc. from March 2006 to December 2012, having responsibility for mergers and acquisitions, licensing, intellectual property management, market research and establishing the company&#8217;s international operations. Previously, Mr. Ebel served as the Executive Director of Corporate Development at CancerVax Corporation, a biotechnology company focused on cancer immunotherapy, and as the Vice President of Strategic Ventures for MP3.com, a publicly traded internet and entertainment company. In addition, Mr. Ebel held positions in marketing and corporate development at Amgen, Inc. and began his career as a consultant in the health care practice of the management consulting firm Arthur D. Little. Mr. Ebel earned an A.B., Magna Cum Laude from Duke University and his M.B.A. from the Wharton School at the University of Pennsylvania. We believe that Mr. Ebel is qualified to serve on our board of directors because of his background working in the dermatology industry and his experience in strategic planning, business transactions, sales operations and executive leadership.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">David McGirr</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;has served as a member of our board of directors since November 2017.  From March 2013 until June 2014, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Mr. McGirr was Senior Advisor to the Chief Executive Officer of Cubist Pharmaceuticals, Inc., a biopharmaceutical company, where he also served as Senior Vice President and Chief Financial Officer from November 2002 to March 2013.  Prior to that, Mr. McGirr was the President and Chief Operating Officer of hippo inc., a venture-financed internet technology company, where Mr. McGirr also served as a member of its board of directors from 1999 to 2003. Previously, Mr. McGirr was the President of GAB Robins North America, Inc., a risk management company, serving also as Chief Executive Officer from 1997 to 1999. Prior to that, Mr. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">121</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">McGirr was a private equity investor from 1995 to 1996. Earlier in his career, Mr. McGirr served in various positions within the S.G. Warburg Group from 1978 to 1995, ultimately as Chief Financial Officer, Chief Administrative Officer and Managing Director of S.G. Warburg &amp; Co., Inc., a position held from 1992 to 1995. Mr. McGirr is currently a board member of the following publicly listed companies: Arsanis, Inc. (since September 2017), Insmed Incorporated (since October 2013), Rhythm Pharmaceuticals, Inc. (since November 2015) and previously served on the boards of LifeCell Corporation (from November 2007 to June 2008), Relypsa, Inc. (from November 2012 to September 2016) and Roka Bioscience, Inc. (from October 2013 to January 2018). Mr. McGirr received his B.Sc. in Civil Engineering from the University of Glasgow and his M.B.A. from The Wharton School at the University of Pennsylvania. We believe that Mr. McGirr is qualified to serve on our board of directors because of his experience as an executive officer or director of a number of public and private pharmaceutical companies.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Aaron Royston, M.D.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;has served as a member of our board of directors since July 2017. Dr. Royston has served as a Partner at venBio, a life sciences investment firm, which he joined in November 2015. Prior to joining venBio, Dr. Royston worked for Vivo Capital, a global life sciences investment firm from July 2014 to October 2015. Previously, he worked at Bain &amp; Company from July 2013 to July 2014, where he advised biotechnology companies on a broad range of strategic and operational issues. Earlier in his career, Dr. Royston coordinated clinical research at Mount Sinai Medical Center, where his research has been published and presented in multiple medical journals and conferences. Dr. Royston received his B.S. in biological sciences from Duke University, and his M.D. and M.B.A. degrees from the University of Pennsylvania. In 2011, Dr. Royston was recognized by the Obama Administration as a Champion of Change for his work in technology and innovation. We believe that Dr. Royston is qualified to serve on our board of directors due to his clinical and biotechnology industry experience.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Scott Whitcup, M.D.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;has served as a member of our board of directors since February 2016. Dr. Whitcup is founder and Chief Executive Officer of Akrivista and Whitecap Biosciences, two companies focused on the development and commercialization of novel therapies in ophthalmology and dermatology. Previously, Dr. Whitcup held various research and development roles from 2000 to 2015 at Allergan, including serving as Executive Vice President, Research and Development and Chief Scientific Officer, where he led the discovery and global development of both pharmaceutical products and medical devices in therapeutic areas including ophthalmology, CNS, urology, dermatology, medical aesthetics and surgical obesity. Before Allergan, Dr. Whitcup was the Clinical Director at the National Eye Institute at the NIH, and Chaired the NIH Medical Executive Committee. Dr.&#160;Whitcup holds a B.A. in Neurobiology and Behavior from Cornell University and an M.D. from Cornell University Medical College. Dr. Whitcup has completed a residency in Internal Medicine at UCLA, a residency in Ophthalmology at Harvard Medical School&#8209;Massachusetts Eye &amp; Ear Infirmary and a fellowship in Uveitis and Ocular Immunology at the National Eye Institute, National Institutes of Health. He is a Diplomate of both the American Board of Internal Medicine and the American Board of Ophthalmology, a licensed M.D. in California and is on the Clinical Faculty of the Department of Ophthalmology, at the Jules Stein Eye Institute, David Geffen School of Medicine at the University of California at Los Angeles. Dr. Whitcup has published more than 250 scientific articles and co&#8209;authored a leading textbook on uveitis and ocular immunology. Dr. Whitcup currently serves on the boards of Semnar Pharmaceutical and Nightstar Therapeutics and previously served on the board of Avanir Pharmaceutical, a publicly listed company, from November 2005 to January 2014. We believe that Dr. Whitcup is qualified to serve on our board of directors due to his clinical development expertise, medical and scientific expertise and his leadership experience with life sciences companies.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Audit Committee</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our audit committee oversees our corporate accounting and financial reporting process. Among other matters, the audit committee:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">appoints our independent registered public accounting firm;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">evaluates the independent registered public accounting firm&#8217;s qualifications, independence and performance; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">determines the engagement of the independent registered public accounting firm;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">122</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reviews and approves the scope of the annual audit and the audit fee;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">discusses with management and the independent registered public accounting firm the results of the annual audit and the review of our quarterly financial statements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">approves the retention of the independent registered public accounting firm to perform any proposed permissible non&#8209;audit services;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">monitors the rotation of partners of the independent registered public accounting firm on our engagement team in accordance with requirements established by the SEC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">is responsible for reviewing our financial statements and our management&#8217;s discussion and analysis of financial condition and results of operations to be included in our annual and quarterly reports to be filed with the SEC; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reviews our critical accounting policies and estimates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">reviews the audit committee charter and the committee&#8217;s performance at least annually.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The current members of our audit committee are Messrs. McGirr, Berns and Ebel, with Mr. McGirr serving as the chairperson of the committee. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq Stock Market LLC. Our board of directors has determined that Mr. McGirr is an audit committee financial expert as defined under the applicable rules of the SEC and has the requisite financial sophistication as defined under the applicable rules and regulations of the Nasdaq Stock Market LLC. Under the rules of the SEC, members of the audit committee must also meet heightened independence standards. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">However, so long as at least one member of the audit committee satisfies the heightened audit committee independence standards on the date of the effectiveness of the registration statement, a majority of members of the audit committee may be exempt from the heightened audit committee independence standards for 90 days from such date and a minority of members of the audit committee may be exempt from the heightened audit committee independence standards for one year from such date. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our board of directors has determined that Messrs. McGirr, Berns and Ebel are independent under the applicable rules of the SEC and the Nasdaq Stock Market LLC. The audit committee operates under a written charter that satisfies the applicable standards of the SEC and the Nasdaq Stock Market LLC.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Compensation Committee Interlocks and Insider Participation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During the year ended December 31, 2017, our compensation committee consisted of Dr. Cha and Messrs. Ebel and McGirr. None of the members of our compensation committee during 2017 nor any of the current members of our compensation committee has at any time been one of our officers or employees. An affiliate of Dr. Cha, Vivo Capital VIII, L.P., has participated in multiple of our equity financing rounds, and acquired shares in our initial public offering. For more information regarding these transactions, see &#8220;Certain Relationships and Related Party Transactions&#8221;. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers on our board of directors or compensation committee.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Code of Business Conduct and Ethics </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have adopted a code of business conduct and ethics that applies to all of our employees, officers and directors, including those officers responsible for financial reporting. Our code of business conduct and ethics is available on our website at www.menlotherapeutics.com. Any amendments to the code, or any waivers of its requirements, will be disclosed on our website. The reference to our web address does not constitute incorporation by reference of the information contained at or available through our website. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Section 16(a) Beneficial Ownership Reporting Compliance</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Section 16(a) of the Exchange Act requires our directors, executive officers and beneficial owners of more than 10% of our common stock to file reports of holdings and transactions in our common stock and our other securities with the SEC. Our directors, executive officers and beneficial owners of more than 10% of our common stock did not become subject to such Section 16(a) reporting requirements until January 29, 2018, after the completion of our fiscal year ended December 31, 2017.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">123</font></div></div><hr style="page-break-after:always"><div><a name="s8FBFC44B270A59069B686D053D06A6DA"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Item 11. Executive Compensation. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following is a discussion of compensation arrangements of our named executive officers, or NEOs. As an &#8220;emerging growth company&#8221; as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our Chief Executive Officer and our other executive officers for the year ended December&#160;31, 2017 were: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Steven Basta, President and Chief Executive Officer;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Kristine Ball, Senior Vice President, Corporate Strategy and Chief Financial Officer; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Paul Kwon, M.D., Chief Medical Officer.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We refer to these executive officers as our named executive officers, or NEOs.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Summary Compensation Table </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table shows information regarding the compensation of our named executive officers for services performed in the year ended December&#160;31, 2017. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Name and Principal Position</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Salary ($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Bonus($) (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Option </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Awards</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">($)(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Non-Equity </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Incentive Plan </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Compensation</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">All Other </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Compensation</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Total ($)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Steven Basta</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">555,900</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">83,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">376,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,015,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">President and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">555,900</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">419,417</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">975,317</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Kristine Ball</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">118,030</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">53,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">825,066</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">996,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Senior Vice President, Corporate Strategy and Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Paul Kwon, M.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">370,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">196,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">78,878</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">645,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Chief Medical Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">328,125</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">98,115</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">193,217</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">619,457</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Bonus represents discretionary amounts paid based on 2016 performance and paid in 2017 and discretionary amounts paid based on 2017 performance and to be paid during the first quarter of 2018. In addition, Dr. Kwon received a one-time performance bonus of $30,000 which was based on 2017 performance and paid in 2017. Mr. Basta was not eligible for a bonus payment for 2016 performance.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The amounts reported in the option awards column represent the grant date fair value of the stock options granted to our named executive officers during 2016 and 2017 as computed in accordance with ASC 718. The assumptions used in calculating the grant date fair value of the stock options reported in the option awards column are set forth in Note 8 to the audited financial statements included in this Annual Report on Form 10-K. Note that the amounts reported in this column reflect the accounting cost for these stock options, and do not correspond to the actual economic value that may be received by our named executive officers from the options. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;">Our named executive officers will only realize compensation at exercise to the extent the trading price of our common stock is greater than the exercise price of such stock options.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;">Ms. Ball joined the Company in September 2017.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">124</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Outstanding Equity Awards at Fiscal Year End</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table sets forth all outstanding equity awards held by each of the named executive officers as of December 31, 2017. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:3%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Option Awards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Stock Awards</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Vesting <br>Commencement</font><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;"><br></font><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Date</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Number of <br>Securities <br>Underlying <br>Unexercised <br>Options <br>Exercisable</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Number of <br>Securities <br>Underlying <br>Unexercised <br>Options <br>Unexercisable</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Option<br>Exercise<br>Price</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Option<br>Expiration</font><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;"><br></font><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Number<br>of<br>Shares<br>or Units<br>of Stock<br>That<br>Have<br>Not<br>Vested</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Market<br>Value of<br>Shares</font><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;"><br></font><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">or Units<br>of Stock<br>That<br>Have<br>Not<br>Vested</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">($)(5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Equity <br>Incentive <br>Plan <br>Awards: <br>Number <br>of <br>Unearned <br>Shares, <br>Units or <br>Other <br>Rights <br>That <br>Have Not <br>Vested</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">Equity <br>Incentive <br>Plan <br>Awards: <br>Market <br>or Payout <br>Value of <br>Unearned <br>Shares, <br>Units or <br>Other <br>Rights <br>That <br>Have Not <br>Vested</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;font-weight:bold;">(#)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">Steven Basta</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">9/1/2015</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">(2)</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">138,865</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">2,360,705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">11/30/2015</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">184,681</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">186,960</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">1.83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">2/2/2026</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">08/24/2017</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6pt;">(4)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">7,075</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">77,834</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">4.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">8/24/2027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:10px;text-indent:-11px;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">Kristine Ball</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">9/11/2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">173,123</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">4.83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">9/14/2027</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:10px;text-indent:-11px;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">Paul Kwon, M.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">1/25/2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">81,809</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">88,923</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">1.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">2/2/2026</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">8/24/2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">1,481</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">16,299</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">4.83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">8/24/2017</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:6.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Except as otherwise noted, options and restricted stock grants vest and, if applicable, become exercisable as to 1/4th of the shares underlying the option or restricted stock grant on the first anniversary of the vesting commencement date and as to 1/48th of the shares underlying the option or restricted stock grant on each monthly anniversary of the vesting commencement date thereafter, subject to the holder continuing to provide services to us through such vesting date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Constitutes 317,405 shares of restricted stock that were issued upon exercise of an immediately exercisable stock option for $0.31 per share, of which 138,865 shares remain subject to repurchase by us at the original purchase price in the event Mr. Basta ceases to provide services to us prior to completion of vesting. The remaining shares of restricted stock vest in equal monthly installments through September 1, 2019.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Option award is exercisable immediately, subject to a repurchase right in favor of the Company which lapses as the option vests. Accordingly, the disclosure in the table above reflects the extent to which this stock option held by Mr. Basta was vested (as opposed to exercisable) as of December&#160;31, 2017. This option award vests as to 1/48th of the shares underlying the award on each monthly anniversary of the vesting commencement date, subject to Mr Basta continuing to provide services to us through such vesting date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">These option awards vest and, if applicable, become exercisable as to 1/48th of the shares underlying the award on each monthly anniversary of the vesting commencement date thereafter, subject to the holder continuing to provide services to us through such vesting date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Amounts are calculated by multiplying the number of shares shown in the table by $17.00, the initial public offering price per share.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Narrative to Summary Compensation Table and Outstanding Equity Awards at Fiscal Year End </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have entered into agreements with each of our named executive officers in connection with his or her employment with us. These agreements set forth the terms and conditions of employment of each NEO, including base salary, initial equity award grants and standard employee benefit plan participation. Our board of directors or the compensation committee reviews each NEO&#8217;s base salary and other compensation from time to time to ensure compensation adequately reflects the NEO&#8217;s qualifications, experience, role and responsibilities.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2017 Salaries</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">For fiscal year 2017, Mr. Basta&#8217;s annual base salary was $555,900, Ms. Ball&#8217;s annual base salary was $380,000, prorated to reflect her September 2017 start date with the Company, and Dr. Kwon&#8217;s annual base salary was $370,000.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">125</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Terms and Conditions of 2017 Annual Bonuses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Each NEO&#8217;s target bonus opportunity is expressed as a percentage of base salary that can be achieved by meeting corporate objectives at a target level. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Each of our NEO&#8217;s target bonus opportunity is originally set in their employment agreements with us. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The 2017 annual bonus for Mr. Basta, Ms. Ball and Dr. Kwon were targeted at 10%, 30% and 30% of their respective base salaries. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">For 2017, all of our NEOs were eligible to earn their annual bonuses pursuant to the achievement of certain performance goals. The performance goals for annual bonuses are reviewed and approved annually by the compensation committee of our board of directors. Following a review of the corporate goals attained in 2017, the overall bonus funding was approved at </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">150% of the target for 2017, and each of our NEO&#8217;s annual bonus was paid at 150% of his or her target bonus amount. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Thus, for fiscal year 2017, Mr. Basta&#8217;s bonus was $83,400, Ms. Ball&#8217;s bonus was $53,200 and Dr. Kwon&#8217;s bonus was $166,500. In addition, Dr. Kwon received a one-time performance bonus for $30,000 which was based on 2017 performance and paid during 2017. </font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:normal;font-weight:normal;">2017 </font><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:normal;">Equity Award Grants</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">All of our NEOs received options to purchase our common stock in fiscal year 2017. See the table above entitled &#8220;Outstanding Equity Awards at Fiscal Year End&#8221; regarding equity awards made in the past fiscal year to our NEOs. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In accordance with Mr. Basta&#8217;s option agreement and offer letter, on the date of a &#8220;Change in Control&#8221; transaction (as defined in</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;the 2011 Stock Incentive Plan, or the &#8220;2011 Plan&#8221;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">), vesting will accelerate with respect to 100% of the options and restricted stock that Mr. Basta holds immediately prior to the Change in Control transaction.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In accordance with our standard form option agreement and form option grant notice, (i) in connection with an Acquisition Event (as defined in the 2011 Plan), each option granted to Ms. Ball and Dr.&#160;Kwon that </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">is scheduled to vest and, if applicable, become exercisable, on or after the twelve month anniversary of such Acquisition Event (ignoring, for this purpose, any accelerated vesting provisions) shall instead vest and, if applicable, become exercisable on the date of such twelve month anniversary</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, subject to the absence of a Termination (as defined in the 2011 Plan) with respect to Ms. Ball and Dr. Kwon and (ii) each option granted to Ms. Ball and Dr. Kwon vests as to 100% of the number of shares subject to such options upon an Acquisition Event if, in connection with or during the twelve month period following an Acquisition Event, either of them incurs a Termination of services as the result of (a) an involuntary termination by the Company without Cause (as defined in the 2011 Plan) or (b) a voluntary termination of service by Ms. Ball and Dr. Kwon for Good Reason (as defined in the 2011 Plan), in each case provided that Ms. Ball and Dr. Kwon execute a general release of claims in favor of us. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under Ms. Ball&#8217;s employment agreement, vesting will also accelerate automatically for the remaining unvested shares upon the 1-year anniversary following a &#8220;change of control&#8221; transaction (as defined in the 2011 Plan), subject to Ms. Ball&#8217;s continued employment during that period.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Change in Control and Severance Provisions</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Steven Basta. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under Mr. Basta&#8217;s employment agreement, in the event Mr. Basta&#8217;s employment with us is terminated without &#8220;cause&#8221; (as defined below) or he resigns from his employment for &#8220;good reason&#8221; (as defined below), and Mr. Basta executes and does not revoke a general release of claims in favor of us, then Mr. Basta will receive the following: (i) an amount equal to his base salary that would have been earned during the twelve months following the date of termination (the &#8220;CEO severance period&#8221;), payable in one lump sum; (ii) continued health benefits pursuant to COBRA for the CEO severance period; and (iii) any stock options or restricted stock awards held by Mr. Basta will become vested and if applicable, exercisable with respect to that number of shares of our common stock that would have vested if Mr. Basta had remained employed during the CEO severance period. Such payments during the CEO severance period will commence on the 60</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;day following Mr. Basta&#8217;s termination date.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, on the date of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">completion</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;of a &#8220;Change in Control&#8221; transaction (as defined in the 2011 Plan), (i) the vesting with respect to 100% of the remaining unvested stock options and other equity awards held by Mr. Basta will accelerate; </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(ii) Mr. Basta will be entitled to receive payment of any target bonus amount pro&#8209;rated for the period from January 1 of the year of termination through the date of the Change in Control; and (iii) Mr. Basta will be entitled to payment of full potential target bonus amount during the CEO severance period.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">126</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">For purposes of Mr. Basta&#8217;s employment agreement:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8220;cause&#8221; means if it has caused or is reasonably expected to result in material injury to the Company: (i) the executive&#8217;s gross negligence or willful failure substantially to perform his or her duties and responsibilities to the Company or deliberate violation of a Company policy, which failure is not corrected&#160;within 30 days&#160;after the board of directors has given the executive written notice specifying the failure in reasonable detail, and he or she had an opportunity to address the board of directors with, at the executive&#8217;s option, counsel present; (ii) the executive&#8217;s intentional commission of any act of fraud, embezzlement or dishonesty against the Company or any other willful misconduct; (iii) the executive&#8217;s improper, unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom the executive owes an obligation of nondisclosure as a result of his or her relationship with the Company; or (iv) the executive&#8217;s willful breach of any material obligations under any written agreement or covenant with the Company, which failure is not corrected&#160;within 30 days&#160;after the board of directors has given the executive written notice specifying the failure in reasonable detail, and the executive has had an opportunity to address the board of directors with, at the executive&#8217;s option, counsel present.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8220;good reason&#8221; means the occurrence at any time of any of the following without the executive&#8217;s prior written consent: (i) removal from the current executive officer position held by such executive with respect to the Company resulting in a material diminution of the executive&#8217;s authority, duties or responsibilities (other than a mere change in title following any merger or consolidation of the Company with another entity); (ii) the assignment of duties or responsibilities materially inconsistent with those customarily associated with the position of such executive officer or a material diminution of the executive&#8217;s position, authority, duties or responsibilities (other than a mere change in title following any merger or consolidation of the Company with another entity); (iii) a material reduction in the executive&#8217;s base salary; (iv) any willful failure or willful breach by the Company of any of the material obligations of the executive&#8217;s employment agreement; or (v) a requirement that the executive relocate his principal place of business by more than 50 miles; provided that the executive will not be deemed to have good reason unless (a) the executive first provides the Company with written notice of the condition giving rise to good reason&#160;within 90 days&#160;of its initial occurrence, and (b) the Company fails to cure such condition&#160;within 30 days&#160;after receiving such written notice.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Kristine Ball.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;Under Ms. Ball&#8217;s employment agreement, in the event Ms. Ball&#8217;s employment with us is terminated without &#8220;cause&#8221; (as defined below) or she resigns from her employment for &#8220;good reason&#8221; (as defined below), and Ms. Ball executes and does not revoke a general release of claims in favor of us, then Ms. Ball will receive an amount equal to six months of her base salary (the &#8220;severance benefits&#8221;).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">For purposes of Ms. Ball&#8217;s employment agreement:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8220;cause&#8221; means (i) the executive&#8217;s gross negligence or willful failure substantially to perform his or her duties and responsibilities to the Company or deliberate violation of a Company policy; (ii) the executive&#8217;s intentional commission of any act of fraud, embezzlement or dishonesty against the Company or any other willful misconduct that has caused or is reasonably expected to result in material injury to the Company; (iii) the executive&#8217;s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom the executive owes an obligation of nondisclosure as a result of his or her relationship with the Company; or (iv) the executive&#8217;s willful breach of any obligations under any written agreement or covenant with the Company.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8220;good reason&#8221; means the occurrence at any time of any of the following without the executive&#8217;s prior written consent: (i) a material diminution of the executive&#8217;s authority, duties or responsibilities (other than a mere change in title following any merger or consolidation of the Company with another entity); (ii) the assignment of duties or responsibilities materially inconsistent with those customarily associated with the position of such executive officer or a material diminution of the executive&#8217;s position, authority, duties or responsibilities (other than a mere change in title following any merger or consolidation of the Company with another entity); (iii) a material reduction in the executive&#8217;s base salary; (iv) any willful failure or willful breach by the Company of any of the material obligations of the executive&#8217;s employment agreement; or (v) a requirement that the executive relocate executive&#8217;s principal place of business by more than 50 miles; provided that the executive will not be deemed to have good reason unless (a) the executive first provides the Company with written notice  of the condition giving rise to good reason within 90 days of its initial occurrence, and (b) the Company fails to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">127</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">cure such condition within 30 days after receiving such written notice.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Paul Kwon, M.D.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;Under Dr. Kwon&#8217;s employment agreement, in the event Dr. Kwon&#8217;s employment with us is terminated without &#8220;cause&#8221; (as defined below) or he resigns from his employment for &#8220;good reason&#8221; (as defined below), and Dr. Kwon executes and does not revoke a general release of claims in favor of us, then Dr. Kwon will receive the following: an amount equal to his base salary that would have been earned during the six months following the date of termination (the &#8220;SVP severance period&#8221;), payable in one lump sum. Such payments will be made on the 60</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;day following Dr. Kwon&#8217;s termination date.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, in the event termination without &#8220;cause&#8221; or for &#8220;good reason&#8221; of Dr. Kwon occurs in connection with or following a change of control, Dr. Kwon will be entitled to (i) an amount equal to his base salary that would have been earned during the SVP severance period; (ii) payment of any target bonus amount pro&#8209;rated for the period from January 1 of the year of termination through the termination date; (iii) payment of full potential target bonus amount during the SVP severance period; and (iv) acceleration of vesting with respect to 100% of the remaining unvested stock options and other equity awards held by Dr. Kwon on the date of consummation of the change of control transaction.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">For purposes of the employment agreement of Dr. Kwon:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8220;cause&#8221; means (i) the executive&#8217;s gross negligence or willful failure substantially to perform his or her duties and responsibilities to the Company or deliberate violation of a Company policy; (ii) the executive&#8217;s intentional commission of any act of fraud, embezzlement or dishonesty against the Company or any other willful misconduct that has caused or is reasonably expected to result in material injury to the Company; (iii) the executive&#8217;s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom the executive owes an obligation of nondisclosure as a result of his or her relationship with the Company; or (iv) the executive&#8217;s willful breach of any obligations under any written agreement or covenant with the Company.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8220;good reason&#8221; means the occurrence at any time of any of the following without the executive&#8217;s prior written consent: (i) a material diminution of the executive&#8217;s authority, duties or responsibilities (other than a mere change in title following any merger or consolidation of the Company with another entity); (ii) the assignment of duties or responsibilities materially inconsistent with those customarily associated with the position of such executive officer or a material diminution of the executive&#8217;s position, authority, duties or responsibilities (other than a mere change in title following any merger or consolidation of the Company with another entity); (iii) a material reduction in the executive&#8217;s base salary; (iv) any willful failure or willful breach by the Company of any of the material obligations of the executive&#8217;s employment agreement; (v) a requirement that the executive relocate his principal place of business by more than 50 miles; or (vi) a requirement that he travel more than 30% of the time;&#160;provided, that, the executive will not be deemed to have good reason unless (a) the executive first provides the Company with written notice of the condition giving rise to good reason&#160;within 90 days&#160;of its initial occurrence, and (b) the Company fails to cure such condition&#160;within 30 days&#160;after receiving such written notice.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Terms and Conditions of 401(k) Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We participate in a tax&#8209;qualified retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees are able to defer eligible compensation subject to applicable annual Internal Revenue Code (the &#8220;Code&#8221;) limits. Employees&#8217; pre&#8209;tax contributions are allocated to each participant&#8217;s individual account and are then invested in selected investment alternatives according to the participants&#8217; directions. Employees are immediately and fully vested in their contributions. The 401(k) plan is intended to be qualified under Section 401(a) of the Code with the 401(k) plan&#8217;s related trust intended to be tax exempt under Section 501(a) of the Code. As a tax&#8209;qualified retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k) plan.</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Employee Benefits and Perquisites</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">All of our full&#8209;time employees, including our NEOs, are eligible to participate in our health and welfare plans, including medical, dental and vision benefits, medical and dependent care flexible spending accounts, short&#8209;term and long&#8209;term disability insurance and life insurance. Unlike the cap that we have for the payment of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">128</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">monthly health care premiums for each of our non&#8209;executive, full&#8209;time employees, we pay the full monthly health premium costs for each of our executive officers, including our NEOs. Other than the payment of health care premiums in full, we do not provide our NEOs with perquisites or other personal benefits, other than the retirement, health and welfare benefits that apply uniformly to all of our employees.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Director Compensation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our board of directors has adopted the following compensation policy that is applicable to all of our non-employee directors upon completion of our initial public offering in January 2018:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Initial Equity Grants.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;Each non-employee director who joins the board receives an option to purchase common stock with a Black-Scholes value of $180,000, with the shares subject to the option vesting in three equal installments on each anniversary of the director&#8217;s service, subject to continued service.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Annual Retainers.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;At each annual meeting of stockholders, each non-employee director who has served in such capacity for at least six months will receive an additional retainer for service on the board consisting of an option to purchase common stock with a Black-Scholes value of $90,000, with the shares subject to the option vesting one year after the grant date, subject to continued service. In addition, each of our non-employee directors will receive an annual cash retainer of $40,000, and our non-employee directors will also receive annual cash compensation for service as chair of our board of directors or as lead independent director, if such positions are appointed, or as a member or chair of committees of our board of directors, as set forth in the table below:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:71%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Additional annual retainer fees for service as Chair of the Board</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$40,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Additional annual retainer fees for service as Lead Independent Director</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$25,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Additional annual retainer fees for service as a member or chair of</font></div><div style="padding-bottom:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">(with chair fees inclusive of fees for service as a member):</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Member</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Audit Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$8,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$16,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Compensation Committee</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$12,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Nominating and Corporate Governance Committee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$4,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$8,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The exercise price per share of each option granted under this policy will be equal to the per share fair market value of our stock on the date of grant. Each such option will have a term of ten years from the date of grant, subject to earlier termination in connection with a termination of the non-employee director&#8217;s service with us. In the event of a change of control transaction, any unvested portion of an equity award granted under this policy will fully vest and become exercisable immediately prior to the effective date of such transaction, subject to the non-employee director&#8217;s continuous service with us on the effective date of such transaction.  Cash retainers will be paid on a quarterly basis in arrears, pro-rated based on the days served in the applicable fiscal quarter. In addition, none of our non-employee directors shall in any event be permitted to receive cash and equity-based compensation (calculated based on grant date fair value) exceeding, in the aggregate, $500,000 in any calendar year.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our director compensation policy was adopted by our board of directors in consideration of a number of factors, including its assessment of a director compensation report from Compensia, which our board of directors engaged to prepare a competitive assessment of non-employee director compensation. The Compensia report delivered to our board of directors in December 2017 recommended a director compensation program based on the 50</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;percentile of a comparator group. In November 2017, our board of directors adopted a policy to pay each non-employee director, excluding those affiliated with principal investors in our company, an annual cash retainer of $25,000 and to grant each such non-employee director an option to purchase 43,280 shares of our common stock upon joining our board of directors. In accordance with the policy, in November 2017, we granted each of Messrs. McGirr and Berns an option to purchase 43,280 shares of our common stock at an exercise price of $7.01 per share. The options granted to Messrs. McGirr and Berns each vest as to 1/4th of the shares underlying such option on the first anniversary of the vesting commencement date and as to 1/48th of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">129</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">such shares underlying the option on each monthly anniversary of the vesting commencement date thereafter, subject to the director&#8217;s continued service to us through the applicable vesting date. In addition, Mr. Ebel was granted an option in November 2017 to purchase 9,097 shares of common stock at an exercise price of $7.01 per share to bring his compensation in line with the non-employee director compensation policy. The option granted to Mr. Ebel vests in equal monthly installments over four years from the date of grant, subject to his continued service to us through the applicable vesting date.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Prior to the adoption of these non-employee director compensation policies, we did not have a formalized non-employee director compensation program. We granted Mr. Ebel a restricted stock purchase award for 12,355 shares of common stock in August 2014, along with an annual cash retainer of $20,000, payable quarterly, in consideration for his becoming a member of, and rendering services to, our board of directors. The restricted stock vests monthly over four years from the vesting commencement date of March 18, 2014, subject to Mr. Ebel&#8217;s continued service to us through the end of the vesting period.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Additionally, in connection with their services as directors, in February 2016, we granted each of Dr. Whitcup and Mr. Ebel an option to purchase 121,964 and 18,164 shares of common stock, respectively. The options granted to Dr. Whitcup and Mr. Ebel have an exercise price of $1.83 per share and vest monthly over four years from the respective vesting commencement dates of December 10, 2015, and February 2, 2016 subject to the director&#8217;s continued service to us through the applicable vesting date. We also reimburse all of our non&#8209;employee directors for all reasonable and customary business expenses incurred in the performance of their duties to us in accordance with Company policy.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In August 2017, we granted Dr. Whitcup and Mr. Ebel refresh option awards with respect to 14,635 and 3,662 shares, respectively, in connection with their continued service as directors. The awards have an exercise price of $4.83 per share and vest monthly over four years from the vesting commencement date of August 24, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition, from time to time, we have compensated directors for additional services provided outside their role as director. For example, during 2016, we entered into a consulting agreement with Dr. Collier, a former member of our board of directors, pursuant to which Dr. Collier provides certain advisory and support services in exchange for options to purchase 31,489 shares of our common stock, with an exercise price of $1.83 per share. The option granted to Dr. Collier vests in two equal tranches. The first tranche of 15,744 shares vests in equal monthly installments over the 48 months commencing on March 8, 2016, and the second tranche of 15,744 shares vests in equal monthly installments over the 12 months commencing on August 10, 2016, the date we entered into the Collaboration Agreement with JT Torii, in each case subject to Dr.&#160;Collier&#8217;s continued service to us through the vesting date.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We also reimburse all of our non-employee directors for all reasonable and customary business expenses in accordance with company policy.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">130</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;font-weight:bold;">Director Compensation Table</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table sets forth information for the fiscal year ended December 31, 2017 regarding the compensation awarded to, earned by or paid to our non&#8209;employee directors:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Fees Earned or Paid</font></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">in Cash ($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Option</font></div><div style="padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Awards ($)</font></div><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#160;(1) (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Total ($)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Albert Cha, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Paul Berns</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">2,083</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">406,304</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">408,387</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">David Collier, M.D.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">John Creecy</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Ted Ebel</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">20,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">101,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">121,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">David McGirr</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">2,083</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">406,304</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">408,387</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Aaron Royston, M.D.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Scott Whitcup, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">64,926</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">64,926</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The amounts reported in the Option Awards column represent the grant date fair value of the stock options granted to the non&#8209;employee members of our board of directors during 2017 as computed in accordance with ASC 718. The assumptions used in calculating the grant date fair value of the stock options reported in the Option Awards column are set forth in Note 8 to the audited financial statements included in this Annual Report on Form 10-K. Note that the amounts reported in this column reflect the accounting cost for these stock options, and do not correspond to the actual economic value that may be received by the non&#8209;employee members of our board of directors from the options.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December&#160;31, 2017, our non&#8209;employee directors held options to purchase the following number of shares of our common stock: Mr. McGirr: 43,280 shares, Mr. Berns: 43,280 shares, Mr. Ebel: 30,923&#160;shares, and Dr. Whitcup: 136,599. In addition, Mr. Ebel held 12,355 shares of restricted stock which vest in equal installments through March 18, 2018, subject to Mr. Ebel&#8217;s continued service to us through the applicable vesting date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Messrs. Berns and McGirr joined our board of directors in November 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">David Collier, M.D. and John Creecy are former members of our board of directors.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">131</font></div></div><hr style="page-break-after:always"><div><a name="sfba4e6e2619643399cfbffddfd8f2eab"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table sets forth information relating to the beneficial ownership of our common stock as of February 28, 2018, by:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding shares of common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">each of our directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">each of our named executive officers; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">all of our current directors and executive officers as a group.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The number of shares beneficially owned by each entity, person, director or executive officer is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60 days after February 28, 2018 through the exercise of any stock option, warrants or other rights. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock held by that person.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The percentage of shares beneficially owned is computed on the basis of 22,977,998 shares of our common stock outstanding as of February 28, 2018. Shares of our common stock that a person has the right to acquire within 60 days after February 28, 2018 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. Unless otherwise indicated below, the address for each beneficial owner listed is c/o Menlo Therapeutics Inc., 200 Cardinal Way, 2nd Floor, Redwood City, California 94063</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">132</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.93162393162393%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:58%;"></td><td style="width:2%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:2%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Name of Beneficial Owner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Number of Shares Owned and Nature of Beneficial Ownership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Percent of Class</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">5% and Greater Stockholders:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Funds Affiliated with Vivo Capital</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">4,011,236</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">17.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Remeditex Ventures, LLC</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">2,761,663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">12.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Funds Affiliated with Presidio Partners</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">2,456,478</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">10.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Merck Sharp &amp; Dohme Corp.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">1,243,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">venBio Global Strategic Fund II, L.P.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(5)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">1,461,552</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">6.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Novo Holdings A/S</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(6)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">1,161,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">FMR LLC </font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">7)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">1,118,054</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">4.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">Named Executive Officers and Directors:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Steven Basta</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(8)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">577,693</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">2.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Kristine Ball</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(9)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Paul Kwon</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(10)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">98,999</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">David McGirr</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(11)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Paul Berns </font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(12)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Albert Cha, M.D., Ph.D.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">4,011,236</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">17.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Aaron Royston, M.D.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(5)(13)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Ted Ebel</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(14)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">23,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Scott Whitcup, M.D.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(15)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">73,584</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:12px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">All current directors and executive officers as a group (9&#160;persons)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(16)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">4,785,074</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">20.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Indicates beneficial ownership of less than 1% of the total outstanding common stock.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The information reported is based on a Schedule 13G filed with the SEC on February 2, 2018 which reports that, as of January 29, 2018, (a) 3,524,541 shares are held  by Vivo Capital Fund VIII, L.P. (&#8220;Vivo Capital&#8221;) and (ii) 486,695 shares  are held by Vivo Capital Surplus Fund VIII, L.P. (&#8220;Vivo Surplus&#8221;). Vivo Capital VIII, LLC (&#8220;Vivo LLC&#8221;) is the general partner of both Vivo Capital and Vivo Surplus. The voting members of Vivo Capital are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these shares, but each of whom may be deemed to have shared voting and dispositive power with respect to these shares and each of whom disclaims beneficial ownership of such shares. The address of Vivo Capital and Vivo Surplus is 505 Hamilton Ave, Suite 207, Palo Alto, CA 94301.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The information reported is based on a Form 4 filed with the SEC on January 29, 2018 which reports that, as of January 29, 2018, 2,761,663 shares are k held by Remeditex Ventures, LLC (&#8220;Remeditex&#8221;). The address of Remeditex is 2727 North Harwood, Suite 200, Dallas, Texas 75201. John Creecy is the chief executive officer of Remeditex, and as such may be deemed to have shared voting and dispositive control over the shares held by Remeditex.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The information reported is based on a Form 4 filed with the SEC on January 29, 2018 which reports that, as of January 29, 2018, (i) 61,410 shares were held by Presidio Partners 2007 (Parallel), L.P. (&#8220;Presidio Parallel&#8221;) and (ii) 2,395,068 shares were held by Presidio Partners 2007, L.P. (&#8220;Presidio Partners&#8221;). Presidio Partners 2007 GP, L.P. (&#8220;Presidio GP&#8221;) is the sole general partner of Presidio Parallel and Presidio Partners. Dr. David Collier, James Watson and Faysal Sohail are the general partners of Presidio GP and may be deemed to have shared voting and dispositive control over the shares held by Presidio Parallel and Presidio Partners. The address of Presidio Parallel and Presidio Partners is 655 Montgomery Street, Suite 6-161, San Francisco, CA 94111.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">133</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The information reported is based on a Schedule 13G filed with the SEC on February 14, 2018 which reports that, as of January 29, 2018, 1,243,168 shares were held by Merck Sharp and Dohme Corp., a direct, wholly owned subsidiary of Merck &amp; Co., Inc., (&#8220;Merck&#8221;) a publicly traded company. Merck is an indirect beneficial owner of the reported securities. The address of Merck Sharp and Dohme Corp. is 126 E. Lincoln Avenue, RY70&#8209;200, Rahway, NJ 07065&#8209;0900.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The information reported is based on a Schedule 13G filed with the SEC on February 14, 2018 which reports that, as of January 29, 2018, 1,461,552 shares were held by venBio Global Strategic Fund II, L.P. (&#8220;venBio&#8221;). The address of venBio is 1700 Owens Street, Suite 595, San Francisco, California 94158. venBio Global Strategic GP II, L.P. (&#8220;venBio GP&#8221;) is the sole general partner of venBio. venBio Global Strategic GP II, Ltd. (&#8220;venBio Ltd.&#8221;) is the sole general partner of venBio GP. Robert Adelman and Corey Goodman are the directors of venBio Ltd. and may be deemed to have shared voting and dispositive control over the shares held by venBio. Dr. Royston is an affiliate of venBio and disclaims beneficial ownership in shares held by venBio except to the extent of any pecuniary interest therein.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The information reported is based on a Schedule 13G filed with the SEC on February 14, 2018 which reports that, as of January 29, 2018, 1,161,182 shares were held by Novo Holdings A/S, a Danish limited liability company, is wholly owned by Novo Nordisk Fonden (the &#8220;Foundation&#8221;), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S, Novozymes A/S and NNIT A/S) and is responsible for managing the Foundation&#8217;s assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The information reported is based on a Schedule 13G filed with the SEC on February 14, 2018 and a Form 4 filed with the SEC on January 29, 2018 which both report that, as of January 29, 2018, 1,118,054 shares were held by F&#8209;Prime Capital Partners Healthcare Fund IV LP (&#8220;F&#8209;Prime&#8221;). The general partner of F-Prime is F-Prime Capital Partners Healthcare Advisors Fund IV, LP (&#8220;FPCPHA&#8221;). &#160;FPCPHA is solely managed by Impresa Management LLC, the general partner of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR, LLC. The address of F&#8209;Prime is One Main Street, 13th Floor, Cambridge, Massachusetts 02142.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(8)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Consists of (i) 18,535 shares of common stock, (ii) 252,085 shares of common stock held by The Shelter Trust under the Basta Revocable Trust (the &#8220;Shelter Trust&#8221;), (iii) 65,319 shares of common stock held by the Basta Revocable Trust dated August 4, 2017 (the &#8220;Basta Trust&#8221;), and (iv) 241,753 shares of common stock issuable upon the exercise of stock options within 60 days of February 28, 2018. As a trustee of each of the Shelter Trust and the Basta Trust, Mr. Basta has shared voting and investment power over the shares of common stock held by each of the Shelter Trust and the Basta Trust.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(9)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">No shares were issuable upon the exercise of options within 60 days of February 28, 2018. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(10)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Consists of 98,99 shares of common stock issuable upon the exercise of stock options within 60 days of February 28, 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(11)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">No shares were issuable upon the exercise of options within 60 days of February 28, 2018 </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(12)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">No shares were issuable upon the exercise of options within 60 days of February 28, 2018. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(13)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Dr. Royston is an affiliate of venBio, but disclaims beneficial ownership in shares held by venBio except to the extent of any pecuniary interest therein. See note (5) above.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(14)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Consists of (i) 12,355 shares of common stock, and (ii) 11,207 shares of common stock issuable upon the exercise of stock options within 60 days of February 28, 2018</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(15)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Consists of 73,584 shares of common stock issuable upon the exercise of stock options within 60 days of February 28, 2018.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">134</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(16)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Beneficial ownership consists of (i) 4,359,531 shares of common stock and (ii) 425,543 shares of common stock that may be acquired pursuant to the exercise of stock options within 60 days of February 28, 2018. Beneficial ownership also includes 294,118 shares of common stock</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Equity Compensation Plan Information </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table contains information about our equity compensation plans as of December 31, 2017. As of December 31, 2017, we had one equity compensation plan, our 2011 Stock Incentive Plan, which was approved by our board of directors and our stockholders. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:25%;"></td><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:1%;"></td></tr><tr><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:16px;text-align:center;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">Equity Compensation Plan Information</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">Plan Category</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:16px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><br></font></div><div style="padding-top:16px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">Number of securities to be issued upon exercise of outstanding options, warrants and rights</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">Weighted-average exercise price of outstanding options, warrants and rights</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;font-weight:bold;">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Equity compensation plans approved  by security holders</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">2,506,926</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">3.50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">411,772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Equity compensation plans not approved by security holders</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">2,506,926</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">3.50</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">411,772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In connection with our IPO, our board of directors and stockholders approved two new equity compensation plans, the Menlo Therapeutics, Inc. 2018 Omnibus Incentive Plan (the &#8220;2018 Plan&#8221;), the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The 2018 Plan and the ESPP became effective on January 29, 2018. The table above does not include any amounts issuable under either the 2018 Plan or the ESPP.</font></div><div><a name="s441532c6419948ccbea091879a5ea9cf"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following is a description of transactions since January 1, 2017 to which we have been a party, in which the amount involved exceeds $120,000, and in which any of our directors, executive officers or beneficial owners of more than 5% of our capital stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">135</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Sales and Purchases of Securities</font></div><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Series C Preferred Stock Financing</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In July 2017, we issued an aggregate of 11,854,463 shares of our Series C convertible preferred stock at a price per share of $4.26 for aggregate proceeds to us of $50.5 million. The table below sets forth the number of shares of Series C convertible preferred stock sold to our directors, executive officers or beneficial owners of more than 5% of a class of our capital stock, or an affiliate or immediate family member thereof:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Number of Shares of Series C Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Number of Shares <br>of Common Stock Issuable upon Conversion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Purchase Price ($)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Presidio Partners 2007, L.P.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">352,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">130,532</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,500,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Remeditex Ventures, LLC</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">821,596</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">304,576</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,499,999</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Vivo Capital Fund VIII, L.P.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,816,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,044,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">12,000,003</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">F-Prime Capital Partners Healthcare Fund IV LP </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">821,596</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">304,576</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,499,999</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#ccecff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">venBio Global Strategic Fund II, L.P.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(5)</sup></font></div></td><td style="vertical-align:bottom;background-color:#ccecff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ccecff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,227,700</font></div></td><td style="vertical-align:bottom;background-color:#ccecff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#ccecff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#ccecff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,196,552</font></div></td><td style="vertical-align:bottom;background-color:#ccecff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#ccecff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#ccecff;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#ccecff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">13,750,002</font></div></td><td style="vertical-align:bottom;background-color:#ccecff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Consists of (i) 8,803 shares of Series C convertible preferred stock purchased by Presidio Partners 2007 (Parallel), L.P. (&#8220;Presidio Parallel&#8221;) and (ii) 343,310 shares of Series C convertible preferred stock purchased by held by Presidio Partners 2007, L.P. (&#8220;Presidio Partners&#8221;). David Collier, M.D., who was a member of our board of directors at the time of the Series C convertible preferred stock financing, is an affiliate of Presidio Parallel and Presidio Partners.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">John Creecy, who was a member of our board of directors at the time of the Series C convertible preferred stock financing, is an affiliate of Remeditex Ventures, LLC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Consists of (i) 2,475,118 shares of Series C convertible preferred stock purchased by Vivo Capital Fund VIII, L.P. (&#8220;Vivo Capital&#8221;) and (ii) 341,784 shares of Series C convertible preferred stock purchased by Vivo Capital Surplus Fund VIII, L.P. (&#8220;Vivo Surplus&#8221;). Albert Cha, M.D., Ph.D., who is a member of our board of directors, is an affiliate of Vivo Capital and Vivo Surplus.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Ketan Patel, M.D., who was a member of our board of directors at the time of the Series C preferred stock financing, is an affiliate of F&#8209;Prime Capital Partners Healthcare Fund IV LP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Aaron Royston, M.D., who is a member of our board of directors, is an affiliate of venBio Global Strategic Fund II, L.P.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:2px;padding-top:5px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-style:normal;font-weight:bold;">Participation in our IPO</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In connection with our IPO, certain of our existing institutional investors, including investors affiliated with certain of our directors, purchased an aggregate of 1,684,118 shares of our common stock at the initial public offering price and on the same terms as the other purchasers in  our IPO. The following table summarizes common stock purchased by members of our board of directors and entities who held more than 5% of our outstanding capital stock at the time of the purchase. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;text-decoration:underline;">Name</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;text-decoration:underline;">Number of Purchased Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;text-decoration:underline;">Aggregate Purchase Price</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:8px;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Vivo Capital LLC</font><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">294,118</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$5,000,006</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">Remeditex Ventures LLC</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">100,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$1,700.000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">venBio Partners, LLC</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">265,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9pt;">$4,505,000</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Director and Executive Officer Compensation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Please see &#8220;Director Compensation&#8221; and &#8220;Executive Compensation&#8221; for information regarding the compensation of our directors and executive officers. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">136</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Employment Agreements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have entered into employment agreements with our executive officers. For more information regarding these agreements, see &#8220;Executive Compensation&#8212;Narrative to Summary Compensation Table and Outstanding Equity Awards at Fiscal Year End.&#8221; </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Indemnification Agreements and Directors&#8217; and Officers&#8217; Liability Insurance</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We have entered into or intend to enter into indemnification agreements with each of our directors and executive officers. These agreements require us to, among other things, indemnify each director and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#8217; fees, judgments, penalties fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#8217;s services as a director or executive officer. We have obtained an insurance policy that insures our directors and officers against certain liabilities, including liabilities arising under applicable securities laws. For additional information see &#8220;Management&#8212;Limitation of Liability and Indemnification Matters.&#8221;</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Investors&#8217; Rights Agreements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">We entered into a second amended and restated investors&#8217; rights agreement with the purchasers of our outstanding preferred stock, including entities with which certain of our directors are affiliated. As of December 31, 2017, the holders of approximately 12.6 million shares of our common stock, including the shares of common stock issuable upon the conversion of our Series A, Series B and Series C convertible preferred stock, are entitled to rights with respect to the registration of their shares under the Securities Act. The investor rights agreement also provided for a right of first offer in favor of certain holders of preferred stock with regard to certain issuances of our securities. The right of first offer terminated upon completion of our January 2018 initial public offering.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Independence of Board of Directors and its Committees</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under the rules of the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Nasdaq Stock Market LLC</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, independent directors must comprise a majority of a listed company&#8217;s board of directors within a specified period of the closing of our initial public offering. In addition,</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and corporate governance&#160;committees be independent. Under the rules of Nasdaq, a director will only qualify as an &#8220;independent director&#8221; if, in the opinion of that company&#8217;s board of&#160;directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Audit committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1)&#160;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries; or (2)&#160;be an affiliated person of the listed company or any of its subsidiaries. We currently satisfy the audit committee independence requirements of Rule 10A-3. Additionally, compensation committee members must not have a relationship with us that is material to the director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our board of directors has undertaken a review of the independence of each director and considered whether each director has a material relationship with us that could compromise his ability to exercise independent judgment in carrying out his responsibilities. As a result of this review, our board of directors determined that all of our directors, except for Mr.&#160;Basta, are &#8220;independent directors&#8221; as defined under the applicable rules and regulations of the SEC, and the listing requirements and rules of Nasdaq. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Policies and Procedures for Related Party Transactions</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Our board of directors has adopted a written related person transaction policy effective in January 2018, setting forth the policies and procedures for the review and approval or ratification of related person transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation S&#8209;K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">137</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">which we were or are to be a participant, where the amount involved exceeds $120,000 and a related person had or will have a direct or indirect material interest, including without limitation purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee will be tasked to consider all relevant facts and circumstances, including but not limited to whether the transaction is on terms comparable to those that could be obtained in an arm&#8217;s length transaction with an unrelated third party and the extent of the related person&#8217;s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><a name="s38c71ed005c04965a26be26792ed57c3"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Item&#160;14. Principal Accounting Fees and Services.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table&#160;summarizes the fees of&#160;Mayer Hoffman McCann, our independent registered public accounting firm,&#160;billed us for each of the years ended December 31, 2017 and 2016.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:622px;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:340px;"></td><td style="width:17px;"></td><td style="width:21px;"></td><td style="width:100px;"></td><td style="width:4px;"></td><td style="width:8px;"></td><td style="width:21px;"></td><td style="width:20px;"></td><td style="width:86px;"></td><td style="width:4px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;color:#000000;font-weight:bold;">&#160;Fiscal Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;color:#000000;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8.5pt;color:#000000;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Audit-related Fees</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">236,172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">45,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Total Fees</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">236,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">45,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)&#160;Fees for 2017 related to the audit of our 2017 financial statements and efforts incurred through December&#160;31, 2017 related to our initial public offering (which was completed in January 2018).</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;All fees described above were pre-approved by the Audit Committee.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">PRE-APPROVAL POLICIES AND PROCEDURES</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Audit Committee has adopted a policy and procedures for the pre-approval of audit and non-audit services rendered by the Company&#8217;s independent registered public accounting firm, Mayer Hoffman McCann. The policy generally pre-approves specified services in the defined categories of audit services, audit-related services and tax services up to specified amounts. Pre-approval may also be given as part of the Audit Committee&#8217;s approval of the scope of the engagement of the independent auditor or on an individual, explicit, case-by-case basis before the independent auditor is engaged to provide each service. The pre-approval of services may be delegated to one or more of the Audit Committee&#8217;s members, but the decision must be reported to the full Audit Committee at its next scheduled meeting.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Audit Committee has determined that the rendering of services other than audit services by Mayer Hoffman McCann is compatible with maintaining the principal accountant&#8217;s independence.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><a name="sccb79c034c7148d596f9939b169c2ff4"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><a name="s735D6C38FAA35889A4476785E1A54C82"></a></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Item 15. Exhibits and Financial Statement Schedules.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">(a) Exhibits.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;See the Exhibit Index immediately preceding the signature page to this Report on Form 10-K, which is incorporated by reference herein.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">(b) Financial Statement Schedules.</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#32;Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">138</font></div></div><hr style="page-break-after:always"><div><a name="s80E903C3F4A950C7B5957E62D0E75C59"></a></div><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Exhibit Index</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Exhibit</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Exhibit Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828017012730/s-1exhibit31.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Form of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-222324) filed January 12, 2018).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828017012730/s-1exhibit35.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Amended and Restated Bylaws, currently in effect (incorporated by reference to Exhibit 3.5 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-222324) filed December 28, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Reference is made to exhibits 3.1 and 3.2.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828018000299/s-1a1exhibit42.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Form of Common Stock Certificate. (incorporated by reference to Exhibit 4.2 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-222324) filed January 12, 2018).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828017012730/s-1exhibit43.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Second Amended and Restated Investors&#8217; Rights Agreement, dated June 28, 2017, by and among the Company and the investors listed therein (incorporated by reference to Exhibit 4.3 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-222324) filed December 28, 2017).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828018000456/s-1a2exhibit101.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Exclusive License Agreement, dated as of December 20, 2012, by and between the Company and Merck Sharp &amp; Dohme Corp (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-222324) filed January 18, 2018).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.2*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828018000456/s-1a2exhibit102.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">License and Collaboration Agreement, dated as of August 10, 2016, by and among the Company, Torii Pharmaceutical Co. Ltd. and Japan Tobacco, Inc (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-222324) filed January 18, 2018).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828017012730/s-1exhibit103.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Sublease, dated September 19, 2017, by and between the Company and Relypsa, Inc. (incorporated by reference to Exhibit 10.3 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-222324) filed December 28, 2017).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.4(a)#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828017012730/s-1exhibit104a.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2011 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.4(a) of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-222324) filed December 28, 2017).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.4(b)#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828017012730/s-1exhibit104b.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Amendment to 2011 Stock Incentive Plan (incorporated by reference to Exhibit 10.4(b) of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-222324) filed December 28, 2017).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.4(c)#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828017012730/s-1exhibit104c.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Form of Stock Option Agreement under 2011 Stock Incentive Plan (incorporated by reference to Exhibit 10.4(c) of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-222324) filed December 28, 2017).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.4(d)#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828017012730/s-1exhibit104d.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Form of Immediately Exercisable Stock Option Agreement under 2011 Stock Incentive Plan (incorporated by reference to Exhibit 10.4(d) of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-222324) filed December 28, 2017).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.5(a)#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828018000299/s-1a1exhibit105a.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2018 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.5(a) of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-222324) filed December 28, 2017).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.5(b)#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828018000299/s-1a1exhibit105b.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.5(b) of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-222324) filed December 28, 2017).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.6#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828018000299/s-1a1exhibit106.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2018 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-222324) filed December 28, 2017).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.7#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828017012730/s-1exhibit107.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Offer Letter, dated as of August 17, 2015 by and between the Company and Steven Basta (incorporated by reference to Exhibit 10.7 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-222324) filed December 28, 2017).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.8#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828017012730/s-1exhibit108.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Offer Letter, dated as of January 14, 2016 by and between the Company and Paul Kwon (incorporated by reference to Exhibit 10.8 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-222324) filed December 28, 2017).</font></a></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">139</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.9#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828017012730/s-1exhibit109.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Offer Letter, dated as of August 15, 2017 by and between the Company and Kristine Ball (incorporated by reference to Exhibit 10.9 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-222324) filed December 28, 2017).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10.10#</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1566044/000162828017012730/s-1exhibit1010.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Form of Indemnification Agreement for directors and executive officers to be entered into following the offering (incorporated by reference to Exhibit 10.12 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-222324) filed December 28, 2017).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">23.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex231123117.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Consent of independent registered public accounting firm.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex311123117.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex312123117.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ex321123117.htm"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Certifications of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">XBRL Instance Document.</font></div><div style="font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Schema Document.</font></div><div style="font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">*</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Registrant has omitted and filed separately with the SEC portions of the exhibit pursuant to a confidential treatment request under Rule 406 promulgated under the Securities Act.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">#</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Indicates management contract or compensatory plan.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">140</font></div></div><hr style="page-break-after:always"><div><a name="sB5F0F198126A5B2E9D899CDBED4D3C3B"></a></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:24px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Signatures</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.88034188034188%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Menlo Therapeutics Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">/s/ Steven Basta</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Steven Basta</font></div><div style="padding-bottom:1px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">March 28, 2018</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">/s/ Steven Basta</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">President, Chief Executive Officer and Director</font></div><div style="padding-bottom:1px;text-align:center;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Steven Basta</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">/s/ Kristine Ball</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Senior Vice President, Corporate Strategy and Chief&#160;Financial&#160;Officer</font></div><div style="padding-bottom:1px;text-align:center;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">(Principal Financial and Accounting Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Kristine Ball</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">/s/ Paul Berns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Paul Berns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">/s/ Albert Cha, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Albert Cha, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">/s/ Ted Ebel</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Ted Ebel</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">/s/ David McGirr</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">David McGirr</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">/s/ Aaron Royston, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Aaron Royston, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">/s/ Scott Whitcup, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">March 28, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Scott Whitcup, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">141</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex231123117.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9A4A20256E980D7E6BB95411E88FD317"></a></div><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;text-indent:480px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;EXHIBIT 23.1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">We hereby consent to the incorporation by reference in Registration Statement No. 333-222758 on Form S-8 of Menlo Therapeutics Inc., of our report dated March 28, 2018,</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">relating to the financial statements, which appear in this Form 10-K.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">/s/ Mayer Hoffman McCann P.C.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">San Diego, California</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">March 28, 2018</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex311123117.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sfd26c8c2c4cc437ea0e852a809d6c53c"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Steven Basta, certify that:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:77.734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Menlo Therapeutics Inc.;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.6015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:84.5703125%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:84.9609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:84.9609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:84.765625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:84.765625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:84.5703125%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:84.9609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&#160;</font><font style="font-family:inherit;font-size:6pt;">&#160;&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 28, 2018</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Steven Basta</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Chief&#160;Executive&#160;Officer and Director</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex312123117.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s42031a219db04c31ab6742c04a56f6dd"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;<br>Exhibit 31.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Kristine Ball, certify that:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:76.953125%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:9%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Menlo Therapeutics Inc.;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:8%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:8%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:8%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:8%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:15%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&#160;</font><font style="font-family:inherit;font-size:6pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 28, 2018</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Kristine Ball</font></div><div style="line-height:120%;text-align:left;padding-left:14px;text-indent:0px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#32;&#32;&#32;&#32;Senior Vice President, Corporate Strategy and Chief&#160;Financial&#160;Officer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex321123117.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6c9d12e033e44fd584ee3837e0d7fe45"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:14px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Annual Report of Menlo Therapeutics Inc. (the &#8220;Company&#8221;) on Form 10-K for the fiscal year ended December 31, 2017, as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), Steven Basta, President and Chief Executive Officer of the Company, and Kristine Ball, </font><font style="font-family:inherit;font-size:9.5pt;">Senior Vice President, Corporate Strategy and Chief&#160;Financial&#160;Officer </font><font style="font-family:inherit;font-size:10pt;">of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:8%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:8%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: March 28, 2018</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Steven Basta</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Chief&#160;Executive&#160;Officer and Director</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Kristine Ball</font></div><div style="line-height:120%;text-align:left;padding-left:14px;text-indent:0px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">&#32;&#32;&#32;&#32;Senior Vice President, Corporate Strategy and Chief&#160;Financial&#160;Officer</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial and Accounting Officer)</font></div><div style="line-height:138%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>mnlo-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:02A4267D4C34578D9AB62625CA14B468,x:a3638b66d60946b1aa75e4be54adba09-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mnlo="http://www.menlotherapeutics.com/20171231" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="mnlo-20171231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:EmployeesandDirectorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:NonemployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan_us-gaap_ConversionOfStockByUniqueDescriptionAxis_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mnlo:ConvertibleStockConvertedintoSharesofCommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_mnlo_DevelopmentandRegulatoryMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mnlo:JTToriiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnlo:DevelopmentandRegulatoryMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Aug10_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_mnlo_CommercialMilestoneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mnlo:JTToriiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnlo:CommercialMilestoneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-10</xbrli:startDate>
			<xbrli:endDate>2016-08-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_ResearchAndDevelopmentArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mnlo:JTToriiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q3Aug10_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mnlo:JTToriiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-08-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Aug10_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mnlo:JTToriiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnlo:DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-10</xbrli:startDate>
			<xbrli:endDate>2016-08-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Aug10_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_mnlo_NonsubstantiveMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mnlo:JTToriiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnlo:NonsubstantiveMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-10</xbrli:startDate>
			<xbrli:endDate>2016-08-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Aug10_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_mnlo_DevelopmentandRegulatoryMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mnlo:JTToriiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnlo:DevelopmentandRegulatoryMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-10</xbrli:startDate>
			<xbrli:endDate>2016-08-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Aug10_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mnlo:JTToriiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-10</xbrli:startDate>
			<xbrli:endDate>2016-08-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan8_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-08</xbrli:startDate>
			<xbrli:endDate>2018-01-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Aug10_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mnlo:JTToriiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnlo:DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-08-10</xbrli:startDate>
			<xbrli:endDate>2016-08-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateNoteSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q4Dec_us-gaap_CounterpartyNameAxis_mnlo_MerckMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mnlo:MerckMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-12-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Oct1_us-gaap_StatementGeographicalAxis_stpr_CA">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q4Dec_us-gaap_CounterpartyNameAxis_mnlo_MerckMember_us-gaap_TypeOfArrangementAxis_mnlo_DevelopmentandRegulatoryMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mnlo:MerckMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mnlo:DevelopmentandRegulatoryMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-12-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3July_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3July31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:NonemployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:NonemployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2011StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2011StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2011StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2011StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2011StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2011StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2011StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2011StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnlo:IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2011StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:EmployeesandDirectorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:EmployeesandDirectorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2011StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_mnlo_EarlyExercisedStockOptionsMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnlo:EarlyExercisedStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2011StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2011StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AwardTypeAxis_mnlo_EarlyExercisedStockOptionsMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnlo:EarlyExercisedStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2011StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_mnlo_EarlyExercisedStockOptionsMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mnlo:EarlyExercisedStockOptionsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2011StockIncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:EmployeesandDirectorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:NonemployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:EmployeesandDirectorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:NonemployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:EmployeesandDirectorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:NonemployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:EmployeesandDirectorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:NonemployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:NonemployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mnlo:NonemployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OptionsOutstandingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:OptionsOutstandingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:OutstandingCommonStockSubjecttoRepurchaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:OptionsAvailableforFutureGrantunderStockOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:OptionsAvailableforFutureGrantunderStockOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:OptionsAvailableforFutureGrantunderStockOptionPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OptionsOutstandingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:OptionsOutstandingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OptionsOutstandingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:OptionsOutstandingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:OutstandingCommonStockSubjecttoRepurchaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mnlo:OutstandingCommonStockSubjecttoRepurchaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_us-gaap_AffiliatedEntityMember_us-gaap_RelatedPartyTransactionAxis_mnlo_DevelopmentServicesFeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">us-gaap:AffiliatedEntityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnlo:DevelopmentServicesFeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_us-gaap_AffiliatedEntityMember_us-gaap_RelatedPartyTransactionAxis_mnlo_DevelopmentServicesFeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">us-gaap:AffiliatedEntityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mnlo:DevelopmentServicesFeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan23_us-gaap_PlanNameAxis_mnlo_A2018EmployeeStockPurchasePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2018EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan23_us-gaap_PlanNameAxis_mnlo_A2018OmnibusIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mnlo:A2018OmnibusIncentivePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan8_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-08</xbrli:startDate>
			<xbrli:endDate>2018-01-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001566044</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="segment">
		<xbrli:measure>mnlo:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="financial_institution">
		<xbrli:measure>mnlo:financial_institution</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="director">
		<xbrli:measure>mnlo:director</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2017Q4YTD" id="Fact-4E34918D7948CACDC20303F45DF21EB1">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q4YTD" id="Fact-495E8930E3A36227F7BF03F12EA3E038">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q4YTD" id="Fact-6716B20CAA00C2065BF703F3EA840A70">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q4YTD" id="Fact-6DA45C946C54608CECF703F356EC5B71">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q4YTD" id="Fact-F96BCDC2A79685DA5E7E03F2FE2F35F2">2017-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q4YTD" id="Fact-D77C784EBF91CD6A3D5503F2A15D9445">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q4YTD" id="Fact-1C0ABAA2EC409A62897803F0ADE05FD6">0001566044
</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q1Feb28" decimals="INF" id="Fact-0F341074D8074B5C37A703F5C2E96FAB" unitRef="shares">22977998</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2017Q4YTD" id="Fact-D3975305407CFCAA3A1E03F8195A8A42">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2017Q4YTD" id="Fact-5744A82EEE364BC8C48603F1950A8041">Non-accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2017Q2" decimals="0" id="Fact-7C2A12DCD9564093E75A03F8C7CA99E6" unitRef="usd">0</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2017Q4YTD" id="Fact-A4F171F53601D54671A103F0510A0EE3">Menlo Therapeutics Inc.</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2017Q4YTD" id="Fact-797955A485F3BD81112803F77055CDEC">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2017Q4YTD" id="Fact-EE2EC3632CC6CD9CEBA003F6E4568CB8">No</dei:EntityWellKnownSeasonedIssuer>
	<mnlo:AccruedClinicalandDevelopmentExpenses contextRef="FI2016Q4" decimals="-3" id="Fact-D88A1D5D3C210106D91206D2E27A1223" unitRef="usd">245000</mnlo:AccruedClinicalandDevelopmentExpenses>
	<mnlo:AccruedClinicalandDevelopmentExpenses contextRef="FI2017Q4" decimals="-3" id="Fact-75BC616E0BD351B716762AC944125333" unitRef="usd">2250000</mnlo:AccruedClinicalandDevelopmentExpenses>
	<mnlo:AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B6631E7A26084ECBD5D0EC22026383BE" unitRef="usd">33000</mnlo:AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions>
	<mnlo:AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7E3A03875E6AF92416C3EC21AE2C46E9" unitRef="usd">33000</mnlo:AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions>
	<mnlo:AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-871B27AA65239360C8B2EC23197BC33E" unitRef="usd">22000</mnlo:AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions>
	<mnlo:AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-222E0374EAE6CCA691D6EC23159A41FC" unitRef="usd">22000</mnlo:AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions>
	<mnlo:CashCashEquivalentsandAvailableforsaleSecurities contextRef="FI2016Q4" decimals="-3" id="Fact-0D4386B23E9C498E47C4F935813ECF66" unitRef="usd">41109000</mnlo:CashCashEquivalentsandAvailableforsaleSecurities>
	<mnlo:CashCashEquivalentsandAvailableforsaleSecurities contextRef="FI2017Q4" decimals="-3" id="Fact-0310ECBD0DABF0E24201F9317B3333AE" unitRef="usd">60958000</mnlo:CashCashEquivalentsandAvailableforsaleSecurities>
	<mnlo:CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax contextRef="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-FF2B834AF51338E520D4F93572BF22A0" unitRef="usd">0</mnlo:CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax>
	<mnlo:CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax contextRef="FI2017Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-7059E0F85C33A8B5D803F930BF3F80BD" unitRef="usd">0</mnlo:CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax>
	<mnlo:CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax contextRef="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-CD92988959D7E57F17ADF93573E04B3C" unitRef="usd">0</mnlo:CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax>
	<mnlo:CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax contextRef="FI2017Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-9A141DC0B1F146E8BF1EF9311B83E4A1" unitRef="usd">0</mnlo:CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax>
	<mnlo:CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax contextRef="FI2016Q4" decimals="-3" id="Fact-FF9C32C4D105B46B69BFF9357EF03D45" unitRef="usd">0</mnlo:CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax>
	<mnlo:CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax contextRef="FI2017Q4" decimals="-3" id="Fact-3CCCCA7FF2B970717DB2F930BF3F3B26" unitRef="usd">0</mnlo:CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax>
	<mnlo:CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax contextRef="FI2016Q4" decimals="-3" id="Fact-7CE31D20BB8CBF55C4E4F9358012D679" unitRef="usd">26000</mnlo:CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax>
	<mnlo:CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax contextRef="FI2017Q4" decimals="-3" id="Fact-5334FF357C2AF49BB6C3F9311B9D8A20" unitRef="usd">51000</mnlo:CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax>
	<mnlo:CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis contextRef="FI2016Q4" decimals="-3" id="Fact-20C1E23C7B5455517C9CF9357DDBEB06" unitRef="usd">41135000</mnlo:CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis>
	<mnlo:CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis contextRef="FI2017Q4" decimals="-3" id="Fact-9D04A6A6696573EC457CF92E73693E46" unitRef="usd">61009000</mnlo:CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis>
	<mnlo:CollaborativeAgreementUpfrontPaymentReceived contextRef="I2016Q3Aug10_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-4209727CA63120D2FB29F7E40BE89A96" unitRef="usd">11000000</mnlo:CollaborativeAgreementUpfrontPaymentReceived>
	<mnlo:CollaborativeArrangementsPotentialMilestonePayments contextRef="D2012Q4Dec_us-gaap_CounterpartyNameAxis_mnlo_MerckMember_us-gaap_TypeOfArrangementAxis_mnlo_DevelopmentandRegulatoryMilestonesMember" decimals="-5" id="Fact-3110B965E382881B2B44076B3F9024D9" unitRef="usd">25000000</mnlo:CollaborativeArrangementsPotentialMilestonePayments>
	<mnlo:CollaborativeArrangementsPotentialMilestoneProceeds contextRef="D2016Q3Aug10_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_mnlo_CommercialMilestoneMember" decimals="-5" id="Fact-6D452890C85A44E9D5D3F81401D2A112" unitRef="usd">15000000</mnlo:CollaborativeArrangementsPotentialMilestoneProceeds>
	<mnlo:CollaborativeArrangementsPotentialMilestoneProceeds contextRef="D2016Q3Aug10_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember" decimals="-6" id="Fact-AF5A4BA5B1ED2BCD5205F818A9ACE03A" unitRef="usd">2000000</mnlo:CollaborativeArrangementsPotentialMilestoneProceeds>
	<mnlo:CollaborativeArrangementsPotentialMilestoneProceeds contextRef="D2016Q3Aug10_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember" decimals="-5" id="Fact-79B6DAC111817559C4D230817C207D49" unitRef="usd">2000000</mnlo:CollaborativeArrangementsPotentialMilestoneProceeds>
	<mnlo:CollaborativeArrangementsPotentialMilestoneProceeds contextRef="D2016Q3Aug10_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_mnlo_DevelopmentandRegulatoryMilestonesMember" decimals="-5" id="Fact-55FC40A5E125713257D0F814D2C17686" unitRef="usd">28000000</mnlo:CollaborativeArrangementsPotentialMilestoneProceeds>
	<mnlo:CollaborativeArrangementsPotentialMilestoneProceeds contextRef="D2016Q3Aug10_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_mnlo_NonsubstantiveMilestonesMember" decimals="-5" id="Fact-8AD21B7B51BA3B4228C3F81ABF3A642A" unitRef="usd">24000000</mnlo:CollaborativeArrangementsPotentialMilestoneProceeds>
	<mnlo:CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod contextRef="D2016Q3Aug10_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" id="Fact-20697A8C728B14D238884B030B6068AF">P6Y</mnlo:CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod>
	<mnlo:DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums contextRef="FD2015Q4YTD" decimals="-3" id="Fact-13CF8BC5CCDF695176D3E5215BF344CD" unitRef="usd">0</mnlo:DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums>
	<mnlo:DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums contextRef="FD2016Q4YTD" decimals="-3" id="Fact-EA8E0871040C4CEBD2F1E50EC99962F4" unitRef="usd">4000</mnlo:DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums>
	<mnlo:DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2FE17F0AE29EEE252F32E5205953610B" unitRef="usd">8000</mnlo:DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums>
	<mnlo:IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A5C7A1D9495DD400A59AE52104D69BFC" unitRef="usd">22000</mnlo:IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets>
	<mnlo:IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-08621F503C9A6E76FEC2E518F3AD47E5" unitRef="usd">555000</mnlo:IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets>
	<mnlo:IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-E9D5404C1C1866668D19E5205C589894" unitRef="usd">1790000</mnlo:IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets>
	<mnlo:IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-823D3D0162514759CCF9E521057D107E" unitRef="usd">0</mnlo:IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets>
	<mnlo:IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-47CC4528212E49E64D68E519D8ABDB33" unitRef="usd">66000</mnlo:IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets>
	<mnlo:IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C13F881E7E95036C0FF4E5205D070CD4" unitRef="usd">-66000</mnlo:IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets>
	<mnlo:IndividualInvestmentPercentofInvestmentPortfolioMaximum contextRef="FI2017Q4" decimals="INF" id="Fact-C9F9D41C673963046EABF7BF8C6B6479" unitRef="number">0.05</mnlo:IndividualInvestmentPercentofInvestmentPortfolioMaximum>
	<mnlo:NumberofDirectorsCommonShareholdersareEntitledtoElect contextRef="FD2017Q4YTD" decimals="INF" id="Fact-2AAE81D59134E15695B84B0CF548A7C6" unitRef="director">3</mnlo:NumberofDirectorsCommonShareholdersareEntitledtoElect>
	<mnlo:NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-E88632617B85CD5903C34B0986318467" unitRef="director">2</mnlo:NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect>
	<mnlo:NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-2B836C3144E5ACFDDCF14B0AED8B7743" unitRef="director">2</mnlo:NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect>
	<mnlo:NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-030281102AEE011542704B0C18436056" unitRef="director">1</mnlo:NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect>
	<mnlo:NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits contextRef="FI2016Q4" decimals="INF" id="Fact-E7FDB8E216ADA85D3478495340517599" unitRef="financial_institution">1</mnlo:NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits>
	<mnlo:NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits contextRef="FI2017Q4" decimals="INF" id="Fact-82F9C135B75FB80E676B4AF4B19BF929" unitRef="financial_institution">1</mnlo:NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits>
	<mnlo:OperatingLeaseMonthlyRentExpense contextRef="D2017Q4Oct1" decimals="0" id="Fact-56CBD2FCBB33473754B607B6DA7C3F71" unitRef="usd">55000</mnlo:OperatingLeaseMonthlyRentExpense>
	<mnlo:TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-FC9FDB922EA8D74A6A9C4964DD904A44" unitRef="usd">7000000</mnlo:TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit>
	<mnlo:TemporaryEquityDividendRatePerDollarAmount contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="2" id="Fact-BCBAA2DA6F23E4D4E333082368C7950A" unitRef="usdPerShare">80.00</mnlo:TemporaryEquityDividendRatePerDollarAmount>
	<mnlo:TemporaryEquityDividendRatePerDollarAmount contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="4" id="Fact-FC46C22BC90F1568021A0824B984C75C" unitRef="usdPerShare">0.2552</mnlo:TemporaryEquityDividendRatePerDollarAmount>
	<mnlo:TemporaryEquityDividendRatePerDollarAmount contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="4" id="Fact-7A9C4E58A33B8CA29EA10825008B0606" unitRef="usdPerShare">0.3408</mnlo:TemporaryEquityDividendRatePerDollarAmount>
	<mnlo:TemporaryEquityIssuedPriceperShare contextRef="I2017Q3July31_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-6BD5961C1D91048E52D807F103AFAFD2" unitRef="usdPerShare">4.26</mnlo:TemporaryEquityIssuedPriceperShare>
	<mnlo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="D2017Q3July_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-BD9A798C4A2A1837680E07EDCB7AB741" unitRef="shares">11854463</mnlo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
	<mnlo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-5713C5943A61F78E8C84EC10FD8BEDED" unitRef="shares">2800</mnlo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
	<mnlo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-22F7E58A01E5353C533EEC137F4DC995" unitRef="shares">14106583</mnlo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
	<mnlo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-59704050C6B569C91166EC1E40F04295" unitRef="shares">11854463</mnlo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
	<mnlo:TemporaryEquityStockIssuedIssuanceCosts contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-770BE05D4BFF4FF1102503E854A80F10" unitRef="usd">179000</mnlo:TemporaryEquityStockIssuedIssuanceCosts>
	<mnlo:TemporaryEquityStockIssuedIssuanceCosts contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-5690CF7DC6BFCCE5BAD903E9179B0D1F" unitRef="usd">173000</mnlo:TemporaryEquityStockIssuedIssuanceCosts>
	<mnlo:TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering contextRef="FD2017Q4YTD" decimals="INF" id="Fact-6DDDC443256DC3FC5FC908380AB4573F" unitRef="usdPerShare">17.21</mnlo:TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering>
	<mnlo:TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering contextRef="FD2017Q4YTD" decimals="INF" id="Fact-E2626137DE8319B8AD3308329907EFF6" unitRef="usd">40000000.0</mnlo:TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-0B6D48E2E327BECC1272E4C802E98BD7" unitRef="usd">1526000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-D75DD751DB86A0E89C3807C9BF561A45" unitRef="usd">2462000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="FI2016Q4" decimals="0" id="Fact-3CA2E134853BA16BD1595DA7366B6749" unitRef="usd">0</us-gaap:AccountsPayableRelatedPartiesCurrent>
	<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="FI2017Q4" decimals="0" id="Fact-15199551BCF082C1CA143E3EC767779F" unitRef="usd">0</us-gaap:AccountsPayableRelatedPartiesCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-AD8A1A5955A90401154E03C8E9C49481" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-11810D0577D9B25DC99807C913360B07" unitRef="usd">786000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D629094310A7FF0251E9E5215D467119" unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-594EF5811D7670070ED2E510B1257DDA" unitRef="usd">-158000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-2E133E90A585795AB836E5205A9A47AC" unitRef="usd">-66000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-3563DB0A0898F61698CEE4C9B8FC2E2D" unitRef="usd">581000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-D9AD2C6A7CB8EF69CB2107C9C000B5A4" unitRef="usd">3559000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4" decimals="-3" id="Fact-AB4FC33A91A31927C6D5E4DDD2701239" unitRef="usd">-26000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4" decimals="-3" id="Fact-3EF2CF61F83F2E47A2B107CD46533716" unitRef="usd">-51000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2016Q4" decimals="-3" id="Fact-8FEBE23B77D13B67FB73E4DAFC32E73F" unitRef="usd">699000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q4" decimals="-3" id="Fact-C5CF792299C9115A959107CD45A9982D" unitRef="usd">2207000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A86921F04925E5DBDEBBEC19856CC94D" unitRef="usd">65000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6A8851EB1CB056CEB41EEC191F76B2B0" unitRef="usd">65000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-85A325D13453F33D6197EC1D2C25506B" unitRef="usd">573000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-81E1D45152BA67E5BA5CEC1CEBF8716C" unitRef="usd">573000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CB55F89A6131A67C1C34EC2011BAF5EB" unitRef="usd">1452000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9D1E6D20BA9BF278B03DEC200DC6F065" unitRef="usd">1452000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-80FFA4600F5A6FEB09FA21F70415BD2C" unitRef="usd">65000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-A33DB96FCF85ED7D62B321F702F154BD" unitRef="usd">64000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-8C58FC619DDA6BD5264021F701536540" unitRef="usd">1000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="-3" id="Fact-3F25E5A6AB8CD972C5ED2C0950664EB2" unitRef="usd">1000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="-3" id="Fact-FA58AC0B806D6555EC812CBA94B6A078" unitRef="usd">64000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-30693DE1309D444E7A7421F68B5141A8" unitRef="usd">573000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-317EF266660DE18BF62421F689BDBFA8" unitRef="usd">316000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-65260C301B25E376DDCB21F6881BF0ED" unitRef="usd">257000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="-3" id="Fact-B8F058317F7B408955EF2C0925166B1D" unitRef="usd">314000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="-3" id="Fact-0AC62173816D2EFC9EAD2CBA56E11F79" unitRef="usd">259000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-279E829D4E6366828AF240C63F2928B0" unitRef="usd">1452000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-2627DA64D8FCBCBD6D7C40C63F2CB10C" unitRef="usd">660000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-3850162A152BE5F8E4E021F41B26B9CD" unitRef="usd">792000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="-3" id="Fact-E90D080D059D4304A1AE49587BFA7CA1" unitRef="usd">791000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="-3" id="Fact-8293803F6A5CDA7095202CB8C98708D3" unitRef="usd">661000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD" decimals="0" id="Fact-116A6A505D6D7F6126EC1C285819B8F2" unitRef="shares">7243265</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember" decimals="0" id="Fact-437D6750B79450A9CF951C2747E214F2" unitRef="shares">1684110</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OptionsOutstandingMember" decimals="0" id="Fact-9235F4B2ABD6FC363D7B1C2330DBA68D" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember" decimals="0" id="Fact-DACD8B10F1A5CAC260141C21D450012E" unitRef="shares">324355</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-4097CA4C4CE4F6221DA71C2115D8C679" unitRef="shares">5234800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD" decimals="0" id="Fact-0010364D18F16EA4FF021C2856D0000F" unitRef="shares">7140987</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember" decimals="0" id="Fact-04AB64279D43220925581C27451001CB" unitRef="shares">198978</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OptionsOutstandingMember" decimals="0" id="Fact-A1B8370BD8303C54506D1C233042359A" unitRef="shares">1485132</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember" decimals="0" id="Fact-1DB41953D4ACFE1B501C1C21D45014DA" unitRef="shares">222077</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-1890D2AF0B2B44951F5F1C2115D8C19D" unitRef="shares">5234800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD" decimals="0" id="Fact-C8C98A39C6F556013EFE1C285581EE25" unitRef="shares">12687739</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember" decimals="0" id="Fact-4AAD745601A7A131EB901C27418FA9AD" unitRef="shares">411772</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OptionsOutstandingMember" decimals="0" id="Fact-67D74590C8021C76FB341C2330D746C1" unitRef="shares">2506926</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember" decimals="0" id="Fact-DD51E039E5B33BE1BFDE1C21D4500D06" unitRef="shares">139636</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-136FC2B52D519161C3D41C2115D84141" unitRef="shares">9629405</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AreaOfRealEstateProperty contextRef="I2017Q4Oct1_us-gaap_StatementGeographicalAxis_stpr_CA" decimals="0" id="Fact-A50209AB5744206EC2C107BA1C8A5F82" unitRef="sqft">14000</us-gaap:AreaOfRealEstateProperty>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-E7BAB3CB25C21AB7435CE4C3A44B2D06" unitRef="usd">42053000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-3" id="Fact-E4F812BFFAC46CBE1C0307C95E9B3329" unitRef="usd">66867000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-EDFA5B241B0807AC6098E4C21D28446D" unitRef="usd">31540000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-43B79CB2190E33F4DD8507C91481F7AD" unitRef="usd">63861000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-4AB27C94A3C5CE1E466130068CEFA3D2" unitRef="usd">22226000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-411F0A43B92046F8AA7130069030B075" unitRef="usd">18883000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-208C0076384857F445F7300692FCD31F" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" decimals="-3" id="Fact-0F635A33992537110A3730068AFAD95D" unitRef="usd">41109000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-23B2F55AB8667A2B140EF92AB7F9D08E" unitRef="usd">19963000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-B11537610D3D1C421CB8F92AB6DFEFB0" unitRef="usd">40995000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-AE25A3F36D26D2FC368EF92AB818B5E8" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" decimals="-3" id="Fact-26EDE37BBE47BB0BEFD6F92AB784BD50" unitRef="usd">60958000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-ED09365F7FF2EE46E9F6F935791E73BC" unitRef="usd">26108000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-EA69845F7961CC7E49F7F9357D24E2AA" unitRef="usd">11193000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-C9F959BF6F489D94CDCAF9317B3343E4" unitRef="usd">46098000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-ED67D74FB321F4ADE1C5F9317B23488E" unitRef="usd">6175000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-6BC5DAEBEEE978F8C396F93576CC5E80" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-735405A3088649843DD9F9357AD96CDE" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-1DAD7C0F3939B97FE5C9F930BF3D8441" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-6797D8E60D33801B1DDBF930BF4EDCA7" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-60018063B9C7878147B8F93577F35E5D" unitRef="usd">26000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-BAFD4C5498265EB78B18F9357C0CE704" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-069E3DE173870329E038F9311BC99F06" unitRef="usd">35000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-EEDBAD41FC6993B3634AF9311B7A9BAE" unitRef="usd">16000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-EEF89A7B745A3B557557F93575A2035C" unitRef="usd">26134000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-06BDE4473A54EF0E043FF93579DCBD6F" unitRef="usd">11193000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-68A132327C54D6D23568F92E735A015B" unitRef="usd">46133000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-07E844CCEF82746B9BBAF92E735A69A9" unitRef="usd">6191000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-5AB0FC0C105A7C31568BE52FBA5D9FA2" unitRef="usd">273000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-1EE2752C04513CB66FD5E52FE3201654" unitRef="usd">43808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-1103E384A50A3EA2A3F3E4C02D3073B5" unitRef="usd">4027000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-E6469EFC48FF2F4AEF99F93571988E40" unitRef="usd">3808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-E166A5902D6AF4823C4607C911F1B3D9" unitRef="usd">10206000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-10703194DD362FB184C3F92E734AB141" unitRef="usd">8685000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-AC190D754D80C229EECDF93574FCADA8" unitRef="usd">3808000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-F79ECB3C9D5D20E801BE30066DAEB501" unitRef="usd">3808000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-2D702B19F8EECDEB52113006707FA394" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-3E8F5A1F09F523A197D93006733812E2" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" decimals="-3" id="Fact-E0D7603C98950E084F0530066B811D25" unitRef="usd">3808000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-D5452E9021F10DAF9229F9317B330BA9" unitRef="usd">8685000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-D72D4DBDEA08088E33A0F92AB6AB1403" unitRef="usd">8685000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-6D5B5E750CDD621666DCF92AB6DF6834" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-C3A767500554626EB2EDF92AB6BD3659" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" decimals="-3" id="Fact-EC2D2346DF7CBF807F55F92AB8A45892" unitRef="usd">8685000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BF99456EC0D208C27163E52F029C971D" unitRef="usd">43535000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A1FB4CBAE56998C5F187E52F02A0428B" unitRef="usd">-39781000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0871CE5687C701510957E52F029A0CED" unitRef="usd">6179000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q4" id="Fact-94150491D0B0E73EFE75E4D05493849F" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-7418195214708C99BBB6E4D0548C654D" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2015Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="0" id="Fact-222E1184833C3AA77CAD21DC3AE950DE" unitRef="shares">2086600</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2017Q4" decimals="INF" id="Fact-3B46AA3C750949B5F26F40B42B1BD7F7" unitRef="shares">12548103</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2017Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="0" id="Fact-EEB735884503DDC70FBC21DDBB24169A" unitRef="shares">3339724</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2018Q1Jan23_us-gaap_PlanNameAxis_mnlo_A2018EmployeeStockPurchasePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-E893DA2A3FDDCA0FEB19646E60EEC96D" unitRef="shares">325000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2018Q1Jan23_us-gaap_PlanNameAxis_mnlo_A2018OmnibusIncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-9A8C8EFD6A3AA16AB17440DDE4BA7B59" unitRef="shares">3000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-A329635784707057B87203DB9B01A81D" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-880E501408CBF64ACD9003DB9B01F164" unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-AB032F3126A93DCACC9C03DC4D07852A" unitRef="shares">36500000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-9DFBB650C7B948CABA2703DC4D1ACFA2" unitRef="shares">55000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-78B510F1EDE6440873D803DC90430D20" unitRef="shares">5280058</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-202468434175D6D1022803DC903E7E79" unitRef="shares">5298593</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9574D05192F5AB4260CBEBFB954A8F08" unitRef="shares">4962653</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C3D86B14CE7055839C1BEBFB4B454342" unitRef="shares">5280058</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-67B5C052BE02412615A903DCDC9EB9C8" unitRef="shares">5280058</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-7DD240B4093566AA2AB0EBFB18078BEC" unitRef="shares">5280058</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-C84636855C77189BDD7C03DCDC9E7090" unitRef="shares">5298593</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-2D85040C962FF0561E24EBFA7184B666" unitRef="shares">5298593</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-9235FF80F02E18144BDDE4D836C13FAB" unitRef="usd">1000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-C56016AD37BEE1086B1E07CD15C701C0" unitRef="usd">1000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-04DC9ACECF70DC73EBE6E5062BBAB473" unitRef="usd">-4608000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-5D3FE6CEE2CAC79FEFFDE4FF7CF88794" unitRef="usd">-14094000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B712A769E3587AD294FAE50564CBC19A" unitRef="usd">-29101000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ConversionOfStockSharesIssued1 contextRef="D2018Q1Jan_us-gaap_ConversionOfStockByUniqueDescriptionAxis_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="0" id="Fact-40D9A4E92A335053042AF70EBF6D81A5" unitRef="shares">9629405</us-gaap:ConversionOfStockSharesIssued1>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="I2018Q1Jan31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-013AD7D43D0B4A3E64F707F89AA7052F" unitRef="shares">9629405</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0666C7385DB3FFC6BF3454715E59D8CB" unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
	<us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2016Q4YTD" decimals="-3" id="Fact-FE8BDB9B0C4CC6AF454E54715E5E973C" unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
	<us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BAB5D6815AAE5E47116254715E522C99" unitRef="usd">316000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
	<us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-B9E9C882F69143761F7D2BF8F87126A2" unitRef="usd">68000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
	<us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-517FFF76E16D5588A8F62BF70DAA578F" unitRef="usd">43000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-78DF65BCA7842AF10005E4C9F80D8F3C" unitRef="usd">1796000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-1D0D9BD0F57D6CF110C407C9C0C0C6F1" unitRef="usd">1796000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-D7C9EA68B55649F20A4BE4CA7D446872" unitRef="usd">8531000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-0820B3DBB99EC56AAAF107C9C267904F" unitRef="usd">6735000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2015Q4" decimals="-3" id="Fact-F71BC3B783AD720EEFC640D6786BCE91" unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2016Q4" decimals="-3" id="Fact-703370D780990841BDD540D678A9A447" unitRef="usd">0</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2017Q4" decimals="-3" id="Fact-90487FE9A3DCF2396D2540D6788A5DA8" unitRef="usd">1791000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2015Q4" decimals="-3" id="Fact-8D7C150283386D4819A31C6C43BF240F" unitRef="usd">6621000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2016Q4" decimals="-3" id="Fact-69E13BBC78EC66502F5F1C62218D4313" unitRef="usd">11631000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2017Q4" decimals="-3" id="Fact-F2A9EABA7FF9194086B039BA090E058A" unitRef="usd">14993000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2015Q4" decimals="-3" id="Fact-6BD5C1BF12B3FD5778F01C6C486E69BC" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2016Q4" decimals="-3" id="Fact-16246AF1BB64D162B2031C631A55F27A" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2017Q4" decimals="-3" id="Fact-3C7C12C42E242EDC637839BA0D182F04" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2015Q4" decimals="-3" id="Fact-7E58398C3B106CC809341C6C3EDB28B9" unitRef="usd">5992000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2016Q4" decimals="-3" id="Fact-E9967D4A2E9880BB37E41C64EB430B1A" unitRef="usd">10458000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2017Q4" decimals="-3" id="Fact-AF4051226E174B359D1939BA03FB8A9F" unitRef="usd">10404000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2015Q4" decimals="-3" id="Fact-643AB13AE7AAC6C349191C6C3FD4E49B" unitRef="usd">362000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-577BCCEFA091E4C85B4C1C6637647873" unitRef="usd">328000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-2D3D1A294A3794886DBF39BA04A4680E" unitRef="usd">226000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2015Q4" decimals="-3" id="Fact-C48F9E112549004317FF1C6C41C88337" unitRef="usd">233000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2016Q4" decimals="-3" id="Fact-2CE9D98F38933201E4D71C6741AD4A2C" unitRef="usd">586000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2017Q4" decimals="-3" id="Fact-12C81CB3C23DD7E1942239BA06C8688C" unitRef="usd">2063000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2015Q4" decimals="-3" id="Fact-5E980F352322D146D8E61C6C40CC8A30" unitRef="usd">34000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2016Q4" decimals="-3" id="Fact-3B1584AB72B34B59CF021C66A80330F5" unitRef="usd">161000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2017Q4" decimals="-3" id="Fact-ABC779A040EF61DFB79939BA0617ABA4" unitRef="usd">274000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="FI2015Q4" decimals="-3" id="Fact-663DE3E120FCC07B01F41C6C42C09EBE" unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="FI2016Q4" decimals="-3" id="Fact-635ED00C1D390705AB731C679FC4176D" unitRef="usd">98000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="FI2017Q4" decimals="-3" id="Fact-46166EB7E0FA2479B1F939BA08348B5B" unitRef="usd">235000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2015Q4" decimals="-3" id="Fact-0D52415C9DB37C739BF41C6C4776509E" unitRef="usd">6621000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4" decimals="-3" id="Fact-119C23565C02BD80073C1C62CE0349CC" unitRef="usd">11631000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2017Q4" decimals="-3" id="Fact-50A649BA9F76363A7F2339BA0C5C1081" unitRef="usd">14993000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-C9ACB16AA43B0EEC0D1DE5062C62E20C" unitRef="usdPerShare">-0.97</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q1QTD" decimals="2" id="Fact-6D0635706F97DFAA2C0E40F4817A565F" unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q2QTD" decimals="2" id="Fact-00126C61B690150E3FE740F3AE0B292E" unitRef="usdPerShare">-0.72</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q3QTD" decimals="2" id="Fact-8BBCA6F624FEC61968D840F2C79914C5" unitRef="usdPerShare">-0.68</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q4QTD" decimals="2" id="Fact-ACE0A7922623622FE9E740F312092119" unitRef="usdPerShare">-0.96</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q4YTD" decimals="2" id="Fact-882BECA32FEFF89EA3DDE502FECB9AA6" unitRef="usdPerShare">-2.82</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q1QTD" decimals="2" id="Fact-A84A4361153D8F89EDF740F402ED5F31" unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q2QTD" decimals="2" id="Fact-8A5B7CB92B882321C82040F36786A836" unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-70AFEEABEAC508E6D74C40F20E13EDC5" unitRef="usdPerShare">-1.59</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q4QTD" decimals="2" id="Fact-C3A1EADFEED6F349FEDB40EF8D915D34" unitRef="usdPerShare">-1.80</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q4YTD" decimals="2" id="Fact-0637B2345544FE3D32D1E505657106CA" unitRef="usdPerShare">-5.69</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2015Q4YTD" decimals="2" id="Fact-DA2AAF4AC6D8E958650268A77EA75801" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2016Q4YTD" decimals="2" id="Fact-B71092EE5ADCDB90FE6568A73B007CF7" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q4YTD" decimals="2" id="Fact-370A0BD419A04C8AD1A468A4E9EDCC31" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q4YTD" decimals="2" id="Fact-7C4E67E5FB503F8A5A6768A778378717" unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q4YTD" decimals="2" id="Fact-D0864019BCB482E85F9668A73598BB3E" unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD" decimals="2" id="Fact-98636C3657631F2731E968A12CC2757E" unitRef="number">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2015Q4YTD" decimals="2" id="Fact-FC032ACFC96A4ADA2BB268A77CE95DCD" unitRef="number">-0.41</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2016Q4YTD" decimals="2" id="Fact-16118F8E3BF5A14FC39268A739299E9D" unitRef="number">-0.36</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2017Q4YTD" decimals="2" id="Fact-C16B09F4F4D26AD9C35668A37A115BBB" unitRef="number">-0.11</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2015Q4YTD" decimals="2" id="Fact-54EE9C284D128F9D4D0368A77DB78C6D" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2016Q4YTD" decimals="2" id="Fact-C4DE9B52788F6328397868A73A1492A6" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2017Q4YTD" decimals="2" id="Fact-EF2BF1DB6CFEA8490E9A68A3F82B3BEF" unitRef="number">-0.24</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="FD2015Q4YTD" decimals="2" id="Fact-589252F1B3EA0E21EEB968A779F1D578" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="FD2016Q4YTD" decimals="2" id="Fact-92241DA0DDC611D7C2B168A736C11D35" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="FD2017Q4YTD" decimals="2" id="Fact-07C70364C544D729996E68A20D2B1F1C" unitRef="number">-0.03</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="FD2015Q4YTD" decimals="2" id="Fact-647E16488074814CD7CC68A77AF5AA1A" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="FD2016Q4YTD" decimals="2" id="Fact-48831972CA9171820EB768A737894F57" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="FD2017Q4YTD" decimals="2" id="Fact-9F130D0271C80C961CCB68A224A1AD93" unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q4YTD" decimals="2" id="Fact-739DE3C6F2D0A9518A9268A77922B192" unitRef="number">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q4YTD" decimals="2" id="Fact-D18AF9482D01CD48B15A68A73627DD73" unitRef="number">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q4YTD" decimals="2" id="Fact-853889EE9ABA7CA094AD68A19186FD61" unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2015Q4YTD" decimals="2" id="Fact-9DE3DF726CC6A745092A68A77BD6B4F7" unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2016Q4YTD" decimals="2" id="Fact-F2DBB96E4C992829106268A738512AA7" unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2017Q4YTD" decimals="2" id="Fact-FEB3762B1EF4FC9750DB68A2EF03542F" unitRef="number">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-9E053F24327B121993AD06D355ECE702" unitRef="usd">273000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-961DB552D2C32164A6512AC942D36835" unitRef="usd">1108000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2017Q4" decimals="-5" id="Fact-5449EB1ADA7B6055BA2721FAFBBA82EF" unitRef="usd">7300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2017Q4YTD" id="Fact-B8D181268B8FA9A7009121FC630E48CB">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F0CCDCA3A1056004583203EC99636854" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2016Q4YTD" decimals="-3" id="Fact-73B53F4CBC35CEB54D9803EC997A5843" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-487DD8BAE9F53FF4E57603EC996FC551" unitRef="usd">-19000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C0543E918801F829B274E506274F65C0" unitRef="usd">1687000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BA3CD1D21A969D4034FDE4F0EC4C342A" unitRef="usd">3751000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-83C43BC42286186D95CEE50560695DA8" unitRef="usd">5168000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-B585B121A7120D559B96E52106247689" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-51A19D286E3A59B73CDCE51B27C35253" unitRef="usd">889000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8AE8AA9882249963D295E520B6935E09" unitRef="usd">620000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F7982AA26E25E5DDAE13549E95480005" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-FAD9D8A921194FD82AB1549E95520B84" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5E080DB3BD9AF7DBF67A549E9534D11B" unitRef="usd">786000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-543BCF6CFAB927B02BAAE52106CB72F0" unitRef="usd">346000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-54780C4CB330E0312DBFE51C49F2043E" unitRef="usd">466000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-166D4613FB7E14358EE2E520B73A0993" unitRef="usd">2976000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C1CC6E4B10F3AFCDF983E521076F0CB6" unitRef="usd">36000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-886D475759580AC1F258E51CCE07A3A2" unitRef="usd">10327000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-66CA6F470D2224F5FDE9E520B7E16AD6" unitRef="usd">-1796000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="FD2015Q4YTD" decimals="-3" id="Fact-04C21AA31B6CC0E70790534EE5784EE5" unitRef="usd">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
	<us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E80079E8125FF8AE470E534EE57ED5E0" unitRef="usd">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
	<us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EB73EB016930274D6E03534EE56FA0D9" unitRef="usd">31000</us-gaap:IncreaseDecreaseInInterestPayableNet>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-563F89F27CF277EB816FE52108189FCD" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7FF52DC974C8169B5E99E51D6BBF7837" unitRef="usd">7000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-7AC411A063F48AC127C7E520B88793F5" unitRef="usd">-12000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2015Q4YTD" decimals="-3" id="Fact-AC75B520D74EBA77099CE50629467830" unitRef="usd">0</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2016Q1QTD" decimals="-3" id="Fact-410948B1BE69C1F2DF5A40F47ECE5002" unitRef="usd">25000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2016Q2QTD" decimals="-3" id="Fact-7E7CDF3AAC63F495D4E540F3ABC0B1B4" unitRef="usd">74000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2016Q3QTD" decimals="-3" id="Fact-A5499B011A207BA8D41E40F2C53E4005" unitRef="usd">77000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2016Q4QTD" decimals="-3" id="Fact-291000B3CCF5A504EA3140F30FC86E7C" unitRef="usd">88000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2016Q4YTD" decimals="-3" id="Fact-249983F560ADB9EAC3ACE4F95F27994B" unitRef="usd">264000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2017Q1QTD" decimals="-3" id="Fact-77E0AE67D7398E30DEB740F3FFE888E0" unitRef="usd">81000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2017Q2QTD" decimals="-3" id="Fact-3EB27F0166CD0FFF28AB40F364CA8801" unitRef="usd">73000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2017Q3QTD" decimals="-3" id="Fact-DA7CAFA07E58020D90E840F20B698C07" unitRef="usd">163000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2017Q4QTD" decimals="-3" id="Fact-A958EDB9E95F51B0B8CD40E806BFE9C5" unitRef="usd">200000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="FD2017Q4YTD" decimals="-3" id="Fact-12E52684C349E0F6E679E5056265BF4B" unitRef="usd">517000</us-gaap:InterestIncomeExpenseNonoperatingNet>
	<us-gaap:InvestmentsAndCash contextRef="FI2017Q4" decimals="-5" id="Fact-2C75B8F026D3853F2177F71489A721B3" unitRef="usd">62500000</us-gaap:InvestmentsAndCash>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-1C1A48A845E6ED45586F300677C7AB7C" unitRef="usd">7225000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-F7A3D2964C169DE228193006820EDB1A" unitRef="usd">11193000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-BB62B8561AE78DD8367930067A936D9C" unitRef="usd">18883000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-183AB4E76F3EE34760F030068531C550" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-463D20E3D74DE0DB8F3830067D4E6990" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-38412E6246C843027BA9300687F065E9" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-E13C9D61CF2F1E63D08E300675D35D0F" unitRef="usd">26108000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-2185C5AA473C4A1E7A1330067FE3430F" unitRef="usd">11193000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-B32511909E563B2DE966F92AB7C50F8A" unitRef="usd">5103000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-6D29E67224196CED4650F92AB78BB9B4" unitRef="usd">6175000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-F288A8183998EFF9A614F92AB706FC77" unitRef="usd">40995000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-F8E2B37D665DE58E866BF92AB73ACBE3" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-E81D4BF29E47657B6B9BF92AB82755F6" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-67C98904395F1107E543F92AB6C03E29" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateNoteSecuritiesMember" decimals="-3" id="Fact-DCD32E58116B84660E4BF92AB81864F3" unitRef="usd">46098000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="Fact-974D46484F79D51B082AF92AB7A871EF" unitRef="usd">6175000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="D2017Q4Oct1" id="Fact-0BC0ABD2F9E2E90CBF284B05AD263F5F">P30M</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-3" id="Fact-B4344A8309FE690B7D12E4CB113134B0" unitRef="usd">12491000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-3" id="Fact-43A70205E4B220DC252D07C9C3B43A63" unitRef="usd">14574000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-B11F1563C1296AED7AAAE4E04937C76D" unitRef="usd">42053000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-4D35B5AE36028A99294507CD9669C67D" unitRef="usd">66867000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-629700E4D430D7F1DB09E4CA2EBCA15A" unitRef="usd">3903000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-588CC4EE8CEB22550F3207C9C1617BA6" unitRef="usd">7817000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5923EFEB047AF060CFD9E506258CD78A" unitRef="usd">0</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2016Q1QTD" decimals="-3" id="Fact-86CA5DC8536FA1C3C33140F47BD99260" unitRef="usd">0</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2016Q2QTD" decimals="-3" id="Fact-3381ED754F1B08A24F6540F3A9AC80E4" unitRef="usd">0</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2016Q3QTD" decimals="-3" id="Fact-BDEA3D5541D72544D23140F2C2B7B6F2" unitRef="usd">224000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2016Q4QTD" decimals="-3" id="Fact-C1E9817FA991476B577340F30D87746A" unitRef="usd">450000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-98041DB6B554BE117AB3E4ED02A7EC08" unitRef="usd">674000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2017Q1QTD" decimals="-3" id="Fact-75EBD207AC039DB982A040F3FCCA21F2" unitRef="usd">449000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2017Q2QTD" decimals="-3" id="Fact-9584B293F42EC0954CF440F361E05C18" unitRef="usd">449000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2017Q3QTD" decimals="-3" id="Fact-BABE00813E4AAFCC616B40F2083B99B9" unitRef="usd">909000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2017Q4QTD" decimals="-3" id="Fact-7F93E2810FA375C6F22740E71C40E0E9" unitRef="usd">2775000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1D8D12D75E0A619794DBE5055E950668" unitRef="usd">4582000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseCosts contextRef="D2012Q4Dec_us-gaap_CounterpartyNameAxis_mnlo_MerckMember" decimals="-5" id="Fact-7491499A7A44055DE5B007612A83E805" unitRef="usd">1000000</us-gaap:LicenseCosts>
	<us-gaap:LongTermInvestments contextRef="FI2016Q4" decimals="-3" id="Fact-7C5DE385BDAFCBB8AD93E4C26AC441FC" unitRef="usd">10420000</us-gaap:LongTermInvestments>
	<us-gaap:LongTermInvestments contextRef="FI2017Q4" decimals="-3" id="Fact-EEFBEBFBBEEF2C14E30807C95CAD33C6" unitRef="usd">2978000</us-gaap:LongTermInvestments>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A188761140CA80DCA3F8E52E8737CDB0" unitRef="usd">47718000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-737B2E16C3BB41B08E1DE52E4701DACB" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F27BA35F462AF9335D9AE52CBF2D5E57" unitRef="usd">49491000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-84B2DFD6F9FB5992A400E52915E5CD79" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-BD9A8A864FD802DD1810E52915E10AA2" unitRef="usd">-37490000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-955B35B12326A16D50FFE52915DFFAA7" unitRef="usd">-15065000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A6788D66CCD290EB3CB5E52108F23DA9" unitRef="usd">-4183000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7F464BDE0AB4D47B8905E51DF378EBE4" unitRef="usd">-2291000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-3014553BEA3EEA2CCDFFE520B93136DF" unitRef="usd">-28247000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-84ECEA65333AE5C6450FE50629EF044F" unitRef="usd">-4608000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-5ED2B2CD8DCAE7B88282EC1B595B1E10" unitRef="usd">-4608000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1QTD" decimals="-3" id="Fact-41C74CF30BF55D1707AA40F480668E77" unitRef="usd">-2272000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2QTD" decimals="-3" id="Fact-FD131038A1A529C54E4B40F3ACEF1FB1" unitRef="usd">-3562000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-8B3AE5426354A42509B740F2C669377B" unitRef="usd">-3398000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4QTD" decimals="-3" id="Fact-E6CF0EB743B569A26BD140F310E47054" unitRef="usd">-4836000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-338CA3E1BE01C73042D7E4FAA1708B78" unitRef="usd">-14068000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-14DFFCEF503FC6141152EC1D735D3ADE" unitRef="usd">-14068000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1QTD" decimals="-3" id="Fact-C382086883488651748B40F401789FEC" unitRef="usd">-5474000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-7E9384B8028418CD5A7240F3665A611A" unitRef="usd">-6153000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-BAB162C8639E3D89FF4D40F20CFB9AB1" unitRef="usd">-8172000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4QTD" decimals="-3" id="Fact-FD60BBD39E7A412E6D2F40E8E9ADD0E1" unitRef="usd">-9277000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B204F220C75659033568E5056314255E" unitRef="usd">-29076000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-9957DC25A5CE7D103B18EC1F7D772FA5" unitRef="usd">-29076000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2015Q4YTD" decimals="-3" id="Fact-30803C37F9FB8E3028091C103C3792EA" unitRef="usd">-4608000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D70990247AD8C1FC71C91C103AEBB471" unitRef="usd">-14068000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q4YTD" decimals="-3" id="Fact-BB71D68FB4D5209652BE6472AED661F4" unitRef="usd">-29076000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="FD2015Q4YTD" decimals="-3" id="Fact-583FEAD05F0106A2BF023E589418E281" unitRef="usd">-4608000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="FD2016Q4YTD" decimals="-3" id="Fact-82D01E848104DAFE344B3E58940F1577" unitRef="usd">-14068000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4857CE91D27C377B26B13E5894272F0D" unitRef="usd">-29076000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2017Q4YTD" decimals="INF" id="Fact-1DB35EBF0940DAA1AE474AE5614CE567" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingExpenses contextRef="FD2015Q4YTD" decimals="-3" id="Fact-95AA86BB714021A885A7E50627F78955" unitRef="usd">4608000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q1QTD" decimals="-3" id="Fact-8A16DE13D3D2A676F30B40F47D3DEDA2" unitRef="usd">2297000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q2QTD" decimals="-3" id="Fact-74131EC74AF42C16227C40F3AAAC17B7" unitRef="usd">3636000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q3QTD" decimals="-3" id="Fact-1D83D1F60560B2DD513440F2C4240E1A" unitRef="usd">3699000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q4QTD" decimals="-3" id="Fact-67F252AB8A2E302D490140F30E9DB02F" unitRef="usd">5374000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4E1FA744885CADBA7C61E4F172EE71DC" unitRef="usd">15006000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q1QTD" decimals="-3" id="Fact-0FF5762ADD6C98FDF51A40F3FE398EC9" unitRef="usd">6004000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q2QTD" decimals="-3" id="Fact-2F7719CF972C2829D62040F363321E7A" unitRef="usd">6675000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q3QTD" decimals="-3" id="Fact-B82B40DEBEA690D9813240F209CDD7DF" unitRef="usd">9244000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q4QTD" decimals="-3" id="Fact-1F767DCD8B9752BB27BE40E782B332C2" unitRef="usd">12252000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F4BD7A0F9CFCED378389E5056111EAFA" unitRef="usd">34175000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-D877DFA05B532F34F638E50628A169D7" unitRef="usd">-4608000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4B4249CDE19449D85C10E4F343B37AEF" unitRef="usd">-14332000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B53D3FDAE8A26DCBD13CE50561C2C971" unitRef="usd">-29593000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2017Q4" decimals="-3" id="Fact-B295872E0BF8B7EE14D62ACC26A4EFA7" unitRef="usd">1504000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-DD33BC86B7BB212E1F1507C45C0785A3" unitRef="usd">656000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2017Q4" decimals="-3" id="Fact-C8F8A2546F026963C2E22ACABFE38E84" unitRef="usd">173000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2017Q4" decimals="-3" id="Fact-636312E3829A6FEF60CC07C3FCED1F38" unitRef="usd">675000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2015Q4YTD" decimals="0" id="Fact-3EBA046D11E9B8C8A40107BDD5B1D43A" unitRef="usd">7000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2016Q4YTD" decimals="0" id="Fact-9DBDA1F719026AE9BA3F07BD0ECE557F" unitRef="usd">208000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2017Q4YTD" decimals="0" id="Fact-7DD25D43CE3F3873079D3978955AD0BF" unitRef="usd">400000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-C531F3B2C0329B3EE6CE1C787168D2FE" unitRef="usd">28200000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-5" id="Fact-E8D20DEA28E2B8C15D301C83C0DB6D9E" unitRef="usd">15000000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-7BF8C947C2BF3E8756D640D37CFD0A65" unitRef="usd">44300000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-5" id="Fact-C0990DE537F65E4D84341C8468A3577F" unitRef="usd">15000000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-AA00EA9D103A3C043A9F06D228BF86FF" unitRef="usd">63000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-2ED3C3BF1EA6B289CEEF2AC944B73FB6" unitRef="usd">201000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3F407C4DE87012356F00E5062B112BFC" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7E05441A53BE35A0A38BE4FDF45A976B" unitRef="usd">-26000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-A682EA3D4FD87D1A8C98EC2556155009" unitRef="usd">-26000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4AFBF4B1789B58C5D29BE505641D7A95" unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-7B7266B90E7BE6F4FBFC07D3E5D9A004" unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-E1EBC733EAF036F32AB6E4CAD3E59958" unitRef="usd">57000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-478FCDAEF07A9807CBED07C9C30FFF34" unitRef="usd">22000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:PaymentsOfFinancingCosts contextRef="FD2015Q4YTD" decimals="-3" id="Fact-612F59147424E3B6F5545353218A83D4" unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
	<us-gaap:PaymentsOfFinancingCosts contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2C4B8B01DA75C03B54EB535321795D0D" unitRef="usd">0</us-gaap:PaymentsOfFinancingCosts>
	<us-gaap:PaymentsOfFinancingCosts contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9619C8998F4567919F7F555192CB64E8" unitRef="usd">867000</us-gaap:PaymentsOfFinancingCosts>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BAC0649E34D18F89164BE5240E1785B7" unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-AF35FA240B2BDCF3FBE6E5240E11DB07" unitRef="usd">55309000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9E78CFB33C0CDBEBA5FEE5240E13C4FF" unitRef="usd">64148000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A8E19436BBE37E9D5E25E5229768F2A8" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F3229688DC6582F0DEA8E522974709B8" unitRef="usd">31000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-897CD70A1BD13E6F21ADE522974F6487" unitRef="usd">27000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-BB6E5B49C5197B3CFAA9E4C1E549B956" unitRef="usd">632000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-3D411E0403950907696107C913DC1534" unitRef="usd">3574000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-E7C54973A5E1E167455BE4C3713A0BFC" unitRef="usd">66000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-AE6629DFF167EDAD0ADA07C95E04084B" unitRef="usd">0</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="D2017Q3July_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-5" id="Fact-0943E45B2B4892233B7807EFBF0E6FC8" unitRef="usd">50500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="D2018Q1Jan_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-5" id="Fact-A0B2D09C0B32E482A7622AC1BFFD3D20" unitRef="usd">125500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4BB8C4EED9B5D2A8AB44E52E85E37B32" unitRef="usd">47620000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="FD2016Q4YTD" decimals="-3" id="Fact-23EDBDE50DE953AA4E04E52E457A0316" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="FD2017Q4YTD" decimals="-3" id="Fact-609A4314F869C08FE402E52BFAF8244A" unitRef="usd">50324000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-2FACE43AE5AD042EAD64E5285D6007BD" unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4901637478D02D12D353E5285D3FA26A" unitRef="usd">14250000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-7F3A8BD0CC1E9CD8FD6EE5285D47E59E" unitRef="usd">43110000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E0A9969AB376FF900859E525378A55F0" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-686A2C4996E52DC1414EE52537924743" unitRef="usd">3600000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4CFC239244107A7C5204E52537AB6D55" unitRef="usd">6000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-3" id="Fact-625B978AF7C4FD80D4E9E52E868B28BF" unitRef="usd">98000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-3" id="Fact-AE4F82A0F7C5BB6B1903E52E4621252C" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F616768F893F2B09A588E52C69C54FEE" unitRef="usd">34000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-570B6FE2A918F2CB08FDE4C2B5B951C9" unitRef="usd">27000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="-3" id="Fact-DA029E38B5FF121E82A607C95D6BE98B" unitRef="usd">28000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-6122F41D806B871437B3F7A393AD7714">P5Y
</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-4D9C1AD238B4BCC20C58F7A32EF03535">P3Y
</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_us-gaap_AffiliatedEntityMember_us-gaap_RelatedPartyTransactionAxis_mnlo_DevelopmentServicesFeesMember" decimals="-5" id="Fact-C90D3777A3438103CF9E1C9A46F98C53" unitRef="usd">800000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_us-gaap_AffiliatedEntityMember_us-gaap_RelatedPartyTransactionAxis_mnlo_DevelopmentServicesFeesMember" decimals="-5" id="Fact-E22098BF205B86C7D3981C991591FEDF" unitRef="usd">1000000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned contextRef="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_ResearchAndDevelopmentArrangementMember" decimals="-5" id="Fact-BE495BA711EFFB912A02F8266300896D" unitRef="usd">800000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
	<us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross contextRef="FD2017Q3QTD_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaap_ResearchAndDevelopmentArrangementMember" decimals="-5" id="Fact-0DD2D0B8DCFF637872CAF8277BACDA95" unitRef="usd">500000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-3AD5DE2A4A6CB3D2022BE50626AB124E" unitRef="usd">2921000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DD6D099574AE40A06D0BE4EEE539DCF3" unitRef="usd">11255000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C6684963815D925F2B74E5055FC074FB" unitRef="usd">29007000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-3" id="Fact-18AB0CEBDA1410F4BCC7E4DEB4CD87B0" unitRef="usd">-30115000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-3" id="Fact-54767FEFDA0734543DB9F715D378616A" unitRef="usd">-59191000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2017Q4QTD_us-gaap_CounterpartyNameAxis_mnlo_JTToriiMember_us-gaap_TypeOfArrangementAxis_mnlo_DevelopmentandRegulatoryMilestonesMember" decimals="-5" id="Fact-E57CBA64D2CFD686C9DA5359E8FAAC31" unitRef="usd">2000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q1Jan_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-34D0B0A4AC81ECEDCAC32AD7A1BD5AD1" unitRef="shares">8050000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q1Jan_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="0" id="Fact-5ADBE631C124E1076873F705E634CAD7" unitRef="shares">8050000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q1Jan_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="0" id="Fact-188BD23196EE49A07F5BF707F73762E4" unitRef="shares">1050000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A08AAD3E81E839E07994E5215DE8504B" unitRef="usd">65000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7912B2BB68889F7C20B9E5113CE5BE22" unitRef="usd">573000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9D8711883639772A1C33E5205B4797F1" unitRef="usd">1452000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" id="Fact-EB9D1E05AD5F267B7D7421EC2D6F3123">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" id="Fact-77029500A734B295719D3E43AF699C28">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-E9D6362B244DA04DD3DC2BF4194C3008" unitRef="shares">222077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-3A0A838D478D4978045D2BF2E44B35E5" unitRef="shares">139636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="INF" id="Fact-5B9507D146E26ED1B9D02CB12A8B198A" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="INF" id="Fact-A68A15D82895B7BBBE882CCCFDC8772A" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="INF" id="Fact-FFD648921FA5B65341B22CB1023E9820" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="INF" id="Fact-89C13020503EDEFC0C182CCCFBD653D0" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="INF" id="Fact-C46A5A1F282E3105301B2CB08E7E2C6C" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="INF" id="Fact-6C2ADB0B76353E18BE2E2CCCF9E88E51" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="INF" id="Fact-7056FB237E0A3E627A772CAC4661D705" unitRef="number">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2015Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="INF" id="Fact-820642546164526A4BE12CC69D2E1196" unitRef="number">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="INF" id="Fact-640044EEE8F4B3316A292CAB94BAD7A0" unitRef="number">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="INF" id="Fact-C41ACE3BE445D63934CE2CC595245100" unitRef="number">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="INF" id="Fact-5FE030D6ABCD25657C732CAA6E47CE3C" unitRef="number">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="INF" id="Fact-16F3C657545D0F1202D52CC47E1330A2" unitRef="number">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2015Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="2" id="Fact-4C68A85F0BDF630903E12CC69BC0C9BB" unitRef="number">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="2" id="Fact-03DCCC82BAE7379997322CAB9310789F" unitRef="number">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="2" id="Fact-12BC9F64B91E63D85A922CC5947DD973" unitRef="number">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="2" id="Fact-D038BBE594632400662C2CAA0DDCBB14" unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="2" id="Fact-74D02D7B79DBF4F2078E2CC47C92C872" unitRef="number">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="3" id="Fact-A2AC6E41C81ADDF348D92CAF72C062C2" unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2015Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="3" id="Fact-9FAC11DA2539117F683F2CCAC4AC308B" unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="3" id="Fact-A2E3DCD55293197FDB7F2CAE5705E0BB" unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="3" id="Fact-FB1182B6DB6ECBED3AF22CC8649348F3" unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="3" id="Fact-62076C40E07378C09E1A2CADB63D45B5" unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="3" id="Fact-7A273792200F125A23B92CC79CCCF6B5" unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2015Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="3" id="Fact-7A9AC003278D83ED525D2CCAC301887C" unitRef="number">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="3" id="Fact-20A8FA27D72DF4D2550D2CAE566EA577" unitRef="number">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2016Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="3" id="Fact-7A3891870E9EC2EB6D0D2CC8630A49CB" unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" decimals="3" id="Fact-64E0B1D0B691296110EC2CAD5281B18E" unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" decimals="3" id="Fact-1E0E20E62FBF2FB53C792CC79B360B67" unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-9B2F265E6F4D26E143DC40C30E6735CB" unitRef="shares">411772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-AE62544CF4DF5F67691E2BFDB4532B13" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DE8DA2D3EC2E79A29DE940CAF37B2A98" unitRef="usd">209000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-52663A066EC2CEDDC3E822139A16E04C" unitRef="shares">317405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-25E76A26558FC6D63D2B22160605A631" unitRef="shares">1485132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-0EF6A74C2A426015D148221692CAFD53" unitRef="shares">1040329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD" decimals="2" id="Fact-50768B9B0BE3A0EEA76664668CF14348" unitRef="usdPerShare">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD" decimals="2" id="Fact-67E73D6A98235A570EB164665F14994A" unitRef="usdPerShare">1.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD" decimals="2" id="Fact-72B25698660885E3EF95646605D840AF" unitRef="usdPerShare">5.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2015Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="0" id="Fact-3BCF71364661607420262B0DC61D0463" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2016Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="-3" id="Fact-82C1FE2A3C873CCE52352B0B8EC415F4" unitRef="usd">3805000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="-3" id="Fact-A6D5055B2A7027A6E5E02B0C83DBE550" unitRef="usd">24033000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2014Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-9FEA411E4DB4351881672B0829040CF8" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2015Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-880CBC50D48762662E542B07B7C3E15D" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-6E492DEE0BF404EB36242AE272F6D201" unitRef="shares">1485132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-BCA493DA4BA79A65D2BF2AE327559557" unitRef="shares">2506926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="2" id="Fact-900DFC793E0E5A00784D2AF363653AD3" unitRef="usdPerShare">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="2" id="Fact-49B4C395387D21A0CEBD2AF3AFC6162D" unitRef="usdPerShare">3.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="2" id="Fact-A72579FF6E3F9ADB45C02AF06717C0B2" unitRef="usdPerShare">0.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="2" id="Fact-53EA104F44FD4AB36BE22AF0C08E1D08" unitRef="usdPerShare">1.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="2" id="Fact-00A7EC4A8404F6D8E93C2AECA2AD52F7" unitRef="usdPerShare">0.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="2" id="Fact-D8502932686F2FE0499F2AEE70BA36B6" unitRef="usdPerShare">1.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="2" id="Fact-EBAEC5418E8A408F98122AEEFDB20D0C" unitRef="usdPerShare">5.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" id="Fact-2184C40D2A17E42FA60421EABCE156FE">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" id="Fact-AD249249DC873FEA2D902CC3BD2DF25A">P1Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" id="Fact-4B87C0B95D4C00EB27632CC3BAC375FA">P1Y0M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" id="Fact-3E2298CE445E4F7131FB2CA94768B346">P3Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" id="Fact-A2122BC3957E4406239E2CA915B278FB">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" id="Fact-DB933021A36D7B80381D2CC270F5B44C">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" id="Fact-704F5CB08CCD01DB061F2CA9131DABE0">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" id="Fact-FF887956EE20823C02D32CC26E84D6C4">P9Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" id="Fact-599AC44E00D1B42750872CA8B2CF052D">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" id="Fact-EA339A02E5A96493364A2CC0B5DDE3CA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" id="Fact-DE41F5E525BF4BFD62042CA77E4A9434">P6Y0M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" id="Fact-FB933003D8B96D2A5FBF2CC0B2DBFCEC">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="FI2016Q4_us-gaap_AwardTypeAxis_mnlo_EarlyExercisedStockOptionsMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-090ADE6F07A7198885CE2B141159027E" unitRef="shares">218216</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="FI2017Q4_us-gaap_AwardTypeAxis_mnlo_EarlyExercisedStockOptionsMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-28AE295EE67CCBB707052B12264C8A20" unitRef="shares">138864</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" id="Fact-9E7D5DCB8379311373BC2AFF69E9407F">P9Y3M26D
</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" id="Fact-506B56BBC584FD9065242AFFC6AABD1D">P8Y9M15D
</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6BAED18C32106C979FF52BFB9078557E" unitRef="usd">1000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2016Q4YTD" decimals="-3" id="Fact-FDCB6E8DAD4763905B232BFB69894D4E" unitRef="usd">182000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A4A1F2387C71A9E888F12BFAD1269FCD" unitRef="usd">539000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-AECDEA60CF678530249921E26BBB7CB2" unitRef="number">1.1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-855E2BA18B619C5C5DA121E0B7242999" unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
	<us-gaap:ShortTermInvestments contextRef="FI2016Q4" decimals="-3" id="Fact-3D3739CC0276B86F02E6E4C16EEF83E8" unitRef="usd">26881000</us-gaap:ShortTermInvestments>
	<us-gaap:ShortTermInvestments contextRef="FI2017Q4" decimals="-3" id="Fact-81FBF648D0A8626C585207C9129F3820" unitRef="usd">49295000</us-gaap:ShortTermInvestments>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_AwardTypeAxis_mnlo_EarlyExercisedStockOptionsMember_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-351391C7DEFEF5EF06DD2B0FE7C0894E" unitRef="shares">317405</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-DFE15DC8E6A33E4AC4EE2ADEE9FD746C" unitRef="shares">317405</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-EE3DF73752CE3224E3CBEC1699C759FC" unitRef="shares">317405</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD" decimals="INF" id="Fact-89CA85841745B70B29CF2BFEF658499F" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_mnlo_A2011StockIncentivePlanMember" decimals="INF" id="Fact-81970F3EF7D8255A74092AE0482CF230" unitRef="shares">18535</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A16C1B6EE974702CFF2207D04B0D18B1" unitRef="shares">18535</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-3" id="Fact-673B78B2040E13DA2BEB07D2E622F80D" unitRef="usd">34000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7705E459F2511D78218807D2094153B1" unitRef="usd">34000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-6D1A83943ABB2EA9896AEBF38B66687B" unitRef="usd">-11410000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-FE715A5AE380FE670C13EBF56321CEF0" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-79DC032C98A2125F5EE3EBF87AD04F8F" unitRef="usd">28000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A34B107DC965CAC465CEEBF98887ADE6" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-9E73DB205211745AAFCBEBF6D1C4267D" unitRef="usd">-11439000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-53467D78C152E6D992BAEBF350785476" unitRef="usd">-15953000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-F05465B1FDA8CEADC934EBF528CB15AA" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C34B027682E687F9876DEBF85239A0BF" unitRef="usd">93000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2F427E4F6A241FF32E8FEBF963989C67" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-97849B89107EAE794BC4EBF6A4C0DBAD" unitRef="usd">-16047000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-B7B5004D101438844399E4DF13D4DD3D" unitRef="usd">-29441000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-09E5CF930D707D7B1E40EBF4F888DCBE" unitRef="usd">-26000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6D23889F0D923A6B6560EBF82A3419E4" unitRef="usd">699000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-4AFE1205D39EFC468DB6EBF936445D6B" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-583472B97A33BFC98B16EBF67DF91104" unitRef="usd">-30115000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-7226A32D54F64F74A12D07CD95C7E77F" unitRef="usd">-57034000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-B4A218842CBB0EAF493FEBF3CE95F168" unitRef="usd">-51000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6F70B82EBE1251866432EBF74B842AC5" unitRef="usd">2207000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7917FB37A7A6DDD31C70EBF8E0861F77" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-8E28F9E1D39D90642F66EBF5B4F3282A" unitRef="usd">-59191000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="D2018Q1Jan8_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-04EF5BB7332AF0CFBE2C309C9AE6DC46" unitRef="number">0.3707</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
	<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="D2018Q1Jan8_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-3867B70F1A58A5FF7809309FCAF42F43" unitRef="number">0.3707</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-605649468E07CE262DE51C81166408F6" unitRef="usd">500000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2016Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-D11AA971176468C974DC1C84B32C38EC" unitRef="usd">400000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-846A4A4FC96D4F3867F840D40F080E4F" unitRef="usd">2100000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-0AF42E7D36AF21AD2DCF49600E956A59" unitRef="usd">900000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-BFC82C68D9A7251761C9EC0187786946" unitRef="usd">11383000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact-98227CC9C65E1CA2FB96EC00E2FE0CEE" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-5829FC1B849D5C0BF8D6EBFF123622FD" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-DB85CB13BC05BE31642BEC0220AC9DC1" unitRef="usd">14183000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact-AA3B788CFFC7B6B0EDDBEC0226B95BBF" unitRef="usd">44820000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-91BBB1DFCFEAC343A362EBFF5B19BCF7" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-94D40C9049D73C233C8DE4D2E7F153BA" unitRef="usd">14183000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact-CF5F2D1D5DAC9F67D24AE4D63680BD75" unitRef="usd">44820000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-C718BBBD8A23033677F3E4D6CD0B3497" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-D5688EF85D4D47A4901707CA43506577" unitRef="usd">14183000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact-2D1877B324ABCEEC72B807CA44EE851D" unitRef="usd">44820000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-2A12236E1929A6094EEF07CA46237989" unitRef="usd">50324000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2016Q4" decimals="-3" id="Fact-46E6CE17B745A8D121130805507DDCB1" unitRef="usd">59300000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-1EBE5FC58EDEC47D74F403D919F81FA3" unitRef="usd">14300000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact-DEB7AD29EEBCE835389C03DA6426B7AA" unitRef="usd">45000000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-3A6033D2B135CED2A4C603DAE508F16B" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2017Q4" decimals="-3" id="Fact-610F7F082B65564F027A08001F76F629" unitRef="usd">109800000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-5756CE2F0F39B7D99E6103D919F80007" unitRef="usd">14300000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact-2900FAE587F4D816B6D703DA622F0FE2" unitRef="usd">45000000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-AC16C3A6F1CB7466E85103DAE38721B5" unitRef="usd">50500000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreferencePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-68481D3028A066300D1B081D316FFBCD" unitRef="usdPerShare">1000.00</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
	<us-gaap:TemporaryEquityLiquidationPreferencePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-2D31FF83AF0BE7D9B090081DE9C3C6B6" unitRef="usdPerShare">3.19</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
	<us-gaap:TemporaryEquityLiquidationPreferencePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-F6345F6C1AC4DB1EECEE081E80C3B140" unitRef="usdPerShare">4.26</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-A03CE59108BAD07AB75E03D70C969ACA" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-CB2543D3737AED95813703DA54CE5064" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-1FAE1E52C8E4473CD23303DAD6178067" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-B40DF00AD81F71C6459207E942658A1A" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-7DD28547A5C3667E3D1A03D62A2DCC38" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-A83C0AA7AE2B701A599303DA53105F0F" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-FC9CFA62258669B0024B03DAD3F8FDA1" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-208226651752F04108E408054E36E846" unitRef="shares">14120883</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-3AFC314EBCDAE537ED0403D76E3CA675" unitRef="shares">14300</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-6C11B0CEDF4CD9E610A303DA58B6C85C" unitRef="shares">14106583</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-3F9DE64836D9D2B6DC5703DAD9C30D74" unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-C646D7AA0993927D2D5308001CFFC6A7" unitRef="shares">28322761</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-81721C5C63AA75CA8B1003D76E4C933C" unitRef="shares">14300</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-E7A9EB89264B1A9A938603DA56F3679E" unitRef="shares">14106583</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-7DC9B989098E4169F6BA03DAD7D682A0" unitRef="shares">14201878</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-31862EDC2768C4D5804B08054F549F2C" unitRef="shares">14120883</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-4FA646C2BB77EB3644C403D809D352B7" unitRef="shares">14300</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-99BC8F60D8EFE84711F003DA5C4F9006" unitRef="shares">14106583</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-0D84ED5C9EF4DA174B9403DADE27ABAC" unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2017Q4" decimals="INF" id="Fact-BD282F4A257E68F61DD108001E2999FE" unitRef="shares">25975346</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-09803CE24ADC5160AAE203D809E6B94F" unitRef="shares">14300</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-0F65F2FB00D24C18501803DA5A888169" unitRef="shares">14106583</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-93D8DF4172F0DB0D2E7603DADC3A6407" unitRef="shares">11854463</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-3634BA9A44625159ADF8EC01838FA8C3" unitRef="shares">11500</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-20375601A37AB9AEB26AEC00DF9C4545" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2014Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-E926DBC82FF49824C82FEBFE42E69308" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-1D0DA222A0CCB8FF8CC0EC021DECE377" unitRef="shares">14300</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-1ECAA22054091CD36AA7EC022470B85B" unitRef="shares">14106583</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2015Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-6403044EA1599DDFD4D5EBFE127A9174" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-A317F189940554937C0C08074303ED3C" unitRef="shares">14120883</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-48A6C9D629A3E9F2520303D87A032F82" unitRef="shares">14300</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-E3F57C602D54D65CBFAB03DA60368E68" unitRef="shares">14106583</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-BDFD804EDC2F6DD3167103DAE1B7AB44" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-4C349DB4D35FDA7D78FC0806E0A81D71" unitRef="shares">25975346</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-9DB81C4DDA3DBBD5D2A403D87A03A63D" unitRef="shares">14300</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-86F94748821DDA00EF9003DA5DF8116B" unitRef="shares">14106583</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-A54FCB33E082FAAC19EF03DADFF40C85" unitRef="shares">11854463</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD" decimals="-3" id="Fact-20A7020218F3250E3488EC147FFD98BE" unitRef="usd">0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-D138E30C09F46EB2A910EC1291AFCB14" unitRef="usd">2800000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact-E9037A4A83F4E04367FDEC138288CEB3" unitRef="usd">44820000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B3F6CB4DA8E57DE5C096EC1F10E762A9" unitRef="usd">0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="-3" id="Fact-C866D1E8D7E9D29FC6F3EC1E42EDCE21" unitRef="usd">50324000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-97ED6F1434EEB97A7E21E5215C9B1207" unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-86E3928E6E7D73834B8DE50F4FB7484B" unitRef="usd">26000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CAA49C6802BE21914D74E52059F83181" unitRef="usd">25000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2014Q4" decimals="-3" id="Fact-C28C35977734EF5369C81C8EB38E0099" unitRef="usd">73000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2015Q4" decimals="-3" id="Fact-212FC49204F96D319D621C8E99F77C42" unitRef="usd">93000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2016Q4" decimals="-3" id="Fact-9850B12A6749366129111C8E52DB56D3" unitRef="usd">229000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2017Q4" decimals="-3" id="Fact-289DCBE6543F3033F50C4961372B953D" unitRef="usd">803000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="FI2017Q4" decimals="0" id="Fact-84C3C96B672B1FC0F0136484E9D6BA25" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-3" id="Fact-ED7FD283139832E0EEF31C9128D01721" unitRef="usd">20000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-3" id="Fact-00B74BB14E46C07D55811C909C51E2DB" unitRef="usd">136000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9C58907B32E1493FE4AD49613662141C" unitRef="usd">515000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-3" id="Fact-39D4F101188D97F1895A1C9128233909" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1182D67C275D65CCF2E11C902F968315" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-78825C9691602F8CACCB496135BF3F3A" unitRef="usd">59000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2015Q4YTD" decimals="-5" id="Fact-3E6D2E1A4764DD6AFBF61C775FA6FB5F" unitRef="usd">1900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2016Q4YTD" decimals="-5" id="Fact-32C337D0129B3DC81F291C770CE4610B" unitRef="usd">5000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2017Q4YTD" decimals="-5" id="Fact-AC273722CA025B19B27640D3492A6A2F" unitRef="usd">3400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2015Q4YTD" decimals="0" id="Fact-295EA98A075AFDF81267E5062D07E7E2" unitRef="shares">4735148</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q4YTD" decimals="0" id="Fact-820E571B6DAC98817B0AE503FFB09874" unitRef="shares">4987133</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q4YTD" decimals="0" id="Fact-A32C2F07B10DA22AA8EEE5056617158A" unitRef="shares">5108121</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2015Q4YTD" decimals="0" id="Fact-D0348645783AFCE8DC581C13CD87C7E6" unitRef="shares">325770</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2016Q4YTD" decimals="0" id="Fact-F852757E3055BB6F2FC91C13CD870E72" unitRef="shares">292925</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2017Q4YTD" decimals="0" id="Fact-4511A390EE749E222A4A2AD34458E7AE" unitRef="shares">177421</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="FD2015Q4YTD" decimals="0" id="Fact-653EDC7253C2C90B0E091C17B4ECD08C" unitRef="shares">5060918</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
	<us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="FD2016Q4YTD" decimals="0" id="Fact-5832057088832537E52C1C17B4FAD4FE" unitRef="shares">5280058</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
	<us-gaap:WeightedAverageNumberOfSharesIssuedBasic contextRef="FD2017Q4YTD" decimals="0" id="Fact-26A624250FB9B21EA8332AD344543025" unitRef="shares">5285542</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
	<us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="FD2017Q4YTD" id="Fact-FE68AF598BD6074B1F8BF938D2BAAEAD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The following table summarizes the available&amp;#8209;for&amp;#8209;sale securities (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;8,685&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;8,685&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Corporate notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;46,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;46,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Government notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;6,191&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;6,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;61,009&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;60,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3,808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3,808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Corporate notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;26,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;26,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Government notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;11,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;11,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;41,135&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;41,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-BA8EDECCA6AB1F322AD2F742B1BAB6F7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) and include all adjustments necessary for the fair presentation of the Company&amp;#8217;s financial position for the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="FD2017Q4YTD" id="Fact-9B3E067560272E5F5676EBEB064B0CDC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) and include all adjustments necessary for the fair presentation of the Company&amp;#8217;s financial position for the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Reverse Stock Split&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;On January 8, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2018, the Company effected a reverse split of shares of the Company&amp;#8217;s common stock at a ratio of 1-for-&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2.6975&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; pursuant to an amendment to the amended and restated certificate of incorporation approved by the Company&amp;#8217;s board of directors and stockholders. The par value and the authorized&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;shares of the common stock were not adjusted as a result of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse split for all periods presented, and the conversion ratio of the preferred stock was adjusted accordingly. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Segments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company operates in &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long&amp;#8209;lived assets are maintained in the United States of America. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Preparation of financial statements in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, stock&amp;#8209;based compensation expense, the resolution of uncertain tax positions and valuation allowance, recovery of long&amp;#8209;lived assets and accruals for research and development costs. Management bases its estimates on historical experience on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Risk and Uncertainties&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company&amp;#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&amp;#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&amp;#8217;s potential drug candidate, uncertainty of market acceptance of the Company&amp;#8217;s product candidate, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company&amp;#8217;s product candidate requires clearances from the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the product candidate will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to complete clinical studies and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Cash and Cash Equivalents &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. The Company limits its credit risk associated with cash and cash equivalents by placing its investments with an institution it believes is highly creditworthy and with highly rated money market funds. As of December&amp;#160;31, 2017 and 2016, cash and cash equivalents consisted of bank deposits, cash and investments in money market funds. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Investment Securities &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company classifies its investment securities as available&amp;#8209;for&amp;#8209;sale. Those investments with maturities less than 12&amp;#160;months at the date of purchase are considered short&amp;#8209;term investments. Those investments with maturities greater than 12&amp;#160;months at the date of purchase are considered long&amp;#8209;term investments. The Company&amp;#8217;s investment securities classified as available&amp;#8209;for&amp;#8209;sale are recorded at fair value based upon quoted market prices at period end. Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of comprehensive income or loss. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight&amp;#8209;line interest method. Dividend and&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Property and Equipment, Net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Property and equipment are stated at cost and depreciated using the straight&amp;#8209;line method over the estimated useful lives of the assets, generally between &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; years. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The carrying amounts of the Company&amp;#8217;s financial instruments, which include cash, accounts payable and accrued liabilities and other current liabilities, and deferred revenue approximate their fair values due to their short maturities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and investments. As of December&amp;#160;31, 2017 and 2016, the majority of our cash, cash equivalents and investments are held by &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; U.S. financial institution in excess of federally insured limits. We invest cash in excess of our current needs in United States Treasury and government agency securities, highly&amp;#8209;rated short or medium&amp;#8209;term debt securities and money market funds and, by policy, diversify our investments to limit the amount of credit exposure. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company has an investment policy which limits the Company to investing in highly rated corporate and government notes, and no individual investment may comprise more than &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; of the total portfolio.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;accounts for income taxes under the asset and liability method which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company&amp;#8217;s assets and liabilities and their financial statement reported amounts. Management makes estimates, assumptions and judgments to determine the Company&amp;#8217;s provision for income taxes and also for deferred tax assets and liabilities, and any valuation allowances recorded against the Company&amp;#8217;s deferred tax assets. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and to the extent the Company believes that recovery is not more likely than not, the Company must establish a valuation allowance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;has adopted ASC 740-10, Accounting for Uncertainty in Income Taxes, that prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&amp;#8217;s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Research and development costs are expensed as incurred. Substantially all of our research and development expenses consist of expenses incurred in connection with the development of serlopitant. These expenses include certain payroll and personnel expenses including stock&amp;#8209;based compensation expense, consulting costs, contract manufacturing costs, and fees paid to clinical research organizations, or CROs, to conduct research and development. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as an expense as the goods are delivered or the related services are performed. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company estimates non&amp;#8209;clinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage non&amp;#8209;clinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Patent Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company has no historical data to support a probable future economic benefit for the arising patent applications, filing and prosecution costs. Therefore, patent costs are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company recognizes rent expense on a straight&amp;#8209;line basis over the non&amp;#8209;cancellable term of the operating lease.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company measures and recognizes compensation expense for all stock&amp;#8209;based awards made to employees, directors and non&amp;#8209;employees, based on estimated fair values recognized using the straight&amp;#8209;line method over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The fair value of options to purchase common stock granted to employees is estimated on the grant date using the Black&amp;#8209;Scholes option valuation model. The calculation of stock&amp;#8209;based compensation expense requires that the Company make certain assumptions and judgments about a number of complex and subjective variables used in the Black&amp;#8209;Scholes model, including the expected term, expected volatility of the underlying common stock, risk&amp;#8209;free interest rate, as well as estimating future forfeitures of unvested stock options. To the extent actual forfeiture results differ from the estimates, the difference will be recorded as a cumulative adjustment in the period the estimates are revised. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company accounts for options issued to non&amp;#8209;employees using the Black&amp;#8209;Scholes option valuation model and is measured and recognized as the stock options are earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Convertible Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company recorded the convertible preferred stock at fair value on the dates of issuance, net of issuance costs. The convertible preferred stock is recorded outside of stockholders&amp;#8217; equity because, in the event of certain deemed liquidation events considered not solely within the Company&amp;#8217;s control, such as a merger, acquisition and sale of all or substantially all of the Company&amp;#8217;s assets, the convertible preferred stock will become redeemable at the option of the holders. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;All outstanding convertible preferred stock converted into common stock in January 2018 upon the effectiveness of the IPO.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Comprehensive income (loss) is defined as the change in equity of the Company during a period from transactions and other events and circumstances excluding transactions resulting from investments and distributions to owners. Comprehensive loss consists of the net loss and changes in accumulated other comprehensive income, which are comprised of unrealized gains (losses) on available&amp;#8209;for&amp;#8209;sale investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;To date, the Company&amp;#8217;s clinical drug candidates have not been approved for sale by the FDA and the Company has not generated any revenue from product sales. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;On August 10, 2016, the Company entered into a license and collaboration agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd., together referred to as &amp;#8220;JT Torii&amp;#8221;, which is referred to as the &amp;#8220;Collaboration Agreement&amp;#8221;. Under the Collaboration Agreement, the Company granted to JT Torii the rights to develop and commercialize products containing serlopitant in Japan for the treatment of diseases and conditions other than nausea or vomiting. In exchange, JT Torii paid an upfront, non&amp;#8209;refundable payment of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$11.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. In addition, the Company is entitled to receive aggregate payments of up to &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$28.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; upon the achievement of specified development and regulatory milestones, and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; upon the achievement of a commercial milestone, as well as tiered royalties from the mid-single digits up to the mid&amp;#8209;teens on sales of licensed products in Japan. The Company&amp;#8217;s performance obligations under the license agreement includes the transfer of intellectual property rights in the form of licenses, obligations to participate on certain development and/or commercialization committees with the collaboration partners and supply manufactured drug product for clinical trials. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company recognizes revenue pursuant to the Collaboration Agreement in connection with the clinical development and commercialization of products covered by the collaboration, including non-refundable upfront license fees, contingent consideration payments based on the achievement of defined collaboration objectives and royalties on sales of commercialized products. To date, the Company has not generated or recognized revenue from sales of its product candidates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Revenue from the Collaboration Agreement is recognized when &lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(i)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;persuasive evidence of an arrangement exists, &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(ii)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;transfer of technology has been completed, services have been performed or products have been delivered, &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(iii)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;the fee is fixed and determinable, and &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(iv)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;collection is reasonably assured. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company evaluates revenue agreements with multiple&amp;#8209;elements in accordance with ASC 605-25 &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Revenue Recognition - Multiple Element Arrangements&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting based on the achievement of certain criteria including whether the deliverable has stand&amp;#8209;alone value. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Upfront payments for licenses are evaluated to determine if the licensee can obtain standalone value from the license separate from the value of the &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;obligations to participate on certain development and/or commercialization committees with the collaboration partners and supply manufactured drug product for clinical trials&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; in the arrangement to be provided by the Company. The Company is reimbursed by JT Torii for the non-commercial supplies of serlopitant at the same rate as charged by the third party manufacturer, which does not include a significant and incremental discount to JT Torii. The assessment of multiple-element arrangements also requires judgment in order to determine the allocation of revenue to each deliverable and the appropriate period of time over which the revenue should be recognized. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Under the Collaboration Agreement, the Company has determined that the license does not have standalone value separate from the research and development services because &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;JT Torii cannot resell such license on a standalone basis or use the license with its available resources to obtain any economic value without the Company&amp;#8217;s participation. T&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;he license and the services are combined as one unit of accounting and upfront payments are recorded initially as deferred revenue in the balance sheet. Revenue is then recognized on a straight-line basis over an estimated performance period that is consistent with the term of performance obligations, unless the Company determines there is a discernible pattern of performance other than straight-line, in which case the Company uses a proportionate performance method to recognize the revenue over the estimated performance period. The Company is recognizing the upfront fee on a straight-line basis over the initial period of performance of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; years, which represents the estimated development period in the territories based on the initial development plan managed by the joint steering committee. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The term of the agreement is through the expiration of the patents associated with serlopitant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any changes in estimated periods of performance on a prospective basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;At the inception of each agreement that includes milestone payments, including the Collaboration Agreement, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non&amp;#8209;refundable payments that are contingent upon achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved, assuming all other revenue recognition criteria are met. Other contingent payments in which a portion of the milestone consideration is refundable or adjusts based on future performance or non&amp;#8209;performance (e.g., through a penalty or claw&amp;#8209;back provision) are not considered to relate solely to past performance, and therefore, not considered substantive. Amounts that are not recognized as revenue due to the uncertainty as to whether they will be retained or because they are expected to be refunded are recorded as a liability. The Company recognizes non&amp;#8209;substantive milestone payments over the remaining estimated period of performance once the milestone is achieved. Contingent payments associated with the achievement of specific objectives in certain contracts that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are recognized as revenue upon achievement of the objective, as long as there are no undelivered elements remaining and no continuing performance obligations by the Company, assuming all other revenue recognition criteria are met. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Under the Collaboration Agreement, the Company is entitled to receive aggregate payments of up to &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$28.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; upon the achievement of specified development and regulatory milestones, and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; upon the achievement of a commercial milestone. Two of the milestones, which amount to &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$2 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; each, relate to the preparation of an IND for submission to regulatory authorities in the territory are considered substantive given that they are triggered by the Company&amp;#8217;s performance relative to the achievement of pre-specified, &amp;#8220;at risk&amp;#8221; milestone events, including the submission of all completed clinical trials data packages and the validation of the manufacturing process. All other milestones, which amount to an aggregate of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$24.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, are considered non-substantive because the milestone is dependent upon the performance of the collaboration partner rather than the Company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&amp;#8217;s balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, current portion. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Expenses related to the collaboration agreement are recorded as a component of research and development in the statement of operations as incurred, and to date have been immaterial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;During the fourth quarter of 2017, the Company achieved a substantive milestone related to the validation of the manufacturing process under the Collaboration Agreement, and recognized revenues of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;On September 1, 2017, the Company entered into a separate services agreement with JT Torii to provide research and development services, including regulatory, chemistry and manufacturing support and related materials that is distinct from the original Collaboration Agreement. The Company evaluated the new services agreement and determined that the research and materials delivered to JT Torii represents a separate earnings process that provides standalone value to JT Torii. The fees received under the services agreement will be recognized as and when such services are performed by the Company and JT Torii consumes the benefits of those services. The Company has no obligation to provide services unless requested by JT Torii and agreed to by us. The Company is eligible to receive reimbursement of estimated costs incurred and payment for research services performed directly by the Company at agreed upon rates. During the year ended December 31, 2017, the Company recognized revenue of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and recorded expenses of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; as research and development expense in the statement of operations related to the new services agreement. The services agreement terminates upon the termination of the Collaboration Agreement or by mutual agreement of the parties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Net Loss per Share of Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted&amp;#8209;average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted&amp;#8209;average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock and common stock options are considered to be potentially dilutive securities. Because the Company has reported a net loss for the years ended December&amp;#160;31, 2017, 2016 and 2015, diluted net loss per common share is the same as basic net loss per common share for those periods. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In November 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016&amp;#8209;18,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force)&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. The update requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016&amp;#8209;18 is effective for public entities for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In March 2016, the FASB issued ASU 2016&amp;#8209;09, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Improvements to Employee Share&amp;#8209;Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; as part of its simplification initiative, which involves several aspects of accounting for share&amp;#8209;based payment transactions, including the income tax effects, statutory withholding requirements, forfeitures and classification on the statement of cash flows. The standard is effective for companies for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years with early adoption permitted. The Company adopted this standard as of January 1, 2017, and there was no impact to the Company&amp;#8217;s financial statements as a result of the adoption. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In February 2016, the FASB issued ASU 2016&amp;#8209;02, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight&amp;#8209;line basis over the term of the lease, respectively. A lessee is also required to record a right&amp;#8209;of&amp;#8209;use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASC 842 supersedes the previous leases standard, ASC 840 &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In January 2016, the FASB issued ASU 2016&amp;#8209;01, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. ASU 2016&amp;#8209;01 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In November 2015, the FASB issued ASU 2015&amp;#8209;17, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Balance Sheet Classification of Deferred Taxes&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; to simplify the presentation of deferred income taxes. The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. We have elected to early adopt ASU 2015&amp;#8209;17 as of the beginning of our fourth quarter ended December&amp;#160;31, 2015 on a prospective basis. There was no impact to the balance sheet amounts as a result of early adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In August 2014, the FASB issued ASU 2014&amp;#8209;15 related to Presentation of Financial Statements &amp;#8209; &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Going Concern (Subtopic 205&amp;#8209;40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. This update provides guidance about management&amp;#8217;s responsibilities in evaluating an entity&amp;#8217;s going concern uncertainties, and about the timing and content of related footnote disclosures. Under this amended guidance, an entity&amp;#8217;s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&amp;#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. This update is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company adopted this standard in 2016 and there was no impact on the financial position, results of operations or related financial statement disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In May 2014, the FASB issued ASU No. 2014&amp;#8209;09, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, which supersedes the revenue recognition requirements in ASC 605, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, FASB issued ASU No. 2015&amp;#8209;14, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, which effectively delayed the adoption date by one year, to an effective date for public entities for annual and interim periods beginning after December 15, 2017. In March, April and May 2016, the FASB issued additional updates to the new revenue standard relating to reporting revenue on a gross versus net basis, identifying performance obligations and licensing arrangements, and narrow&amp;#8209;scope improvements and practical expedients, respectively. The effective date of this additional update is the same as that of ASU 2014&amp;#8209;09. The guidance permits the use of either a retrospective or cumulative effect transition method. The Company has not yet selected a transition method. The Company is still finalizing the analysis to quantify the adoption impact of the provisions of the new standard, but it does not currently expect to have a material impact on the financial position or results of operations. Based on the evaluation of its current collaboration agreement and associated revenue streams, most of the revenue will be recorded consistently under both the current and the new standard. The FASB has issued, and may issue in the future, interpretive guidance which may cause the Company&amp;#8217;s evaluation to change. The Company believes it is following an appropriate timeline to allow for proper recognition, presentation and disclosure upon adoption effective the beginning of fiscal year 2018. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;There are no other recently issued accounting standards that apply to the Company or that are expected to have a material impact on results of operations, financial condition, or cash flows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-3ADCFA1F847DA90593BBF769CEE532AD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Cash and Cash Equivalents &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. The Company limits its credit risk associated with cash and cash equivalents by placing its investments with an institution it believes is highly creditworthy and with highly rated money market funds. As of December&amp;#160;31, 2017 and 2016, cash and cash equivalents consisted of bank deposits, cash and investments in money market funds.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-BA93AD8682EC8B2CE598EBDE762F4902">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Legal Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company&amp;#8217;s industry is characterized by frequent claims and litigation, including claims regarding intellectual property. As a result, the Company may be subject to various legal proceedings from time to time. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Management is not aware of any pending or threatened litigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;License Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In December 2012, the Company entered into an exclusive worldwide royalty free license agreement with Merck Sharp &amp;amp; Dohme Corp., or &amp;#8220;Merck&amp;#8221; for exclusive worldwide rights for the development and commercialization of serlopitant and two other NK&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt;1&lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8209;R antagonists in all human diseases, disorders or conditions, except for the treatment and prevention of nausea or vomiting. The Company paid Merck an upfront non&amp;#8209;refundable, non&amp;#8209;creditable licensing fee of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; dollars and issued to Merck shares of its common stock. In addition, the Company has agreed to make aggregate payments of up to &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; dollars upon the achievement of specified development and regulatory milestones.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Future milestone payments are considered to be contingent consideration and will be accrued when the applicable milestone is achieved. Through December 31, 2017, no milestones have been achieved under the license agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company conducts its operations using leased office facilities. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In September 2017, the Company entered into a lease agreement.&amp;#160;The &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; month lease, beginning on October 1, 2017, provides approximately &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; square feet of office space in Redwood City, California.&amp;#160;Base annual rent is approximately &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$55,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; per month, with annual increases.  The Company recognizes rent expense on a straight&amp;#8209;line basis over the respective lease period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Rent expense for the years ended December 31, 2017, 2016 and 2015 was &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$400,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$208,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$7,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;As of December&amp;#160;31, 2017, total future minimum lease payments under our operating leases are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51020408163265%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;"&gt;Year ending December 31:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total future minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Indemnification&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;As permitted under Delaware law and in accordance with the Company&amp;#8217;s bylaws, the Company is required to indemnify its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of December 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;From time to time, we may have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-85100D03EACE5456C34FF7D67A221FCC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Comprehensive income (loss) is defined as the change in equity of the Company during a period from transactions and other events and circumstances excluding transactions resulting from investments and distributions to owners. Comprehensive loss consists of the net loss and changes in accumulated other comprehensive income, which are comprised of unrealized gains (losses) on available&amp;#8209;for&amp;#8209;sale investments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2017Q4YTD" id="Fact-F1DC42EC6CCC62017AE2F7A6EE3A8E71">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and investments. As of December&amp;#160;31, 2017 and 2016, the majority of our cash, cash equivalents and investments are held by &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; U.S. financial institution in excess of federally insured limits. We invest cash in excess of our current needs in United States Treasury and government agency securities, highly&amp;#8209;rated short or medium&amp;#8209;term debt securities and money market funds and, by policy, diversify our investments to limit the amount of credit exposure. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company has an investment policy which limits the Company to investing in highly rated corporate and government notes, and no individual investment may comprise more than &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; of the total portfolio&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q4YTD" id="Fact-D2E88A2C7C2E517B4BDFEBD5DE2E33A1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Under the Company&amp;#8217;s 2011 Stock Incentive Plan (the &amp;#8220;2011 Plan&amp;#8221;), the Company may grant options to purchase common stock, restricted stock awards, or directly issue shares of common stock to employees, directors and consultants of the Company. During 2015, the Company&amp;#8217;s board of directors and stockholders approved an increase to the shares available under the 2011 Plan to &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2,086,600&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;During 2017, the Company&amp;#8217;s board of directors and stockholders approved an increase to the shares available under the 2011 Plan to &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3,339,724&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;As of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, there were&amp;#160;&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;"&gt;411,772&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;shares of common stock available&amp;#160;for issuance under the 2011 Plan. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Options may be granted at an exercise price per share of not less than &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; of the fair market value at the date of grant. If an incentive stock option is granted to a stockholder holding &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; of the Company&amp;#8217;s outstanding capitalization, then the purchase or exercise price per share must not be less than &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;110%&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; of the fair market value per share of common stock on the grant date. Options granted are exercisable over a maximum term of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; from the date of grant and generally vest over a period of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;four years&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total stock&amp;#8209;based compensation expense for employees and non&amp;#8209;employees recognized in the statements of operations was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;257&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;660&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total stock&amp;#8209;based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;1,452&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;At December 31, 2017, there was approximately &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$7.3 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; of unamortized compensation expense, which was expected to be recognized over a weighted average period of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2.9&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;2011 Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The table below summarizes stock option and restricted award activity under the 2011 Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Number of Shares Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted-Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted- Average Remaining Contractual Term (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Aggregate Intrinsic Value (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Balances at January 1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;317,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;0.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:1px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Exercised &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(317,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;0.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Balances at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,485,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Balances at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,485,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;9.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3,805&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,040,329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5.56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:1px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Exercised &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(18,535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;"&gt;Balances at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2,506,926&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;8.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;24,033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:0px;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Includes early exercise of &lt;/font&gt;&lt;font style="font-family:Trade Gothic;font-size:9.5pt;"&gt;317,405&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; options during the year ended &lt;/font&gt;&lt;font style="font-family:Trade Gothic;font-size:9.5pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:Trade Gothic;font-size:9.5pt;"&gt;138,864&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic;font-size:9.5pt;"&gt;218,216&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; remain unvested as of December 31, 2017 and &lt;/font&gt;&lt;font style="font-family:Trade Gothic;font-size:9.5pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Upon vesting of restricted shares and exercise of options, the Company issues common stock from its authorized shares. During the years ended December 31, 2017, 2016 and 2015, the Company received &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$34,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$98,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; upon the exercise of stock options, respectively. There were &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;139,636&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;222,077&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares of early exercised restricted shares which have not vested at December 31, 2017 and 2016, respectively. As of December 31, 2017 and 2016, the Company had recorded a liability of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$43,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$68,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, respectively for the early exercise of stock options, recorded as other current liabilities and other non&amp;#8209;current liabilities. When options are subject to the Company&amp;#8217;s repurchase right, the Company may buy back any unvested shares at their original exercise price in the event of an employee&amp;#8217;s termination prior to full vesting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The aggregate grant date fair value of employee options vesting during the years ended December 31, 2017, 2016 and 2015 was approximately &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$539,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$182,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, respectively. The aggregate intrinsic value of shares exercised during the year ended December 31, 2017 and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$209,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, respectively. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The weighted average grant date fair value of stock options granted was &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$5.56&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$1.79&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$0.15&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; per share during the years ended December 31, 2017, 2016, and 2015, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;There were &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares exercised in the year ended &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Stock Awards Granted to Employees and Directors&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Stock&amp;#8209;based compensation expense is based on the grant date fair value. The Company recognizes compensation expense for all stock&amp;#8209;based options and restricted awards on a straight&amp;#8209;line basis over the requisite service period of the awards, which is generally the option vesting term of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; years. Stock&amp;#8209; based compensation expense related to awards granted to employees and directors for the years ended December 31, 2017, 2016 and 2015 was approximately &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$791,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$314,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; an &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option valuation model. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. Industry peers consist of several public companies in the biotechnology industry with comparable characteristics, including clinical trials progress and therapeutic indications.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The expected term of the options is based on the average period the stock options are expected to remain outstanding. As the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior, the expected term is calculated as the midpoint between the weighted-average vesting term and the contractual expiration period also known as the simplified method. The risk-free rate is based on U.S. Treasury zero coupon issues with remaining terms consistent with the expected terms of the stock options, as determined at the time of grant. To date, the Company has not declared or paid any cash dividends and does not have any plans to do so in the future. Therefore, the Company used an expected divided yield of zero.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In addition to the assumptions used in the Black&amp;#8209;Scholes valuation model, the Company must also estimate a forfeiture rate to calculate the stock&amp;#8209;based compensation for its equity awards. The Company will continue to use judgment in evaluating the assumptions related to the Company&amp;#8217;s stock&amp;#8209;based compensation on a prospective basis. As the Company continues to accumulate additional data, it may have refinements to its estimates, which could materially impact the Company&amp;#8217;s future stock&amp;#8209;based compensation expense. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The following assumptions were used to calculate the fair value of awards granted to employees and directors during the years indicated:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;6.0 - 6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;4.6 - 6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;75% - 100%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;68% - 74%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;74%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Risk&amp;#8209;free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;1.9% - 2.3%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1.3% - 2.1%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Stock-Based Compensation for Non-employees&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Stock&amp;#8209;based compensation expense related to stock awards granted to non&amp;#8209;employees is recognized as the awards vest. The Company believes that the fair value of the stock&amp;#8209;based awards granted is more reliably measurable than the fair value of the services received. The fair value of stock awards granted is calculated using the Black&amp;#8209;Scholes option valuation model. Stock&amp;#8209; based compensation expense related to awards granted to non&amp;#8209;employees for the years ended December 31, 2017, 2016 and 2015 was approximately &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$661,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$259,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$64,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The fair values of common stock awards granted to non&amp;#8209;employees were calculated using the following assumptions for the periods presented:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;8.3 - 10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;9.3 - 10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1.0 - 1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;74% - 100%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;84% - 86%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;62% - 74%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Risk&amp;#8209;free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;2.1% - 2.5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1.6% - 2.5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;0.5% - 0.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-C6EB6679BFCAD3C5CBF6F81F30CC22D4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Net Loss per Share of Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted&amp;#8209;average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted&amp;#8209;average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock and common stock options are considered to be potentially dilutive securities. Because the Company has reported a net loss for the years ended December&amp;#160;31, 2017, 2016 and 2015, diluted net loss per common share is the same as basic net loss per common share for those periods. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2017Q4YTD" id="Fact-AA8051FE1E954B9514A8EBD1C983145B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Net loss attributable to common stockholders, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(29,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(14,068&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(4,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Weighted&amp;#8209;average common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,285,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,280,058&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,060,918&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Less: weighted&amp;#8209;average common shares subject to repurchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(177,421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(292,925&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(325,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Weighted&amp;#8209;average common shares used to compute basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,108,121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;4,987,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;4,735,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Net loss per share attributable to common stockholders:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(5.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(2.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(0.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Convertible preferred stock issuable upon conversion to common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;9,629,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,234,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,234,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Outstanding common stock subject to repurchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;139,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;222,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;"&gt;324,355&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2,506,926&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,485,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Stock options available for issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;411,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;198,978&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,684,110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;12,687,739&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;7,140,987&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;7,243,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="FD2017Q4YTD" id="Fact-E79C7831FC98F2ED6711F914F57374F4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements Using&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;in&amp;#160;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;8,685&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;8,685&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Corporate notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;46,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;40,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Government notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;6,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;6,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;60,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;19,963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;40,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements Using&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;in&amp;#160;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3,808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3,808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Corporate notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;26,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;7,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;18,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Government notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;11,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;11,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;41,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;22,226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;18,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
	<us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-324CB9A977F0E9AADB52EBE8E533A639">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The fair value of our financial instruments reflects the amounts that we estimate we would receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose and recognize the fair value of our assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Level 1 &amp;#8209; Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Level 2 &amp;#8209; Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Level 3 &amp;#8209; Inputs that are unobservable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;During the years presented, the Company has not changed the manner in which it values assets and liabilities that are measured at fair value using Level 3 inputs. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the years ended December 31, 2017 and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements Using&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;in&amp;#160;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;8,685&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;8,685&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Corporate notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;46,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;40,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Government notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;6,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;6,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;60,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;19,963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;40,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements Using&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;in&amp;#160;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3,808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3,808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Corporate notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;26,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;7,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;18,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Government notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;11,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;11,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;41,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;22,226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;18,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company uses a market approach for determining the fair value of all its Level&amp;#160;1 and Level&amp;#160;2 money market funds and marketable securities. To value its money market funds, the Company values the funds at $1 stable net asset value, which is the market pricing convention for identical assets that the Company has the ability to access.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The investments are classified as available&amp;#8209;for&amp;#8209;sale securities. At December 31, 2017 and 2016, the balance in the Company&amp;#8217;s accumulated other comprehensive income was comprised solely of activity related to the Company&amp;#8217;s available&amp;#8209;for&amp;#8209;sale securities. There were no realized gains or losses recognized on the sale or maturity of available&amp;#8209;for&amp;#8209;sale securities for the years ended December 31, 2017 and 2016 and as a result, the Company did not reclassify any amounts out of accumulated other comprehensive income for the year. The Company has a limited number of available&amp;#8209;for&amp;#8209;sale securities in insignificant loss positions as of December 31, 2017 and 2016, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized cost for the investment at maturity. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The following table summarizes the available&amp;#8209;for&amp;#8209;sale securities (in thousands): &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;8,685&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;8,685&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Corporate notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;46,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;46,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Government notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;6,191&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;6,175&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;61,009&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;60,958&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3,808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3,808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Corporate notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;26,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;26,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Government notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;11,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;11,193&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;41,135&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;41,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-A39E70C39B63A89D5828F910CF32E1DD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The fair value of our financial instruments reflects the amounts that we estimate we would receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose and recognize the fair value of our assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Level 1 &amp;#8209; Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Level 2 &amp;#8209; Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Level 3 &amp;#8209; Inputs that are unobservable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;During the years presented, the Company has not changed the manner in which it values assets and liabilities that are measured at fair value using Level 3 inputs. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2017Q4YTD" id="Fact-E17C50BC3FE6C0F020F7F79FCF123C9D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The carrying amounts of the Company&amp;#8217;s financial instruments, which include cash, accounts payable and accrued liabilities and other current liabilities, and deferred revenue approximate their fair values due to their short maturities. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="FD2017Q4YTD" id="Fact-200350DF619E9F1FA4E8F7C99A906A26">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Patent Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company has no historical data to support a probable future economic benefit for the arising patent applications, filing and prosecution costs. Therefore, patent costs are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-F3E756339FE783F9B701EBCEA7C7549B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company did not record a provision or benefit for income taxes during the years ended December 31, 2017, 2016 and 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The following is a reconciliation of the statutory federal income tax rate to the Company&amp;#8217;s effective tax rate:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:624px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:244px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:107px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:107px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:108px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Statutory Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;State Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Permanent Differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;General Business Credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Change in Valuation Allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Tax Reform - Tax Rate Change&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;"&gt;Deferred Tax Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;NOLs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;10,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;10,458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,992&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Depreciation and Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;328&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;362&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Stock&amp;#8209;Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Research &amp;amp; Development Credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2,063&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Deferred Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,791&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Other Accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;235&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total Deferred Tax Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;11,631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;6,621&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Valuation Allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(14,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(11,631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(6,621&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Net Deferred Tax Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:0px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:0px;text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:0px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:0px;text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:0px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:0px;text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The net change in the total valuation allowance for the years ended December 31, 2017, 2016 and 2015 was an increase of approximately &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$3.4 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;As of December 31, 2017 and 2016, the Company had net operating loss carryforwards for federal income tax purposes of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$44.3 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$28.2 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, respectively which expire beginning in the year 2031 and federal research and development tax credits of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, respectively which expire beginning in the year 2031.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;As of December 31, 2017 and 2016, the Company had net operating loss carryforwards for state income tax purposes of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, respectively which expire beginning in the year 2031 and state research and development tax credits of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, respectively which do not expire. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Federal and state tax laws impose substantial restrictions on the utilization of the net operating loss and credit carryforwards in the event of an ownership change as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&amp;#8217;s ability to utilize these carryforwards may be limited as a result of such ownership change. Such a limitation could result in the expiration of carryforwards before they are utilized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company has adopted ASC 740-10, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Accounting for Uncertainty in Income Taxes&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, that prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&amp;#8217;s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction of the provision for income taxes in the period that such determination is made. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;As of December 31, 2017 the Company had  &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; accrued interest and penalties related to uncertain tax positions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company filed US and California tax returns with varying statues of limitations. The federal and California tax years from 2011 to 2017 remain open to examination due to the carryover of unused net operating losses and tax credits. The Company does not expect any material changes to the estimated amount of liability associated with its uncertain tax positions within the next 12 months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Uncertain Tax Positions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The following table summarizes the activity related to unrecognized tax benefits (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;"&gt;Tax Benefits:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Unrecognized Benefit &amp;#8209; beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Gross Increases(Decreases) &amp;#8209; prior period tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Gross Increases(Decreases) &amp;#8209; current period tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;515&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total Unrecognized Benefit &amp;#8209; end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;803&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;"&gt;Tax Reform&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the &amp;#8220;Tax Act&amp;#8221;) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 34% to 21% (the &amp;#8220;Rate Reduction&amp;#8221;) effective for tax years beginning after December 31, 2017. The Company reduced deferred tax assets at December 31, 2017 for the effect of the Rate Reduction. The Rate Reduction did not impact the Company's provision for income taxes for 2017 due to the full valuation allowance on deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. The Company determined that &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$7.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; of the reduction in deferred tax assets resulting from Rate Reduction was both provisional and a reasonable estimate at December 31, 2017. Additionally, the Company is still in the process of analyzing certain provisions of the Act including the application of new executive compensation limitation provisions under Internal Revenue Section 162(m). These items are subject to revisions from further analysis of the Tax Act and interpretation of any additional guidance issued by the U.S. Treasury Department, IRS, FASB, and other standard-setting and regulatory bodies.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-4AF667CBFB792887CC32F7C53F4B93EF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;accounts for income taxes under the asset and liability method which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company&amp;#8217;s assets and liabilities and their financial statement reported amounts. Management makes estimates, assumptions and judgments to determine the Company&amp;#8217;s provision for income taxes and also for deferred tax assets and liabilities, and any valuation allowances recorded against the Company&amp;#8217;s deferred tax assets. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and to the extent the Company believes that recovery is not more likely than not, the Company must establish a valuation allowance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;has adopted ASC 740-10, Accounting for Uncertainty in Income Taxes, that prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&amp;#8217;s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:LesseeLeasesPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-F3FFAE368B81F012C02BF7CE7FC59D59">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company recognizes rent expense on a straight&amp;#8209;line basis over the non&amp;#8209;cancellable term of the operating lease.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
	<us-gaap:MarketableSecuritiesPolicy contextRef="FD2017Q4YTD" id="Fact-A6441DB495DA3AA03613F78EE063878B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Investment Securities &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company classifies its investment securities as available&amp;#8209;for&amp;#8209;sale. Those investments with maturities less than 12&amp;#160;months at the date of purchase are considered short&amp;#8209;term investments. Those investments with maturities greater than 12&amp;#160;months at the date of purchase are considered long&amp;#8209;term investments. The Company&amp;#8217;s investment securities classified as available&amp;#8209;for&amp;#8209;sale are recorded at fair value based upon quoted market prices at period end. Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of comprehensive income or loss. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight&amp;#8209;line interest method. Dividend and&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
	<us-gaap:NatureOfOperations contextRef="FD2017Q4YTD" id="Fact-44983887D27B092E2116EBEC8CE0F949">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Formation and Business of the Company&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Menlo Therapeutics Inc., or the &amp;#8220;Company&amp;#8221;, is a late&amp;#8209;stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The Company is concurrently evaluating the use of serlopitant for the treatment of refractory chronic cough, a cough that persists for at least eight weeks despite treatment of any identified underlying cause. The Company believes that its product candidate, serlopitant, a highly selective once&amp;#8209;daily, oral small molecule inhibitor of the neurokinin 1 receptor, or NK&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt;1&lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8209;R, has the potential to significantly alleviate itch and cough symptoms. Pruritus associated with atopic dermatitis, psoriasis and prurigo nodularis, as well as refractory chronic cough, each represents a significant patient need.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company was incorporated in Delaware in October 2011. Since commencing operations, the Company has devoted substantially all of its resources to developing its product candidate, including conducting clinical trials and providing general and administrative support for these operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Initial Public Offering&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In January 2018, the Company completed its initial public offering (&amp;#8220;IPO&amp;#8221;) of shares of its common stock, pursuant to which the Company issued &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;8,050,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares of common stock, which includes &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,050,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares issued pursuant to the over-allotment option granted to its underwriters, and received net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$125.5 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, after deducting underwriting discounts, commissions and offering expenses. In connection with the completion of the Company's IPO, all shares of convertible preferred stock converted into &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;9,629,405&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares of common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Liquidity and Capital Resources&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Since inception, the Company has incurred losses and negative cash flows from operations. For the year ended December 31, 2017, the Company incurred a net loss of $&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;29.1 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and used &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$28.2 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; of cash in operations. As of December&amp;#160;31, 2017, the Company had cash, cash equivalents and investments of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$62.5 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$59.2 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company&amp;#8217;s research and development activities. Management plans to finance operations through equity or debt financing arrangements, and/or third&amp;#8209;party collaboration funding. There can be no assurances that, in the event that the Company requires additional financing, such financing will be available on terms which are favorable to the Company, or at all. If the Company is unable to raise additional funding to meet its working capital needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company believes that its existing cash, cash equivalents and investments as of December&amp;#160;31, 2017 together with funds available from the January 2018 IPO, will provide sufficient funds to enable it to meet its obligations for at least the next twelve months.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-DD10E25F8FFB99FD3E21F822BBA2F796">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In November 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016&amp;#8209;18,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force)&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. The update requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016&amp;#8209;18 is effective for public entities for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In March 2016, the FASB issued ASU 2016&amp;#8209;09, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Improvements to Employee Share&amp;#8209;Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; as part of its simplification initiative, which involves several aspects of accounting for share&amp;#8209;based payment transactions, including the income tax effects, statutory withholding requirements, forfeitures and classification on the statement of cash flows. The standard is effective for companies for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years with early adoption permitted. The Company adopted this standard as of January 1, 2017, and there was no impact to the Company&amp;#8217;s financial statements as a result of the adoption. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In February 2016, the FASB issued ASU 2016&amp;#8209;02, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight&amp;#8209;line basis over the term of the lease, respectively. A lessee is also required to record a right&amp;#8209;of&amp;#8209;use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASC 842 supersedes the previous leases standard, ASC 840 &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In January 2016, the FASB issued ASU 2016&amp;#8209;01, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. ASU 2016&amp;#8209;01 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In November 2015, the FASB issued ASU 2015&amp;#8209;17, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Balance Sheet Classification of Deferred Taxes&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; to simplify the presentation of deferred income taxes. The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. We have elected to early adopt ASU 2015&amp;#8209;17 as of the beginning of our fourth quarter ended December&amp;#160;31, 2015 on a prospective basis. There was no impact to the balance sheet amounts as a result of early adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In August 2014, the FASB issued ASU 2014&amp;#8209;15 related to Presentation of Financial Statements &amp;#8209; &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Going Concern (Subtopic 205&amp;#8209;40): Disclosure of Uncertainties about an Entity&amp;#8217;s Ability to Continue as a Going Concern&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. This update provides guidance about management&amp;#8217;s responsibilities in evaluating an entity&amp;#8217;s going concern uncertainties, and about the timing and content of related footnote disclosures. Under this amended guidance, an entity&amp;#8217;s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&amp;#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. This update is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company adopted this standard in 2016 and there was no impact on the financial position, results of operations or related financial statement disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In May 2014, the FASB issued ASU No. 2014&amp;#8209;09, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, which supersedes the revenue recognition requirements in ASC 605, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, FASB issued ASU No. 2015&amp;#8209;14, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, which effectively delayed the adoption date by one year, to an effective date for public entities for annual and interim periods beginning after December 15, 2017. In March, April and May 2016, the FASB issued additional updates to the new revenue standard relating to reporting revenue on a gross versus net basis, identifying performance obligations and licensing arrangements, and narrow&amp;#8209;scope improvements and practical expedients, respectively. The effective date of this additional update is the same as that of ASU 2014&amp;#8209;09. The guidance permits the use of either a retrospective or cumulative effect transition method. The Company has not yet selected a transition method. The Company is still finalizing the analysis to quantify the adoption impact of the provisions of the new standard, but it does not currently expect to have a material impact on the financial position or results of operations. Based on the evaluation of its current collaboration agreement and associated revenue streams, most of the revenue will be recorded consistently under both the current and the new standard. The FASB has issued, and may issue in the future, interpretive guidance which may cause the Company&amp;#8217;s evaluation to change. The Company believes it is following an appropriate timeline to allow for proper recognition, presentation and disclosure upon adoption effective the beginning of fiscal year 2018. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;There are no other recently issued accounting standards that apply to the Company or that are expected to have a material impact on results of operations, financial condition, or cash flows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PreferredStockTextBlock contextRef="FD2017Q4YTD" id="Fact-274AAEBB88039D9AA1F7EBDC9728D288">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Convertible Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;As of December 31, 2017, the Company&amp;#8217;s Certificate of Incorporation, as amended, authorized the Company to issue up to &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;28,322,761&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares of convertible preferred stock, par value of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$0.001&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,300&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; were designated Series A convertible preferred stock and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,106,583&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; are designated Series B convertible preferred stock, and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,201,878&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares are designated Series C convertible preferred stock. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In July 2017, the Company issued &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;11,854,463&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares of Series C convertible preferred stock to investors at &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$4.26&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; per share with gross proceeds of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$50.5 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In January 2018, the Company completed its initial public offering (&amp;#8220;IPO&amp;#8221;) of shares of its common stock, pursuant to which the Company issued &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;8,050,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares of common stock, which includes &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,050,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares issued pursuant to the over-allotment option granted to its underwriters, and received net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$125.5 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, after deducting underwriting discounts, commissions and offering expenses. In connection with the completion of the Company's IPO, all shares of convertible preferred stock converted into &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;9,629,405&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares of common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company had outstanding convertible preferred stock as of the times set forth below as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares Issued and Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Aggregate Liquidation Preference&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Series A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Series B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,106,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,106,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;45,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Series C&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,201,878&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;11,854,463&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;50,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;28,322,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;25,975,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;109,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares Issued and Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Aggregate Liquidation Preference&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Series A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Series B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,106,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,106,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;45,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,120,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,120,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;59,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Significant terms of the Series A, B and C convertible preferred stock as of December 31, 2017 (collectively, the &amp;#8220;Preferred Stock&amp;#8221;) are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Liquidation Preference&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In the event of any liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, the holders of the then outstanding shares of Series A convertible stock and Series B convertible preferred stock and Series C convertible preferred stock are first entitled to receive the amount of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$3.19&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$4.26&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; per share, respectively plus all declared but unpaid dividends for such shares, prior and in preference to any distribution of any assets of the Company to the holders of the common stock. If, upon the occurrence of such event, the proceeds distributed among the holders of the Series A, B and C convertible preferred stock are insufficient to permit the full payment of the aforesaid preferential amounts to each holder the convertible preferred stock, then the entire proceeds legally available for distribution to the convertible preferred stock shall be distributed ratably among the holders of the Series A, B and C convertible preferred stock in proportion to the full preferential amount that each such holder of convertible preferred stock is otherwise entitled to receive.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Upon completion of the distributions required by the above&amp;#8209;mentioned liquidation preferences, any remaining proceeds shall be distributed among the holders of Series B and C convertible preferred stock and common stock pro rata based on the number of shares of common stock held by each, assuming full conversion of the Series B and C convertible preferred stock to common stock at the then&amp;#8209;effective conversion price for such shares.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Dividends&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The holders of shares of Series A, B and C convertible preferred stock are entitled to receive non&amp;#8209;cumulative dividends, out of any assets legally available, prior and in preference to any declaration or payment of any dividend on the common stock, at the applicable dividend rate of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$80.00&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; per annum for each share of Series A convertible preferred stock, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$0.2552&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; per annum for each share of Series B convertible preferred &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;stock and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$0.3408&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; per share per annum for each share of Series C convertible preferred stock&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, all subject to adjustment from time to time for recapitalizations, payable when and if declared by the Company&amp;#8217;s board of directors. The Company has never declared any dividends on its convertible preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Voting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The holder of each share of Series B and C convertible preferred stock are entitled to one vote for each share of common stock into which such preferred stock could then be converted and, with respect to such vote, such holder has full voting rights and powers equal to the voting rights and powers of the holders of common stock and is entitled to notice of any stockholders&amp;#8217; meeting in accordance with the Company&amp;#8217;s bylaws. The holders of shares of Series A convertible preferred stock do not have a right to vote, other than as required by Delaware law and for certain directors, as set forth below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The holders of shares of Series A convertible preferred stock are entitled to elect &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; of the Company&amp;#8217;s directors. The holders of Series B convertible preferred stock are entitled to elect &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; of the Company&amp;#8217;s directors. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The holders of Series C convertible preferred stock are entitled to elect &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; of the Company&amp;#8217;s directors. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The holders of outstanding common stock are entitled to elect &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; of the Company&amp;#8217;s directors. The holders of convertible preferred stock and common stock, voting together as a single class, and not as separate series, and on an as converted basis, are entitled to elect any remaining directors of the Company, subject to the approval of the then serving members of the Company&amp;#8217;s directors.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Conversion&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The holder of each share of convertible preferred stock has the option to convert each share of convertible preferred stock into such number of fully paid and nonassessable shares of common stock as is determined by dividing the applicable original issue price for such series by the applicable conversion price for such series in effect on the date the certificate is surrendered for conversion. Each share of convertible preferred stock shall automatically be converted into shares of common stock at the conversion rate at the time in effect for such series of convertible preferred stock immediately prior to the earlier of (i) sale of the Company&amp;#8217;s common stock in a firm commitment underwritten public offering pursuant to a registration statement under the Securities Act of 1933, as amended, with gross proceeds of not less than &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$40.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; in the aggregate and an offering price to the public of no less than &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$17.21&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; per share, or (ii) upon the receipt by the Corporation of a written request or agreement of the holders of a majority of the outstanding Series A, B and C convertible preferred stock, voting together as a single class and on an as converted basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The conversion price of the convertible preferred stock was initially set at an amount equal to the issue price. The Series B and C convertible preferred stock conversion price is subject to adjustment for stock dividends, stock splits, re&amp;#8209;capitalization and upon the occurrence of certain triggering events related to anti&amp;#8209;dilution protection rights. In the event that a future preferred stock financing should occur at a price lower than the last preferred financing round, the conversion ratios of the existing preferred stock are changed to protect the ownership position of existing investors.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PreferredStockTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-7A8B3D5E02F54C0C033AF790BB81EA01">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Property and Equipment, Net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Property and equipment are stated at cost and depreciated using the straight&amp;#8209;line method over the estimated useful lives of the assets, generally between &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; years. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2017Q4YTD" id="Fact-9B5293B69A3EC3A6B64F40E2E986FE4B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;"&gt;Selected Unaudited Quarterly Financial Data&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The following tables show a summary of the Company&amp;#8217;s unaudited quarterly financial data for each of the four quarters of 2017 and 2016 (in thousands, except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="33" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="30" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-top:2px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:2px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#160;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Collaboration and service revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;2,775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;909&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;449&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;449&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;12,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;9,244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;6,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;6,004&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(9,277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(8,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(6,153&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(5,474&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Basic and diluted net loss per common share (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(1.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(1.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(1.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(1.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="33" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="30" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;September 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-top:2px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:2px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#160;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Collaboration and service revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;450&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;5,374&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;3,699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;3,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;2,297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(4,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(3,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(3,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(2,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Basic and diluted net loss per common share (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(0.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(0.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(0.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(0.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Basic and diluted net loss per common share are computed independently for each of the quarters presented. Therefore, the sum of quarterly basic and diluted per share information may not equal annual basic and diluted net loss per common share.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-EC842B37AB5D7E1B37C6EBCA8147D79E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Related Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;From 2011 through 2016, the Company has operated with significant consulting and management services provided by Velocity Pharmaceutical Development, LLC (&amp;#8220;VPD&amp;#8221;). Development services fees paid to VPD under the Development Services Agreement were &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; for the years ended December 31, 2016 and 2015, respectively. The Company also reimbursed VPD for consulting, travel and other expenses incurred on our behalf. As of December 31, 2017 and 2016, the Company did not have any outstanding liabilities to VPD. Several managing directors of VPD have served as officers and directors of the Company. David Collier, M.D., a former member of the Company&amp;#8217;s board of directors, is the Chief Executive Officer of VPD, and Xiaoming Zhang, Ph.D., our Senior Vice President, Non&amp;#8209;Clinical and Pharmaceutical Development, is a Venture Partner of VPD.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2017Q4YTD" id="Fact-000354D34887447FD8A7F7C695863018">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Research and development costs are expensed as incurred. Substantially all of our research and development expenses consist of expenses incurred in connection with the development of serlopitant. These expenses include certain payroll and personnel expenses including stock&amp;#8209;based compensation expense, consulting costs, contract manufacturing costs, and fees paid to clinical research organizations, or CROs, to conduct research and development. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as an expense as the goods are delivered or the related services are performed. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company estimates non&amp;#8209;clinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage non&amp;#8209;clinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-1ACAE0C67E3BC5813130F7D96F5503C0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;To date, the Company&amp;#8217;s clinical drug candidates have not been approved for sale by the FDA and the Company has not generated any revenue from product sales. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;On August 10, 2016, the Company entered into a license and collaboration agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd., together referred to as &amp;#8220;JT Torii&amp;#8221;, which is referred to as the &amp;#8220;Collaboration Agreement&amp;#8221;. Under the Collaboration Agreement, the Company granted to JT Torii the rights to develop and commercialize products containing serlopitant in Japan for the treatment of diseases and conditions other than nausea or vomiting. In exchange, JT Torii paid an upfront, non&amp;#8209;refundable payment of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$11.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. In addition, the Company is entitled to receive aggregate payments of up to &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$28.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; upon the achievement of specified development and regulatory milestones, and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; upon the achievement of a commercial milestone, as well as tiered royalties from the mid-single digits up to the mid&amp;#8209;teens on sales of licensed products in Japan. The Company&amp;#8217;s performance obligations under the license agreement includes the transfer of intellectual property rights in the form of licenses, obligations to participate on certain development and/or commercialization committees with the collaboration partners and supply manufactured drug product for clinical trials. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company recognizes revenue pursuant to the Collaboration Agreement in connection with the clinical development and commercialization of products covered by the collaboration, including non-refundable upfront license fees, contingent consideration payments based on the achievement of defined collaboration objectives and royalties on sales of commercialized products. To date, the Company has not generated or recognized revenue from sales of its product candidates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Revenue from the Collaboration Agreement is recognized when &lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(i)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;persuasive evidence of an arrangement exists, &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(ii)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;transfer of technology has been completed, services have been performed or products have been delivered, &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(iii)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;the fee is fixed and determinable, and &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(iv)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;collection is reasonably assured. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company evaluates revenue agreements with multiple&amp;#8209;elements in accordance with ASC 605-25 &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;"&gt;Revenue Recognition - Multiple Element Arrangements&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting based on the achievement of certain criteria including whether the deliverable has stand&amp;#8209;alone value. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Upfront payments for licenses are evaluated to determine if the licensee can obtain standalone value from the license separate from the value of the &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;obligations to participate on certain development and/or commercialization committees with the collaboration partners and supply manufactured drug product for clinical trials&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; in the arrangement to be provided by the Company. The Company is reimbursed by JT Torii for the non-commercial supplies of serlopitant at the same rate as charged by the third party manufacturer, which does not include a significant and incremental discount to JT Torii. The assessment of multiple-element arrangements also requires judgment in order to determine the allocation of revenue to each deliverable and the appropriate period of time over which the revenue should be recognized. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Under the Collaboration Agreement, the Company has determined that the license does not have standalone value separate from the research and development services because &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;JT Torii cannot resell such license on a standalone basis or use the license with its available resources to obtain any economic value without the Company&amp;#8217;s participation. T&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;he license and the services are combined as one unit of accounting and upfront payments are recorded initially as deferred revenue in the balance sheet. Revenue is then recognized on a straight-line basis over an estimated performance period that is consistent with the term of performance obligations, unless the Company determines there is a discernible pattern of performance other than straight-line, in which case the Company uses a proportionate performance method to recognize the revenue over the estimated performance period. The Company is recognizing the upfront fee on a straight-line basis over the initial period of performance of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; years, which represents the estimated development period in the territories based on the initial development plan managed by the joint steering committee. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The term of the agreement is through the expiration of the patents associated with serlopitant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any changes in estimated periods of performance on a prospective basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;At the inception of each agreement that includes milestone payments, including the Collaboration Agreement, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non&amp;#8209;refundable payments that are contingent upon achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved, assuming all other revenue recognition criteria are met. Other contingent payments in which a portion of the milestone consideration is refundable or adjusts based on future performance or non&amp;#8209;performance (e.g., through a penalty or claw&amp;#8209;back provision) are not considered to relate solely to past performance, and therefore, not considered substantive. Amounts that are not recognized as revenue due to the uncertainty as to whether they will be retained or because they are expected to be refunded are recorded as a liability. The Company recognizes non&amp;#8209;substantive milestone payments over the remaining estimated period of performance once the milestone is achieved. Contingent payments associated with the achievement of specific objectives in certain contracts that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are recognized as revenue upon achievement of the objective, as long as there are no undelivered elements remaining and no continuing performance obligations by the Company, assuming all other revenue recognition criteria are met. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Under the Collaboration Agreement, the Company is entitled to receive aggregate payments of up to &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$28.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; upon the achievement of specified development and regulatory milestones, and &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; upon the achievement of a commercial milestone. Two of the milestones, which amount to &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$2 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; each, relate to the preparation of an IND for submission to regulatory authorities in the territory are considered substantive given that they are triggered by the Company&amp;#8217;s performance relative to the achievement of pre-specified, &amp;#8220;at risk&amp;#8221; milestone events, including the submission of all completed clinical trials data packages and the validation of the manufacturing process. All other milestones, which amount to an aggregate of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$24.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, are considered non-substantive because the milestone is dependent upon the performance of the collaboration partner rather than the Company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&amp;#8217;s balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, current portion. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Expenses related to the collaboration agreement are recorded as a component of research and development in the statement of operations as incurred, and to date have been immaterial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;During the fourth quarter of 2017, the Company achieved a substantive milestone related to the validation of the manufacturing process under the Collaboration Agreement, and recognized revenues of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;On September 1, 2017, the Company entered into a separate services agreement with JT Torii to provide research and development services, including regulatory, chemistry and manufacturing support and related materials that is distinct from the original Collaboration Agreement. The Company evaluated the new services agreement and determined that the research and materials delivered to JT Torii represents a separate earnings process that provides standalone value to JT Torii. The fees received under the services agreement will be recognized as and when such services are performed by the Company and JT Torii consumes the benefits of those services. The Company has no obligation to provide services unless requested by JT Torii and agreed to by us. The Company is eligible to receive reimbursement of estimated costs incurred and payment for research services performed directly by the Company at agreed upon rates. During the year ended December 31, 2017, the Company recognized revenue of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and recorded expenses of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; as research and development expense in the statement of operations related to the new services agreement. The services agreement terminates upon the termination of the Collaboration Agreement or by mutual agreement of the parties.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-C851E2A21870EEC1008C06CF75F5284B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Accrued personnel expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;273&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Accrued clinical and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3,559&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2017Q4YTD" id="Fact-545A75A06642EAB343691C1E7F5C7193">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Convertible preferred stock issuable upon conversion to common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;9,629,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,234,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,234,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Outstanding common stock subject to repurchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;139,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;222,077&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;"&gt;324,355&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2,506,926&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,485,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Stock options available for issuance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;411,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;198,978&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,684,110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;12,687,739&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;7,140,987&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;7,243,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2017Q4YTD" id="Fact-1181D47F0C889AE2FBE721F26D97E39E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total stock&amp;#8209;based compensation expense for employees and non&amp;#8209;employees recognized in the statements of operations was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;792&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;257&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;660&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total stock&amp;#8209;based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;1,452&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;573&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-D50A003078EAC52210191C519B42863B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;"&gt;Deferred Tax Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;NOLs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;10,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;10,458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,992&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Depreciation and Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;328&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;362&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Stock&amp;#8209;Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Research &amp;amp; Development Credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2,063&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Deferred Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,791&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Other Accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;235&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total Deferred Tax Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;11,631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;6,621&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Valuation Allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(14,993&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(11,631&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(6,621&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Net Deferred Tax Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:0px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:0px;text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:0px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:0px;text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:0px;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:0px;text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2017Q4YTD" id="Fact-65918F9989155DABCB8A1C0E3EC1CA98">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Net loss attributable to common stockholders, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(29,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(14,068&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(4,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Weighted&amp;#8209;average common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,285,542&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,280,058&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,060,918&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Less: weighted&amp;#8209;average common shares subject to repurchase&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(177,421&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(292,925&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(325,770&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Weighted&amp;#8209;average common shares used to compute basic and diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5,108,121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;4,987,133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;4,735,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Net loss per share attributable to common stockholders:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(5.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(2.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(0.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2017Q4YTD" id="Fact-58A3DFFFF4B1DB5FF94A689F9935D199">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The following is a reconciliation of the statutory federal income tax rate to the Company&amp;#8217;s effective tax rate:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:624px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:244px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:107px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:107px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:5px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:108px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Statutory Rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;State Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Permanent Differences&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;General Business Credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Change in Valuation Allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Tax Reform - Tax Rate Change&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-1444FC5EA3DF9D9C6FDA07C1699CCAFA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;As of December&amp;#160;31, 2017, total future minimum lease payments under our operating leases are as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51020408163265%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;"&gt;Year ending December 31:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total future minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="FD2017Q4YTD" id="Fact-7F94DE4801B8109F588F40E39D08D06C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The following tables show a summary of the Company&amp;#8217;s unaudited quarterly financial data for each of the four quarters of 2017 and 2016 (in thousands, except per share amounts):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="33" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="30" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-top:2px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:2px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#160;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;March 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Collaboration and service revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;2,775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;909&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;449&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;449&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;12,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;9,244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;6,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;6,004&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(9,277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(8,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(6,153&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(5,474&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Basic and diluted net loss per common share (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(1.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(1.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(1.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(1.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="33" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:0%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="30" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;September 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="padding-top:2px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;June 30,&lt;/font&gt;&lt;/div&gt;&lt;div style="padding-bottom:2px;text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;&amp;#160;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;March 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Collaboration and service revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;450&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;5,374&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;3,699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;3,636&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;2,297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(4,836&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(3,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(3,562&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(2,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;Basic and diluted net loss per common share (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(0.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(0.68&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(0.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;(0.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:24px;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Basic and diluted net loss per common share are computed independently for each of the quarters presented. Therefore, the sum of quarterly basic and diluted per share information may not equal annual basic and diluted net loss per common share.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock contextRef="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_NonemployeeMember" id="Fact-497673034ED0A79DCF8F2CBC776A5CF0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The fair values of common stock awards granted to non&amp;#8209;employees were calculated using the following assumptions for the periods presented:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;8.3 - 10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;9.3 - 10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1.0 - 1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;74% - 100%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;84% - 86%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;62% - 74%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Risk&amp;#8209;free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;2.1% - 2.5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1.6% - 2.5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;0.5% - 0.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2017Q4YTD" id="Fact-2F4B980926439833046922044FC1EC41">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The table below summarizes stock option and restricted award activity under the 2011 Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Number of Shares Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted-Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted- Average Remaining Contractual Term (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Aggregate Intrinsic Value (in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Balances at January 1, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;317,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;0.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:1px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Exercised &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(317,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;0.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Balances at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,485,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Balances at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,485,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;9.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3,805&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,040,329&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;5.56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-top:1px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Exercised &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(18,535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;"&gt;Balances at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2,506,926&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;8.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;24,033&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9.5pt;padding-left:0px;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Includes early exercise of &lt;/font&gt;&lt;font style="font-family:Trade Gothic;font-size:9.5pt;"&gt;317,405&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; options during the year ended &lt;/font&gt;&lt;font style="font-family:Trade Gothic;font-size:9.5pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, of which &lt;/font&gt;&lt;font style="font-family:Trade Gothic;font-size:9.5pt;"&gt;138,864&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Trade Gothic;font-size:9.5pt;"&gt;218,216&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; remain unvested as of December 31, 2017 and &lt;/font&gt;&lt;font style="font-family:Trade Gothic;font-size:9.5pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2017Q4YTD_us-gaap_TitleOfIndividualAxis_mnlo_EmployeesandDirectorsMember" id="Fact-13CC3E71929496CD07A42C95972476D0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The following assumptions were used to calculate the fair value of awards granted to employees and directors during the years indicated:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;6.0 - 6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;4.6 - 6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;75% - 100%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;68% - 74%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;74%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Risk&amp;#8209;free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;1.9% - 2.3%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1.3% - 2.1%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-1593ACDC0A47D50338F3F75085C54414">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Segments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company operates in &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long&amp;#8209;lived assets are maintained in the United States of America. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2017Q4YTD" id="Fact-C7A9B59B1D9F58E8B7D0F7D028DB7AD5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company measures and recognizes compensation expense for all stock&amp;#8209;based awards made to employees, directors and non&amp;#8209;employees, based on estimated fair values recognized using the straight&amp;#8209;line method over the requisite service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The fair value of options to purchase common stock granted to employees is estimated on the grant date using the Black&amp;#8209;Scholes option valuation model. The calculation of stock&amp;#8209;based compensation expense requires that the Company make certain assumptions and judgments about a number of complex and subjective variables used in the Black&amp;#8209;Scholes model, including the expected term, expected volatility of the underlying common stock, risk&amp;#8209;free interest rate, as well as estimating future forfeitures of unvested stock options. To the extent actual forfeiture results differ from the estimates, the difference will be recorded as a cumulative adjustment in the period the estimates are revised. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company accounts for options issued to non&amp;#8209;employees using the Black&amp;#8209;Scholes option valuation model and is measured and recognized as the stock options are earned.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-9391B9CE2C73A8123DA9EBD9CAC33262">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;As of December 31, 2017, the Company&amp;#8217;s Certificate of Incorporation, as amended, authorizes the Company to issue &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;55,000,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares of &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$0.0001&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; par value common stock. Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the board of directors, subject to the prior rights of holders of all classes of preferred stock outstanding. The Company has never declared any dividends on common stock. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;As of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, there were&amp;#160;&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;"&gt;12,548,103&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#160;shares of common stock reserved&amp;#160;available&amp;#160;for issuance.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="FD2017Q4YTD" id="Fact-F5895E9FFB4BD060229EF7D51DC2608A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Convertible Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company recorded the convertible preferred stock at fair value on the dates of issuance, net of issuance costs. The convertible preferred stock is recorded outside of stockholders&amp;#8217; equity because, in the event of certain deemed liquidation events considered not solely within the Company&amp;#8217;s control, such as a merger, acquisition and sale of all or substantially all of the Company&amp;#8217;s assets, the convertible preferred stock will become redeemable at the option of the holders. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;All outstanding convertible preferred stock converted into common stock in January 2018 upon the effectiveness of the IPO.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
	<us-gaap:StockholdersEquityPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-0B0E1F59EA9A622D982BF74F6E33ED98">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Reverse Stock Split&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;On January 8, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2018, the Company effected a reverse split of shares of the Company&amp;#8217;s common stock at a ratio of 1-for-&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2.6975&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; pursuant to an amendment to the amended and restated certificate of incorporation approved by the Company&amp;#8217;s board of directors and stockholders. The par value and the authorized&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;shares of the common stock were not adjusted as a result of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse split for all periods presented, and the conversion ratio of the preferred stock was adjusted accordingly. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2017Q4YTD" id="Fact-4E332EFC4D0A9222C611EBCCF780AE1A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;On January 8, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2018, the Company effected a reverse split of shares of the Company&amp;#8217;s common stock at a ratio of 1-for-&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2.6975&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; pursuant to an amendment to the amended and restated certificate of incorporation approved by the Company&amp;#8217;s board of directors and stockholders. The par value and the authorized&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;shares of the common stock were not adjusted as a result of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse split for all periods presented, and the conversion ratio of the preferred stock was adjusted accordingly. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company adopted a 2018 Omnibus Incentive Plan, or 2018 Plan, effective on January 23, 2018. The 2018 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights and other stock and cash-based awards (including annual cash incentives and long-term cash incentives). The Company has reserved for issuance pursuant to awards under the 2018 Plan, &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3,000,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares of our common stock. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company adopted a 2018 Employee Stock Purchase Plan, or ESPP, effective on January 23, 2018. &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The ESPP will enable eligible employees of the Company and designated affiliates to purchase shares of common stock at a discount following its effectiveness. The Company has reserved &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;325,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares of common stock for issuance under the ESPP.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;In January 2018, the Company completed its initial public offering (&amp;#8220;IPO&amp;#8221;) of shares of its common stock, pursuant to which the Company issued &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;8,050,000&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares of common stock and received net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$125.5 million&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;, after deducting underwriting discounts, commissions and offering expenses. In connection with the completion of the Company's IPO, all shares of convertible preferred stock converted into &lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;9,629,405&lt;/font&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt; shares of common stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:SummaryOfIncomeTaxContingenciesTextBlock contextRef="FD2017Q4YTD" id="Fact-2E66D401F1FC957BD3E41C5F36A7A506">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The following table summarizes the activity related to unrecognized tax benefits (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;"&gt;Tax Benefits:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Unrecognized Benefit &amp;#8209; beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Gross Increases(Decreases) &amp;#8209; prior period tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Gross Increases(Decreases) &amp;#8209; current period tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;515&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total Unrecognized Benefit &amp;#8209; end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;"&gt;803&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
	<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="FD2017Q4YTD" id="Fact-252B96C4FF04F45A81E6EBE603DAC4BB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Balance Sheets Components&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Accrued Expenses and Other Current Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Accrued personnel expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;1,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;273&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Accrued clinical and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;2,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;245&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;3,559&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
	<us-gaap:TemporaryEquityTableTextBlock contextRef="FD2017Q4YTD" id="Fact-6D4C72A7D911CB4D6CAA07E732A0797B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;The Company had outstanding convertible preferred stock as of the times set forth below as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares Issued and Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Aggregate Liquidation Preference&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Series A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Series B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,106,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,106,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;45,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Series C&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,201,878&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;11,854,463&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;50,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;28,322,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;25,975,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;109,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares Issued and Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;Aggregate Liquidation Preference&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Series A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Series B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,106,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,106,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;45,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,120,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;14,120,883&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;59,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TemporaryEquityTableTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2017Q4YTD" id="Fact-6A4A143D506F9D7A5D12F76581A50572">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"&gt;&lt;font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"&gt;Preparation of financial statements in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, stock&amp;#8209;based compensation expense, the resolution of uncertain tax positions and valuation allowance, recovery of long&amp;#8209;lived assets and accruals for research and development costs. Management bases its estimates on historical experience on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mnlo-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.menlotherapeutics.com/20171231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mnlo="http://www.menlotherapeutics.com/20171231" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlo-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlo-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlo-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnlo-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="BalanceSheets" roleURI="http://www.menlotherapeutics.com/role/BalanceSheets">
        <link:definition>1001000 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsComponents" roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsComponents">
        <link:definition>2110100 - Disclosure - Balance Sheets Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsComponentsDetails" roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsComponentsDetails">
        <link:definition>2410402 - Disclosure - Balance Sheets Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsComponentsTables" roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsComponentsTables">
        <link:definition>2310301 - Disclosure - Balance Sheets Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsParenthetical">
        <link:definition>1001001 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingencies">
        <link:definition>2113100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails" roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesDetails">
        <link:definition>2413402 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesFutureMinimumOperatingLeasePaymentsDetails" roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumOperatingLeasePaymentsDetails">
        <link:definition>2413403 - Disclosure - Commitments and Contingencies - Future Minimum Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2313301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://www.menlotherapeutics.com/role/CommonStock">
        <link:definition>2119100 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockDetails" roleURI="http://www.menlotherapeutics.com/role/CommonStockDetails">
        <link:definition>2419401 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStock" roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStock">
        <link:definition>2116100 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockConvertiblePreferredStockOutstandingDetails" roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockConvertiblePreferredStockOutstandingDetails">
        <link:definition>2416403 - Disclosure - Convertible Preferred Stock - Convertible Preferred Stock Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockDetails" roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockDetails">
        <link:definition>2416402 - Disclosure - Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertiblePreferredStockTables" roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockTables">
        <link:definition>2316301 - Disclosure - Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeiDocument" roleURI="http://www.menlotherapeutics.com/role/DeiDocument">
        <link:definition>0001000 - Document - DEI Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurements">
        <link:definition>2107100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAvailableForSaleSecuritiesDetails" roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurementsAvailableForSaleSecuritiesDetails">
        <link:definition>2407403 - Disclosure - Fair Value Measurements (Available-for-Sale Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAvailableForSaleSecuritiesDetailsCalc2" roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurementsAvailableForSaleSecuritiesDetailsCalc2">
        <link:definition>2407403 - Disclosure - Fair Value Measurements (Available-for-Sale Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurementsDetails">
        <link:definition>2407402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurementsTables">
        <link:definition>2307301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FormationAndBusinessOfCompany" roleURI="http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompany">
        <link:definition>2101100 - Disclosure - Formation and Business of the Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FormationAndBusinessOfCompanyDetails" roleURI="http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompanyDetails">
        <link:definition>2401401 - Disclosure - Formation and Business of the Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.menlotherapeutics.com/role/IncomeTaxes">
        <link:definition>2128100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2428404 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>2428403 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>2428402 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesTables">
        <link:definition>2328301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUncertainTaxPositionsDetails" roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesUncertainTaxPositionsDetails">
        <link:definition>2428405 - Disclosure - Income Taxes - Uncertain Tax Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributableToCommonStockholders" roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholders">
        <link:definition>2125100 - Disclosure - Net Loss per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributableToCommonStockholdersAntidilutiveSharesDetails" roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersAntidilutiveSharesDetails">
        <link:definition>2425403 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Antidilutive Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributableToCommonStockholdersDetails" roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>2425402 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAttributableToCommonStockholdersTables" roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>2325301 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.menlotherapeutics.com/role/RelatedPartyTransactions">
        <link:definition>2131100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.menlotherapeutics.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2431401 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedUnauditedQuarterlyFinancialData" roleURI="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialData">
        <link:definition>2135100 - Disclosure - Selected Unaudited Quarterly Financial Data</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedUnauditedQuarterlyFinancialDataDetails" roleURI="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataDetails">
        <link:definition>2435402 - Disclosure - Selected Unaudited Quarterly Financial Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelectedUnauditedQuarterlyFinancialDataTables" roleURI="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataTables">
        <link:definition>2335301 - Disclosure - Selected Unaudited Quarterly Financial Data (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPolicies">
        <link:definition>2104100 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2404403 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>2404404 - Disclosure - Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesRevenueRecognitionDetails" roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails">
        <link:definition>2404405 - Disclosure - Significant Accounting Policies - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesReverseStockSplitDetails" roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesReverseStockSplitDetails">
        <link:definition>2404402 - Disclosure - Significant Accounting Policies - Reverse Stock Split (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementOfCashFlows" roleURI="http://www.menlotherapeutics.com/role/StatementOfCashFlows">
        <link:definition>1004000 - Statement - Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" roleURI="http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitParenthetical">
        <link:definition>1003001 - Statement - Statement of Convertible Preferred Stock and Stockholders' Deficit (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementOfConvertiblePreferredStockAndStockholdersDeficitStatement" roleURI="http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitStatement">
        <link:definition>1003000 - Statement - Statement of Convertible Preferred Stock and Stockholders' Deficit Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.menlotherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensation">
        <link:definition>2122100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationDetails" roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationDetails">
        <link:definition>2422402 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationFairValueAssumptionsForDirectorEmployeeAndNonEmployeeGrantsDetails" roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationFairValueAssumptionsForDirectorEmployeeAndNonEmployeeGrantsDetails">
        <link:definition>2422404 - Disclosure - Stock-Based Compensation - Fair Value Assumptions for Director, Employee and Non-Employee Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionAndRestrictedStockActivityDetails" roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationStockOptionAndRestrictedStockActivityDetails">
        <link:definition>2422403 - Disclosure - Stock-Based Compensation - Stock Option and Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationTables">
        <link:definition>2322301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.menlotherapeutics.com/role/SubsequentEvents">
        <link:definition>2134100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.menlotherapeutics.com/role/SubsequentEventsDetails">
        <link:definition>2434401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="mnlo_A2011StockIncentivePlanMember" name="A2011StockIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_A2018EmployeeStockPurchasePlanMember" name="A2018EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_A2018OmnibusIncentivePlanMember" name="A2018OmnibusIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mnlo_AccruedClinicalandDevelopmentExpenses" name="AccruedClinicalandDevelopmentExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions" name="AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mnlo_CashCashEquivalentsandAvailableforsaleSecurities" name="CashCashEquivalentsandAvailableforsaleSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax" name="CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax" name="CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax" name="CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax" name="CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis" name="CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mnlo_CollaborativeAgreementUpfrontPaymentReceived" name="CollaborativeAgreementUpfrontPaymentReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mnlo_CollaborativeArrangementsPotentialMilestonePayments" name="CollaborativeArrangementsPotentialMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mnlo_CollaborativeArrangementsPotentialMilestoneProceeds" name="CollaborativeArrangementsPotentialMilestoneProceeds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod" name="CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_CommercialMilestoneMember" name="CommercialMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember" name="ConvertibleStockConvertedintoSharesofCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums" name="DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_DevelopmentServicesFeesMember" name="DevelopmentServicesFeesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember" name="DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember" name="DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_DevelopmentandRegulatoryMilestonesMember" name="DevelopmentandRegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_EarlyExercisedStockOptionsMember" name="EarlyExercisedStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_EmployeesandDirectorsMember" name="EmployeesandDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_EntityAbstract" name="EntityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember" name="IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets" name="IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets" name="IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum" name="IndividualInvestmentPercentofInvestmentPortfolioMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mnlo_JTToriiMember" name="JTToriiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract" name="LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_MerckMember" name="MerckMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_NonemployeeMember" name="NonemployeeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_NonsubstantiveMilestonesMember" name="NonsubstantiveMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect" name="NumberofDirectorsCommonShareholdersareEntitledtoElect" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect" name="NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits" name="NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="mnlo_OperatingLeaseMonthlyRentExpense" name="OperatingLeaseMonthlyRentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember" name="OptionsAvailableforFutureGrantunderStockOptionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_OptionsOutstandingMember" name="OptionsOutstandingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mnlo_OutstandingCommonStockSubjecttoRepurchaseMember" name="OutstandingCommonStockSubjecttoRepurchaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit" name="TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mnlo_TemporaryEquityDividendRatePerDollarAmount" name="TemporaryEquityDividendRatePerDollarAmount" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="mnlo_TemporaryEquityIssuedPriceperShare" name="TemporaryEquityIssuedPriceperShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mnlo_TemporaryEquityStockIssuedIssuanceCosts" name="TemporaryEquityStockIssuedIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering" name="TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering" name="TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>mnlo-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheets" xlink:href="mnlo-20171231.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsComponents" xlink:href="mnlo-20171231.xsd#BalanceSheetsComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsComponentsDetails" xlink:href="mnlo-20171231.xsd#BalanceSheetsComponentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsComponentsTables" xlink:href="mnlo-20171231.xsd#BalanceSheetsComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsParenthetical" xlink:href="mnlo-20171231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingencies" xlink:href="mnlo-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesDetails" xlink:href="mnlo-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumOperatingLeasePaymentsDetails" xlink:href="mnlo-20171231.xsd#CommitmentsAndContingenciesFutureMinimumOperatingLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:href="mnlo-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommonStock" xlink:href="mnlo-20171231.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommonStockDetails" xlink:href="mnlo-20171231.xsd#CommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStock" xlink:href="mnlo-20171231.xsd#ConvertiblePreferredStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockConvertiblePreferredStockOutstandingDetails" xlink:href="mnlo-20171231.xsd#ConvertiblePreferredStockConvertiblePreferredStockOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockDetails" xlink:href="mnlo-20171231.xsd#ConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockTables" xlink:href="mnlo-20171231.xsd#ConvertiblePreferredStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/DeiDocument" xlink:href="mnlo-20171231.xsd#DeiDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurements" xlink:href="mnlo-20171231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurementsAvailableForSaleSecuritiesDetails" xlink:href="mnlo-20171231.xsd#FairValueMeasurementsAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurementsAvailableForSaleSecuritiesDetailsCalc2" xlink:href="mnlo-20171231.xsd#FairValueMeasurementsAvailableForSaleSecuritiesDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurementsDetails" xlink:href="mnlo-20171231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurementsTables" xlink:href="mnlo-20171231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompany" xlink:href="mnlo-20171231.xsd#FormationAndBusinessOfCompany" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompanyDetails" xlink:href="mnlo-20171231.xsd#FormationAndBusinessOfCompanyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxes" xlink:href="mnlo-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="mnlo-20171231.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="mnlo-20171231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:href="mnlo-20171231.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesTables" xlink:href="mnlo-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:href="mnlo-20171231.xsd#IncomeTaxesUncertainTaxPositionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:href="mnlo-20171231.xsd#NetLossPerShareAttributableToCommonStockholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersAntidilutiveSharesDetails" xlink:href="mnlo-20171231.xsd#NetLossPerShareAttributableToCommonStockholdersAntidilutiveSharesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="mnlo-20171231.xsd#NetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:href="mnlo-20171231.xsd#NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/RelatedPartyTransactions" xlink:href="mnlo-20171231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/RelatedPartyTransactionsDetails" xlink:href="mnlo-20171231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialData" xlink:href="mnlo-20171231.xsd#SelectedUnauditedQuarterlyFinancialData" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataDetails" xlink:href="mnlo-20171231.xsd#SelectedUnauditedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataTables" xlink:href="mnlo-20171231.xsd#SelectedUnauditedQuarterlyFinancialDataTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPolicies" xlink:href="mnlo-20171231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesReverseStockSplitDetails" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesReverseStockSplitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StatementOfCashFlows" xlink:href="mnlo-20171231.xsd#StatementOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:href="mnlo-20171231.xsd#StatementOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitStatement" xlink:href="mnlo-20171231.xsd#StatementOfConvertiblePreferredStockAndStockholdersDeficitStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="mnlo-20171231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensation" xlink:href="mnlo-20171231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationDetails" xlink:href="mnlo-20171231.xsd#StockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationFairValueAssumptionsForDirectorEmployeeAndNonEmployeeGrantsDetails" xlink:href="mnlo-20171231.xsd#StockBasedCompensationFairValueAssumptionsForDirectorEmployeeAndNonEmployeeGrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationStockOptionAndRestrictedStockActivityDetails" xlink:href="mnlo-20171231.xsd#StockBasedCompensationStockOptionAndRestrictedStockActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationTables" xlink:href="mnlo-20171231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SubsequentEvents" xlink:href="mnlo-20171231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SubsequentEventsDetails" xlink:href="mnlo-20171231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_11e98ceb-5737-f44d-6a16-2d8b64b1228d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_11e98ceb-5737-f44d-6a16-2d8b64b1228d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4b3bbfa7-a312-00ec-9070-7ec1d5e4ff40" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4b3bbfa7-a312-00ec-9070-7ec1d5e4ff40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_d585eba8-c5c0-6186-d29a-3180d2b06f0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_ShortTermInvestments_d585eba8-c5c0-6186-d29a-3180d2b06f0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_c62504ca-c588-7676-b66d-68002db39ddb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_LongTermInvestments_c62504ca-c588-7676-b66d-68002db39ddb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_ef4e4b46-3d67-31d7-7beb-cac5e3c307b0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_ef4e4b46-3d67-31d7-7beb-cac5e3c307b0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheetsComponents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheetsComponentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_AccruedClinicalandDevelopmentExpenses" xlink:label="loc_mnlo_AccruedClinicalandDevelopmentExpenses_E6663EEB819912E0FCAC06D2D753281C" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_mnlo_AccruedClinicalandDevelopmentExpenses_E6663EEB819912E0FCAC06D2D753281C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheetsComponentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_5046b63b-148e-eb12-dd52-2a1e8f1e69c0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_5046b63b-148e-eb12-dd52-2a1e8f1e69c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CommonStock" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/CommonStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/ConvertiblePreferredStock" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockConvertiblePreferredStockOutstandingDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/DeiDocument" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/FairValueMeasurementsAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1932fd43-f07d-5e04-493b-eca2ebb13c97" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1932fd43-f07d-5e04-493b-eca2ebb13c97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e96beffd-8ab7-62f8-402b-cfa1adccd68f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e96beffd-8ab7-62f8-402b-cfa1adccd68f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:to="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_2B404E0C77C1BBF1CE7254238EEFFC2E" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:to="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_2B404E0C77C1BBF1CE7254238EEFFC2E" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_1039901EBFA63E1E07DC542276BE062A" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:to="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_1039901EBFA63E1E07DC542276BE062A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91fe4b11-d4f7-61c5-b8e1-4b77ba5422d2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91fe4b11-d4f7-61c5-b8e1-4b77ba5422d2" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis" xlink:label="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_28E42D8F68A55CA6287D5439A932FB43" xlink:type="locator" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_12FE1F8053D88A522D49543DFB53E992" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_28E42D8F68A55CA6287D5439A932FB43" xlink:to="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_12FE1F8053D88A522D49543DFB53E992" xlink:type="arc" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_12FE1F8053D88A522D49543DFB53E992" xlink:to="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_2B404E0C77C1BBF1CE7254238EEFFC2E" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_12FE1F8053D88A522D49543DFB53E992" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1932fd43-f07d-5e04-493b-eca2ebb13c97" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_A5AD084FD3DE35426716543FFF93AE77" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_28E42D8F68A55CA6287D5439A932FB43" xlink:to="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_A5AD084FD3DE35426716543FFF93AE77" xlink:type="arc" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_A5AD084FD3DE35426716543FFF93AE77" xlink:to="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_1039901EBFA63E1E07DC542276BE062A" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_A5AD084FD3DE35426716543FFF93AE77" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e96beffd-8ab7-62f8-402b-cfa1adccd68f" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashCashEquivalentsandAvailableforsaleSecurities" xlink:label="loc_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_E68E42B56CD1533F922B30380A47562C" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_28E42D8F68A55CA6287D5439A932FB43" xlink:to="loc_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_E68E42B56CD1533F922B30380A47562C" xlink:type="arc" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_E68E42B56CD1533F922B30380A47562C" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91fe4b11-d4f7-61c5-b8e1-4b77ba5422d2" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_E68E42B56CD1533F922B30380A47562C" xlink:to="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/FairValueMeasurementsAvailableForSaleSecuritiesDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis" xlink:label="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C603B9D850249348B3E544390B25857_28E42D8F68A55CA6287D5439A932FB43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2C603B9D850249348B3E544390B25857_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C603B9D850249348B3E544390B25857_28E42D8F68A55CA6287D5439A932FB43" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2C603B9D850249348B3E544390B25857_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2C603B9D850249348B3E544390B25857_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_2C603B9D850249348B3E544390B25857_28E42D8F68A55CA6287D5439A932FB43" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2C603B9D850249348B3E544390B25857_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b86af6cd-ef38-8a02-5297-9329a99c960d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91fe4b11-d4f7-61c5-b8e1-4b77ba5422d2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b86af6cd-ef38-8a02-5297-9329a99c960d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91fe4b11-d4f7-61c5-b8e1-4b77ba5422d2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_b851ddfc-ce9b-3407-931e-669b0dd9719b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b86af6cd-ef38-8a02-5297-9329a99c960d" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_b851ddfc-ce9b-3407-931e-669b0dd9719b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompany" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompanyDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b361a033-37cf-a2bc-6e1f-0297b90aa5a9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b361a033-37cf-a2bc-6e1f-0297b90aa5a9" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3541201a-a025-b00d-aec1-2cb167bdef44" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3541201a-a025-b00d-aec1-2cb167bdef44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_282bf2b0-848d-b911-5d17-5d4663ae6cab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_282bf2b0-848d-b911-5d17-5d4663ae6cab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f7e9e6da-5d57-5f97-5d33-52f319506ef0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f7e9e6da-5d57-5f97-5d33-52f319506ef0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d2622f64-9e39-fc5b-64b5-c22437d85e64" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d2622f64-9e39-fc5b-64b5-c22437d85e64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d5bdadc0-cf22-f4bf-e68b-7f9b7b17d502" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d5bdadc0-cf22-f4bf-e68b-7f9b7b17d502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_15879a4f-8e9c-9b96-ebf4-a2ce569ab390" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_15879a4f-8e9c-9b96-ebf4-a2ce569ab390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46929883-d93f-69b0-5ded-4c800feeb57f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b361a033-37cf-a2bc-6e1f-0297b90aa5a9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46929883-d93f-69b0-5ded-4c800feeb57f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_29919d14-72a3-6197-982a-3a6269f21038" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_29919d14-72a3-6197-982a-3a6269f21038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c48cf597-7f94-3186-bb2a-448703ee500e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c48cf597-7f94-3186-bb2a-448703ee500e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_4bf40f66-4966-4e08-f808-09c48e89b11b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_4bf40f66-4966-4e08-f808-09c48e89b11b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_da65932b-cd40-eea6-a739-ea25b8caa8a5" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_da65932b-cd40-eea6-a739-ea25b8caa8a5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bd3fb4a2-dba4-9f41-2b9f-30441850eb67" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bd3fb4a2-dba4-9f41-2b9f-30441850eb67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e1bd5e97-dd80-bb67-1b32-f0283be3c62d" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_e1bd5e97-dd80-bb67-1b32-f0283be3c62d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8718aa1e-c40a-73dd-11d3-b6a4475e0d37" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_8718aa1e-c40a-73dd-11d3-b6a4475e0d37" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersAntidilutiveSharesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b05b11c6-4f40-7f94-a079-f671de0859b5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_6817192b-2f21-8dd8-90a4-a59d75e496b2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b05b11c6-4f40-7f94-a079-f671de0859b5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_6817192b-2f21-8dd8-90a4-a59d75e496b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_cc151808-e94f-9234-40b1-6f50235bd8e8" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b05b11c6-4f40-7f94-a079-f671de0859b5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_cc151808-e94f-9234-40b1-6f50235bd8e8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialData" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesReverseStockSplitDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/StatementOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums" xlink:label="loc_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums_34E4B7B3D1A65C954884538D324C753E" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums_34E4B7B3D1A65C954884538D324C753E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_d14e3c18-d772-85f9-a4cd-3beba56d2e42" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_d14e3c18-d772-85f9-a4cd-3beba56d2e42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ee12cc29-63c9-040c-19f2-17921f90c9bb" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ee12cc29-63c9-040c-19f2-17921f90c9bb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5b3d4a64-864e-a67c-1d85-8163ad700c58" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5b3d4a64-864e-a67c-1d85-8163ad700c58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_7c9b8031-2c89-2c7f-60e7-6af976eb8a29" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_7c9b8031-2c89-2c7f-60e7-6af976eb8a29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets" xlink:label="loc_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets_2DB53BD962EBFB6EA3FCF8762B397E9A" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets_2DB53BD962EBFB6EA3FCF8762B397E9A" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets" xlink:label="loc_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets_393DDD9ACC867445A158E519CD0D2053" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets_393DDD9ACC867445A158E519CD0D2053" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5ffad1f9-ed26-c38a-cad9-7d2f16245ec2" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_5ffad1f9-ed26-c38a-cad9-7d2f16245ec2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_a3cce359-4901-8e47-7521-d2fa73471a4d" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_a3cce359-4901-8e47-7521-d2fa73471a4d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_d3d89aab-5be8-f6a4-66e9-41f55e0839cd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_d3d89aab-5be8-f6a4-66e9-41f55e0839cd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b49c7a2f-2986-824d-e7cb-bc082ac0e888" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b49c7a2f-2986-824d-e7cb-bc082ac0e888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_ee229799-b721-537b-63bf-a353b2d0682e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_ee229799-b721-537b-63bf-a353b2d0682e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_7b8a0794-7d87-21cc-a206-45c556522750" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_7b8a0794-7d87-21cc-a206-45c556522750" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitStatement" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_2c9f311a-e7a2-ea5a-e3c9-f8d74251bac8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_LicenseAndServicesRevenue_2c9f311a-e7a2-ea5a-e3c9-f8d74251bac8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_b45ea963-e439-fc81-a491-c6c695e6ceb3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_b45ea963-e439-fc81-a491-c6c695e6ceb3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_57e8ae74-d8b6-c629-9bee-2d0929cd3999" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_57e8ae74-d8b6-c629-9bee-2d0929cd3999" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensationFairValueAssumptionsForDirectorEmployeeAndNonEmployeeGrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensationStockOptionAndRestrictedStockActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.menlotherapeutics.com/role/SubsequentEventsDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>mnlo-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheets" xlink:href="mnlo-20171231.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsComponents" xlink:href="mnlo-20171231.xsd#BalanceSheetsComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsComponentsDetails" xlink:href="mnlo-20171231.xsd#BalanceSheetsComponentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsComponentsTables" xlink:href="mnlo-20171231.xsd#BalanceSheetsComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsParenthetical" xlink:href="mnlo-20171231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingencies" xlink:href="mnlo-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesDetails" xlink:href="mnlo-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumOperatingLeasePaymentsDetails" xlink:href="mnlo-20171231.xsd#CommitmentsAndContingenciesFutureMinimumOperatingLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:href="mnlo-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommonStock" xlink:href="mnlo-20171231.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommonStockDetails" xlink:href="mnlo-20171231.xsd#CommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStock" xlink:href="mnlo-20171231.xsd#ConvertiblePreferredStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockConvertiblePreferredStockOutstandingDetails" xlink:href="mnlo-20171231.xsd#ConvertiblePreferredStockConvertiblePreferredStockOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockDetails" xlink:href="mnlo-20171231.xsd#ConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockTables" xlink:href="mnlo-20171231.xsd#ConvertiblePreferredStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/DeiDocument" xlink:href="mnlo-20171231.xsd#DeiDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurements" xlink:href="mnlo-20171231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurementsAvailableForSaleSecuritiesDetails" xlink:href="mnlo-20171231.xsd#FairValueMeasurementsAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurementsDetails" xlink:href="mnlo-20171231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurementsTables" xlink:href="mnlo-20171231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompany" xlink:href="mnlo-20171231.xsd#FormationAndBusinessOfCompany" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompanyDetails" xlink:href="mnlo-20171231.xsd#FormationAndBusinessOfCompanyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxes" xlink:href="mnlo-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="mnlo-20171231.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="mnlo-20171231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:href="mnlo-20171231.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesTables" xlink:href="mnlo-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:href="mnlo-20171231.xsd#IncomeTaxesUncertainTaxPositionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:href="mnlo-20171231.xsd#NetLossPerShareAttributableToCommonStockholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersAntidilutiveSharesDetails" xlink:href="mnlo-20171231.xsd#NetLossPerShareAttributableToCommonStockholdersAntidilutiveSharesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="mnlo-20171231.xsd#NetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:href="mnlo-20171231.xsd#NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/RelatedPartyTransactions" xlink:href="mnlo-20171231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/RelatedPartyTransactionsDetails" xlink:href="mnlo-20171231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialData" xlink:href="mnlo-20171231.xsd#SelectedUnauditedQuarterlyFinancialData" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataDetails" xlink:href="mnlo-20171231.xsd#SelectedUnauditedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataTables" xlink:href="mnlo-20171231.xsd#SelectedUnauditedQuarterlyFinancialDataTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPolicies" xlink:href="mnlo-20171231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesReverseStockSplitDetails" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesReverseStockSplitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StatementOfCashFlows" xlink:href="mnlo-20171231.xsd#StatementOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:href="mnlo-20171231.xsd#StatementOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitStatement" xlink:href="mnlo-20171231.xsd#StatementOfConvertiblePreferredStockAndStockholdersDeficitStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="mnlo-20171231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensation" xlink:href="mnlo-20171231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationDetails" xlink:href="mnlo-20171231.xsd#StockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationFairValueAssumptionsForDirectorEmployeeAndNonEmployeeGrantsDetails" xlink:href="mnlo-20171231.xsd#StockBasedCompensationFairValueAssumptionsForDirectorEmployeeAndNonEmployeeGrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationStockOptionAndRestrictedStockActivityDetails" xlink:href="mnlo-20171231.xsd#StockBasedCompensationStockOptionAndRestrictedStockActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationTables" xlink:href="mnlo-20171231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SubsequentEvents" xlink:href="mnlo-20171231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SubsequentEventsDetails" xlink:href="mnlo-20171231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C6219322BDD54D888981547353D4B6F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064" xlink:to="loc_us-gaap_StatementTable_C6219322BDD54D888981547353D4B6F0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3FA6922DAB3ED8257F51547353D41538" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_C6219322BDD54D888981547353D4B6F0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3FA6922DAB3ED8257F51547353D41538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_DBAA8EBF423356FA3AFA547353D4DE3C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3FA6922DAB3ED8257F51547353D41538" xlink:to="loc_us-gaap_ClassOfStockDomain_DBAA8EBF423356FA3AFA547353D4DE3C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_DBAA8EBF423356FA3AFA547353D4DE3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3FA6922DAB3ED8257F51547353D41538" xlink:to="loc_us-gaap_ClassOfStockDomain_DBAA8EBF423356FA3AFA547353D4DE3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_E6C39CCB6318908D122E547353D42FD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_DBAA8EBF423356FA3AFA547353D4DE3C" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_E6C39CCB6318908D122E547353D42FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_973C1C02872E33B46A89547353D4EC47" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_DBAA8EBF423356FA3AFA547353D4DE3C" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_973C1C02872E33B46A89547353D4EC47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6994735003AD40F208F5547353D4FD3E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_DBAA8EBF423356FA3AFA547353D4DE3C" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6994735003AD40F208F5547353D4FD3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064" xlink:to="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7580E51F309E1404522C547353D5E01D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7580E51F309E1404522C547353D5E01D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_F4A9962C6B584EDE250C547353D58F2F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:to="loc_us-gaap_ShortTermInvestments_F4A9962C6B584EDE250C547353D58F2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_EFC0F2A0C2629B931E93547353D59A84" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_EFC0F2A0C2629B931E93547353D59A84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1EC5DCE8642B50CA3C5E547353D5BD64" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1EC5DCE8642B50CA3C5E547353D5BD64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_12331DDF0B92670AB9CF547353D56195" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:to="loc_us-gaap_AssetsCurrent_12331DDF0B92670AB9CF547353D56195" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_2E5DDAF661A3C2F7B02A547353D50B65" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:to="loc_us-gaap_LongTermInvestments_2E5DDAF661A3C2F7B02A547353D50B65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0716A5F4EF673A3FE062547353D5F238" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0716A5F4EF673A3FE062547353D5F238" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_CD53779554EF447005FF547353D52182" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_CD53779554EF447005FF547353D52182" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_E134DAEB003AF380386C547353D54226" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:to="loc_us-gaap_Assets_E134DAEB003AF380386C547353D54226" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract" xlink:label="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064" xlink:to="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_6568C07AA8B9EA1B2319547353D6EB54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:to="loc_us-gaap_AccountsPayableCurrent_6568C07AA8B9EA1B2319547353D6EB54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_42CE7F53B5389CB7872F547353D69492" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_42CE7F53B5389CB7872F547353D69492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_F91173A3A42CB268D415547353D62364" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:to="loc_us-gaap_DeferredRevenueCurrent_F91173A3A42CB268D415547353D62364" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_A8950A10EC17090F456B547353D6C7CA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:to="loc_us-gaap_LiabilitiesCurrent_A8950A10EC17090F456B547353D6C7CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_6E5580085A3A40178E7E547353D614BA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_6E5580085A3A40178E7E547353D614BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_F5B7E6F7616EBD3E5C8F547353D65CF0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_F5B7E6F7616EBD3E5C8F547353D65CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_88CDB362B9DC3B3E245A547353D60C55" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_Liabilities_88CDB362B9DC3B3E245A547353D60C55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_F35DADA3AE03A9A9FCCE547353D7F3AB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_CommitmentsAndContingencies_F35DADA3AE03A9A9FCCE547353D7F3AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_45B7545AA16A47652195547353D72653" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_45B7545AA16A47652195547353D72653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_286969AF39FBCE1FC840547353D76C39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:to="loc_us-gaap_CommonStockValue_286969AF39FBCE1FC840547353D76C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_D31E0FC5F81110C3CB92547353D704F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:to="loc_us-gaap_AdditionalPaidInCapital_D31E0FC5F81110C3CB92547353D704F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_13B8E5126698C1D8F3AE547353D7FD6E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_13B8E5126698C1D8F3AE547353D7FD6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_B3AFA382AE88B11985BF547353D789C7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_B3AFA382AE88B11985BF547353D789C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6E7FB04C0A4604AD6E19547353D7D808" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:to="loc_us-gaap_StockholdersEquity_6E7FB04C0A4604AD6E19547353D7D808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ADBB05047361FF6E8022547353D77A13" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ADBB05047361FF6E8022547353D77A13" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheetsComponents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheetsComponentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheetsComponentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C8D1F0C28A46406AD5702FF76BBBC280" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_StatementTable_C8D1F0C28A46406AD5702FF76BBBC280" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6BA84BAE0C41CAEF0E902FF76BBB0F33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_C8D1F0C28A46406AD5702FF76BBBC280" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6BA84BAE0C41CAEF0E902FF76BBB0F33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_0C909CDE62E2A758D1912FF76BBC65AE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6BA84BAE0C41CAEF0E902FF76BBB0F33" xlink:to="loc_us-gaap_ClassOfStockDomain_0C909CDE62E2A758D1912FF76BBC65AE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_0C909CDE62E2A758D1912FF76BBC65AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6BA84BAE0C41CAEF0E902FF76BBB0F33" xlink:to="loc_us-gaap_ClassOfStockDomain_0C909CDE62E2A758D1912FF76BBC65AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7A0255AC6DF9D254BE4B2FF76BBCC24D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0C909CDE62E2A758D1912FF76BBC65AE" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7A0255AC6DF9D254BE4B2FF76BBCC24D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1EB6D055895F08DDBEA72FF76BBCE90A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0C909CDE62E2A758D1912FF76BBC65AE" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1EB6D055895F08DDBEA72FF76BBCE90A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_892E5AA5BF09BDF5304B2FF76BBC27B5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0C909CDE62E2A758D1912FF76BBC65AE" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_892E5AA5BF09BDF5304B2FF76BBC27B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_D1DE6A17AE536DDB5DA43067F6066D90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_D1DE6A17AE536DDB5DA43067F6066D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_57E22CE44114164DD917306D08497ACA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_57E22CE44114164DD917306D08497ACA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_7571388359F1B2F81F47306FB150EB69" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_7571388359F1B2F81F47306FB150EB69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_E725A0CFE69EEF6999AB30281099EA57" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_E725A0CFE69EEF6999AB30281099EA57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_A3435B48DB11CC36A136306AF39DDCF6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_A3435B48DB11CC36A136306AF39DDCF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_601DD1497DB8E6B1EEC92FF76BC22758" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_601DD1497DB8E6B1EEC92FF76BC22758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_10B79B381C8AE95CE0BF2FF76BC2C83A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_10B79B381C8AE95CE0BF2FF76BC2C83A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3094E2AFAACD554341842FF76BC27480" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_CommonStockSharesIssued_3094E2AFAACD554341842FF76BC27480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3306E1BCC36D18B90EA02FF76BC259D7" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3306E1BCC36D18B90EA02FF76BC259D7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_0016B78D12DD93F8B0615D29D8742CD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:to="loc_us-gaap_StatementGeographicalAxis_0016B78D12DD93F8B0615D29D8742CD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_0016B78D12DD93F8B0615D29D8742CD4" xlink:to="loc_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_0016B78D12DD93F8B0615D29D8742CD4" xlink:to="loc_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd#stpr_CA" xlink:label="loc_stpr_CA_BEC629A08E695092D2B75D29D8748809" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21" xlink:to="loc_stpr_CA_BEC629A08E695092D2B75D29D8748809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_84F54CAE9286DCA088315D29D8744908" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:to="loc_us-gaap_TypeOfArrangementAxis_84F54CAE9286DCA088315D29D8744908" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_84F54CAE9286DCA088315D29D8744908" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_84F54CAE9286DCA088315D29D8744908" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DevelopmentandRegulatoryMilestonesMember" xlink:label="loc_mnlo_DevelopmentandRegulatoryMilestonesMember_0D6820AB006E0FAD58B95D29D8740CA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5" xlink:to="loc_mnlo_DevelopmentandRegulatoryMilestonesMember_0D6820AB006E0FAD58B95D29D8740CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_A56551B6CCDA488AE21F5D29D8744E91" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:to="loc_us-gaap_CounterpartyNameAxis_A56551B6CCDA488AE21F5D29D8744E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_A56551B6CCDA488AE21F5D29D8744E91" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_A56551B6CCDA488AE21F5D29D8744E91" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_MerckMember" xlink:label="loc_mnlo_MerckMember_0BA6C8B9018BD30CBEC45D29D874D2C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6" xlink:to="loc_mnlo_MerckMember_0BA6C8B9018BD30CBEC45D29D874D2C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_516BADEF1CD528ADF65F5D29D8749524" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:to="loc_us-gaap_LicenseCosts_516BADEF1CD528ADF65F5D29D8749524" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CollaborativeArrangementsPotentialMilestonePayments" xlink:label="loc_mnlo_CollaborativeArrangementsPotentialMilestonePayments_87AAFA3E3CD6E6FA50985D29D8752778" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:to="loc_mnlo_CollaborativeArrangementsPotentialMilestonePayments_87AAFA3E3CD6E6FA50985D29D8752778" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_DF726D8F0FBBA9434F775D29D87587D2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_DF726D8F0FBBA9434F775D29D87587D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_FA59D05A99CB7180866F5D29D8758111" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_FA59D05A99CB7180866F5D29D8758111" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_OperatingLeaseMonthlyRentExpense" xlink:label="loc_mnlo_OperatingLeaseMonthlyRentExpense_310EDBBA96C545D0D0B05D29D875375E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:to="loc_mnlo_OperatingLeaseMonthlyRentExpense_310EDBBA96C545D0D0B05D29D875375E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_9E0FEEC7200E16CB8BD45D29D8754FA7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_9E0FEEC7200E16CB8BD45D29D8754FA7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumOperatingLeasePaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CommonStock" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/CommonStockDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/ConvertiblePreferredStock" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockConvertiblePreferredStockOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_6AD1D6B7302F3FA9C3D53974E21A8435" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_04C754A31C039E30A1973974E219A7D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6AD1D6B7302F3FA9C3D53974E21A8435" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_04C754A31C039E30A1973974E219A7D0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ABD7117B2A279962A5183974E21A3031" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_04C754A31C039E30A1973974E219A7D0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ABD7117B2A279962A5183974E21A3031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A33898EBDA8D13D314543974E21AEA72_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ABD7117B2A279962A5183974E21A3031" xlink:to="loc_us-gaap_ClassOfStockDomain_A33898EBDA8D13D314543974E21AEA72_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A33898EBDA8D13D314543974E21AEA72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ABD7117B2A279962A5183974E21A3031" xlink:to="loc_us-gaap_ClassOfStockDomain_A33898EBDA8D13D314543974E21AEA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_348CB837A0144E3BC99D3974E21ACC72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A33898EBDA8D13D314543974E21AEA72" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_348CB837A0144E3BC99D3974E21ACC72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_71639DEAC6B91CCFAA2C3974E21AD2F4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A33898EBDA8D13D314543974E21AEA72" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_71639DEAC6B91CCFAA2C3974E21AD2F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_2130C3DDBDF0E0F3C9753974E21A16DE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A33898EBDA8D13D314543974E21AEA72" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_2130C3DDBDF0E0F3C9753974E21A16DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_6DE79C990D207A1E7DAB39C67DB87A32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6AD1D6B7302F3FA9C3D53974E21A8435" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_6DE79C990D207A1E7DAB39C67DB87A32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_B999B711109CC691E0C8398BAEE7B7BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6AD1D6B7302F3FA9C3D53974E21A8435" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_B999B711109CC691E0C8398BAEE7B7BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_87ACE2262EE500E0FE31399205900ED6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6AD1D6B7302F3FA9C3D53974E21A8435" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_87ACE2262EE500E0FE31399205900ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_2425DF1839D0252D1E1639AF20B37B4B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6AD1D6B7302F3FA9C3D53974E21A8435" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_2425DF1839D0252D1E1639AF20B37B4B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_013D00FE6F98F11347AA5440F89ABC3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_013D00FE6F98F11347AA5440F89ABC3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_013D00FE6F98F11347AA5440F89ABC3E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_013D00FE6F98F11347AA5440F89ABC3E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_ECDE816EFEF8F51CFC975440F89A9BE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6" xlink:to="loc_us-gaap_IPOMember_ECDE816EFEF8F51CFC975440F89A9BE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_7C32B961CEE8F74E63945440F89B045B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6" xlink:to="loc_us-gaap_OverAllotmentOptionMember_7C32B961CEE8F74E63945440F89B045B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_F98C09854B14F0B40A155440F89B0FC3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_F98C09854B14F0B40A155440F89B0FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_F98C09854B14F0B40A155440F89B0FC3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_F98C09854B14F0B40A155440F89B0FC3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2F36F9A1FA5B7A332F7B5440F89B558F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B" xlink:to="loc_us-gaap_SubsequentEventMember_2F36F9A1FA5B7A332F7B5440F89B558F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8A630BF5B493054096D75440F89B3737" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8A630BF5B493054096D75440F89B3737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8A630BF5B493054096D75440F89B3737" xlink:to="loc_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8A630BF5B493054096D75440F89B3737" xlink:to="loc_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_8EB429153DC5CDAA40895440F89B50E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_8EB429153DC5CDAA40895440F89B50E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0E0AF994A6DECB41777D5440F89C2137" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_0E0AF994A6DECB41777D5440F89C2137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_DD2A4A9210CA6F8F303D5440F89C984B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_DD2A4A9210CA6F8F303D5440F89C984B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_1E674227F58A34BE65A85440F89C8924" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_1E674227F58A34BE65A85440F89C8924" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A359941E2A347A6A32855440F89C5AA9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A359941E2A347A6A32855440F89C5AA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_4ACD6B50509343E2C9565440F89CC0C6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_4ACD6B50509343E2C9565440F89CC0C6" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityIssuedPriceperShare" xlink:label="loc_mnlo_TemporaryEquityIssuedPriceperShare_5B86F4285B977FAF8CC15440F89C0531" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_mnlo_TemporaryEquityIssuedPriceperShare_5B86F4285B977FAF8CC15440F89C0531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E37D5AF9D628C23AA2C25448AE99B96D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E37D5AF9D628C23AA2C25448AE99B96D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_446A7BE0633FB8636DE65440F89C5783" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_446A7BE0633FB8636DE65440F89C5783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_799F5CC7CE99C664C2445440F89C63AE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_799F5CC7CE99C664C2445440F89C63AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_0252498DC890F543C7395440F89C0B26" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_0252498DC890F543C7395440F89C0B26" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityDividendRatePerDollarAmount" xlink:label="loc_mnlo_TemporaryEquityDividendRatePerDollarAmount_CC521A73AE7568716BB25440F89C7294" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_mnlo_TemporaryEquityDividendRatePerDollarAmount_CC521A73AE7568716BB25440F89C7294" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect" xlink:label="loc_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect_AFECC191D94D3C2F96295440F89DC536" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect_AFECC191D94D3C2F96295440F89DC536" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect" xlink:label="loc_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect_712ED576091617BB6CCA5440F89DD052" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect_712ED576091617BB6CCA5440F89DD052" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering" xlink:label="loc_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering_43B100353CDCAAB6814B5440F89D4DAB" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering_43B100353CDCAAB6814B5440F89D4DAB" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering" xlink:label="loc_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering_C485F57597272CE50B685440F89DF51E" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering_C485F57597272CE50B685440F89DF51E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/DeiDocument" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/FairValueMeasurementsAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3FD67C09DC87421586655440F8C1EAB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3FD67C09DC87421586655440F8C1EAB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4B87DAEC7D7016CAB28E5440F8C249AD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3FD67C09DC87421586655440F8C1EAB5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4B87DAEC7D7016CAB28E5440F8C249AD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4B87DAEC7D7016CAB28E5440F8C249AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3FD67C09DC87421586655440F8C1EAB5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4B87DAEC7D7016CAB28E5440F8C249AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2C5DA0A9CB810422CA075440F8C2DF57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4B87DAEC7D7016CAB28E5440F8C249AD" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2C5DA0A9CB810422CA075440F8C2DF57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85D6DDACDB64A56B48885440F8C29884" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85D6DDACDB64A56B48885440F8C29884" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_B51C9DAB0B480C42A4DE5440F8C256C7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85D6DDACDB64A56B48885440F8C29884" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_B51C9DAB0B480C42A4DE5440F8C256C7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_B51C9DAB0B480C42A4DE5440F8C256C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85D6DDACDB64A56B48885440F8C29884" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_B51C9DAB0B480C42A4DE5440F8C256C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_3FC8D8340DBF77FD8D195440F8C29CBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_B51C9DAB0B480C42A4DE5440F8C256C7" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_3FC8D8340DBF77FD8D195440F8C29CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4C1EEA14B549EBCCD8015440F8C22A79" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_B51C9DAB0B480C42A4DE5440F8C256C7" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4C1EEA14B549EBCCD8015440F8C22A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D43B54C05EC99C8767F55440F8C3073F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D43B54C05EC99C8767F55440F8C3073F" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_5E4FE07DDEBF018C11F65440F8C36BB1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_5E4FE07DDEBF018C11F65440F8C36BB1" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_92E6E940A8BEA5991BAF5440F8C39B1A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_92E6E940A8BEA5991BAF5440F8C39B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1AFED2AFB787D43B8CEB5440F8C311F3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1AFED2AFB787D43B8CEB5440F8C311F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3EC3E4802D28D0158E8E5440F8C316BF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3EC3E4802D28D0158E8E5440F8C316BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_981DA87253EA566D219F5440F8C3E7CD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_981DA87253EA566D219F5440F8C3E7CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C974AE36EE1CFA4392295440F8C30923" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C974AE36EE1CFA4392295440F8C30923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_2155FB286013F8CF82155440F8C30392" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_us-gaap_AvailableForSaleSecurities_2155FB286013F8CF82155440F8C30392" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis" xlink:label="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_F46647ED0033FEB01A415440F8C3289B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_F46647ED0033FEB01A415440F8C3289B" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_DC710C8EE1ED645D352D5440F8C3F251" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_DC710C8EE1ED645D352D5440F8C3F251" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_7D1A57CE38BB3B1FB3495440F8C3F31E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_7D1A57CE38BB3B1FB3495440F8C3F31E" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashCashEquivalentsandAvailableforsaleSecurities" xlink:label="loc_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_BDCFF446313223029E05544200375598" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_BDCFF446313223029E05544200375598" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4F207AB4DB3CF16E88C95D29D89681A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_4F207AB4DB3CF16E88C95D29D89681A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4F207AB4DB3CF16E88C95D29D89681A6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4F207AB4DB3CF16E88C95D29D89681A6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9D7C1A0CBAFBC193142A5D29D8975460" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9D7C1A0CBAFBC193142A5D29D8975460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_A6C3C3D57F6B6342DF4F5D29D896EC65" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_A6C3C3D57F6B6342DF4F5D29D896EC65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_A6C3C3D57F6B6342DF4F5D29D896EC65" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_A6C3C3D57F6B6342DF4F5D29D896EC65" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_4C6EB0969FE2D660120E5D74FF301FA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_4C6EB0969FE2D660120E5D74FF301FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CD6BCC536D129E34FC8A5D76BD4F88CF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CD6BCC536D129E34FC8A5D76BD4F88CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_AAE2AB7D21823DA99FE65D29D8973E17" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_AAE2AB7D21823DA99FE65D29D8973E17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_AAE2AB7D21823DA99FE65D29D8973E17" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2345F05FB0CC266D50285D29D8975064" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_AAE2AB7D21823DA99FE65D29D8973E17" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2345F05FB0CC266D50285D29D8975064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2345F05FB0CC266D50285D29D8975064" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_55B7067D671D7E9381F85D29D897416A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_55B7067D671D7E9381F85D29D897416A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_D61914EA9077121B30A75D29D89891A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_D61914EA9077121B30A75D29D89891A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_624D27777E600DFA42845D29D898F4A9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_624D27777E600DFA42845D29D898F4A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_624D27777E600DFA42845D29D898F4A9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_624D27777E600DFA42845D29D898F4A9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_C5E197B93DBB251E89D65D29D89850C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_C5E197B93DBB251E89D65D29D89850C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E2192BB7CB08AFB5C29F5D29D8987F56" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_E2192BB7CB08AFB5C29F5D29D8987F56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_BA6DE56191F0955D9A975D29D8988C17" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_BA6DE56191F0955D9A975D29D8988C17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B2E80FE0EF16D5FCC3CF5D29D8988E48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B2E80FE0EF16D5FCC3CF5D29D8988E48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4C0CA29821E835EBA29C5D29D899F6F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4C0CA29821E835EBA29C5D29D899F6F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_24E83FF9E08FDF39C4E95D29D8993E68" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_24E83FF9E08FDF39C4E95D29D8993E68" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompany" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompanyDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_B1199A685BEDA3B2637F53FB2B3F47A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_B1199A685BEDA3B2637F53FB2B3F47A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_B1199A685BEDA3B2637F53FB2B3F47A4" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_B1199A685BEDA3B2637F53FB2B3F47A4" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember" xlink:label="loc_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_D1FCAF046F2AF30B210D53FB2B3F3646" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272" xlink:to="loc_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_D1FCAF046F2AF30B210D53FB2B3F3646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6D62E16CAD3A2D8ADF8753FB2B3FB1DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6D62E16CAD3A2D8ADF8753FB2B3FB1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_048C42B04406C4AB7C8153FB2B3FD96E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6D62E16CAD3A2D8ADF8753FB2B3FB1DB" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_048C42B04406C4AB7C8153FB2B3FD96E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_048C42B04406C4AB7C8153FB2B3FD96E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6D62E16CAD3A2D8ADF8753FB2B3FB1DB" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_048C42B04406C4AB7C8153FB2B3FD96E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_7B65DE554CBF8DDCB64D53FB2B4061F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_048C42B04406C4AB7C8153FB2B3FD96E" xlink:to="loc_us-gaap_IPOMember_7B65DE554CBF8DDCB64D53FB2B4061F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1B0D102746BE1FFE3BB253FB2B401957" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_048C42B04406C4AB7C8153FB2B3FD96E" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1B0D102746BE1FFE3BB253FB2B401957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_EEB4293D8DAF68FAD12153FB2B4056D4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_EEB4293D8DAF68FAD12153FB2B4056D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_002FC8AAF46ADBCBAB7B53FB2B408E2A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_EEB4293D8DAF68FAD12153FB2B4056D4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_002FC8AAF46ADBCBAB7B53FB2B408E2A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_002FC8AAF46ADBCBAB7B53FB2B408E2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_EEB4293D8DAF68FAD12153FB2B4056D4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_002FC8AAF46ADBCBAB7B53FB2B408E2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_C1F61BDCD0D3AACABA7153FB2B4024C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_002FC8AAF46ADBCBAB7B53FB2B408E2A" xlink:to="loc_us-gaap_SubsequentEventMember_C1F61BDCD0D3AACABA7153FB2B4024C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91C39BA70C22433BEA505409D1F6DD53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91C39BA70C22433BEA505409D1F6DD53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8930A61244A12CB07D8F53FB2B404B7F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8930A61244A12CB07D8F53FB2B404B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_CE179E151F39A02733ED53FB2B40C265" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_CE179E151F39A02733ED53FB2B40C265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9D67BF2DF602A316C0DB53FB2B40EAB7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_NetIncomeLoss_9D67BF2DF602A316C0DB53FB2B40EAB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A1998BF95D10AA3FAC9D53FB2B406B5F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A1998BF95D10AA3FAC9D53FB2B406B5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="loc_us-gaap_InvestmentsAndCash_1DF6AEBDD5D94FB19FAB53FB2B4028C1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_InvestmentsAndCash_1DF6AEBDD5D94FB19FAB53FB2B4028C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9E3A19C8DB9104D355F453FB2B416A8A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9E3A19C8DB9104D355F453FB2B416A8A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_CB10BA50D236855D9532648483ABA96F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_CB10BA50D236855D9532648483ABA96F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_CB10BA50D236855D9532648483ABA96F" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_CB10BA50D236855D9532648483ABA96F" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_FABB03E1742A465828DB648483ACB3D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910" xlink:to="loc_us-gaap_ResearchMember_FABB03E1742A465828DB648483ACB3D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_34801363164571A79FC4648483AC8DC7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_34801363164571A79FC4648483AC8DC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_34801363164571A79FC4648483AC8DC7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_34801363164571A79FC4648483AC8DC7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_DF408A904D9D38D521F1648483AC1BDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B" xlink:to="loc_us-gaap_DomesticCountryMember_DF408A904D9D38D521F1648483AC1BDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_0D17C56239D8FF31FEA5648483ACE139" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_0D17C56239D8FF31FEA5648483ACE139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_623B16D35B4C4C2F5DDA648483AC459D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_623B16D35B4C4C2F5DDA648483AC459D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_23F3CFF8D23125C976FB648483AC77F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:to="loc_us-gaap_OperatingLossCarryforwards_23F3CFF8D23125C976FB648483AC77F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_9250E17EAA8CCB4259D4648483AC146D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_9250E17EAA8CCB4259D4648483AC146D" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit_AF78EB83B19EB905E7CB648483ACC218" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:to="loc_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit_AF78EB83B19EB905E7CB648483ACC218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ED560AD7E01022DF855648483AC0DBA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ED560AD7E01022DF855648483AC0DBA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersAntidilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03CA3B0257AA5D69C1993E3F09978C14" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8D32FFF3F75D90883573E3F0996A891" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03CA3B0257AA5D69C1993E3F09978C14" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8D32FFF3F75D90883573E3F0996A891" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8538E30EF724C0FF8EB03E3F0996F32C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8D32FFF3F75D90883573E3F0996A891" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8538E30EF724C0FF8EB03E3F0996F32C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8538E30EF724C0FF8EB03E3F0996F32C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8538E30EF724C0FF8EB03E3F0996F32C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_D8272A36141192DFD4FD3E3F09970855" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_D8272A36141192DFD4FD3E3F09970855" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_OutstandingCommonStockSubjecttoRepurchaseMember" xlink:label="loc_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember_65527C34FC073241AB223E3F099744EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:to="loc_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember_65527C34FC073241AB223E3F099744EB" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_OptionsOutstandingMember" xlink:label="loc_mnlo_OptionsOutstandingMember_0ABEE2C20091AD6275823E5DD6742D45" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:to="loc_mnlo_OptionsOutstandingMember_0ABEE2C20091AD6275823E5DD6742D45" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember" xlink:label="loc_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember_2137DA419B6586F114EC3E5F2E87C349" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:to="loc_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember_2137DA419B6586F114EC3E5F2E87C349" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C5A6FBF2095C4FFFC7AD3E3F0997DAA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03CA3B0257AA5D69C1993E3F09978C14" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C5A6FBF2095C4FFFC7AD3E3F0997DAA5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_6FEAA6BA8CE96DBC0F415D29D77760A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8" xlink:to="loc_us-gaap_CounterpartyNameAxis_6FEAA6BA8CE96DBC0F415D29D77760A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2B0906E852BECE8DD73E5D29D778A1F6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_6FEAA6BA8CE96DBC0F415D29D77760A0" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2B0906E852BECE8DD73E5D29D778A1F6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2B0906E852BECE8DD73E5D29D778A1F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_6FEAA6BA8CE96DBC0F415D29D77760A0" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2B0906E852BECE8DD73E5D29D778A1F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AffiliatedEntityMember" xlink:label="loc_us-gaap_AffiliatedEntityMember_5C51CE3DD85A100DC87D5D29D7787698" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2B0906E852BECE8DD73E5D29D778A1F6" xlink:to="loc_us-gaap_AffiliatedEntityMember_5C51CE3DD85A100DC87D5D29D7787698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3F504CB3697B34D8A4155D29D778F8BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3F504CB3697B34D8A4155D29D778F8BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3F504CB3697B34D8A4155D29D778F8BF" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3F504CB3697B34D8A4155D29D778F8BF" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DevelopmentServicesFeesMember" xlink:label="loc_mnlo_DevelopmentServicesFeesMember_132A3980A03AD2E252CF5D29D77889C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF" xlink:to="loc_mnlo_DevelopmentServicesFeesMember_132A3980A03AD2E252CF5D29D77889C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_B7A03D167A866811103F5D29D7786D1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_B7A03D167A866811103F5D29D7786D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9D7428297C45AD7BBE775D29D779DB61" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9D7428297C45AD7BBE775D29D779DB61" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialData" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A828C2A48A82399340B030A92AF7CCE2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_DAD2F30B89EA6E686CD330A92AF30B2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A828C2A48A82399340B030A92AF7CCE2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_DAD2F30B89EA6E686CD330A92AF30B2B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E3286768C4EDC2A5724B30A92AF6720B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_DAD2F30B89EA6E686CD330A92AF30B2B" xlink:to="loc_us-gaap_RangeAxis_E3286768C4EDC2A5724B30A92AF6720B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_B26B1272F7FBDA423BC530A92AF6AADE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_E3286768C4EDC2A5724B30A92AF6720B" xlink:to="loc_us-gaap_RangeMember_B26B1272F7FBDA423BC530A92AF6AADE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_B26B1272F7FBDA423BC530A92AF6AADE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_E3286768C4EDC2A5724B30A92AF6720B" xlink:to="loc_us-gaap_RangeMember_B26B1272F7FBDA423BC530A92AF6AADE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_C718263B46028D9BF2E930A92B1606D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_B26B1272F7FBDA423BC530A92AF6AADE" xlink:to="loc_us-gaap_MinimumMember_C718263B46028D9BF2E930A92B1606D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_F1DA4BD2FB2707170A5C30A92B24D49C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_B26B1272F7FBDA423BC530A92AF6AADE" xlink:to="loc_us-gaap_MaximumMember_F1DA4BD2FB2707170A5C30A92B24D49C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8D45ED65A049078F2FBB30A92B05A886" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A828C2A48A82399340B030A92AF7CCE2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8D45ED65A049078F2FBB30A92B05A886" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodTable" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0DAA63C4EE6E270866DD5D29D8A59765" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0DAA63C4EE6E270866DD5D29D8A59765" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0DAA63C4EE6E270866DD5D29D8A59765" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0DAA63C4EE6E270866DD5D29D8A59765" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_94162A6009EFE9A3DE255D29D8A50D3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementMember_94162A6009EFE9A3DE255D29D8A50D3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_3882A6863BB68D0715335D29D8A58137" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:to="loc_us-gaap_CounterpartyNameAxis_3882A6863BB68D0715335D29D8A58137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1A79E1DCACB15D75026B5D29D8A5DD22_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_3882A6863BB68D0715335D29D8A58137" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1A79E1DCACB15D75026B5D29D8A5DD22_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1A79E1DCACB15D75026B5D29D8A5DD22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_3882A6863BB68D0715335D29D8A58137" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1A79E1DCACB15D75026B5D29D8A5DD22" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_JTToriiMember" xlink:label="loc_mnlo_JTToriiMember_BA39B5429B83128D84255D29D8A58F72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1A79E1DCACB15D75026B5D29D8A5DD22" xlink:to="loc_mnlo_JTToriiMember_BA39B5429B83128D84255D29D8A58F72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9099CE1E81EDD8D6D4805D29D8A5E4CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9099CE1E81EDD8D6D4805D29D8A5E4CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9099CE1E81EDD8D6D4805D29D8A5E4CC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9099CE1E81EDD8D6D4805D29D8A5E4CC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_333A923E36DB315861285D29D8A6D8F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_333A923E36DB315861285D29D8A6D8F1" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DevelopmentandRegulatoryMilestonesMember" xlink:label="loc_mnlo_DevelopmentandRegulatoryMilestonesMember_34EFEC3F1A3FB109F19D5D29D8A65C6A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:to="loc_mnlo_DevelopmentandRegulatoryMilestonesMember_34EFEC3F1A3FB109F19D5D29D8A65C6A" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CommercialMilestoneMember" xlink:label="loc_mnlo_CommercialMilestoneMember_C455A3E2D32E8DB0C13F5D29D8A65E1C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:to="loc_mnlo_CommercialMilestoneMember_C455A3E2D32E8DB0C13F5D29D8A65E1C" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember" xlink:label="loc_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember_9CC8E79AD91776774F865D29D8A6B894" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:to="loc_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember_9CC8E79AD91776774F865D29D8A6B894" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember" xlink:label="loc_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember_E2787C401C64147A3EC65D29D8A60E39" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:to="loc_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember_E2787C401C64147A3EC65D29D8A60E39" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NonsubstantiveMilestonesMember" xlink:label="loc_mnlo_NonsubstantiveMilestonesMember_7C73CD03AFFD1229ECEA5D29D8A651CB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:to="loc_mnlo_NonsubstantiveMilestonesMember_7C73CD03AFFD1229ECEA5D29D8A651CB" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CollaborativeAgreementUpfrontPaymentReceived" xlink:label="loc_mnlo_CollaborativeAgreementUpfrontPaymentReceived_BE5A9BBD9A3B43B291405D29D8A69524" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:to="loc_mnlo_CollaborativeAgreementUpfrontPaymentReceived_BE5A9BBD9A3B43B291405D29D8A69524" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CollaborativeArrangementsPotentialMilestoneProceeds" xlink:label="loc_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds_16025C5267100F3D521F5D29D8A6A336" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:to="loc_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds_16025C5267100F3D521F5D29D8A6A336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_027F4B6F403F3EF23D535D29D8A7D6A7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_027F4B6F403F3EF23D535D29D8A7D6A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1E2138615A16A335FC645D29D8A7C0BE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1E2138615A16A335FC645D29D8A7C0BE" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod" xlink:label="loc_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod_7ACB5AF96ACC42ABFC3D5D29D8A75B05" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:to="loc_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod_7ACB5AF96ACC42ABFC3D5D29D8A75B05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_725A459C2A695FD5245C5D29D8A7693E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_725A459C2A695FD5245C5D29D8A7693E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesReverseStockSplitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_D5DB499CBBAEF6E850D05440F8E763B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_E8FE295707F84F2A72025440F8E70B93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_D5DB499CBBAEF6E850D05440F8E763B3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_E8FE295707F84F2A72025440F8E70B93" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2870414B46C0B905951B5440F8E74006" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E8FE295707F84F2A72025440F8E70B93" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2870414B46C0B905951B5440F8E74006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C88D8D3B559E2ED3FBA25440F8E75148_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2870414B46C0B905951B5440F8E74006" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C88D8D3B559E2ED3FBA25440F8E75148_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C88D8D3B559E2ED3FBA25440F8E75148" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2870414B46C0B905951B5440F8E74006" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C88D8D3B559E2ED3FBA25440F8E75148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2C67DF9F5C10CC7116065440F8E7B830" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_C88D8D3B559E2ED3FBA25440F8E75148" xlink:to="loc_us-gaap_SubsequentEventMember_2C67DF9F5C10CC7116065440F8E7B830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7D3F059F49B08FF799E05440F8E78C09" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E8FE295707F84F2A72025440F8E70B93" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7D3F059F49B08FF799E05440F8E78C09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CFEA8A10B31AA8BE9E8E5440F8E759D2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7D3F059F49B08FF799E05440F8E78C09" xlink:to="loc_us-gaap_ClassOfStockDomain_CFEA8A10B31AA8BE9E8E5440F8E759D2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CFEA8A10B31AA8BE9E8E5440F8E759D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7D3F059F49B08FF799E05440F8E78C09" xlink:to="loc_us-gaap_ClassOfStockDomain_CFEA8A10B31AA8BE9E8E5440F8E759D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A5D02DE734CD9F821B445440F8E7E2EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_CFEA8A10B31AA8BE9E8E5440F8E759D2" xlink:to="loc_us-gaap_CommonStockMember_A5D02DE734CD9F821B445440F8E7E2EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_07219C9D3938D365D6DD5440F8E779C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_D5DB499CBBAEF6E850D05440F8E763B3" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_07219C9D3938D365D6DD5440F8E779C5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/StatementOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D393DBFDB2042311A7B03023C6FADCF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_CB514B491766F599AEA73023C6F9DF1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_D393DBFDB2042311A7B03023C6FADCF5" xlink:to="loc_us-gaap_StatementTable_CB514B491766F599AEA73023C6F9DF1B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_BBE7CE7648FA24E538B63023C6F92E46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_CB514B491766F599AEA73023C6F9DF1B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_BBE7CE7648FA24E538B63023C6F92E46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_FCF0EB95AF06555821BA3023C6F92405_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_BBE7CE7648FA24E538B63023C6F92E46" xlink:to="loc_us-gaap_EquityComponentDomain_FCF0EB95AF06555821BA3023C6F92405_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_FCF0EB95AF06555821BA3023C6F92405" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_BBE7CE7648FA24E538B63023C6F92E46" xlink:to="loc_us-gaap_EquityComponentDomain_FCF0EB95AF06555821BA3023C6F92405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_A6617438F2351B0714E83023C6F92499" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_FCF0EB95AF06555821BA3023C6F92405" xlink:to="loc_us-gaap_PreferredStockMember_A6617438F2351B0714E83023C6F92499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5D000A0A32F7CCEC84F73023C6F91753" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_CB514B491766F599AEA73023C6F9DF1B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5D000A0A32F7CCEC84F73023C6F91753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D26F77B568D9163AB3693023C6F9B2CF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5D000A0A32F7CCEC84F73023C6F91753" xlink:to="loc_us-gaap_ClassOfStockDomain_D26F77B568D9163AB3693023C6F9B2CF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D26F77B568D9163AB3693023C6F9B2CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5D000A0A32F7CCEC84F73023C6F91753" xlink:to="loc_us-gaap_ClassOfStockDomain_D26F77B568D9163AB3693023C6F9B2CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_D76102B72B5DEDA8C0243023C6FA09B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D26F77B568D9163AB3693023C6F9B2CF" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_D76102B72B5DEDA8C0243023C6FA09B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_2CBE47186CE9B093E9793023C6FA1B83" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D26F77B568D9163AB3693023C6F9B2CF" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_2CBE47186CE9B093E9793023C6FA1B83" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityStockIssuedIssuanceCosts" xlink:label="loc_mnlo_TemporaryEquityStockIssuedIssuanceCosts_4DB0282211CF889D5FEA302CB9285EB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D393DBFDB2042311A7B03023C6FADCF5" xlink:to="loc_mnlo_TemporaryEquityStockIssuedIssuanceCosts_4DB0282211CF889D5FEA302CB9285EB0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitStatement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_294673D23C0FD3604BD86464F433D6DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_782C978F64C89C8C526F6464F424CCB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_294673D23C0FD3604BD86464F433D6DB" xlink:to="loc_us-gaap_StatementTable_782C978F64C89C8C526F6464F424CCB2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4D27D20ACD7AB76CD7CF6464F4332450" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_782C978F64C89C8C526F6464F424CCB2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4D27D20ACD7AB76CD7CF6464F4332450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4D27D20ACD7AB76CD7CF6464F4332450" xlink:to="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4D27D20ACD7AB76CD7CF6464F4332450" xlink:to="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9A7F37451F4E79014A2C6464F433C726" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:to="loc_us-gaap_CommonStockMember_9A7F37451F4E79014A2C6464F433C726" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5A1D8A83A55D2D13CA9E6464F4336CF7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5A1D8A83A55D2D13CA9E6464F4336CF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_AB3B8CEDFC4D3644909A6464F433F8B9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:to="loc_us-gaap_RetainedEarningsMember_AB3B8CEDFC4D3644909A6464F433F8B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C04A7DA8254487A7F7236464F4331D26" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C04A7DA8254487A7F7236464F4331D26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3B6D1A29C0BAEC9FFA796464F433EA9E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_782C978F64C89C8C526F6464F424CCB2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3B6D1A29C0BAEC9FFA796464F433EA9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_905A06709A2009C2EA706464F4331E27_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3B6D1A29C0BAEC9FFA796464F433EA9E" xlink:to="loc_us-gaap_ClassOfStockDomain_905A06709A2009C2EA706464F4331E27_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_905A06709A2009C2EA706464F4331E27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3B6D1A29C0BAEC9FFA796464F433EA9E" xlink:to="loc_us-gaap_ClassOfStockDomain_905A06709A2009C2EA706464F4331E27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_DBFBDBD145066E7FF2096464F433957F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_905A06709A2009C2EA706464F4331E27" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_DBFBDBD145066E7FF2096464F433957F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_BCA8B404118C2ADB28CC6464F4338D1A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_905A06709A2009C2EA706464F4331E27" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_BCA8B404118C2ADB28CC6464F4338D1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_734778DA95F51E91AFB66464F43379F9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_905A06709A2009C2EA706464F4331E27" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_734778DA95F51E91AFB66464F43379F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_294673D23C0FD3604BD86464F433D6DB" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3B47CC0B91973CB3CD966464F43312B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_3B47CC0B91973CB3CD966464F43312B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_62CA0E50A3E9E144C0006464F433F927" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_62CA0E50A3E9E144C0006464F433F927" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_FA01CE1596FEF4AEA1116464F433C0C5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_FA01CE1596FEF4AEA1116464F433C0C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B0ABB02879A3D16834476464F433A1C5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_StockholdersEquity_B0ABB02879A3D16834476464F433A1C5" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_C1BAF3F203417FB049596464F4330492" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_C1BAF3F203417FB049596464F4330492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_F855665F541DCEC3D9AD6464F43300E0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_F855665F541DCEC3D9AD6464F43300E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81A03DCDAD8668A3CE4F6464F433A546" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81A03DCDAD8668A3CE4F6464F433A546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10C5E5077D6F9D568C066464F4335341" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10C5E5077D6F9D568C066464F4335341" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions" xlink:label="loc_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions_674A741A50BF824EB2E56464F433AA54" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions_674A741A50BF824EB2E56464F433AA54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_38A2759AA8B1DFE78DEF6464F433DF4F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_38A2759AA8B1DFE78DEF6464F433DF4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B8E0A1E28E2FD59018226464F43316EF" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B8E0A1E28E2FD59018226464F43316EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DC6437086915CD7E8C1E6464F4335C1B" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_NetIncomeLoss_DC6437086915CD7E8C1E6464F4335C1B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_41C1935E0DC1DDF250056463C6A609F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_41C1935E0DC1DDF250056463C6A609F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_41C1935E0DC1DDF250056463C6A609F0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_41C1935E0DC1DDF250056463C6A609F0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F9C6475353D32A11657D6463C6A77C30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F9C6475353D32A11657D6463C6A77C30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6243FAC9897CB9670E396463C6A8FA99" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6243FAC9897CB9670E396463C6A8FA99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D6B238F288A01E328D1A6463C6A8EB9A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:to="loc_us-gaap_PlanNameAxis_D6B238F288A01E328D1A6463C6A8EB9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_D6B238F288A01E328D1A6463C6A8EB9A" xlink:to="loc_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_D6B238F288A01E328D1A6463C6A8EB9A" xlink:to="loc_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_A2011StockIncentivePlanMember" xlink:label="loc_mnlo_A2011StockIncentivePlanMember_7E332082A30912BC59A76463C6A94A29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F" xlink:to="loc_mnlo_A2011StockIncentivePlanMember_7E332082A30912BC59A76463C6A94A29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_CCD422B88F644F9F86966463C6A9927B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:to="loc_us-gaap_AwardTypeAxis_CCD422B88F644F9F86966463C6A9927B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_CCD422B88F644F9F86966463C6A9927B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_CCD422B88F644F9F86966463C6A9927B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_398ADF63D92662CDC5206463C6A95440" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_398ADF63D92662CDC5206463C6A95440" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember" xlink:label="loc_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_38DD10CD3D0544AC85AC6463C6A96E78" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:to="loc_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_38DD10CD3D0544AC85AC6463C6A96E78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1D399AF334D489DF92756463C6A943E4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:to="loc_us-gaap_RestrictedStockMember_1D399AF334D489DF92756463C6A943E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_ED961E995D526E3E6D846463C6A90513" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:to="loc_us-gaap_TitleOfIndividualAxis_ED961E995D526E3E6D846463C6A90513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_ED961E995D526E3E6D846463C6A90513" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_ED961E995D526E3E6D846463C6A90513" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_EmployeesandDirectorsMember" xlink:label="loc_mnlo_EmployeesandDirectorsMember_B8298CB731192FBAABAF6463C6AADC31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9" xlink:to="loc_mnlo_EmployeesandDirectorsMember_B8298CB731192FBAABAF6463C6AADC31" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NonemployeeMember" xlink:label="loc_mnlo_NonemployeeMember_2CBCD260606739A54C466463C6AA3ABD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9" xlink:to="loc_mnlo_NonemployeeMember_2CBCD260606739A54C466463C6AA3ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2D6CF7F2691BA26F51E66463C6AA7A4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2D6CF7F2691BA26F51E66463C6AA7A4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FECD37FBE3EBC0BEF4C86463C6AA1F93" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FECD37FBE3EBC0BEF4C86463C6AA1F93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E2184FD7D24BDBB38D056463C6AAAEEF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E2184FD7D24BDBB38D056463C6AAAEEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D492FA825C9CF1E3FDB46463C6AA36BB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D492FA825C9CF1E3FDB46463C6AA36BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61618D4D06FA5616ED9E6463C6AA63C6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61618D4D06FA5616ED9E6463C6AA63C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_EF2449E21CEFB6604E736463C6ABA77E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_EF2449E21CEFB6604E736463C6ABA77E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_31F9CFF3BBA1D0A97A006463C6ABB86A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_31F9CFF3BBA1D0A97A006463C6ABB86A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56DDB42576D3097F6BBD6463C6ABCB71" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56DDB42576D3097F6BBD6463C6ABCB71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_B6D72782CC9CC0443BB36463C6AB1B59" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_B6D72782CC9CC0443BB36463C6AB1B59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B82CC86397E8807BC2B46463C6ABE103" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B82CC86397E8807BC2B46463C6ABE103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_92A44FC979D6053EC9EA6463C6AB4A7B" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_92A44FC979D6053EC9EA6463C6AB4A7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8DF52612E8726CC9815B6463C6AB39AA" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8DF52612E8726CC9815B6463C6AB39AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D632F2AA6B1279291F7D6463C6ABA913" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D632F2AA6B1279291F7D6463C6ABA913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF0BF0A4BF82A6F39C1C6466051DD965" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF0BF0A4BF82A6F39C1C6466051DD965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7FA079CD0EC22D9A5D026463C6ABADB2" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7FA079CD0EC22D9A5D026463C6ABADB2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensationFairValueAssumptionsForDirectorEmployeeAndNonEmployeeGrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DF9D1758B764D1C7F2675D29D7E0702B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DF9D1758B764D1C7F2675D29D7E0702B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_5B95BC022E3860057A9D5D29D7E09208" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DF9D1758B764D1C7F2675D29D7E0702B" xlink:to="loc_us-gaap_TitleOfIndividualAxis_5B95BC022E3860057A9D5D29D7E09208" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_401D3FAA70A1386EB18D5D29D7E03A32_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5B95BC022E3860057A9D5D29D7E09208" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_401D3FAA70A1386EB18D5D29D7E03A32_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_401D3FAA70A1386EB18D5D29D7E03A32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5B95BC022E3860057A9D5D29D7E09208" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_401D3FAA70A1386EB18D5D29D7E03A32" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_EmployeesandDirectorsMember" xlink:label="loc_mnlo_EmployeesandDirectorsMember_39DC4B7DE5DCA2B8A9EE5D29D7E1358C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_401D3FAA70A1386EB18D5D29D7E03A32" xlink:to="loc_mnlo_EmployeesandDirectorsMember_39DC4B7DE5DCA2B8A9EE5D29D7E1358C" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NonemployeeMember" xlink:label="loc_mnlo_NonemployeeMember_790536F0ACAC1E1756625D29D7E1DE03" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_401D3FAA70A1386EB18D5D29D7E03A32" xlink:to="loc_mnlo_NonemployeeMember_790536F0ACAC1E1756625D29D7E1DE03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E40F2F28918A6982E6BC5D29D7E1442B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DF9D1758B764D1C7F2675D29D7E0702B" xlink:to="loc_us-gaap_RangeAxis_E40F2F28918A6982E6BC5D29D7E1442B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_E40F2F28918A6982E6BC5D29D7E1442B" xlink:to="loc_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_E40F2F28918A6982E6BC5D29D7E1442B" xlink:to="loc_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_0C698D6FB5FC5ECAE4915D29D7E1E0D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F" xlink:to="loc_us-gaap_MinimumMember_0C698D6FB5FC5ECAE4915D29D7E1E0D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D584E0443B12798192065D29D7E15E30" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F" xlink:to="loc_us-gaap_MaximumMember_D584E0443B12798192065D29D7E15E30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_903A35C47239C7382A565D29D7E19DBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_903A35C47239C7382A565D29D7E19DBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1B8C0DB0231871C85F375D29D7E2B382" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1B8C0DB0231871C85F375D29D7E2B382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_34C74754058EB4A82DE15D29D7E228CE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_34C74754058EB4A82DE15D29D7E228CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9F9528D2EC15AABC777B5D29D7E23D9C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9F9528D2EC15AABC777B5D29D7E23D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_A81F7AC8D88B7199116E5D29D7E21F65" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_A81F7AC8D88B7199116E5D29D7E21F65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_F76D0948D31F796C8B5B5D29D7E28756" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_F76D0948D31F796C8B5B5D29D7E28756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4768C5D4280F035A66145D29D7E2D8F4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4768C5D4280F035A66145D29D7E2D8F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FFE622846A4C96F3BE455D29D7E2719A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FFE622846A4C96F3BE455D29D7E2719A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensationStockOptionAndRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DAB189353F13AB1DB5CF53E14D72037C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DAB189353F13AB1DB5CF53E14D72037C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A6015C786BC94AD93F5A53E14D726905" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DAB189353F13AB1DB5CF53E14D72037C" xlink:to="loc_us-gaap_AwardTypeAxis_A6015C786BC94AD93F5A53E14D726905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3672AD568E0413A4E47B53E14D7208B1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_A6015C786BC94AD93F5A53E14D726905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3672AD568E0413A4E47B53E14D7208B1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3672AD568E0413A4E47B53E14D7208B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_A6015C786BC94AD93F5A53E14D726905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3672AD568E0413A4E47B53E14D7208B1" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_EarlyExercisedStockOptionsMember" xlink:label="loc_mnlo_EarlyExercisedStockOptionsMember_435D75ABEFCB895FBD6E53E14D72602B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3672AD568E0413A4E47B53E14D7208B1" xlink:to="loc_mnlo_EarlyExercisedStockOptionsMember_435D75ABEFCB895FBD6E53E14D72602B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4BBE2A564D9301C24F4353E14D733A0E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DAB189353F13AB1DB5CF53E14D72037C" xlink:to="loc_us-gaap_PlanNameAxis_4BBE2A564D9301C24F4353E14D733A0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_204C8986BC4D8905364053E14D734194_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4BBE2A564D9301C24F4353E14D733A0E" xlink:to="loc_us-gaap_PlanNameDomain_204C8986BC4D8905364053E14D734194_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_204C8986BC4D8905364053E14D734194" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4BBE2A564D9301C24F4353E14D733A0E" xlink:to="loc_us-gaap_PlanNameDomain_204C8986BC4D8905364053E14D734194" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_A2011StockIncentivePlanMember" xlink:label="loc_mnlo_A2011StockIncentivePlanMember_D75BF869E721631D95F253E14D73815F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_204C8986BC4D8905364053E14D734194" xlink:to="loc_mnlo_A2011StockIncentivePlanMember_D75BF869E721631D95F253E14D73815F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F73BFE11D2010564ADBD53E2FAA8EFFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F73BFE11D2010564ADBD53E2FAA8EFFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_682D30F5506319BBDCE453E52D874057" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_682D30F5506319BBDCE453E52D874057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C136D72C34E1E7515CFE53E14D740EA7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C136D72C34E1E7515CFE53E14D740EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_838417F508EA488BA07153EEC8827F06" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_838417F508EA488BA07153EEC8827F06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B2A0CA73A589F19D2EBF53EA03466017" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B2A0CA73A589F19D2EBF53EA03466017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CE2B46D830C3E6002B7A53EBB516D66A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CE2B46D830C3E6002B7A53EBB516D66A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6857BAEC47010BCB287C53F26C8B2150" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6857BAEC47010BCB287C53F26C8B2150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56CA22EFB66B73BA1B6C53F4697C1EA8" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56CA22EFB66B73BA1B6C53F4697C1EA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_158A3ACE035F3F6B523D53E14D74FD41" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_158A3ACE035F3F6B523D53E14D74FD41" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64E1B0AE1C0FF560911C5473518D418B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ED81AA15767C7736A3EC5473518DF406" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64E1B0AE1C0FF560911C5473518D418B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ED81AA15767C7736A3EC5473518DF406" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_722493B1DDF46DF265D05473518DBCAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ED81AA15767C7736A3EC5473518DF406" xlink:to="loc_us-gaap_TitleOfIndividualAxis_722493B1DDF46DF265D05473518DBCAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_725CCA3E205361BE1AC15473518DE1D1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_722493B1DDF46DF265D05473518DBCAD" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_725CCA3E205361BE1AC15473518DE1D1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_725CCA3E205361BE1AC15473518DE1D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_722493B1DDF46DF265D05473518DBCAD" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_725CCA3E205361BE1AC15473518DE1D1" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_EmployeesandDirectorsMember" xlink:label="loc_mnlo_EmployeesandDirectorsMember_8841B434E930756856F55473518DA5F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_725CCA3E205361BE1AC15473518DE1D1" xlink:to="loc_mnlo_EmployeesandDirectorsMember_8841B434E930756856F55473518DA5F4" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NonemployeeMember" xlink:label="loc_mnlo_NonemployeeMember_89B8EBF209600DE30E6B5473518D1015" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_725CCA3E205361BE1AC15473518DE1D1" xlink:to="loc_mnlo_NonemployeeMember_89B8EBF209600DE30E6B5473518D1015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2DDF05905DDF803B4C705473518E1AD2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64E1B0AE1C0FF560911C5473518D418B" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2DDF05905DDF803B4C705473518E1AD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B5EC26ADE2DACE63C5C5473518D945F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64E1B0AE1C0FF560911C5473518D418B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B5EC26ADE2DACE63C5C5473518D945F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3AA5756627194CE63285473518EFE24" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64E1B0AE1C0FF560911C5473518D418B" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3AA5756627194CE63285473518EFE24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_9B734E227000479514E65473518E2859" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64E1B0AE1C0FF560911C5473518D418B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_9B734E227000479514E65473518E2859" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.menlotherapeutics.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:to="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_739477790B505A6C30F36464F390C887" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:to="loc_us-gaap_PlanNameAxis_739477790B505A6C30F36464F390C887" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_D41235A0771FFC0186746464F390E35B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_739477790B505A6C30F36464F390C887" xlink:to="loc_us-gaap_PlanNameDomain_D41235A0771FFC0186746464F390E35B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_D41235A0771FFC0186746464F390E35B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_739477790B505A6C30F36464F390C887" xlink:to="loc_us-gaap_PlanNameDomain_D41235A0771FFC0186746464F390E35B" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_A2018OmnibusIncentivePlanMember" xlink:label="loc_mnlo_A2018OmnibusIncentivePlanMember_50CD00561518833631476464F3902886" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_D41235A0771FFC0186746464F390E35B" xlink:to="loc_mnlo_A2018OmnibusIncentivePlanMember_50CD00561518833631476464F3902886" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_A2018EmployeeStockPurchasePlanMember" xlink:label="loc_mnlo_A2018EmployeeStockPurchasePlanMember_0F7625F79D92068DC9F3646F1B914ECD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_D41235A0771FFC0186746464F390E35B" xlink:to="loc_mnlo_A2018EmployeeStockPurchasePlanMember_0F7625F79D92068DC9F3646F1B914ECD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D80882E3435CD343C1C96464F390CF6E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_D80882E3435CD343C1C96464F390CF6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_95092CFDC1579F447A996464F3909361_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D80882E3435CD343C1C96464F390CF6E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_95092CFDC1579F447A996464F3909361_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_95092CFDC1579F447A996464F3909361" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D80882E3435CD343C1C96464F390CF6E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_95092CFDC1579F447A996464F3909361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_233559007FD6779419C46464F390CAD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_95092CFDC1579F447A996464F3909361" xlink:to="loc_us-gaap_IPOMember_233559007FD6779419C46464F390CAD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_87A9C1C06000201E4FA36464F3903D14" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_87A9C1C06000201E4FA36464F3903D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E7C63D39A976C64CE8216464F3905E7B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_87A9C1C06000201E4FA36464F3903D14" xlink:to="loc_us-gaap_EquityComponentDomain_E7C63D39A976C64CE8216464F3905E7B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E7C63D39A976C64CE8216464F3905E7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_87A9C1C06000201E4FA36464F3903D14" xlink:to="loc_us-gaap_EquityComponentDomain_E7C63D39A976C64CE8216464F3905E7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_AA71D6DA02AA165D341F6464F390E418" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E7C63D39A976C64CE8216464F3905E7B" xlink:to="loc_us-gaap_CommonStockMember_AA71D6DA02AA165D341F6464F390E418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_08265055D0721572C3556464F390C939" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_08265055D0721572C3556464F390C939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_DC3E8EEE752555BC19A06464F390E7ED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_08265055D0721572C3556464F390C939" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_DC3E8EEE752555BC19A06464F390E7ED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_DC3E8EEE752555BC19A06464F390E7ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_08265055D0721572C3556464F390C939" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_DC3E8EEE752555BC19A06464F390E7ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_79867C0DACA6ADA93BB96464F390DE27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_DC3E8EEE752555BC19A06464F390E7ED" xlink:to="loc_us-gaap_SubsequentEventMember_79867C0DACA6ADA93BB96464F390DE27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B1C1E2B02E13E81296956464F3903F72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B1C1E2B02E13E81296956464F3903F72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E5DF7A62EEA88E3A0D3D6464F39074AA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E5DF7A62EEA88E3A0D3D6464F39074AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_24A562D05B923C1CA0B26464F390FB12" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_24A562D05B923C1CA0B26464F390FB12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1DEBBC8F535702EDA20A6464F3907A7E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1DEBBC8F535702EDA20A6464F3907A7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C1ECB5023CE359A99E5C6464F390C36D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C1ECB5023CE359A99E5C6464F390C36D" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mnlo-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2664409D845574B1EB235D29D8738334_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2664409D845574B1EB235D29D8738334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2664409D845574B1EB235D29D8738334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2664409D845574B1EB235D29D8738334" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2664409D845574B1EB235D29D8738334" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Indefinite-lived Intangible Assets by Major Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:to="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_0016B78D12DD93F8B0615D29D8742CD4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_0016B78D12DD93F8B0615D29D8742CD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_0016B78D12DD93F8B0615D29D8742CD4_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_0016B78D12DD93F8B0615D29D8742CD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_0016B78D12DD93F8B0615D29D8742CD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_0016B78D12DD93F8B0615D29D8742CD4" xlink:to="lab_us-gaap_StatementGeographicalAxis_0016B78D12DD93F8B0615D29D8742CD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21" xlink:to="lab_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21" xlink:type="arc" />
    <link:label id="lab_stpr_CA_BEC629A08E695092D2B75D29D8748809_terseLabel_en-US" xlink:label="lab_stpr_CA_BEC629A08E695092D2B75D29D8748809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CALIFORNIA</link:label>
    <link:label id="lab_stpr_CA_BEC629A08E695092D2B75D29D8748809_label_en-US" xlink:label="lab_stpr_CA_BEC629A08E695092D2B75D29D8748809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd#stpr_CA" xlink:label="loc_stpr_CA_BEC629A08E695092D2B75D29D8748809" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA_BEC629A08E695092D2B75D29D8748809" xlink:to="lab_stpr_CA_BEC629A08E695092D2B75D29D8748809" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_84F54CAE9286DCA088315D29D8744908_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_84F54CAE9286DCA088315D29D8744908" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_84F54CAE9286DCA088315D29D8744908_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_84F54CAE9286DCA088315D29D8744908" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_84F54CAE9286DCA088315D29D8744908" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_84F54CAE9286DCA088315D29D8744908" xlink:to="lab_us-gaap_TypeOfArrangementAxis_84F54CAE9286DCA088315D29D8744908" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5" xlink:type="arc" />
    <link:label id="lab_mnlo_DevelopmentandRegulatoryMilestonesMember_0D6820AB006E0FAD58B95D29D8740CA6_terseLabel_en-US" xlink:label="lab_mnlo_DevelopmentandRegulatoryMilestonesMember_0D6820AB006E0FAD58B95D29D8740CA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestones</link:label>
    <link:label id="lab_mnlo_DevelopmentandRegulatoryMilestonesMember_0D6820AB006E0FAD58B95D29D8740CA6_label_en-US" xlink:label="lab_mnlo_DevelopmentandRegulatoryMilestonesMember_0D6820AB006E0FAD58B95D29D8740CA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestones [Member]</link:label>
    <link:label id="lab_mnlo_DevelopmentandRegulatoryMilestonesMember_0D6820AB006E0FAD58B95D29D8740CA6_documentation_en-US" xlink:label="lab_mnlo_DevelopmentandRegulatoryMilestonesMember_0D6820AB006E0FAD58B95D29D8740CA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DevelopmentandRegulatoryMilestonesMember" xlink:label="loc_mnlo_DevelopmentandRegulatoryMilestonesMember_0D6820AB006E0FAD58B95D29D8740CA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DevelopmentandRegulatoryMilestonesMember_0D6820AB006E0FAD58B95D29D8740CA6" xlink:to="lab_mnlo_DevelopmentandRegulatoryMilestonesMember_0D6820AB006E0FAD58B95D29D8740CA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_A56551B6CCDA488AE21F5D29D8744E91_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_A56551B6CCDA488AE21F5D29D8744E91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_A56551B6CCDA488AE21F5D29D8744E91_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_A56551B6CCDA488AE21F5D29D8744E91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_A56551B6CCDA488AE21F5D29D8744E91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_A56551B6CCDA488AE21F5D29D8744E91" xlink:to="lab_us-gaap_CounterpartyNameAxis_A56551B6CCDA488AE21F5D29D8744E91" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6" xlink:type="arc" />
    <link:label id="lab_mnlo_MerckMember_0BA6C8B9018BD30CBEC45D29D874D2C7_terseLabel_en-US" xlink:label="lab_mnlo_MerckMember_0BA6C8B9018BD30CBEC45D29D874D2C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merck</link:label>
    <link:label id="lab_mnlo_MerckMember_0BA6C8B9018BD30CBEC45D29D874D2C7_label_en-US" xlink:label="lab_mnlo_MerckMember_0BA6C8B9018BD30CBEC45D29D874D2C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_mnlo_MerckMember_0BA6C8B9018BD30CBEC45D29D874D2C7_documentation_en-US" xlink:label="lab_mnlo_MerckMember_0BA6C8B9018BD30CBEC45D29D874D2C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merck [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_MerckMember" xlink:label="loc_mnlo_MerckMember_0BA6C8B9018BD30CBEC45D29D874D2C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_MerckMember_0BA6C8B9018BD30CBEC45D29D874D2C7" xlink:to="lab_mnlo_MerckMember_0BA6C8B9018BD30CBEC45D29D874D2C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2_label_en-US" xlink:label="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:to="lab_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseCosts_516BADEF1CD528ADF65F5D29D8749524_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseCosts_516BADEF1CD528ADF65F5D29D8749524" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing fee</link:label>
    <link:label id="lab_us-gaap_LicenseCosts_516BADEF1CD528ADF65F5D29D8749524_label_en-US" xlink:label="lab_us-gaap_LicenseCosts_516BADEF1CD528ADF65F5D29D8749524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_516BADEF1CD528ADF65F5D29D8749524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseCosts_516BADEF1CD528ADF65F5D29D8749524" xlink:to="lab_us-gaap_LicenseCosts_516BADEF1CD528ADF65F5D29D8749524" xlink:type="arc" />
    <link:label id="lab_mnlo_CollaborativeArrangementsPotentialMilestonePayments_87AAFA3E3CD6E6FA50985D29D8752778_terseLabel_en-US" xlink:label="lab_mnlo_CollaborativeArrangementsPotentialMilestonePayments_87AAFA3E3CD6E6FA50985D29D8752778" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements, potential milestone payments</link:label>
    <link:label id="lab_mnlo_CollaborativeArrangementsPotentialMilestonePayments_87AAFA3E3CD6E6FA50985D29D8752778_label_en-US" xlink:label="lab_mnlo_CollaborativeArrangementsPotentialMilestonePayments_87AAFA3E3CD6E6FA50985D29D8752778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements, Potential Milestone Payments</link:label>
    <link:label id="lab_mnlo_CollaborativeArrangementsPotentialMilestonePayments_87AAFA3E3CD6E6FA50985D29D8752778_documentation_en-US" xlink:label="lab_mnlo_CollaborativeArrangementsPotentialMilestonePayments_87AAFA3E3CD6E6FA50985D29D8752778" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements, Potential Milestone Payments</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CollaborativeArrangementsPotentialMilestonePayments" xlink:label="loc_mnlo_CollaborativeArrangementsPotentialMilestonePayments_87AAFA3E3CD6E6FA50985D29D8752778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CollaborativeArrangementsPotentialMilestonePayments_87AAFA3E3CD6E6FA50985D29D8752778" xlink:to="lab_mnlo_CollaborativeArrangementsPotentialMilestonePayments_87AAFA3E3CD6E6FA50985D29D8752778" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_DF726D8F0FBBA9434F775D29D87587D2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_DF726D8F0FBBA9434F775D29D87587D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_DF726D8F0FBBA9434F775D29D87587D2_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_DF726D8F0FBBA9434F775D29D87587D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_DF726D8F0FBBA9434F775D29D87587D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_DF726D8F0FBBA9434F775D29D87587D2" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_DF726D8F0FBBA9434F775D29D87587D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_FA59D05A99CB7180866F5D29D8758111_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_FA59D05A99CB7180866F5D29D8758111" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leased office space, square footage</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_FA59D05A99CB7180866F5D29D8758111_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_FA59D05A99CB7180866F5D29D8758111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_FA59D05A99CB7180866F5D29D8758111" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty_FA59D05A99CB7180866F5D29D8758111" xlink:to="lab_us-gaap_AreaOfRealEstateProperty_FA59D05A99CB7180866F5D29D8758111" xlink:type="arc" />
    <link:label id="lab_mnlo_OperatingLeaseMonthlyRentExpense_310EDBBA96C545D0D0B05D29D875375E_terseLabel_en-US" xlink:label="lab_mnlo_OperatingLeaseMonthlyRentExpense_310EDBBA96C545D0D0B05D29D875375E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, monthly expense</link:label>
    <link:label id="lab_mnlo_OperatingLeaseMonthlyRentExpense_310EDBBA96C545D0D0B05D29D875375E_label_en-US" xlink:label="lab_mnlo_OperatingLeaseMonthlyRentExpense_310EDBBA96C545D0D0B05D29D875375E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Monthly Rent Expense</link:label>
    <link:label id="lab_mnlo_OperatingLeaseMonthlyRentExpense_310EDBBA96C545D0D0B05D29D875375E_documentation_en-US" xlink:label="lab_mnlo_OperatingLeaseMonthlyRentExpense_310EDBBA96C545D0D0B05D29D875375E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Monthly Rent Expense</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_OperatingLeaseMonthlyRentExpense" xlink:label="loc_mnlo_OperatingLeaseMonthlyRentExpense_310EDBBA96C545D0D0B05D29D875375E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_OperatingLeaseMonthlyRentExpense_310EDBBA96C545D0D0B05D29D875375E" xlink:to="lab_mnlo_OperatingLeaseMonthlyRentExpense_310EDBBA96C545D0D0B05D29D875375E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_9E0FEEC7200E16CB8BD45D29D8754FA7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_9E0FEEC7200E16CB8BD45D29D8754FA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_9E0FEEC7200E16CB8BD45D29D8754FA7_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_9E0FEEC7200E16CB8BD45D29D8754FA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_9E0FEEC7200E16CB8BD45D29D8754FA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_9E0FEEC7200E16CB8BD45D29D8754FA7" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_9E0FEEC7200E16CB8BD45D29D8754FA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6DD3FB8806748EDC531553FB2A57DBE4_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6DD3FB8806748EDC531553FB2A57DBE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6DD3FB8806748EDC531553FB2A57DBE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6DD3FB8806748EDC531553FB2A57DBE4" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6DD3FB8806748EDC531553FB2A57DBE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseAndServicesRevenue_937FCA85EE18990EEF6853FB2A572230_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServicesRevenue_937FCA85EE18990EEF6853FB2A572230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and license revenue</link:label>
    <link:label id="lab_us-gaap_LicenseAndServicesRevenue_937FCA85EE18990EEF6853FB2A572230_label_en-US" xlink:label="lab_us-gaap_LicenseAndServicesRevenue_937FCA85EE18990EEF6853FB2A572230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Services Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_937FCA85EE18990EEF6853FB2A572230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServicesRevenue_937FCA85EE18990EEF6853FB2A572230" xlink:to="lab_us-gaap_LicenseAndServicesRevenue_937FCA85EE18990EEF6853FB2A572230" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_65646A28B5653475186953FB2A57BA6B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_65646A28B5653475186953FB2A57BA6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_65646A28B5653475186953FB2A57BA6B_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_65646A28B5653475186953FB2A57BA6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_65646A28B5653475186953FB2A57BA6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_65646A28B5653475186953FB2A57BA6B" xlink:to="lab_us-gaap_OperatingExpenses_65646A28B5653475186953FB2A57BA6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_C9E5F3F4A5895964CCB553FB2A5877B7_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_C9E5F3F4A5895964CCB553FB2A5877B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_C9E5F3F4A5895964CCB553FB2A5877B7_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_C9E5F3F4A5895964CCB553FB2A5877B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_C9E5F3F4A5895964CCB553FB2A5877B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_C9E5F3F4A5895964CCB553FB2A5877B7" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_C9E5F3F4A5895964CCB553FB2A5877B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_EE121CDEC2E0E9E6327E53FB2A587725_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_EE121CDEC2E0E9E6327E53FB2A587725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_EE121CDEC2E0E9E6327E53FB2A587725_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_EE121CDEC2E0E9E6327E53FB2A587725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EE121CDEC2E0E9E6327E53FB2A587725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_EE121CDEC2E0E9E6327E53FB2A587725" xlink:to="lab_us-gaap_NetIncomeLoss_EE121CDEC2E0E9E6327E53FB2A587725" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_F2DE09B66F29789FCA3A53FB2A583E07_netLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_F2DE09B66F29789FCA3A53FB2A583E07" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_F2DE09B66F29789FCA3A53FB2A583E07_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_F2DE09B66F29789FCA3A53FB2A583E07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_F2DE09B66F29789FCA3A53FB2A583E07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_F2DE09B66F29789FCA3A53FB2A583E07" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_F2DE09B66F29789FCA3A53FB2A583E07" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_D3AA34811A5848A15DED5D29D8A4576A_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_D3AA34811A5848A15DED5D29D8A4576A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D3AA34811A5848A15DED5D29D8A4576A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D3AA34811A5848A15DED5D29D8A4576A" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_D3AA34811A5848A15DED5D29D8A4576A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodTable" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0DAA63C4EE6E270866DD5D29D8A59765_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0DAA63C4EE6E270866DD5D29D8A59765" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0DAA63C4EE6E270866DD5D29D8A59765_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0DAA63C4EE6E270866DD5D29D8A59765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0DAA63C4EE6E270866DD5D29D8A59765" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0DAA63C4EE6E270866DD5D29D8A59765" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0DAA63C4EE6E270866DD5D29D8A59765" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementMember_94162A6009EFE9A3DE255D29D8A50D3A_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementMember_94162A6009EFE9A3DE255D29D8A50D3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementMember_94162A6009EFE9A3DE255D29D8A50D3A_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementMember_94162A6009EFE9A3DE255D29D8A50D3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_94162A6009EFE9A3DE255D29D8A50D3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementMember_94162A6009EFE9A3DE255D29D8A50D3A" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementMember_94162A6009EFE9A3DE255D29D8A50D3A" xlink:type="arc" />
    <link:label id="lab_mnlo_JTToriiMember_BA39B5429B83128D84255D29D8A58F72_terseLabel_en-US" xlink:label="lab_mnlo_JTToriiMember_BA39B5429B83128D84255D29D8A58F72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JT Torii</link:label>
    <link:label id="lab_mnlo_JTToriiMember_BA39B5429B83128D84255D29D8A58F72_label_en-US" xlink:label="lab_mnlo_JTToriiMember_BA39B5429B83128D84255D29D8A58F72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JT Torii [Member]</link:label>
    <link:label id="lab_mnlo_JTToriiMember_BA39B5429B83128D84255D29D8A58F72_documentation_en-US" xlink:label="lab_mnlo_JTToriiMember_BA39B5429B83128D84255D29D8A58F72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">JT Torii [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_JTToriiMember" xlink:label="loc_mnlo_JTToriiMember_BA39B5429B83128D84255D29D8A58F72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_JTToriiMember_BA39B5429B83128D84255D29D8A58F72" xlink:to="lab_mnlo_JTToriiMember_BA39B5429B83128D84255D29D8A58F72" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_333A923E36DB315861285D29D8A6D8F1_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_333A923E36DB315861285D29D8A6D8F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_333A923E36DB315861285D29D8A6D8F1_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_333A923E36DB315861285D29D8A6D8F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_333A923E36DB315861285D29D8A6D8F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_333A923E36DB315861285D29D8A6D8F1" xlink:to="lab_us-gaap_CollaborativeArrangementMember_333A923E36DB315861285D29D8A6D8F1" xlink:type="arc" />
    <link:label id="lab_mnlo_CommercialMilestoneMember_C455A3E2D32E8DB0C13F5D29D8A65E1C_terseLabel_en-US" xlink:label="lab_mnlo_CommercialMilestoneMember_C455A3E2D32E8DB0C13F5D29D8A65E1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Milestone</link:label>
    <link:label id="lab_mnlo_CommercialMilestoneMember_C455A3E2D32E8DB0C13F5D29D8A65E1C_label_en-US" xlink:label="lab_mnlo_CommercialMilestoneMember_C455A3E2D32E8DB0C13F5D29D8A65E1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Milestone [Member]</link:label>
    <link:label id="lab_mnlo_CommercialMilestoneMember_C455A3E2D32E8DB0C13F5D29D8A65E1C_documentation_en-US" xlink:label="lab_mnlo_CommercialMilestoneMember_C455A3E2D32E8DB0C13F5D29D8A65E1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Milestone [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CommercialMilestoneMember" xlink:label="loc_mnlo_CommercialMilestoneMember_C455A3E2D32E8DB0C13F5D29D8A65E1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CommercialMilestoneMember_C455A3E2D32E8DB0C13F5D29D8A65E1C" xlink:to="lab_mnlo_CommercialMilestoneMember_C455A3E2D32E8DB0C13F5D29D8A65E1C" xlink:type="arc" />
    <link:label id="lab_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember_9CC8E79AD91776774F865D29D8A6B894_terseLabel_en-US" xlink:label="lab_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember_9CC8E79AD91776774F865D29D8A6B894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestone, Preparation of Investigational New Drug Submission, Milestone One</link:label>
    <link:label id="lab_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember_9CC8E79AD91776774F865D29D8A6B894_label_en-US" xlink:label="lab_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember_9CC8E79AD91776774F865D29D8A6B894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestone, Preparation of Investigational New Drug Submission, Milestone One [Member]</link:label>
    <link:label id="lab_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember_9CC8E79AD91776774F865D29D8A6B894_documentation_en-US" xlink:label="lab_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember_9CC8E79AD91776774F865D29D8A6B894" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestone, Preparation of Investigational New Drug Submission, Milestone One [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember" xlink:label="loc_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember_9CC8E79AD91776774F865D29D8A6B894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember_9CC8E79AD91776774F865D29D8A6B894" xlink:to="lab_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember_9CC8E79AD91776774F865D29D8A6B894" xlink:type="arc" />
    <link:label id="lab_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember_E2787C401C64147A3EC65D29D8A60E39_terseLabel_en-US" xlink:label="lab_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember_E2787C401C64147A3EC65D29D8A60E39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestone, Preparation of Investigational New Drug Submission, Milestone Two</link:label>
    <link:label id="lab_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember_E2787C401C64147A3EC65D29D8A60E39_label_en-US" xlink:label="lab_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember_E2787C401C64147A3EC65D29D8A60E39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestone, Preparation of Investigational New Drug Submission, Milestone Two [Member]</link:label>
    <link:label id="lab_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember_E2787C401C64147A3EC65D29D8A60E39_documentation_en-US" xlink:label="lab_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember_E2787C401C64147A3EC65D29D8A60E39" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development and Regulatory Milestone, Preparation of Investigational New Drug Submission, Milestone Two [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember" xlink:label="loc_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember_E2787C401C64147A3EC65D29D8A60E39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember_E2787C401C64147A3EC65D29D8A60E39" xlink:to="lab_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember_E2787C401C64147A3EC65D29D8A60E39" xlink:type="arc" />
    <link:label id="lab_mnlo_NonsubstantiveMilestonesMember_7C73CD03AFFD1229ECEA5D29D8A651CB_terseLabel_en-US" xlink:label="lab_mnlo_NonsubstantiveMilestonesMember_7C73CD03AFFD1229ECEA5D29D8A651CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-substantive Milestones</link:label>
    <link:label id="lab_mnlo_NonsubstantiveMilestonesMember_7C73CD03AFFD1229ECEA5D29D8A651CB_label_en-US" xlink:label="lab_mnlo_NonsubstantiveMilestonesMember_7C73CD03AFFD1229ECEA5D29D8A651CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-substantive Milestones [Member]</link:label>
    <link:label id="lab_mnlo_NonsubstantiveMilestonesMember_7C73CD03AFFD1229ECEA5D29D8A651CB_documentation_en-US" xlink:label="lab_mnlo_NonsubstantiveMilestonesMember_7C73CD03AFFD1229ECEA5D29D8A651CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-substantive Milestones [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NonsubstantiveMilestonesMember" xlink:label="loc_mnlo_NonsubstantiveMilestonesMember_7C73CD03AFFD1229ECEA5D29D8A651CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_NonsubstantiveMilestonesMember_7C73CD03AFFD1229ECEA5D29D8A651CB" xlink:to="lab_mnlo_NonsubstantiveMilestonesMember_7C73CD03AFFD1229ECEA5D29D8A651CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:type="arc" />
    <link:label id="lab_mnlo_CollaborativeAgreementUpfrontPaymentReceived_BE5A9BBD9A3B43B291405D29D8A69524_terseLabel_en-US" xlink:label="lab_mnlo_CollaborativeAgreementUpfrontPaymentReceived_BE5A9BBD9A3B43B291405D29D8A69524" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, upfront payment received</link:label>
    <link:label id="lab_mnlo_CollaborativeAgreementUpfrontPaymentReceived_BE5A9BBD9A3B43B291405D29D8A69524_label_en-US" xlink:label="lab_mnlo_CollaborativeAgreementUpfrontPaymentReceived_BE5A9BBD9A3B43B291405D29D8A69524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Upfront Payment Received</link:label>
    <link:label id="lab_mnlo_CollaborativeAgreementUpfrontPaymentReceived_BE5A9BBD9A3B43B291405D29D8A69524_documentation_en-US" xlink:label="lab_mnlo_CollaborativeAgreementUpfrontPaymentReceived_BE5A9BBD9A3B43B291405D29D8A69524" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Upfront Payment Received</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CollaborativeAgreementUpfrontPaymentReceived" xlink:label="loc_mnlo_CollaborativeAgreementUpfrontPaymentReceived_BE5A9BBD9A3B43B291405D29D8A69524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CollaborativeAgreementUpfrontPaymentReceived_BE5A9BBD9A3B43B291405D29D8A69524" xlink:to="lab_mnlo_CollaborativeAgreementUpfrontPaymentReceived_BE5A9BBD9A3B43B291405D29D8A69524" xlink:type="arc" />
    <link:label id="lab_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds_16025C5267100F3D521F5D29D8A6A336_terseLabel_en-US" xlink:label="lab_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds_16025C5267100F3D521F5D29D8A6A336" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements, potential milestone proceeds</link:label>
    <link:label id="lab_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds_16025C5267100F3D521F5D29D8A6A336_label_en-US" xlink:label="lab_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds_16025C5267100F3D521F5D29D8A6A336" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements, Potential Milestone Proceeds</link:label>
    <link:label id="lab_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds_16025C5267100F3D521F5D29D8A6A336_documentation_en-US" xlink:label="lab_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds_16025C5267100F3D521F5D29D8A6A336" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements, Potential Milestone Proceeds</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CollaborativeArrangementsPotentialMilestoneProceeds" xlink:label="loc_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds_16025C5267100F3D521F5D29D8A6A336" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds_16025C5267100F3D521F5D29D8A6A336" xlink:to="lab_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds_16025C5267100F3D521F5D29D8A6A336" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_027F4B6F403F3EF23D535D29D8A7D6A7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_027F4B6F403F3EF23D535D29D8A7D6A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of revenue recognized for each milestone</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_027F4B6F403F3EF23D535D29D8A7D6A7_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_027F4B6F403F3EF23D535D29D8A7D6A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_027F4B6F403F3EF23D535D29D8A7D6A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_027F4B6F403F3EF23D535D29D8A7D6A7" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_027F4B6F403F3EF23D535D29D8A7D6A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1E2138615A16A335FC645D29D8A7C0BE_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1E2138615A16A335FC645D29D8A7C0BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development arrangement, contract to perform for others, compensation earned</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1E2138615A16A335FC645D29D8A7C0BE_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1E2138615A16A335FC645D29D8A7C0BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1E2138615A16A335FC645D29D8A7C0BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1E2138615A16A335FC645D29D8A7C0BE" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1E2138615A16A335FC645D29D8A7C0BE" xlink:type="arc" />
    <link:label id="lab_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod_7ACB5AF96ACC42ABFC3D5D29D8A75B05_terseLabel_en-US" xlink:label="lab_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod_7ACB5AF96ACC42ABFC3D5D29D8A75B05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements, revenue recognition, initial performance period</link:label>
    <link:label id="lab_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod_7ACB5AF96ACC42ABFC3D5D29D8A75B05_label_en-US" xlink:label="lab_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod_7ACB5AF96ACC42ABFC3D5D29D8A75B05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements, Revenue Recognition, Initial Performance Period</link:label>
    <link:label id="lab_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod_7ACB5AF96ACC42ABFC3D5D29D8A75B05_documentation_en-US" xlink:label="lab_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod_7ACB5AF96ACC42ABFC3D5D29D8A75B05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements, Revenue Recognition, Initial Performance Period</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod" xlink:label="loc_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod_7ACB5AF96ACC42ABFC3D5D29D8A75B05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod_7ACB5AF96ACC42ABFC3D5D29D8A75B05" xlink:to="lab_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod_7ACB5AF96ACC42ABFC3D5D29D8A75B05" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_725A459C2A695FD5245C5D29D8A7693E_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_725A459C2A695FD5245C5D29D8A7693E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_725A459C2A695FD5245C5D29D8A7693E_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_725A459C2A695FD5245C5D29D8A7693E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_725A459C2A695FD5245C5D29D8A7693E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_725A459C2A695FD5245C5D29D8A7693E" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_725A459C2A695FD5245C5D29D8A7693E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_0327C84300F74CFB693A5440F89A53EB_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_0327C84300F74CFB693A5440F89A53EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0327C84300F74CFB693A5440F89A53EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_0327C84300F74CFB693A5440F89A53EB" xlink:to="lab_us-gaap_EquityAbstract_0327C84300F74CFB693A5440F89A53EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_013D00FE6F98F11347AA5440F89ABC3E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_013D00FE6F98F11347AA5440F89ABC3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_013D00FE6F98F11347AA5440F89ABC3E_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_013D00FE6F98F11347AA5440F89ABC3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_013D00FE6F98F11347AA5440F89ABC3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_013D00FE6F98F11347AA5440F89ABC3E" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_013D00FE6F98F11347AA5440F89ABC3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IPOMember_ECDE816EFEF8F51CFC975440F89A9BE7_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember_ECDE816EFEF8F51CFC975440F89A9BE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_ECDE816EFEF8F51CFC975440F89A9BE7_label_en-US" xlink:label="lab_us-gaap_IPOMember_ECDE816EFEF8F51CFC975440F89A9BE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_ECDE816EFEF8F51CFC975440F89A9BE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_ECDE816EFEF8F51CFC975440F89A9BE7" xlink:to="lab_us-gaap_IPOMember_ECDE816EFEF8F51CFC975440F89A9BE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_7C32B961CEE8F74E63945440F89B045B_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_7C32B961CEE8F74E63945440F89B045B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_7C32B961CEE8F74E63945440F89B045B_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_7C32B961CEE8F74E63945440F89B045B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_7C32B961CEE8F74E63945440F89B045B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_7C32B961CEE8F74E63945440F89B045B" xlink:to="lab_us-gaap_OverAllotmentOptionMember_7C32B961CEE8F74E63945440F89B045B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_F98C09854B14F0B40A155440F89B0FC3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_F98C09854B14F0B40A155440F89B0FC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_F98C09854B14F0B40A155440F89B0FC3_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_F98C09854B14F0B40A155440F89B0FC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_F98C09854B14F0B40A155440F89B0FC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_F98C09854B14F0B40A155440F89B0FC3" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_F98C09854B14F0B40A155440F89B0FC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_2F36F9A1FA5B7A332F7B5440F89B558F_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_2F36F9A1FA5B7A332F7B5440F89B558F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_2F36F9A1FA5B7A332F7B5440F89B558F_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_2F36F9A1FA5B7A332F7B5440F89B558F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2F36F9A1FA5B7A332F7B5440F89B558F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_2F36F9A1FA5B7A332F7B5440F89B558F" xlink:to="lab_us-gaap_SubsequentEventMember_2F36F9A1FA5B7A332F7B5440F89B558F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8A630BF5B493054096D75440F89B3737_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_8A630BF5B493054096D75440F89B3737" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8A630BF5B493054096D75440F89B3737_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_8A630BF5B493054096D75440F89B3737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8A630BF5B493054096D75440F89B3737" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8A630BF5B493054096D75440F89B3737" xlink:to="lab_us-gaap_StatementClassOfStockAxis_8A630BF5B493054096D75440F89B3737" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:to="lab_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_8EB429153DC5CDAA40895440F89B50E9_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_8EB429153DC5CDAA40895440F89B50E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_8EB429153DC5CDAA40895440F89B50E9_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_8EB429153DC5CDAA40895440F89B50E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_8EB429153DC5CDAA40895440F89B50E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_8EB429153DC5CDAA40895440F89B50E9" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_8EB429153DC5CDAA40895440F89B50E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_0E0AF994A6DECB41777D5440F89C2137_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_0E0AF994A6DECB41777D5440F89C2137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_0E0AF994A6DECB41777D5440F89C2137_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_0E0AF994A6DECB41777D5440F89C2137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0E0AF994A6DECB41777D5440F89C2137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_0E0AF994A6DECB41777D5440F89C2137" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_0E0AF994A6DECB41777D5440F89C2137" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_DD2A4A9210CA6F8F303D5440F89C984B_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_DD2A4A9210CA6F8F303D5440F89C984B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_DD2A4A9210CA6F8F303D5440F89C984B_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_DD2A4A9210CA6F8F303D5440F89C984B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_DD2A4A9210CA6F8F303D5440F89C984B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_DD2A4A9210CA6F8F303D5440F89C984B" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_DD2A4A9210CA6F8F303D5440F89C984B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="lab_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_1E674227F58A34BE65A85440F89C8924_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_1E674227F58A34BE65A85440F89C8924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock authorized (shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_1E674227F58A34BE65A85440F89C8924_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_1E674227F58A34BE65A85440F89C8924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_1E674227F58A34BE65A85440F89C8924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_1E674227F58A34BE65A85440F89C8924" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_1E674227F58A34BE65A85440F89C8924" xlink:type="arc" />
    <link:label id="lab_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A359941E2A347A6A32855440F89C5AA9_terseLabel_en-US" xlink:label="lab_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A359941E2A347A6A32855440F89C5AA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of preferred stock (shares)</link:label>
    <link:label id="lab_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A359941E2A347A6A32855440F89C5AA9_label_en-US" xlink:label="lab_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A359941E2A347A6A32855440F89C5AA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A359941E2A347A6A32855440F89C5AA9_documentation_en-US" xlink:label="lab_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A359941E2A347A6A32855440F89C5AA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A359941E2A347A6A32855440F89C5AA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A359941E2A347A6A32855440F89C5AA9" xlink:to="lab_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A359941E2A347A6A32855440F89C5AA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_4ACD6B50509343E2C9565440F89CC0C6_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_4ACD6B50509343E2C9565440F89CC0C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_4ACD6B50509343E2C9565440F89CC0C6_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_4ACD6B50509343E2C9565440F89CC0C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_4ACD6B50509343E2C9565440F89CC0C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_4ACD6B50509343E2C9565440F89CC0C6" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_4ACD6B50509343E2C9565440F89CC0C6" xlink:type="arc" />
    <link:label id="lab_mnlo_TemporaryEquityIssuedPriceperShare_5B86F4285B977FAF8CC15440F89C0531_terseLabel_en-US" xlink:label="lab_mnlo_TemporaryEquityIssuedPriceperShare_5B86F4285B977FAF8CC15440F89C0531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred shares issued, price per share (in USD per share)</link:label>
    <link:label id="lab_mnlo_TemporaryEquityIssuedPriceperShare_5B86F4285B977FAF8CC15440F89C0531_label_en-US" xlink:label="lab_mnlo_TemporaryEquityIssuedPriceperShare_5B86F4285B977FAF8CC15440F89C0531" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Issued, Price per Share</link:label>
    <link:label id="lab_mnlo_TemporaryEquityIssuedPriceperShare_5B86F4285B977FAF8CC15440F89C0531_documentation_en-US" xlink:label="lab_mnlo_TemporaryEquityIssuedPriceperShare_5B86F4285B977FAF8CC15440F89C0531" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity Issued, Price per Share</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityIssuedPriceperShare" xlink:label="loc_mnlo_TemporaryEquityIssuedPriceperShare_5B86F4285B977FAF8CC15440F89C0531" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_TemporaryEquityIssuedPriceperShare_5B86F4285B977FAF8CC15440F89C0531" xlink:to="lab_mnlo_TemporaryEquityIssuedPriceperShare_5B86F4285B977FAF8CC15440F89C0531" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E37D5AF9D628C23AA2C25448AE99B96D_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E37D5AF9D628C23AA2C25448AE99B96D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E37D5AF9D628C23AA2C25448AE99B96D_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E37D5AF9D628C23AA2C25448AE99B96D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E37D5AF9D628C23AA2C25448AE99B96D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E37D5AF9D628C23AA2C25448AE99B96D" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E37D5AF9D628C23AA2C25448AE99B96D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_446A7BE0633FB8636DE65440F89C5783_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_446A7BE0633FB8636DE65440F89C5783" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance initial public offering, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_446A7BE0633FB8636DE65440F89C5783_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_446A7BE0633FB8636DE65440F89C5783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_446A7BE0633FB8636DE65440F89C5783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_446A7BE0633FB8636DE65440F89C5783" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_446A7BE0633FB8636DE65440F89C5783" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_799F5CC7CE99C664C2445440F89C63AE_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_799F5CC7CE99C664C2445440F89C63AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares issued upon conversion of convertible stock (shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_799F5CC7CE99C664C2445440F89C63AE_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_799F5CC7CE99C664C2445440F89C63AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_799F5CC7CE99C664C2445440F89C63AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_799F5CC7CE99C664C2445440F89C63AE" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_799F5CC7CE99C664C2445440F89C63AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_0252498DC890F543C7395440F89C0B26_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_0252498DC890F543C7395440F89C0B26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, liquiditiy preference per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_0252498DC890F543C7395440F89C0B26_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_0252498DC890F543C7395440F89C0B26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Liquidation Preference Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_0252498DC890F543C7395440F89C0B26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_0252498DC890F543C7395440F89C0B26" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_0252498DC890F543C7395440F89C0B26" xlink:type="arc" />
    <link:label id="lab_mnlo_TemporaryEquityDividendRatePerDollarAmount_CC521A73AE7568716BB25440F89C7294_terseLabel_en-US" xlink:label="lab_mnlo_TemporaryEquityDividendRatePerDollarAmount_CC521A73AE7568716BB25440F89C7294" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, dividend per annum (in USD per share)</link:label>
    <link:label id="lab_mnlo_TemporaryEquityDividendRatePerDollarAmount_CC521A73AE7568716BB25440F89C7294_label_en-US" xlink:label="lab_mnlo_TemporaryEquityDividendRatePerDollarAmount_CC521A73AE7568716BB25440F89C7294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Dividend Rate, Per-Dollar-Amount</link:label>
    <link:label id="lab_mnlo_TemporaryEquityDividendRatePerDollarAmount_CC521A73AE7568716BB25440F89C7294_documentation_en-US" xlink:label="lab_mnlo_TemporaryEquityDividendRatePerDollarAmount_CC521A73AE7568716BB25440F89C7294" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Dividend Rate, Per-Dollar-Amount</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityDividendRatePerDollarAmount" xlink:label="loc_mnlo_TemporaryEquityDividendRatePerDollarAmount_CC521A73AE7568716BB25440F89C7294" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_TemporaryEquityDividendRatePerDollarAmount_CC521A73AE7568716BB25440F89C7294" xlink:to="lab_mnlo_TemporaryEquityDividendRatePerDollarAmount_CC521A73AE7568716BB25440F89C7294" xlink:type="arc" />
    <link:label id="lab_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect_AFECC191D94D3C2F96295440F89DC536_terseLabel_en-US" xlink:label="lab_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect_AFECC191D94D3C2F96295440F89DC536" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of directors preferred shareholders are entitled to elect</link:label>
    <link:label id="lab_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect_AFECC191D94D3C2F96295440F89DC536_label_en-US" xlink:label="lab_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect_AFECC191D94D3C2F96295440F89DC536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Directors Temporary Equity Holders are Entitled to Elect</link:label>
    <link:label id="lab_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect_AFECC191D94D3C2F96295440F89DC536_documentation_en-US" xlink:label="lab_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect_AFECC191D94D3C2F96295440F89DC536" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Directors Temporary Equity Holders are Entitled to Elect</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect" xlink:label="loc_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect_AFECC191D94D3C2F96295440F89DC536" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect_AFECC191D94D3C2F96295440F89DC536" xlink:to="lab_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect_AFECC191D94D3C2F96295440F89DC536" xlink:type="arc" />
    <link:label id="lab_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect_712ED576091617BB6CCA5440F89DD052_terseLabel_en-US" xlink:label="lab_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect_712ED576091617BB6CCA5440F89DD052" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of directors common shareholders are entitled to elect</link:label>
    <link:label id="lab_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect_712ED576091617BB6CCA5440F89DD052_label_en-US" xlink:label="lab_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect_712ED576091617BB6CCA5440F89DD052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Directors Common Shareholders are Entitled to Elect</link:label>
    <link:label id="lab_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect_712ED576091617BB6CCA5440F89DD052_documentation_en-US" xlink:label="lab_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect_712ED576091617BB6CCA5440F89DD052" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Directors Common Shareholders are Entitled to Elect</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect" xlink:label="loc_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect_712ED576091617BB6CCA5440F89DD052" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect_712ED576091617BB6CCA5440F89DD052" xlink:to="lab_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect_712ED576091617BB6CCA5440F89DD052" xlink:type="arc" />
    <link:label id="lab_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering_43B100353CDCAAB6814B5440F89D4DAB_terseLabel_en-US" xlink:label="lab_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering_43B100353CDCAAB6814B5440F89D4DAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold proceeds of public stock offering of Company common shares that triggers automatic conversion of preferred convertible shares into common shares</link:label>
    <link:label id="lab_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering_43B100353CDCAAB6814B5440F89D4DAB_label_en-US" xlink:label="lab_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering_43B100353CDCAAB6814B5440F89D4DAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Terms of Conversion, Trigger, Minimum Proceeds from Public Offering</link:label>
    <link:label id="lab_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering_43B100353CDCAAB6814B5440F89D4DAB_documentation_en-US" xlink:label="lab_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering_43B100353CDCAAB6814B5440F89D4DAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Terms of Conversion, Trigger, Minimum Proceeds from Public Offering</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering" xlink:label="loc_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering_43B100353CDCAAB6814B5440F89D4DAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering_43B100353CDCAAB6814B5440F89D4DAB" xlink:to="lab_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering_43B100353CDCAAB6814B5440F89D4DAB" xlink:type="arc" />
    <link:label id="lab_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering_C485F57597272CE50B685440F89DF51E_terseLabel_en-US" xlink:label="lab_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering_C485F57597272CE50B685440F89DF51E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold price per share in public stock offering of Company common shares that triggers automatic conversion of preferred convertible shares into common shares (in USD per share)</link:label>
    <link:label id="lab_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering_C485F57597272CE50B685440F89DF51E_label_en-US" xlink:label="lab_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering_C485F57597272CE50B685440F89DF51E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Terms of Conversion, Trigger, Minimum Pricer per Share in Public Offering</link:label>
    <link:label id="lab_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering_C485F57597272CE50B685440F89DF51E_documentation_en-US" xlink:label="lab_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering_C485F57597272CE50B685440F89DF51E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Terms of Conversion, Trigger, Minimum Pricer per Share in Public Offering</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering" xlink:label="loc_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering_C485F57597272CE50B685440F89DF51E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering_C485F57597272CE50B685440F89DF51E" xlink:to="lab_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering_C485F57597272CE50B685440F89DF51E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_E3667208190BCA556C85547353D49601_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_E3667208190BCA556C85547353D49601" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_E3667208190BCA556C85547353D49601" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E3667208190BCA556C85547353D49601" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_E3667208190BCA556C85547353D49601" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_C6219322BDD54D888981547353D4B6F0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_C6219322BDD54D888981547353D4B6F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_C6219322BDD54D888981547353D4B6F0_label_en-US" xlink:label="lab_us-gaap_StatementTable_C6219322BDD54D888981547353D4B6F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C6219322BDD54D888981547353D4B6F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_C6219322BDD54D888981547353D4B6F0" xlink:to="lab_us-gaap_StatementTable_C6219322BDD54D888981547353D4B6F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064" xlink:to="lab_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:to="lab_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:to="lab_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7580E51F309E1404522C547353D5E01D_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7580E51F309E1404522C547353D5E01D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7580E51F309E1404522C547353D5E01D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7580E51F309E1404522C547353D5E01D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7580E51F309E1404522C547353D5E01D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7580E51F309E1404522C547353D5E01D" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7580E51F309E1404522C547353D5E01D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_F4A9962C6B584EDE250C547353D58F2F_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_F4A9962C6B584EDE250C547353D58F2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short&#8209;term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_F4A9962C6B584EDE250C547353D58F2F_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_F4A9962C6B584EDE250C547353D58F2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_F4A9962C6B584EDE250C547353D58F2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_F4A9962C6B584EDE250C547353D58F2F" xlink:to="lab_us-gaap_ShortTermInvestments_F4A9962C6B584EDE250C547353D58F2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_EFC0F2A0C2629B931E93547353D59A84_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_EFC0F2A0C2629B931E93547353D59A84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_EFC0F2A0C2629B931E93547353D59A84_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_EFC0F2A0C2629B931E93547353D59A84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_EFC0F2A0C2629B931E93547353D59A84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_EFC0F2A0C2629B931E93547353D59A84" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_EFC0F2A0C2629B931E93547353D59A84" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1EC5DCE8642B50CA3C5E547353D5BD64_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1EC5DCE8642B50CA3C5E547353D5BD64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1EC5DCE8642B50CA3C5E547353D5BD64_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1EC5DCE8642B50CA3C5E547353D5BD64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1EC5DCE8642B50CA3C5E547353D5BD64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1EC5DCE8642B50CA3C5E547353D5BD64" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1EC5DCE8642B50CA3C5E547353D5BD64" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_12331DDF0B92670AB9CF547353D56195_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_12331DDF0B92670AB9CF547353D56195" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_12331DDF0B92670AB9CF547353D56195_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_12331DDF0B92670AB9CF547353D56195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_12331DDF0B92670AB9CF547353D56195" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_12331DDF0B92670AB9CF547353D56195" xlink:to="lab_us-gaap_AssetsCurrent_12331DDF0B92670AB9CF547353D56195" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_2E5DDAF661A3C2F7B02A547353D50B65_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_2E5DDAF661A3C2F7B02A547353D50B65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long&#8209;term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_2E5DDAF661A3C2F7B02A547353D50B65_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_2E5DDAF661A3C2F7B02A547353D50B65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_2E5DDAF661A3C2F7B02A547353D50B65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_2E5DDAF661A3C2F7B02A547353D50B65" xlink:to="lab_us-gaap_LongTermInvestments_2E5DDAF661A3C2F7B02A547353D50B65" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0716A5F4EF673A3FE062547353D5F238_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0716A5F4EF673A3FE062547353D5F238" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0716A5F4EF673A3FE062547353D5F238_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0716A5F4EF673A3FE062547353D5F238" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0716A5F4EF673A3FE062547353D5F238" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0716A5F4EF673A3FE062547353D5F238" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0716A5F4EF673A3FE062547353D5F238" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_CD53779554EF447005FF547353D52182_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_CD53779554EF447005FF547353D52182" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other long&#8209;term assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_CD53779554EF447005FF547353D52182_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_CD53779554EF447005FF547353D52182" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_CD53779554EF447005FF547353D52182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_CD53779554EF447005FF547353D52182" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_CD53779554EF447005FF547353D52182" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_E134DAEB003AF380386C547353D54226_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_E134DAEB003AF380386C547353D54226" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_E134DAEB003AF380386C547353D54226_label_en-US" xlink:label="lab_us-gaap_Assets_E134DAEB003AF380386C547353D54226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_E134DAEB003AF380386C547353D54226" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_E134DAEB003AF380386C547353D54226" xlink:to="lab_us-gaap_Assets_E134DAEB003AF380386C547353D54226" xlink:type="arc" />
    <link:label id="lab_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC_terseLabel_en-US" xlink:label="lab_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</link:label>
    <link:label id="lab_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC_label_en-US" xlink:label="lab_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Convertible Preferred Stock and Stockholders' Deficit [Abstract]</link:label>
    <link:label id="lab_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC_documentation_en-US" xlink:label="lab_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities, Convertible Preferred Stock and Stockholders' Deficit [Abstract]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract" xlink:label="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="lab_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6568C07AA8B9EA1B2319547353D6EB54_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_6568C07AA8B9EA1B2319547353D6EB54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6568C07AA8B9EA1B2319547353D6EB54_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_6568C07AA8B9EA1B2319547353D6EB54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_6568C07AA8B9EA1B2319547353D6EB54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_6568C07AA8B9EA1B2319547353D6EB54" xlink:to="lab_us-gaap_AccountsPayableCurrent_6568C07AA8B9EA1B2319547353D6EB54" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_42CE7F53B5389CB7872F547353D69492_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_42CE7F53B5389CB7872F547353D69492" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_42CE7F53B5389CB7872F547353D69492_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_42CE7F53B5389CB7872F547353D69492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_42CE7F53B5389CB7872F547353D69492" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_42CE7F53B5389CB7872F547353D69492" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_42CE7F53B5389CB7872F547353D69492" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_F91173A3A42CB268D415547353D62364_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_F91173A3A42CB268D415547353D62364" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_F91173A3A42CB268D415547353D62364_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_F91173A3A42CB268D415547353D62364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_F91173A3A42CB268D415547353D62364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_F91173A3A42CB268D415547353D62364" xlink:to="lab_us-gaap_DeferredRevenueCurrent_F91173A3A42CB268D415547353D62364" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_A8950A10EC17090F456B547353D6C7CA_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_A8950A10EC17090F456B547353D6C7CA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_A8950A10EC17090F456B547353D6C7CA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_A8950A10EC17090F456B547353D6C7CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_A8950A10EC17090F456B547353D6C7CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_A8950A10EC17090F456B547353D6C7CA" xlink:to="lab_us-gaap_LiabilitiesCurrent_A8950A10EC17090F456B547353D6C7CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_6E5580085A3A40178E7E547353D614BA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_6E5580085A3A40178E7E547353D614BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, long&#8209;term</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_6E5580085A3A40178E7E547353D614BA_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_6E5580085A3A40178E7E547353D614BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_6E5580085A3A40178E7E547353D614BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_6E5580085A3A40178E7E547353D614BA" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_6E5580085A3A40178E7E547353D614BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_F5B7E6F7616EBD3E5C8F547353D65CF0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_F5B7E6F7616EBD3E5C8F547353D65CF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non&#8209;current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_F5B7E6F7616EBD3E5C8F547353D65CF0_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_F5B7E6F7616EBD3E5C8F547353D65CF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_F5B7E6F7616EBD3E5C8F547353D65CF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_F5B7E6F7616EBD3E5C8F547353D65CF0" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_F5B7E6F7616EBD3E5C8F547353D65CF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_88CDB362B9DC3B3E245A547353D60C55_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_88CDB362B9DC3B3E245A547353D60C55" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_88CDB362B9DC3B3E245A547353D60C55_label_en-US" xlink:label="lab_us-gaap_Liabilities_88CDB362B9DC3B3E245A547353D60C55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_88CDB362B9DC3B3E245A547353D60C55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_88CDB362B9DC3B3E245A547353D60C55" xlink:to="lab_us-gaap_Liabilities_88CDB362B9DC3B3E245A547353D60C55" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_F35DADA3AE03A9A9FCCE547353D7F3AB_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_F35DADA3AE03A9A9FCCE547353D7F3AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (see Note 5)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_F35DADA3AE03A9A9FCCE547353D7F3AB_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_F35DADA3AE03A9A9FCCE547353D7F3AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_F35DADA3AE03A9A9FCCE547353D7F3AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_F35DADA3AE03A9A9FCCE547353D7F3AB" xlink:to="lab_us-gaap_CommitmentsAndContingencies_F35DADA3AE03A9A9FCCE547353D7F3AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_45B7545AA16A47652195547353D72653_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_45B7545AA16A47652195547353D72653" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_45B7545AA16A47652195547353D72653_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_45B7545AA16A47652195547353D72653" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_45B7545AA16A47652195547353D72653" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_45B7545AA16A47652195547353D72653" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_45B7545AA16A47652195547353D72653" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:to="lab_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_286969AF39FBCE1FC840547353D76C39_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_286969AF39FBCE1FC840547353D76C39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value, 55,000,000 and 36,500,000 shares authorized at December 31, 2017 and 2016, respectively; 5,298,593 and 5,280,058 shares issued and outstanding at December 31, 2017 and 2016, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_286969AF39FBCE1FC840547353D76C39_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_286969AF39FBCE1FC840547353D76C39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_286969AF39FBCE1FC840547353D76C39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_286969AF39FBCE1FC840547353D76C39" xlink:to="lab_us-gaap_CommonStockValue_286969AF39FBCE1FC840547353D76C39" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_D31E0FC5F81110C3CB92547353D704F7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_D31E0FC5F81110C3CB92547353D704F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid&#8209;in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_D31E0FC5F81110C3CB92547353D704F7_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_D31E0FC5F81110C3CB92547353D704F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_D31E0FC5F81110C3CB92547353D704F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_D31E0FC5F81110C3CB92547353D704F7" xlink:to="lab_us-gaap_AdditionalPaidInCapital_D31E0FC5F81110C3CB92547353D704F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_13B8E5126698C1D8F3AE547353D7FD6E_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_13B8E5126698C1D8F3AE547353D7FD6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_13B8E5126698C1D8F3AE547353D7FD6E_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_13B8E5126698C1D8F3AE547353D7FD6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_13B8E5126698C1D8F3AE547353D7FD6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_13B8E5126698C1D8F3AE547353D7FD6E" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_13B8E5126698C1D8F3AE547353D7FD6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_B3AFA382AE88B11985BF547353D789C7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_B3AFA382AE88B11985BF547353D789C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_B3AFA382AE88B11985BF547353D789C7_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_B3AFA382AE88B11985BF547353D789C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_B3AFA382AE88B11985BF547353D789C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_B3AFA382AE88B11985BF547353D789C7" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_B3AFA382AE88B11985BF547353D789C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_6E7FB04C0A4604AD6E19547353D7D808_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_6E7FB04C0A4604AD6E19547353D7D808" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6E7FB04C0A4604AD6E19547353D7D808_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_6E7FB04C0A4604AD6E19547353D7D808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6E7FB04C0A4604AD6E19547353D7D808" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_6E7FB04C0A4604AD6E19547353D7D808" xlink:to="lab_us-gaap_StockholdersEquity_6E7FB04C0A4604AD6E19547353D7D808" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ADBB05047361FF6E8022547353D77A13_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_ADBB05047361FF6E8022547353D77A13" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ADBB05047361FF6E8022547353D77A13_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_ADBB05047361FF6E8022547353D77A13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ADBB05047361FF6E8022547353D77A13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ADBB05047361FF6E8022547353D77A13" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_ADBB05047361FF6E8022547353D77A13" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_B02825F708B17E63BEB2EBCCD1D9D4A6_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_B02825F708B17E63BEB2EBCCD1D9D4A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_B02825F708B17E63BEB2EBCCD1D9D4A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_B02825F708B17E63BEB2EBCCD1D9D4A6" xlink:to="lab_us-gaap_SubsequentEventsAbstract_B02825F708B17E63BEB2EBCCD1D9D4A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_682E362F6E26EA7CB5C2EBCCF779550C_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_682E362F6E26EA7CB5C2EBCCF779550C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_682E362F6E26EA7CB5C2EBCCF779550C_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_682E362F6E26EA7CB5C2EBCCF779550C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_682E362F6E26EA7CB5C2EBCCF779550C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_682E362F6E26EA7CB5C2EBCCF779550C" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_682E362F6E26EA7CB5C2EBCCF779550C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_0C00620B28F490E409B04AE4D62F4D60_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_0C00620B28F490E409B04AE4D62F4D60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_0C00620B28F490E409B04AE4D62F4D60_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_0C00620B28F490E409B04AE4D62F4D60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0C00620B28F490E409B04AE4D62F4D60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_0C00620B28F490E409B04AE4D62F4D60" xlink:to="lab_us-gaap_NumberOfOperatingSegments_0C00620B28F490E409B04AE4D62F4D60" xlink:type="arc" />
    <link:label id="lab_mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits_1A7996E0FA9E3EF6EDC34AE4D62FFDCE_terseLabel_en-US" xlink:label="lab_mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits_1A7996E0FA9E3EF6EDC34AE4D62FFDCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of financial institutions holding majority of Company cash and cash equivalents and investments in excess of federally insured limits</link:label>
    <link:label id="lab_mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits_1A7996E0FA9E3EF6EDC34AE4D62FFDCE_label_en-US" xlink:label="lab_mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits_1A7996E0FA9E3EF6EDC34AE4D62FFDCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Financial Institutions Holding Majority of Company Cash and Investments in Excess of Federally Insured Limits</link:label>
    <link:label id="lab_mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits_1A7996E0FA9E3EF6EDC34AE4D62FFDCE_documentation_en-US" xlink:label="lab_mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits_1A7996E0FA9E3EF6EDC34AE4D62FFDCE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Financial Institutions Holding Majority of Company Cash and Investments in Excess of Federally Insured Limits</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits" xlink:label="loc_mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits_1A7996E0FA9E3EF6EDC34AE4D62FFDCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits_1A7996E0FA9E3EF6EDC34AE4D62FFDCE" xlink:to="lab_mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits_1A7996E0FA9E3EF6EDC34AE4D62FFDCE" xlink:type="arc" />
    <link:label id="lab_mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum_CAC33A3CC63AB6E73BFD4AE4D6300081_terseLabel_en-US" xlink:label="lab_mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum_CAC33A3CC63AB6E73BFD4AE4D6300081" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual investment limit as a percentage of the total investment portfolio (percent)</link:label>
    <link:label id="lab_mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum_CAC33A3CC63AB6E73BFD4AE4D6300081_label_en-US" xlink:label="lab_mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum_CAC33A3CC63AB6E73BFD4AE4D6300081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual Investment, Percent of Investment Portfolio, Maximum</link:label>
    <link:label id="lab_mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum_CAC33A3CC63AB6E73BFD4AE4D6300081_documentation_en-US" xlink:label="lab_mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum_CAC33A3CC63AB6E73BFD4AE4D6300081" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Individual Investment, Percent of Investment Portfolio, Maximum</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum" xlink:label="loc_mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum_CAC33A3CC63AB6E73BFD4AE4D6300081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum_CAC33A3CC63AB6E73BFD4AE4D6300081" xlink:to="lab_mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum_CAC33A3CC63AB6E73BFD4AE4D6300081" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_E9A23F202D47BCCF494DEBE8B25CFCF6_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_E9A23F202D47BCCF494DEBE8B25CFCF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E9A23F202D47BCCF494DEBE8B25CFCF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E9A23F202D47BCCF494DEBE8B25CFCF6" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_E9A23F202D47BCCF494DEBE8B25CFCF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_089D619DD172FB831346EBE8E51B8CF7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_089D619DD172FB831346EBE8E51B8CF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_089D619DD172FB831346EBE8E51B8CF7_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_089D619DD172FB831346EBE8E51B8CF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Inputs, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_089D619DD172FB831346EBE8E51B8CF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_089D619DD172FB831346EBE8E51B8CF7" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_089D619DD172FB831346EBE8E51B8CF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_2885135CEBAA7D9A95865D29D77748C1_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_2885135CEBAA7D9A95865D29D77748C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_2885135CEBAA7D9A95865D29D77748C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2885135CEBAA7D9A95865D29D77748C1" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_2885135CEBAA7D9A95865D29D77748C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AffiliatedEntityMember_5C51CE3DD85A100DC87D5D29D7787698_terseLabel_en-US" xlink:label="lab_us-gaap_AffiliatedEntityMember_5C51CE3DD85A100DC87D5D29D7787698" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Velocity Pharmaceutical Development, LLC</link:label>
    <link:label id="lab_us-gaap_AffiliatedEntityMember_5C51CE3DD85A100DC87D5D29D7787698_label_en-US" xlink:label="lab_us-gaap_AffiliatedEntityMember_5C51CE3DD85A100DC87D5D29D7787698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AffiliatedEntityMember" xlink:label="loc_us-gaap_AffiliatedEntityMember_5C51CE3DD85A100DC87D5D29D7787698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AffiliatedEntityMember_5C51CE3DD85A100DC87D5D29D7787698" xlink:to="lab_us-gaap_AffiliatedEntityMember_5C51CE3DD85A100DC87D5D29D7787698" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_3F504CB3697B34D8A4155D29D778F8BF_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_3F504CB3697B34D8A4155D29D778F8BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_3F504CB3697B34D8A4155D29D778F8BF_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_3F504CB3697B34D8A4155D29D778F8BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3F504CB3697B34D8A4155D29D778F8BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3F504CB3697B34D8A4155D29D778F8BF" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_3F504CB3697B34D8A4155D29D778F8BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF" xlink:type="arc" />
    <link:label id="lab_mnlo_DevelopmentServicesFeesMember_132A3980A03AD2E252CF5D29D77889C5_terseLabel_en-US" xlink:label="lab_mnlo_DevelopmentServicesFeesMember_132A3980A03AD2E252CF5D29D77889C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Services Fees</link:label>
    <link:label id="lab_mnlo_DevelopmentServicesFeesMember_132A3980A03AD2E252CF5D29D77889C5_label_en-US" xlink:label="lab_mnlo_DevelopmentServicesFeesMember_132A3980A03AD2E252CF5D29D77889C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Services Fees [Member]</link:label>
    <link:label id="lab_mnlo_DevelopmentServicesFeesMember_132A3980A03AD2E252CF5D29D77889C5_documentation_en-US" xlink:label="lab_mnlo_DevelopmentServicesFeesMember_132A3980A03AD2E252CF5D29D77889C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Services Fees [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DevelopmentServicesFeesMember" xlink:label="loc_mnlo_DevelopmentServicesFeesMember_132A3980A03AD2E252CF5D29D77889C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DevelopmentServicesFeesMember_132A3980A03AD2E252CF5D29D77889C5" xlink:to="lab_mnlo_DevelopmentServicesFeesMember_132A3980A03AD2E252CF5D29D77889C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_B7A03D167A866811103F5D29D7786D1B_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_B7A03D167A866811103F5D29D7786D1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party expenses</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_B7A03D167A866811103F5D29D7786D1B_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_B7A03D167A866811103F5D29D7786D1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_B7A03D167A866811103F5D29D7786D1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_B7A03D167A866811103F5D29D7786D1B" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_B7A03D167A866811103F5D29D7786D1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_9D7428297C45AD7BBE775D29D779DB61_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_9D7428297C45AD7BBE775D29D779DB61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_9D7428297C45AD7BBE775D29D779DB61_label_en-US" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_9D7428297C45AD7BBE775D29D779DB61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9D7428297C45AD7BBE775D29D779DB61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9D7428297C45AD7BBE775D29D779DB61" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_9D7428297C45AD7BBE775D29D779DB61" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_A5D02DE734CD9F821B445440F8E7E2EF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_A5D02DE734CD9F821B445440F8E7E2EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_A5D02DE734CD9F821B445440F8E7E2EF_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_A5D02DE734CD9F821B445440F8E7E2EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A5D02DE734CD9F821B445440F8E7E2EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_A5D02DE734CD9F821B445440F8E7E2EF" xlink:to="lab_us-gaap_CommonStockMember_A5D02DE734CD9F821B445440F8E7E2EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_07219C9D3938D365D6DD5440F8E779C5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_07219C9D3938D365D6DD5440F8E779C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued for every share converted in reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_07219C9D3938D365D6DD5440F8E779C5_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_07219C9D3938D365D6DD5440F8E779C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_07219C9D3938D365D6DD5440F8E779C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_07219C9D3938D365D6DD5440F8E779C5" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_07219C9D3938D365D6DD5440F8E779C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_C0197288CF50800BE35568A0D066872F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_C0197288CF50800BE35568A0D066872F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C0197288CF50800BE35568A0D066872F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C0197288CF50800BE35568A0D066872F" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_C0197288CF50800BE35568A0D066872F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B1E3651CAD11DBD6CF1468A12C50D28C_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B1E3651CAD11DBD6CF1468A12C50D28C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B1E3651CAD11DBD6CF1468A12C50D28C_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B1E3651CAD11DBD6CF1468A12C50D28C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B1E3651CAD11DBD6CF1468A12C50D28C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B1E3651CAD11DBD6CF1468A12C50D28C" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B1E3651CAD11DBD6CF1468A12C50D28C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8A3A20CE7A1592DFEC9068A1912805AE_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8A3A20CE7A1592DFEC9068A1912805AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State Tax</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8A3A20CE7A1592DFEC9068A1912805AE_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8A3A20CE7A1592DFEC9068A1912805AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8A3A20CE7A1592DFEC9068A1912805AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8A3A20CE7A1592DFEC9068A1912805AE" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8A3A20CE7A1592DFEC9068A1912805AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_C496191FC650FE9C59D668A59601F410_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_C496191FC650FE9C59D668A59601F410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Permanent Differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_C496191FC650FE9C59D668A59601F410_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_C496191FC650FE9C59D668A59601F410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_C496191FC650FE9C59D668A59601F410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_C496191FC650FE9C59D668A59601F410" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_C496191FC650FE9C59D668A59601F410" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_78FEDAB4A1B0F0F015E468A20D1F8ADD_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_78FEDAB4A1B0F0F015E468A20D1F8ADD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_78FEDAB4A1B0F0F015E468A20D1F8ADD_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_78FEDAB4A1B0F0F015E468A20D1F8ADD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_78FEDAB4A1B0F0F015E468A20D1F8ADD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_78FEDAB4A1B0F0F015E468A20D1F8ADD" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_78FEDAB4A1B0F0F015E468A20D1F8ADD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A0FDD4A0675412A9402E68A2EEF71990_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A0FDD4A0675412A9402E68A2EEF71990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Business Credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A0FDD4A0675412A9402E68A2EEF71990_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A0FDD4A0675412A9402E68A2EEF71990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A0FDD4A0675412A9402E68A2EEF71990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A0FDD4A0675412A9402E68A2EEF71990" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A0FDD4A0675412A9402E68A2EEF71990" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_62911C3122C13146FAED68A379E5F1E9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_62911C3122C13146FAED68A379E5F1E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_62911C3122C13146FAED68A379E5F1E9_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_62911C3122C13146FAED68A379E5F1E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_62911C3122C13146FAED68A379E5F1E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_62911C3122C13146FAED68A379E5F1E9" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_62911C3122C13146FAED68A379E5F1E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_558F9B5EC7839920020068A3F800AFF3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_558F9B5EC7839920020068A3F800AFF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Reform - Tax Rate Change</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_558F9B5EC7839920020068A3F800AFF3_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_558F9B5EC7839920020068A3F800AFF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_558F9B5EC7839920020068A3F800AFF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_558F9B5EC7839920020068A3F800AFF3" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_558F9B5EC7839920020068A3F800AFF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952F266A6BA616D4C8B368A4E9CC8673_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952F266A6BA616D4C8B368A4E9CC8673" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952F266A6BA616D4C8B368A4E9CC8673_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952F266A6BA616D4C8B368A4E9CC8673" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952F266A6BA616D4C8B368A4E9CC8673" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952F266A6BA616D4C8B368A4E9CC8673" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952F266A6BA616D4C8B368A4E9CC8673" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6" xlink:to="lab_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_72D7BF51999EE868039F53A95C144638_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_72D7BF51999EE868039F53A95C144638" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_72D7BF51999EE868039F53A95C144638_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_72D7BF51999EE868039F53A95C144638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_72D7BF51999EE868039F53A95C144638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_72D7BF51999EE868039F53A95C144638" xlink:to="lab_us-gaap_OperatingExpensesAbstract_72D7BF51999EE868039F53A95C144638" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9026C0E984B62C0B04FA53A95C1458AA_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_9026C0E984B62C0B04FA53A95C1458AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9026C0E984B62C0B04FA53A95C1458AA_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_9026C0E984B62C0B04FA53A95C1458AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9026C0E984B62C0B04FA53A95C1458AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_9026C0E984B62C0B04FA53A95C1458AA" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_9026C0E984B62C0B04FA53A95C1458AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_349D7555D25A5BD2F31553A95C14FC8C_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_349D7555D25A5BD2F31553A95C14FC8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_349D7555D25A5BD2F31553A95C14FC8C_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_349D7555D25A5BD2F31553A95C14FC8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_349D7555D25A5BD2F31553A95C14FC8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_349D7555D25A5BD2F31553A95C14FC8C" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_349D7555D25A5BD2F31553A95C14FC8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_9C80744B8AE16B21468453A95C142DDE_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_9C80744B8AE16B21468453A95C142DDE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_9C80744B8AE16B21468453A95C142DDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_9C80744B8AE16B21468453A95C142DDE" xlink:to="lab_us-gaap_OperatingExpenses_9C80744B8AE16B21468453A95C142DDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_88BE9CD6D7A9160C375553A95C152A1E_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_88BE9CD6D7A9160C375553A95C152A1E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_88BE9CD6D7A9160C375553A95C152A1E_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_88BE9CD6D7A9160C375553A95C152A1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_88BE9CD6D7A9160C375553A95C152A1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_88BE9CD6D7A9160C375553A95C152A1E" xlink:to="lab_us-gaap_OperatingIncomeLoss_88BE9CD6D7A9160C375553A95C152A1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_018ED5A267F7A9902A1B53A95C156EF4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_018ED5A267F7A9902A1B53A95C156EF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income and other expense, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_018ED5A267F7A9902A1B53A95C156EF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_018ED5A267F7A9902A1B53A95C156EF4" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_018ED5A267F7A9902A1B53A95C156EF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_BDE4FFB770200FB3289353C4F5ABB9F1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_BDE4FFB770200FB3289353C4F5ABB9F1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BDE4FFB770200FB3289353C4F5ABB9F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_BDE4FFB770200FB3289353C4F5ABB9F1" xlink:to="lab_us-gaap_NetIncomeLoss_BDE4FFB770200FB3289353C4F5ABB9F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9ED7647C7114A17A242853A95C1511C7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9ED7647C7114A17A242853A95C1511C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9ED7647C7114A17A242853A95C1511C7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9ED7647C7114A17A242853A95C1511C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9ED7647C7114A17A242853A95C1511C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9ED7647C7114A17A242853A95C1511C7" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9ED7647C7114A17A242853A95C1511C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A89F081CF06E0470534053A95C158943_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A89F081CF06E0470534053A95C158943" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on available&#8209;for&#8209;sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A89F081CF06E0470534053A95C158943_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A89F081CF06E0470534053A95C158943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A89F081CF06E0470534053A95C158943" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A89F081CF06E0470534053A95C158943" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A89F081CF06E0470534053A95C158943" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5C711377DFA96CA3EFD153A95C15328C_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_5C711377DFA96CA3EFD153A95C15328C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5C711377DFA96CA3EFD153A95C15328C_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_5C711377DFA96CA3EFD153A95C15328C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5C711377DFA96CA3EFD153A95C15328C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5C711377DFA96CA3EFD153A95C15328C" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_5C711377DFA96CA3EFD153A95C15328C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_A933A40B183026813E1153A95C15F725_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_A933A40B183026813E1153A95C15F725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholder per share, basic and diluted (in USD per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_A933A40B183026813E1153A95C15F725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_A933A40B183026813E1153A95C15F725" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_A933A40B183026813E1153A95C15F725" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E9DAA91B4EC2690E7D2853A95C158A2E_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E9DAA91B4EC2690E7D2853A95C158A2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted&#8209;average number of common shares used to compute basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E9DAA91B4EC2690E7D2853A95C158A2E_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E9DAA91B4EC2690E7D2853A95C158A2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E9DAA91B4EC2690E7D2853A95C158A2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E9DAA91B4EC2690E7D2853A95C158A2E" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E9DAA91B4EC2690E7D2853A95C158A2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2F92A81335F0D7E2EC7330CCDCA5C4A6_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2F92A81335F0D7E2EC7330CCDCA5C4A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2F92A81335F0D7E2EC7330CCDCA5C4A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2F92A81335F0D7E2EC7330CCDCA5C4A6" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2F92A81335F0D7E2EC7330CCDCA5C4A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_B8C9F62AFDE97208F41B30CCDCB8E39E_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_B8C9F62AFDE97208F41B30CCDCB8E39E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheets Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_B8C9F62AFDE97208F41B30CCDCB8E39E_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_B8C9F62AFDE97208F41B30CCDCB8E39E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_B8C9F62AFDE97208F41B30CCDCB8E39E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_B8C9F62AFDE97208F41B30CCDCB8E39E" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_B8C9F62AFDE97208F41B30CCDCB8E39E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_31BB8128ED764ACB9BAD6464F4240FC0_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_31BB8128ED764ACB9BAD6464F4240FC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_31BB8128ED764ACB9BAD6464F4240FC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_31BB8128ED764ACB9BAD6464F4240FC0" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_31BB8128ED764ACB9BAD6464F4240FC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4D27D20ACD7AB76CD7CF6464F4332450_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_4D27D20ACD7AB76CD7CF6464F4332450" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4D27D20ACD7AB76CD7CF6464F4332450_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_4D27D20ACD7AB76CD7CF6464F4332450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4D27D20ACD7AB76CD7CF6464F4332450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4D27D20ACD7AB76CD7CF6464F4332450" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_4D27D20ACD7AB76CD7CF6464F4332450" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:to="lab_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_5A1D8A83A55D2D13CA9E6464F4336CF7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_5A1D8A83A55D2D13CA9E6464F4336CF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_5A1D8A83A55D2D13CA9E6464F4336CF7_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_5A1D8A83A55D2D13CA9E6464F4336CF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5A1D8A83A55D2D13CA9E6464F4336CF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_5A1D8A83A55D2D13CA9E6464F4336CF7" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_5A1D8A83A55D2D13CA9E6464F4336CF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_AB3B8CEDFC4D3644909A6464F433F8B9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_AB3B8CEDFC4D3644909A6464F433F8B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_AB3B8CEDFC4D3644909A6464F433F8B9_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_AB3B8CEDFC4D3644909A6464F433F8B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_AB3B8CEDFC4D3644909A6464F433F8B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_AB3B8CEDFC4D3644909A6464F433F8B9" xlink:to="lab_us-gaap_RetainedEarningsMember_AB3B8CEDFC4D3644909A6464F433F8B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C04A7DA8254487A7F7236464F4331D26_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C04A7DA8254487A7F7236464F4331D26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C04A7DA8254487A7F7236464F4331D26_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C04A7DA8254487A7F7236464F4331D26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C04A7DA8254487A7F7236464F4331D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C04A7DA8254487A7F7236464F4331D26" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C04A7DA8254487A7F7236464F4331D26" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_3B47CC0B91973CB3CD966464F43312B4_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_3B47CC0B91973CB3CD966464F43312B4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, beginning</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_3B47CC0B91973CB3CD966464F43312B4_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_3B47CC0B91973CB3CD966464F43312B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3B47CC0B91973CB3CD966464F43312B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_3B47CC0B91973CB3CD966464F43312B4" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_3B47CC0B91973CB3CD966464F43312B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_62CA0E50A3E9E144C0006464F433F927_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_62CA0E50A3E9E144C0006464F433F927" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, beginning</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_62CA0E50A3E9E144C0006464F433F927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_62CA0E50A3E9E144C0006464F433F927" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_62CA0E50A3E9E144C0006464F433F927" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_FA01CE1596FEF4AEA1116464F433C0C5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_FA01CE1596FEF4AEA1116464F433C0C5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Common stock, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_FA01CE1596FEF4AEA1116464F433C0C5_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_FA01CE1596FEF4AEA1116464F433C0C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_FA01CE1596FEF4AEA1116464F433C0C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_FA01CE1596FEF4AEA1116464F433C0C5" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_FA01CE1596FEF4AEA1116464F433C0C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_B0ABB02879A3D16834476464F433A1C5_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_B0ABB02879A3D16834476464F433A1C5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B0ABB02879A3D16834476464F433A1C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_B0ABB02879A3D16834476464F433A1C5" xlink:to="lab_us-gaap_StockholdersEquity_B0ABB02879A3D16834476464F433A1C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_F855665F541DCEC3D9AD6464F43300E0_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_F855665F541DCEC3D9AD6464F43300E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of preferred stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_F855665F541DCEC3D9AD6464F43300E0_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_F855665F541DCEC3D9AD6464F43300E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_F855665F541DCEC3D9AD6464F43300E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_F855665F541DCEC3D9AD6464F43300E0" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_F855665F541DCEC3D9AD6464F43300E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81A03DCDAD8668A3CE4F6464F433A546_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81A03DCDAD8668A3CE4F6464F433A546" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of unvested stock options (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81A03DCDAD8668A3CE4F6464F433A546_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81A03DCDAD8668A3CE4F6464F433A546" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81A03DCDAD8668A3CE4F6464F433A546" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81A03DCDAD8668A3CE4F6464F433A546" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81A03DCDAD8668A3CE4F6464F433A546" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10C5E5077D6F9D568C066464F4335341_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10C5E5077D6F9D568C066464F4335341" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock on exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10C5E5077D6F9D568C066464F4335341_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10C5E5077D6F9D568C066464F4335341" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10C5E5077D6F9D568C066464F4335341" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10C5E5077D6F9D568C066464F4335341" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10C5E5077D6F9D568C066464F4335341" xlink:type="arc" />
    <link:label id="lab_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions_674A741A50BF824EB2E56464F433AA54_terseLabel_en-US" xlink:label="lab_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions_674A741A50BF824EB2E56464F433AA54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of early exercised stock options</link:label>
    <link:label id="lab_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions_674A741A50BF824EB2E56464F433AA54_label_en-US" xlink:label="lab_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions_674A741A50BF824EB2E56464F433AA54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Additional Paid-in Capital, Vesting of Early Exercised Stock Options</link:label>
    <link:label id="lab_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions_674A741A50BF824EB2E56464F433AA54_documentation_en-US" xlink:label="lab_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions_674A741A50BF824EB2E56464F433AA54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustment to Additional Paid-in Capital, Vesting of Early Exercised Stock Options</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions" xlink:label="loc_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions_674A741A50BF824EB2E56464F433AA54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions_674A741A50BF824EB2E56464F433AA54" xlink:to="lab_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions_674A741A50BF824EB2E56464F433AA54" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_38A2759AA8B1DFE78DEF6464F433DF4F_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_38A2759AA8B1DFE78DEF6464F433DF4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_38A2759AA8B1DFE78DEF6464F433DF4F_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_38A2759AA8B1DFE78DEF6464F433DF4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_38A2759AA8B1DFE78DEF6464F433DF4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_38A2759AA8B1DFE78DEF6464F433DF4F" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_38A2759AA8B1DFE78DEF6464F433DF4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_45524479744F3FCDEA246464F4337C48_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_45524479744F3FCDEA246464F4337C48" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, ending</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_45524479744F3FCDEA246464F4337C48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_45524479744F3FCDEA246464F4337C48" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_45524479744F3FCDEA246464F4337C48" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1924CF3B8B12719C74636464F4338DB2_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1924CF3B8B12719C74636464F4338DB2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, ending</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1924CF3B8B12719C74636464F4338DB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1924CF3B8B12719C74636464F4338DB2" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1924CF3B8B12719C74636464F4338DB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8A4E8635CAC39784A8F46464F4331574_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_8A4E8635CAC39784A8F46464F4331574" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Common stock, ending (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8A4E8635CAC39784A8F46464F4331574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_8A4E8635CAC39784A8F46464F4331574" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_8A4E8635CAC39784A8F46464F4331574" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_81B5331326B5CA2613E46464F433EB83_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_81B5331326B5CA2613E46464F433EB83" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, ending</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_81B5331326B5CA2613E46464F433EB83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_81B5331326B5CA2613E46464F433EB83" xlink:to="lab_us-gaap_StockholdersEquity_81B5331326B5CA2613E46464F433EB83" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_590FF1AF4A1CBDCB15A36464F3B7E093_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_590FF1AF4A1CBDCB15A36464F3B7E093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_590FF1AF4A1CBDCB15A36464F3B7E093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_590FF1AF4A1CBDCB15A36464F3B7E093" xlink:to="lab_us-gaap_EarningsPerShareAbstract_590FF1AF4A1CBDCB15A36464F3B7E093" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_5D8C885C4F339E8EB6E66464F3B7D682_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_5D8C885C4F339E8EB6E66464F3B7D682" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_5D8C885C4F339E8EB6E66464F3B7D682_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_5D8C885C4F339E8EB6E66464F3B7D682" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_5D8C885C4F339E8EB6E66464F3B7D682" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_5D8C885C4F339E8EB6E66464F3B7D682" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_5D8C885C4F339E8EB6E66464F3B7D682" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_E00FF9D810C4012603DD6464F3B79691_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_E00FF9D810C4012603DD6464F3B79691" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders, basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_E00FF9D810C4012603DD6464F3B79691_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_E00FF9D810C4012603DD6464F3B79691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_E00FF9D810C4012603DD6464F3B79691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_E00FF9D810C4012603DD6464F3B79691" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_E00FF9D810C4012603DD6464F3B79691" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5CC135FAD56F23D3C7336464F3B7BB59_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5CC135FAD56F23D3C7336464F3B7BB59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders, diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5CC135FAD56F23D3C7336464F3B7BB59_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5CC135FAD56F23D3C7336464F3B7BB59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5CC135FAD56F23D3C7336464F3B7BB59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5CC135FAD56F23D3C7336464F3B7BB59" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5CC135FAD56F23D3C7336464F3B7BB59" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_235AAEB003DBD46F78896464F3B7699E_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract_235AAEB003DBD46F78896464F3B7699E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_235AAEB003DBD46F78896464F3B7699E_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract_235AAEB003DBD46F78896464F3B7699E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_235AAEB003DBD46F78896464F3B7699E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_235AAEB003DBD46F78896464F3B7699E" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract_235AAEB003DBD46F78896464F3B7699E" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_40EDA1C4DDFCA8ABD5BE6464F3C62982_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_40EDA1C4DDFCA8ABD5BE6464F3C62982" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted&#8209;average common shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_40EDA1C4DDFCA8ABD5BE6464F3C62982_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_40EDA1C4DDFCA8ABD5BE6464F3C62982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_40EDA1C4DDFCA8ABD5BE6464F3C62982" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_40EDA1C4DDFCA8ABD5BE6464F3C62982" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_40EDA1C4DDFCA8ABD5BE6464F3C62982" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_55E359171D5F82D189FD6464F3C646B1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_55E359171D5F82D189FD6464F3C646B1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: weighted&#8209;average common shares subject to repurchase (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_55E359171D5F82D189FD6464F3C646B1_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_55E359171D5F82D189FD6464F3C646B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_55E359171D5F82D189FD6464F3C646B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_55E359171D5F82D189FD6464F3C646B1" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_55E359171D5F82D189FD6464F3C646B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4120E87D3B2341DDF6876464F3C6C906_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4120E87D3B2341DDF6876464F3C6C906" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted&#8209;average number of common shares used to compute basic and diluted net loss per share (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4120E87D3B2341DDF6876464F3C6C906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4120E87D3B2341DDF6876464F3C6C906" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4120E87D3B2341DDF6876464F3C6C906" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_29894A4123E05C3DD3BB6464F3C672BE_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_29894A4123E05C3DD3BB6464F3C672BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share attributable to common stockholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_29894A4123E05C3DD3BB6464F3C672BE_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_29894A4123E05C3DD3BB6464F3C672BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_29894A4123E05C3DD3BB6464F3C672BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_29894A4123E05C3DD3BB6464F3C672BE" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_29894A4123E05C3DD3BB6464F3C672BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_8BAF892C463D657F2EC66464F3C66F4F_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_8BAF892C463D657F2EC66464F3C66F4F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in USD per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_8BAF892C463D657F2EC66464F3C66F4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_8BAF892C463D657F2EC66464F3C66F4F" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_8BAF892C463D657F2EC66464F3C66F4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_511C994564CB7B7CED623035021AB5EC_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_511C994564CB7B7CED623035021AB5EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_511C994564CB7B7CED623035021AB5EC_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_511C994564CB7B7CED623035021AB5EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_511C994564CB7B7CED623035021AB5EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_511C994564CB7B7CED623035021AB5EC" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_511C994564CB7B7CED623035021AB5EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_692B5417E6636DC121266463C6A0D22C_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_692B5417E6636DC121266463C6A0D22C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_692B5417E6636DC121266463C6A0D22C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_692B5417E6636DC121266463C6A0D22C" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_692B5417E6636DC121266463C6A0D22C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_41C1935E0DC1DDF250056463C6A609F0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_41C1935E0DC1DDF250056463C6A609F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_41C1935E0DC1DDF250056463C6A609F0_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_41C1935E0DC1DDF250056463C6A609F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_41C1935E0DC1DDF250056463C6A609F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_41C1935E0DC1DDF250056463C6A609F0" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_41C1935E0DC1DDF250056463C6A609F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_F9C6475353D32A11657D6463C6A77C30_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_F9C6475353D32A11657D6463C6A77C30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_F9C6475353D32A11657D6463C6A77C30_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_F9C6475353D32A11657D6463C6A77C30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F9C6475353D32A11657D6463C6A77C30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F9C6475353D32A11657D6463C6A77C30" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_F9C6475353D32A11657D6463C6A77C30" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6243FAC9897CB9670E396463C6A8FA99_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6243FAC9897CB9670E396463C6A8FA99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6243FAC9897CB9670E396463C6A8FA99_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6243FAC9897CB9670E396463C6A8FA99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6243FAC9897CB9670E396463C6A8FA99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6243FAC9897CB9670E396463C6A8FA99" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6243FAC9897CB9670E396463C6A8FA99" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_D6B238F288A01E328D1A6463C6A8EB9A_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_D6B238F288A01E328D1A6463C6A8EB9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_D6B238F288A01E328D1A6463C6A8EB9A_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_D6B238F288A01E328D1A6463C6A8EB9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D6B238F288A01E328D1A6463C6A8EB9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_D6B238F288A01E328D1A6463C6A8EB9A" xlink:to="lab_us-gaap_PlanNameAxis_D6B238F288A01E328D1A6463C6A8EB9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F" xlink:to="lab_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F" xlink:type="arc" />
    <link:label id="lab_mnlo_A2011StockIncentivePlanMember_7E332082A30912BC59A76463C6A94A29_terseLabel_en-US" xlink:label="lab_mnlo_A2011StockIncentivePlanMember_7E332082A30912BC59A76463C6A94A29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2011 Stock Incentive Plan</link:label>
    <link:label id="lab_mnlo_A2011StockIncentivePlanMember_7E332082A30912BC59A76463C6A94A29_label_en-US" xlink:label="lab_mnlo_A2011StockIncentivePlanMember_7E332082A30912BC59A76463C6A94A29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2011 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_mnlo_A2011StockIncentivePlanMember_7E332082A30912BC59A76463C6A94A29_documentation_en-US" xlink:label="lab_mnlo_A2011StockIncentivePlanMember_7E332082A30912BC59A76463C6A94A29" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2011 Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_A2011StockIncentivePlanMember" xlink:label="loc_mnlo_A2011StockIncentivePlanMember_7E332082A30912BC59A76463C6A94A29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_A2011StockIncentivePlanMember_7E332082A30912BC59A76463C6A94A29" xlink:to="lab_mnlo_A2011StockIncentivePlanMember_7E332082A30912BC59A76463C6A94A29" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_CCD422B88F644F9F86966463C6A9927B_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_CCD422B88F644F9F86966463C6A9927B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_CCD422B88F644F9F86966463C6A9927B_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_CCD422B88F644F9F86966463C6A9927B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_CCD422B88F644F9F86966463C6A9927B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_CCD422B88F644F9F86966463C6A9927B" xlink:to="lab_us-gaap_AwardTypeAxis_CCD422B88F644F9F86966463C6A9927B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_398ADF63D92662CDC5206463C6A95440_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_398ADF63D92662CDC5206463C6A95440" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_398ADF63D92662CDC5206463C6A95440_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_398ADF63D92662CDC5206463C6A95440" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_398ADF63D92662CDC5206463C6A95440" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_398ADF63D92662CDC5206463C6A95440" xlink:to="lab_us-gaap_EmployeeStockOptionMember_398ADF63D92662CDC5206463C6A95440" xlink:type="arc" />
    <link:label id="lab_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_38DD10CD3D0544AC85AC6463C6A96E78_terseLabel_en-US" xlink:label="lab_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_38DD10CD3D0544AC85AC6463C6A96E78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive Stock Option Granted to Stockholder Holding 10% of the Company's Outstanding Capitalization</link:label>
    <link:label id="lab_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_38DD10CD3D0544AC85AC6463C6A96E78_label_en-US" xlink:label="lab_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_38DD10CD3D0544AC85AC6463C6A96E78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Stock Option Granted to Stockholder Holding 10% of the Company's Outstanding Capitalization [Member]</link:label>
    <link:label id="lab_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_38DD10CD3D0544AC85AC6463C6A96E78_documentation_en-US" xlink:label="lab_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_38DD10CD3D0544AC85AC6463C6A96E78" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive Stock Option Granted to Stockholder Holding 10% of the Company's Outstanding Capitalization [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember" xlink:label="loc_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_38DD10CD3D0544AC85AC6463C6A96E78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_38DD10CD3D0544AC85AC6463C6A96E78" xlink:to="lab_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_38DD10CD3D0544AC85AC6463C6A96E78" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_1D399AF334D489DF92756463C6A943E4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_1D399AF334D489DF92756463C6A943E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_1D399AF334D489DF92756463C6A943E4_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_1D399AF334D489DF92756463C6A943E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1D399AF334D489DF92756463C6A943E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_1D399AF334D489DF92756463C6A943E4" xlink:to="lab_us-gaap_RestrictedStockMember_1D399AF334D489DF92756463C6A943E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_ED961E995D526E3E6D846463C6A90513_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_ED961E995D526E3E6D846463C6A90513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_ED961E995D526E3E6D846463C6A90513_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_ED961E995D526E3E6D846463C6A90513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_ED961E995D526E3E6D846463C6A90513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_ED961E995D526E3E6D846463C6A90513" xlink:to="lab_us-gaap_TitleOfIndividualAxis_ED961E995D526E3E6D846463C6A90513" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9" xlink:type="arc" />
    <link:label id="lab_mnlo_EmployeesandDirectorsMember_B8298CB731192FBAABAF6463C6AADC31_terseLabel_en-US" xlink:label="lab_mnlo_EmployeesandDirectorsMember_B8298CB731192FBAABAF6463C6AADC31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_mnlo_EmployeesandDirectorsMember_B8298CB731192FBAABAF6463C6AADC31_label_en-US" xlink:label="lab_mnlo_EmployeesandDirectorsMember_B8298CB731192FBAABAF6463C6AADC31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_mnlo_EmployeesandDirectorsMember_B8298CB731192FBAABAF6463C6AADC31_documentation_en-US" xlink:label="lab_mnlo_EmployeesandDirectorsMember_B8298CB731192FBAABAF6463C6AADC31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_EmployeesandDirectorsMember" xlink:label="loc_mnlo_EmployeesandDirectorsMember_B8298CB731192FBAABAF6463C6AADC31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_EmployeesandDirectorsMember_B8298CB731192FBAABAF6463C6AADC31" xlink:to="lab_mnlo_EmployeesandDirectorsMember_B8298CB731192FBAABAF6463C6AADC31" xlink:type="arc" />
    <link:label id="lab_mnlo_NonemployeeMember_2CBCD260606739A54C466463C6AA3ABD_terseLabel_en-US" xlink:label="lab_mnlo_NonemployeeMember_2CBCD260606739A54C466463C6AA3ABD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-employees</link:label>
    <link:label id="lab_mnlo_NonemployeeMember_2CBCD260606739A54C466463C6AA3ABD_label_en-US" xlink:label="lab_mnlo_NonemployeeMember_2CBCD260606739A54C466463C6AA3ABD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-employee [Member]</link:label>
    <link:label id="lab_mnlo_NonemployeeMember_2CBCD260606739A54C466463C6AA3ABD_documentation_en-US" xlink:label="lab_mnlo_NonemployeeMember_2CBCD260606739A54C466463C6AA3ABD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-employee [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NonemployeeMember" xlink:label="loc_mnlo_NonemployeeMember_2CBCD260606739A54C466463C6AA3ABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_NonemployeeMember_2CBCD260606739A54C466463C6AA3ABD" xlink:to="lab_mnlo_NonemployeeMember_2CBCD260606739A54C466463C6AA3ABD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2D6CF7F2691BA26F51E66463C6AA7A4B_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2D6CF7F2691BA26F51E66463C6AA7A4B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares available under the Plan (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2D6CF7F2691BA26F51E66463C6AA7A4B_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2D6CF7F2691BA26F51E66463C6AA7A4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2D6CF7F2691BA26F51E66463C6AA7A4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2D6CF7F2691BA26F51E66463C6AA7A4B" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2D6CF7F2691BA26F51E66463C6AA7A4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FECD37FBE3EBC0BEF4C86463C6AA1F93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FECD37FBE3EBC0BEF4C86463C6AA1F93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for issuenace under the Plan (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FECD37FBE3EBC0BEF4C86463C6AA1F93_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FECD37FBE3EBC0BEF4C86463C6AA1F93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FECD37FBE3EBC0BEF4C86463C6AA1F93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FECD37FBE3EBC0BEF4C86463C6AA1F93" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FECD37FBE3EBC0BEF4C86463C6AA1F93" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E2184FD7D24BDBB38D056463C6AAAEEF_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E2184FD7D24BDBB38D056463C6AAAEEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise price as a percent of fair value on grant date (percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E2184FD7D24BDBB38D056463C6AAAEEF_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E2184FD7D24BDBB38D056463C6AAAEEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E2184FD7D24BDBB38D056463C6AAAEEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E2184FD7D24BDBB38D056463C6AAAEEF" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E2184FD7D24BDBB38D056463C6AAAEEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D492FA825C9CF1E3FDB46463C6AA36BB_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D492FA825C9CF1E3FDB46463C6AA36BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D492FA825C9CF1E3FDB46463C6AA36BB_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D492FA825C9CF1E3FDB46463C6AA36BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D492FA825C9CF1E3FDB46463C6AA36BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D492FA825C9CF1E3FDB46463C6AA36BB" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D492FA825C9CF1E3FDB46463C6AA36BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61618D4D06FA5616ED9E6463C6AA63C6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61618D4D06FA5616ED9E6463C6AA63C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61618D4D06FA5616ED9E6463C6AA63C6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61618D4D06FA5616ED9E6463C6AA63C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61618D4D06FA5616ED9E6463C6AA63C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61618D4D06FA5616ED9E6463C6AA63C6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61618D4D06FA5616ED9E6463C6AA63C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_EF2449E21CEFB6604E736463C6ABA77E_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_EF2449E21CEFB6604E736463C6ABA77E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock&#8209;based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_EF2449E21CEFB6604E736463C6ABA77E_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_EF2449E21CEFB6604E736463C6ABA77E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_EF2449E21CEFB6604E736463C6ABA77E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_EF2449E21CEFB6604E736463C6ABA77E" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_EF2449E21CEFB6604E736463C6ABA77E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_31F9CFF3BBA1D0A97A006463C6ABB86A_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_31F9CFF3BBA1D0A97A006463C6ABB86A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_31F9CFF3BBA1D0A97A006463C6ABB86A_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_31F9CFF3BBA1D0A97A006463C6ABB86A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_31F9CFF3BBA1D0A97A006463C6ABB86A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_31F9CFF3BBA1D0A97A006463C6ABB86A" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_31F9CFF3BBA1D0A97A006463C6ABB86A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56DDB42576D3097F6BBD6463C6ABCB71_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56DDB42576D3097F6BBD6463C6ABCB71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized compensation expense, recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56DDB42576D3097F6BBD6463C6ABCB71_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56DDB42576D3097F6BBD6463C6ABCB71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56DDB42576D3097F6BBD6463C6ABCB71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56DDB42576D3097F6BBD6463C6ABCB71" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56DDB42576D3097F6BBD6463C6ABCB71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_B6D72782CC9CC0443BB36463C6AB1B59_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_B6D72782CC9CC0443BB36463C6AB1B59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_B6D72782CC9CC0443BB36463C6AB1B59_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_B6D72782CC9CC0443BB36463C6AB1B59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_B6D72782CC9CC0443BB36463C6AB1B59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_B6D72782CC9CC0443BB36463C6AB1B59" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_B6D72782CC9CC0443BB36463C6AB1B59" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B82CC86397E8807BC2B46463C6ABE103_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B82CC86397E8807BC2B46463C6ABE103" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Early exercised restricted shares that had not vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B82CC86397E8807BC2B46463C6ABE103_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B82CC86397E8807BC2B46463C6ABE103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B82CC86397E8807BC2B46463C6ABE103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B82CC86397E8807BC2B46463C6ABE103" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B82CC86397E8807BC2B46463C6ABE103" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_92A44FC979D6053EC9EA6463C6AB4A7B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_92A44FC979D6053EC9EA6463C6AB4A7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability for early exercise of stock options</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_92A44FC979D6053EC9EA6463C6AB4A7B_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_92A44FC979D6053EC9EA6463C6AB4A7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_92A44FC979D6053EC9EA6463C6AB4A7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_92A44FC979D6053EC9EA6463C6AB4A7B" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_92A44FC979D6053EC9EA6463C6AB4A7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8DF52612E8726CC9815B6463C6AB39AA_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8DF52612E8726CC9815B6463C6AB39AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate grant date fair value of options vested during the year</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8DF52612E8726CC9815B6463C6AB39AA_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8DF52612E8726CC9815B6463C6AB39AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8DF52612E8726CC9815B6463C6AB39AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8DF52612E8726CC9815B6463C6AB39AA" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8DF52612E8726CC9815B6463C6AB39AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D632F2AA6B1279291F7D6463C6ABA913_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D632F2AA6B1279291F7D6463C6ABA913" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate instrinsic value of shares exercised during the year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D632F2AA6B1279291F7D6463C6ABA913_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D632F2AA6B1279291F7D6463C6ABA913" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D632F2AA6B1279291F7D6463C6ABA913" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D632F2AA6B1279291F7D6463C6ABA913" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D632F2AA6B1279291F7D6463C6ABA913" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF0BF0A4BF82A6F39C1C6466051DD965_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF0BF0A4BF82A6F39C1C6466051DD965" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value of options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF0BF0A4BF82A6F39C1C6466051DD965_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF0BF0A4BF82A6F39C1C6466051DD965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF0BF0A4BF82A6F39C1C6466051DD965" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF0BF0A4BF82A6F39C1C6466051DD965" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF0BF0A4BF82A6F39C1C6466051DD965" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7FA079CD0EC22D9A5D026463C6ABADB2_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7FA079CD0EC22D9A5D026463C6ABADB2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options exercised during the year (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7FA079CD0EC22D9A5D026463C6ABADB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7FA079CD0EC22D9A5D026463C6ABADB2" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7FA079CD0EC22D9A5D026463C6ABADB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_A6617438F2351B0714E83023C6F92499_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_A6617438F2351B0714E83023C6F92499" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_A6617438F2351B0714E83023C6F92499_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_A6617438F2351B0714E83023C6F92499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_A6617438F2351B0714E83023C6F92499" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_A6617438F2351B0714E83023C6F92499" xlink:to="lab_us-gaap_PreferredStockMember_A6617438F2351B0714E83023C6F92499" xlink:type="arc" />
    <link:label id="lab_mnlo_TemporaryEquityStockIssuedIssuanceCosts_4DB0282211CF889D5FEA302CB9285EB0_terseLabel_en-US" xlink:label="lab_mnlo_TemporaryEquityStockIssuedIssuanceCosts_4DB0282211CF889D5FEA302CB9285EB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock issuance costs</link:label>
    <link:label id="lab_mnlo_TemporaryEquityStockIssuedIssuanceCosts_4DB0282211CF889D5FEA302CB9285EB0_label_en-US" xlink:label="lab_mnlo_TemporaryEquityStockIssuedIssuanceCosts_4DB0282211CF889D5FEA302CB9285EB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued, Issuance Costs</link:label>
    <link:label id="lab_mnlo_TemporaryEquityStockIssuedIssuanceCosts_4DB0282211CF889D5FEA302CB9285EB0_documentation_en-US" xlink:label="lab_mnlo_TemporaryEquityStockIssuedIssuanceCosts_4DB0282211CF889D5FEA302CB9285EB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityStockIssuedIssuanceCosts" xlink:label="loc_mnlo_TemporaryEquityStockIssuedIssuanceCosts_4DB0282211CF889D5FEA302CB9285EB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_TemporaryEquityStockIssuedIssuanceCosts_4DB0282211CF889D5FEA302CB9285EB0" xlink:to="lab_mnlo_TemporaryEquityStockIssuedIssuanceCosts_4DB0282211CF889D5FEA302CB9285EB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AC807EB2C69F471981A0546789B82572_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AC807EB2C69F471981A0546789B82572" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOLs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AC807EB2C69F471981A0546789B82572_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AC807EB2C69F471981A0546789B82572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AC807EB2C69F471981A0546789B82572" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AC807EB2C69F471981A0546789B82572" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AC807EB2C69F471981A0546789B82572" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E8F439C70EEB60F49D90546789B99775_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E8F439C70EEB60F49D90546789B99775" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E8F439C70EEB60F49D90546789B99775_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E8F439C70EEB60F49D90546789B99775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E8F439C70EEB60F49D90546789B99775" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E8F439C70EEB60F49D90546789B99775" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E8F439C70EEB60F49D90546789B99775" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0978FBE91FA974E260F0546789B90024_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0978FBE91FA974E260F0546789B90024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock&#8209;Based Compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0978FBE91FA974E260F0546789B90024_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0978FBE91FA974E260F0546789B90024" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0978FBE91FA974E260F0546789B90024" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0978FBE91FA974E260F0546789B90024" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0978FBE91FA974E260F0546789B90024" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_22D6CB0F82A5DE646835546789B979A4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_22D6CB0F82A5DE646835546789B979A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research &amp; Development Credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_22D6CB0F82A5DE646835546789B979A4_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_22D6CB0F82A5DE646835546789B979A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_22D6CB0F82A5DE646835546789B979A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_22D6CB0F82A5DE646835546789B979A4" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_22D6CB0F82A5DE646835546789B979A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_4D335F2BB0B385F235B5546789B9C500_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_4D335F2BB0B385F235B5546789B9C500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_4D335F2BB0B385F235B5546789B9C500_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_4D335F2BB0B385F235B5546789B9C500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_4D335F2BB0B385F235B5546789B9C500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_4D335F2BB0B385F235B5546789B9C500" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_4D335F2BB0B385F235B5546789B9C500" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_55DD62A32B624873154F546789B984DD_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_55DD62A32B624873154F546789B984DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_55DD62A32B624873154F546789B984DD_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_55DD62A32B624873154F546789B984DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_55DD62A32B624873154F546789B984DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_55DD62A32B624873154F546789B984DD" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_55DD62A32B624873154F546789B984DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_03B3788A48E574C22D86546789BEC492_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_03B3788A48E574C22D86546789BEC492" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_03B3788A48E574C22D86546789BEC492_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_03B3788A48E574C22D86546789BEC492" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_03B3788A48E574C22D86546789BEC492" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_03B3788A48E574C22D86546789BEC492" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_03B3788A48E574C22D86546789BEC492" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_BE7F3F6E3C5F9F151669546789BF1657_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_BE7F3F6E3C5F9F151669546789BF1657" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_BE7F3F6E3C5F9F151669546789BF1657_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_BE7F3F6E3C5F9F151669546789BF1657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_BE7F3F6E3C5F9F151669546789BF1657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_BE7F3F6E3C5F9F151669546789BF1657" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_BE7F3F6E3C5F9F151669546789BF1657" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_946CF531CC6FF3B76659546789BFE4AC_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_946CF531CC6FF3B76659546789BFE4AC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_946CF531CC6FF3B76659546789BFE4AC_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_946CF531CC6FF3B76659546789BFE4AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_946CF531CC6FF3B76659546789BFE4AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_946CF531CC6FF3B76659546789BFE4AC" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_946CF531CC6FF3B76659546789BFE4AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2521D9CE876BF9F1F87CEBD1C97399D6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_2521D9CE876BF9F1F87CEBD1C97399D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2521D9CE876BF9F1F87CEBD1C97399D6_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_2521D9CE876BF9F1F87CEBD1C97399D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2521D9CE876BF9F1F87CEBD1C97399D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_2521D9CE876BF9F1F87CEBD1C97399D6" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_2521D9CE876BF9F1F87CEBD1C97399D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_7B7E9F9842FFF7F774094958A77FE8B6_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_7B7E9F9842FFF7F774094958A77FE8B6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Benefit - beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_7B7E9F9842FFF7F774094958A77FE8B6_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_7B7E9F9842FFF7F774094958A77FE8B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7B7E9F9842FFF7F774094958A77FE8B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_7B7E9F9842FFF7F774094958A77FE8B6" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_7B7E9F9842FFF7F774094958A77FE8B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1EDA1904D91150CF90F54958A77F399B_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1EDA1904D91150CF90F54958A77F399B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Increases(Decreases) &#8209; prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1EDA1904D91150CF90F54958A77F399B_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1EDA1904D91150CF90F54958A77F399B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1EDA1904D91150CF90F54958A77F399B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1EDA1904D91150CF90F54958A77F399B" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1EDA1904D91150CF90F54958A77F399B" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C74211BA7E6D28CE8144958A77F1465_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C74211BA7E6D28CE8144958A77F1465" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Increases(Decreases) &#8209; current period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C74211BA7E6D28CE8144958A77F1465_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C74211BA7E6D28CE8144958A77F1465" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C74211BA7E6D28CE8144958A77F1465" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C74211BA7E6D28CE8144958A77F1465" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C74211BA7E6D28CE8144958A77F1465" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_65E675299D1156ABBB074958A78007B7_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_65E675299D1156ABBB074958A78007B7" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Benefit - end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_65E675299D1156ABBB074958A78007B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_65E675299D1156ABBB074958A78007B7" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_65E675299D1156ABBB074958A78007B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_6DE79C990D207A1E7DAB39C67DB87A32_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_6DE79C990D207A1E7DAB39C67DB87A32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock outstanding (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_6DE79C990D207A1E7DAB39C67DB87A32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_6DE79C990D207A1E7DAB39C67DB87A32" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_6DE79C990D207A1E7DAB39C67DB87A32" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_B999B711109CC691E0C8398BAEE7B7BC_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_B999B711109CC691E0C8398BAEE7B7BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, liquidation value</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_B999B711109CC691E0C8398BAEE7B7BC_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_B999B711109CC691E0C8398BAEE7B7BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_B999B711109CC691E0C8398BAEE7B7BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference_B999B711109CC691E0C8398BAEE7B7BC" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference_B999B711109CC691E0C8398BAEE7B7BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_2425DF1839D0252D1E1639AF20B37B4B_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_2425DF1839D0252D1E1639AF20B37B4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_2425DF1839D0252D1E1639AF20B37B4B_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_2425DF1839D0252D1E1639AF20B37B4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_2425DF1839D0252D1E1639AF20B37B4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued_2425DF1839D0252D1E1639AF20B37B4B" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued_2425DF1839D0252D1E1639AF20B37B4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_E40F2F28918A6982E6BC5D29D7E1442B_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_E40F2F28918A6982E6BC5D29D7E1442B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_E40F2F28918A6982E6BC5D29D7E1442B_label_en-US" xlink:label="lab_us-gaap_RangeAxis_E40F2F28918A6982E6BC5D29D7E1442B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E40F2F28918A6982E6BC5D29D7E1442B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_E40F2F28918A6982E6BC5D29D7E1442B" xlink:to="lab_us-gaap_RangeAxis_E40F2F28918A6982E6BC5D29D7E1442B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F_label_en-US" xlink:label="lab_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F" xlink:to="lab_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_0C698D6FB5FC5ECAE4915D29D7E1E0D4_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_0C698D6FB5FC5ECAE4915D29D7E1E0D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_0C698D6FB5FC5ECAE4915D29D7E1E0D4_label_en-US" xlink:label="lab_us-gaap_MinimumMember_0C698D6FB5FC5ECAE4915D29D7E1E0D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_0C698D6FB5FC5ECAE4915D29D7E1E0D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_0C698D6FB5FC5ECAE4915D29D7E1E0D4" xlink:to="lab_us-gaap_MinimumMember_0C698D6FB5FC5ECAE4915D29D7E1E0D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_D584E0443B12798192065D29D7E15E30_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_D584E0443B12798192065D29D7E15E30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_D584E0443B12798192065D29D7E15E30_label_en-US" xlink:label="lab_us-gaap_MaximumMember_D584E0443B12798192065D29D7E15E30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D584E0443B12798192065D29D7E15E30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_D584E0443B12798192065D29D7E15E30" xlink:to="lab_us-gaap_MaximumMember_D584E0443B12798192065D29D7E15E30" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_903A35C47239C7382A565D29D7E19DBF_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_903A35C47239C7382A565D29D7E19DBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_903A35C47239C7382A565D29D7E19DBF_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_903A35C47239C7382A565D29D7E19DBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_903A35C47239C7382A565D29D7E19DBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_903A35C47239C7382A565D29D7E19DBF" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_903A35C47239C7382A565D29D7E19DBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1B8C0DB0231871C85F375D29D7E2B382_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1B8C0DB0231871C85F375D29D7E2B382" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1B8C0DB0231871C85F375D29D7E2B382_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1B8C0DB0231871C85F375D29D7E2B382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1B8C0DB0231871C85F375D29D7E2B382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1B8C0DB0231871C85F375D29D7E2B382" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1B8C0DB0231871C85F375D29D7E2B382" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_34C74754058EB4A82DE15D29D7E228CE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_34C74754058EB4A82DE15D29D7E228CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility, minimum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_34C74754058EB4A82DE15D29D7E228CE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_34C74754058EB4A82DE15D29D7E228CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_34C74754058EB4A82DE15D29D7E228CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_34C74754058EB4A82DE15D29D7E228CE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_34C74754058EB4A82DE15D29D7E228CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9F9528D2EC15AABC777B5D29D7E23D9C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9F9528D2EC15AABC777B5D29D7E23D9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility, maximum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9F9528D2EC15AABC777B5D29D7E23D9C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9F9528D2EC15AABC777B5D29D7E23D9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9F9528D2EC15AABC777B5D29D7E23D9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9F9528D2EC15AABC777B5D29D7E23D9C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9F9528D2EC15AABC777B5D29D7E23D9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_A81F7AC8D88B7199116E5D29D7E21F65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_A81F7AC8D88B7199116E5D29D7E21F65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_A81F7AC8D88B7199116E5D29D7E21F65_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_A81F7AC8D88B7199116E5D29D7E21F65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_A81F7AC8D88B7199116E5D29D7E21F65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_A81F7AC8D88B7199116E5D29D7E21F65" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_A81F7AC8D88B7199116E5D29D7E21F65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_F76D0948D31F796C8B5B5D29D7E28756_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_F76D0948D31F796C8B5B5D29D7E28756" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_F76D0948D31F796C8B5B5D29D7E28756_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_F76D0948D31F796C8B5B5D29D7E28756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_F76D0948D31F796C8B5B5D29D7E28756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_F76D0948D31F796C8B5B5D29D7E28756" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_F76D0948D31F796C8B5B5D29D7E28756" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4768C5D4280F035A66145D29D7E2D8F4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4768C5D4280F035A66145D29D7E2D8F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4768C5D4280F035A66145D29D7E2D8F4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4768C5D4280F035A66145D29D7E2D8F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4768C5D4280F035A66145D29D7E2D8F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4768C5D4280F035A66145D29D7E2D8F4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4768C5D4280F035A66145D29D7E2D8F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FFE622846A4C96F3BE455D29D7E2719A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FFE622846A4C96F3BE455D29D7E2719A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FFE622846A4C96F3BE455D29D7E2719A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FFE622846A4C96F3BE455D29D7E2719A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FFE622846A4C96F3BE455D29D7E2719A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FFE622846A4C96F3BE455D29D7E2719A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FFE622846A4C96F3BE455D29D7E2719A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_19072DAC7640C1AFC3BB30CD479FECB6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_19072DAC7640C1AFC3BB30CD479FECB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued personnel expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_19072DAC7640C1AFC3BB30CD479FECB6_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_19072DAC7640C1AFC3BB30CD479FECB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_19072DAC7640C1AFC3BB30CD479FECB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_19072DAC7640C1AFC3BB30CD479FECB6" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_19072DAC7640C1AFC3BB30CD479FECB6" xlink:type="arc" />
    <link:label id="lab_mnlo_AccruedClinicalandDevelopmentExpenses_468F61F9913FF12365F930CD479F63D0_terseLabel_en-US" xlink:label="lab_mnlo_AccruedClinicalandDevelopmentExpenses_468F61F9913FF12365F930CD479F63D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical and development expenses</link:label>
    <link:label id="lab_mnlo_AccruedClinicalandDevelopmentExpenses_468F61F9913FF12365F930CD479F63D0_label_en-US" xlink:label="lab_mnlo_AccruedClinicalandDevelopmentExpenses_468F61F9913FF12365F930CD479F63D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical and Development Expenses</link:label>
    <link:label id="lab_mnlo_AccruedClinicalandDevelopmentExpenses_468F61F9913FF12365F930CD479F63D0_documentation_en-US" xlink:label="lab_mnlo_AccruedClinicalandDevelopmentExpenses_468F61F9913FF12365F930CD479F63D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical and Development Expenses</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_AccruedClinicalandDevelopmentExpenses" xlink:label="loc_mnlo_AccruedClinicalandDevelopmentExpenses_468F61F9913FF12365F930CD479F63D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_AccruedClinicalandDevelopmentExpenses_468F61F9913FF12365F930CD479F63D0" xlink:to="lab_mnlo_AccruedClinicalandDevelopmentExpenses_468F61F9913FF12365F930CD479F63D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AB0349559567C5721BB930CD479F7C26_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AB0349559567C5721BB930CD479F7C26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AB0349559567C5721BB930CD479F7C26_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AB0349559567C5721BB930CD479F7C26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AB0349559567C5721BB930CD479F7C26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_AB0349559567C5721BB930CD479F7C26" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_AB0349559567C5721BB930CD479F7C26" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_FBC0836ABE2BF4F1173930CD479F269A_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_FBC0836ABE2BF4F1173930CD479F269A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_FBC0836ABE2BF4F1173930CD479F269A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_FBC0836ABE2BF4F1173930CD479F269A" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_FBC0836ABE2BF4F1173930CD479F269A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_915E8665578954362099EBCEA7B27D94_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_915E8665578954362099EBCEA7B27D94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_915E8665578954362099EBCEA7B27D94_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_915E8665578954362099EBCEA7B27D94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_915E8665578954362099EBCEA7B27D94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_915E8665578954362099EBCEA7B27D94" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_915E8665578954362099EBCEA7B27D94" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5F3AA8A05C6E852FD42940E39CF9C292_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5F3AA8A05C6E852FD42940E39CF9C292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Unaudited Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5F3AA8A05C6E852FD42940E39CF9C292_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5F3AA8A05C6E852FD42940E39CF9C292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5F3AA8A05C6E852FD42940E39CF9C292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5F3AA8A05C6E852FD42940E39CF9C292" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5F3AA8A05C6E852FD42940E39CF9C292" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A7832E442E948136E6DE689F99209181_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A7832E442E948136E6DE689F99209181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A7832E442E948136E6DE689F99209181_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A7832E442E948136E6DE689F99209181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A7832E442E948136E6DE689F99209181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A7832E442E948136E6DE689F99209181" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A7832E442E948136E6DE689F99209181" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_D1D6E212226D5EDFFEE8689ED4A9E0EC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_D1D6E212226D5EDFFEE8689ED4A9E0EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_D1D6E212226D5EDFFEE8689ED4A9E0EC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_D1D6E212226D5EDFFEE8689ED4A9E0EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_D1D6E212226D5EDFFEE8689ED4A9E0EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_D1D6E212226D5EDFFEE8689ED4A9E0EC" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_D1D6E212226D5EDFFEE8689ED4A9E0EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_463F92A49139E5A9FC3E689ED4A95EC5_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_463F92A49139E5A9FC3E689ED4A95EC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_463F92A49139E5A9FC3E689ED4A95EC5_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_463F92A49139E5A9FC3E689ED4A95EC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_463F92A49139E5A9FC3E689ED4A95EC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_463F92A49139E5A9FC3E689ED4A95EC5" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_463F92A49139E5A9FC3E689ED4A95EC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8F50AFB5AF37DDBAB2195551CE480608_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8F50AFB5AF37DDBAB2195551CE480608" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8F50AFB5AF37DDBAB2195551CE480608_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8F50AFB5AF37DDBAB2195551CE480608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8F50AFB5AF37DDBAB2195551CE480608" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8F50AFB5AF37DDBAB2195551CE480608" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8F50AFB5AF37DDBAB2195551CE480608" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72" xlink:type="arc" />
    <link:label id="lab_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums_4D2F5D75F96ED24B42335551CE4B2D72_terseLabel_en-US" xlink:label="lab_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums_4D2F5D75F96ED24B42335551CE4B2D72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums_4D2F5D75F96ED24B42335551CE4B2D72_label_en-US" xlink:label="lab_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums_4D2F5D75F96ED24B42335551CE4B2D72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Excluding Amortization of Discounts and Premiums</link:label>
    <link:label id="lab_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums_4D2F5D75F96ED24B42335551CE4B2D72_documentation_en-US" xlink:label="lab_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums_4D2F5D75F96ED24B42335551CE4B2D72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Excluding Amortization of Discounts and Premiums</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums" xlink:label="loc_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums_4D2F5D75F96ED24B42335551CE4B2D72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums_4D2F5D75F96ED24B42335551CE4B2D72" xlink:to="lab_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums_4D2F5D75F96ED24B42335551CE4B2D72" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_BBD98ACCB7BED278EC045551CE4BBB50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_BBD98ACCB7BED278EC045551CE4BBB50" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on available&#8209;for&#8209;sale investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_BBD98ACCB7BED278EC045551CE4BBB50_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_BBD98ACCB7BED278EC045551CE4BBB50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_BBD98ACCB7BED278EC045551CE4BBB50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments_BBD98ACCB7BED278EC045551CE4BBB50" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments_BBD98ACCB7BED278EC045551CE4BBB50" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6EF7ADF0BC34A7C4E5525551CE509F6B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6EF7ADF0BC34A7C4E5525551CE509F6B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of premium on investment securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6EF7ADF0BC34A7C4E5525551CE509F6B_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6EF7ADF0BC34A7C4E5525551CE509F6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6EF7ADF0BC34A7C4E5525551CE509F6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6EF7ADF0BC34A7C4E5525551CE509F6B" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6EF7ADF0BC34A7C4E5525551CE509F6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_EB9AD7DA325DD3D3AD145551CE505061_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_EB9AD7DA325DD3D3AD145551CE505061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock&#8209;based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_EB9AD7DA325DD3D3AD145551CE505061_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_EB9AD7DA325DD3D3AD145551CE505061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_EB9AD7DA325DD3D3AD145551CE505061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_EB9AD7DA325DD3D3AD145551CE505061" xlink:to="lab_us-gaap_ShareBasedCompensation_EB9AD7DA325DD3D3AD145551CE505061" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_16C095961F6E9B6A8A8D5551CE50296B_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_16C095961F6E9B6A8A8D5551CE50296B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on disposal of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_16C095961F6E9B6A8A8D5551CE50296B_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_16C095961F6E9B6A8A8D5551CE50296B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_16C095961F6E9B6A8A8D5551CE50296B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_16C095961F6E9B6A8A8D5551CE50296B" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_16C095961F6E9B6A8A8D5551CE50296B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_CD9144F489C24CF00E2C5551CE513428_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_CD9144F489C24CF00E2C5551CE513428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_CD9144F489C24CF00E2C5551CE513428_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_CD9144F489C24CF00E2C5551CE513428" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_CD9144F489C24CF00E2C5551CE513428" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_CD9144F489C24CF00E2C5551CE513428" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_CD9144F489C24CF00E2C5551CE513428" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_837B7B887CBD77D7EFC75551CE51F284_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_837B7B887CBD77D7EFC75551CE51F284" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_837B7B887CBD77D7EFC75551CE51F284_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_837B7B887CBD77D7EFC75551CE51F284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_837B7B887CBD77D7EFC75551CE51F284" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_837B7B887CBD77D7EFC75551CE51F284" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_837B7B887CBD77D7EFC75551CE51F284" xlink:type="arc" />
    <link:label id="lab_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets_60B46CF12FCC2DEDF16A5551CE51D544_negatedLabel_en-US" xlink:label="lab_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets_60B46CF12FCC2DEDF16A5551CE51D544" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets_60B46CF12FCC2DEDF16A5551CE51D544_label_en-US" xlink:label="lab_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets_60B46CF12FCC2DEDF16A5551CE51D544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets_60B46CF12FCC2DEDF16A5551CE51D544_documentation_en-US" xlink:label="lab_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets_60B46CF12FCC2DEDF16A5551CE51D544" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses and Other Current Assets</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets" xlink:label="loc_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets_60B46CF12FCC2DEDF16A5551CE51D544" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets_60B46CF12FCC2DEDF16A5551CE51D544" xlink:to="lab_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets_60B46CF12FCC2DEDF16A5551CE51D544" xlink:type="arc" />
    <link:label id="lab_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets_6AAD9B3BA0F9A06160E95551CE5169D8_negatedTerseLabel_en-US" xlink:label="lab_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets_6AAD9B3BA0F9A06160E95551CE5169D8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other long&#8209;term assets</link:label>
    <link:label id="lab_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets_6AAD9B3BA0F9A06160E95551CE5169D8_label_en-US" xlink:label="lab_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets_6AAD9B3BA0F9A06160E95551CE5169D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses and Other Long-term Assets</link:label>
    <link:label id="lab_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets_6AAD9B3BA0F9A06160E95551CE5169D8_documentation_en-US" xlink:label="lab_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets_6AAD9B3BA0F9A06160E95551CE5169D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses and Other Long-term Assets</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets" xlink:label="loc_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets_6AAD9B3BA0F9A06160E95551CE5169D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets_6AAD9B3BA0F9A06160E95551CE5169D8" xlink:to="lab_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets_6AAD9B3BA0F9A06160E95551CE5169D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D7FD8A7D5D739E1ADE2A5551CE51DB0F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D7FD8A7D5D739E1ADE2A5551CE51DB0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D7FD8A7D5D739E1ADE2A5551CE51DB0F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D7FD8A7D5D739E1ADE2A5551CE51DB0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D7FD8A7D5D739E1ADE2A5551CE51DB0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D7FD8A7D5D739E1ADE2A5551CE51DB0F" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D7FD8A7D5D739E1ADE2A5551CE51DB0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1E15E76E839D97E756895551CE525D85_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1E15E76E839D97E756895551CE525D85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1E15E76E839D97E756895551CE525D85_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1E15E76E839D97E756895551CE525D85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1E15E76E839D97E756895551CE525D85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1E15E76E839D97E756895551CE525D85" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_1E15E76E839D97E756895551CE525D85" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_3EFD5973BDE4747D80AF5551CE5272CD_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_3EFD5973BDE4747D80AF5551CE5272CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_3EFD5973BDE4747D80AF5551CE5272CD_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_3EFD5973BDE4747D80AF5551CE5272CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_3EFD5973BDE4747D80AF5551CE5272CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_3EFD5973BDE4747D80AF5551CE5272CD" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_3EFD5973BDE4747D80AF5551CE5272CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_13F5F5823DF8885041415551CE52AE31_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_13F5F5823DF8885041415551CE52AE31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non&#8209;current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_13F5F5823DF8885041415551CE52AE31_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_13F5F5823DF8885041415551CE52AE31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_13F5F5823DF8885041415551CE52AE31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_13F5F5823DF8885041415551CE52AE31" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_13F5F5823DF8885041415551CE52AE31" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_25BA2C8D1C8B0E4CCB6A5551CE52CE75_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_25BA2C8D1C8B0E4CCB6A5551CE52CE75" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_25BA2C8D1C8B0E4CCB6A5551CE52CE75_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_25BA2C8D1C8B0E4CCB6A5551CE52CE75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_25BA2C8D1C8B0E4CCB6A5551CE52CE75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_25BA2C8D1C8B0E4CCB6A5551CE52CE75" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_25BA2C8D1C8B0E4CCB6A5551CE52CE75" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D1B2520427A3BDBB260F5551CE52566F_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D1B2520427A3BDBB260F5551CE52566F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D1B2520427A3BDBB260F5551CE52566F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D1B2520427A3BDBB260F5551CE52566F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D1B2520427A3BDBB260F5551CE52566F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D1B2520427A3BDBB260F5551CE52566F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D1B2520427A3BDBB260F5551CE52566F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9882A6FCA5C8F92927085551CE532285_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9882A6FCA5C8F92927085551CE532285" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9882A6FCA5C8F92927085551CE532285_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9882A6FCA5C8F92927085551CE532285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9882A6FCA5C8F92927085551CE532285" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9882A6FCA5C8F92927085551CE532285" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9882A6FCA5C8F92927085551CE532285" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_81BBEAFC29C88CA1B3B05551CE536BDB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_81BBEAFC29C88CA1B3B05551CE536BDB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_81BBEAFC29C88CA1B3B05551CE536BDB_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_81BBEAFC29C88CA1B3B05551CE536BDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_81BBEAFC29C88CA1B3B05551CE536BDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_81BBEAFC29C88CA1B3B05551CE536BDB" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_81BBEAFC29C88CA1B3B05551CE536BDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_FAE6064CA6129F01573F5551CE538517_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_FAE6064CA6129F01573F5551CE538517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_FAE6064CA6129F01573F5551CE538517_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_FAE6064CA6129F01573F5551CE538517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_FAE6064CA6129F01573F5551CE538517" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_FAE6064CA6129F01573F5551CE538517" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_FAE6064CA6129F01573F5551CE538517" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0F67FCB990028C0F7C575551CE53C353_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0F67FCB990028C0F7C575551CE53C353" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0F67FCB990028C0F7C575551CE53C353_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0F67FCB990028C0F7C575551CE53C353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0F67FCB990028C0F7C575551CE53C353" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0F67FCB990028C0F7C575551CE53C353" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0F67FCB990028C0F7C575551CE53C353" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4063933C8E7248C1A5405551CE53EC68_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4063933C8E7248C1A5405551CE53EC68" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4063933C8E7248C1A5405551CE53EC68_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4063933C8E7248C1A5405551CE53EC68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4063933C8E7248C1A5405551CE53EC68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4063933C8E7248C1A5405551CE53EC68" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4063933C8E7248C1A5405551CE53EC68" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4A5E46EE7A7C659758895551CE533A4E_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4A5E46EE7A7C659758895551CE533A4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4A5E46EE7A7C659758895551CE533A4E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4A5E46EE7A7C659758895551CE533A4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4A5E46EE7A7C659758895551CE533A4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4A5E46EE7A7C659758895551CE533A4E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4A5E46EE7A7C659758895551CE533A4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_F7CDB5AF04D95F22D8145551CE53EA1F_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_F7CDB5AF04D95F22D8145551CE53EA1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_F7CDB5AF04D95F22D8145551CE53EA1F_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_F7CDB5AF04D95F22D8145551CE53EA1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_F7CDB5AF04D95F22D8145551CE53EA1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_F7CDB5AF04D95F22D8145551CE53EA1F" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_F7CDB5AF04D95F22D8145551CE53EA1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_74E1B5F47563D79B5B2C5551CE548503_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_74E1B5F47563D79B5B2C5551CE548503" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_74E1B5F47563D79B5B2C5551CE548503_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_74E1B5F47563D79B5B2C5551CE548503" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_74E1B5F47563D79B5B2C5551CE548503" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts_74E1B5F47563D79B5B2C5551CE548503" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts_74E1B5F47563D79B5B2C5551CE548503" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4C6B347B5DFD2339BADA5551CE545200_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4C6B347B5DFD2339BADA5551CE545200" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4C6B347B5DFD2339BADA5551CE545200_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4C6B347B5DFD2339BADA5551CE545200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4C6B347B5DFD2339BADA5551CE545200" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4C6B347B5DFD2339BADA5551CE545200" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4C6B347B5DFD2339BADA5551CE545200" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_99398E2EE75AC679ABB35551CE542E50_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_99398E2EE75AC679ABB35551CE542E50" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_99398E2EE75AC679ABB35551CE542E50_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_99398E2EE75AC679ABB35551CE542E50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_99398E2EE75AC679ABB35551CE542E50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_99398E2EE75AC679ABB35551CE542E50" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_99398E2EE75AC679ABB35551CE542E50" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC9862B3B39240AF9BDF5551CE540D5B_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC9862B3B39240AF9BDF5551CE540D5B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC9862B3B39240AF9BDF5551CE540D5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC9862B3B39240AF9BDF5551CE540D5B" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC9862B3B39240AF9BDF5551CE540D5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_39DABEC75D9E773A3F025551CE542EFB_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_39DABEC75D9E773A3F025551CE542EFB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_39DABEC75D9E773A3F025551CE542EFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_39DABEC75D9E773A3F025551CE542EFB" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_39DABEC75D9E773A3F025551CE542EFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1B79931D5F3EA37C661F5551CE54B8B3_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1B79931D5F3EA37C661F5551CE54B8B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1B79931D5F3EA37C661F5551CE54B8B3_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1B79931D5F3EA37C661F5551CE54B8B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1B79931D5F3EA37C661F5551CE54B8B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1B79931D5F3EA37C661F5551CE54B8B3" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1B79931D5F3EA37C661F5551CE54B8B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_00CAB3212CB048D925855551CE546597_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_00CAB3212CB048D925855551CE546597" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_00CAB3212CB048D925855551CE546597_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_00CAB3212CB048D925855551CE546597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_00CAB3212CB048D925855551CE546597" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_00CAB3212CB048D925855551CE546597" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_00CAB3212CB048D925855551CE546597" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_B1199A685BEDA3B2637F53FB2B3F47A4_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_B1199A685BEDA3B2637F53FB2B3F47A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_B1199A685BEDA3B2637F53FB2B3F47A4_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_B1199A685BEDA3B2637F53FB2B3F47A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_B1199A685BEDA3B2637F53FB2B3F47A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_B1199A685BEDA3B2637F53FB2B3F47A4" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_B1199A685BEDA3B2637F53FB2B3F47A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272" xlink:to="lab_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272" xlink:type="arc" />
    <link:label id="lab_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_D1FCAF046F2AF30B210D53FB2B3F3646_terseLabel_en-US" xlink:label="lab_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_D1FCAF046F2AF30B210D53FB2B3F3646" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Stock Converted into Shares of Common Stock</link:label>
    <link:label id="lab_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_D1FCAF046F2AF30B210D53FB2B3F3646_label_en-US" xlink:label="lab_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_D1FCAF046F2AF30B210D53FB2B3F3646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Stock Converted into Shares of Common Stock [Member]</link:label>
    <link:label id="lab_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_D1FCAF046F2AF30B210D53FB2B3F3646_documentation_en-US" xlink:label="lab_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_D1FCAF046F2AF30B210D53FB2B3F3646" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Stock Converted into Shares of Common Stock [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember" xlink:label="loc_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_D1FCAF046F2AF30B210D53FB2B3F3646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_D1FCAF046F2AF30B210D53FB2B3F3646" xlink:to="lab_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_D1FCAF046F2AF30B210D53FB2B3F3646" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_CE179E151F39A02733ED53FB2B40C265_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_CE179E151F39A02733ED53FB2B40C265" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares issued upon conversion of convertible stock (shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_CE179E151F39A02733ED53FB2B40C265_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_CE179E151F39A02733ED53FB2B40C265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_CE179E151F39A02733ED53FB2B40C265" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1_CE179E151F39A02733ED53FB2B40C265" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1_CE179E151F39A02733ED53FB2B40C265" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A1998BF95D10AA3FAC9D53FB2B406B5F_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A1998BF95D10AA3FAC9D53FB2B406B5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A1998BF95D10AA3FAC9D53FB2B406B5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A1998BF95D10AA3FAC9D53FB2B406B5F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_A1998BF95D10AA3FAC9D53FB2B406B5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAndCash_1DF6AEBDD5D94FB19FAB53FB2B4028C1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash_1DF6AEBDD5D94FB19FAB53FB2B4028C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_1DF6AEBDD5D94FB19FAB53FB2B4028C1_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash_1DF6AEBDD5D94FB19FAB53FB2B4028C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="loc_us-gaap_InvestmentsAndCash_1DF6AEBDD5D94FB19FAB53FB2B4028C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash_1DF6AEBDD5D94FB19FAB53FB2B4028C1" xlink:to="lab_us-gaap_InvestmentsAndCash_1DF6AEBDD5D94FB19FAB53FB2B4028C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_E8C8F92EBFC0B7B91F921C0E3EA0D19F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_E8C8F92EBFC0B7B91F921C0E3EA0D19F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_E8C8F92EBFC0B7B91F921C0E3EA0D19F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_E8C8F92EBFC0B7B91F921C0E3EA0D19F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_E8C8F92EBFC0B7B91F921C0E3EA0D19F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_E8C8F92EBFC0B7B91F921C0E3EA0D19F" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_E8C8F92EBFC0B7B91F921C0E3EA0D19F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7647B7F5807FD594F0EA1C1E7F4C03C5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7647B7F5807FD594F0EA1C1E7F4C03C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7647B7F5807FD594F0EA1C1E7F4C03C5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7647B7F5807FD594F0EA1C1E7F4C03C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7647B7F5807FD594F0EA1C1E7F4C03C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7647B7F5807FD594F0EA1C1E7F4C03C5" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7647B7F5807FD594F0EA1C1E7F4C03C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockTextBlock_B348C0E8F0291FACD77BEBDC970D6FBF_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock_B348C0E8F0291FACD77BEBDC970D6FBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockTextBlock_B348C0E8F0291FACD77BEBDC970D6FBF_label_en-US" xlink:label="lab_us-gaap_PreferredStockTextBlock_B348C0E8F0291FACD77BEBDC970D6FBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock_B348C0E8F0291FACD77BEBDC970D6FBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockTextBlock_B348C0E8F0291FACD77BEBDC970D6FBF" xlink:to="lab_us-gaap_PreferredStockTextBlock_B348C0E8F0291FACD77BEBDC970D6FBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_8721425396741D1F458F306651B11C2C_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_8721425396741D1F458F306651B11C2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Formation and Business of the Company</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_8721425396741D1F458F306651B11C2C_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_8721425396741D1F458F306651B11C2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_8721425396741D1F458F306651B11C2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_8721425396741D1F458F306651B11C2C" xlink:to="lab_us-gaap_NatureOfOperations_8721425396741D1F458F306651B11C2C" xlink:type="arc" />
    <link:label id="lab_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507_label_en-US" xlink:label="lab_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Abstract]</link:label>
    <link:label id="lab_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507_documentation_en-US" xlink:label="lab_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity [Abstract]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_EntityAbstract" xlink:label="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="lab_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_F47ABBAEDC865876A26D03F050EB8D4C_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_F47ABBAEDC865876A26D03F050EB8D4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_F47ABBAEDC865876A26D03F050EB8D4C_label_en-US" xlink:label="lab_dei_EntityRegistrantName_F47ABBAEDC865876A26D03F050EB8D4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_F47ABBAEDC865876A26D03F050EB8D4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_F47ABBAEDC865876A26D03F050EB8D4C" xlink:to="lab_dei_EntityRegistrantName_F47ABBAEDC865876A26D03F050EB8D4C" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_DE09D3A06C73A5187E4203F0ADD2E13D_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_DE09D3A06C73A5187E4203F0ADD2E13D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_DE09D3A06C73A5187E4203F0ADD2E13D_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_DE09D3A06C73A5187E4203F0ADD2E13D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_DE09D3A06C73A5187E4203F0ADD2E13D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_DE09D3A06C73A5187E4203F0ADD2E13D" xlink:to="lab_dei_EntityCentralIndexKey_DE09D3A06C73A5187E4203F0ADD2E13D" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_E6B672022FAEFACAB1E503F12E99D23C_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_E6B672022FAEFACAB1E503F12E99D23C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_E6B672022FAEFACAB1E503F12E99D23C_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_E6B672022FAEFACAB1E503F12E99D23C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_E6B672022FAEFACAB1E503F12E99D23C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_E6B672022FAEFACAB1E503F12E99D23C" xlink:to="lab_dei_CurrentFiscalYearEndDate_E6B672022FAEFACAB1E503F12E99D23C" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_FB89BDC0AF21E8600F7F03F194F717A3_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_FB89BDC0AF21E8600F7F03F194F717A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_FB89BDC0AF21E8600F7F03F194F717A3_label_en-US" xlink:label="lab_dei_EntityFilerCategory_FB89BDC0AF21E8600F7F03F194F717A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_FB89BDC0AF21E8600F7F03F194F717A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_FB89BDC0AF21E8600F7F03F194F717A3" xlink:to="lab_dei_EntityFilerCategory_FB89BDC0AF21E8600F7F03F194F717A3" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_91821513D86EEB495AF703F2A139B279_terseLabel_en-US" xlink:label="lab_dei_DocumentType_91821513D86EEB495AF703F2A139B279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_91821513D86EEB495AF703F2A139B279_label_en-US" xlink:label="lab_dei_DocumentType_91821513D86EEB495AF703F2A139B279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_91821513D86EEB495AF703F2A139B279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_91821513D86EEB495AF703F2A139B279" xlink:to="lab_dei_DocumentType_91821513D86EEB495AF703F2A139B279" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_C4FF33E8F8A4A427A8CB03F2FE12E415_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_C4FF33E8F8A4A427A8CB03F2FE12E415" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_C4FF33E8F8A4A427A8CB03F2FE12E415_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_C4FF33E8F8A4A427A8CB03F2FE12E415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_C4FF33E8F8A4A427A8CB03F2FE12E415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_C4FF33E8F8A4A427A8CB03F2FE12E415" xlink:to="lab_dei_DocumentPeriodEndDate_C4FF33E8F8A4A427A8CB03F2FE12E415" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_6058B161F62902BD004303F356E1B397_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_6058B161F62902BD004303F356E1B397" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6058B161F62902BD004303F356E1B397_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_6058B161F62902BD004303F356E1B397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_6058B161F62902BD004303F356E1B397" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_6058B161F62902BD004303F356E1B397" xlink:to="lab_dei_DocumentFiscalYearFocus_6058B161F62902BD004303F356E1B397" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0AB1F52EFB6DC134B36603F3EA78DEE5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0AB1F52EFB6DC134B36603F3EA78DEE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0AB1F52EFB6DC134B36603F3EA78DEE5_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0AB1F52EFB6DC134B36603F3EA78DEE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0AB1F52EFB6DC134B36603F3EA78DEE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_0AB1F52EFB6DC134B36603F3EA78DEE5" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0AB1F52EFB6DC134B36603F3EA78DEE5" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_7CF7999636F56CA3D3D303F45DD61977_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_7CF7999636F56CA3D3D303F45DD61977" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_7CF7999636F56CA3D3D303F45DD61977_label_en-US" xlink:label="lab_dei_AmendmentFlag_7CF7999636F56CA3D3D303F45DD61977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_7CF7999636F56CA3D3D303F45DD61977" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_7CF7999636F56CA3D3D303F45DD61977" xlink:to="lab_dei_AmendmentFlag_7CF7999636F56CA3D3D303F45DD61977" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_CBA3E60D7BD3F5BDBD8303F5C2DD4B01_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_CBA3E60D7BD3F5BDBD8303F5C2DD4B01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_CBA3E60D7BD3F5BDBD8303F5C2DD4B01_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_CBA3E60D7BD3F5BDBD8303F5C2DD4B01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_CBA3E60D7BD3F5BDBD8303F5C2DD4B01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_CBA3E60D7BD3F5BDBD8303F5C2DD4B01" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_CBA3E60D7BD3F5BDBD8303F5C2DD4B01" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_2BDC7073BF7741F7156903F6E74B4545_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_2BDC7073BF7741F7156903F6E74B4545" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_2BDC7073BF7741F7156903F6E74B4545_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_2BDC7073BF7741F7156903F6E74B4545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_2BDC7073BF7741F7156903F6E74B4545" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_2BDC7073BF7741F7156903F6E74B4545" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_2BDC7073BF7741F7156903F6E74B4545" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_3FADBEBD1F29821541EC03F7702BE0BB_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_3FADBEBD1F29821541EC03F7702BE0BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_3FADBEBD1F29821541EC03F7702BE0BB_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_3FADBEBD1F29821541EC03F7702BE0BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_3FADBEBD1F29821541EC03F7702BE0BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_3FADBEBD1F29821541EC03F7702BE0BB" xlink:to="lab_dei_EntityVoluntaryFilers_3FADBEBD1F29821541EC03F7702BE0BB" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_1AB032238A4466276B9803F8192D35A9_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_1AB032238A4466276B9803F8192D35A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1AB032238A4466276B9803F8192D35A9_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_1AB032238A4466276B9803F8192D35A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_1AB032238A4466276B9803F8192D35A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_1AB032238A4466276B9803F8192D35A9" xlink:to="lab_dei_EntityCurrentReportingStatus_1AB032238A4466276B9803F8192D35A9" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_A0F45691227B01C2805C03F8C79EA81C_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_A0F45691227B01C2805C03F8C79EA81C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_A0F45691227B01C2805C03F8C79EA81C_label_en-US" xlink:label="lab_dei_EntityPublicFloat_A0F45691227B01C2805C03F8C79EA81C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_A0F45691227B01C2805C03F8C79EA81C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_A0F45691227B01C2805C03F8C79EA81C" xlink:to="lab_dei_EntityPublicFloat_A0F45691227B01C2805C03F8C79EA81C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CEA2A8637DB805CEC012EBDE762FCD91_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CEA2A8637DB805CEC012EBDE762FCD91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CEA2A8637DB805CEC012EBDE762FCD91_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CEA2A8637DB805CEC012EBDE762FCD91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CEA2A8637DB805CEC012EBDE762FCD91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CEA2A8637DB805CEC012EBDE762FCD91" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CEA2A8637DB805CEC012EBDE762FCD91" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_CB10BA50D236855D9532648483ABA96F_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_CB10BA50D236855D9532648483ABA96F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_CB10BA50D236855D9532648483ABA96F_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_CB10BA50D236855D9532648483ABA96F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_CB10BA50D236855D9532648483ABA96F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_CB10BA50D236855D9532648483ABA96F" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_CB10BA50D236855D9532648483ABA96F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_FABB03E1742A465828DB648483ACB3D9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_FABB03E1742A465828DB648483ACB3D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Development Tax Credit</link:label>
    <link:label id="lab_us-gaap_ResearchMember_FABB03E1742A465828DB648483ACB3D9_label_en-US" xlink:label="lab_us-gaap_ResearchMember_FABB03E1742A465828DB648483ACB3D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_FABB03E1742A465828DB648483ACB3D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_FABB03E1742A465828DB648483ACB3D9" xlink:to="lab_us-gaap_ResearchMember_FABB03E1742A465828DB648483ACB3D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_34801363164571A79FC4648483AC8DC7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_34801363164571A79FC4648483AC8DC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_34801363164571A79FC4648483AC8DC7_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_34801363164571A79FC4648483AC8DC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_34801363164571A79FC4648483AC8DC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_34801363164571A79FC4648483AC8DC7" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_34801363164571A79FC4648483AC8DC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_DF408A904D9D38D521F1648483AC1BDA_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_DF408A904D9D38D521F1648483AC1BDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal Tax</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_DF408A904D9D38D521F1648483AC1BDA_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_DF408A904D9D38D521F1648483AC1BDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_DF408A904D9D38D521F1648483AC1BDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_DF408A904D9D38D521F1648483AC1BDA" xlink:to="lab_us-gaap_DomesticCountryMember_DF408A904D9D38D521F1648483AC1BDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_0D17C56239D8FF31FEA5648483ACE139_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_0D17C56239D8FF31FEA5648483ACE139" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State Tax</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_0D17C56239D8FF31FEA5648483ACE139_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_0D17C56239D8FF31FEA5648483ACE139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_0D17C56239D8FF31FEA5648483ACE139" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_0D17C56239D8FF31FEA5648483ACE139" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_0D17C56239D8FF31FEA5648483ACE139" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_623B16D35B4C4C2F5DDA648483AC459D_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_623B16D35B4C4C2F5DDA648483AC459D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_623B16D35B4C4C2F5DDA648483AC459D_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_623B16D35B4C4C2F5DDA648483AC459D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_623B16D35B4C4C2F5DDA648483AC459D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_623B16D35B4C4C2F5DDA648483AC459D" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_623B16D35B4C4C2F5DDA648483AC459D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_23F3CFF8D23125C976FB648483AC77F7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_23F3CFF8D23125C976FB648483AC77F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_23F3CFF8D23125C976FB648483AC77F7_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_23F3CFF8D23125C976FB648483AC77F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_23F3CFF8D23125C976FB648483AC77F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_23F3CFF8D23125C976FB648483AC77F7" xlink:to="lab_us-gaap_OperatingLossCarryforwards_23F3CFF8D23125C976FB648483AC77F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_9250E17EAA8CCB4259D4648483AC146D_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_9250E17EAA8CCB4259D4648483AC146D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_9250E17EAA8CCB4259D4648483AC146D_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_9250E17EAA8CCB4259D4648483AC146D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_9250E17EAA8CCB4259D4648483AC146D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_9250E17EAA8CCB4259D4648483AC146D" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_9250E17EAA8CCB4259D4648483AC146D" xlink:type="arc" />
    <link:label id="lab_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit_AF78EB83B19EB905E7CB648483ACC218_terseLabel_en-US" xlink:label="lab_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit_AF78EB83B19EB905E7CB648483ACC218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in deferred tax assets resulting from the rate reduction</link:label>
    <link:label id="lab_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit_AF78EB83B19EB905E7CB648483ACC218_label_en-US" xlink:label="lab_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit_AF78EB83B19EB905E7CB648483ACC218" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Change in Deferred Tax Asset, Provisional Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit_AF78EB83B19EB905E7CB648483ACC218_documentation_en-US" xlink:label="lab_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit_AF78EB83B19EB905E7CB648483ACC218" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Change in Deferred Tax Asset, Provisional Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit_AF78EB83B19EB905E7CB648483ACC218" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit_AF78EB83B19EB905E7CB648483ACC218" xlink:to="lab_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit_AF78EB83B19EB905E7CB648483ACC218" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ED560AD7E01022DF855648483AC0DBA_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ED560AD7E01022DF855648483AC0DBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest and penalties related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ED560AD7E01022DF855648483AC0DBA_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ED560AD7E01022DF855648483AC0DBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ED560AD7E01022DF855648483AC0DBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ED560AD7E01022DF855648483AC0DBA" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ED560AD7E01022DF855648483AC0DBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_4F207AB4DB3CF16E88C95D29D89681A6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_4F207AB4DB3CF16E88C95D29D89681A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_4F207AB4DB3CF16E88C95D29D89681A6_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_4F207AB4DB3CF16E88C95D29D89681A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4F207AB4DB3CF16E88C95D29D89681A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4F207AB4DB3CF16E88C95D29D89681A6" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis_4F207AB4DB3CF16E88C95D29D89681A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9D7C1A0CBAFBC193142A5D29D8975460_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_9D7C1A0CBAFBC193142A5D29D8975460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9D7C1A0CBAFBC193142A5D29D8975460_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_9D7C1A0CBAFBC193142A5D29D8975460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9D7C1A0CBAFBC193142A5D29D8975460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_9D7C1A0CBAFBC193142A5D29D8975460" xlink:to="lab_us-gaap_MoneyMarketFundsMember_9D7C1A0CBAFBC193142A5D29D8975460" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_A6C3C3D57F6B6342DF4F5D29D896EC65_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_A6C3C3D57F6B6342DF4F5D29D896EC65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_A6C3C3D57F6B6342DF4F5D29D896EC65_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_A6C3C3D57F6B6342DF4F5D29D896EC65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_A6C3C3D57F6B6342DF4F5D29D896EC65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_A6C3C3D57F6B6342DF4F5D29D896EC65" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_A6C3C3D57F6B6342DF4F5D29D896EC65" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateNoteSecuritiesMember_4C6EB0969FE2D660120E5D74FF301FA9_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNoteSecuritiesMember_4C6EB0969FE2D660120E5D74FF301FA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate notes</link:label>
    <link:label id="lab_us-gaap_CorporateNoteSecuritiesMember_4C6EB0969FE2D660120E5D74FF301FA9_label_en-US" xlink:label="lab_us-gaap_CorporateNoteSecuritiesMember_4C6EB0969FE2D660120E5D74FF301FA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Note Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_4C6EB0969FE2D660120E5D74FF301FA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNoteSecuritiesMember_4C6EB0969FE2D660120E5D74FF301FA9" xlink:to="lab_us-gaap_CorporateNoteSecuritiesMember_4C6EB0969FE2D660120E5D74FF301FA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CD6BCC536D129E34FC8A5D76BD4F88CF_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CD6BCC536D129E34FC8A5D76BD4F88CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government notes</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CD6BCC536D129E34FC8A5D76BD4F88CF_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CD6BCC536D129E34FC8A5D76BD4F88CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CD6BCC536D129E34FC8A5D76BD4F88CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CD6BCC536D129E34FC8A5D76BD4F88CF" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CD6BCC536D129E34FC8A5D76BD4F88CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_AAE2AB7D21823DA99FE65D29D8973E17_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_AAE2AB7D21823DA99FE65D29D8973E17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_AAE2AB7D21823DA99FE65D29D8973E17_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_AAE2AB7D21823DA99FE65D29D8973E17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_AAE2AB7D21823DA99FE65D29D8973E17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_AAE2AB7D21823DA99FE65D29D8973E17" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_AAE2AB7D21823DA99FE65D29D8973E17" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2345F05FB0CC266D50285D29D8975064_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2345F05FB0CC266D50285D29D8975064" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2345F05FB0CC266D50285D29D8975064_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2345F05FB0CC266D50285D29D8975064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2345F05FB0CC266D50285D29D8975064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2345F05FB0CC266D50285D29D8975064" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2345F05FB0CC266D50285D29D8975064" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_55B7067D671D7E9381F85D29D897416A_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_55B7067D671D7E9381F85D29D897416A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_55B7067D671D7E9381F85D29D897416A_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_55B7067D671D7E9381F85D29D897416A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_55B7067D671D7E9381F85D29D897416A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_55B7067D671D7E9381F85D29D897416A" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_55B7067D671D7E9381F85D29D897416A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_D61914EA9077121B30A75D29D89891A4_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_D61914EA9077121B30A75D29D89891A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_D61914EA9077121B30A75D29D89891A4_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_D61914EA9077121B30A75D29D89891A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_D61914EA9077121B30A75D29D89891A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_D61914EA9077121B30A75D29D89891A4" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_D61914EA9077121B30A75D29D89891A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_624D27777E600DFA42845D29D898F4A9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_624D27777E600DFA42845D29D898F4A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_624D27777E600DFA42845D29D898F4A9_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_624D27777E600DFA42845D29D898F4A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_624D27777E600DFA42845D29D898F4A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_624D27777E600DFA42845D29D898F4A9" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_624D27777E600DFA42845D29D898F4A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_C5E197B93DBB251E89D65D29D89850C5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_C5E197B93DBB251E89D65D29D89850C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_C5E197B93DBB251E89D65D29D89850C5_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_C5E197B93DBB251E89D65D29D89850C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_C5E197B93DBB251E89D65D29D89850C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_C5E197B93DBB251E89D65D29D89850C5" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_C5E197B93DBB251E89D65D29D89850C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_E2192BB7CB08AFB5C29F5D29D8987F56_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_E2192BB7CB08AFB5C29F5D29D8987F56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_E2192BB7CB08AFB5C29F5D29D8987F56_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_E2192BB7CB08AFB5C29F5D29D8987F56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E2192BB7CB08AFB5C29F5D29D8987F56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_E2192BB7CB08AFB5C29F5D29D8987F56" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_E2192BB7CB08AFB5C29F5D29D8987F56" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_BA6DE56191F0955D9A975D29D8988C17_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_BA6DE56191F0955D9A975D29D8988C17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_BA6DE56191F0955D9A975D29D8988C17_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_BA6DE56191F0955D9A975D29D8988C17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_BA6DE56191F0955D9A975D29D8988C17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_BA6DE56191F0955D9A975D29D8988C17" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_BA6DE56191F0955D9A975D29D8988C17" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B2E80FE0EF16D5FCC3CF5D29D8988E48_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B2E80FE0EF16D5FCC3CF5D29D8988E48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B2E80FE0EF16D5FCC3CF5D29D8988E48_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B2E80FE0EF16D5FCC3CF5D29D8988E48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B2E80FE0EF16D5FCC3CF5D29D8988E48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B2E80FE0EF16D5FCC3CF5D29D8988E48" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B2E80FE0EF16D5FCC3CF5D29D8988E48" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_4C0CA29821E835EBA29C5D29D899F6F5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_4C0CA29821E835EBA29C5D29D899F6F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_4C0CA29821E835EBA29C5D29D899F6F5_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_4C0CA29821E835EBA29C5D29D899F6F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4C0CA29821E835EBA29C5D29D899F6F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_4C0CA29821E835EBA29C5D29D899F6F5" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_4C0CA29821E835EBA29C5D29D899F6F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_24E83FF9E08FDF39C4E95D29D8993E68_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_24E83FF9E08FDF39C4E95D29D8993E68" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_24E83FF9E08FDF39C4E95D29D8993E68_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_24E83FF9E08FDF39C4E95D29D8993E68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_24E83FF9E08FDF39C4E95D29D8993E68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_24E83FF9E08FDF39C4E95D29D8993E68" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_24E83FF9E08FDF39C4E95D29D8993E68" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7EC366C23E62D33C231441272C80FE36_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7EC366C23E62D33C231441272C80FE36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Assets and Liabilities Carried at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7EC366C23E62D33C231441272C80FE36_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7EC366C23E62D33C231441272C80FE36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7EC366C23E62D33C231441272C80FE36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7EC366C23E62D33C231441272C80FE36" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7EC366C23E62D33C231441272C80FE36" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_F5007B00B76BA19F938B4114A9B819D0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_F5007B00B76BA19F938B4114A9B819D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_F5007B00B76BA19F938B4114A9B819D0_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_F5007B00B76BA19F938B4114A9B819D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_F5007B00B76BA19F938B4114A9B819D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_F5007B00B76BA19F938B4114A9B819D0" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_F5007B00B76BA19F938B4114A9B819D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:to="lab_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:type="arc" />
    <link:label id="lab_mnlo_A2018OmnibusIncentivePlanMember_50CD00561518833631476464F3902886_terseLabel_en-US" xlink:label="lab_mnlo_A2018OmnibusIncentivePlanMember_50CD00561518833631476464F3902886" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Omnibus Incentive Plan</link:label>
    <link:label id="lab_mnlo_A2018OmnibusIncentivePlanMember_50CD00561518833631476464F3902886_label_en-US" xlink:label="lab_mnlo_A2018OmnibusIncentivePlanMember_50CD00561518833631476464F3902886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018 Omnibus Incentive Plan [Member]</link:label>
    <link:label id="lab_mnlo_A2018OmnibusIncentivePlanMember_50CD00561518833631476464F3902886_documentation_en-US" xlink:label="lab_mnlo_A2018OmnibusIncentivePlanMember_50CD00561518833631476464F3902886" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2018 Omnibus Incentive Plan [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_A2018OmnibusIncentivePlanMember" xlink:label="loc_mnlo_A2018OmnibusIncentivePlanMember_50CD00561518833631476464F3902886" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_A2018OmnibusIncentivePlanMember_50CD00561518833631476464F3902886" xlink:to="lab_mnlo_A2018OmnibusIncentivePlanMember_50CD00561518833631476464F3902886" xlink:type="arc" />
    <link:label id="lab_mnlo_A2018EmployeeStockPurchasePlanMember_0F7625F79D92068DC9F3646F1B914ECD_terseLabel_en-US" xlink:label="lab_mnlo_A2018EmployeeStockPurchasePlanMember_0F7625F79D92068DC9F3646F1B914ECD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mnlo_A2018EmployeeStockPurchasePlanMember_0F7625F79D92068DC9F3646F1B914ECD_label_en-US" xlink:label="lab_mnlo_A2018EmployeeStockPurchasePlanMember_0F7625F79D92068DC9F3646F1B914ECD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_mnlo_A2018EmployeeStockPurchasePlanMember_0F7625F79D92068DC9F3646F1B914ECD_documentation_en-US" xlink:label="lab_mnlo_A2018EmployeeStockPurchasePlanMember_0F7625F79D92068DC9F3646F1B914ECD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2018 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_A2018EmployeeStockPurchasePlanMember" xlink:label="loc_mnlo_A2018EmployeeStockPurchasePlanMember_0F7625F79D92068DC9F3646F1B914ECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_A2018EmployeeStockPurchasePlanMember_0F7625F79D92068DC9F3646F1B914ECD" xlink:to="lab_mnlo_A2018EmployeeStockPurchasePlanMember_0F7625F79D92068DC9F3646F1B914ECD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:to="lab_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E5DF7A62EEA88E3A0D3D6464F39074AA_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E5DF7A62EEA88E3A0D3D6464F39074AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for issuance (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E5DF7A62EEA88E3A0D3D6464F39074AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E5DF7A62EEA88E3A0D3D6464F39074AA" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E5DF7A62EEA88E3A0D3D6464F39074AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_DAD2F30B89EA6E686CD330A92AF30B2B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_DAD2F30B89EA6E686CD330A92AF30B2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_DAD2F30B89EA6E686CD330A92AF30B2B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_DAD2F30B89EA6E686CD330A92AF30B2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_DAD2F30B89EA6E686CD330A92AF30B2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_DAD2F30B89EA6E686CD330A92AF30B2B" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_DAD2F30B89EA6E686CD330A92AF30B2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_A828C2A48A82399340B030A92AF7CCE2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_A828C2A48A82399340B030A92AF7CCE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_A828C2A48A82399340B030A92AF7CCE2_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_A828C2A48A82399340B030A92AF7CCE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A828C2A48A82399340B030A92AF7CCE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A828C2A48A82399340B030A92AF7CCE2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_A828C2A48A82399340B030A92AF7CCE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8D45ED65A049078F2FBB30A92B05A886_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8D45ED65A049078F2FBB30A92B05A886" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives of plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8D45ED65A049078F2FBB30A92B05A886_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8D45ED65A049078F2FBB30A92B05A886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8D45ED65A049078F2FBB30A92B05A886" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8D45ED65A049078F2FBB30A92B05A886" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8D45ED65A049078F2FBB30A92B05A886" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C67DD63A1D396550F0FEEBCA81320F00_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C67DD63A1D396550F0FEEBCA81320F00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C67DD63A1D396550F0FEEBCA81320F00_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C67DD63A1D396550F0FEEBCA81320F00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C67DD63A1D396550F0FEEBCA81320F00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C67DD63A1D396550F0FEEBCA81320F00" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C67DD63A1D396550F0FEEBCA81320F00" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_601DD1497DB8E6B1EEC92FF76BC22758_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_601DD1497DB8E6B1EEC92FF76BC22758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_601DD1497DB8E6B1EEC92FF76BC22758_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_601DD1497DB8E6B1EEC92FF76BC22758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_601DD1497DB8E6B1EEC92FF76BC22758" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_601DD1497DB8E6B1EEC92FF76BC22758" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_601DD1497DB8E6B1EEC92FF76BC22758" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_10B79B381C8AE95CE0BF2FF76BC2C83A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_10B79B381C8AE95CE0BF2FF76BC2C83A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_10B79B381C8AE95CE0BF2FF76BC2C83A_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_10B79B381C8AE95CE0BF2FF76BC2C83A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_10B79B381C8AE95CE0BF2FF76BC2C83A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_10B79B381C8AE95CE0BF2FF76BC2C83A" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_10B79B381C8AE95CE0BF2FF76BC2C83A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3094E2AFAACD554341842FF76BC27480_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_3094E2AFAACD554341842FF76BC27480" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3094E2AFAACD554341842FF76BC27480_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_3094E2AFAACD554341842FF76BC27480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3094E2AFAACD554341842FF76BC27480" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_3094E2AFAACD554341842FF76BC27480" xlink:to="lab_us-gaap_CommonStockSharesIssued_3094E2AFAACD554341842FF76BC27480" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3306E1BCC36D18B90EA02FF76BC259D7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_3306E1BCC36D18B90EA02FF76BC259D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock outstanding (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3306E1BCC36D18B90EA02FF76BC259D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_3306E1BCC36D18B90EA02FF76BC259D7" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_3306E1BCC36D18B90EA02FF76BC259D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A37A5326DC6383B1B880EBD5DE0DA09F_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A37A5326DC6383B1B880EBD5DE0DA09F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A37A5326DC6383B1B880EBD5DE0DA09F_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A37A5326DC6383B1B880EBD5DE0DA09F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A37A5326DC6383B1B880EBD5DE0DA09F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A37A5326DC6383B1B880EBD5DE0DA09F" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A37A5326DC6383B1B880EBD5DE0DA09F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D43B54C05EC99C8767F55440F8C3073F_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D43B54C05EC99C8767F55440F8C3073F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Money market funds, amortized cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D43B54C05EC99C8767F55440F8C3073F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D43B54C05EC99C8767F55440F8C3073F" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_D43B54C05EC99C8767F55440F8C3073F" xlink:type="arc" />
    <link:label id="lab_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_5E4FE07DDEBF018C11F65440F8C36BB1_terseLabel_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_5E4FE07DDEBF018C11F65440F8C36BB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds, unrealized gains</link:label>
    <link:label id="lab_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_5E4FE07DDEBF018C11F65440F8C36BB1_label_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_5E4FE07DDEBF018C11F65440F8C36BB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_5E4FE07DDEBF018C11F65440F8C36BB1_documentation_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_5E4FE07DDEBF018C11F65440F8C36BB1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_5E4FE07DDEBF018C11F65440F8C36BB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_5E4FE07DDEBF018C11F65440F8C36BB1" xlink:to="lab_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_5E4FE07DDEBF018C11F65440F8C36BB1" xlink:type="arc" />
    <link:label id="lab_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_92E6E940A8BEA5991BAF5440F8C39B1A_terseLabel_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_92E6E940A8BEA5991BAF5440F8C39B1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds, unrealized losses</link:label>
    <link:label id="lab_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_92E6E940A8BEA5991BAF5440F8C39B1A_label_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_92E6E940A8BEA5991BAF5440F8C39B1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label id="lab_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_92E6E940A8BEA5991BAF5440F8C39B1A_documentation_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_92E6E940A8BEA5991BAF5440F8C39B1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_92E6E940A8BEA5991BAF5440F8C39B1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_92E6E940A8BEA5991BAF5440F8C39B1A" xlink:to="lab_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_92E6E940A8BEA5991BAF5440F8C39B1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1AFED2AFB787D43B8CEB5440F8C311F3_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1AFED2AFB787D43B8CEB5440F8C311F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds, fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1AFED2AFB787D43B8CEB5440F8C311F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1AFED2AFB787D43B8CEB5440F8C311F3" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1AFED2AFB787D43B8CEB5440F8C311F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3EC3E4802D28D0158E8E5440F8C316BF_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3EC3E4802D28D0158E8E5440F8C316BF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3EC3E4802D28D0158E8E5440F8C316BF_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3EC3E4802D28D0158E8E5440F8C316BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3EC3E4802D28D0158E8E5440F8C316BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3EC3E4802D28D0158E8E5440F8C316BF" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3EC3E4802D28D0158E8E5440F8C316BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_981DA87253EA566D219F5440F8C3E7CD_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_981DA87253EA566D219F5440F8C3E7CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_981DA87253EA566D219F5440F8C3E7CD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_981DA87253EA566D219F5440F8C3E7CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_981DA87253EA566D219F5440F8C3E7CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_981DA87253EA566D219F5440F8C3E7CD" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_981DA87253EA566D219F5440F8C3E7CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C974AE36EE1CFA4392295440F8C30923_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C974AE36EE1CFA4392295440F8C30923" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C974AE36EE1CFA4392295440F8C30923_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C974AE36EE1CFA4392295440F8C30923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C974AE36EE1CFA4392295440F8C30923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C974AE36EE1CFA4392295440F8C30923" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C974AE36EE1CFA4392295440F8C30923" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_2155FB286013F8CF82155440F8C30392_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_2155FB286013F8CF82155440F8C30392" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_2155FB286013F8CF82155440F8C30392_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_2155FB286013F8CF82155440F8C30392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_2155FB286013F8CF82155440F8C30392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_2155FB286013F8CF82155440F8C30392" xlink:to="lab_us-gaap_AvailableForSaleSecurities_2155FB286013F8CF82155440F8C30392" xlink:type="arc" />
    <link:label id="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_F46647ED0033FEB01A415440F8C3289B_totalLabel_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_F46647ED0033FEB01A415440F8C3289B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_F46647ED0033FEB01A415440F8C3289B_label_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_F46647ED0033FEB01A415440F8C3289B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_F46647ED0033FEB01A415440F8C3289B_documentation_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_F46647ED0033FEB01A415440F8C3289B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis" xlink:label="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_F46647ED0033FEB01A415440F8C3289B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_F46647ED0033FEB01A415440F8C3289B" xlink:to="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_F46647ED0033FEB01A415440F8C3289B" xlink:type="arc" />
    <link:label id="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_DC710C8EE1ED645D352D5440F8C3F251_totalLabel_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_DC710C8EE1ED645D352D5440F8C3F251" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_DC710C8EE1ED645D352D5440F8C3F251_label_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_DC710C8EE1ED645D352D5440F8C3F251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_DC710C8EE1ED645D352D5440F8C3F251_documentation_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_DC710C8EE1ED645D352D5440F8C3F251" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_DC710C8EE1ED645D352D5440F8C3F251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_DC710C8EE1ED645D352D5440F8C3F251" xlink:to="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_DC710C8EE1ED645D352D5440F8C3F251" xlink:type="arc" />
    <link:label id="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_7D1A57CE38BB3B1FB3495440F8C3F31E_negatedTotalLabel_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_7D1A57CE38BB3B1FB3495440F8C3F31E" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_7D1A57CE38BB3B1FB3495440F8C3F31E_label_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_7D1A57CE38BB3B1FB3495440F8C3F31E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label id="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_7D1A57CE38BB3B1FB3495440F8C3F31E_documentation_en-US" xlink:label="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_7D1A57CE38BB3B1FB3495440F8C3F31E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_7D1A57CE38BB3B1FB3495440F8C3F31E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_7D1A57CE38BB3B1FB3495440F8C3F31E" xlink:to="lab_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_7D1A57CE38BB3B1FB3495440F8C3F31E" xlink:type="arc" />
    <link:label id="lab_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_BDCFF446313223029E05544200375598_totalLabel_en-US" xlink:label="lab_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_BDCFF446313223029E05544200375598" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_BDCFF446313223029E05544200375598_label_en-US" xlink:label="lab_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_BDCFF446313223029E05544200375598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Available-for-sale Securities</link:label>
    <link:label id="lab_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_BDCFF446313223029E05544200375598_documentation_en-US" xlink:label="lab_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_BDCFF446313223029E05544200375598" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Available-for-sale Securities</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashCashEquivalentsandAvailableforsaleSecurities" xlink:label="loc_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_BDCFF446313223029E05544200375598" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_BDCFF446313223029E05544200375598" xlink:to="lab_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_BDCFF446313223029E05544200375598" xlink:type="arc" />
    <link:label id="lab_mnlo_EarlyExercisedStockOptionsMember_435D75ABEFCB895FBD6E53E14D72602B_terseLabel_en-US" xlink:label="lab_mnlo_EarlyExercisedStockOptionsMember_435D75ABEFCB895FBD6E53E14D72602B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Early Exercised Stock Options</link:label>
    <link:label id="lab_mnlo_EarlyExercisedStockOptionsMember_435D75ABEFCB895FBD6E53E14D72602B_label_en-US" xlink:label="lab_mnlo_EarlyExercisedStockOptionsMember_435D75ABEFCB895FBD6E53E14D72602B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Early Exercised Stock Options [Member]</link:label>
    <link:label id="lab_mnlo_EarlyExercisedStockOptionsMember_435D75ABEFCB895FBD6E53E14D72602B_documentation_en-US" xlink:label="lab_mnlo_EarlyExercisedStockOptionsMember_435D75ABEFCB895FBD6E53E14D72602B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Early Exercised Stock Options [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_EarlyExercisedStockOptionsMember" xlink:label="loc_mnlo_EarlyExercisedStockOptionsMember_435D75ABEFCB895FBD6E53E14D72602B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_EarlyExercisedStockOptionsMember_435D75ABEFCB895FBD6E53E14D72602B" xlink:to="lab_mnlo_EarlyExercisedStockOptionsMember_435D75ABEFCB895FBD6E53E14D72602B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F73BFE11D2010564ADBD53E2FAA8EFFC_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F73BFE11D2010564ADBD53E2FAA8EFFC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balances, beginning (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F73BFE11D2010564ADBD53E2FAA8EFFC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F73BFE11D2010564ADBD53E2FAA8EFFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F73BFE11D2010564ADBD53E2FAA8EFFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F73BFE11D2010564ADBD53E2FAA8EFFC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F73BFE11D2010564ADBD53E2FAA8EFFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_682D30F5506319BBDCE453E52D874057_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_682D30F5506319BBDCE453E52D874057" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_682D30F5506319BBDCE453E52D874057_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_682D30F5506319BBDCE453E52D874057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_682D30F5506319BBDCE453E52D874057" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_682D30F5506319BBDCE453E52D874057" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_682D30F5506319BBDCE453E52D874057" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C136D72C34E1E7515CFE53E14D740EA7_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C136D72C34E1E7515CFE53E14D740EA7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C136D72C34E1E7515CFE53E14D740EA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C136D72C34E1E7515CFE53E14D740EA7" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C136D72C34E1E7515CFE53E14D740EA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8FEBE17A6995B8EA83EC53E32C4A3F0D_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8FEBE17A6995B8EA83EC53E32C4A3F0D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balances, ending (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8FEBE17A6995B8EA83EC53E32C4A3F0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8FEBE17A6995B8EA83EC53E32C4A3F0D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8FEBE17A6995B8EA83EC53E32C4A3F0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_838417F508EA488BA07153EEC8827F06_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_838417F508EA488BA07153EEC8827F06" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_838417F508EA488BA07153EEC8827F06_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_838417F508EA488BA07153EEC8827F06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_838417F508EA488BA07153EEC8827F06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_838417F508EA488BA07153EEC8827F06" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_838417F508EA488BA07153EEC8827F06" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B2A0CA73A589F19D2EBF53EA03466017_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B2A0CA73A589F19D2EBF53EA03466017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B2A0CA73A589F19D2EBF53EA03466017_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B2A0CA73A589F19D2EBF53EA03466017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B2A0CA73A589F19D2EBF53EA03466017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B2A0CA73A589F19D2EBF53EA03466017" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B2A0CA73A589F19D2EBF53EA03466017" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CE2B46D830C3E6002B7A53EBB516D66A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CE2B46D830C3E6002B7A53EBB516D66A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised, exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CE2B46D830C3E6002B7A53EBB516D66A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CE2B46D830C3E6002B7A53EBB516D66A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CE2B46D830C3E6002B7A53EBB516D66A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CE2B46D830C3E6002B7A53EBB516D66A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CE2B46D830C3E6002B7A53EBB516D66A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6857BAEC47010BCB287C53F26C8B2150_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6857BAEC47010BCB287C53F26C8B2150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6857BAEC47010BCB287C53F26C8B2150_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6857BAEC47010BCB287C53F26C8B2150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6857BAEC47010BCB287C53F26C8B2150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6857BAEC47010BCB287C53F26C8B2150" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6857BAEC47010BCB287C53F26C8B2150" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56CA22EFB66B73BA1B6C53F4697C1EA8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56CA22EFB66B73BA1B6C53F4697C1EA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56CA22EFB66B73BA1B6C53F4697C1EA8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56CA22EFB66B73BA1B6C53F4697C1EA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56CA22EFB66B73BA1B6C53F4697C1EA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56CA22EFB66B73BA1B6C53F4697C1EA8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56CA22EFB66B73BA1B6C53F4697C1EA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_158A3ACE035F3F6B523D53E14D74FD41_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_158A3ACE035F3F6B523D53E14D74FD41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested options included in early exercise (shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_158A3ACE035F3F6B523D53E14D74FD41_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_158A3ACE035F3F6B523D53E14D74FD41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_158A3ACE035F3F6B523D53E14D74FD41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_158A3ACE035F3F6B523D53E14D74FD41" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_158A3ACE035F3F6B523D53E14D74FD41" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_EF967D327E5A3CCD6E4C2ABA35D61149_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_EF967D327E5A3CCD6E4C2ABA35D61149" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December 31:</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_EF967D327E5A3CCD6E4C2ABA35D61149_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_EF967D327E5A3CCD6E4C2ABA35D61149" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_EF967D327E5A3CCD6E4C2ABA35D61149" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_EF967D327E5A3CCD6E4C2ABA35D61149" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_EF967D327E5A3CCD6E4C2ABA35D61149" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3D41BAE5214B5C6440672ABA35D6DD96_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3D41BAE5214B5C6440672ABA35D6DD96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3D41BAE5214B5C6440672ABA35D6DD96_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3D41BAE5214B5C6440672ABA35D6DD96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3D41BAE5214B5C6440672ABA35D6DD96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3D41BAE5214B5C6440672ABA35D6DD96" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3D41BAE5214B5C6440672ABA35D6DD96" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3EF39D8541B85D8AD3F22ABA35D6F04D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3EF39D8541B85D8AD3F22ABA35D6F04D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3EF39D8541B85D8AD3F22ABA35D6F04D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3EF39D8541B85D8AD3F22ABA35D6F04D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3EF39D8541B85D8AD3F22ABA35D6F04D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3EF39D8541B85D8AD3F22ABA35D6F04D" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3EF39D8541B85D8AD3F22ABA35D6F04D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6618F2BEB8CF82C4C8BF2ACD93213DBB_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6618F2BEB8CF82C4C8BF2ACD93213DBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6618F2BEB8CF82C4C8BF2ACD93213DBB_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6618F2BEB8CF82C4C8BF2ACD93213DBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6618F2BEB8CF82C4C8BF2ACD93213DBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6618F2BEB8CF82C4C8BF2ACD93213DBB" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6618F2BEB8CF82C4C8BF2ACD93213DBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4437A4209A9C4DA9E0D2ABA35D634FD_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4437A4209A9C4DA9E0D2ABA35D634FD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4437A4209A9C4DA9E0D2ABA35D634FD_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4437A4209A9C4DA9E0D2ABA35D634FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4437A4209A9C4DA9E0D2ABA35D634FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4437A4209A9C4DA9E0D2ABA35D634FD" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4437A4209A9C4DA9E0D2ABA35D634FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_DE0ABFA0A18BE6E9B5B640E2E98678F6_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_DE0ABFA0A18BE6E9B5B640E2E98678F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Unaudited Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_DE0ABFA0A18BE6E9B5B640E2E98678F6_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_DE0ABFA0A18BE6E9B5B640E2E98678F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_DE0ABFA0A18BE6E9B5B640E2E98678F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_DE0ABFA0A18BE6E9B5B640E2E98678F6" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_DE0ABFA0A18BE6E9B5B640E2E98678F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_10722F9CF8BDB700483E07C1698FAD32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_10722F9CF8BDB700483E07C1698FAD32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_10722F9CF8BDB700483E07C1698FAD32_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_10722F9CF8BDB700483E07C1698FAD32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_10722F9CF8BDB700483E07C1698FAD32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_10722F9CF8BDB700483E07C1698FAD32" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_10722F9CF8BDB700483E07C1698FAD32" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_A8D1B7F508E67BF8452B39A96EDD76FB_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock_A8D1B7F508E67BF8452B39A96EDD76FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_A8D1B7F508E67BF8452B39A96EDD76FB_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock_A8D1B7F508E67BF8452B39A96EDD76FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_A8D1B7F508E67BF8452B39A96EDD76FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock_A8D1B7F508E67BF8452B39A96EDD76FB" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock_A8D1B7F508E67BF8452B39A96EDD76FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8D32FFF3F75D90883573E3F0996A891_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8D32FFF3F75D90883573E3F0996A891" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8D32FFF3F75D90883573E3F0996A891_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8D32FFF3F75D90883573E3F0996A891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8D32FFF3F75D90883573E3F0996A891" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8D32FFF3F75D90883573E3F0996A891" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8D32FFF3F75D90883573E3F0996A891" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8538E30EF724C0FF8EB03E3F0996F32C_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8538E30EF724C0FF8EB03E3F0996F32C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8538E30EF724C0FF8EB03E3F0996F32C_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8538E30EF724C0FF8EB03E3F0996F32C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8538E30EF724C0FF8EB03E3F0996F32C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8538E30EF724C0FF8EB03E3F0996F32C" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8538E30EF724C0FF8EB03E3F0996F32C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_D8272A36141192DFD4FD3E3F09970855_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_D8272A36141192DFD4FD3E3F09970855" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock issuable upon conversion to common stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_D8272A36141192DFD4FD3E3F09970855_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_D8272A36141192DFD4FD3E3F09970855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_D8272A36141192DFD4FD3E3F09970855" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_D8272A36141192DFD4FD3E3F09970855" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_D8272A36141192DFD4FD3E3F09970855" xlink:type="arc" />
    <link:label id="lab_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember_65527C34FC073241AB223E3F099744EB_terseLabel_en-US" xlink:label="lab_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember_65527C34FC073241AB223E3F099744EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding common stock subject to repurchase</link:label>
    <link:label id="lab_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember_65527C34FC073241AB223E3F099744EB_label_en-US" xlink:label="lab_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember_65527C34FC073241AB223E3F099744EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Common Stock Subject to Repurchase [Member]</link:label>
    <link:label id="lab_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember_65527C34FC073241AB223E3F099744EB_documentation_en-US" xlink:label="lab_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember_65527C34FC073241AB223E3F099744EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Outstanding Common Stock Subject to Repurchase [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_OutstandingCommonStockSubjecttoRepurchaseMember" xlink:label="loc_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember_65527C34FC073241AB223E3F099744EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember_65527C34FC073241AB223E3F099744EB" xlink:to="lab_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember_65527C34FC073241AB223E3F099744EB" xlink:type="arc" />
    <link:label id="lab_mnlo_OptionsOutstandingMember_0ABEE2C20091AD6275823E5DD6742D45_terseLabel_en-US" xlink:label="lab_mnlo_OptionsOutstandingMember_0ABEE2C20091AD6275823E5DD6742D45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding</link:label>
    <link:label id="lab_mnlo_OptionsOutstandingMember_0ABEE2C20091AD6275823E5DD6742D45_label_en-US" xlink:label="lab_mnlo_OptionsOutstandingMember_0ABEE2C20091AD6275823E5DD6742D45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Outstanding [Member]</link:label>
    <link:label id="lab_mnlo_OptionsOutstandingMember_0ABEE2C20091AD6275823E5DD6742D45_documentation_en-US" xlink:label="lab_mnlo_OptionsOutstandingMember_0ABEE2C20091AD6275823E5DD6742D45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options Outstanding [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_OptionsOutstandingMember" xlink:label="loc_mnlo_OptionsOutstandingMember_0ABEE2C20091AD6275823E5DD6742D45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_OptionsOutstandingMember_0ABEE2C20091AD6275823E5DD6742D45" xlink:to="lab_mnlo_OptionsOutstandingMember_0ABEE2C20091AD6275823E5DD6742D45" xlink:type="arc" />
    <link:label id="lab_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember_2137DA419B6586F114EC3E5F2E87C349_terseLabel_en-US" xlink:label="lab_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember_2137DA419B6586F114EC3E5F2E87C349" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options available for issuance</link:label>
    <link:label id="lab_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember_2137DA419B6586F114EC3E5F2E87C349_label_en-US" xlink:label="lab_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember_2137DA419B6586F114EC3E5F2E87C349" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Available for Future Grant under Stock Option Plan [Member]</link:label>
    <link:label id="lab_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember_2137DA419B6586F114EC3E5F2E87C349_documentation_en-US" xlink:label="lab_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember_2137DA419B6586F114EC3E5F2E87C349" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options Available for Future Grant under Stock Option Plan [Member]</link:label>
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember" xlink:label="loc_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember_2137DA419B6586F114EC3E5F2E87C349" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember_2137DA419B6586F114EC3E5F2E87C349" xlink:to="lab_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember_2137DA419B6586F114EC3E5F2E87C349" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03CA3B0257AA5D69C1993E3F09978C14_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03CA3B0257AA5D69C1993E3F09978C14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03CA3B0257AA5D69C1993E3F09978C14_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03CA3B0257AA5D69C1993E3F09978C14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03CA3B0257AA5D69C1993E3F09978C14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03CA3B0257AA5D69C1993E3F09978C14" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03CA3B0257AA5D69C1993E3F09978C14" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C5A6FBF2095C4FFFC7AD3E3F0997DAA5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C5A6FBF2095C4FFFC7AD3E3F0997DAA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive securities excluded from the calculation of EPS</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C5A6FBF2095C4FFFC7AD3E3F0997DAA5_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C5A6FBF2095C4FFFC7AD3E3F0997DAA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C5A6FBF2095C4FFFC7AD3E3F0997DAA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C5A6FBF2095C4FFFC7AD3E3F0997DAA5" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C5A6FBF2095C4FFFC7AD3E3F0997DAA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1C08D221881E815065B5EBD9CA9A8BA8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1C08D221881E815065B5EBD9CA9A8BA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1C08D221881E815065B5EBD9CA9A8BA8_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1C08D221881E815065B5EBD9CA9A8BA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1C08D221881E815065B5EBD9CA9A8BA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1C08D221881E815065B5EBD9CA9A8BA8" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1C08D221881E815065B5EBD9CA9A8BA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D18363A872803C1D1EBC30CD1271EA5A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D18363A872803C1D1EBC30CD1271EA5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D18363A872803C1D1EBC30CD1271EA5A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D18363A872803C1D1EBC30CD1271EA5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D18363A872803C1D1EBC30CD1271EA5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D18363A872803C1D1EBC30CD1271EA5A" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_D18363A872803C1D1EBC30CD1271EA5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2DDF05905DDF803B4C705473518E1AD2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2DDF05905DDF803B4C705473518E1AD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Allocation of Recognized Period Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2DDF05905DDF803B4C705473518E1AD2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2DDF05905DDF803B4C705473518E1AD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2DDF05905DDF803B4C705473518E1AD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2DDF05905DDF803B4C705473518E1AD2" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2DDF05905DDF803B4C705473518E1AD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B5EC26ADE2DACE63C5C5473518D945F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B5EC26ADE2DACE63C5C5473518D945F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B5EC26ADE2DACE63C5C5473518D945F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B5EC26ADE2DACE63C5C5473518D945F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B5EC26ADE2DACE63C5C5473518D945F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B5EC26ADE2DACE63C5C5473518D945F" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B5EC26ADE2DACE63C5C5473518D945F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3AA5756627194CE63285473518EFE24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3AA5756627194CE63285473518EFE24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3AA5756627194CE63285473518EFE24_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3AA5756627194CE63285473518EFE24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3AA5756627194CE63285473518EFE24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3AA5756627194CE63285473518EFE24" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3AA5756627194CE63285473518EFE24" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_9B734E227000479514E65473518E2859_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_9B734E227000479514E65473518E2859" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_9B734E227000479514E65473518E2859_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_9B734E227000479514E65473518E2859" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_9B734E227000479514E65473518E2859" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_9B734E227000479514E65473518E2859" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_9B734E227000479514E65473518E2859" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6F1EAFBED9B3257D5EBC307CD95A9AFF_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6F1EAFBED9B3257D5EBC307CD95A9AFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6F1EAFBED9B3257D5EBC307CD95A9AFF_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6F1EAFBED9B3257D5EBC307CD95A9AFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6F1EAFBED9B3257D5EBC307CD95A9AFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6F1EAFBED9B3257D5EBC307CD95A9AFF" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6F1EAFBED9B3257D5EBC307CD95A9AFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_8D7F7E5BECC327B4B165307CD95AD7B8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock_8D7F7E5BECC327B4B165307CD95AD7B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse Stock Split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_8D7F7E5BECC327B4B165307CD95AD7B8_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock_8D7F7E5BECC327B4B165307CD95AD7B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_8D7F7E5BECC327B4B165307CD95AD7B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock_8D7F7E5BECC327B4B165307CD95AD7B8" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock_8D7F7E5BECC327B4B165307CD95AD7B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_2A54E70962EDAC2FC25F307CD95A4680_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_2A54E70962EDAC2FC25F307CD95A4680" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_2A54E70962EDAC2FC25F307CD95A4680_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_2A54E70962EDAC2FC25F307CD95A4680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2A54E70962EDAC2FC25F307CD95A4680" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2A54E70962EDAC2FC25F307CD95A4680" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_2A54E70962EDAC2FC25F307CD95A4680" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_AD5FDA87F859D90101C3307CD95A2D2D_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_AD5FDA87F859D90101C3307CD95A2D2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_AD5FDA87F859D90101C3307CD95A2D2D_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_AD5FDA87F859D90101C3307CD95A2D2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_AD5FDA87F859D90101C3307CD95A2D2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_AD5FDA87F859D90101C3307CD95A2D2D" xlink:to="lab_us-gaap_UseOfEstimates_AD5FDA87F859D90101C3307CD95A2D2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A6C4A0B56E8F8432EBAD307CD95A7BB3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A6C4A0B56E8F8432EBAD307CD95A7BB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A6C4A0B56E8F8432EBAD307CD95A7BB3_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A6C4A0B56E8F8432EBAD307CD95A7BB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A6C4A0B56E8F8432EBAD307CD95A7BB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A6C4A0B56E8F8432EBAD307CD95A7BB3" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A6C4A0B56E8F8432EBAD307CD95A7BB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_84A16971B03272E91767307CD95B6D0F_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_84A16971B03272E91767307CD95B6D0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_84A16971B03272E91767307CD95B6D0F_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_84A16971B03272E91767307CD95B6D0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_84A16971B03272E91767307CD95B6D0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_84A16971B03272E91767307CD95B6D0F" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_84A16971B03272E91767307CD95B6D0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_17C9B4765A06A73F6C79307CD95B56FE_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_17C9B4765A06A73F6C79307CD95B56FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_17C9B4765A06A73F6C79307CD95B56FE_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_17C9B4765A06A73F6C79307CD95B56FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_17C9B4765A06A73F6C79307CD95B56FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_17C9B4765A06A73F6C79307CD95B56FE" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_17C9B4765A06A73F6C79307CD95B56FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_294ACFCBC16ABCBA0CB9307CD95BF209_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_294ACFCBC16ABCBA0CB9307CD95BF209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_294ACFCBC16ABCBA0CB9307CD95BF209_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_294ACFCBC16ABCBA0CB9307CD95BF209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_294ACFCBC16ABCBA0CB9307CD95BF209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_294ACFCBC16ABCBA0CB9307CD95BF209" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_294ACFCBC16ABCBA0CB9307CD95BF209" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_D77757440BBC8044AD01307CD95BD841_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_D77757440BBC8044AD01307CD95BD841" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_D77757440BBC8044AD01307CD95BD841_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_D77757440BBC8044AD01307CD95BD841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_D77757440BBC8044AD01307CD95BD841" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_D77757440BBC8044AD01307CD95BD841" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_D77757440BBC8044AD01307CD95BD841" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_6E2A4589E284E8FDECBB307CD95B4332_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_6E2A4589E284E8FDECBB307CD95B4332" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_6E2A4589E284E8FDECBB307CD95B4332_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_6E2A4589E284E8FDECBB307CD95B4332" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6E2A4589E284E8FDECBB307CD95B4332" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_6E2A4589E284E8FDECBB307CD95B4332" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_6E2A4589E284E8FDECBB307CD95B4332" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_7A425E03FF04F937F66F307CD95BEFC4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_7A425E03FF04F937F66F307CD95BEFC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_7A425E03FF04F937F66F307CD95BEFC4_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_7A425E03FF04F937F66F307CD95BEFC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7A425E03FF04F937F66F307CD95BEFC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7A425E03FF04F937F66F307CD95BEFC4" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_7A425E03FF04F937F66F307CD95BEFC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_35580FE9E4F083F3E608307CD95B2142_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_35580FE9E4F083F3E608307CD95B2142" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent Costs</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_35580FE9E4F083F3E608307CD95B2142_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_35580FE9E4F083F3E608307CD95B2142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_35580FE9E4F083F3E608307CD95B2142" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_35580FE9E4F083F3E608307CD95B2142" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_35580FE9E4F083F3E608307CD95B2142" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_D76F663F3F83EB2316C8307CD95B3216_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_D76F663F3F83EB2316C8307CD95B3216" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_D76F663F3F83EB2316C8307CD95B3216_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_D76F663F3F83EB2316C8307CD95B3216" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_D76F663F3F83EB2316C8307CD95B3216" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_D76F663F3F83EB2316C8307CD95B3216" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_D76F663F3F83EB2316C8307CD95B3216" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_515FF59F4A4437599E43307CD95B0AFA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_515FF59F4A4437599E43307CD95B0AFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_515FF59F4A4437599E43307CD95B0AFA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_515FF59F4A4437599E43307CD95B0AFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_515FF59F4A4437599E43307CD95B0AFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_515FF59F4A4437599E43307CD95B0AFA" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_515FF59F4A4437599E43307CD95B0AFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_2A05BA97B8EAB19364BE3098EC03AECB_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_2A05BA97B8EAB19364BE3098EC03AECB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_2A05BA97B8EAB19364BE3098EC03AECB_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_2A05BA97B8EAB19364BE3098EC03AECB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_2A05BA97B8EAB19364BE3098EC03AECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_2A05BA97B8EAB19364BE3098EC03AECB" xlink:to="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_2A05BA97B8EAB19364BE3098EC03AECB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2AD9B2C2FBC6F6DC8B0E307CD95B199C_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2AD9B2C2FBC6F6DC8B0E307CD95B199C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2AD9B2C2FBC6F6DC8B0E307CD95B199C_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2AD9B2C2FBC6F6DC8B0E307CD95B199C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2AD9B2C2FBC6F6DC8B0E307CD95B199C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2AD9B2C2FBC6F6DC8B0E307CD95B199C" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2AD9B2C2FBC6F6DC8B0E307CD95B199C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1C63CBD146982DC1FF14307CD95B0768_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1C63CBD146982DC1FF14307CD95B0768" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1C63CBD146982DC1FF14307CD95B0768_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1C63CBD146982DC1FF14307CD95B0768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1C63CBD146982DC1FF14307CD95B0768" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1C63CBD146982DC1FF14307CD95B0768" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1C63CBD146982DC1FF14307CD95B0768" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_4099CCF07BA4ADF659CA307CD95BD4D3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_4099CCF07BA4ADF659CA307CD95BD4D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_4099CCF07BA4ADF659CA307CD95BD4D3_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_4099CCF07BA4ADF659CA307CD95BD4D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_4099CCF07BA4ADF659CA307CD95BD4D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_4099CCF07BA4ADF659CA307CD95BD4D3" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_4099CCF07BA4ADF659CA307CD95BD4D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C80A3308C1CED3AD57A1307CD95BA4E8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C80A3308C1CED3AD57A1307CD95BA4E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C80A3308C1CED3AD57A1307CD95BA4E8_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C80A3308C1CED3AD57A1307CD95BA4E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C80A3308C1CED3AD57A1307CD95BA4E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C80A3308C1CED3AD57A1307CD95BA4E8" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C80A3308C1CED3AD57A1307CD95BA4E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C1EA154E2D3C9DF21265307CD95C019C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C1EA154E2D3C9DF21265307CD95C019C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C1EA154E2D3C9DF21265307CD95C019C_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C1EA154E2D3C9DF21265307CD95C019C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C1EA154E2D3C9DF21265307CD95C019C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C1EA154E2D3C9DF21265307CD95C019C" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C1EA154E2D3C9DF21265307CD95C019C" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mnlo-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheets" xlink:href="mnlo-20171231.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsComponents" xlink:href="mnlo-20171231.xsd#BalanceSheetsComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsComponentsDetails" xlink:href="mnlo-20171231.xsd#BalanceSheetsComponentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsComponentsTables" xlink:href="mnlo-20171231.xsd#BalanceSheetsComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/BalanceSheetsParenthetical" xlink:href="mnlo-20171231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingencies" xlink:href="mnlo-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesDetails" xlink:href="mnlo-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumOperatingLeasePaymentsDetails" xlink:href="mnlo-20171231.xsd#CommitmentsAndContingenciesFutureMinimumOperatingLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:href="mnlo-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommonStock" xlink:href="mnlo-20171231.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/CommonStockDetails" xlink:href="mnlo-20171231.xsd#CommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStock" xlink:href="mnlo-20171231.xsd#ConvertiblePreferredStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockConvertiblePreferredStockOutstandingDetails" xlink:href="mnlo-20171231.xsd#ConvertiblePreferredStockConvertiblePreferredStockOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockDetails" xlink:href="mnlo-20171231.xsd#ConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockTables" xlink:href="mnlo-20171231.xsd#ConvertiblePreferredStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/DeiDocument" xlink:href="mnlo-20171231.xsd#DeiDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurements" xlink:href="mnlo-20171231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurementsAvailableForSaleSecuritiesDetails" xlink:href="mnlo-20171231.xsd#FairValueMeasurementsAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurementsDetails" xlink:href="mnlo-20171231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FairValueMeasurementsTables" xlink:href="mnlo-20171231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompany" xlink:href="mnlo-20171231.xsd#FormationAndBusinessOfCompany" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompanyDetails" xlink:href="mnlo-20171231.xsd#FormationAndBusinessOfCompanyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxes" xlink:href="mnlo-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:href="mnlo-20171231.xsd#IncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="mnlo-20171231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:href="mnlo-20171231.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesTables" xlink:href="mnlo-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:href="mnlo-20171231.xsd#IncomeTaxesUncertainTaxPositionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:href="mnlo-20171231.xsd#NetLossPerShareAttributableToCommonStockholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersAntidilutiveSharesDetails" xlink:href="mnlo-20171231.xsd#NetLossPerShareAttributableToCommonStockholdersAntidilutiveSharesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="mnlo-20171231.xsd#NetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:href="mnlo-20171231.xsd#NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/RelatedPartyTransactions" xlink:href="mnlo-20171231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/RelatedPartyTransactionsDetails" xlink:href="mnlo-20171231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialData" xlink:href="mnlo-20171231.xsd#SelectedUnauditedQuarterlyFinancialData" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataDetails" xlink:href="mnlo-20171231.xsd#SelectedUnauditedQuarterlyFinancialDataDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataTables" xlink:href="mnlo-20171231.xsd#SelectedUnauditedQuarterlyFinancialDataTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPolicies" xlink:href="mnlo-20171231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesReverseStockSplitDetails" xlink:href="mnlo-20171231.xsd#SignificantAccountingPoliciesReverseStockSplitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StatementOfCashFlows" xlink:href="mnlo-20171231.xsd#StatementOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:href="mnlo-20171231.xsd#StatementOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitStatement" xlink:href="mnlo-20171231.xsd#StatementOfConvertiblePreferredStockAndStockholdersDeficitStatement" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="mnlo-20171231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensation" xlink:href="mnlo-20171231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationDetails" xlink:href="mnlo-20171231.xsd#StockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationFairValueAssumptionsForDirectorEmployeeAndNonEmployeeGrantsDetails" xlink:href="mnlo-20171231.xsd#StockBasedCompensationFairValueAssumptionsForDirectorEmployeeAndNonEmployeeGrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationStockOptionAndRestrictedStockActivityDetails" xlink:href="mnlo-20171231.xsd#StockBasedCompensationStockOptionAndRestrictedStockActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/StockBasedCompensationTables" xlink:href="mnlo-20171231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SubsequentEvents" xlink:href="mnlo-20171231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.menlotherapeutics.com/role/SubsequentEventsDetails" xlink:href="mnlo-20171231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_E3667208190BCA556C85547353D49601" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C6219322BDD54D888981547353D4B6F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E3667208190BCA556C85547353D49601" xlink:to="loc_us-gaap_StatementTable_C6219322BDD54D888981547353D4B6F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3FA6922DAB3ED8257F51547353D41538" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C6219322BDD54D888981547353D4B6F0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3FA6922DAB3ED8257F51547353D41538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_DBAA8EBF423356FA3AFA547353D4DE3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3FA6922DAB3ED8257F51547353D41538" xlink:to="loc_us-gaap_ClassOfStockDomain_DBAA8EBF423356FA3AFA547353D4DE3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_E6C39CCB6318908D122E547353D42FD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_DBAA8EBF423356FA3AFA547353D4DE3C" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_E6C39CCB6318908D122E547353D42FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_973C1C02872E33B46A89547353D4EC47" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_DBAA8EBF423356FA3AFA547353D4DE3C" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_973C1C02872E33B46A89547353D4EC47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_6994735003AD40F208F5547353D4FD3E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_DBAA8EBF423356FA3AFA547353D4DE3C" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_6994735003AD40F208F5547353D4FD3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C6219322BDD54D888981547353D4B6F0" xlink:to="loc_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064" xlink:to="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7580E51F309E1404522C547353D5E01D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7580E51F309E1404522C547353D5E01D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_F4A9962C6B584EDE250C547353D58F2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:to="loc_us-gaap_ShortTermInvestments_F4A9962C6B584EDE250C547353D58F2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_EFC0F2A0C2629B931E93547353D59A84" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_EFC0F2A0C2629B931E93547353D59A84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1EC5DCE8642B50CA3C5E547353D5BD64" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1EC5DCE8642B50CA3C5E547353D5BD64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_12331DDF0B92670AB9CF547353D56195" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1A9819A94EFEE1BD3E3D547353D4D5A2" xlink:to="loc_us-gaap_AssetsCurrent_12331DDF0B92670AB9CF547353D56195" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_2E5DDAF661A3C2F7B02A547353D50B65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:to="loc_us-gaap_LongTermInvestments_2E5DDAF661A3C2F7B02A547353D50B65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0716A5F4EF673A3FE062547353D5F238" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0716A5F4EF673A3FE062547353D5F238" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_CD53779554EF447005FF547353D52182" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_CD53779554EF447005FF547353D52182" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_E134DAEB003AF380386C547353D54226" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73EEBA600BAF0BA88AB0547353D4A583" xlink:to="loc_us-gaap_Assets_E134DAEB003AF380386C547353D54226" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract" xlink:label="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3387F5F0C3F12A838CEB547353D44064" xlink:to="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_6568C07AA8B9EA1B2319547353D6EB54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:to="loc_us-gaap_AccountsPayableCurrent_6568C07AA8B9EA1B2319547353D6EB54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_42CE7F53B5389CB7872F547353D69492" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_42CE7F53B5389CB7872F547353D69492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_F91173A3A42CB268D415547353D62364" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:to="loc_us-gaap_DeferredRevenueCurrent_F91173A3A42CB268D415547353D62364" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_A8950A10EC17090F456B547353D6C7CA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_241F0CC9C9877EBA00F7547353D66491" xlink:to="loc_us-gaap_LiabilitiesCurrent_A8950A10EC17090F456B547353D6C7CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_6E5580085A3A40178E7E547353D614BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_6E5580085A3A40178E7E547353D614BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_F5B7E6F7616EBD3E5C8F547353D65CF0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_F5B7E6F7616EBD3E5C8F547353D65CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_88CDB362B9DC3B3E245A547353D60C55" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_Liabilities_88CDB362B9DC3B3E245A547353D60C55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_F35DADA3AE03A9A9FCCE547353D7F3AB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_CommitmentsAndContingencies_F35DADA3AE03A9A9FCCE547353D7F3AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_45B7545AA16A47652195547353D72653" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_45B7545AA16A47652195547353D72653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_286969AF39FBCE1FC840547353D76C39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:to="loc_us-gaap_CommonStockValue_286969AF39FBCE1FC840547353D76C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_D31E0FC5F81110C3CB92547353D704F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:to="loc_us-gaap_AdditionalPaidInCapital_D31E0FC5F81110C3CB92547353D704F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_13B8E5126698C1D8F3AE547353D7FD6E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_13B8E5126698C1D8F3AE547353D7FD6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_B3AFA382AE88B11985BF547353D789C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_B3AFA382AE88B11985BF547353D789C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6E7FB04C0A4604AD6E19547353D7D808" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F21037E3021351A48BBF547353D7BE9A" xlink:to="loc_us-gaap_StockholdersEquity_6E7FB04C0A4604AD6E19547353D7D808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ADBB05047361FF6E8022547353D77A13" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_LiabilitiesConvertiblePreferredStockandStockholdersDeficitAbstract_71F958124816081B6D8C547353D6DFAC" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ADBB05047361FF6E8022547353D77A13" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheetsComponents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2F92A81335F0D7E2EC7330CCDCA5C4A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_82049356049CDE17D53E307CD9360204" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2F92A81335F0D7E2EC7330CCDCA5C4A6" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_82049356049CDE17D53E307CD9360204" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheetsComponentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4A8B79A0A6B5E6734B4E30CD479BF6D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6209892984313B3CE284307CD9310A50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4A8B79A0A6B5E6734B4E30CD479BF6D6" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6209892984313B3CE284307CD9310A50" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_AccruedClinicalandDevelopmentExpenses" xlink:label="loc_mnlo_AccruedClinicalandDevelopmentExpenses_0CAC170C817BDC4C013C307CD9317689" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4A8B79A0A6B5E6734B4E30CD479BF6D6" xlink:to="loc_mnlo_AccruedClinicalandDevelopmentExpenses_0CAC170C817BDC4C013C307CD9317689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_25D94D0414923C209CA1307CD9313076" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4A8B79A0A6B5E6734B4E30CD479BF6D6" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_25D94D0414923C209CA1307CD9313076" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_876AE28EB659161B097A307CD931DE79" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4A8B79A0A6B5E6734B4E30CD479BF6D6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_876AE28EB659161B097A307CD931DE79" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheetsComponentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8B96709F47B64FDFB34E30CD126AB7F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_99C339FD7E6D68532CF5307CD933E203" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8B96709F47B64FDFB34E30CD126AB7F0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_99C339FD7E6D68532CF5307CD933E203" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_43550BB0EADF24970D162FF76BB9CAFF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_C8D1F0C28A46406AD5702FF76BBBC280" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_43550BB0EADF24970D162FF76BB9CAFF" xlink:to="loc_us-gaap_StatementTable_C8D1F0C28A46406AD5702FF76BBBC280" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6BA84BAE0C41CAEF0E902FF76BBB0F33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C8D1F0C28A46406AD5702FF76BBBC280" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6BA84BAE0C41CAEF0E902FF76BBB0F33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_0C909CDE62E2A758D1912FF76BBC65AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6BA84BAE0C41CAEF0E902FF76BBB0F33" xlink:to="loc_us-gaap_ClassOfStockDomain_0C909CDE62E2A758D1912FF76BBC65AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7A0255AC6DF9D254BE4B2FF76BBCC24D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0C909CDE62E2A758D1912FF76BBC65AE" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7A0255AC6DF9D254BE4B2FF76BBCC24D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_1EB6D055895F08DDBEA72FF76BBCE90A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0C909CDE62E2A758D1912FF76BBC65AE" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_1EB6D055895F08DDBEA72FF76BBCE90A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_892E5AA5BF09BDF5304B2FF76BBC27B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0C909CDE62E2A758D1912FF76BBC65AE" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_892E5AA5BF09BDF5304B2FF76BBC27B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_C8D1F0C28A46406AD5702FF76BBBC280" xlink:to="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_D1DE6A17AE536DDB5DA43067F6066D90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_D1DE6A17AE536DDB5DA43067F6066D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_57E22CE44114164DD917306D08497ACA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_57E22CE44114164DD917306D08497ACA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_7571388359F1B2F81F47306FB150EB69" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_7571388359F1B2F81F47306FB150EB69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_E725A0CFE69EEF6999AB30281099EA57" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_E725A0CFE69EEF6999AB30281099EA57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_A3435B48DB11CC36A136306AF39DDCF6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_A3435B48DB11CC36A136306AF39DDCF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_601DD1497DB8E6B1EEC92FF76BC22758" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_601DD1497DB8E6B1EEC92FF76BC22758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_10B79B381C8AE95CE0BF2FF76BC2C83A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_10B79B381C8AE95CE0BF2FF76BC2C83A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3094E2AFAACD554341842FF76BC27480" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_CommonStockSharesIssued_3094E2AFAACD554341842FF76BC27480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3306E1BCC36D18B90EA02FF76BC259D7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E0269924257AB10083AF2FF76BBC6604" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3306E1BCC36D18B90EA02FF76BC259D7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ACF1D36F8EC8B114794CEBDE2C7E2A81" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CEA2A8637DB805CEC012EBDE762FCD91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ACF1D36F8EC8B114794CEBDE2C7E2A81" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_CEA2A8637DB805CEC012EBDE762FCD91" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2664409D845574B1EB235D29D8738334" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2664409D845574B1EB235D29D8738334" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_0016B78D12DD93F8B0615D29D8742CD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:to="loc_us-gaap_StatementGeographicalAxis_0016B78D12DD93F8B0615D29D8742CD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_0016B78D12DD93F8B0615D29D8742CD4" xlink:to="loc_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd#stpr_CA" xlink:label="loc_stpr_CA_BEC629A08E695092D2B75D29D8748809" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_55C12DAE11D43E52B8FE5D29D8749F21" xlink:to="loc_stpr_CA_BEC629A08E695092D2B75D29D8748809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_84F54CAE9286DCA088315D29D8744908" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:to="loc_us-gaap_TypeOfArrangementAxis_84F54CAE9286DCA088315D29D8744908" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_84F54CAE9286DCA088315D29D8744908" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DevelopmentandRegulatoryMilestonesMember" xlink:label="loc_mnlo_DevelopmentandRegulatoryMilestonesMember_0D6820AB006E0FAD58B95D29D8740CA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A78C96D8B37FC73F173E5D29D874E1C5" xlink:to="loc_mnlo_DevelopmentandRegulatoryMilestonesMember_0D6820AB006E0FAD58B95D29D8740CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_A56551B6CCDA488AE21F5D29D8744E91" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:to="loc_us-gaap_CounterpartyNameAxis_A56551B6CCDA488AE21F5D29D8744E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_A56551B6CCDA488AE21F5D29D8744E91" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_MerckMember" xlink:label="loc_mnlo_MerckMember_0BA6C8B9018BD30CBEC45D29D874D2C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_D7A7565E8AC5B176376B5D29D874D2D6" xlink:to="loc_mnlo_MerckMember_0BA6C8B9018BD30CBEC45D29D874D2C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTable_737FBA3414FC6EE882E15D29D8734F49" xlink:to="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_516BADEF1CD528ADF65F5D29D8749524" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:to="loc_us-gaap_LicenseCosts_516BADEF1CD528ADF65F5D29D8749524" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CollaborativeArrangementsPotentialMilestonePayments" xlink:label="loc_mnlo_CollaborativeArrangementsPotentialMilestonePayments_87AAFA3E3CD6E6FA50985D29D8752778" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:to="loc_mnlo_CollaborativeArrangementsPotentialMilestonePayments_87AAFA3E3CD6E6FA50985D29D8752778" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_DF726D8F0FBBA9434F775D29D87587D2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_DF726D8F0FBBA9434F775D29D87587D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_FA59D05A99CB7180866F5D29D8758111" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_FA59D05A99CB7180866F5D29D8758111" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_OperatingLeaseMonthlyRentExpense" xlink:label="loc_mnlo_OperatingLeaseMonthlyRentExpense_310EDBBA96C545D0D0B05D29D875375E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:to="loc_mnlo_OperatingLeaseMonthlyRentExpense_310EDBBA96C545D0D0B05D29D875375E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_9E0FEEC7200E16CB8BD45D29D8754FA7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems_E401DAAA716CD00CCE5B5D29D874DEA2" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_9E0FEEC7200E16CB8BD45D29D8754FA7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3E04F74B09BCD89D0A112ABA35D68C46" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_EF967D327E5A3CCD6E4C2ABA35D61149" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3E04F74B09BCD89D0A112ABA35D68C46" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_EF967D327E5A3CCD6E4C2ABA35D61149" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3D41BAE5214B5C6440672ABA35D6DD96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_EF967D327E5A3CCD6E4C2ABA35D61149" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3D41BAE5214B5C6440672ABA35D6DD96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3EF39D8541B85D8AD3F22ABA35D6F04D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_EF967D327E5A3CCD6E4C2ABA35D61149" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3EF39D8541B85D8AD3F22ABA35D6F04D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6618F2BEB8CF82C4C8BF2ACD93213DBB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_EF967D327E5A3CCD6E4C2ABA35D61149" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6618F2BEB8CF82C4C8BF2ACD93213DBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4437A4209A9C4DA9E0D2ABA35D634FD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_EF967D327E5A3CCD6E4C2ABA35D61149" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E4437A4209A9C4DA9E0D2ABA35D634FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72E6BDD1451E9E7B8CC2075D3EEEDEFC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_10722F9CF8BDB700483E07C1698FAD32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_72E6BDD1451E9E7B8CC2075D3EEEDEFC" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_10722F9CF8BDB700483E07C1698FAD32" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_14A72EFBF46F01A6CDEAEBD734091205" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1C08D221881E815065B5EBD9CA9A8BA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_14A72EFBF46F01A6CDEAEBD734091205" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1C08D221881E815065B5EBD9CA9A8BA8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_051444B3E09DA4732C7A408FC3D0664E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8DEB50C6DBCAC0348956408FC3D04FF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_051444B3E09DA4732C7A408FC3D0664E" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8DEB50C6DBCAC0348956408FC3D04FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_698A89828E8105C7991D408FC3DF330D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_051444B3E09DA4732C7A408FC3D0664E" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_698A89828E8105C7991D408FC3DF330D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_D453EB24BD7E1FA6AE2840B4AA29ADB1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_051444B3E09DA4732C7A408FC3D0664E" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_D453EB24BD7E1FA6AE2840B4AA29ADB1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/ConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_EBA0F9B8704EB5FBE8E6EBDC67F27F0E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaap_PreferredStockTextBlock_B348C0E8F0291FACD77BEBDC970D6FBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_EBA0F9B8704EB5FBE8E6EBDC67F27F0E" xlink:to="loc_us-gaap_PreferredStockTextBlock_B348C0E8F0291FACD77BEBDC970D6FBF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockConvertiblePreferredStockOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1A71FC72097A849827C93974E219AE94" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_04C754A31C039E30A1973974E219A7D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1A71FC72097A849827C93974E219AE94" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_04C754A31C039E30A1973974E219A7D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ABD7117B2A279962A5183974E21A3031" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_04C754A31C039E30A1973974E219A7D0" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ABD7117B2A279962A5183974E21A3031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A33898EBDA8D13D314543974E21AEA72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ABD7117B2A279962A5183974E21A3031" xlink:to="loc_us-gaap_ClassOfStockDomain_A33898EBDA8D13D314543974E21AEA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_348CB837A0144E3BC99D3974E21ACC72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A33898EBDA8D13D314543974E21AEA72" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_348CB837A0144E3BC99D3974E21ACC72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_71639DEAC6B91CCFAA2C3974E21AD2F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A33898EBDA8D13D314543974E21AEA72" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_71639DEAC6B91CCFAA2C3974E21AD2F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_2130C3DDBDF0E0F3C9753974E21A16DE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A33898EBDA8D13D314543974E21AEA72" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_2130C3DDBDF0E0F3C9753974E21A16DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_6AD1D6B7302F3FA9C3D53974E21A8435" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_04C754A31C039E30A1973974E219A7D0" xlink:to="loc_us-gaap_ClassOfStockLineItems_6AD1D6B7302F3FA9C3D53974E21A8435" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_6DE79C990D207A1E7DAB39C67DB87A32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6AD1D6B7302F3FA9C3D53974E21A8435" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_6DE79C990D207A1E7DAB39C67DB87A32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_B999B711109CC691E0C8398BAEE7B7BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6AD1D6B7302F3FA9C3D53974E21A8435" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_B999B711109CC691E0C8398BAEE7B7BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_87ACE2262EE500E0FE31399205900ED6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6AD1D6B7302F3FA9C3D53974E21A8435" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_87ACE2262EE500E0FE31399205900ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_2425DF1839D0252D1E1639AF20B37B4B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6AD1D6B7302F3FA9C3D53974E21A8435" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_2425DF1839D0252D1E1639AF20B37B4B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0327C84300F74CFB693A5440F89A53EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0327C84300F74CFB693A5440F89A53EB" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_013D00FE6F98F11347AA5440F89ABC3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_013D00FE6F98F11347AA5440F89ABC3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_013D00FE6F98F11347AA5440F89ABC3E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_ECDE816EFEF8F51CFC975440F89A9BE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6" xlink:to="loc_us-gaap_IPOMember_ECDE816EFEF8F51CFC975440F89A9BE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_7C32B961CEE8F74E63945440F89B045B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F8B37AEB2A063ACD978E5440F89A3FB6" xlink:to="loc_us-gaap_OverAllotmentOptionMember_7C32B961CEE8F74E63945440F89B045B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_F98C09854B14F0B40A155440F89B0FC3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_F98C09854B14F0B40A155440F89B0FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_F98C09854B14F0B40A155440F89B0FC3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2F36F9A1FA5B7A332F7B5440F89B558F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_645B8D0347EAD694B5685440F89BA44B" xlink:to="loc_us-gaap_SubsequentEventMember_2F36F9A1FA5B7A332F7B5440F89B558F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8A630BF5B493054096D75440F89B3737" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8A630BF5B493054096D75440F89B3737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8A630BF5B493054096D75440F89B3737" xlink:to="loc_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_8EB429153DC5CDAA40895440F89B50E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_8EB429153DC5CDAA40895440F89B50E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_0E0AF994A6DECB41777D5440F89C2137" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_0E0AF994A6DECB41777D5440F89C2137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_DD2A4A9210CA6F8F303D5440F89C984B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_913AC4702A942514DF565440F89BB737" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_DD2A4A9210CA6F8F303D5440F89C984B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_26464530C0DBC3329E9B5440F89AC8EA" xlink:to="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_1E674227F58A34BE65A85440F89C8924" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_1E674227F58A34BE65A85440F89C8924" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A359941E2A347A6A32855440F89C5AA9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_A359941E2A347A6A32855440F89C5AA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_4ACD6B50509343E2C9565440F89CC0C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_4ACD6B50509343E2C9565440F89CC0C6" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityIssuedPriceperShare" xlink:label="loc_mnlo_TemporaryEquityIssuedPriceperShare_5B86F4285B977FAF8CC15440F89C0531" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_mnlo_TemporaryEquityIssuedPriceperShare_5B86F4285B977FAF8CC15440F89C0531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E37D5AF9D628C23AA2C25448AE99B96D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E37D5AF9D628C23AA2C25448AE99B96D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_446A7BE0633FB8636DE65440F89C5783" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_446A7BE0633FB8636DE65440F89C5783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_799F5CC7CE99C664C2445440F89C63AE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_799F5CC7CE99C664C2445440F89C63AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_0252498DC890F543C7395440F89C0B26" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_0252498DC890F543C7395440F89C0B26" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityDividendRatePerDollarAmount" xlink:label="loc_mnlo_TemporaryEquityDividendRatePerDollarAmount_CC521A73AE7568716BB25440F89C7294" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_mnlo_TemporaryEquityDividendRatePerDollarAmount_CC521A73AE7568716BB25440F89C7294" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect" xlink:label="loc_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect_AFECC191D94D3C2F96295440F89DC536" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect_AFECC191D94D3C2F96295440F89DC536" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect" xlink:label="loc_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect_712ED576091617BB6CCA5440F89DD052" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect_712ED576091617BB6CCA5440F89DD052" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering" xlink:label="loc_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering_43B100353CDCAAB6814B5440F89D4DAB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering_43B100353CDCAAB6814B5440F89D4DAB" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering" xlink:label="loc_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering_C485F57597272CE50B685440F89DF51E" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_91FB773099DD394281F35440F89CC891" xlink:to="loc_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering_C485F57597272CE50B685440F89DF51E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/ConvertiblePreferredStockTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_21C617F700905DC197853974E228650D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_D79D61EEAE16BF07994039A8B59D04BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_21C617F700905DC197853974E228650D" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_D79D61EEAE16BF07994039A8B59D04BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/DeiDocument" xlink:type="extended">
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_EntityAbstract" xlink:label="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_F47ABBAEDC865876A26D03F050EB8D4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="loc_dei_EntityRegistrantName_F47ABBAEDC865876A26D03F050EB8D4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_DE09D3A06C73A5187E4203F0ADD2E13D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="loc_dei_EntityCentralIndexKey_DE09D3A06C73A5187E4203F0ADD2E13D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_E6B672022FAEFACAB1E503F12E99D23C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="loc_dei_CurrentFiscalYearEndDate_E6B672022FAEFACAB1E503F12E99D23C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_FB89BDC0AF21E8600F7F03F194F717A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="loc_dei_EntityFilerCategory_FB89BDC0AF21E8600F7F03F194F717A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_91821513D86EEB495AF703F2A139B279" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="loc_dei_DocumentType_91821513D86EEB495AF703F2A139B279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_C4FF33E8F8A4A427A8CB03F2FE12E415" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="loc_dei_DocumentPeriodEndDate_C4FF33E8F8A4A427A8CB03F2FE12E415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_6058B161F62902BD004303F356E1B397" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="loc_dei_DocumentFiscalYearFocus_6058B161F62902BD004303F356E1B397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0AB1F52EFB6DC134B36603F3EA78DEE5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0AB1F52EFB6DC134B36603F3EA78DEE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_7CF7999636F56CA3D3D303F45DD61977" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="loc_dei_AmendmentFlag_7CF7999636F56CA3D3D303F45DD61977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_CBA3E60D7BD3F5BDBD8303F5C2DD4B01" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_CBA3E60D7BD3F5BDBD8303F5C2DD4B01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_2BDC7073BF7741F7156903F6E74B4545" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_2BDC7073BF7741F7156903F6E74B4545" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_3FADBEBD1F29821541EC03F7702BE0BB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="loc_dei_EntityVoluntaryFilers_3FADBEBD1F29821541EC03F7702BE0BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_1AB032238A4466276B9803F8192D35A9" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="loc_dei_EntityCurrentReportingStatus_1AB032238A4466276B9803F8192D35A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_A0F45691227B01C2805C03F8C79EA81C" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mnlo_EntityAbstract_301DADC4D6F98739228A03F00E689507" xlink:to="loc_dei_EntityPublicFloat_A0F45691227B01C2805C03F8C79EA81C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E9A23F202D47BCCF494DEBE8B25CFCF6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_089D619DD172FB831346EBE8E51B8CF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E9A23F202D47BCCF494DEBE8B25CFCF6" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_089D619DD172FB831346EBE8E51B8CF7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/FairValueMeasurementsAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_BD470CBBB57777545D615440F8C13DBF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_BD470CBBB57777545D615440F8C13DBF" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_3FD67C09DC87421586655440F8C1EAB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_3FD67C09DC87421586655440F8C1EAB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4B87DAEC7D7016CAB28E5440F8C249AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_3FD67C09DC87421586655440F8C1EAB5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4B87DAEC7D7016CAB28E5440F8C249AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2C5DA0A9CB810422CA075440F8C2DF57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4B87DAEC7D7016CAB28E5440F8C249AD" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2C5DA0A9CB810422CA075440F8C2DF57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85D6DDACDB64A56B48885440F8C29884" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85D6DDACDB64A56B48885440F8C29884" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_B51C9DAB0B480C42A4DE5440F8C256C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_85D6DDACDB64A56B48885440F8C29884" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_B51C9DAB0B480C42A4DE5440F8C256C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_3FC8D8340DBF77FD8D195440F8C29CBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_B51C9DAB0B480C42A4DE5440F8C256C7" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_3FC8D8340DBF77FD8D195440F8C29CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4C1EEA14B549EBCCD8015440F8C22A79" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_B51C9DAB0B480C42A4DE5440F8C256C7" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_4C1EEA14B549EBCCD8015440F8C22A79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EAAA1B9B78F8F892DC725440F8C1FC3C" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D43B54C05EC99C8767F55440F8C3073F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_D43B54C05EC99C8767F55440F8C3073F" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_5E4FE07DDEBF018C11F65440F8C36BB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax_5E4FE07DDEBF018C11F65440F8C36BB1" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_92E6E940A8BEA5991BAF5440F8C39B1A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax_92E6E940A8BEA5991BAF5440F8C39B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1AFED2AFB787D43B8CEB5440F8C311F3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1AFED2AFB787D43B8CEB5440F8C311F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3EC3E4802D28D0158E8E5440F8C316BF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3EC3E4802D28D0158E8E5440F8C316BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_981DA87253EA566D219F5440F8C3E7CD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_981DA87253EA566D219F5440F8C3E7CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C974AE36EE1CFA4392295440F8C30923" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C974AE36EE1CFA4392295440F8C30923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_2155FB286013F8CF82155440F8C30392" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_us-gaap_AvailableForSaleSecurities_2155FB286013F8CF82155440F8C30392" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis" xlink:label="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_F46647ED0033FEB01A415440F8C3289B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis_F46647ED0033FEB01A415440F8C3289B" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_DC710C8EE1ED645D352D5440F8C3F251" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax_DC710C8EE1ED645D352D5440F8C3F251" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax" xlink:label="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_7D1A57CE38BB3B1FB3495440F8C3F31E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax_7D1A57CE38BB3B1FB3495440F8C3F31E" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CashCashEquivalentsandAvailableforsaleSecurities" xlink:label="loc_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_BDCFF446313223029E05544200375598" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0819F2191588B867AC945440F8C2A09B" xlink:to="loc_mnlo_CashCashEquivalentsandAvailableforsaleSecurities_BDCFF446313223029E05544200375598" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_F288114978738E4C879A5D29D895C758" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_F288114978738E4C879A5D29D895C758" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_4F207AB4DB3CF16E88C95D29D89681A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_4F207AB4DB3CF16E88C95D29D89681A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_4F207AB4DB3CF16E88C95D29D89681A6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9D7C1A0CBAFBC193142A5D29D8975460" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1B924E86A5332BB9F3B05D29D897CC73" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9D7C1A0CBAFBC193142A5D29D8975460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_A6C3C3D57F6B6342DF4F5D29D896EC65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_A6C3C3D57F6B6342DF4F5D29D896EC65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_A6C3C3D57F6B6342DF4F5D29D896EC65" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateNoteSecuritiesMember" xlink:label="loc_us-gaap_CorporateNoteSecuritiesMember_4C6EB0969FE2D660120E5D74FF301FA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E" xlink:to="loc_us-gaap_CorporateNoteSecuritiesMember_4C6EB0969FE2D660120E5D74FF301FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CD6BCC536D129E34FC8A5D76BD4F88CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5CA27829D3FA19F457B25D29D896469E" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_CD6BCC536D129E34FC8A5D76BD4F88CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_AAE2AB7D21823DA99FE65D29D8973E17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_AAE2AB7D21823DA99FE65D29D8973E17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2345F05FB0CC266D50285D29D8975064" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_AAE2AB7D21823DA99FE65D29D8973E17" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2345F05FB0CC266D50285D29D8975064" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2345F05FB0CC266D50285D29D8975064" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_55B7067D671D7E9381F85D29D897416A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_55B7067D671D7E9381F85D29D897416A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_D61914EA9077121B30A75D29D89891A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53818924D0CB3B57EDF75D29D897F0A7" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_D61914EA9077121B30A75D29D89891A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_624D27777E600DFA42845D29D898F4A9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_624D27777E600DFA42845D29D898F4A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_624D27777E600DFA42845D29D898F4A9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_C5E197B93DBB251E89D65D29D89850C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_C5E197B93DBB251E89D65D29D89850C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E2192BB7CB08AFB5C29F5D29D8987F56" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_E2192BB7CB08AFB5C29F5D29D8987F56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_BA6DE56191F0955D9A975D29D8988C17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6BD621F9CE25307AE4EA5D29D898DCE0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_BA6DE56191F0955D9A975D29D8988C17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_521FEF62FF1295053FC65D29D895B082" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B2E80FE0EF16D5FCC3CF5D29D8988E48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_B2E80FE0EF16D5FCC3CF5D29D8988E48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_4C0CA29821E835EBA29C5D29D899F6F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_4C0CA29821E835EBA29C5D29D899F6F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_24E83FF9E08FDF39C4E95D29D8993E68" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3B595C8EEC0F29BBA7205D29D8982F78" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_24E83FF9E08FDF39C4E95D29D8993E68" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_CCF145BF899A59FD919E4114A9B850D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7EC366C23E62D33C231441272C80FE36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_CCF145BF899A59FD919E4114A9B850D1" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7EC366C23E62D33C231441272C80FE36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_F5007B00B76BA19F938B4114A9B819D0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_CCF145BF899A59FD919E4114A9B850D1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_F5007B00B76BA19F938B4114A9B819D0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompany" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2E8433E8A6EEBE36226A2FF8B4D9AEE5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_8721425396741D1F458F306651B11C2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2E8433E8A6EEBE36226A2FF8B4D9AEE5" xlink:to="loc_us-gaap_NatureOfOperations_8721425396741D1F458F306651B11C2C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompanyDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4F30D84D0E7BC4988CB753FB2B3F4C56" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4F30D84D0E7BC4988CB753FB2B3F4C56" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_B1199A685BEDA3B2637F53FB2B3F47A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_B1199A685BEDA3B2637F53FB2B3F47A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_B1199A685BEDA3B2637F53FB2B3F47A4" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember" xlink:label="loc_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_D1FCAF046F2AF30B210D53FB2B3F3646" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_A62ED4B7C59C096F6AD853FB2B3F5272" xlink:to="loc_mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember_D1FCAF046F2AF30B210D53FB2B3F3646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6D62E16CAD3A2D8ADF8753FB2B3FB1DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6D62E16CAD3A2D8ADF8753FB2B3FB1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_048C42B04406C4AB7C8153FB2B3FD96E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6D62E16CAD3A2D8ADF8753FB2B3FB1DB" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_048C42B04406C4AB7C8153FB2B3FD96E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_7B65DE554CBF8DDCB64D53FB2B4061F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_048C42B04406C4AB7C8153FB2B3FD96E" xlink:to="loc_us-gaap_IPOMember_7B65DE554CBF8DDCB64D53FB2B4061F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_1B0D102746BE1FFE3BB253FB2B401957" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_048C42B04406C4AB7C8153FB2B3FD96E" xlink:to="loc_us-gaap_OverAllotmentOptionMember_1B0D102746BE1FFE3BB253FB2B401957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_EEB4293D8DAF68FAD12153FB2B4056D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_EEB4293D8DAF68FAD12153FB2B4056D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_002FC8AAF46ADBCBAB7B53FB2B408E2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_EEB4293D8DAF68FAD12153FB2B4056D4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_002FC8AAF46ADBCBAB7B53FB2B408E2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_C1F61BDCD0D3AACABA7153FB2B4024C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_002FC8AAF46ADBCBAB7B53FB2B408E2A" xlink:to="loc_us-gaap_SubsequentEventMember_C1F61BDCD0D3AACABA7153FB2B4024C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_F637FF0BD2228339B39753FB2B3F09FE" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91C39BA70C22433BEA505409D1F6DD53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91C39BA70C22433BEA505409D1F6DD53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8930A61244A12CB07D8F53FB2B404B7F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_8930A61244A12CB07D8F53FB2B404B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_CE179E151F39A02733ED53FB2B40C265" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_CE179E151F39A02733ED53FB2B40C265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9D67BF2DF602A316C0DB53FB2B40EAB7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_NetIncomeLoss_9D67BF2DF602A316C0DB53FB2B40EAB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A1998BF95D10AA3FAC9D53FB2B406B5F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_A1998BF95D10AA3FAC9D53FB2B406B5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAndCash" xlink:label="loc_us-gaap_InvestmentsAndCash_1DF6AEBDD5D94FB19FAB53FB2B4028C1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_InvestmentsAndCash_1DF6AEBDD5D94FB19FAB53FB2B4028C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9E3A19C8DB9104D355F453FB2B416A8A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_76B8EC86F1083BEB015653FB2B40E83D" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9E3A19C8DB9104D355F453FB2B416A8A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8DD74F3D434CF8F8DC51EBCE850D2F4B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_915E8665578954362099EBCEA7B27D94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8DD74F3D434CF8F8DC51EBCE850D2F4B" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_915E8665578954362099EBCEA7B27D94" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_AA56C75474F48AF788A9648483ABF900" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_AA56C75474F48AF788A9648483ABF900" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_CB10BA50D236855D9532648483ABA96F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_CB10BA50D236855D9532648483ABA96F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_CB10BA50D236855D9532648483ABA96F" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_FABB03E1742A465828DB648483ACB3D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_EF6F065D54A444F4760A648483AC8910" xlink:to="loc_us-gaap_ResearchMember_FABB03E1742A465828DB648483ACB3D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_34801363164571A79FC4648483AC8DC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_34801363164571A79FC4648483AC8DC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_34801363164571A79FC4648483AC8DC7" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_DF408A904D9D38D521F1648483AC1BDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B" xlink:to="loc_us-gaap_DomesticCountryMember_DF408A904D9D38D521F1648483AC1BDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_0D17C56239D8FF31FEA5648483ACE139" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_481451C34B374C5B7C34648483AC251B" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_0D17C56239D8FF31FEA5648483ACE139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_B6C550D7CE888C0C90AF648483AB74F4" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_623B16D35B4C4C2F5DDA648483AC459D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_623B16D35B4C4C2F5DDA648483AC459D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_23F3CFF8D23125C976FB648483AC77F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:to="loc_us-gaap_OperatingLossCarryforwards_23F3CFF8D23125C976FB648483AC77F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_9250E17EAA8CCB4259D4648483AC146D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_9250E17EAA8CCB4259D4648483AC146D" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit_AF78EB83B19EB905E7CB648483ACC218" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:to="loc_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit_AF78EB83B19EB905E7CB648483ACC218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ED560AD7E01022DF855648483AC0DBA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_572EDD5406407942A502648483AC92E3" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4ED560AD7E01022DF855648483AC0DBA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_14AFB939E23B91E6A943546789B8BFD3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AC807EB2C69F471981A0546789B82572" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_14AFB939E23B91E6A943546789B8BFD3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_AC807EB2C69F471981A0546789B82572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E8F439C70EEB60F49D90546789B99775" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_14AFB939E23B91E6A943546789B8BFD3" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_E8F439C70EEB60F49D90546789B99775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0978FBE91FA974E260F0546789B90024" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_14AFB939E23B91E6A943546789B8BFD3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0978FBE91FA974E260F0546789B90024" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_22D6CB0F82A5DE646835546789B979A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_14AFB939E23B91E6A943546789B8BFD3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_22D6CB0F82A5DE646835546789B979A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_4D335F2BB0B385F235B5546789B9C500" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_14AFB939E23B91E6A943546789B8BFD3" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_4D335F2BB0B385F235B5546789B9C500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_55DD62A32B624873154F546789B984DD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_14AFB939E23B91E6A943546789B8BFD3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_55DD62A32B624873154F546789B984DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_03B3788A48E574C22D86546789BEC492" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_14AFB939E23B91E6A943546789B8BFD3" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_03B3788A48E574C22D86546789BEC492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_BE7F3F6E3C5F9F151669546789BF1657" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_14AFB939E23B91E6A943546789B8BFD3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_BE7F3F6E3C5F9F151669546789BF1657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_946CF531CC6FF3B76659546789BFE4AC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_14AFB939E23B91E6A943546789B8BFD3" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_946CF531CC6FF3B76659546789BFE4AC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C0197288CF50800BE35568A0D066872F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B1E3651CAD11DBD6CF1468A12C50D28C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C0197288CF50800BE35568A0D066872F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_B1E3651CAD11DBD6CF1468A12C50D28C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8A3A20CE7A1592DFEC9068A1912805AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C0197288CF50800BE35568A0D066872F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8A3A20CE7A1592DFEC9068A1912805AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_C496191FC650FE9C59D668A59601F410" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C0197288CF50800BE35568A0D066872F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_C496191FC650FE9C59D668A59601F410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_78FEDAB4A1B0F0F015E468A20D1F8ADD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C0197288CF50800BE35568A0D066872F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_78FEDAB4A1B0F0F015E468A20D1F8ADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A0FDD4A0675412A9402E68A2EEF71990" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C0197288CF50800BE35568A0D066872F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_A0FDD4A0675412A9402E68A2EEF71990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_62911C3122C13146FAED68A379E5F1E9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C0197288CF50800BE35568A0D066872F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_62911C3122C13146FAED68A379E5F1E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_558F9B5EC7839920020068A3F800AFF3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C0197288CF50800BE35568A0D066872F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_558F9B5EC7839920020068A3F800AFF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952F266A6BA616D4C8B368A4E9CC8673" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C0197288CF50800BE35568A0D066872F" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_952F266A6BA616D4C8B368A4E9CC8673" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_999CAF55FF007619223B689ED4A7E398" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A7832E442E948136E6DE689F99209181" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_999CAF55FF007619223B689ED4A7E398" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_A7832E442E948136E6DE689F99209181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_D1D6E212226D5EDFFEE8689ED4A9E0EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_999CAF55FF007619223B689ED4A7E398" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_D1D6E212226D5EDFFEE8689ED4A9E0EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_463F92A49139E5A9FC3E689ED4A95EC5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_999CAF55FF007619223B689ED4A7E398" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_463F92A49139E5A9FC3E689ED4A95EC5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/IncomeTaxesUncertainTaxPositionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3BBAEC7F0F435228B4DF4958A77F462E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7B7E9F9842FFF7F774094958A77FE8B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3BBAEC7F0F435228B4DF4958A77F462E" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7B7E9F9842FFF7F774094958A77FE8B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1EDA1904D91150CF90F54958A77F399B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3BBAEC7F0F435228B4DF4958A77F462E" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1EDA1904D91150CF90F54958A77F399B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C74211BA7E6D28CE8144958A77F1465" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3BBAEC7F0F435228B4DF4958A77F462E" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3C74211BA7E6D28CE8144958A77F1465" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_65E675299D1156ABBB074958A78007B7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3BBAEC7F0F435228B4DF4958A77F462E" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_65E675299D1156ABBB074958A78007B7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholders" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5D5A0DF4EB585E8D8321EBD18B38B04A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2521D9CE876BF9F1F87CEBD1C97399D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5D5A0DF4EB585E8D8321EBD18B38B04A" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2521D9CE876BF9F1F87CEBD1C97399D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersAntidilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_55FEC8C18324CCB1AB0E3E3F0996B8A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8D32FFF3F75D90883573E3F0996A891" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_55FEC8C18324CCB1AB0E3E3F0996B8A6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8D32FFF3F75D90883573E3F0996A891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8538E30EF724C0FF8EB03E3F0996F32C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8D32FFF3F75D90883573E3F0996A891" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8538E30EF724C0FF8EB03E3F0996F32C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8538E30EF724C0FF8EB03E3F0996F32C" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_D8272A36141192DFD4FD3E3F09970855" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_D8272A36141192DFD4FD3E3F09970855" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_OutstandingCommonStockSubjecttoRepurchaseMember" xlink:label="loc_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember_65527C34FC073241AB223E3F099744EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:to="loc_mnlo_OutstandingCommonStockSubjecttoRepurchaseMember_65527C34FC073241AB223E3F099744EB" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_OptionsOutstandingMember" xlink:label="loc_mnlo_OptionsOutstandingMember_0ABEE2C20091AD6275823E5DD6742D45" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:to="loc_mnlo_OptionsOutstandingMember_0ABEE2C20091AD6275823E5DD6742D45" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember" xlink:label="loc_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember_2137DA419B6586F114EC3E5F2E87C349" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76E4B14C67A6D7865D703E3F09968CF8" xlink:to="loc_mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember_2137DA419B6586F114EC3E5F2E87C349" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03CA3B0257AA5D69C1993E3F09978C14" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8D32FFF3F75D90883573E3F0996A891" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03CA3B0257AA5D69C1993E3F09978C14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C5A6FBF2095C4FFFC7AD3E3F0997DAA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03CA3B0257AA5D69C1993E3F09978C14" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C5A6FBF2095C4FFFC7AD3E3F0997DAA5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_590FF1AF4A1CBDCB15A36464F3B7E093" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_5D8C885C4F339E8EB6E66464F3B7D682" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_590FF1AF4A1CBDCB15A36464F3B7E093" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_5D8C885C4F339E8EB6E66464F3B7D682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_E00FF9D810C4012603DD6464F3B79691" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_5D8C885C4F339E8EB6E66464F3B7D682" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_E00FF9D810C4012603DD6464F3B79691" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5CC135FAD56F23D3C7336464F3B7BB59" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_5D8C885C4F339E8EB6E66464F3B7D682" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5CC135FAD56F23D3C7336464F3B7BB59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_235AAEB003DBD46F78896464F3B7699E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_590FF1AF4A1CBDCB15A36464F3B7E093" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_235AAEB003DBD46F78896464F3B7699E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_40EDA1C4DDFCA8ABD5BE6464F3C62982" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_235AAEB003DBD46F78896464F3B7699E" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_40EDA1C4DDFCA8ABD5BE6464F3C62982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_55E359171D5F82D189FD6464F3C646B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_235AAEB003DBD46F78896464F3B7699E" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_55E359171D5F82D189FD6464F3C646B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4120E87D3B2341DDF6876464F3C6C906" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_235AAEB003DBD46F78896464F3B7699E" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4120E87D3B2341DDF6876464F3C6C906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_29894A4123E05C3DD3BB6464F3C672BE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_590FF1AF4A1CBDCB15A36464F3B7E093" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_29894A4123E05C3DD3BB6464F3C672BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_8BAF892C463D657F2EC66464F3C66F4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_29894A4123E05C3DD3BB6464F3C672BE" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_8BAF892C463D657F2EC66464F3C66F4F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_985E9C49EBA9A32912FF1C0DF9F63CC3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_E8C8F92EBFC0B7B91F921C0E3EA0D19F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_985E9C49EBA9A32912FF1C0DF9F63CC3" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_E8C8F92EBFC0B7B91F921C0E3EA0D19F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7647B7F5807FD594F0EA1C1E7F4C03C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_985E9C49EBA9A32912FF1C0DF9F63CC3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7647B7F5807FD594F0EA1C1E7F4C03C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_F681CA69105C65424B59EBCA43DD3C05" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C67DD63A1D396550F0FEEBCA81320F00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_F681CA69105C65424B59EBCA43DD3C05" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C67DD63A1D396550F0FEEBCA81320F00" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_2885135CEBAA7D9A95865D29D77748C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2885135CEBAA7D9A95865D29D77748C1" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_6FEAA6BA8CE96DBC0F415D29D77760A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8" xlink:to="loc_us-gaap_CounterpartyNameAxis_6FEAA6BA8CE96DBC0F415D29D77760A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2B0906E852BECE8DD73E5D29D778A1F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_6FEAA6BA8CE96DBC0F415D29D77760A0" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2B0906E852BECE8DD73E5D29D778A1F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AffiliatedEntityMember" xlink:label="loc_us-gaap_AffiliatedEntityMember_5C51CE3DD85A100DC87D5D29D7787698" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_2B0906E852BECE8DD73E5D29D778A1F6" xlink:to="loc_us-gaap_AffiliatedEntityMember_5C51CE3DD85A100DC87D5D29D7787698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_3F504CB3697B34D8A4155D29D778F8BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_3F504CB3697B34D8A4155D29D778F8BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_3F504CB3697B34D8A4155D29D778F8BF" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DevelopmentServicesFeesMember" xlink:label="loc_mnlo_DevelopmentServicesFeesMember_132A3980A03AD2E252CF5D29D77889C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_91517441CBBD029BB45B5D29D77840FF" xlink:to="loc_mnlo_DevelopmentServicesFeesMember_132A3980A03AD2E252CF5D29D77889C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0E6A59DDEA5A0CC355265D29D77743F8" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_B7A03D167A866811103F5D29D7786D1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_B7A03D167A866811103F5D29D7786D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9D7428297C45AD7BBE775D29D779DB61" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_BA2AA695BA2F18C29ADF5D29D778BDF5" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9D7428297C45AD7BBE775D29D779DB61" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialData" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_EB296602D8D3B33B5F0D40E2B31A6EDD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_DE0ABFA0A18BE6E9B5B640E2E98678F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_EB296602D8D3B33B5F0D40E2B31A6EDD" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_DE0ABFA0A18BE6E9B5B640E2E98678F6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6DD3FB8806748EDC531553FB2A57DBE4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_937FCA85EE18990EEF6853FB2A572230" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6DD3FB8806748EDC531553FB2A57DBE4" xlink:to="loc_us-gaap_LicenseAndServicesRevenue_937FCA85EE18990EEF6853FB2A572230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_65646A28B5653475186953FB2A57BA6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6DD3FB8806748EDC531553FB2A57DBE4" xlink:to="loc_us-gaap_OperatingExpenses_65646A28B5653475186953FB2A57BA6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_C9E5F3F4A5895964CCB553FB2A5877B7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6DD3FB8806748EDC531553FB2A57DBE4" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_C9E5F3F4A5895964CCB553FB2A5877B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EE121CDEC2E0E9E6327E53FB2A587725" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6DD3FB8806748EDC531553FB2A57DBE4" xlink:to="loc_us-gaap_NetIncomeLoss_EE121CDEC2E0E9E6327E53FB2A587725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_F2DE09B66F29789FCA3A53FB2A583E07" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_6DD3FB8806748EDC531553FB2A57DBE4" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_F2DE09B66F29789FCA3A53FB2A583E07" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_06BDA4E448C7FBE9C74940E2B32C20A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5F3AA8A05C6E852FD42940E39CF9C292" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_06BDA4E448C7FBE9C74940E2B32C20A9" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_5F3AA8A05C6E852FD42940E39CF9C292" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3E485A0D8ACE47C5E1613002E4E7C12A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_511C994564CB7B7CED623035021AB5EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3E485A0D8ACE47C5E1613002E4E7C12A" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_511C994564CB7B7CED623035021AB5EC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B5C58A656157557548E44AE4D62FFA25" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0C00620B28F490E409B04AE4D62F4D60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B5C58A656157557548E44AE4D62FFA25" xlink:to="loc_us-gaap_NumberOfOperatingSegments_0C00620B28F490E409B04AE4D62F4D60" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits" xlink:label="loc_mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits_1A7996E0FA9E3EF6EDC34AE4D62FFDCE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B5C58A656157557548E44AE4D62FFA25" xlink:to="loc_mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits_1A7996E0FA9E3EF6EDC34AE4D62FFDCE" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum" xlink:label="loc_mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum_CAC33A3CC63AB6E73BFD4AE4D6300081" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B5C58A656157557548E44AE4D62FFA25" xlink:to="loc_mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum_CAC33A3CC63AB6E73BFD4AE4D6300081" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6F1EAFBED9B3257D5EBC307CD95A9AFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6F1EAFBED9B3257D5EBC307CD95A9AFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_8D7F7E5BECC327B4B165307CD95AD7B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_8D7F7E5BECC327B4B165307CD95AD7B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2A54E70962EDAC2FC25F307CD95A4680" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2A54E70962EDAC2FC25F307CD95A4680" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_AD5FDA87F859D90101C3307CD95A2D2D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_UseOfEstimates_AD5FDA87F859D90101C3307CD95A2D2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A6C4A0B56E8F8432EBAD307CD95A7BB3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A6C4A0B56E8F8432EBAD307CD95A7BB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_84A16971B03272E91767307CD95B6D0F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_84A16971B03272E91767307CD95B6D0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_17C9B4765A06A73F6C79307CD95B56FE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_17C9B4765A06A73F6C79307CD95B56FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_294ACFCBC16ABCBA0CB9307CD95BF209" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_294ACFCBC16ABCBA0CB9307CD95BF209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_D77757440BBC8044AD01307CD95BD841" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_D77757440BBC8044AD01307CD95BD841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6E2A4589E284E8FDECBB307CD95B4332" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_6E2A4589E284E8FDECBB307CD95B4332" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7A425E03FF04F937F66F307CD95BEFC4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7A425E03FF04F937F66F307CD95BEFC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_35580FE9E4F083F3E608307CD95B2142" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_35580FE9E4F083F3E608307CD95B2142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_D76F663F3F83EB2316C8307CD95B3216" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_D76F663F3F83EB2316C8307CD95B3216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_515FF59F4A4437599E43307CD95B0AFA" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_515FF59F4A4437599E43307CD95B0AFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_2A05BA97B8EAB19364BE3098EC03AECB" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_2A05BA97B8EAB19364BE3098EC03AECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2AD9B2C2FBC6F6DC8B0E307CD95B199C" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_2AD9B2C2FBC6F6DC8B0E307CD95B199C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1C63CBD146982DC1FF14307CD95B0768" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1C63CBD146982DC1FF14307CD95B0768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_4099CCF07BA4ADF659CA307CD95BD4D3" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_4099CCF07BA4ADF659CA307CD95BD4D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C80A3308C1CED3AD57A1307CD95BA4E8" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C80A3308C1CED3AD57A1307CD95BA4E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C1EA154E2D3C9DF21265307CD95C019C" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8A25A4EB9AC9B2CC5D30307CD95ADC05" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_C1EA154E2D3C9DF21265307CD95C019C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_85E0FE1582C9850B2E4430A928592CC7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_DAD2F30B89EA6E686CD330A92AF30B2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_85E0FE1582C9850B2E4430A928592CC7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_DAD2F30B89EA6E686CD330A92AF30B2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E3286768C4EDC2A5724B30A92AF6720B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_DAD2F30B89EA6E686CD330A92AF30B2B" xlink:to="loc_us-gaap_RangeAxis_E3286768C4EDC2A5724B30A92AF6720B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_B26B1272F7FBDA423BC530A92AF6AADE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_E3286768C4EDC2A5724B30A92AF6720B" xlink:to="loc_us-gaap_RangeMember_B26B1272F7FBDA423BC530A92AF6AADE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_C718263B46028D9BF2E930A92B1606D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_B26B1272F7FBDA423BC530A92AF6AADE" xlink:to="loc_us-gaap_MinimumMember_C718263B46028D9BF2E930A92B1606D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_F1DA4BD2FB2707170A5C30A92B24D49C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_B26B1272F7FBDA423BC530A92AF6AADE" xlink:to="loc_us-gaap_MaximumMember_F1DA4BD2FB2707170A5C30A92B24D49C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A828C2A48A82399340B030A92AF7CCE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_DAD2F30B89EA6E686CD330A92AF30B2B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A828C2A48A82399340B030A92AF7CCE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8D45ED65A049078F2FBB30A92B05A886" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A828C2A48A82399340B030A92AF7CCE2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_8D45ED65A049078F2FBB30A92B05A886" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D3AA34811A5848A15DED5D29D8A4576A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodTable" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D3AA34811A5848A15DED5D29D8A4576A" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0DAA63C4EE6E270866DD5D29D8A59765" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0DAA63C4EE6E270866DD5D29D8A59765" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_0DAA63C4EE6E270866DD5D29D8A59765" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_94162A6009EFE9A3DE255D29D8A50D3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6A2C9D74061CF0D40F525D29D8A5761F" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementMember_94162A6009EFE9A3DE255D29D8A50D3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_3882A6863BB68D0715335D29D8A58137" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:to="loc_us-gaap_CounterpartyNameAxis_3882A6863BB68D0715335D29D8A58137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1A79E1DCACB15D75026B5D29D8A5DD22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_3882A6863BB68D0715335D29D8A58137" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1A79E1DCACB15D75026B5D29D8A5DD22" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_JTToriiMember" xlink:label="loc_mnlo_JTToriiMember_BA39B5429B83128D84255D29D8A58F72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1A79E1DCACB15D75026B5D29D8A5DD22" xlink:to="loc_mnlo_JTToriiMember_BA39B5429B83128D84255D29D8A58F72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9099CE1E81EDD8D6D4805D29D8A5E4CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9099CE1E81EDD8D6D4805D29D8A5E4CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9099CE1E81EDD8D6D4805D29D8A5E4CC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_333A923E36DB315861285D29D8A6D8F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_333A923E36DB315861285D29D8A6D8F1" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DevelopmentandRegulatoryMilestonesMember" xlink:label="loc_mnlo_DevelopmentandRegulatoryMilestonesMember_34EFEC3F1A3FB109F19D5D29D8A65C6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:to="loc_mnlo_DevelopmentandRegulatoryMilestonesMember_34EFEC3F1A3FB109F19D5D29D8A65C6A" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CommercialMilestoneMember" xlink:label="loc_mnlo_CommercialMilestoneMember_C455A3E2D32E8DB0C13F5D29D8A65E1C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:to="loc_mnlo_CommercialMilestoneMember_C455A3E2D32E8DB0C13F5D29D8A65E1C" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember" xlink:label="loc_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember_9CC8E79AD91776774F865D29D8A6B894" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:to="loc_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember_9CC8E79AD91776774F865D29D8A6B894" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember" xlink:label="loc_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember_E2787C401C64147A3EC65D29D8A60E39" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:to="loc_mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember_E2787C401C64147A3EC65D29D8A60E39" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NonsubstantiveMilestonesMember" xlink:label="loc_mnlo_NonsubstantiveMilestonesMember_7C73CD03AFFD1229ECEA5D29D8A651CB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8B8D82CF67D5158964545D29D8A571E3" xlink:to="loc_mnlo_NonsubstantiveMilestonesMember_7C73CD03AFFD1229ECEA5D29D8A651CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodLineItems" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodTable_16F5532AD26145D373E75D29D8A5F561" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CollaborativeAgreementUpfrontPaymentReceived" xlink:label="loc_mnlo_CollaborativeAgreementUpfrontPaymentReceived_BE5A9BBD9A3B43B291405D29D8A69524" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:to="loc_mnlo_CollaborativeAgreementUpfrontPaymentReceived_BE5A9BBD9A3B43B291405D29D8A69524" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CollaborativeArrangementsPotentialMilestoneProceeds" xlink:label="loc_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds_16025C5267100F3D521F5D29D8A6A336" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:to="loc_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds_16025C5267100F3D521F5D29D8A6A336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_027F4B6F403F3EF23D535D29D8A7D6A7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_027F4B6F403F3EF23D535D29D8A7D6A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1E2138615A16A335FC645D29D8A7C0BE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1E2138615A16A335FC645D29D8A7C0BE" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod" xlink:label="loc_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod_7ACB5AF96ACC42ABFC3D5D29D8A75B05" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:to="loc_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod_7ACB5AF96ACC42ABFC3D5D29D8A75B05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_725A459C2A695FD5245C5D29D8A7693E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodLineItems_CB179F3D3D4F749B97285D29D8A62804" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_725A459C2A695FD5245C5D29D8A7693E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesReverseStockSplitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_BE7D2C2FAC54E7B61CB45440F8E65FFF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_E8FE295707F84F2A72025440F8E70B93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BE7D2C2FAC54E7B61CB45440F8E65FFF" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_E8FE295707F84F2A72025440F8E70B93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2870414B46C0B905951B5440F8E74006" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E8FE295707F84F2A72025440F8E70B93" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2870414B46C0B905951B5440F8E74006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C88D8D3B559E2ED3FBA25440F8E75148" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2870414B46C0B905951B5440F8E74006" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C88D8D3B559E2ED3FBA25440F8E75148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2C67DF9F5C10CC7116065440F8E7B830" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_C88D8D3B559E2ED3FBA25440F8E75148" xlink:to="loc_us-gaap_SubsequentEventMember_2C67DF9F5C10CC7116065440F8E7B830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7D3F059F49B08FF799E05440F8E78C09" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E8FE295707F84F2A72025440F8E70B93" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7D3F059F49B08FF799E05440F8E78C09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CFEA8A10B31AA8BE9E8E5440F8E759D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7D3F059F49B08FF799E05440F8E78C09" xlink:to="loc_us-gaap_ClassOfStockDomain_CFEA8A10B31AA8BE9E8E5440F8E759D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A5D02DE734CD9F821B445440F8E7E2EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_CFEA8A10B31AA8BE9E8E5440F8E759D2" xlink:to="loc_us-gaap_CommonStockMember_A5D02DE734CD9F821B445440F8E7E2EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_D5DB499CBBAEF6E850D05440F8E763B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_E8FE295707F84F2A72025440F8E70B93" xlink:to="loc_us-gaap_ClassOfStockLineItems_D5DB499CBBAEF6E850D05440F8E763B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_07219C9D3938D365D6DD5440F8E779C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_D5DB499CBBAEF6E850D05440F8E763B3" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_07219C9D3938D365D6DD5440F8E779C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/StatementOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8F50AFB5AF37DDBAB2195551CE480608" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8F50AFB5AF37DDBAB2195551CE480608" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7498FCCFDC49575121115551CE4A9C96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8F50AFB5AF37DDBAB2195551CE480608" xlink:to="loc_us-gaap_NetIncomeLoss_7498FCCFDC49575121115551CE4A9C96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8F50AFB5AF37DDBAB2195551CE480608" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums" xlink:label="loc_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums_4D2F5D75F96ED24B42335551CE4B2D72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72" xlink:to="loc_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums_4D2F5D75F96ED24B42335551CE4B2D72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_BBD98ACCB7BED278EC045551CE4BBB50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_BBD98ACCB7BED278EC045551CE4BBB50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6EF7ADF0BC34A7C4E5525551CE509F6B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6EF7ADF0BC34A7C4E5525551CE509F6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_EB9AD7DA325DD3D3AD145551CE505061" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72" xlink:to="loc_us-gaap_ShareBasedCompensation_EB9AD7DA325DD3D3AD145551CE505061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_16C095961F6E9B6A8A8D5551CE50296B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_16C095961F6E9B6A8A8D5551CE50296B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_CD9144F489C24CF00E2C5551CE513428" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_E658952D2907A5B13DE95551CE4B8A72" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_CD9144F489C24CF00E2C5551CE513428" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8F50AFB5AF37DDBAB2195551CE480608" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_837B7B887CBD77D7EFC75551CE51F284" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_837B7B887CBD77D7EFC75551CE51F284" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets" xlink:label="loc_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets_60B46CF12FCC2DEDF16A5551CE51D544" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5" xlink:to="loc_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets_60B46CF12FCC2DEDF16A5551CE51D544" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets" xlink:label="loc_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets_6AAD9B3BA0F9A06160E95551CE5169D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5" xlink:to="loc_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets_6AAD9B3BA0F9A06160E95551CE5169D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D7FD8A7D5D739E1ADE2A5551CE51DB0F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D7FD8A7D5D739E1ADE2A5551CE51DB0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1E15E76E839D97E756895551CE525D85" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1E15E76E839D97E756895551CE525D85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_3EFD5973BDE4747D80AF5551CE5272CD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_3EFD5973BDE4747D80AF5551CE5272CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_13F5F5823DF8885041415551CE52AE31" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_997F6D6316ADAD7946AE5551CE51B7C5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_13F5F5823DF8885041415551CE52AE31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_25BA2C8D1C8B0E4CCB6A5551CE52CE75" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_25BA2C8D1C8B0E4CCB6A5551CE52CE75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D1B2520427A3BDBB260F5551CE52566F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D1B2520427A3BDBB260F5551CE52566F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9882A6FCA5C8F92927085551CE532285" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D1B2520427A3BDBB260F5551CE52566F" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9882A6FCA5C8F92927085551CE532285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_81BBEAFC29C88CA1B3B05551CE536BDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D1B2520427A3BDBB260F5551CE52566F" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_81BBEAFC29C88CA1B3B05551CE536BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_FAE6064CA6129F01573F5551CE538517" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D1B2520427A3BDBB260F5551CE52566F" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities_FAE6064CA6129F01573F5551CE538517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0F67FCB990028C0F7C575551CE53C353" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_D1B2520427A3BDBB260F5551CE52566F" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_0F67FCB990028C0F7C575551CE53C353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4063933C8E7248C1A5405551CE53EC68" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4063933C8E7248C1A5405551CE53EC68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4A5E46EE7A7C659758895551CE533A4E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4A5E46EE7A7C659758895551CE533A4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_F7CDB5AF04D95F22D8145551CE53EA1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4A5E46EE7A7C659758895551CE533A4E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_F7CDB5AF04D95F22D8145551CE53EA1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0C26ABBC39D6C53C4D235551CE53381C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4A5E46EE7A7C659758895551CE533A4E" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0C26ABBC39D6C53C4D235551CE53381C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_74E1B5F47563D79B5B2C5551CE548503" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4A5E46EE7A7C659758895551CE533A4E" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_74E1B5F47563D79B5B2C5551CE548503" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4C6B347B5DFD2339BADA5551CE545200" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4C6B347B5DFD2339BADA5551CE545200" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_99398E2EE75AC679ABB35551CE542E50" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_99398E2EE75AC679ABB35551CE542E50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC9862B3B39240AF9BDF5551CE540D5B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC9862B3B39240AF9BDF5551CE540D5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_39DABEC75D9E773A3F025551CE542EFB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_39DABEC75D9E773A3F025551CE542EFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1B79931D5F3EA37C661F5551CE54B8B3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FB6819B459E8A2847AB95551CE4682F3" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1B79931D5F3EA37C661F5551CE54B8B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_00CAB3212CB048D925855551CE546597" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1B79931D5F3EA37C661F5551CE54B8B3" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_00CAB3212CB048D925855551CE546597" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_59094FCA524562CE12753023C6F9EE8A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_CB514B491766F599AEA73023C6F9DF1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_59094FCA524562CE12753023C6F9EE8A" xlink:to="loc_us-gaap_StatementTable_CB514B491766F599AEA73023C6F9DF1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_BBE7CE7648FA24E538B63023C6F92E46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_CB514B491766F599AEA73023C6F9DF1B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_BBE7CE7648FA24E538B63023C6F92E46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_FCF0EB95AF06555821BA3023C6F92405" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_BBE7CE7648FA24E538B63023C6F92E46" xlink:to="loc_us-gaap_EquityComponentDomain_FCF0EB95AF06555821BA3023C6F92405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_A6617438F2351B0714E83023C6F92499" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_FCF0EB95AF06555821BA3023C6F92405" xlink:to="loc_us-gaap_PreferredStockMember_A6617438F2351B0714E83023C6F92499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5D000A0A32F7CCEC84F73023C6F91753" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_CB514B491766F599AEA73023C6F9DF1B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5D000A0A32F7CCEC84F73023C6F91753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D26F77B568D9163AB3693023C6F9B2CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5D000A0A32F7CCEC84F73023C6F91753" xlink:to="loc_us-gaap_ClassOfStockDomain_D26F77B568D9163AB3693023C6F9B2CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_D76102B72B5DEDA8C0243023C6FA09B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D26F77B568D9163AB3693023C6F9B2CF" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_D76102B72B5DEDA8C0243023C6FA09B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_2CBE47186CE9B093E9793023C6FA1B83" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D26F77B568D9163AB3693023C6F9B2CF" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_2CBE47186CE9B093E9793023C6FA1B83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D393DBFDB2042311A7B03023C6FADCF5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_CB514B491766F599AEA73023C6F9DF1B" xlink:to="loc_us-gaap_StatementLineItems_D393DBFDB2042311A7B03023C6FADCF5" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityStockIssuedIssuanceCosts" xlink:label="loc_mnlo_TemporaryEquityStockIssuedIssuanceCosts_4DB0282211CF889D5FEA302CB9285EB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D393DBFDB2042311A7B03023C6FADCF5" xlink:to="loc_mnlo_TemporaryEquityStockIssuedIssuanceCosts_4DB0282211CF889D5FEA302CB9285EB0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitStatement" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_31BB8128ED764ACB9BAD6464F4240FC0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_782C978F64C89C8C526F6464F424CCB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_31BB8128ED764ACB9BAD6464F4240FC0" xlink:to="loc_us-gaap_StatementTable_782C978F64C89C8C526F6464F424CCB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4D27D20ACD7AB76CD7CF6464F4332450" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_782C978F64C89C8C526F6464F424CCB2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4D27D20ACD7AB76CD7CF6464F4332450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4D27D20ACD7AB76CD7CF6464F4332450" xlink:to="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9A7F37451F4E79014A2C6464F433C726" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:to="loc_us-gaap_CommonStockMember_9A7F37451F4E79014A2C6464F433C726" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5A1D8A83A55D2D13CA9E6464F4336CF7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5A1D8A83A55D2D13CA9E6464F4336CF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_AB3B8CEDFC4D3644909A6464F433F8B9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:to="loc_us-gaap_RetainedEarningsMember_AB3B8CEDFC4D3644909A6464F433F8B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C04A7DA8254487A7F7236464F4331D26" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E84FA40482BB24DBA7B16464F4338F4E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_C04A7DA8254487A7F7236464F4331D26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3B6D1A29C0BAEC9FFA796464F433EA9E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_782C978F64C89C8C526F6464F424CCB2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3B6D1A29C0BAEC9FFA796464F433EA9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_905A06709A2009C2EA706464F4331E27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3B6D1A29C0BAEC9FFA796464F433EA9E" xlink:to="loc_us-gaap_ClassOfStockDomain_905A06709A2009C2EA706464F4331E27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_DBFBDBD145066E7FF2096464F433957F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_905A06709A2009C2EA706464F4331E27" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_DBFBDBD145066E7FF2096464F433957F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_BCA8B404118C2ADB28CC6464F4338D1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_905A06709A2009C2EA706464F4331E27" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_BCA8B404118C2ADB28CC6464F4338D1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_734778DA95F51E91AFB66464F43379F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_905A06709A2009C2EA706464F4331E27" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_734778DA95F51E91AFB66464F43379F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_294673D23C0FD3604BD86464F433D6DB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_782C978F64C89C8C526F6464F424CCB2" xlink:to="loc_us-gaap_StatementLineItems_294673D23C0FD3604BD86464F433D6DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_294673D23C0FD3604BD86464F433D6DB" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3B47CC0B91973CB3CD966464F43312B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_3B47CC0B91973CB3CD966464F43312B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_62CA0E50A3E9E144C0006464F433F927" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_62CA0E50A3E9E144C0006464F433F927" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_FA01CE1596FEF4AEA1116464F433C0C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_FA01CE1596FEF4AEA1116464F433C0C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_B0ABB02879A3D16834476464F433A1C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_StockholdersEquity_B0ABB02879A3D16834476464F433A1C5" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_C1BAF3F203417FB049596464F4330492" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_C1BAF3F203417FB049596464F4330492" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_F855665F541DCEC3D9AD6464F43300E0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_F855665F541DCEC3D9AD6464F43300E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81A03DCDAD8668A3CE4F6464F433A546" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81A03DCDAD8668A3CE4F6464F433A546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10C5E5077D6F9D568C066464F4335341" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10C5E5077D6F9D568C066464F4335341" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions" xlink:label="loc_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions_674A741A50BF824EB2E56464F433AA54" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions_674A741A50BF824EB2E56464F433AA54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_38A2759AA8B1DFE78DEF6464F433DF4F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_38A2759AA8B1DFE78DEF6464F433DF4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B8E0A1E28E2FD59018226464F43316EF" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B8E0A1E28E2FD59018226464F43316EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DC6437086915CD7E8C1E6464F4335C1B" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_NetIncomeLoss_DC6437086915CD7E8C1E6464F4335C1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_45524479744F3FCDEA246464F4337C48" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_45524479744F3FCDEA246464F4337C48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1924CF3B8B12719C74636464F4338DB2" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1924CF3B8B12719C74636464F4338DB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8A4E8635CAC39784A8F46464F4331574" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8A4E8635CAC39784A8F46464F4331574" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_81B5331326B5CA2613E46464F433EB83" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_F03E3A79CB31A22136746464F433D3D1" xlink:to="loc_us-gaap_StockholdersEquity_81B5331326B5CA2613E46464F433EB83" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_FEFE61760CA34739608D53A95C142273" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6" xlink:to="loc_us-gaap_LicenseAndServicesRevenue_FEFE61760CA34739608D53A95C142273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_72D7BF51999EE868039F53A95C144638" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_72D7BF51999EE868039F53A95C144638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9026C0E984B62C0B04FA53A95C1458AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_72D7BF51999EE868039F53A95C144638" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9026C0E984B62C0B04FA53A95C1458AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_349D7555D25A5BD2F31553A95C14FC8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_72D7BF51999EE868039F53A95C144638" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_349D7555D25A5BD2F31553A95C14FC8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_9C80744B8AE16B21468453A95C142DDE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_72D7BF51999EE868039F53A95C144638" xlink:to="loc_us-gaap_OperatingExpenses_9C80744B8AE16B21468453A95C142DDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_88BE9CD6D7A9160C375553A95C152A1E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6" xlink:to="loc_us-gaap_OperatingIncomeLoss_88BE9CD6D7A9160C375553A95C152A1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_018ED5A267F7A9902A1B53A95C156EF4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_018ED5A267F7A9902A1B53A95C156EF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BDE4FFB770200FB3289353C4F5ABB9F1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6" xlink:to="loc_us-gaap_NetIncomeLoss_BDE4FFB770200FB3289353C4F5ABB9F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9ED7647C7114A17A242853A95C1511C7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9ED7647C7114A17A242853A95C1511C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A89F081CF06E0470534053A95C158943" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9ED7647C7114A17A242853A95C1511C7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_A89F081CF06E0470534053A95C158943" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5C711377DFA96CA3EFD153A95C15328C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5C711377DFA96CA3EFD153A95C15328C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_A933A40B183026813E1153A95C15F725" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_A933A40B183026813E1153A95C15F725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E9DAA91B4EC2690E7D2853A95C158A2E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_FBE411C3D3C480F72A0B53A95C13B6D6" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E9DAA91B4EC2690E7D2853A95C158A2E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31C8AF74A6E86F79F596EBD54B66D615" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A37A5326DC6383B1B880EBD5DE0DA09F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31C8AF74A6E86F79F596EBD54B66D615" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_A37A5326DC6383B1B880EBD5DE0DA09F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_692B5417E6636DC121266463C6A0D22C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_692B5417E6636DC121266463C6A0D22C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_41C1935E0DC1DDF250056463C6A609F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_41C1935E0DC1DDF250056463C6A609F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_41C1935E0DC1DDF250056463C6A609F0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F9C6475353D32A11657D6463C6A77C30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F9C6475353D32A11657D6463C6A77C30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6243FAC9897CB9670E396463C6A8FA99" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3E243376CAA6A4D506636463C6A732EC" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6243FAC9897CB9670E396463C6A8FA99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_D6B238F288A01E328D1A6463C6A8EB9A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:to="loc_us-gaap_PlanNameAxis_D6B238F288A01E328D1A6463C6A8EB9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_D6B238F288A01E328D1A6463C6A8EB9A" xlink:to="loc_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_A2011StockIncentivePlanMember" xlink:label="loc_mnlo_A2011StockIncentivePlanMember_7E332082A30912BC59A76463C6A94A29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_EFFE79E4F177391685C16463C6A9A74F" xlink:to="loc_mnlo_A2011StockIncentivePlanMember_7E332082A30912BC59A76463C6A94A29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_CCD422B88F644F9F86966463C6A9927B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:to="loc_us-gaap_AwardTypeAxis_CCD422B88F644F9F86966463C6A9927B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_CCD422B88F644F9F86966463C6A9927B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_398ADF63D92662CDC5206463C6A95440" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_398ADF63D92662CDC5206463C6A95440" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember" xlink:label="loc_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_38DD10CD3D0544AC85AC6463C6A96E78" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:to="loc_mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember_38DD10CD3D0544AC85AC6463C6A96E78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1D399AF334D489DF92756463C6A943E4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2645D41CF19E2E5A351C6463C6A96BF6" xlink:to="loc_us-gaap_RestrictedStockMember_1D399AF334D489DF92756463C6A943E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_ED961E995D526E3E6D846463C6A90513" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:to="loc_us-gaap_TitleOfIndividualAxis_ED961E995D526E3E6D846463C6A90513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_ED961E995D526E3E6D846463C6A90513" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_EmployeesandDirectorsMember" xlink:label="loc_mnlo_EmployeesandDirectorsMember_B8298CB731192FBAABAF6463C6AADC31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9" xlink:to="loc_mnlo_EmployeesandDirectorsMember_B8298CB731192FBAABAF6463C6AADC31" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NonemployeeMember" xlink:label="loc_mnlo_NonemployeeMember_2CBCD260606739A54C466463C6AA3ABD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6C8CC825262E4D9B00CF6463C6A93BF9" xlink:to="loc_mnlo_NonemployeeMember_2CBCD260606739A54C466463C6AA3ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_89B8A9AB40FE633DB47A6463C6A6C704" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2D6CF7F2691BA26F51E66463C6AA7A4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2D6CF7F2691BA26F51E66463C6AA7A4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FECD37FBE3EBC0BEF4C86463C6AA1F93" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_FECD37FBE3EBC0BEF4C86463C6AA1F93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E2184FD7D24BDBB38D056463C6AAAEEF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_E2184FD7D24BDBB38D056463C6AAAEEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D492FA825C9CF1E3FDB46463C6AA36BB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D492FA825C9CF1E3FDB46463C6AA36BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61618D4D06FA5616ED9E6463C6AA63C6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_61618D4D06FA5616ED9E6463C6AA63C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_EF2449E21CEFB6604E736463C6ABA77E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_EF2449E21CEFB6604E736463C6ABA77E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_31F9CFF3BBA1D0A97A006463C6ABB86A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_31F9CFF3BBA1D0A97A006463C6ABB86A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56DDB42576D3097F6BBD6463C6ABCB71" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_56DDB42576D3097F6BBD6463C6ABCB71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_B6D72782CC9CC0443BB36463C6AB1B59" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_B6D72782CC9CC0443BB36463C6AB1B59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B82CC86397E8807BC2B46463C6ABE103" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B82CC86397E8807BC2B46463C6ABE103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_92A44FC979D6053EC9EA6463C6AB4A7B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_92A44FC979D6053EC9EA6463C6AB4A7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8DF52612E8726CC9815B6463C6AB39AA" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8DF52612E8726CC9815B6463C6AB39AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D632F2AA6B1279291F7D6463C6ABA913" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_D632F2AA6B1279291F7D6463C6ABA913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF0BF0A4BF82A6F39C1C6466051DD965" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BF0BF0A4BF82A6F39C1C6466051DD965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7FA079CD0EC22D9A5D026463C6ABADB2" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A7ABD1C86FEE0A0910E66463C6AA7C67" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7FA079CD0EC22D9A5D026463C6ABADB2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensationFairValueAssumptionsForDirectorEmployeeAndNonEmployeeGrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3E99A8FA26523A4DC0325D29D7E05FE4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DF9D1758B764D1C7F2675D29D7E0702B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3E99A8FA26523A4DC0325D29D7E05FE4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DF9D1758B764D1C7F2675D29D7E0702B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_5B95BC022E3860057A9D5D29D7E09208" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DF9D1758B764D1C7F2675D29D7E0702B" xlink:to="loc_us-gaap_TitleOfIndividualAxis_5B95BC022E3860057A9D5D29D7E09208" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_401D3FAA70A1386EB18D5D29D7E03A32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5B95BC022E3860057A9D5D29D7E09208" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_401D3FAA70A1386EB18D5D29D7E03A32" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_EmployeesandDirectorsMember" xlink:label="loc_mnlo_EmployeesandDirectorsMember_39DC4B7DE5DCA2B8A9EE5D29D7E1358C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_401D3FAA70A1386EB18D5D29D7E03A32" xlink:to="loc_mnlo_EmployeesandDirectorsMember_39DC4B7DE5DCA2B8A9EE5D29D7E1358C" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NonemployeeMember" xlink:label="loc_mnlo_NonemployeeMember_790536F0ACAC1E1756625D29D7E1DE03" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_401D3FAA70A1386EB18D5D29D7E03A32" xlink:to="loc_mnlo_NonemployeeMember_790536F0ACAC1E1756625D29D7E1DE03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E40F2F28918A6982E6BC5D29D7E1442B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DF9D1758B764D1C7F2675D29D7E0702B" xlink:to="loc_us-gaap_RangeAxis_E40F2F28918A6982E6BC5D29D7E1442B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_E40F2F28918A6982E6BC5D29D7E1442B" xlink:to="loc_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_0C698D6FB5FC5ECAE4915D29D7E1E0D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F" xlink:to="loc_us-gaap_MinimumMember_0C698D6FB5FC5ECAE4915D29D7E1E0D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D584E0443B12798192065D29D7E15E30" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9577B4CE04D9472051085D29D7E1442F" xlink:to="loc_us-gaap_MaximumMember_D584E0443B12798192065D29D7E15E30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DF9D1758B764D1C7F2675D29D7E0702B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_903A35C47239C7382A565D29D7E19DBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_903A35C47239C7382A565D29D7E19DBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1B8C0DB0231871C85F375D29D7E2B382" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1B8C0DB0231871C85F375D29D7E2B382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_34C74754058EB4A82DE15D29D7E228CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_34C74754058EB4A82DE15D29D7E228CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9F9528D2EC15AABC777B5D29D7E23D9C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9F9528D2EC15AABC777B5D29D7E23D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_A81F7AC8D88B7199116E5D29D7E21F65" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_A81F7AC8D88B7199116E5D29D7E21F65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_F76D0948D31F796C8B5B5D29D7E28756" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_F76D0948D31F796C8B5B5D29D7E28756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4768C5D4280F035A66145D29D7E2D8F4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4768C5D4280F035A66145D29D7E2D8F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FFE622846A4C96F3BE455D29D7E2719A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_84CCA95451577A69EF2C5D29D7E1F573" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FFE622846A4C96F3BE455D29D7E2719A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensationStockOptionAndRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_757791A4032ED3B7870553E14D72A090" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DAB189353F13AB1DB5CF53E14D72037C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_757791A4032ED3B7870553E14D72A090" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DAB189353F13AB1DB5CF53E14D72037C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A6015C786BC94AD93F5A53E14D726905" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DAB189353F13AB1DB5CF53E14D72037C" xlink:to="loc_us-gaap_AwardTypeAxis_A6015C786BC94AD93F5A53E14D726905" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3672AD568E0413A4E47B53E14D7208B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_A6015C786BC94AD93F5A53E14D726905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3672AD568E0413A4E47B53E14D7208B1" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_EarlyExercisedStockOptionsMember" xlink:label="loc_mnlo_EarlyExercisedStockOptionsMember_435D75ABEFCB895FBD6E53E14D72602B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3672AD568E0413A4E47B53E14D7208B1" xlink:to="loc_mnlo_EarlyExercisedStockOptionsMember_435D75ABEFCB895FBD6E53E14D72602B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_4BBE2A564D9301C24F4353E14D733A0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DAB189353F13AB1DB5CF53E14D72037C" xlink:to="loc_us-gaap_PlanNameAxis_4BBE2A564D9301C24F4353E14D733A0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_204C8986BC4D8905364053E14D734194" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4BBE2A564D9301C24F4353E14D733A0E" xlink:to="loc_us-gaap_PlanNameDomain_204C8986BC4D8905364053E14D734194" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_A2011StockIncentivePlanMember" xlink:label="loc_mnlo_A2011StockIncentivePlanMember_D75BF869E721631D95F253E14D73815F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_204C8986BC4D8905364053E14D734194" xlink:to="loc_mnlo_A2011StockIncentivePlanMember_D75BF869E721631D95F253E14D73815F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DAB189353F13AB1DB5CF53E14D72037C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F73BFE11D2010564ADBD53E2FAA8EFFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F73BFE11D2010564ADBD53E2FAA8EFFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_682D30F5506319BBDCE453E52D874057" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_682D30F5506319BBDCE453E52D874057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C136D72C34E1E7515CFE53E14D740EA7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_C136D72C34E1E7515CFE53E14D740EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8FEBE17A6995B8EA83EC53E32C4A3F0D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8FEBE17A6995B8EA83EC53E32C4A3F0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_838417F508EA488BA07153EEC8827F06" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_838417F508EA488BA07153EEC8827F06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B2A0CA73A589F19D2EBF53EA03466017" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_B2A0CA73A589F19D2EBF53EA03466017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CE2B46D830C3E6002B7A53EBB516D66A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_CE2B46D830C3E6002B7A53EBB516D66A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6857BAEC47010BCB287C53F26C8B2150" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6857BAEC47010BCB287C53F26C8B2150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56CA22EFB66B73BA1B6C53F4697C1EA8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_56CA22EFB66B73BA1B6C53F4697C1EA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_158A3ACE035F3F6B523D53E14D74FD41" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FCFE3FDB59BAA4227DAB53E14D73BDF5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_158A3ACE035F3F6B523D53E14D74FD41" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F4E92B6E094544642BB25473518DC66E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ED81AA15767C7736A3EC5473518DF406" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F4E92B6E094544642BB25473518DC66E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ED81AA15767C7736A3EC5473518DF406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_722493B1DDF46DF265D05473518DBCAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ED81AA15767C7736A3EC5473518DF406" xlink:to="loc_us-gaap_TitleOfIndividualAxis_722493B1DDF46DF265D05473518DBCAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_725CCA3E205361BE1AC15473518DE1D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_722493B1DDF46DF265D05473518DBCAD" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_725CCA3E205361BE1AC15473518DE1D1" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_EmployeesandDirectorsMember" xlink:label="loc_mnlo_EmployeesandDirectorsMember_8841B434E930756856F55473518DA5F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_725CCA3E205361BE1AC15473518DE1D1" xlink:to="loc_mnlo_EmployeesandDirectorsMember_8841B434E930756856F55473518DA5F4" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_NonemployeeMember" xlink:label="loc_mnlo_NonemployeeMember_89B8EBF209600DE30E6B5473518D1015" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_725CCA3E205361BE1AC15473518DE1D1" xlink:to="loc_mnlo_NonemployeeMember_89B8EBF209600DE30E6B5473518D1015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64E1B0AE1C0FF560911C5473518D418B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ED81AA15767C7736A3EC5473518DF406" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64E1B0AE1C0FF560911C5473518D418B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2DDF05905DDF803B4C705473518E1AD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64E1B0AE1C0FF560911C5473518D418B" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2DDF05905DDF803B4C705473518E1AD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B5EC26ADE2DACE63C5C5473518D945F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64E1B0AE1C0FF560911C5473518D418B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8B5EC26ADE2DACE63C5C5473518D945F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3AA5756627194CE63285473518EFE24" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64E1B0AE1C0FF560911C5473518D418B" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_B3AA5756627194CE63285473518EFE24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_9B734E227000479514E65473518E2859" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64E1B0AE1C0FF560911C5473518D418B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_9B734E227000479514E65473518E2859" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_B02825F708B17E63BEB2EBCCD1D9D4A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_682E362F6E26EA7CB5C2EBCCF779550C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_B02825F708B17E63BEB2EBCCD1D9D4A6" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_682E362F6E26EA7CB5C2EBCCF779550C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.menlotherapeutics.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_41A9B539055BD2276FE06464F3907567" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_41A9B539055BD2276FE06464F3907567" xlink:to="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_739477790B505A6C30F36464F390C887" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:to="loc_us-gaap_PlanNameAxis_739477790B505A6C30F36464F390C887" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_D41235A0771FFC0186746464F390E35B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_739477790B505A6C30F36464F390C887" xlink:to="loc_us-gaap_PlanNameDomain_D41235A0771FFC0186746464F390E35B" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_A2018OmnibusIncentivePlanMember" xlink:label="loc_mnlo_A2018OmnibusIncentivePlanMember_50CD00561518833631476464F3902886" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_D41235A0771FFC0186746464F390E35B" xlink:to="loc_mnlo_A2018OmnibusIncentivePlanMember_50CD00561518833631476464F3902886" xlink:type="arc" />
    <link:loc xlink:href="mnlo-20171231.xsd#mnlo_A2018EmployeeStockPurchasePlanMember" xlink:label="loc_mnlo_A2018EmployeeStockPurchasePlanMember_0F7625F79D92068DC9F3646F1B914ECD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_D41235A0771FFC0186746464F390E35B" xlink:to="loc_mnlo_A2018EmployeeStockPurchasePlanMember_0F7625F79D92068DC9F3646F1B914ECD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D80882E3435CD343C1C96464F390CF6E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_D80882E3435CD343C1C96464F390CF6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_95092CFDC1579F447A996464F3909361" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D80882E3435CD343C1C96464F390CF6E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_95092CFDC1579F447A996464F3909361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_233559007FD6779419C46464F390CAD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_95092CFDC1579F447A996464F3909361" xlink:to="loc_us-gaap_IPOMember_233559007FD6779419C46464F390CAD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_87A9C1C06000201E4FA36464F3903D14" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_87A9C1C06000201E4FA36464F3903D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E7C63D39A976C64CE8216464F3905E7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_87A9C1C06000201E4FA36464F3903D14" xlink:to="loc_us-gaap_EquityComponentDomain_E7C63D39A976C64CE8216464F3905E7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_AA71D6DA02AA165D341F6464F390E418" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E7C63D39A976C64CE8216464F3905E7B" xlink:to="loc_us-gaap_CommonStockMember_AA71D6DA02AA165D341F6464F390E418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_08265055D0721572C3556464F390C939" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_08265055D0721572C3556464F390C939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_DC3E8EEE752555BC19A06464F390E7ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_08265055D0721572C3556464F390C939" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_DC3E8EEE752555BC19A06464F390E7ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_79867C0DACA6ADA93BB96464F390DE27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_DC3E8EEE752555BC19A06464F390E7ED" xlink:to="loc_us-gaap_SubsequentEventMember_79867C0DACA6ADA93BB96464F390DE27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5589699B9072B5D165776464F390C89B" xlink:to="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B1C1E2B02E13E81296956464F3903F72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_B1C1E2B02E13E81296956464F3903F72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E5DF7A62EEA88E3A0D3D6464F39074AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E5DF7A62EEA88E3A0D3D6464F39074AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_24A562D05B923C1CA0B26464F390FB12" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_24A562D05B923C1CA0B26464F390FB12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1DEBBC8F535702EDA20A6464F3907A7E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1DEBBC8F535702EDA20A6464F3907A7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C1ECB5023CE359A99E5C6464F390C36D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_DCEE1C5830D0E815A3C56464F3903E38" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_C1ECB5023CE359A99E5C6464F390C36D" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>chronicitchcougha02.jpg
<TEXT>
begin 644 chronicitchcougha02.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P@ 1" <%"WD# 1$  A$! Q$!_\0
M'0 !  $% 0$!              0" P4&!P@!"?_$ !L! 0 " P$!
M       ! @,$!08'_]H # ,!  (0 Q    'U2
M
M
M
M
M
M
M
M
M
M
M
M
M #R 94
M     Z =J  . &J
M               ]5  &E'G\E@
M           Q1Z_          /*IZJ
M                             /*IZJ  /*IZJ
M                                        /*IZJ  .5 ZJ
M                                     #RJ>J@         #RJ>J@
M                                                        #RJ>
MJ@ #RJ>J@
M       #RJ>J@ #E0.J@
M     \JGJH          \JGJH
M                        \JGJH  \JGJH
M                                   \JGJH  Y4#JH
M                                /*IZJ          /*IZJ
M                                                   /*IZJ  /*
MIZJ
M  /*IZJ  .5 ZJ        "&3
M #RJ>J@         #RJ>J@
M                    #RJ>J@ #RJ>J@
M                               #RJ>J@ #E0.J@      'FLX\=Y.0G
MMD^@^'TXN<=-F/4A25%)4>;CTB?#Z                            >53
MU4          >53U4
M                >53U4  >53U4       8,\ED4ZR:>>L0 #!'E<Z*>@
M        <X-N,R:423S8>K#)@ 'GLT(]2&=!A3BAZ%  !XM/:0  !QXXV;\>
MAP #SF=Y,F  <>.P@   'EX]0@   'F<Z\;T>53U4  <J!U4       'AL]R
M'YXF;/69YJ+)[7//QR\L'4CDYWXXH=N.'EPBG5ST
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MU >7SD9ZP,P33#$XWPYF;$>/STT=/-.(9NQRXW4V0
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MR>=2-R/*IZJ  .5 ZJ 45G5N7U]?T.C8QY)V?7V_K\;+;>F
M                           !Y5/50         !Y5/50 !JO*Z_*O+>M
MQ^OLCM?M/"[)TN8   !R\Y@=J//X-_.''93T :08@\KF9+AZ9/,0/91XZ/;1
MXV,L7#1#UJ<%.<';C73U4:T>6CU^>*SUV>,C7CTR:H=@/,AU4R!YY.^E)H1I
MA[U                         !Y5/50 !Y5/50 !R#R/L]/X_:  RFUJ]
MU]S\_O7H      !K!Q ]+   T0T@[D           #"'"#TD
M               >53U4  <J!U4$?'DX;X?WV*U=L 5VCL'KO%[9UN.
M                                   /*IZJ          /*IZJ !S7S
M?J.=^=]+]F*8D=K]IX79.ES    ,*8,V4U,&W'+2.=I-?.1'6#63<#62*#HI
MSPZ2:::4;88PWTU4I->-E-Y(AHQT$YN=*.($\ZV<4-^,.9PR)IAK9UPY$;:=
M)                         !Y5/50 !Y5/50 !Q+Q7N[MJ;?U^+\3S?SG
MIX6#..N>M\;N?9X@
M        \JGJH  Y4#JH,1J;G#O#^^W;M\'8NAS<1J;G.?.^FIB<WNZ/=/<^
M   B'/S/FV '"SN@   !ASGAUL     X8=R/H .9'30   <C.AF9       ,
M.<\.MFIFV      \JGJH          \JGJH '&_'>VE9<6[=KA<4\7[D=K]I
MX79.ES
M/*IZJ  /*IZJ  (.#/.SX .>>>])S/S7J1U#T_E-_P"_YT" 6R80R,90QYF
M            #3C83(     Y\=!     !#-6-U (IBC/@  Y\=!
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ME8W0[X<".R'G8]!'!BX#L9L1D#S29H[&< /3!R@O'/#TB>:S&'H0SY?
M       !Y5/50 !RH'50#4N3V..^/]J!5,;GV>)TCT?F,ELZH
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MGJPK-2-M,$<U.OFM&:.2'5#-&I VTU$VXQIH)L9M!K9;-#.R%T
M  'E4]5  '*@=5 (^/)K_/Z-NM\#H]#0.!Z*S2\W-A[K[KY_-S8
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M     <^+9T4    &KFT     %DP9L0  -1-N     ,663-
M           'E4]5  '*@=5   -!X/H>7>7]8.J>I\EO?=\^    !KA$-F,0
M4&Q UPB&W         MG 3O!42#EYU   Y@=./H !@"@V(           \JG
MJH          \JGJH  &+U=O@G@_H0[7[3PNR=+F
M                 #1SG)UDV4              'E4]5  'E4]5  &K<OK<
M<\?[:BL[UW.!U3U/D?L@
M             /*IZJ  .5 ZJ#Y#[( :3Q>[R;R?L!U+U'D]][WG@!JQSLFF
M%.QF-,0:6;&< /0QMIRXS)@#J9S$VPZ&<?,*=A.0'1CFQUHT PIV,Y =D)QQ
M V@T\A'H(\9'IX\VG93JIQ<Z";H>8C-G<SD1MAHQFC-FSG+3.'4P
M #RJ>J@         #RJ>J@ :]S^EAM/=AX<_-O-^G'0._P"=RNWI[%T.;F-S
M2                                                     \JGJH
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M<O-[NB  !YA,P=T.;D,Z(<A-Z+!D#23H!N8
M                  /*IZJ  /*IZJ  ,3J;D;'E  $B^++[FF!Y4.VFK'&3
MI)G39SD)L!U X<>GCS$7STN>4SU">=39C>SB!ECMAYI/3IYW,@=W.!%1MYC3
M;3FYT P0/IF34S%'I@\P'IX\Q$D]*'T\;G12X6C.&H&1.XDT\\D8]$GGP](G
ME<]'G$ST*>8#T(<9-5.VFKFH&S'0 <^.X'E\]"G%S$FU&8,"8(Z^<N,4>F0
M     >53U4  <J!U4 U_G]'5>7U\?K[/U&6V]/<.OQ<GM:H    %LN %LN'G
MP[^7 "R7@4%8!\+9=*"LH/I4"V:6<^.\@MEP %DO ^'PJ *"L &)-'.G
M      \JGJH          \JGJH         \H'9#1C4S<S"'?3CACB$=X.2G
M?@                                           >53U4  >53U4
M    #SJ98Z8><CKQCS4".9,]%GFDEF]G+#NAR0[X>3"">DS&&@G1CDYOAE#0
MCMYRPPIE36S<SGILIU,X$9,W8WTXR>C3S22S>SG!Z7/AYT,0;H8LZT<C+QW\
MT,QAQP]!'FX[F:$;\33H!Y/+9WDY@98Z8>9C''M$U(\]'=3@YF#T >5"P>HS
MSV8 [:;V<:/1H      /*IZJ  .5 ZJ
M                #RJ>J@         #RJ>J@        6CQL;,=@.6G93AI
MC#O1SHM&^F1-\                                           !Y5/
M50 !Y5/50                             .;FK'<0  #S4>DBL
M       &O'(2>=P        /*IZJ  .5 ZJ       4&/,F  :F;8 #5#82@
MF@  &/(9G              #4S;           #RJ>J@         #RJ>J@
M          <:--/2A6
M   #RJ>J@ #RJ>J@
M              #RJ>J@ #E0.J@      & ,423X;8:";&<:.R%1F#23CQV(
ME'PRQ.-4,Z4G 3<24=.!J)OH-#-N,&2208$W UPDDDP!NYIQ;-U,$9TUDBFS
M&N$LSQHQRT]'F",&9$R1?-/-T/.1Z$->,V?3$FW@   'E4]5          'E
M4]5
M  'E4]5  'E4]5         C'PE    UXRA-
M                    /*IZJ  .5 ZJ       <#.@G""8;6;F:J;6<_(YN
M!\.4FS&4,D:@?#:B2;&:$8(Z :N:*5'JLP!QDZ4<:)Y'-U,X<</2IP@EG33B
MAD3M)JYT4X,:D=Q-#,89(WDT0]('C<RIU8T8A&X&P')3?S*'-22=).I    '
ME4]5          'E4]5
M                  'E4]5  'E4]5        @F),49TBF1+Y!)A.-9,N<!
M/0IK1MX                                           /*IZJ  .5
MZJ       >;39SHIQ4QQVTY0=+-!-"-B.I'+RZ?3O9QLU0B'HTYJ;F<G.IF(
M.2'HLV8P)YM,\=*-T.!&SFVFJ&NDDP!MITTT4Y*>N#EAC3E9N!Z$/.YC#-F]
M&[''#$';#FAIIE#K)R4L':3CQ:/28    /*IZJ          /*IZJ
M                                                    /*IZJ  /
M*IZJ       !Y,.Z'*#=3&',S>B::J9(VHTHO%TW4ZP7
M                           #RJ>J@ #E0.J@      &MGTV,UP^FNFP&
M?.:FWD@UDV$L RI:.'&EGKDQ9K9E"49$T8F&[&J&*-V.7G1C'GTGG/SJ)S<V
MPM&R'##?C=2T<W-M+9GS#&-(AN9'+9 ,@5FH&4-I.;F\G/#J!KYL@    /*I
MZJ          /*IZJ
M                /*IZJ  /*IZJ       +9IQQ@O$8[^>?26>BC@)BC?BH
MTH[R>8CUR                                           #RJ>J@ #
ME0.J@               U4S!D@          #"&;                !Y5/
M50         !Y5/50
M               !Y5/50 !Y5/50      !CSB)U,Q1'.8FV&U&SF/-+()U<
MU0T\V4Z4                                           #RJ>J@ #E
M0.J@                                             \JGJH
M    \JGJH
M        \JGJH  \JGJH         YT:P=J*@
M                        #RJ>J@ #E0.J@          YB=-/H
M                          /*IZJ          /*IZJ
M                                             /*IZJ  /*IZJ
M                                                        /*IZ
MJ  .5 ZJ       <I-/-A-6(A,)9S<[^<R,,;@63L)LP
M              !Y5/50         !Y5/50
M                                 !Y5/50 !Y5/50
M                                            !Y5/50 !RH'50
M   #S0>DSS8>E3S05GI8\WF\FE'6S031#U4
M      #RJ>J@         #RJ>J@
M                         #RJ>J@ #RJ>J@
M                                    #RJ>J@ #E0.J@      '+S6C
M?SFIV$U8Z0<).HG)#HQC"DZ>                               #RJ>J
M@         #R 94
M              Z =J  . &J
M                        ]5  &E'G\E@
M                    Q1Z_  (1'      +ID
M
M
M                                  #B&#B>?M3R0     '8]GTGHW9]
M(
M
M                                                        !Q#!
MQ//VIY(     #L>SZ3T;L^D
M
M
M                   XA@XGG[4\D     !V/9])Z-V?2
M          #&F -Q
M
M                      /D32D5(^S                     XA@XGG[4
M\D     !V/9])Z-V?2                         <J.C$PK
M                                                       *9A"I
M(                                                        'P0
MUO1[7S+K8BF>U6]J)N3":Y?)K[)GTY%\0                   XA@XGG[4
M\D     !V/9])Z-V?2                        #0S?
M                                                     8O-CKAD
M<60                                                      "-3
M)B\6S$IFLUR1*Y,;J=&#CV)W0X^E>F\]MWE/34"61G'>FN.6W#/I9W8T*I@
M                 <0P<3S]J>2      ['L^D]&[/I
M       ,:5&0
M                  !A-G#<B<OKY0
M                      !3$X7!NXG!MT5R5H^ILQ:'3-CM7H9'>Y/(?>>+
MQNYJ=M^:_0J"VB@H,S?#AL&]EXG>>OY>N:@                 <0P<3S]J
M>2      ['L^D]&[/I                        .:'2P
M                                                  "BMK-<GR)^
MRJFM<UU_=UKT,]JY@
M       /D3%KDUS0[7U.3V>?@=?=^5O66XO5"H^F-P;V0S:>F^AX/+O9>3L9
M*=^^7_1[F+)8IDHF%\=I&?R:^F<KTV[]CRL.^*ZF=;%FLF"_:@J1]F
M        !Q#!Q//VIY(     #L>SZ3T;L^D                       %L
MP1L(             *$4R^%R%20 ,+EQYK%DL3$6U:96)C-8L@
M                               IBV.P;=JN2];'7-*[5KFM4QK._J?:
M6V73V;]\0                                                %,3
M@\6U@\&Y'QYKB;];:9V^3I/5TLJQ;3R>GN'#[/V  @XMF9EU]<ZO,YUZOS/1
M_*^ER^ANRL.:A$2F>)3)(SZ<BV/!:G4KVN?'IE^WQ51:\"DG7Q9[-I['L:,B
M^(             <0P<3S]J>2      ['L^D]&[/I
M    !%,(;*             "#>O+NAI#=]38PF7'LF#-J>S@V+!EPN7'KV?%
MV3E]#D/3T,OBR#7,^'8<&7>M39T?;U]MUL^L;&&;2V7Q7SN+*
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M@ $''?%8<V-QY,=BR1*7JE,O3*Y<6=V-?(Y<8                @&"-L
M            .+=7G2:VVG7S<XWM38<.5#9L&;G&]J9?%D[/R^AR'IZ$^EL5
MDI8F,WBR:YGQ9S#DJ,QBR83+CVK7S;=K;
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MZ3T;L^D'R&(PYL!K[&-Q9(M;Q*7BTM%K>F  RN;%N.YI[5N:ER8
M      L$(R@             !J&SKR(M#M7 9L6'RX\?>O0=+:PV7'G,63=M
M39TW:U]NUL^G;.O9M&#RX][T]G3-O7V;7S9"E]7V,.;PY-FP9@
M                         (],NNZ/9QN+8^9]6F^$?)@#/6Q9*V+Y$Z;V
M>73%MMXO7IB?D3E-G1OWQ           :MO:.&V=?,ZVQC<^'>^5U
M                         ,#BVN?Z?5CY\62UL^7M3%ZG3RNQHWX7(D0L
M6S8KDRVYS--[?'AY:[YYKT%*=*OL:%]#^<_)B_BR4Z/3VCA=K;>5T<C6E4Q4
M5'T02@8=J1?%>OBI(V3'K_4YVN]7F8#J\V_KY]CXO7W+C]*?CMJ?-]#M?H?'
MSM?)0F=?%E\FM>OC^@         XA@XGG[4\D     !V/9])Z-V?21:6PV#/
MCL>2+2T2EXM;Q*7BTM%K>F   EWIO?0T-NW-0              8LU<WP
M             Q.3'"O78\&8
M      6JWU_2Z^(U>C5GTXM\:0^("7Q&4G'G[Z]*VD]OD4+;EP>U\/D6NVQY
MG;YH         '.^QR863%TCC=C0>MRJ)C9M+=V32W
M             !KF';Y[K=/3?6>9@;^CNWFO0V-[1P.2_P!W.?:R4N4MD-;8
MS',Z>W<CI3M;8UKK<O7.KS=]\CZSG/HN+H?M/%Y[G[N]<+L;+R.G]P;%W%FL
M:^X3D,NI]  (&+:GY=7X?3X?)4GV:1-K6YYTM?">A\[*FESE=C6O0^>Z_P"
M]ME]?-]5QD9,GDP;EM<R7DP@        <0P<3S]J>2      [%L^D[_E]1C\
M>2)CM%K>+2T2EXM;Q*7BTM%K>F    V#8U^@='GY3-B             %HB&
M0
M!B-;H:CS/0S\VIMW3\](OBQ.+9U'5Z=FMQ\F ,A;'LF35HBVC][C69;QY[O4
MQ(&8V>=*RX         !S+M\;Z;-H[ENT5Q.D]/F]=\]WP
M                ,#BV>:ZW4Y_[GQN&ZW,KK;H7DO3YO0WX7&]#LUM6<HOB
MQVWK8'I<_4NWR/L3D=#?U_:PP]K5Q_5Y,_5V<CKYKF/))Q9:H6<E+63':K?*
MZNQF]#=SG.W\[S=^_CR")3/+O@CURR+8@!\/LUC5RXW%LM_F\L]WXG7>GSY^
MGM].^?>[NZVQE+X94TP-,_1MSE9C8T/H       !Q#!Q//VIY(     #L&QZ
M7OF3U$2MXF.T6MXM+1*7BUO$I>+2T6MZ8    #+YL.<SX/LMZW]"]:
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M7QR+8@!<OCUK1[.8W.5H_H>']PYY^KGEZ6W\QY;!7-<Y?!K>/:ZCO<7)Y](
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M35,  #4]/JZOJ]3X@"1;'N6QSK%<N@>BX,/-3HOE/2VXN*YK?MBV+?XX
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MQ<;LX.F>/]7;BXKFER:[5TN"
M     -3P[G/];H["I6?8DM9K;';FMJ/I.!B>AHY;D];.\CK;+H[.8U\OV)P]
M-GG?<Y>+]7X_,\KIY/F=' =OC]"\GZ?EON?&=.^?^^P&S34?1^=N]#E;KP>S
MN/![4/4Z-<UR&;4    C9L6J=GDZ?WN)"IGV'R_J^E\[)*MBIBVO:77EY,&1
MSZ=$Q8+";!9(Z8YFLF#6^5Z/H/:\EL^WS*YJ      !Q#!Q//VIY(     #L
M&QZ7OF3U$2MXF.T6MXM+1*7BUO$I>+2T6MZ8      =1ZW+V/9U@
M  ! ,$;8 :3K=KF&EZ;<]CCY3)JT1. Q;^O8NAF\FE\3B,>WT+;\_KN+H3K8
M8-,_7NAY$    :%U-+*X,NT:6P   !HF_H;WH;X
M ^$#+CQF?'B\V/#[&+#[.+#;&+#;&+";6*%DID<-]CT]C9-//L>GGVC2V<[J
MYOH            !R?B>QM18?$)9G+I[7M\OF'H.3@]O6ZIXOV%JF3X7;8[D
MUVOI<"NU0                                       !K.':YGJ]799
MQ:M&:1"7"G-CTOUWEJ[5W_S/HL]R>KK.AV\AFU(>/8D;G.UGU_CM3ZW,SWEO
M6](Y6SC:9.<^V\=O?F?1_.3W-<[G%UGU'E>S^#]K-HBY*:IZ+S^E]WC97G[^
MQ^0]IM^+%7-0$A;K;XFY-/H/LQA+VTGT?G]>[O"W+@]OH'G^U]Q9<+J]++[/
M/%N5@L)L$<O6I(QYM8P[EG8TLU?!T/<Y64RZGV0     '$,'$\_:GD@
M.P;'I>^9/41*WB8[1:WBTM$I>+6\2EXM+1:WI@     ,UGP]:['(
M    L$(R@            !SWK:.P:F?8M3.   !H^]H[QH[P
M              &.S8\!M8=?V\&N;F#6=W7UO<P2L=MNT-G=.;M[OS-O-:^8
M           <EX/MK,7K11*DJ5Z!T?/\[]+Y_4]S%UKPOM;-,GQ,F^&N:[;T
M_/7+5   '#MG!E:SUS!FI*BDJ*2H'P^GP\^[6OZ#U=CG>7'H^6DZ';M;/25'
M-<V.?5O./)4"DJ                      !'K;B^EV\PC78R7B7#%]#5U/
MU_DNB^1]1LO+Z4N&M:'<V/=X][9TN:^DX6H=/2WSS'H]GX/>UO0[64Z7 ^;>
MES;W'C>A?,?J5'1Y>+]5X^[CR:WU.=V+PGM*X536N8UGI://O2\"S:O1/,>B
MSW*ZF+U][&8-V%AV;<7'TE9-?(Y]/(YM3%:^_L.YR/E\>D^AX6D^AX71/-][
M://>@C4S3<FO\+<HY&6@8=J1#%QDHV-&F8NS6LWC8Y^R[7-JF     !Q#!Q/
M/VIY(     #L&QZ7OF3U$2MXF.T6MXM+1*7BUO$I>+2T6MZ8    "Z;-DB3-
M=[['&NV@           8LU<WP     'PLQ>_-      .<=C0VS0V<WK9@
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M6/IL<^U?0="VO/[!FY\VV$    #F?:Y^[\S;RN#*   !H^]H[QH[P
M                        QF;'S[K:/-^SH:_M8>C<C>ZWP.GF];,
M  !3$\SX'ML%J=6;EULEGTIV75F9=>1?#\F--]+YS2>OSNN_/O?1<>:3?#>F
M@VSJ>>NVH   .?Y<?&-C#GJVSM;9"K&6C,5MB;5UVT2H;[CR:?>E\U>]?3.G
ML^<=O7Z=AR<DSXMSQWZ7AR<+V<&:K:HU^]>EX<NB9,?H75V
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M28GQ/TUJ]<M6<_6T9&F9:;5CO8F,E6<;:,9,9VMM:O7*UGX;!6P
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M?=XG,_2\'T)X'V$+%M0\6S\!/S:NR]#B
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M=HM;Q:6B4O%K>)2\6EHM;TP'TZ7GI6    8)'0NQQ@          !#,.;(
M           <A]!R^L\#IW8D   6YC3MS3W72W0
M            !'O7A'J./IW0U/2'C^]L&IG     &B\?U.K<_NR+XHU,UR:R
M\FO.S:DS+KR+X9>37UGM<CE/K/->C/G_ +'&X-V%BV?H15,;9TN!(R80
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M'$\_:GD@     .P;'I>^9/41*WB8[1:WBTM$I>+6\2EXM+1:WI@)TN@YJ
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ML&QZ7OF3U$2MXF.T6MXM+1*7BUO$I>+2T6MZ8#=LM<S:    +43>W^;LFUK
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M/BS=;7X;=CMRO/CRU9J.SZ^;@&U@G0E1/3\.75KTZ=AR@
M        #6=#L\LQ[=-\?R8O5M+1,B;&[IZ;Z?S_ $_P7NXV'9S^WRX,M!7E
M(DHDDHDHDF(ZO,P77Y72O)>G%$6U/G][<NGYRBM]%])P)V&^V\+M:)R?4Y;8
MT)^?3Y?]%^>;]Y'U>YZEI%L0 I3J_/[NU=#@C'[&'B'M?+=K\5ZO7.'ZK;^E
MY[X4Q:#BVOI=MC^5L+<6KFOQ/-_2<*'O\_I7C?60:9L7K;]_<YD4C%C#M6<V
MOG;Z^7Q;/0^MY?[,   #B&#B>?M3R0     '8-CTO?,GJ(E;Q,=HM;Q:6B4O
M%K>)2\6EHM;TPK.D9JW)@   "W"O?YVS;6L           +1$,@ #Q1P_>?,
M6_(Q;DJ+2$2[8<SDT=@SZ$^^#6</1UW'L1YI:G''E'OK46Q_06XFXBJ2'U-_
MV/CK'CO8J;+'N?<>W>IFR5L>V[/(P./8@S23N\F]M\[6N9V?DQ2CX1%[,KJM
M]2E'R7RFQ]P]"73:EQ:9$[)GYV3RZFH8=R#,1E;$UHOK?)QBVMB8V(R]Q&48
M9TXA]/373\ON.?2                    Y+WN9H'5TO3/C/0    874Z?-
M^%[++;.A9IE@XMF-3-,RZ\W+K3,FM*R8)63!1M:?G'Z7X'U+\W]K:P;6!U.J
M3]14C)9]+:NEP0  (IS,ZL                                  <SY/
MI]0S8 +I,A,B=)]CY38?*^NW?58G3ZFP;?+U.,V M64C(S3)S7(3CO$2F?6^
MYQ;.Q@WWS7H!@-3JS,NOD\^C1%L!UN5K_4YO2O-]W :?5V3<Y-4UA[&OQ#V_
ME.V>!]K+I:3?  -8T>WL^]Q ,!OZG)/6>=[#\^]W8P[&9VN;1%J(M@M3JY?9
MY\?'FUG0[?P^)FY=;/[?*YOZ_P K32V]>5]/A=+K2-WDQ4Q2SK[T7)AAY,._
MX\G1NQY3[,   #B&#B>?M3R0     '8-CTO?,GJ(E;Q,=HM;Q:6B4O%K>)2\
M6EHM;TPSMHW++4    ")LZ>X;^B           ,<:X;H #Q_YOZA?OKR)P:E
MC[>M8NU9C+6KEKZ&]Y_-2)Q( $BQ,0YF5:,?6^,IEHE73/?B\OVWSZCPWT>5
M-+,S@:=2'&;Y*;;4V_-Y^_.+(;W(NY<&!Y?I(\TCEU;(Y-?'5R6ZY:*Y?E<O
MRF>6I+OK7;8\)CZ<2NS4C(7T\W?F5( I6C3CBVQQ[4AQEH6MH^Q:36\I$A'H
M_K^.VS9YP                   $6]?*GNO-^A_(]S;M#:   &"T^ISSB>P
MRNSH1L>>#BV:(O>MBF9->3DP2<F&;DUI&?5\U?4/GGIKYW[*7K;6OZ?6MUR$
M7)KE,^CM'2X0  '(CK16                                  <GY'JM
M<SZH%TF0EHYK[SQW5?F_T3,[.AC]3I0[4U[8U-VRZF6G';3;BWR)L1DL4RZO
MW^']M3>?.]['XMO#:O1VG?X8BTS?=S0T+TG WGA=>KF=>;EUI^;5J5T[L<W3
M>QS.R>/]* !@M7J9;8T+]L0'._0\:#FQ;)X?WVT=#A41:F+0<.UC\.YA-7I9
M_;Y67V>>,3K]#"ZO1V??XG*/;>/RW,Z6>\IZWYFU8U<MC+KV-3I6+XH&QIYF
M)[#T?/2\NN   .(8.)Y^U/)      =@V/2]\R>HB5O$QVBUO%I:)2\6MXE+Q
M:6BUO3#H&6L^T     8F^+>^KR@          !&,89P 'CWB>X^0&'C;UNN]
M%9*S*,.VWY=U4D?04URTX][*)Z'N\#GVMOQXO\/B/LUL^T\/<\7[?Y,:AC[&
MJUZ%J5<X\M.MNU^-?G%F>AQODQ@^?V*8O13:NTV=^V>7B9P8'%M4GU'T'U.M
M8^II>/MDD_3>LG!V"_,3*'T ^EG'N="VN;KF/)BZ9/B/DOAZ)ZWD-KV-
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M<?CWO/%Y;D]:W6=Q\OZ7&:^_91;3!V^;DK4V1'2>EYZN:@  <0P<3S]J>2
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MR8)>37\]_2_GW<O'>EV?F[N*U]_$:_0^E^V+8MWCYK<Y@  X\=A
M                          ,3K;_+>9Z3&[?-^3%TEPU?TO!V/G;FT<GJ
M2:7U;3ZV3Z/#U>FQ7"4B22B4B22D8/I\_3.CK=*\GZ;8MWCQZ9K-,OPPFKTM
M@W>3K/7Y6$Z&CTGSG<^5M8KER&74$/-CX7[?RG>_"^MNTL ,9@WLGGT0!AMS
M6X=Z;D^A/&>C^0HBU$7TCD^GVCH<.5?!3%@+^3#A-3IR,NOI/IO-\Q]GY+,<
MSH]F^?\ MM6Y/IJ.EPJ-3IX[<YFSWU]:P[W;^CYW)9],  #B&#B>?M3R0
M  '8-CTO?,GJ(E;Q,=HM;Q:6B4O'K?992HM;K>B)N3      I(FSI[EOZ(
M        $ P1M@ /)?!][2$VZY\K>FTY=30M7K0*9[T6NSBKFEZV*].'[-=4
MQ=O7\?6B1GJFF5OS=ZS^:^'R8^$?V_A'B?<1BRR35KD7^1DL4S54RUS79>UY
M&WK[.-T>OK6+M8ZF[\3,G7V++QIUM;Z FDCJQ[8X:U4Y*$6(B3%I41-1>B]2
M*1,8>F_KN/L0J[":Y*^CMF7@_$V8R>C.QXK;=GF@
M>8O:^>Z?Q.CT[B]   "Q3+Q_S'T//[G*LURP\>Q8IEHBTK)@E9,$F^"1?#)R
M8>'?2/GW6O,]S=^3OX_#MX#3ZPDWP[9TN!D,^F !K!C3>0
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MQYN=3=,G$^J_)CTMU/*[?GT@                    .3]WFZ!UM'TOXST
M   XYY?Z-F]KF6XO8IEQV'<M5OD<^G=M29DUY637E9,'%_H/A>@<3I]'XO1Q
M^';US2[(EWP;OU_+W;4  X\=A
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M/]7&8-[7=+L?#)Y]+=NMYD #2"<;2
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MZ7OF3U$2MXF.T6MXM+55OL,K=;T5M16X      Q"+^QK;;O:,BU0
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M=Y+OXK7W]:T>U\3M&_P]DW^* .;FWF9
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M:+6\6EI46S*;=;T5M16X     'PM;FAM>YJ  #X0$6"^3T_0     ",8PS@
M/%O"][:F*)QV[X%;HS55RW:Y<K&;9K8]_P!OD;=L\?,9=/(7U[UJ#&X]G7,'
M2U[!OX''LXBN77*SKU;W?>?/,=X?VX^H'V,GVF:J,ERFSD8R[_Z?Y[D.)ZS<
M<_+VW9Y&3R:VI:W6YUJ=K3<&]AJWB3BHOKTH^(IE\124B8I0IGKQ[N4KL[9E
MU-@R:^RY^;L^QS*YC4M;IZ7@Z&M8]C#UM%MBM7UOB/473\SN>;3
M             \X>PX,O';T)Y/N   <TX'M<?AW)F37CURX_#MUS7(9M03,N
MM+R:^E^H\S@NYPN^^,])C<&[JVAW?D3M/0X.R;_& I.1'7P
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M_-^B_"^HC4SZ=S/1TK;3T.#LN_Q0.5'228
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M3ZG^<>T&#U.IK^GU]IW^%L_1X8Y"=;*P
M         0<.SR'F>EE[7.Q>GU+FKT;/0XM[+KRL>27-:\&WJ^+<B[7.DDE$
MHDHDDI$DDHDEV8XA]"\+U#YA]0S>SSKUL82^S6N:U373>[QK>3'OO [%4Q5,
M5((^G.O0\:QH]+IG,S_$P\>Q,R:U*:8M\B;%<M4UHBUI/#OH'B-^\SZ':N-U
MY&+(+U\7Q.@<?U<W-JW\NO)V-"W?%%3%(\3%E9QYX63#N>ON=4[?CKEJ   #
MB&#B>?M3R0 V[)O>H]SV'*\'&S5MC8K[7D;1\0 .Q[/I/1NSZ0"%COC,&?[B
MS7*VMUO16U%;@    ##S3?>OR (:,5*9")*,BD   $E.Q1(   &+-7-\
M        !K>YK\^ZVEV7SO5    Y5U>5U7E=4
M                #C?H>5J70UO2/CN\   *8MK'/[>J\_O1<6?(9]/(YM2;
MEU:-K4\X?2_ ^H_G'M)=)AXMG ZG5RVQH[/T>%AS33I0
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MPM3<OQ:BMJ*W IB:I$  "DB;.IN6_H "@UB:_     ?3:8M]   !:(AD
M         :COZNG='5Z_Y_J    <GZW*ZQR>J
M                !'M7RI[KS/1^/T.U><Z]42   !AM3I:5RO33\VG/S:LC
M)@\T_3_GOI#P/KLYJY8>/9A8ME$[7T^!QT[$                   ? ?#X
M?"D%( /H*CZ?3Z?3Z          #6M#M<_Q;;)KXE<?227M+J2KXIN?2QNMT
M-=SZLHDHDHDDDDHDDA$HQF]I<[]3YOJ7A/<7K8KDU&+P;N&UNE.RZN5W>5HO
MJ_+[=Q^GL'/W*ICZC[,1Z9M!ITL/[;P'8/'^FIBV!U.KGMOE4IIB?B:8M3$T
MQ:/:./\ N?&X'I:'H/YA]% D9,.'UNAA=;H9S?XL9,<R^37P&'<Q>GU;=J0]
MC2BVKMFON]0[?C963    !Q#!Q//VIY( =<S]OK&;MBTKRG#Q>38.* .Q[/I
M/1NSZ0  :WJ;56MMJVHK< 1<.:[>EV] !\,'--\ZO)O6@ 1D:[,     34YZ
M)    QQKAN@            -&Z>G@-O#UC@](   43'*^KR^K\GJ@
M                                #S/[3S&!QY^N<'I]:YNZ    .9\#
MVTO)KS\VK)R8/._TKP/<_&^DVW0V<5K;]J,ENM[_ %/.XTWH
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M(FF7BX                               $+)3D&&N%WL&_;E.D<??
ML4R\K\[[R?FU)F76D6Q7KX^+?0/#]"XW0Z/Q.A#Q[.+U][4,F'==_B;9:H
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M/I  !KVMLU:FY16U%;@#!UGH'9XGV0     $%&"F   !4;/%J@   " 8(VP
M           '*.[S<EAOT7D;X   PN;#J&YI])YO2       '$KZ>XQEUR<=
M1N=<VEVPW4Y^+U MFN3CZ+78T&V#I%-C(+                         #
MC6SAUOTO()]$^1[@  '/N)Z[!ZG4RFQHR+X9%\-ZV/E?M/(Y>L==\UV(U,^&
MU>ES#/H][V^;)R80             /A06"(8XQAC3A1T\\XG83H1#.ND S8
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M6T>U+=\5_#L_8M@X=![/%      'PUN8LH 'T^'TS,3D4@   "P0C*
M       X]Z'E[%IY]_Y6Z  +4QB,V'6=G6IET3G=        <2OIU&46R46P
M,TS<7PLTM(MEJ8NQ.=B^ FF46W:N;8XR                         6CE
MYU4\Y>OX&Y\[:ZQPNI5$@"+BS\?\S]$R^SSY-\$C)BD7PW[8^3>W\=5DQ=V\
MCWXV/-R?%M[A$[UO<>7EUP            /A01B&8HQ!A#RB>OCAAZ'-L,@
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M+8_8T8>SH9;G=RJF3&UF;O<_8]K6OVJ     !9,+,14?3()RT381>3<
M,4:R;V            #B?I.1NG.V]XYFX+<QA<V'!Y\&%SX<5EQ?$7(M\F,U
M@S;!K[&P:^Q-I<     #59Q?2^F2F$K+6BHH1 F*$9&+2TR(G1[8=_KGGK
M                       <T-\)YPOT_#YSV-'?>5T.^^5[0 U+F^@T7C^I
MRNSH7[8I-\,B^'6^[Q.>>J\RM7T7X7U,+'GXU3/U?'FV;H<27EUP
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M8#/@^2GX[X3/AO5G:=7:S^OGU7;U=8V=:#DI\)^.]R)V+7V-CUMC)8\H
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MW0N-O<MP[/0=;H3<NMMG2X'V8           H(QBS"&GGD<]Z&!.F@
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M6SK:OM:UVL[7J[6Q:VQ4D   <8OI[C&:HUZ<<B)P4TZ/78V.,@
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M/ZK4^=WZNQP:IIF]+;D7PR+XKML=VU,CGT\7K[T/'L;+O<7+[7/
M I+!CS G'3H)S<]"&<                     !Q,\GGL,V$SIDR\5
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M.!BVX>+9VOH\";FU@        !21S$FMFOGF\]0G4P
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M'D<^GE-C0D7Q<P\_[C'8=J?M\W+[7-TKU'F]DYVYF>1UX=,V.UM^QCS[!O\
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M2Y-+MJ7+4KFERU;DTKFM<UG9=6-3/A];H9[=Y6S;_$      '$,'$\_:GD@
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M0\>%!Z=-*.@G"2"=(.H'F4]OGBL]FE\     %)Q@NELZ"9PDE0
M  -;T.SJW/[T3%L8_%MTUG']#GX/TWE>I<'I_-7=UK1[5$6 %=L7VT*VJ+]\
M5ZV.Y:EVU+EJ79I<MCN6I<FER:W+4KFLS+KT1:U6^NZ78Z+W/'2LF
M<0P<3S]J>2      [%L>D]$9?40XSXV-J-7+&C+&KFC5RQ:XLACYV@]CS=7H
MO$9+Q7U61C[7QTOH ,O73VBG+    I+6WH[9NZ8        U0NFS      @9
M:<8]'R>?=;2ZGP^CU?@]*;COCLN/RW[?SO5N'TNI\+HS*7AWI,I?0^II<;]%
MR_4'B?0C0^II>?O6<7L'GNIU?@]$0LM><]C0YSV-&_BGLGG^KNG.VP   !8F
MOTO1:W,7(F/:NEVU=9MKYJN;*1?(1>0M:1 FF,FF&MAAQ;L^+H_0
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M:N;.XN?@/0_/M9]!XS>_"_9=9Q>I  'TW/'Q9<80   ,7DP;SU.8
M+1$,@   8VF.]-IEK#$9\7FOV7 ETOZ!\GVL_JYP//OK.)A=G#Z:\5Z"I( Y
M3W>;H?4T_27CN\!SGKZ'!O4\;TAX_O;?S]H#X:3TM/C_ *'EVY=F\[U=UYNV
M      .=9-'$6Q9JN;*QDRD9+L3$FL57%VQX:<6J6Q=TP=2:L
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M)<       /A&)0   -;-D                 ()Y%.LFZ&RF2+@
M   -3YO?P>GU8F//#Q[/R$W-K0^IQ]7[W$V#Q?N;>OMTQ(KFN6V-#)[&C*OA
M3%JN2U7)1$BJ8NVQWK8[]\4BV*J:VHO;KDJFN$U>G*R8-WZWF+]\0
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MV^S7Z7)K=M27EUI>37DWPWKX[DTJFOV2'PKFHQ^'<CUR[1T.'L6[Q[EJ
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M0>I3R =*,2:4>VCQ*1ST*<R+ATP\QG826<@/49YP)IU4U@]-
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M\3K?0X.O='SEF<=2+1!E8P[>[\WT>UZO6U3;YN!ZG F'6:6V:M@
M!;FMR+6YK&O71^IS-LT-[+:^Q]@/DOL!4D?$43%R+6YK5$_2'DIH_4YFUZ&]
MF-;8^E$Q<BU*!4D     :UH=KF_"]G-RZ^>V^3(R89%L5_)AEY,$'%LYC9YV
M6VM     #X0S73SD8H]H@ (^%N8HE7$W8D    8,A&TFC&Y&NFL&?(!T Y^9
MLT,ZJ<A-Z/)YWPZX:*9@UPN&[F#-N           !"- , ;V;$3"H
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MBSZM,6UZ^*GH\&U:NQ5IITUU;)?.<_M="U=Z[;'J4VT?K^:R!UNEMFK8
M                          #%Z^]R;S?OY-\6<V^5-S:TBV&1DPR;X;%<
MN0S:F9V^:    !9,.:@0C-F_@ ^(^%,Q\E9F+<KE9DUFI(          &I&V
M@               &G'YZ'N@W8S!>          !B]?>Y/YOWTC)AHB]VV/(
M9M7)9]'D'TCYUT7B=/H_#Z6G<STE<UWSL>4NWQ@                <0P<3
MS]J>2      [!L>E[_F]9&KFBQFC5RQHRQJYHU<L:N:S6^Y8>,-7OU<1;;
M %AE^PZ+C\T--Q6W++4 ##UG=>QQI%J@      "T1#(   X!EQXTWGB^HV*M
MK-<O.NIP+.US\H9'4Q<SQ8M[S[.P:G?S>MO#";&E<Z'$^6KO438B=3,?K[V=
MYW=O6Q8J43K>9RY?O3-5MQO)3'UOU#A>NFY->%CV.8=WR,^U-LAU;'DX!EQX
MTZ)PO792VM"JT/I\JUM<_*'<,5]-3@S[S/09G'GIB<+L:5WH<2B*:'H<VB%?
M2WLIJ]G?]#KUS75,VOJ?6\Y..M4MLU;
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MEC5S1JY=<KTZ*7Z3B\R-%MW]5OU=D<SZ@  8UMS6#?<7G[S'KF37S6+9E3
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MBX?"1$9K7;%DO@+K)\*@7"),=%QVQTQS7)6T?2@J*C[,=1Q9,S$@
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M@XLG+<V*+,=#Q9.89L>_8KXVT6@0YC-5MI.2G3,.3'3&VTOY;W=7U+I;0
M    YIP?:Z[H]B7DP9#-IY'/IS\VK)R8)-\/V8R^USI%\0  %!C#4S5S<S=P
M  #X8C+CCY,=XIF*9BDB(XS2_;,N+ Q/.:7GVKTW)C^3%,J44S%,J44RHF+5
MJV[1:FMJU;<Q9M6U:*9C+XLF:P9M1W=3)<_H=*YG0J2  .0:F'-7M]-KRVYW
MKX\K>8\-IR6Q=8PM(DRR-ISM[:+AQP*NI;.3*WL    !S\\%GNPW(R96
M       :%QO5PL.U+RZ\K)@T[T/G]*]-YWNGSWW$7'GS6WS<OM<X
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M6U-;5JVK19M7)<GK]%Y71@@&0B<_6920             .!'#3UR;033Z
M       :3R?3X+3ZEZV.7EUY>37O7Q>=_J'SGLWS[WFQZ&UFMOF9;9T
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MJMUO16UNEJ*VMUO16U%;@   1F37;]+%6W/J-WQ<+&UIO78XMVT:#Q^QF5@
M,?FUMUZ7.       BF+,\   ".B0D6"^6RX"R72,B4FR7#X5@%DO M%TMEP%
M)44E0*2H %LN I*BDJ!;+A8+X+)>  +)>!:+A07            #DN?%H67'
MN..^F9*0)C?,6206#5<E-OQWY_EQW4YZD[QCOS7-CN&<I:^:Y:O2\.7HV+(
M  +2,.5E)],B?20FE&(*DC'Z76S&;4G9M6J8 ^$#%GP6OOS,NME-C2  %DPY
MSXY.>ORZ     6IC7MO3IM%,J44S%,J4<XIDZ'DQ4S&OQ;*VK5:MNU;5HM6K
M;FMJT6;5M6K$I>'CR6BW,46JV,'S/@L2S_(Z_9>3TI5;   <QUL46(RMK8>E
M<S>U)@Z5CQ%2>D;&3&UC1<./+VMG\EM7Q4W#-?3\-.N;>8     >-3H1V8SA
M>          .><3V&&U.C-RZTO)@EY=:1?%Q3Z#X;(:&_P!G\EZ'/;O*OWQ
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MKXJ]>V\O*-7%&AE[S63;3:AA:5M0REYRMIMF_9\@     X603JQL9)
M    -(Y/I]/Y?HLOL\_[MZ,#J\C7>WQ=(]%P<IS]_P!#>&]5G-SE?9
M           <0P<3S]J>2      [%L>D]$9?46ZWHK:W6]%;6Z6HK:W6]%;4
M5N      ,'5T'M<4:AH[LK5W0 ,'5T#M<7Z      " 8 VX
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M>1D,N,      62&9(
M                 &&1*346BR   #$:76FYM2YFU;$Q\,R?"/BSX[7WY.76
MR.QI  4&.-2-#/0A>     !'M36-_2I1\E0CY*F8I+<Q;M6U:+<UM6KSO#EC
MRW/:UH:WV)^WI\RX+=ZV9BU:MJT6IK83E.7U.O\ (ZFP8<OT
M      &DGEL]+&WF3*@         0L.SQ_S/T2J8V'<Y$S+K:QZ+SNY<CI><
M?J'SOT]\\]AL=M<                 <0P<3S]J>2      [%L>D]$9?46Z
MWHK:W6]%;6Z6HK:W6]%;45N      ,/-=]Z_'%JLZ+Q^UFK0 +<37O<[9MO5
M      &*-6-^             ,+,?3,Q(MF(F,W$X>8OPR*0->F+Y-A-2
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M'M72K5W"MHDQT.EXJ($M:M&6AE8G+Q,!'R6$F)L3GHG-1(
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M7>Z6TVU;QBY;E6;1K$QA;1*AL$3(2,K#5)B',;%%LE#69CN&/(
M                          !BT5II!+1</J<83P#!:769M2=FU:)K>*$T
M$/%GQVOOUY=:5L:7P J*#$GGDU0]Y      U_;U,5GP4S%,J2W:MJU;<Q:M6
MU:+4UM6K:M&(6W[D]7>=/9P-,?"=?5V?)E[=GV0,)GP<ZW]/>-'=V77RUI @
M5KYBU-&'$>A-K<W3)E       I+5JVIK4F]6U<3]       (!R<W\V D
M      &L<_M\YX?LIV76SNYRI>37E9,'&O>>*W?F[76^1M@
M   #B&#B>?M3R0     '8]GTGHW9](                       !IIN0
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MT;L^D                        UPSY<             !R^].H4N
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M;!N\C(YM.7EU^4>U\AF<4]KX._\ 9@                #B&#B>?M3R0
M  '8]GTGHW9](                        .:G0R^
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M      ['L^D]&[/I                         -?,8139S+
M                                                &**D6TW2TB(4
MEY/PE@&"TNMD<VID<VK3,43'PN1-K%GQVOOR<NMD=C2 'PAFKG!#NATD
M%B8TGH:%G-AMVK:M%J:VK5M6BU:MJT6IK:M6U:+5JV9B7I[O:>#VI=; "S$>
M;-+G:\=PV=SI67,-.P:VJ8L/1MG<RU[@ #DNKI:-@U\E:_H'?Z0M370.MR])
MZG-KB;]+7ZVOUM?I>_2UZMK];7:VO5M7$UQ.IVGKO+Z%V)      U$Y(=2-J
M)A]          -?TNOS+@>VR.;4S>WR\AFU./^\\3MG.W>P\?9N6H
M         !Q#!Q//VIY(     #L>SZ3T;L^D
M
M &(1'3<*R\4@I/I] ,)I=:5FU,AFU;\QB-C%$R4V/3V(V+/CM??DY=;([&D
M/A#-6//)WDZ@     0;5U'<U<+M:M&7%]M6U:MJU;4Q:M6Q:(I9K>]AS976V
M=OT]K=-78NQ( CQ7@'/YF..G[6YTG/L@ 6(CF&/#L]K[??(!;B-7PX,[ERS[
M7P6SK<M[W$UF8M8\DFLS8F]6V-Q9-ZR8[];WZ6US%EUC%EZ1DQY0Q%HGZVSO
MNGM?0     #G1P8]"FUDT^@         &+U][DWF_?S<NME]GGY78T.)?1?
M](\[W.I\^;U\8                '+<?.Y-@X8     '0\O6[1FZX
M
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M>7^C2LF#+[//RNQH>?OJ?S3NWA/8;WCP7[X@
M
M                         !AB45%DH*@  ##Z76G9M2]FU:9KI?5T]+ZF
MEVWRW:C8L\+7WYN76R>QI5 %!CS43QZ=Y/28      !\/B/@!4GZ"A'FS4TM
M=K3T9L[NV9,@   &F8\6MQ7J63-=F=,PZ_)M31RELG=-[HZ]6GFC5THJ;$SF
M,\9/T/-V#HZ\BMN8\[H1L63DFAO=UW]'C>CN^A=[2RAL!R/6V8U9TK'D[IGP
M=6R8]2R.L<OH7XD      :D<G.GFTDP^@         $*+<?\I]*OWQY;8T*N
MKQ.'_2_G7I?YI[W,;/-E7QUE0
M
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M:^@3-[CSMGGX?O>>SNEL9.DSCZ  4F,FN[18
M
M                       "&6205D $D &OZ76F9M3)9M6J8LGFKW'G.N>:
MZ^V<CIPM;>D9=>=L:/T^GP^E@P)IB=\-Q              -(.9':S5#H@
M  .*:'-P%,5M-N9MEJ9M$N]MMOFN=+!/ZVK>K>_2UZMKU;5Q-<35"N)KB:HF
MJ)Q%HW#2W,C2X      PYS0W\SI?      !J")":C%%   IE7Q1C,DL^@  '
MPP:N^K?0
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M8>8      R,3L,2
M                                          /A!+9> (Y.,#I=:7FU
M)>;5JF!S[KZ'+>]SO17A?3X[7WY.76R.QI  4&,--+QT\
M   T7#@X/KZDJU_4>WO5RXWZ3SVK[VG?PWD<39^</9MZ]K4OMIW#-L-S'?[6
MM?K;"8LNF8,W7LV*N%437$UIJK-::ZJDUQ,29RFOGS.+(     *3SX;H;R94
MK      !#1IAG$XL(E&&,\91.FHK*"RG D@R!*+I]+1&,@9.:[;%@
M     !Q3/BX'MZP     '7];/Z(ULX
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MR^1R.FDK):+9=-T3(             !Q3/BX'MZP     '7];/Z(ULX
M                   %HP9C#=
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MN![>L     !U_6S^B-;.                        !RXZB
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MB-;.                       !8.<G30
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M,3<!!1D2>D    ?2890             '%,^+@>WK      =?UL_HC6S@
M                    :B;<
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MUL_HC6S@                       :L;2
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M/J(!/"-M6             '%,^+@>WK      =?UL_HC6S@
M         "*:<;V   "%K[,7!G                 $W8UI6?
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MHFF)0KB:T_(8F\8V5$3?K>16:CZGZCZ5%R)OQ,VDY/'DR6.]^LU1-2:$5I
M\_GGP]E&TDXJ        -?(!-+AAC+ &MF>,.BR7IB8BL)^0JF/ICRA.YQ:<
M             #BF?%P/;U@     .OZV?T1K9P
M!BS5S?    8W6W8>'9CZN3Y                 "3FQ9WI\K[(
M          <Q[?%L7K%R4Z3Q>OJ'0T)%;ZMO:.9UMB!EQY3!FZ1QNQRWN\3<
M^;T.?];ES<>27CR8_-AI)V+)C<^'KOGN^      (Z,4F>"V6"LJ(1D"27#1^
M-ZK&:V]7-?EJ[AV?*W+4TOA^OV+=Y$6F:Q;#G>IP*RH'PH+!)/B,.:^G3#NY
MD0        8ND92\@ :]CKL.2P   ^')._PL-M:N4PYL[KYY%+51(HE;%;7J
MVK(4L5:(\6OX[[)@S9_#ER&.]Z'U((^%,J"W,1[1&FMBT4$B)F5M*I-^+?0
M0S2S#&Z&=)         !08 @%TE@A$X^ $ @GU ^E(3/)QG2X
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M?0  <</(1[@-L,B5@         H--,H"&9TPA*     !G2X
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M^,K&'I7K.WF    H1J&YK:GN:D:]/D376UVMY./)F,63.8<F4QWEUM7$_0
M         "(:<:P;T9\DGT         C&I&3*B&9(UQ%*<N2     ?3(D\
M           '%,^+@>WK      =?UL_HC6S@                      "&
M8<V0   &-UMV)BV (VMEHI8                "N:[!U>3>R8P
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M.                       (QC#.    QNMNQ,6P!\B8NIF^1(
M       %_+AV'J\G[,                #0,N/9*6S=;    #'S&NWKN6.^
M"M75KUWW%>2D#GV7'T'%D       LF&1]/A*3DC%&1(!\*P0-#JP\&[-S:M*
M<9@WL7K[V+U]_)9]+'X=O;>KYG8^CPP  !622.8$U$U([ ;$
M                      84UDUTWHSQ)/H        -71KY;3L!9(<XT7^I
MH1OZ=/1C44IGGQ,PO%PI+10C'%Z:[M%P            !Q3/BX'MZP     '
M7];/Z(ULX                       QQKAN@   ,;K;L3%L "W2T75S(
M               9';U,UT>:               !JUZ<9V,/<M;/J62D<VZE
M^:YL72L.7F6;%T[#EYWEQRH;ICORO/CS%9Z_KY?->YK]>P9><9<>Y8[S(G 7
MKSS+C]":NQSK+CZ+BR<TS8NL8,N6K8    89%PMIOE"(A2?4U$L Q^AU8F#=
MFYM6E.,P;V+U][%Z^_DL^EC\.WMO5\SL?1X8   I)Q20#5CR.>D3L0
M                           !YP.(GL(V@R!6         :6B>FV8@I+P
M!2B<F&4&1+"/A9+927$7I51.33@YKOT6^@            '%,^+@>WK
M =?UL_HC6S@                      "T1#(    TWE^BR&;4NJ@"Q@RQ\
M&0                 9SH\S(;>H               /AQ_8PXB8T_)38Z6H
MEZ U,_G_ &\'<]7/Q+9P1Y5'TZUKY='RTZA@R\3V<'?=78\X[>M\EWC5S\GS
MXL+:+QGJ6OD&8[?K9_H    ,(CZFZ5'P   $#0ZL/!NS<VK2G&8-[%Z^]B]?
M?R6?2Q^';VWJ^9V/H\,  "HC$XO%@PQJ9H1MIUP
M &",X?0  #!&</H    .>&//AN9F20         #33(%HP!(*SZ4E@O&!,.;
MP9DJ   ,:0YKOT6             '%,^+@>WK      =?UL_HC6S@
M               #%FKF^    T+B^KNY=7-Y], "'J9[6*X
M   %5HV3K\:1EQ               :[>O*\V+<,=]8R4R-9S-;:5DIN>.^DY
M:='PY-7O2@S$6TZ]-PI?I&')PW9P0ICI^'+IV2G7=?+P':P#H.+)JMZ[KCOC
M;1TC#D     P*,@GZ4EH   &.T.O%P;<W-JTIQF#>Q>OO8O7W\CGTX&':V[J
M^9V+H\,  5E@B&2)121#73SZ9L]+               &@GE\[J=E,89<QQ(*
MS&F8(A#,N8L\CGKPTH\RD4]5&XE);/(YZ\+1/+1',F  #Q>9D]$&PDPJ
M     !A3#F1,0643C'&3,B:H22 GZ84RI/))<*BT0"23IKN,6
M  '%,^+@>WK      =?UL_HC6S@                      "P0C*    T+
MB^K^UQV\E]CVN4 *8F#I;--9                 OY,>S=CB56@
M                         8 R!462.72H  &.T.O%P;<W-JTIQF#>Q>OO
M8O7W\CGTX&':VKJ^9V7H\.H^GPI*2R4(O)(R:1;,::R<X.;GL@K
M     -&/'9ZQ//Y&.QG#3T"<#,F=R/(AGSU4>7C6#]!#R2>F3!''SAAZF.$F
ML'L$\^'TD&VGJ  %)YD-Y-F-G,F7           :L6D9*:YR+ZX3"^#7R^0$
M1"<1$QRV?"HD$I%LW0DI             '%,^+@>WK      =?UL_HC6S@
M                    " 8(VP   &A<7U=ND1;L[L:.1R8 !:QW@:6T
M             ,CMZ>P=3D@                                #"$HN
M QX)1</A&+0(VAUX^#;FYM6E.,P;V+U][%Z^_D<^G P[6S=;S.P]#A5'T^%)
M;/I(3<1#,RD?"R8<T8XH>N"6              :L80\L$$[P2S03T0>/CN9\
M.0'0#+&GFC'MT\T&W&NF>.1'I8X>:,=P.8'6#CY[/+H ,:>'#TV;V9@O'T
M         LHO)&GF;,85 O@H,64(%)27"LD)GF?              .*9\7 ]
MO6      Z_K9_1&MG                       $,PYL@   -!XOJ[&.UW8
MUL[FT:5Y%L8 BZ^:'JYP                !G>ER\MO:(
M  $&8X7LX.RZ^;#6C=L=P            !$()*/A41SZ?2LE%\&OZ'7@8-N;
MFU:4XS!O:7U^=-\QZW(9]2!AVMLZOF<]T>';/A47"^?2TBT6S,) I(Q@S53Q
MP>NCKP             -9.*G9#&G+CNAR(W(B&G'>SF!F38SC1D3M!9.$&1.
MX'*SJAP(R)V(X6; 3#J14 </.+GH8VHSA**@          035$1S(%Q,PQA>
M*"\3      9\              XIGQ<#V]8     #K^MG]$:V<
M             1C&&<   !SOB>NUG3Z^V]'@;%M<S7='IYW;T*YJ ,=I;5G#
ME                 ^S&T=GAR\^                 8:U?,FYK;_BR9RM
MM7O27$_#H.+)JN2F@9:=,P9-3R4SM;:3DI2>E-/8O)        Q9>*B,3B*9
M$  U/4ZE&IO3<VK2G&8-[2NWR9OE/99'/J0,.UMG5\SG^CPJ4 DBE/Q%2;!F
M$W  4$,U\Y6="*3H8                            !KYJ)S8[.;"3"L
M          UM&$):9"(A"3DBZ4D-&63(    !\)9DP             <4SXN
M![>L     !U_6S^B-;.                       ,<:X;H   #0.-ZN#6<
M)AZ&T;'*RK6Q;:V+;Y@ IB<7S]VBD@                7\N/:^UP;EZ@
M             8:U>8YL?-\V/I&')SO-CZ9@R:MDKL]+1)7X63<L=N9YL=N6
M6K/8=?-DHD        0",9 ME9) *3B?I.1E?-^CVKD]:;FU:4XS!O:=V.9)
M\O[#(Y].!AVMJZOF<_T>' +B)!\*#Z7DY,^@  MD$U\XJ<1/T)/H
M                   !$/S;/5AT\V$GEP           &L(DI$$  %Q&-):
M;A,+I46SX#Z5F),D9T             '%,^+@>WK      =?UL_HC6S@
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M             <4SXN![>L     !U_6S^B-;.
M,6:N;X   #1N/ZG.;7*HI;4=7JX'6ZVZ[7!^S5EG,YM( 0];8@:>R
M          ,]TN7FNCS0                               ,:C6TWS:"
M^ # JZ^MSKT?)T_K:>Z<'M="XO1S/.Z&,P;W$OHG@]N\)[[:.;O_ ';Y62ZO
MG,P5%@C %P^D-&SF12  !:,>:\<&.H&VFY               'BDPYM!Z:/-
MYG3'GI8X$:P;.8<U\]+'DTNGL\RP !C#SZ:\=_-A,@73Z            8LQ
MQ((Q073Z13&'Q$M$DE%:8J2*"@K*R2GXK#-N6             '%,^+@>WK
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MDGP I*TY(CHV5(             XIGQ<#V]8     #KFKL=\TMK[,3+TJD
M                   !#,.;(   #0^-ZK#X=F7FT\?JZG*>#I=^]53#XO01
MXS;STO/:]I]',[.G6@"SCR8CF;WQ(                &0V=3:NWPOL@
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MVIX>I+R:FD:&EV;LZU&'8TS6[.X[O%HPY(EKYG/I@"%K;&-T=L
M       9WI<S/]/E                              <J1I28)%)AT4R@
M!@][6TSLZ&T\K<HM$3+3&1-_G[5>.VH>S\SV_P EZ+,ZN<    #'E$URT3GD
M@   "@C&+,$<1,$>FC+F7                    ,42#P$=Q.MF=,J22L
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M"F"/-9L!ZG,H7P                 "T6SP@;X=L,\9LGEXJ
M    ,>C!)R9C"@O(B$TDF#+YCDUF/,J3207"HMD$MF5FNQQ8
M <4SXN![>L     !UW5V/0.CN6ZVHK>W2U%;VZVMTM16UNM_B0 !8B8L(E9L
M%[-K[)O:6P;&             "T1#(    TGD>FRNQH6<.2'3+K6#K93-H92
M=>\C5L/2R-];+SK:WAZVR;O*G9=4                   9+9TI>77
M                    &I'-2(#9CII/!91S@VA/TB%E$?+3G/I.3C[1VWRW
M8RE;_2,: C+(EIQ2=%[G.S7#Z,8EF0)9?+A]/A8,:90R*+TUW.+@     ?"V
M1C%F#,">;#>STN98O@               %DMGB0V<ZJ;49TR9*+A]
M         ->5K6^(RZ(BU@F@PQ60T62^0DV2@^'TNDY%9L9+2
M  .*9\7 ]O6      Z[J['H'1W+=;45O;I:BM[=;6Z6HK:W6_P 2    !CJ3
MC\F';.AH9S/A            Q9JYO@   -(Y'IYF34N544G 4W<;79E6Q;)?
MGT1.D:_=VW/QIC'J^MV]SZ?GKUL8                  &2V=*7EUP
M            !'O212X   &F'.".#;3I1+   -=FD.+5IB7IK?;Y_,>WS^B<
M#I[IQ>AGP?#GG8T,EQ][.IPR+<QH_>YO0.!T[*8A9+10#Z72232XBTC>DW4@
M      4EDAF*, 8$\]&W'I0F&=              ,(3#Q ;J=#-M-@,H32\5
M                  @(GI&LF7,>7"V7@62 BD^'PI+A<+I-3ERL
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MDL$(QA@S G#R@])FN'9P           ?#AYUD\#':C=3:S.&3)Q?*CZ
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M6?0                 # (QY6F4B&6$R204D(RI=/H   !])1-
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M-Z.=G43DIT<Y2;$:L<T.H'CP]MG%#L1G#(F1)A*+I4?0
M  #6T24U$8I  +B())342BX4GP^@%1$)IDP             <4SXN![>L
M  !UW5V/0.CN6ZVHK>W2U%;VZVMTM#I?!8LF;NO3$>)U2:92S6;X]SQ9L->F
M4B8DQC)C/UMK=J;/@S_#*7J  +,3!V-/>^CH       ",8PS@   -2Y7H/M*
MXR,V)U^E=R8-DS\Z_;'A,.W@HP0\_!V3%Z21%M=Q[VS9.=D;Z\&,\G-CR&36
MU6.?J%>7N]NOL4[H     'P ^@     &%TH@X(VCJ6R6SI2\NN
M               !1,<1]+R-2W];N?F.QM>CL@:0BI&-6RQ]FN'B;!%)Z<N"
M'FQ\J]!R^G^=ZNQX[Q,E.)>MXFL]#5[-Y7K[SR.B    !09<F@
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M9<            ^'PH*"R62P1RR1RT6B@^%)4"Z7"Z2"Z22\7RZ7"L^GT
M                  &)(A*(I]*2V?#X0$2RZ2RXF,$4E!45E]-*(R-E6
M          '%,^+@>WK      ==U=CT#H[ENMJ*WMTM16]NMK=+45M;K?5+U
ME1-6')#K.2O&8O4"B)KF  /AS3)BV_7SY:R-$3[Q]!KZG1^QR       !:(A
MD    :ERO07IQ6XM@<.[LNSS-?U^AF)UH<9IF37PV'>E9,.9S:<3#FTW#U\]
METMFW.4B,3J;NF9-+G.30ZS7H[UL4IA'P9M9T,GG_P CHCZ>C_9]"5EG6:[V
M.P=#>]SSN8VM&PRQ<6>/KYJ"(OBXS8B-F/3-\B;R+LQ9BUC7W[T1DMGFS+<K
MSCYCF6X=X[^;JO=P3]C5          T+J\O#;.ON_,Z-J8SFMLXC8UYV++HW
M4YG1>/U\-L:^H]'0RVOGS^IM6YB32\++CR6#+B]C#B-C7M3&R:>Y#R8\SK;&
M+SX,UK;-ZM@ !P_TW(B7IWKRW9^I  T%&;346R$?  #2^QH8'=U\[I;&PZ>?
M Y<<;8QXO9Q:=V^3W'QOI,_J9Y!<+9:/@!47C'&%1G39T@             ?
M#X4E)24%)24@I*@5%145E145'T^@                       &!+Y;))B3
M) &')9'1;+Z":CZ?3X!,1X9U;(              XIGQ<#V]8 =#Q9-_Q9 !
MP?:P14 ==U=CT#H[ENMJ*WMTM16]NMK=+45MIEHVG'EN@&,I:+#.Y*C&4MD[
MU  %HUF]+FOFV+)6[, 8*<?1.OR0      !BS5S?    :ERN^QJ)8>FULVUS
M=?U>A=FE$9,OFTK&/)AZ[><R:?V(BQDTK5[VW;7$V#8YT>F;%UV8%=C8,_/G
MY]:/ARTTMBL,^7O+:-F(GWMZC]5O?)O@<72R.71S5]2_DQ43:S3+;QVLT5%R
MX#XFS%H--F'&:3;#D[ZLR^&[FQZQKX\1A=!W;2LN";GU@         .5=[AP
M,N+:-'=D4OJ/1Y^U:&]A-G7HFO5.#W.7=WB[GS>AK.]IP\F.Q:H^E^EHN2D[
M%D^I^(E8\F)V,$S'?:='>V32W  .?]72Y/WN9Z3\;W[L2  -",N72,8$ODX
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M;1:+A> +)27(G*)DJX:8VJ+SP
M              1S!&0!&F*XFX5      R16             #BF?%P/;U@
M!ZCTMKSEN:^)FH '7=78] Z.Y;K:BM[=+45O;K:W2VC7KN6#/\2$3\/LQ:B=
M%C-E-B<SETX^+'<U]C+60:S62[0!RB^/JU,GT P<XNA]?E       " 8(VP
M  &H<GT,##EESBQ==G.Y]*-CR86FY\I?,9]"_6,-&U09>=:XC#5VI-\6.;4^
M<,;'LIK5?%>FEN5G%L7+X\ODT12FA/P%F,EJN2Q%Z4U1.B<G0YEQ>:.L=[L[
MAN[]C+BOY=::QR5+RL6</*K^5S$;F_T]/0FF+6XMLN[RLUM<\
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MT^E*8[%R+;\9L.'J=&U?5W<F"].*Y:FQ[O)S&UH@
M   8?8Q><?8<'U!XGT-ZM@   ->*"^:]>NJ]WFZ)U=+<>%TNB<S<FXKC![>O
MRST/+W_R?<VPP)3-=)]#S.B>>Z<.!%PJ/I]!26RY*\0(G>UI8
M                                     -35^K#(%\C$4J)Y=,.3BX5@
M   ^%U&02             .*9\7 ]O6 $^)RL6UNU/IN..^FY* #KNKL>@='
M<A4O'I>S2UJM[%+:Q6^5IDS<P33%JIJ +"-5Q[6I9?136*<P2XPS\?*VG)C
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M'&O2<GH/F^K=F/A\+A<*BDH+93$W4[ 9\
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M#]+)I<    "X9T
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M+LZ')O2<FFV/N_CO0[%H[(     SA=
M                  !;1 *3))K,&9,%LA%1919+Q930? ?2^CZ3S()
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MV#NOCO0[%I;(    %DR1E0
M          "T7#Z02@L%)673Z"@L! ^ K/J;Q?)8             !Q3/BX'
MMZP [OK9[AK=J@<NSX[* .NZNQZ!T=RW6U%;VZ6M5OJDVJQ[%5-O%QM8V-B
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MGI63S&7VN; IFUK6V\I:^PWI*8K\THBU".;;&GW?HZ    @DX    YT= +H
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M$2C+GR:[U%JP
M8@O I/I8+A]+9%1(*BZ5EE/U%(*BI-Q$<G)D@             XIGQ<#V]8
M    #KNKL>@='<MUM16]NEJ*WMUM:I?GEZ[7AVZ(RV%[*]I>VM2GX5HNJW5+
MZEY2^QWXI<FOT&L7I+P984.A];DWIC1-/;WSH:%ZT       1C'&:   !K'(
M[>'TN@ /A<MCN(M+7%;<7KFEM:5;%'KEJ0RUCLJU1B;\_2<WDAN^+U>S3GKK
M,>N2*R6ZW^E,Q6 41:B<,&^CD:=*[:EV*US'T%!&IEXYY'F8S5P]J]=M[3T9
M^)HK:W6UA;,;O/SNYS@                    !HW3T^6=SG>C/(=T
M 8\U<R9$5V9,I-LY\;H#X<R[G-SO$Z.P1.#(\UKB<!U-/9>7NT$<M% /A<+Q
M)+R(J-M3E4@                                                6
MB&?"012DO@MEHJ*$4EP^'T 'U%M,DR*0             .*9\7 ]O6
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M1VCE;EN%:;A6 BE-LOEXS"<V2
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MY$CX0F2]:LV^"/6\:F:W6]N9^%=;W<NML^]RLKMZ0
M T[H:O$_2\CTOXSOWJV      %!SI$F8$:)V=..+Q,-9,F#2.QH:WT]2;CMU
M'SW4GX<G.>YS>4>DY'I'PGIIF*X    &9)
M                        !"(Q)/A=(EJVZVK+Y]    !])@
M   !Q3/BX'MZP     '7];/Z U-G'8<MVF16U%;VZVMTM16UNM_B1J]Z3(G&
M37;J9 /H!8-$RX=VQY9D2   !:B;LP!A\VKO_2YX    %@@&6   !C=3<U;B
M]WY   !) ) "K-CEY,22%*8D7Q^7!A.QY;)9,4A/PL(Q=L<OF]O;N?VOH*$Q
M*Y4Q-G%=M5,6Z7 H3"KFFY=:9;'36;-<EJM[*\=-,7DY-?9=WF97<T0
M              ,+LX?.7K^%Z)\CW,]JYP      -4(TUQ<6G&11BB.1 G/
M'-/0<O9^-O[=@RR37MW7XAZWAQ<N'O?C/19[3V    !47S,
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MA]!^)]+E-?*   !]/A\-B
M          ,*@5IDD='TH*DR228Y%!6$W"LJ!\*2A'PF%](
MXIGQ<#V]8     #K^MG]$:V<#6M3:E8\RMK=+45M;K?XD?(FU%KUJ    #3<
M%Y5E]&9R1(F  (U9DVB!68NQJ= Z7/     $(PQLP   !\AJG$[V/U=L
M "K-23DQ 6;4T7T'C,]&3+1ER$7EQ;X1)ICIIB)QZMCR=&X7KOB]JN3X7YQU
M(J-+X^K%QQT#N;*9AQDNS21?#3>E[%EQ._J9O3V(>//%B],3)OBV'>YF7W=
M                  #"[.'SOZWA]A\_U.@\G>        T=$],@I()2  8/
M=U^<>@Y>U<S<RNODQ]ZQ<M9&.V W]7"='G]]\3ZB07RDM%  )!8,&B0;FGZ
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MAWMKZ&SK'8YT7<TMMX?6U3N\C)Z>S(P9LUSMZU%K"_Q%^:[!O\O,[W/
M             &F]'4X7Z?C]P\SU]VYNX        -)+Y.*37RT9,J!J_2T^
M;^AY>X\G>^PN8[;WS-NSBRV%<+GIKO;YW0?.]6A/TEDHO I+)!/BOU.11.3F
M$@                                               #$HEICEHN
M^'PAGPRY]   !')2)*0            !Q3/BX'MZP     '7];/Z(ULX ^&F
MZ&[-P[%R)MUO\2 *8FS6PO6K5,    6HG#J8RLUTR3K1"K.=R5IV]'>-_2
M    &--;-V     (.MLZEP^_\B0    *<D+U^S'TM6Q:EZ/Q6QUS2(OJDXL?
M..W,51;+1?-)U^V&KD>CW31Z_P B:$JW^D>M?/G(X\.M?0?8ZV3OE^6KH7KO
M,V\N*/FQV<F/K7@_84PM3:U6_P F*T;%T.7G-_F@                "S:O
M'?0\O3.CJ]^\KVL[JY@        ,0:>;*?2&:X9PES',?0\O5-S!OOG^GF=+
M8^1-Y$Q%Y&23;NYKV-#=^)T*)BR5%Z%4OI;+1()$6RJ,=-946V-(
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MA$8)DE9 )0*2."A'P)MGP^ ^E9<1?)20             .*9\7 ]O6
MZ_K9_1&MG   T3G;\O7VY,@  !C:3#B<E:)EH    ^1/V8 P=\/0^KRP
M !C#6#>@     #6.-V\5I;P    JR5NVH*ICXG7MWE0NQYS0)K8FF5FMTB1.
M&6VF+)ILO&]/N&CUJ86UK<6O32[-4Q\K/Q(%E:UEQ\6^F>!N8\G:/FGO/M+_
M !/P^Q/V^/8NAR\UO\X               6YCG_6TN3][F;%I['8O/=3,:^4
M          " 8(ES&A=72T#N<Y6>@^;ZVZ:>Q? .3^DY%?-W.J\W;Q9#5QV:
MF$ZNEN?$Z%*+A6?0#X4"5XQZ=JBV8
M                  !\!]+):*RD^'T^@ME*/@/A]/I45)NEX
M   XIGQ<#V]8     #K^MG]$:V<   <^YG1EZ^W*E=M4   8REHD,U>+DP
M  ,/2V>Z7*V'9P      "P0#+      %%;:AP?01<.<   #[>+MJ?"NU:8M'
M3I?H?%Y#+BQB(LU^ F)LS36L&UU_@>OE4R4EI;Z75:IBJ:VZW^@I+2]V<<#>
MT^'?3?";!R.EU?P/L;^#/04Q-RU=@Z'*S?0YP              P6SAYSV-#
MG_6TMSYVWU;A='-:V8           #G?7T>?=32UG<P;-S]KIW&WYNCLX0V0
M B9*><_=>8ZKY;N[AH[&1P9?I@]G#H/4TM_X?1%(/@!]/H$6S1FR0
M                                          12RBHD)C%\CE9273Z
M    5EX              XIGQ<#V]8     #K^MG]$:V<   #3]+;P6CT,[,
MR;5L1.,I-!E;Q(F !@L=KTLO>H  ^'TQ-)G[W/V[=U       ()@S:@
M 1L.;3^#Z&BM@  !]O%<T )MIQV?5TWM>6;&K)/A#1BHFYJ='HW(]%EL.S\*
M$_$UJU ( %M879K4C!=31Y/[WQT/9P=!\AZ;<?,=^]BRUS78.CR\WT.:
M        *4:QO:^D=+4T3J:<JENC<?>Z#R=Z52P            &O[6"I.=U
M<V'(1@C/%P B'*O5</-Z.W$R4Z'Q.C-Q7YQW>;K6_K=L\GVP    !F20
M                                           #X"D@()NE**$BX"@^
MEX^@    $@ ^@            XIGQ<#V]8     #K^MG]$:V<    6JSIVGM
MXK3W<[-K\P,+CM;,]DJ (E9P]+9S)6_, "-$XJL;!T>;LNUK@      "$88V
M8       Q>EO:OQNV   /MHJFH)%"?A1-,5GUL=DPT3%^M\IAV<ACS51(")"
M0(^E2/J*4T)K5J /DQJ_<Y6G>DX>O]CF;!QNGM7!['0->=HV=(
M0,M-:W-?6-[7U+?UM>V\&R:>?>.9N;UR]S)X<@                P!@3.
M$8SQH77T=&W]7;N;M[/S]J_6WGOVWGH>7#Z4\%ZCZ     9DD
M                                      M%@N%)2  #XCXFHJ*CZ?
M#Z628?0             <4SXN![>L     !U_6S^B-;.     *8:7H[N)T]W
M8+3=F*(G XYGV9*]0!A,=AF\E1:B=9K&_=;DY3+C        C&.,T
M#7>5U\+SND   DF "0         0201]3]0 *4T6C"]3GX'K\W'=GD-S5D4G
M-ZV;-:V7*X,N1PWFX[R\=K]9^%JT?"Q>(]JQKUC7K!RTQ^:F*S8\3L8L+LXL
M3GQ3,=]ET\^S:6QM>AL['IYZD@                #%FDFT@$<SIJ^7%S#M
MZ'2?/]3*3&I]/4P^UAY5Z+DWHKZ5\#ZFN)     R)D
M                               4D,OEHM%X 'P^H)I*2M!-9]!\!;1<
M+A=2             .*9\7 ]O6      Z_K9_1&MG      %N)T_2V\=J[=Z
MF7+6C3L4S<N/-1>9: ->QVN[.I=K:U:N\=#0EWJ        ,::V;L
M#Y$ZEP^_!UMD  ) :;O\G<M#K?$)?8GXA+[$@#XCZGXCZD     @)! D 9[I
M\K/=+EV;5P.UAP6UAPFSBP>SAPVSBP^QB KA<K,BMI%+2J6G8KS\5\AAOEL&
M3,:^7+Z^7*X,GU(                   UTU0V@N MFP&KG,N]RY%+W:6^4
MMN6EL:YT=3EWH>7,QU]!^)],    !64&P@
M                      $,NGPI/I4 4EDK145E*?@1\!]";A;1=3=
M        !Q3/BX'MZP     '7];/Z(ULX       &*Q9,)@S;'LZ\V]=5U-G
M!Z>Y8PY_MJ;-T>?LVUK          "T1#(        %G'DT[@^AM8\@ "0',
MNOYVS:D#)AD5OG-;=PFQIW(G*8=F-?'5%HF3##OBV?4Z.I[O+ZGQO2Y'%L
M       9[I<K/=/E@                            #"FO(@F;3-!9-D,
M.<PZFG'S8]AU,TW8QZFB9COM/.VM.['/^9\'4O/=GX6@   2##!&Y)
M                                           H+1]*@70"DM H/B!]
M/H!\/I27"^D             #BF?%P/;U@     .OZV?T1K9P
M           !C#6#>@        0-7:U/B=[Y$@  <VZ_GZHD9?!M8W-K9/#L
MT3&,RZV*SZTBF273+<B95,L#+@Z!R^Y(ID         SW3Y6>Z?+
M                     A&A36Y$V$YTG%@P:,R<K[6AB>EJ3,-]RYFYU+G;
M6-K;69J,/NX(&6FT<S<D$TDEXK/A262P0D6IBQ$[>9!(
M                                'PM'TN'T ^ ^@H*3X@? ?3Z5)K
M            !Q3/BX'MZP     '7];/Z(ULX
ML$ RP        !@^;T]?Y?6                    SW3Y6>Z?+
M                     U$Q*)B8I(+Q#%Z<H])R<A2^7U,VW<C>R=9SR=:+
M!9-8W]:7>F?YVU423Y$V$@7D29B,@G(1:"C)3&QQ8
M                              #X?0                      #BF?
M%P/;U@     .OZV?T1K9P                      !!,&;4         #5
MN+W,9I[H    PFSIZON<W?.9V[];ZAO\JS:FWZ'5O5N          !GNGRL]
MT^6                            !IQ<1,328@L&L=72Y]Z#E[!S]K;.3
MN[!H;0P>_JX?:P[IQNA402GH:M1M'/VHQ +:*RF8K/D3\3DB0#"F6FNRQ8
M
M           #BF?%P/;U@     .OZV?T1K9P                      !"
M,,;,         "W2VH<+T,;#F    Y5VO-=4XWI='Z/&PFQIS\>:S->A<ONR
M:9           ,]T^5GNGRP                            ->, 9\CVC
MGO4TM'[G.R>MFZ/YSJS<.0 <5]MYO?O/=?,<K=UXMDGI:FQUG:.?M     0"
M*C*S&RQ8
M                     #BF?%P/;U@     .OZV?T1K9P
M        !&,<9H          B8,^H<+T%-;   #F78\[E,.SA-C3D5O)IDCV
MIT+E]V33(          !GNGRL]T^6                            !9.
M+]'4Q?7T<+MX=@Y^UE^-O[3JYL@4F&1?1*./^R\_+U=G=>)T*-/8QL3ANMHR
M\=]UYNWER:?0  ?#!D<R*,R9I(
M                                       '%,^+@>WK      =?UL_H
MC6S@                      #&FMF[           Q.COZSQ^T   /DHM\
M4JF2+?'>K<78L@          !GNGRL]T^6
M   .?9L=ZT9S7RV3XK>34C6#<4W4C!;6#CG<YR\=$\_TLUK9N0>JXTO4S;3P
M.I%!*+Y=*@6RR90R*/LUW*+@
M                                     #BF?%P/;U@     .OZV?T1K
M9P                      !:(AD           #6^1V,/H=$
M       #/=/E9[I\L                             6C742$VU=B3]39
M-1-E ,9GQ:#OZV]<W;^X[Z7T-7F_IN1G=++U7RW;MIMEHI/@*R\7D4'PVI,H
M
M              '%,^+@>WK      =?UL_HC6S@
M #&&L&]           %,3KW*Z]-;                 #);FED]S2
M                        ^&/1D#ZD:N90OD$H,)O:V4T=G&[FO@MO#:M7
M0>UH935OTWRW;^% !\/I<*RLEIEF4+P
M                                             .*9\7 ]O6
MZ_K9_1&MG                       %@@&6
M                                     !8,&?#-$HI-1-D-;+YJ/7T:
MHF729F.T3+6->NF]72S^GDZ;Y_K@    #)%X
M                                                  '%,^+@>WK
M     =?UL_HC6S@                      ""8,VH
M                                           LFH(R2"8!*38)9?,<
M:UUM&+DI/U\V)V\&W<_:SFGGN1.B]CG9#!EVKG;@     GE\
M
M  '%,^+@>WK      =?UL_HC6S@                      "DU$W
M                                                       P):1C
MDWC*(M%DBD>6O]C1@9\6R<[:JK:9IY\S"\D8#=UZZSG-3.    !45&1
M
M         !Q3/BX'MZP     '7];/Z(ULX                       &NF
MQ
M &!03+*#X60#4.KI9C5S975S51(^HB%Y,HP>Y@NPS>IG    'TH/IE
M
M         <4SXN![>L     !U_6S^B-;.                       !RLZ
MH
M 8)$A-P^$<    (L%HDEF5XOQ-PN%124GP^%1662"BZ9I-0
M
M!Q3/BX'MZP     '7];/Z(ULX                       'PU0VP
M      &E6K&->M'7<=["+J;2+R8Z(\M8F($QT2EZ$7TV0B^F(BZFZ8F8UR8W
MFMHR)28:)B0                                ,0"0?""1">5 ^GP M
MHD'Q,0M(NEX%":RZ5GT^%LI19+J;Z+Q,2
M                                              !Q3/BX'MZP
M '7];/Z(ULX                        UXMF:)8           .?6KQK+
MC])X<O'LE,8C;JVPMHWJEN69*=#I;1;5R,3DTP$9>)UBU;9LL6&*1M,3K<QB
M9C.Q.%F-HK;6[1W3%>0D                                6#$$\^EL
ML%\NEHLE1]/A$1)*2072VF,4H%(/H/A4"6FXB.B^M.
M                                                        .*9\
M7 ]O6      Z_K9_1&MG                         I-9,4;.98
M    '/K5P5HLHP$QLL6FPV:)YI>N+1U6E^=7K(ADT[U2>>7KB)BM,^&S1.9B
M>"Y<?H[#EX_DI=,Q$[76>57IVK'DSL2
M   !BRZ?2HH/I:)Q= !@"44HJ*"HO%P^E2:2D^E01\+)04&534
M
M    <4SXN![>L     !U_6S^B-;.
M     !$1](4I<,-,9B)O$0B2S$3@YB:5PF)AHLRK)\3@9C,0XODIW/'DUZ8S
M,,!,9N)Q$MCB0                                !012HH)):+Y6  8
MTR1;(1:1>/A0?   ?2L^'PR":P
M                                        <4SXN![>L     !U_6S^
MB-;.
M                              +9')!;)   +1= !'+(0!\  "9!?
M
M            !SR].=9L8     &Z8K]4QY
M
M +907P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M7?P3^N:Y^FT,_O&AGBS[_J?]WS[_ *GX=4?X)I=_!/ZYKGZ;0S^\:&>+/O\
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M]ZF:G6Z:K$<<VXYICH[ 2QC6K4HK*Q2DD)R:=W9CVD<'E,.S8N^-2!@&RUU
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MT#FXZ!S<= YN.@<W'0.;CH'-QT#FXZ!S<= YN.@<W'0.;CH'-QT#FXZ!S<=
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M YAM6L.X%$4'=/W"#N#V+8=QBT9#T&1&[&+*7&#&86;(8S]T@QG,!P1[VOE
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M1$@^?LXC>P)$4MZ9:3MPHL5V:Y&I&FRWHT4'8QR'>;([R2%S%N!(RC_6XE]
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MPVN#'?3M0]9O(>.T?WN\) 19/+3WF^1]YOD'+.6\S10U1(SS1/-3XKL-SA2
M3;ZR-I\CX,@(2^H)XZA0074/"WAG'D*2^0X,@$V\I1MOI'"D!''63-0Y9/(P
M&N)<ELJN-WF^8[T>-:K)]"2L'P5F_O=ZODJ6[+LA#:X,>U@\T@TO\3<?WN#(
M"&WUIX;^\:7T)-F2^FJCG&B>CLXW.5V!V3=7:RIT>$SG2B+(;66RBFT_86N)
MIH\E,G))+4K-,[W7\@<H+K(W\Z03>,8)_&L3_FH6Y"LAFE+%I)N<*>?K(>*S
M9T"CQLL>A:9_/S'^8Y+B[&0G765IC-[9K*)J%F3[;..4#2D8+IJ7Z7F=;WC1
M/7BG\;I('=E5Y]T6RR" @("0D$(OR&OV^0X8E+&I]P?%TDR&YLIWB6T2@Y%4
MRIF1Q09]DK'V4BJTU8;EC*Z=F^HZ-;"JCS=H-0,QOF0YEQ(*P60YF,Z#@-.D
M] >;!GL.';+9./()Y/CSVP4[.E6+TZKA0NF\4T_@I:QV_0F?FN9V1TU%062:
MBMQ&DD5R\/JF[VTSV:<&OAVW*U^.UCF+8[I_0-N1(K:7-2,[24N4EI"/,;Q6
MK8=;=*/(BN!M7J9TC@-$>TT@AEK&Y+P>1NRY@3^VO_9]CU+^G\W3GZPPH&#!
MB0K<;4(L%<M;+*8[?89;2M*<V3,0%[S'@=5M4VG8D1_D2_9%I2V5DTN#=^&Q
M/A.>@>:2^S75[-5!\6S:-TN>;22['=2(*"Y6R026I>Z46^Q.3&=AT%G->IZM
M%3!E))*['W(K;*6VS27/;B1#21-U9%RG9L([5""5,W4BK07(3$$E$O849#1(
M1V6:-Z'(4DHK3*6VY"22[N$(Z21-A)(GMFSLD>]/>21R-PA&21S9+)+86X7)
M0F2;B;"+L6G?3#V'&KD$XFR07(H2DT.)),LTESNZ7;&21SFTDJ6:4D*M)<C(
M22';))&UN%Z:[P>);R(NFC:7+G'8MU#+3A1G6UK%3$GZ<LR)9:?QFG\N<:L\
MLR&AK:>-"@OY/AU%4]RUM5B15EV+K!&[.;6Z>1X\BUJ8]Q#+3Y]D4M W35V-
M8L6.KN,2*VN+[%#MIM1A"(,[(<6C9 36G.UV14-.4^-T'3T0R(RQVM:GY7Z"
M^+98! 0$!(($(_L::/V>,P\L2W C&8&22L7Q&%B37CV"5$W@T[O^&4PF5&TH
M>65(+J[BT,&MM+/+J33JWD7&-^09@S!F#,&8,P9@S!.&@V+920;;$]N=!5$.
MEF&EQ)[2\62-2*K)F,S:G.Y]*Y;&Z:+R533?J&=YW5R+*I:SQA;<^:[T[A,(
MX..9K#DE)3G3+Q9B\ZG&:&)R-+AS#CUKE;CM?E59/[SA^7GBY[.+U]P_%N8+
MQ+2PH%ZBQD\Q(2$@AE;._7XW(Y>ZF'[S8K_LFI?T_FZ<_6+[#!A7L#ZS?5&J
M34$H)!>&PHTOC==K7T+)Q/8XO=)M.\?9'^1.^DJBV5U^6XKPVB-Z'#<XL3S[
M7V5>!*-6'^(SV%%]\X7M=DK,PA)(3-V<HKVP^V=]-,]L@24&&UDXACV2(I\"
M2#/=*#M=5&_?-<48;;)IN3].[]-VS/I%?0AQLG41EJ!?[65^5D]D3\P^?UTQ
M]328L<HS:C)*7=I4Z/V=K?LCU^SDEH)Q,52H[DKXRB-((]X@\Z3+4!M26HO[
MY2U/.-H)M$[Z:7[97K;7'8%R<?!JB.XE))+T#S1/LU&.PJ-7GK?))WAFJ6$!
M 0$ @09_8W\-HXA$"41^%9B2L:@6ZJVDP#.;@KCRI+.PR5M+P(R>0QF^1Y3"
MQF-!@HS:MG/M0*_#SK5TGBV@S!F#,&8,P9@S!F#,&8,Q3_AM6\]M;=:O\\S^
MSM?L(T81;J+,D]BC,DO5MQD\R\EVL8\5HG*:+Z9:$NHZ'J*6OB.",L(/T]I)
MY6$7L)(2$BV9YBL:<-EUYTG3:^,#]WV/4OZ?S=.?K%!84O8.(IP^[U.!N.AG
MR764/I=H2(Y*I,!3<Q+R/B:"V%V1_D6)[(5>6R#>M<2NCKXC'@D)WV*)S?K?
M/=6EIJ!+CSX?BF?*(MA)/E9S_P"$\XXEILFW)YOM<5IAWBM]D@^*Y)CE(0S*
M42WW>"VPC@1XGOBR+<;%D?Y=*22DOP)4L^7DK62$$A4H2&N*TP[Q6^R9MDN[
MI;I[T,.*W$-ER[4%"E"=LY.-MY>P,TPF4DEJ3^&J:TI:6GTNLI2J6%MDXW!6
MI/:^[P6X[7":4TY"4TZE]M"N;G*/CR3]HA^Q G%Q' C\*4ZKE)KKI,H0TIU<
MYI2VV'BD-??WG0U\+5!+?V$78@(" 0($>Z33WN&LS"G22$+)9$XH@4@$^D<5
M)A:R,2UBWHXN0JQK32'C%YY1EM):>&OP9/B4;)1)Q>NF7 RUB3+QS%("ZO'/
M#M!F-H,P9@S!F#,&8,P9@S!F#,&8I=WC+R*#'3U&[(&V\E#IY^0&<:@,AF*S
M']=JOD%M01M/[U[OZ(L-&"]-D;G8D)"1\1):X$BG?YBL8$$OLFI?T_FZ<_6*
M"@4;?!()!'YBDDHI5(@S4TII23[8_P BT^CB%LBR&^,Q5+WHGAQ\]TO/L6U/
M5^'0GJW&/$^UQFH[O%1:?2&6TI#/'8A2.*@1_:_V1OFB0KF)9D1B;\HBV"8?
M,O"4QS+$1_CM3OIU))1.M\1J,[OI$?VO]B/P[(.'S3@GH-R&PX3K,EE<AT+2
M3B86^V4DR*.R6QDRVE'5P5!'XEGV2?8Z)<G@(B,\O'2DD%"^4^[PFX[7!:$U
MDW6H[Q2&9?Q4DEE);-QIEXGD"M]K?J=09;T2HKL?N;"LPC)94Z5(E,Q$1;2'
M.,=^UW%'?M;Q-I;$6<-QF):1)YYCD[E.FFN6+.)*G1X*8MI#G')F,0TN6L-E
MZ5-CP41+*)/\KX Y+1!+Z%^)USAI&S8HTDI]52TZ'*)XAW7)0$PWR"(SH3$<
M'+[ \?#*'[4;A#<(@J,1GP%D.$X.&L&E0?VD4N3PDU^J$V#8TU@=M5>7*3[/
M'J3:RJNG01H;\!F#,&8,P9@S!F#,&8,P9@U!3R2!O[1O+,'O&JJQ]EU+%;%C
M^-QQ++<&>Q91_(I;I^UE>&#=29N6>7DN.1LIK',)JL;?AK#"O87ILB/\ZCVH
M2$A((9$SP;;%7MZ)'+\.&6QO['J7]/YNG/UFX9@D$GM/SGF$2$O5:T R-!B/
M\BV^D:+8T(I<&=X:T^%<>?*?Y:-16I7E1Y#K"7E=G!0;H0@FR[";(G#$>.B,
M@/-\9LO81)(E=JVB</LX:>($()LNS=(S!))/:E)(+P+03B>PTD?8223VK03B
M1P4<7L0V2%>%31*7V$VDEF6TFVTM(]3J3_IX>5VE52Z?TR4(M)\>VRN]<JHD
MC.+MWN:#I]"?JLVE.4])P,9[FP6>Y)I,2HN_WKVOZ/O=0:MAAS%,=AP(M1%5
MFM]EM C&G\VE\_CF.X:F9'RQ24Y?CM;2')\AQPFD;%2!PV@;#:@AY<8^::',
M-@C(PM9-IWC=5V?_ ,0V"\!GL#CI!X]H@%^'XE"0KV6[)2H[>CCLUEII+#7E
MN%M3X\O15.J[)&05D1UI]N0V9C:#,&8,P9@S!F%OH2%3$CC.*&QU0X)#=20V
MA:]TJ6N4^ZPUPT>/.I4^)68E%NHD6SR*2NR5>7%)9Y;DBZ ZJ7?3IW5\UZX7
ME5E06EG>9%#AHM4KH\5LY-M35N86=R*6^LBO\DR+N5#]MD5*UC%C(M:; OS;
MGF9MJ1;%98/;KMJ2,H)]-D1?G(ZMJ2"0D$,AF%-LL6=W9;)?@,%NM?8]2_I_
M-TW^M!]I^@>CH?)%6A*Q;_3]DTN#=^$SX-QY\MCF8F/51T=+_7M2?]/CT)NQ
MPW")BZF]G-(Q[+7LCQAM&H=8MZ%!U#BL5>:QGK:DK<AQWD::=!L*K$[_ +@D
MVTU69Y!J1'4=9B621K"+2S589>Y/==62LZB\CC^-_P"@N,BIURL4;2O+_(F>
M^ZXM2E;'PTLUJ^ X;8X+9CAJ;/=4X?;_ /Q"#V#CCCJ'&4-]789!PM@A?+\2
MS$I0RW*RH9&$9M R1'F'\%_N\698ZK(ZMOJ-6.5N)W"["PPRGLY<V$YAE$WG
MM6JGJ;--O6F8,P_*2P.<6L?F5CEC4"CMI'L(&8,P9@S"E["KX2YKT"&4=OR-
M0UF[%]D=C#ZVQL8\+%$MSKAE-OG;SI,,Z=1-L&:TFWU#U$D<+'\J/NG#/]+A
M.!UZ86/5/Y_/HWZAJ/J#9IAT;OZ)AN#1>5QKS,ETL8R3(,<HF<>;BJ#9^FR1
M :7N+(.R6HR3OHQ"SR"9PT1EN,4;O"M&R_"^'V34OZ?S=-_K0?:?H[/V]M^G
M</PVGN$7M\^P=4Q Q*P>M<;_ *](BLRT--(90==$.0_&:E(8I8$9SXA-)7H=
M"Z&M<6ZREJ%I[ ,SBU\6"'&TO(BUD2"J3"CS2B5T6 ),1B8A"$M(EU<.<<>(
MS#1Y#GUJ$[B1L"CVJ\:E;LA)[>W=&X-A!0=$+Y?A,.F)9C*<.L<CN-*\3F8T
MQYBO@H]JO'M!F#,97:V%77N+-Q>GDCBXN9@S![ 9@S!F#,&8,P9@S"E["A05
MSG*ZN3'1Y.48XN]%-%G1H[>*650_3U\^*N#0KC9%:Q%SZVBK.YJJKH%PKR_H
M5W4K)Z%>0,9'5.7-3"C%"AX[0KIG+;%Y3MQ*P9V<,CJG;JJA1BA0_,RC)&<5
MK(&HA6^11%AHP7I;]O?@".YM!$2A+??0+Z)RQ=U\MC3#G!?C>U'V34OZ?S=-
M_K0?:?HYWMD]ETUQ:Z*OB1O!8HWX=>YQ8/G/-)?9KJ]FJ@_WJ3[LDO@%^2Y]
M0@*<)(.089<V.=B@Z(7R_"8>/V3%C'LXHU6#+R)+/F/JW&_&9@S!F#,&8O\
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ME.*(@1 B!$"($0(NR6]P%Q%[[7FRJV).5P&F)T0-^GN&.!/3\6%;4)"1F/\
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M-HW"\$AKCQY$53#JFAAU<IAOPOOMQFI.H$=MVFR>)<GVN-I>0K&8:E1(+,%
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M<0W(,EH;)*1O2@29R@5?-="<=4X&<=0D-5#2 B(A )!%ZN7*:@Q49= LZV'
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M#R+G_8MN&2UK4Z<Q.U-8@G@VI5?(ER$FQ!0ZIQF7OK\#S>X?V/X"+(XZ/O\
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M^*D9IFIY05T[1*D\ZABOLFYJ.U"R<1XHEXZ4XE/P VI+Q*E;[A;=G9)]^\]
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MMK&PRO#!WJGI8Z9MF#FD!PL5M"CY,[$SLGVNV91QN9QGB^XD#7?M+^*?\O\
M'MULXWI6?[WJHVC#!EJ4_;$Q[+0%'MB4'I@$*&9D[,;-^UH\,^+Q'MK1FU0S
MXI[VQC$\V"FVNQN40NCM:H/@H-KDFTP6NZMCXM.\>UVS'#DH]UU4[5CBZ,72
M/Z*.HEJ*EAD/>-^TOXI_R_Q[=-GE8SAM=ES-C/.)[-^V>VSVU!L;A2S23&\A
MOS-F/+Z87[MTWDW?#VNN;6W4G\0SXC?M+^*?\O\ 'M]L9G;?OVK)CJ+>'MR
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M5-Y4752!A"EOPVHB5S<-@G-+8+%0-&"Z?&]CL;%%)Q![&14SI,SHFL#18)Q
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M8J" NC%BMDP<27BGN_RJB!E0S ]?>[/G_P!S5(P5T7%8<E+L""7.]C[E4_\
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M,FFY/CHML;3BGJHIZ4]GZJHJMD;5PR5+BQP_WP*V@*%I:VBN?$G_ ']NLK=
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MXX\FG3W*B?#717#L+QJ%)$^(V>.:#8W6T.E&QXWRQ-F;@<B)**;_ '-4\XD
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M=P[*+2-?7M;V@J7R0WD@:HS,"-0>X(RO/?OL5>R$SPA4#O0>UVAZXQ@NQ)S
MXW3V!^J+;MPK ,.%-;A%DQ@9H@P!V).B#C=<)HLG,#C=/;C%EA%L*X 0&$6'
MK>N'30T5//@.%VG-V/'>5S_!2&S=Q115?6< <./ME34KH@W'VW=RH78:AJ<J
M;4E1?>.,I^2.JJ/*'V9H:D <*30J>GP9]RS:@]15#7CAR_FI8"SX)S"W-J$W
MBN(TH&^^.8Q"P"PA N&A6-_XBK<TL(S:FR7UW3-QL(W4KL4?PWF3P0^\:0Y4
M5"8ZAQ?HW3?=,II)3>R:R.E;B*ED,KL1YQ=9,87'WIC6TK,3M4]YD=B.]IQ*
M<80UB9$^3LA-9%#G(;E2U+I,AD-XL7!JVA+PQ@:G&YZW:WD!\?KS=D#HO<MH
MRNDG+3H-^SIC-!TM1DIVX)7-'CS-C_S/E^^ZQ6!!@0 &X;@\$V"K7X,.2,SN
MYOZICGX0;(&XYAC8[N1IAW%&!X1!&OKFL[85.X-B%TZH'<C,]R$3W:KA-9VR
MBX>B$V-STV!HU0:!HJCN36%^F_ [5"1S>]"H_$$V1KM#[(5<>-E_!;-@;AXK
M_DGQL<+.%PLHWF+PYFQVVA<[WJ;3<455U98[@P"[S^BI:(0?>/S>>]0CE-8Z
M;N;D%.WD]7\[I^J9<_=CO0 :+!'M*4WD/LRUV%4E;88'Z)]*UXQ0E/A+38BR
M#2%%4/BR[E>"7_Q*?1N.8S3J9[4QF'-!I.B<QS>T.K<P%=)B$GBI;->0J20-
M=9&3P1<2@PE 6WLIK#%*;(301=@)U8\]D)SB\W=SXJ9TF87$BIQ9F93WND-W
M;W&P5*W$0%5'[U-Q297YC6>*@Z4MUM3M==M;R ^/UYNR'CI,6T:1X?QF"X.Y
MK7/-FBZH8#3PX7:J=V.5SO$\S8WI_+]T.=>V90Z0S0'@MH-<<-O>L$GC_OYJ
M,'AM1%Q9-Q X3SS"QR=3'T2G,<W4>M73-:IWXWW44;G-R38!Z2#0W122X<@L
MWE,A#=>94:A4_>GQAZ>PLU3'EAR0P2A&G!T3H7!![V)M1^)->UVG6\5GCO>[
M +HR -Q(&XOZ\CD;".$_3N*<61#$\KE&.HXI[^9LG^'^:F[MQ113A=0PLIV8
M&+:-(^=[71A'(9JD;D7[G'I%$W-_9H&R@JW1J.N9*+/7 IY.RC0 Z.7V?_Y?
MHF4>#TBKLC&93ZV)J.TFC1&I%4/>.M+05616LX)G1<"A&$&@<QA$#<?I%.<7
MF[N>(GGN0B:.VY8X6=EM_BGSODR/-E/<J&/TO!2NQ/)5(/O+J1MGEH7#/>@
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MFI;=E^JJ!9_G>$(- 3W!C<13G%YQ%6-L2I3>/F32&=^%JBA$+;]ZHAD2JF/
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M(B&J8P,;A"J&WC.Z:##TV**3B-NJ5O!A'O7$37JICX4I:.=L]E@9$9$'K:<
M<X/\48B-%9P72726$E4]*Z9U@H*)D.937V6T68FB3>/-[#7=8!/Q83@U1%4\
M8; *"+@LPJPUWV'.  TW6&F]^+"<&J(JGC#8!00\%F'?8'7S#9+\-1;Q&Z07
M"***<BJ74A2]MWMCLF;'#PSZ*EC]()BQ8LFI[<**E8V1I:>].:6DM*@?Q(6N
M41PO!W3:)_:/J3:WD!\?KUVQ=7_+]T$$$$$$$$_L'?2]CJ6]H+:4>D@ZEPNT
MCSQE)$<$Y&=DXE.B94,P2:*M8&/:T>&YC!'D$591=I4/DS\4\IA5=Y(?'<=$
M$YH<+% 6%@J'ROR1B8QYD:,RFDI^<3OAO".Z+RC?BI%B-U&IF-$SCSG9!$FZ
MC*VAY4?#G4OD GDIA5=Y(?'<0CA;JN@=%9;.])/*82JK^'=O'L!0NP5+#[]S
ME(+%%%.15/Y13>4/G=_9:CJ.33!_=WH$$7"=$"@+*3174K_!5[,%0[WK9S[Q
M%O@AJH78V J?N4G;/J3:WD!\?KUVQ=7_ "_=!!!!!!!!.'W;C[M]*.@3U,?;
M"K>DRW5.%B1YW3'' U%B:Q5SKS$>&]\=\PL!3&85L\W#FIS$UBV@;-:W<=$-
M]$ZTP]Z>Q!BJ.A"X[PCN:<)!3A?,+AIK;9I[L3B[<.8S[R-KE)@C&)YLH9X9
M#A:Y5SL4Q]W.H3BBMX)S$UBV@;-:S<\V%T<]S#B"V<[IEOBG,08JXX8;>.\>
MP$1PO:[<Y2BZ****A\H%/Y0HZ^=W6)7]E-FUV#[B73NWO3T];79TFO6SGVE+
M?%=ZII>&<]%,X$BRF\H?4FUO(#X_7KMBZO\ E^Z""""""""D;AIW;]GMQQO"
MTZB'M*?/+??I8>?.+//FY-D9_!-EOKNV?4"-W#?H5PU/(VF9B<G.+CB/.IY>
M#('( /&)NB(#!B<JF;CR8MQT0W@D&X4$C:AF(+AJOG#SPV:#<3A%RC*[N39C
MH[?L^<2,X3M0N&J^<1,X3=3O',H:IK&F.15$SJB0O=N8\OUW$VS*XS4#?=23
M\"3/0K"'9A$-C&)VBJ)N/(7;GB[5963!8*.0Q/#PHW-G9C8L%LRJVH$\G1T&
M\>P+#B:"G)R>+(HHJ/R@4_E"G:^?8EB]DZ3:;X.A)FU0U,50+QE/3T];39C@
M)\% _ARM<BF>*:I_*'U)M;R ^/UZ[8NK_E^Z"""""""BBMF55>1._9GI*2(/
MS&J.7/BTNGYE/[1W.-IASZD9@^;S:6WL[.Z.MGC&%KE)(^4XGF_415$L/DRI
M:B6;MNWG1#F,D=&<3#9/K)Y!A<[?-H-[.SN!(S"Y?4VMC1))N=XYAT5E91BV
MZ0W*LH38VWQ5,T.3'*6>2;RAOO.BP K !OBFDA-XS92U<TPL]W,'FKGV7$ZA
MQL$TW&]SL*Q^/GU,;P,/N"*<G)R**;VPI_*%.U\PNK]?=8UC"QA8PL86,+&%
MC:L;5C:L;5C:L85QYD7 (&XN@\'+UB"1F%#M.:/)_2";(V9F-J>IF8V%OBM%
M&['&URBS8FJI\IZDVMY ?'Z]=L75_P OW0000004#+FZ"K/(G?LPYNW5$?IC
MGCHMW2=L[IC:2_/J1T0?-WMQ!%I"#25ISGR'0(2.":[$+\\Z(=0YN(*Q"#"5
MISQS2T%8!O>VQ5E$W._/*"/4#S0Y!,%SN<["NGJFNN$PDZISB'63G6R")<U.
MOAS0Q6R3'7R.Y^3KH.!3G85T[7377"#G%!Q!L4]Q&00Q=Z<ZV01QC-8KMNL3
MCHG%P1.5TPDZ^84)O3,13DY.110U4_E"GZ^8V5E>VO-.[(+M>96*L5<A<1P[
MT)WA"I\0FRM=IU>-JN +H.%[E/=W)I!T1> @0=%B"!NL80-UB"#@4]ULDUP.
M7JFC:YD-BBBJR/AU#VJA=BAMX*GT(6A57V_4FUO(#X_7KMBZO^7[[@@@@@HQ
MA%D%7OLT-WT#\$MCW[K7%BG#";<U@N5(<MTG;.Z?MIANP'G3"\9\Y/..F^'O
M5U=75U=76N^ZNKJZNKJZ'4C<>?:ZX86BNKJZNKJZUW'J!YH=$PV*O9/U1T4?
M>HT[M)^JPN=JG]E,T3>UNR.2> -$_0+"3WH-PJ-/[2<W$@2TV*/;3]$WLE1Z
M)XN%?*R L/,-F&]*WY_YW.3DY%'=/Y0I^OF=D6^"OONL6X&R/F-UB*QK$TZK
M #HBPC=%4$9.0-^H>>Y7N+ (#"U1C).S< GFP3389!,%LRF#$;J0V%D#E8!-
M&$*-O>O33^X>J:6'BO5K"P116UV6E:_Q6SG=)S53=Z=JJOM#U)M;R ^/UZ[8
MNK_E^Z"""""C%W(*6H;"/>GO,CL3M^BI*T2="37=4-L^_-8+"Z>;G=)VSNF\
MH5 ;LYQ%P1Z@='X(,)36X1;GCV$+ 5PT6W7#0%D8U@3LW63@!H@,34!860;8
MWW%E\T(_%$77#]Z#;!-;A1;<W1;?-!ELRG-Q+AJV5DUN'<T7=YCLH_\ 6^>Y
MR<G)R**F[94FOFKF\]^NX"Z-FE/%CYC="7Q5FO">PL5.^XZAV3L2QWT4G90R
M"&;RGBX6-$Y)@L$\=ZQI_93<@F:DIV3KH&_JBCAX4>>I1116UF8H0[P*I'89
MFJFT*>JOT?4FUO(#X_7KMBZO^7[INX((*,",7<I*RV3$27&YYU/7NCZ,F85V
M5+.@406FQWM;=.-M\G;.Z7ME4QU'/>+.(]LRT%8!YF&@>8['/W!^/TW.3DY.
M114G:*DU\V<.=;HW0;=$X=%JG7OGYG#D+E32 BP5,AS+J_,LYVJ-^Y-;;UE0
MP\>=K>Y%%.158SB0/:@<)NJ;..ZD57HWU)M;R ^/UZ[8NK_E^Z""#5A#<W%<
MH#>P$Z1S^TAU#'NC-VE,V@=)1=1"&H%XW(PEIL5HG&YWR=L[I.V5 ;/Y\XL_
M^R[5LMQ;"?BKD[G)R<CN(NIVX7>;NRYH=A6(VMN;KFG&Y\UIVV"N%=9JRL/7
M.QF=M^XIR**D;@>6^"V<[%2L4O<JH]GU)M;R ^/UZ[8NK_E^Z""XMM$23KO'
M5 D9A15SAT9<T'AXNU$;Y.V=S^T4TV(//J1F#[8/T0:XB]TQU\CNN#NN-UQN
MN%<%/=;1 W5[*X.ZX5[*X/FELU"2V($)M?)'KFF[5B/;%ERZG=Z2-1"?23IX
MOQ)U1&N-?1-Z6JJ^V/AYNX9=1&+GS'5"&1W<N3$=HV6&!NKKICXR>@U,S5NH
M!OU(-^<#=UO4VQQ]P?C]$[(HIR**VBS!4N]ZV+)>)S/ J4])5!N[U)M;R ^/
MUZ[8NK_E^ZNKWYHZQDCHS=J95M/:63LQND[901UW,-V@\ZH'1O[82:+$0$P=
MZ)N[-&WHIYR0C%D_(671LF')-&)$8#DI!WIK0,T.F<TYN'1/S 36=Y3NUFFA
MNH\UB\B$]'FM4:J^V/AYN4>>R_=OPGJ@QQT"$#N]<.)O:<L<+=!=&I([(LG3
MR.[T2@,1L%#'9 6ZA][)F)%V=@KN!S3G84,16,WL%B+3TD7.U5\KIIN+H/)T
M0<;V*<ZRNX9E--Q<IG>?4VQS]P1[U*,[HIR**VA,)IS;NR6Q7VF<SQ"D/WBE
M-WGU)M;R ^/UZ[8WI_+]]PYHZYDCH^RG53B+<V W9SI1=A]L)-$T7:F&QLCT
M79K$Q2!"3)/S%T'-0((R37843C*DT377R0. YIQQ9!/R 3=$7#0IO:R\UB\B
M$]'FM4:J^V/AYP[7GL=A*Z&+W(O;:P"$CAD$#Q'=)<)U[)PPFV]K"_1<)H[3
ME>%OO7' [+49WGO1<3KS=5##9-;;J9/#<P$YW0;WE'-^Z/Q1S>I-$[)JT:F"
MP0S>5J]2'):-3.SZFV,[ML3VX@BIYHX1>0V3]I0>A=WP"JMH3VL&8;H,<6E_
M<%LU^"J8GGIGU+M;R ^/UZ[8WI_+]]PYH\Q[M],=1SK7%O;*VZPW6&ZPW1A6
MMNL K75K;[ ^;1>1">CS6J-5?;'P\X.O5L#7'I'=/D_??J=<@H8;)C;=4YN)
M"_>L)&B />@W.Z.831860;8W3FW3FXDX7%D,DUMD6YW"P7U3A<60R]3;)?AJ
M+>(W2LMFG '55,DK>C"VY/Y!;1AX6'&[$\IU+PJ$L[]5$_AR-?X*;(N]2[6\
M@/C]>NV-Z?R_?<.:/,7=D[X#9XY\@L\C^R\7D0GH\UJC57VQ\/-W&PZUDSF*
M9X>01NP$KA%&-P1YS6EQL%##9-9;V!IG\.9CO?N(N+)XL;(J2EDFK>(\=$*5
MN)A;NQ8V8O$#U+M;R ^/UZ[8WI_+]]PYH\Q?V#O!L;\^H%G^K+J_,O?=IS2;
M*_L]%Y$)Z/-:HU5]L?#S>4]W7-9=-B08%A"P!/A#E+"69CF,C+U%#9-;;V#I
MI.+"U^Z<=).114S<,CA[U3NQ0#U+M;R ^/UZ[8WI_+]U=8EC7$]RXON7&]RX
M_N7*/<N4>Y<I]RY3[ERGW+E/N7*?<N4^Y<I]RY3[ERGW+E/N7*?<N4^Y<I]R
MY3[D^HQ-M;F-J+"UERGW+E/N7*?<N4^Y<I]REDXG=ZLU*LKK%N%E?-'1 V"!
MNB;*Z<NY=RU5U=8E=7O[+Q>1">CS6J-5?;'P\V)LB;F_6QLNFLMSBVZJ8>&;
MC1:J.GOFY,B0%N82!J@X'U_LB3%"6>&ZH"***K1:H<J(W@]2[6\@/C]>NV/_
M #/E^_L=WH!.5LD-$U=Z=H@$-5WHYIR.B]%-7>CJB$!DF^R\7D0GH\UJC57V
MQ\/-I'7RZUHN5&VVY[L(7$<4V3QYDL?$:6IM.&:)K+<TFPNB;JZC=B'F-P%C
M;XK$/5>R9,$^#QW3CHHHIRVB+5!6S_)N'J7:WD!\?KUVQ_YGR_?V.S"N4Y9H
M#)-6A1T0T0U6BN4Y'1=RS" S1U10T3?9>+R(3T>:U1JK[8^'FKW81UT(0W3Z
MC==#3JGB[;;X1E?K7.#=4ZJ:-$ZI>=$7N.IY@)&B$C@FOOZHADX4C7^"!OF$
M\7"<BG+:?E_DMG:.]2[6\@/C]>NV/_,^7[^R!%_:F+R(3T>:U1JK[8^'FKG8
MC?KJ?3>]F,61C>$R(ZNY[Y+FP0<4QV+>^(.S0@'?S.(U @Z<^29D>J?5.=V<
ME<G7J0;%-]4;.EXM.WW9(J46<BG+:OEA\%L[T_DCZDVMY ?'Z]=L?^9\OW_M
MS%Y$)Z/-:HU5]L?#S23L]?3'+GD@:H/!YT.O/E=G973783S9)6Q]I253GY-R
MZSO3?5&QI,WQ_-%3!%.6U?+CX+9HR>?@G:^I-K>0'Q^O7;'_ )GR_?\ MS%Y
M$)Z.^^YJC57VQ\/-"GMMUU-<%#FG)%US<[HW7RWR18LPA"Y-;A%N?,+&ZNFC
M$;;R0T7*EK.Z-7)S/6QBYNAZHV6ZU2!X[GI[4Y;3-ZA;.;]TX^].U]2;6\@/
MC]>NV/\ S/E^_P#;F+R(3T=TALF&YW-4:J^V/AYJ1=.B180CS\)*$3BA3IL%
MDV.W.(N++3+="._G:+BA->'<PBZX#4UH;INEG;%JI9G2G-1QND-FI\+H^THX
MG2=E!A+L"<PL-BA"[#BYC6%VBX3D01KN.BB'JFA.&I9\=ST].5<<52]4 M2_
M,_LGZ^I*ZG=4QAC/%?9,_B/]^2^R9_$?[\E]DS^(_P!^2^R9_$?[\E]DS^(_
MWY+[)G\1_OR7V3/XC_?DOLF?Q'^_)?9,_B/]^2^R9_$?[\E]DS^(_P!^2^R9
M_$?[\E]DS^(_WY*@I'TN+'W_ -N8O(A/1W3FP4+KOW-4:J^V/AYOA1C",(7
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MZ?VD]PLAV%&I$'"R9F;IO:4B&GGE3.2<#5LH-:PX4Y%-3%M36#_\DQ.\L_\
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M8)&X2J>S'ESNY.F=))B46M\)^)W5#\$9W0/QQ@_VCDTZZ+J M>8YP9JFNQ+
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ME$H[Y7<-A>G$O-W*DD+) WN*P%8"N$5PBJQN%P'J9]&Q[BZZB@9#V>LJY+G
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M"_I*G>9(FO/FE=Z/KZ_4338>@S5,I&ZOU5X8?<N5 Y,%U_V'_P#BFTS-79H
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MY-0R1S3EB1S&\%'59;C9#^_,FG71^R5AS+;K<VV^PW-W6W6&ZW]^I-.NC_\
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M7G"W546R RTE1F?)5VU6P_5P9N_PF4]15'$&DW4.PI-9'6'EJH]DTL>;A?\
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MMU[@;]G^%RVAX6\C38^K04T;X,;T(:>6(F,:)C<;@U;1=X6K9[FV<SJIZ>2
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MJA.5EL?QN6V/Z4_KS#3N6N#QA*=%;,*-OWBFN+C8A8.W9.?@R"RD<G/P9!.
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M=Q%3PEK"U_5-9/!DS,*+BY\3O-E>)R?XCW53T]QJ>MD@RU"@J8Z@=@JHIF5
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M/&H6+S5VG=965E965E961<T:HRMZ+%([1""1VJ%&>J%(T(0,",#"G4OX489
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MGAFJXKCX6JTSO@N 3XG(0,'1!H&G+HIYD]U^YGT#5HHFN<"X%"+/$XW3^W*
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M'\5H>-%4R\:4O_*.'Q=]/T[JP6!JX;4"YNCD*B4=04*WS"],9Y+TN-"HB/5
M@Z>R*O[0("[BG"Q1!;F$UUW(2$(HCHFY9;B+Y**3%V7:\KH"3V5P'+@.7 <N
M Y<!RX#EP'+@.7 <N Y<!RX#EP'+@.7 <N Y<!RX#EP'+@.7 <N Y<!RX#EP
M'+@.7 <N Y<!RX#EP'+@.7 <N Y<!RX#E$26]KW%I:!TO;DR"<Z*%N#$&K'0
MQ9^(IVTG 6B;925$LOC=RQ$B@?\ SR_*2'Q=]/T]0L%A"MYK !F$V:5FN:CG
M9)I[&JOM FLN+IU^NYPPFXY'_B"!N-SP1VVJ.02"_LF/3W#CB?*<+ J;9[8N
MU)F55US8>PS-R<XO.)W<1C_^'N_GE^4D/B[Z?IZJ6@ILLD?Q"CF9)I[$J_M
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M["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\
M7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>
MPO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_U
MQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y
M["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\
M7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>
MPO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_U
MQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y
M["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\
M7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>
MPO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_U
MQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y
M["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\ 7'@Y["_UQX.>PO\
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MRCA;S IMX49-K3.Y\V>2S?\ ")FUAV/,V>32C*7Z%/OAP$5!<8J#Z*8RP/\
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MO9#:V14H5KJ.6)]KY2MJ F#82A20@V*<4.N9+:5-,KNMM)MI6-54ZH0TF5[
M1727FPW_ !?"&V9%A4PZF82LH3C2BNN&Y><95+O9Q:K"L:0)U$BXJ4[,:=SU
MUFR*5,90EI5LO/K0+*!KTA&4!/RRY8N.)*0O7=N/3LC)+2XEY9;>0I&NNT[#
M#5O/6+0K7-4I#4_D\)5.MIL+;)IG$ZJ<<)E?P:X_8%D+=EZGIB<>^4!HIPIS
M+>CHB^MR>:).9D&"_,LDH4A.)2?Z^^!/Y3E'&&V$$H+OE+P]U8F9!ZX.C15Y
MJM1AYJ2E%3#*S4V$YUM7'M$2:IICL&00ZDO"P$536_&^,F=@2JYG-%RW8U5L
MT]T9.EIALM/MM44@ZMSY.?Z?^>K?93_5_P U,9,_6?S5;PJ40E(UF*)*GC]0
M71H2P'*J.\M^N.VR_.A4=J<TO--Q_-3(GZ[[GBV6_P!3]_?%".W/;!@.6+;R
M[6P:ANR_VOXCW+*?(C^-,96]-O[T97_RR_=&5O0;^]&2?0<^[##+2;;HDF7$
M@?5LD^JL3,OEUME+U0IIUY92FFL5PAL'L)Q2U )#+JG;^8F  * :HE7)MMQ;
M;Z[%6_)XX6IS*#3K2DWM%!)4-EFD2SDFVI##3BG3]1%^/NA'^61[U1*99D*M
M,OV5U1^3=Q]>/3'9::)>""AYL>2ND+_RR_>F$?Y9'O5'ZGX0]_E%?Q)W)64*
ME"52P'$HU%1)OAUV6=9F9U;-&5Y\J<*]MFMT99Y&OOPK_.,_=C*_^67[HRSR
M-??AV8>0<VU-EV@_PU?T,3,I)S'9C\TBP @$61M,9;_4_?W,J_Y1W^ Q/?Y;
M[PA[T#"_\LOWIC*4Q+]_:EUJ0=AIC$XK+\P+5 I"7GK <)K:-:PI&1 CL-"
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MCY.?Z?\ GJWV4_U?\U,9,_6?S5;KCIP0DJBTZJ[4@8#>A224J&!$%MSOZ/\
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M !Z@(5(3+ <E"D)S?)A&<4N;<1_A*<%/4*PC*LNVME]'!;2KM8T;.'TKEO\
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ME*M5PL_Q+,9"R2V=.9F*^Y(_B,-LM@-2["* ; (RYE50OF9BGO4?XAN/9?\
MD[,V)IR]V65Y6VFVNPP\7V0Q-RR@EU*<#Q^HQ-.8HD&:#]D)]ZS$_-5H66%K
M'+2Z,]2^9>4OF&C\#&7<J+%M,HLH;KMX(/0DPQ+)X<Q, 4X@"??2).20 ,TV
M JFM6L],?*7*ODES-H/$5'_BF'58HR?+W?LT]ZXFD6J.S7:$#;7A>JL9-"]'
MM.>4?2TOC&6\JK&E-3%*]*C_ !0?*1D]C[O6ONN6_P!3]_??)S_3_P ]7<#+
M,'MOE*'D[J9M\?HTGW[Z:5)H4%3*K3A6JU7^ZG<<G9*7+;RP4WK)"1Q0PB?2
MM:656DA*[,4&$?AI+:T3VU*Z)-U,(4M1HE(J8F<H*&G/S;K]3RT^&X\W(I6
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MC<LV.+_H&,EM4H2UG#]K2^,2K8TFI!%_*D%7\1I$O+#A3$P+N( GWTB5DT)
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M_4_?\4RDY,)SDI)'22<"4T2!T@GFC*=L"S8"0..T*0B:!LO!I6;XBMPV??6
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MI6904XI&LC^]<-MSLDU-S;B:O..BT:[!LB<9E;2I602M2+1K9N ITJ,?)[)
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MKMJT;ZX5I"FW$A:%"RI*A<1&?3DY)56H2M:E(Z*P_E)F7L3KZ;#CMHWBZZF
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MQWS_ &F.^?[3 0A=5'B/_P"C$QZ0^]W9_P"S[E?_ *,3'I#[W=G_ +/N5_\
MHQ,>D/O=V?\ L^Y7TKGIR8:EFL+3JK,.,2#YF%-IM*5FU!/21_\ H6,>D/O=
MV?\ L^Y7THY+9%E4R\JRY8=GYQ)H2,0A&)A*)J7:F$I5:"74!0!VP$I 2D8
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M0PVM*U5%EM"!LA+3[#LM:P4O"$J>J5*X*$XF++DG,(7YL2[KB7"7Q5#8%_\
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MAC)<@G.*:4GA$"NTQ^#K([*[%S=FNNFV#+S: AW.E5 :W71E#LUM*$O6;-%
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MRVD)V) BI@-#@M^^$)-RN$KEA6;V<*+"R$N^2M6N"EY!H#1:(0ZT$J0J\&.
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MW;$], NBR@:MQ=#6M]T!!580JZ !@-PM+Q\E6PP0H87+1YPA.95:2L5K%I7
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M4IU0.V^%*=85-H94$A@:P!#2$Y%F&'4*J'+!-VS") /I4ET*0"%XX&)+[?\
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M,+<. NW77=:E70$)UZ]@@-H&EJ3MXS&DN@\U._Y%B'Q]?X11&DK;%M?!V[8
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ML(X(C#\P>R4#M3]_(K7&:6>TOZ/(=7<+:+GAZXH;E"+\=N^J8F.*A]<2BO\
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MWPD^2;C!IP%7CN%.YNM^52J>6"R>"Z/7#G)">3=M)T5^^+JV?5&DBO)"@4%
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M$K+SO;G#1 6VI-H\XW'6<GS!>6T+2@6U)NY_$&<CY%F R=!M7:TJM.*Y1QB
M";1V]QS4TBRZGO;Z>$C^]D*;6O.SRS54PD= Y(;E7DYYXFJP@\%.V$/R[@<:
M5@1XSA%U\7C<QW-!,:47B$H;\GA1:28\U<*NK9OW$'7AN'SML674_P!(N0.Y
MT'.=[0"IBJ[SLWM=P)\T0.[,>D/O;UM]E90Z@U2H0E$Z>Q)C6?(/5 +<RRL'
MS5@Q:>G64<5NIZ(5)R-I+"N&Z;BOBY-[,?9]RMY9&X7&^^L*#R>:$. $6DA5
M#N'=&[V(TM*6BXG.5.**WTB@PBPO@>[N=4]\1>(2ORL%<O<I>9G)9,RY+@AO
M.7I%>**"X=P;827LIY&G7#0JTG)59OO/F_WR]Q=1*)+BVG$NEM.*DC^Z\T,Y
M&RHPF7"=&VI%II?I1.IEPA+ 2R&PWP;.<12D%O*3LK6CM6ED6S>:4&-8RLZ:
M]CJ4VE.PJ%JOO'<<RE]-M6-DUH(T$%7+= 4V0T1@0([?,..<2E710"I@K$HX
M$@5JH6??N52HI/%"&U*#B$8 B,Q,,K84."I.D!#C*7$FND!O+7EG@B"I1JHX
MG<0X/*%=XW+MWV??#K0O-FI.TPJNBNWHJC2%",1M$)6@U2=Z\KZM(-!6@J=R
M_OB;E;TL2NF[K5J3%I]U3BN6,(NJ([6Z5I\U=\6'.U.[-OC5G_$6!\8E54TF
M0">?&,G _DT@'FOAF7<O;104YJPTW=:*[AQ1DN26;/:TD\\(ETI34D64[ (R
M>P+@YIGW_&%HH D-4Y32)INMC.JT3R0U(S* 6B=$CC,(ET!*BW2RE>&%8;[-
M=:0TGR6H"1@+HE?-HKX0TE#I;;X0*(>HM2FVTFE==\3,TY>H7BNJL-!L I01
M4C72^,RJ]M%QY *Q)2J !=2[C,,RZ^]HH*>N)=A(&<%]VH1(2:<0,/5$E*(Z
M/4(D)&M&PD=4+; "1<E"880<75UIQ0X;(MN-Z1XS 5YZRKX?#?96RVK_ /F$
MR<V?_$C13\=^XCS54CMC:5#C$7)*/1,*4EU2DD4LG?<\<T#Q94Q,+LH& UJ.
MP1V'-V)5+ZJ,JV?5,*R?,-U;-]L<,*V@PW*2;0981@D;S)<N"0PLK6K82*4]
MYAA181-S5G\8)<-M*NFZ'I634X6G'2]VPUI4 4]4=BJ"YN:'";9\CE,)EYIE
MW)ZE&@6LVD5XS"IYYI;R0H)LHQOB6F$-.O3+R;78P(JB^FD>:.Q TN4FZ52A
MR\+VT,"8G5'2-$-HO4LP,[DV80R?+2L$]$&9<<2VP$VRXHT $*1*R;\VD&F<
M)" >2.Q6PY+31%4MO>5R&&'GF''\\NR @PRAB6=F[2$K710%BHK3C,#)+TH^
MV2M*,\:4TJ4/)?$Q-O=Z807%<T369E79?,6:E="#6O5&5_\ ++]T?A!LD);>
M#94/)52H]QZ(:FJC/A.;?&Q8_NO/&4/\N/XH2Y.+)6OO;+=ZUP$O9/F&FC@X
M"%>J/PBPYGY7-ET*1K B899EG6%,I"M,B\1*I>EG9@OU(L$"E/\ N#E@MK4Q
MF _8\JA$)FA+NF84LH$K45NI?79?"<K*'8;&E;SJN#0[84B5DWYM(-,X2$ \
MD=BMAR6FB*I;>\KD,,//,./YY=D!!AD2[+DZZM"5J2D@!%16A.V'$,)6Q,MB
MJF7-FT;C\RZ:-,H+BN01-97F!:S-IX^FK#X]'=')X*<RA+3+G?L5A1U*BW-5
M#LQ0E(.BCBY?&\(PW,(PC""=0A3AQ6;46DQ?HF*'23"DFZAAQM13M%8T3?LW
M+2>%%E?3%%_M"*I-H1>D[O!//&DKHC"O+!J DZHHF*63&$81A2-)71&B*;Z@
MBIPA3AUFO=V/2'WN[3'V?<K=X]X)!T%"E)M-K."^+=1;H,:5,8IZ813"FXM:
MU! I>HZA$S-KT9-:Z2R"FALCRN?=S2L1AW,M_DGL.7Q3*>2YII++\N0XS9_*
M-'RNXL.SRE-M/.9L+2FM+JWQV3).L+RHI0LJE\5;;7]8(F:A=E!2%8V<^+/J
MB7GIQEQQY:E@T<(%RN*$2\JRAAA&"$"@WI4HA(&LP1G<^K8U?ZXI+,(9'G+T
MC!6M3[C6W!'5!4^\B793>I9OI%F4SCJ?\1W7R"%K::);3PEZA >F%J>56A0+
M@(HPRAKT1$XK8RKW0VCSE 05]^E_\1.KEW,VF82R_J2[@KG@J<EU61Y:-(11
M,PI:?-=TH FY<I^LU?ZH*VYE!IY."NB+5.)*82RH462+N6*8MG@F%-'%!NY-
MU;AU09MV]Q>$*3M%(^T8LJN.I6R.QG[D*P.K>ML#$Z1A25]\=&EQ0^."Z@W1
M4BA%RD[82M)JDW[A6ZL(2-9@M2P+36M>LQ=O:X*VQF'SI:B?&61G<VE!ONK6
M%LG@J39@O%[.74 LTA,PTZ6'QK@/SDPJ:6, <(0M+F;=1=6F,"W-J6]6]:A6
MZ$-5L%' 5LA")F>6XRG! AA,J^93,X681,S<R9EQ'!&H0)EEXL/C7"'9F>6]
M9\C5N9MWE"AB(L-SZDM[!4?&%T67%KQ)%(6IF;4RTO$#'DA3Z7*II1*:0_-J
M=SA<K06<*F$SJG=%.#=F+:9Y,K,II:M70PTRZ9JA"G'3KVPQ,EVB&Z:%GCAB
M9+M$-TT+/'"%6\TZC!4)5.S:IA*<$0P Z&FV_)LQF$KS5X.%8:9!K8%*[V=4
MWW]X9AH#$J5=$G))P8:"*[3K._M:EBNY3?JCF@>*I2I82I=R03C!:/:BW>A_
MS3#B\LMEF5EUTL ]^/%]7CBF],I-5%#:0XGA(5M@S\N\5R[9^=2QLJ3RC5$X
M)W2G))-HK IG$]=T.Y4GY1S*3Q"E"F(63PO?TQ*NL9+?EGVJA2U#A#5&3U3%
MK/66+5O&%Y0F95N:F%NE SR0H) V"&6)5.;:3/M!*1J"B+O7$E.RS:GVY>V'
M$(O*:TOIS0QDO+4BAMI*0W;LA;1Y4ZHE6&%4;F716Q@4 5I[HEYI4NVY,35I
M2UK36ZT0!ZH2Y()S"0IN82AOR3K _O7&3?TRO=#$U-2C<X_-BTI3R:V17 ;(
MDLJ-)HEP9ARFT<'U5Z(R>0OM\_1MS['#]8'3#+JA1V;.?/)Y/JOYXRO_ )9?
MNC+T@]P75) /FFAH8F,DS>@A]18<!U.#@GX<\90_RX_BAU4TA4S*RSB$9@:T
MBE4\]_3#N3TY%?:5=FE$"C9&R,LMO)6$(SMBW^CU1E+]"GWQDGT'/NQ_^[F_
MX4Q.3D\TF9S!2E#3@JF_6=L2V3Y%L2K#S]Z&Q04O53II$O-*EVW)B:M*6M::
MW6B /5"7)!.82%-S"4-^2=8']ZXR;^F5[HEIEZ2:FGYI)4M;Z0K7@-D)EFN]
MAQ]KF"5=6X)1)H[.KL_8%Y^'3#;RA1V<5GCZ/D^J_G[K-3;DNJ:2A/>TCW[!
MQP<H9RVM?#;/!*=D,OV%-9Q-JPO$>/N[2+/3N4U1:PBXQ:VP@@TU&L54*C:(
MN$;.3<NC9%XZ(X0YXX:.F.^)Z8QKR11M-(JL]V#8X2[H'=V/2'WN[3'V?<K=
MKO A=4E)M)6CA).T0PAZ82@NW(MFEK<:MIM8TT:QWO\ ^F8;H*"R-4*?F'4L
MM)Q6LT$..9A?8BB4)#R>^)V\D!*0$I%P U;H(Q$!0[D'$\-LUAMT>4/$Y7*1
MM)FI=*D)*32TDZCM[B9>=ET3+)OLK$!UO)B"H&HSBU+'03#DG-M!V6<X2*TX
M]4(E))K,2Z,$5)]^\K,/!!U)Q4>:"F39L#SW<>B+)4[-+\T=4!4VZ&$^:G25
M LL!Q?GNZ1BQ7M:-0\HP+1T!@@80P)Q% K2S7%QP&TI"4"ZR!="F/R3MZ-R<
M/U:=)B33M>1[XH;P84_("BL2QMY(((H1J,)E)Y548(=5JXC';Y=MSCI?TP3+
M/+8.Q6D(6&F^R4H\IF^*H5>+BEP5A#\VC-WU)1?!2T\AT<6(YH#;EU='=LN)
M"D\>[1( '%N67$UWA)N A<VL=K!T!N3R=50KIK'FN#!4&4>T?-KMA;J^"F,Z
M\;O)1J'<+8N(BAX:;C]&YQU@*7MJ1!#+26Z[.Z9$R9BU*UR@\.2Y'K[@VYYI
MIN5BN^5R>+*(%L@<$:X4^^5,.-*HAO#-1+O3<KV.L:(5@'1YU-_*+9E$S&3E
MMZ=H4TJ^=JB8D9?)Q:<F$YM2EKM4!V71-SL\V6E38"$,K%#8VGEAPORRGI90
M+=< ZBN(.W"*2F39EYXX)<(2*\U8SBDV%*6THIV1_J%_"&_\_+_<B30[)*F)
M5]))<0:$&)3\$9,=1-&H6HH 6Z=5R:UB0DD#.3\BVVJP/*(30I']ZH_!D]).
M.YE1L4-%)^J0>./PDXP6I)+@*U>2A*<$UUGKC)OZ97NC)7Z/XF)V5 J[9SC7
MIB\=7/$CDQ*S96]1(\VU2T?5ZH;9;%EMM(2D; (RO_EE^Z,J?I$>XPUER63L
M1,6=1\E7PZ(RB=68'\4(^4$LV5L%:';8%R%II<>6GK@%63YD/ZT@IL]/](5,
MN2QE _;;"":W85B9$S*%Q5DLNM$V==Q!B7RG,RO8LA>U+CWWZX__ '<W_"F,
MJ?I$>XP4RR;<S+K#R$#R]1'K]4?@R>DG'<RHV*&BD_5(/''X2<8+4DEP%:O)
M0E.":ZSUQDW],KW1DK]'\3'^IF?X5[C.2V5:#2DRPIJ/EG^_-AMEL66VTA*1
ML [J014'$&%Y0I:EL429X*5[>3BA4R^O\5\DZR?-Y83,2ZJI-Q2<4G8?'FD[
M7!N;3%\5&$<D5$)2]0*(I748M,?LQ10H>/>XF,8Q[M4[I7Y(N3 [NQZ0^]W:
M8^S[E;E-\9><92\P=2M4+:1,//LDU0EU5<V-@@MKR'-J;0I02XR0NV-1NCL@
M2+G MYHG3PPIMB7 R,).4NSCDR[I4XDB&.R&0_V.39M85Y-<4%PWM@X*[D0<
M##TN<6U>)Y4;!(5V.LI(.L"HC)DPHU4Y+H*CQTO[J79AP-HX]<%$F.QVO/\
M+/5%$A;SR^<F Y/JH/\ !0?>8S;#26D_5&XZ\\:-I&K$PI9N&H;(3/S*:_X2
M#_% ?IVRE*[B;5:I-H$;BAYZTI^/PB2'_D!W5/,@(FQT+Y84A:2E:30@ZH3(
M3"K_ ,DH_P ,%!) .-(L-ILIBDPPAWC(OZ8*I1^Q]1R\=,6W&UH P=;PZ80'
MU9^S@I7"Z8"2O,.^:[=Z^YJ;5P5;(2A HE.X54TC=7<!6A*B,"1$NSJ423W$
MP$G!=WTUEW+1O2\_V,P?_&W=4<I[@ZWK(NW:;XPF#XFY,/KL-(%\',*S:D7N
MMJX28E9EYBRMGA!&#HV*@)2 E(N &K?E*@%).(,6V9*7:7YR&@#N674)<3L4
M*Q:8E&&%;6VPF"AQ(6DXI4*B AM"6TCR4B@@/%E!='EV;^F"AU"7$'%*Q416
M7E66"?\ ";"=S./2;#SGGK;!,!*4A*1J$676TNIV+%8"4@)2, (G)P(+BF6R
MI*0,3JB8RK--KHPDV5K32KBOZ5Z=P@BH,66FT-)V(32*$5$:"$IY!%"*B,X)
M&6SGGYI-=P=D2S+],,X@*@-N-(6@8)4FH$62 4X4BRTVAI.Q":;F<>DV'G//
M6V"8"4I"4C4(LNMI=3L6*P$I 2D8 074LH#IQ6$WF'G&F\\ZE!*&_.-+A$SE
M7*TLME:4FQG,5+5B>BO3X@WE-+JIC)[8LED?D./GVPG*.E+Y/7HZ0N>_O;X]
M+#ZV[571%-4$:H(@IBG#1L,45PMAQBK1M#8<8HI)2>/Q*IW>QT8GA0/$&/2'
MWN[3'V?<KN-/-AD,K":5M5BYY%?[XH05&KE@ D;>X!6O7W+B=3_?N\36MRY"
M157)#4Q*J"Y=P50I(H".X67'DI5LBK3B5\FZN8=U7!/G'9!>?578G4F+#>BV
M.&X<$Q99359X3AQ.\S#2OQ9H_M*VPVT>])TG.2  * :M[*M><LJZ/^XE>*T?
M]IWAFF$_C*!>!Y8@$&A&N-,_C#=S@V\>]*D)[&=\YO#H@J6G.,_XJ,.?9 #;
MEMK_  UWB VK\7?/D+U\A[O*G50C>Z3S:3QJC1>;/(H;Q#FQ0,(5Q?3$_-@T
M<2W9;](W#UF)"2I13;0M^D;U>NO<74:JU&X-^.6#XFE<E:?0P"I4LG^+CA&4
M0XY*2DJJ]Q-Q</F=?TZI"TA2%"A2<##AFE(EY1M-ZL @<4#-HM9,!LU(TU?6
M_I"'6UA;:Q5*AK\<E?2W+L=R_@[E1@J!QW;N-M.Q4674V?2O$5;53T341HT7
M&F@I[K?=O+"+W3ZHMJO)\18](?>[M,?9]RNXK'%6%K0ZM"DZ-F-*8-.)-(,L
M@E0;.)[A0\%7<I9_S%^)S+:!5:FE #FC)TM,HS3[;5%(.K?A+9HZY<.(14F
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MWE>BX.+;%1AOV.6!"N7>!T8*Q@I5>DBA@J15QG;LY=[<+*/.,!M/!3"6ARF
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ML)TCBM7G&&5TP52%!(TEZ(A*0+@*0F[R(P@IIP%$0+M9]^[A^1^,.&G!2!&
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M"%NN<(Z2H7,+N6[JV"'K6%F&JXV1#M-D(">#2Z$/:DW'DA#C=ZVS: VP'!A
M4Y<WJ1M@H/!(I"I=?#;U[1NUQ. $ 'A8F"MD6VC>IK9R0E:>"8"T][9J*[3"
M4C@MWGEW%)U)40-R7:/ 4J_<6DX.7B,Z>].BR3L,6C 6[=3@HV0%H[XV;0A*
MTX'\P+(YX/+">3N/'N;=S&+Q&R,8N.XTQ,-V]+1(-+-8.4&)EQY(;*4-N@52
M3KKR=T(U;UA:W%R\RP:H>;QY(1E-YC.S*$A(M<&[73;N3S$HV79AQ%A*!KJ;
M_5$A+.)L.(;TD[";S[_%2ZXH(3M48IG<X=B!'XK(.N_6,8-2H_OEC\:R@XOZ
MJ<(O;+A^NJ.U-(;]%-/'I0R+J6I9^TAQ5@%5>?BKT0IJ8>6[V2FE5JKI"_K\
M99;Y5;YUOS%%,2ZMB;/1="H7]",>D/O=VF/L^Y6[I8;(N%.ZT(J(ML:"M:=1
MBRL4.\;]$0KFAD?4$.(\Y)$4\TTWTRSYB_[]WB$RV@56II0 YHR=+3*,T^VU
M12#JWY3T1?<H7&#YU19Y:Q0WB%MX5$6%:+J+E)W)@C"HW7Z\*UN,M)OS:K:C
MLB\0!J*@#N(ED^DODW%(P.H\<:0HM.BH<<';44BA%1L,*1A419-SB;B-R8(P
MJ-UP'\H@$<VYFD\ '3/PW'0,:0A0P(A"".T#25Q\6X4G W0IE8/:^"K:(<KL
MA%<:"*1F%_9.W<<4,$-V#R[K!/!M;E$Z3JKDIA#>P11("1L$'SK1K%<58 0$
MZ]>X"COB#:3"5C7#.VV(HH C88T>$+Q%=>L;-QTC@J<44\GC3)9=6T5/ $H-
M+J&&IV7RHY58J$%U0/3"Y&<5G5!-I"U8\ABV^ZAE'G.*H(I+S33RMB%@G<S?
M9TO;PIG!N6.SY:ULSHBM;ML+=1-L*:1PEAP$"")>9:>(Q"%@F&D2;K)?M=L2
M;RGFB7/9#*II304MIM8J#KN@*F'VV$G#.*I%)>:9>5YJ%@F J8?;82;@7%!,
M-M+FFDN.4LIMWG9%J8?;83M<52#V/,M/D8A"J]SX<7*&^XSAN<L+!%1QQHDH
MC06E7JCO=>0QWI4< QA2+S%V,'EW,!%0;,<..$(Q$:MQ1*J)&-8+ZY=J9:M$
MI0=$@<L2LXIDR^?;#F;)K2O=*[.X2W8;RF'W)@)M(-]*'^D)!-H@8[?$<8N%
M8PI 3B3 4\"KBK2.UR[:3MI?OU+6;*$BI.P0'Y9S.M'!0[C.H7)+EFF%64K7
MY>^G9(6>PY=O9?:N_KW0R4TI:$6PL*;X0(_LPPN4EA6G?'#:57;Q<WC*/0^)
M@;U[8JBH=;\Q5>F#RP>,_0C'I#[W=IC[/N5XG18K':S:$44*;C?HB.>$#BW)
MMGZU1OGT:EIKX@\]2UFT%5.2)6?#>:#Z+5@FM.XH*O(-0-T.4TQ=7<HD4W2O
M613<LIYR<3N%)UP-<$@"IQ.\37R37=MTTMNY1(IN@TO&!W+A3=HD #8-[10J
M-T5%:;AH *X[M%"HW,Y33I2NZHCRK]\E1Q3ANE8&D8I 2D42/&I?]./X3#+3
M<H$L $(F%H5MZ(5E-3R7G'!8"4^1MKQPX,I/EN096I ":G#DVQ+3&0WU)6DZ
M2=*[8=*)!#9L=F(SBZ;*"[UPTIUQT3*T!16DW \D2&36W";2;*UX$A('OBSV
M2KL_-USEE?#V84I$]+K)4&.#74"#=ZH=:=>4B5:HM2$^4=42[DHXHIH'$VC?
MQB&IYNUG)E6E4W8");**2YGG& 56E77B^'W9Q:LRD6K(. U)$2LU(.+;"CMO
M21&2I@W%TA1IMLQ+92FYAPOJ*74A)NIJK .44N+DM&B4^;35SQV;DI=X39+8
M6;N4&_N)48M.&B=D<#UQ=5,65Z28X4<,1=?%3A%L\PW5\V_V[AY>XNLDE*7$
ME)*<80_*SZ0A2N \F^G*.J$-H%E"!9 XNZ'N&3AE1QUOMW:<WK5Q[I:>RA+-
M.@T*%.@$<L!;2TN(."D&H[C>H1=4Q<BG+%ZJ<D7DF,-W.+$ =P=+&9$HI%AV
MUP[[KHD6U]BIR=9M:\Y0W_&#DS)+*)B;2*N..<!N)-C*8EWV9I5A*F*U!NZX
MD;%GMKFG:%= 8^^&7WV&9;)RZG-GO@%+HGY&4ET3#J%V&4ZA3A*482QEE+*V
M7$6PJ7&']X1^$C+2\O* CM"KUT.V/PC2RG,9ZAY*PB;FK 4M2J6!04AYF2EF
MW7\X:+5<AMO57CA>2<II:+EFTEQJ&FF6NR)U\V6FOC'9<]+R\Q*^6EGA-PU-
MS5A*W*\ 4%*QE;*!_+S%![_O=UFLFH99E$R[Q3: M*--=]WJAEUU=MY)*%GC
M_P"J>,(/U/C%-F]44\%L6 =L.H\Y%8$)^A&/2'WN[3'V?<KQ72'/%221LW$#
M:O=2=3J/[]V^EE^=H^(/,ULYQ!37E$2D@7,Z6$6;8%*_F_+_ *<?PF&)9W@.
M-J'K,/9.?N#A**?7$..SLJ'Y-Q:ET4BH(.RNR*HR>VZKS4RJ?C$K,LHT&*I4
M , ?^H:0XPZJ9;0$T%+)YXR=E%+5"E%IQ \D* AKLF091,)2 K\6!J8G'9"5
M$JV+2#1L)M7<7+#JW&E.2[E$K*<4[(8;EFU);H$"HO UJ,2KB1H-N4/%41+9
M-L.9Y#-%5&C==#[4XVK-D6"4CH4(E93)[3BPDG$8F,F2]:YHA%=M$QD_]"GW
M0_(938/:CBI%1AJI>(M9.SG82;5;7FTU\_<4-Q9;%PNC7TQ8<%%:C%#>-AC@
M>N,".>*MKBKAKO%\VY<(U1C&.\5Z7<9=K,9_. J5I4I_=\=B2K3[3K#55YQ(
MITU[L=^&FEAN9:7G&E';LA=K,HRN%T3A0INO]\,3N5<LK=4TL+#+7!_OFAV9
MF93./N\)6<4/<8<.1);/=MSK@<-39UPF>6[8)N['Q7:V?UAB<2FP'4ULUK3=
MTJ\T:#1YXQ"(TW"J,*\L7"F^!(T8%W<9"12=*9F!_?K$7#10G")J=ELIB3+S
MI#G:0LDXZ^6$3L]-NY1FF^ 7+DIY!$C*JTFI=O.+'K_XPMQ7!0DJ,34^L=NF
M'3?Q?]UAEI6DW)M!1'K^\(S0Q?=2BGK^$%@7'-H8'J^%8\U3<I_N(ZS#*Z=L
M?[8H^[U1E.8\B71FQRW#X*B8SEXE&>U@\W_(PJ7M=MF39 XM?]\<$8*:E:?:
MIUQ*[7*N'G/53NKF45SJI=#B4VFT-U)(%,>B%LLES2556=.OQAA?*-T%U80.
M..UAQ\_^-$64L*E4J\I?",./ :#=*GEACC-F$<GT*QZ0^]W:8^S[E>,,#:O=
MEG_-53?,N^8OQ"9<1<M#:E#HB0FYE5M]UNTH@4_-^P^TAY&-EQ-1 0V@(0,$
MI% ([(,JSG\<[FQ:Z8L/-(=1YJTU$6VI)AM?G!L5W,X)&7"]H;&Y:5(2Y5MS
M0AQMI 2FP:)0(R@B9ESFU)2++J+CC!['EVF*XYM(%8*%I"T&XI4*@PI4O+-,
M*5B6T 0!,,-O@?XB08/8\NTQ7&PFD67V6WTXT<2%0$(2$I%P P$5F)5IX[5H
M!,6&&4,H\UM-!W'FW1![@ON*O2[B')532M&PEM1H8R@O*#.9?=6E(%H*T1KN
MY?5W8]S*\GR?9*_*7CF^.FN%*5PB:FZD,)_PUK3ZZ_'NHJ-&!=W*5<8?['F9
M95I"B+M75"AE";$X\HUJ$V0!LAXY(RBAF7<5:S+J*TAUR?GS.+7<$A-E*8GL
MIN.I7GTV$) X(NZHF99M8;6Z@HM'56)>4M6RV+U#6:UC*&4774N&8N2 ."/[
MI&3E9U*&9=RVM!'"PB79#H;;0[;748PY)M.)9MD5)&H&L,2Z<&D!'0(GG774
MO.S3MLE(_O;'X3R;."4F5"RNTFH,-.34]V3-9P*=<6/)'DI$.2C3H:*R*E6R
MM88ETX-(".@=U[-?9=>1;"++5,3#;293L=A]9O4NTJO_ 'XQ7S5 [E-<7BL)
M1+LVW%>4>"GEAK..%^:<O4K8-@AYHCMA1G%<N/PAM?FJ!AKD^A6/2'WN[3'V
M?<KQB3&USJW7=J=*&U<6]7Q7PPKZH[NMM=Z%@I,,RDLFPPT+*037\^TG:.Z*
MW=&Z+]>]5Z7<#%MV=#%$FF=21?"'6EAQI8"DK2;B.ZD]U4Y9[&F3^6;&/*-<
M34J^4J3G;:%I.-W](TE7[(T6EF.\GIB]*D]P"E"Z!=]$3LDT 7E@%NOG UB4
MF)B8EVB%VP$$J-Q'C#J-J=RL [B7W4_B[8%F_'^S"T><DC<E%[4#Z%8](?>[
MM,?9]RO&)$?7ZMU:/.%(*#BA5-ZI.T4BQK0HCN\Y^A7[HR42:G,XGQQ2%SC*
M5IN(*\(2VW-LK6K!(5CNJ<6;*$BI/%"^QG+=C&HIN9]X**:V:(%\-S+5<VO"
MUCO&U/A:K9H @0W..KL,N %-U]\(?85;;5@?S12K9O,:B*4WN,7 F#4$;G%N
MA6,;#NJ]+N$SFA;>+:K"1K-(TI&8 K9M9LTKRPQ+IX+3:4#F'=0GNI4HT BR
MU5#>W68JH1A&$815-QB\7;=Y93>J M<"[Z*#8F\],-+H4MH5=MXH9F6JYMP5
M%<?&'4;%;Z81YKBAZXE>*H]?T*QZ0^]W:8^S[E1PH[X8[Z8[\8^<*CYRKH_K
M'SI71_6/GB^C^L?/5]']8^?+Z/ZQ\_7T?UCY^OH_K'S]?1_6/GZ^C^L?/U]'
M]8^?KZ/ZQ\_7T?UCY^OH_K'S]?1_6/GZ^C^L?/U]']8^?KZ/ZQ\_7T?UAMU<
MRIVQJ(_KO'%MS2F@LUH!_6/GZ^C^L?/U]']8^?KZ/ZQ\_7T?UCY^OH_K#G;<
MY;XJ=W)5P=<-3,FL.2R^ I(H/''V'K5BTLZ)XX;?07;;9M"JH9EW@NT[@0+A
M?KBPD.NI'EH%T+?!SDLILVN36(GIF4:?2&@"YG,==*7PY-N.3"I4J40U74<+
MJPU,M!00MT4"L=<2K*[;CVE5#8PTC"E2Y-4\)"Q>("'E*4X?R;8J82SILN*N
M&<%QB2Y5?")$SR%K9S;5 WC6S"9IA#B91()LGA8T@OLA:4A5FBQ?!R<$N9ZI
M%::-PK'83MM*Z5*SP1=6+%EZQ_B6;H" 53"L>U8""[+DW7%*L1^993%#JW=M
M(IG$B+W.B.UME1VTBR;E1I*)C@[CD86A&B>:,(N, :]S'<-0<8QCA1PA'"$<
M(1C&B(M.*"?2,-J'EDGNI)@D]U '>AAQP+M\:B*CO9W*(%!M@%0BX;RU,O(9
M!PM'&,VQ-(6OS<#]#95,MDZ9<8SZEAQ+1L4-^//#+$TV6G$%5QV5KXPE?GIW
M#O)H?6KZHIYKI'N^A6/2'WN[/_9]ROI+L&::S>8?<2W>#:1:J#Z_''V&WLPJ
MTLV^>,\Y/%]-FEB_KB7_ $7Q,3"$,(26VBH.4TJ@;8RNWY*45'.D]4912H!2
M38J#]J'FBV@MYQS0(NUPE"$A"0Z+DB@UPV\ZPAUQZU:*Q761=$TT.#FU#H4(
M?FG)5<ZH*40V-6SHAEUK)C\NZG%5DZ6S5&3BNY=]>6@C)_(U_#',?YD.?IC[
MA"OTCG\)A+*^"XMM!IQTAE;#"&E)<":I&JAA"W&$N+?!M*4*GFB:&K-CW_F9
MG!P?*$5Q3MB@C-(P\I44L#GBY('-!4=4%PXJWBX,;#MBA&<$;.([F&YC!Y=S
M",(PW+S%T2S7G.VN@?UB5 4JPA*UJ2#<=&GQ[K8& [JEI.*_= --S.4M.&Y"
M-L%?92V_JMZ($(EY]6=;6:!TXIY=XI&W7&T0+MZZ^16PFM-L+>?45K5 (N(U
MQ9>-IYG1*MHU>(WJ COB>F.&.GQ)\$A-4$:1IJ@AIU#A3C856GC 7K0=\L^<
MD&)A&QROJ_I]"L>D/O=V?^S[E?24A(/,V9:<2H-S-K\H/)IR>./S#$BXXJTJ
ME6E%)KR0RV]DZPTI0"E9E8H(E_T7Q,*R:[*J6>"74()*ARQ-(6/QEY"B4CDN
M$3N?8<9M6*9Q-*XPY.R\NIY)65I(25 UQK2&5+E5"9+E2TA)J!?JB6;=0IM8
MM52H4/",33CLNXVV4KHI22 =(0N>DF3,-+)-$BN.((A*&,E%!UJ6#3X1*9AE
MQZR55S::TPB290RM;J W:0E-2-&!)N)+3JD+N6*4-HD0[*,R2E6S72;) .VL
M-.3+:UXJ6]31J4'7##R9=U3.<:.<"39U:X2EEI;J@Z#90*G Q*H<06U@&J5"
MA%\3)?EW618I5:2-?YF]KP\TQ0)#?'6*#=2T-<4WBX&^QIRQPA!O&.W<PC",
M(OH.>+UCFC12511]"%I\TBL!^6D)>7?LV2MIL)/J[I=PCW;B3= W&/-LW;K%
MOAV!7EIW)]I/"(NW7G2*!PBG-W6JUA(XX[6DN>J-&C8XHTG%'GWEQ(C&L4-Q
M[O(.^=+V>A1ZXGD;4)/0?Z^,.-^<*10[U/Z(>\Q.#T?C]"L>D/O=V?\ L^Y7
MTDAA]2V[#B74.M&BD*!Q$%%H6P*D:_'67)<(LI19-I5-?YQU,*=/-N647JB]
M1YHX1A0W^&X<<8Q,<*.%&)C7'!W&6I684TG,VB!RGJC*7X1F>R$,!NSVM*:5
MM;!Q=SK!5W99X]W-JT2+TJV13,E?&F^$O30 2F\-[=^MB5<+3";BI.*HSC3[
MC:]H5"DO4$RWPJ>4-NZ5I[2X<2,#%772Z/-I2 E(HD8 ;BEN*"$)Q4K 19!=
M<'G)1=&=EG0XG7M&_P!->EYHQBC7:D^N*J45':>XLG650.[)5,RK,PI/!+K8
M52)@-MH;&<5P137XRYL5I#<&ZU^B'O,3GV/C]"L>D/O=V?\ L^Y7TFG+.1EA
MO*;:;"V5\"91YIX^.&U.(S;A2"I -;)V5_/FIPBC8H(O4.<Q<33BBB[CN!L8
MJ@".,QQ[JNXJ]+?F&5S.=M**6ZH52ZL3*9-Q]S/D%6>(.'(!M[FKNZM_;F7D
MM)X]<!M$R LX!8*:[II!210BX[CJQP0U0](WZ90=Z;TB-IW&WDX8+&U.]JXJ
M_4D8F"EOM*.+'NC+0\@5,#NTF]D^9,LI;UA1 !K=QPVF:FW'DK"R0HW$^,LN
M<=G>M_HA[S$X?0^,#Z$8](?>[L_]GW*^E,P9A^54E06AV7794E0AUC*C\M.,
MI':IEL%+B_2&$+EIYQV74FFF65%!YP(1.23N>EUULKLD8&FO\]DM#GBR+A'#
M$5&&T1YJML7*'3%=?+%%BL6S@,-XH=Q5Z6_,9E,HE[-65U*Z<>R'YE<L);-N
MYNR%VJW ]S(BBL-O=DTO@;U;AP0"HPM]TU4KU;CDL\2I3'!4?-W2ZR0ETX@X
M&**L(3YU8S;=^M2CKWXF::#@H>7<;: UW\0W2I:@E(UF"B5_>'X05+)4HZSW
M5Q_SE7<D#NS3$[G,VVO.#-JI?!<E$N!3>%I=<1XRH^:0=Z1YJ (FC]80/H1C
MTA][NS_V?<K_ -6NJV705$T&J,3&-4'&#NW[U4"IJD[J(IQ;Q7I=P4ZT^RVE
MVRD!==D/RTPZV\MQ[.6FJTI0#X=TO$5:-VR.V((XQ%RAO^%T1HH48N39C3),
M TBF]<:\])3"FUBBDFAW'IE0H'+D[Y3KJPVVG%1@AF5<>1YQ-FL6$U9?_P -
M>ODWA0M(4DZC%1G$\0,6646=IUG<TC:<U($5<-$ZD#",_,JLHK9N%:F%B662
MI&*5"AAM<T5 +-!9%8[/<)[&LI54"^AP]\%^6)+859TA2^!D^VM<Q;S>@FHK
MO&C.+4G.ULA*:X0 774\9:,!^5>2^T?*3N+IPE: @'N[4XB73,J6\&K*E4IH
MJ-?5#3+DHVR'JU*5&ZB?Z>,O^C7>S)XZ>J%GSE5^A6FY=-X(54UIKZXP1_NZ
MHP1_NZHP1_NZHP1_NZHP1_NZHP1_NZHP1_NZHP1_NZHP1_NZHP1_NZHP1_NZ
MHP1_NZHP1_NZH69A-RZ7I!V'BX__ %:]Z7=%;@VC'<;/UH2.(QB-U7I=P;;F
MG5)6@@JH@FZ''I!TNH;5942DIOY^[7B,(T%$<ABYQ4=\,<,Q>M73%\81A&$%
M2B$)&LQ1IYMVGF*!W_;$Z7G)QBTJV[Q*-T  4 U#?,2P-&Z6SQ[B7$&RM)J"
M(9=-Q6@*]6X923([(\MSS/ZQVQ?9;>M+N/3 25]C/>8[U[A:E=)6MS4.2"I1
M*E'$G<9_S _A5$C-WEIUL+]))Q$9/<0;2%*)!&L4@?H&/>F'4MG\;>?4&_JZ
M*=*/PE-I_&71VM*O)&WE.\R3^M^Y#;\Q+L,.&42O/4HJW8]=\91%_8]$\EK<
MEV-FD8'=VI-I]#"D/AVTL5\E0^,,NKFFGDLUK9!&*?Z^,O#:@[UUSSU%42XV
MMA722?\ W X-M^\Q[@J*15)LF--%1MAM2<0X/<883MK[MW&#45THPC&.%'"$
M<*-L;(<5M0G7&4D['P?]OC!4;@+S"B5$2X.@WLA+C2BVM."DF*N=_;T5\?'W
M(MT+[XQ0G5RF F8E5,)/EI5:I"7&U!:%7A2=>XEUH6G6_)VB*$4,!*00CRE[
M(2A-R4B@A2QWY6BV..%*4;2C>2=TL)?66/\ #)NBB^UJX\(NW&?\P/X51)*0
M*OL-9Q''M$2TFN]<NX;)^J8'^78]Z85E)D5<8>4'!]2@OYHL.G\;8T7/K;%1
MFWW%./\ ^"R*J'+"W\GI_&7&K;(73$BZ!5ENG'FNN,D_K?N0QE9F8SZ5-H<<
M;**60H?U@(EV&Y9QE5EU"-9\[GW'3J31,#N[3T\I:4.*LIL)K?"T2BUE2[P%
MHI@/&2%&\C#>/N:PF[EA*1B32$H&"4@;FR+C7D_]NH7S;P61?&-.+=OW,8N2
M3!J*;FEN+52]*DF)2AH;8$7@+$:2"F,8-",8PC",(PC9%Z^B.UIKQF$OMO,H
M24!!MUK6O)$XA^9;F,^4D9L&ZE?&'FQBI!2.B*$4.Y,N4T5D <W_ 'N]ENHS
MSBE6&F@:6E1V=+9&;<DSA886:CIOC\,+E\RX&G%EFNM%1]V'>P<DRTUF^$&F
M'%4_W0C)N5)/L&96JPE::TM>:0<-Q]U/"2@D0I2C51O).Y,2RKT-D*3Q5QW:
MK9;6=JD@Q1*0D;!N*LFK3>BCKWW:U4&S5%'AFSM&$--290M0="[U74H>N)27
M=IG&T!*J0Z[(9LR[AM65*I9XH_!K5E4P&FT7F@T2.J')6<2BTMTJH#44H($U
MDXMF3M8*730.*3$T\EI"77%MVUA-ZK]9B1_0(_AW)#L,(.9MVK:J8V>J&)"9
M 5^+I9< ]&AAU3F;5).)*5$+Q\TT_O'<F#_Y#[_$,GHD)54SFU+4NS2["GQA
M2IN4<8"&U"JQ=6[QBPCA^Z%E7#M&M8.ZAK6XKU"&!J2;9YMRB!SQI6E?52(H
MH*85JM1PTN"+VSS&/*'-&BL>/E2C1(O),?.F?W@CYTS^\$!*9EHJ-P 6-TI5
M,M!0N(*Q'SIG]X(^=,_O! 4DU2;P1N677FVU8T4H"/G3/[P1\Z9_>"+33B7$
MX52:[EIUQ+:<*J-(^=,_O!'SIG]X(LM/-N*QHE0.X5*-$B\DQ\Z9_>"/G3/[
MP0$IF6BHW !8W2E4RT%"X@K$?.F?W@CYTS^\$!235)O!&Y9=>;;5C12@(^=,
M_O!'SIG]X(M-.)<3A5)KN6G7$MIPJHTCYTS^\$?.F?W@BRT\VXK&B5 [A4HT
M2+R3'SIG]X(^=,_O! 2F9:*C< %C=*53+04+B"L1\Z9_>"/G3/[P0%)-4F\$
M;EEUYMM6-%* CYTS^\$?.F?W@BTTXEQ.%4FNY:=<2VG"JC2/G3/[P1\Z9_>"
M++3S;BL:)4#N%2C1(O),?.F?W@CYTS^\$!*9EHJ-P 6-TI5,M!0N(*Q'SIG]
MX(^=,_O! 4DU2;P1N677FVU8T4H"/G3/[P1\Z9_>"+33B7$X52:[EIUQ+:<*
MJ-(^=,_O!'SIG]X(LM/-N*QHE0.X5*-$B\DQ\Z9_>"/G3/[P0$IF6BHW !8W
M2E4RT%"X@K$?.F?W@CYTS^\$!235)O!&Y9=>;;5C12@(^=,_O!'SIG]X(M-.
M)<3A5)KN6G7$MIPJHTCYTS^\$?.F?W@BRT\VXK&B5 [A4HT2+R3'SIG]X(^=
M,_O! 2F9:*C< %C=*53+04+B"L1\Z9_>"/G3/[P0%)-4F\$;EEUYMM6-%* C
MYTS^\$?.F?W@BTTXEQ.%4FNY:=<2VG"JC2/G3/[P1\Z9_>"++3S;BL:)4#N%
M2C1(O),?.F?W@CYTS^\$!*9EHJ-P 6-TI5,M!0N(*Q'SIG]X(^=,_O! 4DU2
M;P1N677FVU8T4H"/G3/[P1\Z9_>"+33B7$X52:[EIUQ+:<*J-(^=,_O!'SIG
M]X(LM/-N*QHE0.X5*-$B\DQ\Z9_>"/G3/[P0$IF6BHW !8W2E4RT%"X@K$?.
MF?W@CYTS^\$!235)O!&Y9=>;;5C12@(^=,_O!'SIG]X(M-.)<3A5)KN6G7$M
MIPJHTCYTS^\$?.F?W@BRT\VXK&B5 [A4HT2+R3'SIG]X(^=,_O! 2F9:*C<
M%C=*53+04+B"L1\Z9_>"/G3/[P0%)-4F\$;EEUYMM6-%* BJ'FU#B4([XGIC
M1(/)N:1 Y8[XGI@C.)KRP#O.'T"+@I?-!*6Z)VF*E5*Q?57*8N W%Q=>-D78
M[#%VC$T@CR:W<5\,N>8L*W<(.(OBYPB+G([Y%[D7K)C"O+N([)=L*5>D!)-8
M=EY%Q:W&TVS:19N\9+K1S;IQK@8[<ZD(^IC"6VQ90G ;K#TJ@NJE%E2FTXE)
M&,2^3LIL*#3(L(F&KZ#ZPB>F)9U+S#DJX4K0;CHF,K&=G&)0*#=G/.!-KA85
MAHY+JXE3K:<X@8V:55_>S<6VK@J%#!0L<AVQ0"IA2G!1UV\C8-ZXH<-6@GN
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M)9930PI1-5;8LN@MJU'48 I?W0<5WCK'I#[W=G^;W*^D7W@*EM!53D$2<\M
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ML7'9AP65.NG5L$=D.!<M-ZWF?*](:X"YB9F9H \"H2D\NN$,LH#;2!92A(N
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M'<GSBBXXVFTE:L;L08GI23?6IQYQ2--1H@6L>*&'')U3V<TN&2%;0:PAP8*
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M0UFCG!J/-%XI%Z0>6.#3DC%0CAF.^>J.^>J.^>J+U*C@UY8H(M/*S:>/$P$
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M+*DE1)U")V:."4_UB9>.*E6?[Z=ZPQ-.O-MM+M]I-+7% *,G-O+'E3';/?=
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MW;E(IY0PCCWH,8&"H[C[&%M-!RPIMP65I-"#N-L-"JUGHA#:>"@!(B^*[I$
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MCS4W\NOQ#LF:*K)4$)0@54M1U 070@!:P*JI>>Y(]'KW =NXKDW+XJ-[=O#
MWY9F EQQJZTVK3;B4E)69+R'5H"AYR5&E"-L9.;9<S3JVVDH<\TVS0PA_+.5
MG9\(_)W^\F E";*1< -42N3Y)A#T\_2BG,!4T$2"LK+EBHV\V)>NCP:U]49)
M"KQI>\0A*4)2EMU%D)\FXQD@#@VF[7)95"00C,=A7VL+=/\ E$[3_&^$90*.
M%1->2T*PQ8I:MKSG+7JI&5S+T[&H[2F%,X*1E&MQ.<IZHR,#>-+WIAM"$H2E
MMY%@)\FXQD>SP:MVN2RJ&&&)K)GX/>E[ 20JU9IZ.,97E)IQMQPI<7VHF@%D
M;>2'G@@!U;Y"EZR !3=KN&NN* 12%>+KF% J2TXTL@<24PU)2<JYP[6U1Z([
M&7WP%)53:55CLF:F5I0.UM)1Q1D](P#9$3?^7/NB?]/[L+EU/%J5;[8NFN'9
M5I2EI2L&JL>%#LRCOB2H)Y2JD.SDZXXHJ64BBO68GRPZ7=*TW;'!K1,.O98F
M2J96K E73=#DG+/%V3=M6:ZZ7@Q,2S3N94\L(*^*R*PW-2SCBJ*"5V_?#&4)
MA:^R95M0!!X5]+^B#-O+=#C3U E!%#2AV0SDE"[#*2E--53?6'9B54YG61:-
MHUM",H)=5;6RA:*G&E+H67WUHE6+@E&-3#,LDE26DA-3KWC4DDW)TU\NJ'9U
M8O5H(Y-?B DF>&KAG8(2A. W@9;-&R:*<^$- 7"_W07RBV4H!"!Y2^.#,+8)
MMZW-$4@)<[&;:\QE)KN-RB3AIK^$ BXB\0TZ/+2%=T3R_G(EP8*N.Y9UF*"\
MC&PFL=[<5ZH2 $HM7!(QC245>J+D@0H<\!1%H;1C%;E"+C2*I%U(Q(B\ Q>C
MUQ@8P/1&"HT45BKG[,5_LQ?CB?'6/2'WMZW,L&BT>OBA-' R_K9<-_-MCMC#
M3GI(!@T"&4#'4(<DI!>=6L65O)P XMZ_S>Y6^F)=JF<<306H;1YJ0-Y?%.^,
M^8=7)!+2]7.F,U9#:V[B@>\;M2: 0^\,%*NY(#+8JI7J@-HYU;=Y96*B*5K#
MI\HBR.4PTTI6;4E(%ES1/KBI4 -M8R\X\L!A]QM;2DFU:T;\(I)2CCQ\XBB8
M3-SSF=?'!0."C?R$Q(S"Y=WLG%.O1..V$LY98S2O_P Y8%4\Z>J$ORCZ)AD^
M6VJHW[4LM]M,P[4H:*M)7((3E6:?7,YE-):75P&3K5QGN:/1W*12*G7OJQ1.
M,45T[P[E2: :XLVE'ZP%T!:%!23K&YAN+GI?*#LD^YPJ"OQ$"<>F%SLT."M8
MH!QQ*935,EM3%C0LUK956,(OOAA],PN3FV11+J16Z J;RO,S,U6]YP5T=E*Q
M*.JF"QF*W!-:X=4=BJ=+(M!5H"L(R0]5UD-A%O \L /3[LQ*@VNQZ61SWP\R
M'E/YQ=JI32D+9<2%MK%E23K$."4RJ_*L+Q;LUNZ1"FY>JEKO<=7BJ%3[$\N1
M>7PJ(M7[1>*1DIM4ZXCL%%BT4U*\.J.PU.EC3"[8%<(;R/,=O82V&R<">.%-
MR?RAFY:6)[TD'X*'NAW(XF'%)<0M)>7>JJM<&32\7Q;*[133<Y=\KQ=((J"^
MS<>1,=K0E'HBD3'I)_BAKTU>^)*8 J@6D$[-GQCL*7E75S3C5A>Q-UYB?]/[
ML3WH)]\3'I)_BAUAL5<)4I(VT56')2<0X*+*DE(]491##!;HJC85BJE#"Y?*
MLFG/!5SBFK7,8S63I,(=2@JSP:"8>F4(SI:<"K.W1AJ5E6W!504NV/5"Y4I.
M?S*EE.O;2')5]+A4XZ"DH&VZ&LIA%II2DK'-B(<EI5+A=>%DVA2R(RAGDV''
MD+<LG$"ET3?Z7X;QQY9HA";1BN+K[D-,-\%M-GN=MU80([1+.O#;';I1QL1V
MM=_FG&,VWIS"L$[(*UFTZN]1W:FX18;T6=:O.BQ2@@.NJLH0"2>:%S;Z?QA=
MX2KR$ZHLJX/NBI-!M@MRO;G?.\D=<+4_:SIO-K&!$L>*GK[I:V7PE>T5_.,I
M.$7FR?.U&*(-2<5[("4B@&XISR4W)W5<D(Y(KP5;1%X#G&+C&-E6Q5T81P1'
M!C@QP8X,7"/.Y(J<?=X\QZ0^]O9HS*G!FK- @TQKU1,2K)46T4I:QO2#\8HW
M,NH&Q*R([:ZMWTU5WS_-[E;Y^9;2%+;%:*PQA*MHKO@XTJRH0DN'L>83@OR3
M&("]8K%7' GE@LLZ+1Q.M477F+^_*X1^&_3V,L(89-<X16JHL98>>4R> M)T
M("TH*T'"CAH8RI(-2"&S(%L9TWV[2:PXU)_)WLZ632R_V:ANU=YIAMV<E.P9
ME5;4OG Y9O\ .$>"/_\ DFNJ''9.4[.F4TLR^<#=J_SC#;4Y\G>P995;4QV<
MARS=YHAG\'9(_"MJMO\ &4LV,*8XZ^B'OPCDC\%6:6/QE+UO&N&&KIAQJ3^3
MO9TLFEF8[.0W:N\TQDQV<E.P9E4R;4OG Y9N5Y0W,_(S*Y9SZIN/*-<6LI9,
M,NBFC-#1#GV3?S[QV5>EYQ;S9IHM@)/.3'9$C,"7<>:N6DI<S*Z?"#,FW.Y0
M7PYV9-IP\FSNB/1[F=P0=W7!*:WJ /)N/C%*2*;F.[=%>Y[>Y#=*6U66^+7%
M4K(/+!M=\3C"O%^R%2S*G_\ %+8M=.X6WFT.MG%*Q40&V6T--CR4)H(+;B$N
M(.*5"H,*S$JRU:N-E %8*&&&V4G%+: D&%=CRS3%K'-H":P6WFT.MG%*Q40&
MV6T--CR4)H(SCTFPZOSE(%8"&T!"!@E(H!%M^49=7YRD"L4EV&V!_P"--(M9
MM5G.5K358C.MR;"'<;0;%=S/]AL9VM;>;%:[8*'4)<0<4J%1&<:DF$+\X-BZ
M%(6D+0JXI4*@P4R[+;"3>0VD)WC<HDZ3NDKT1_?JAR<4-%K11R_W[^YJ<5P4
MBL*FI@%2*T0WMBF?;:^J%TI%4KSJ>(VH3V.C,N"]2DFZ*\-PXJ.Z5*- (J=%
MC4GSMU#&,DTJJSYYV15Z:2P^G"S>KH@IEFR^*TMK%T)[/F2&_P#"1_=("]"U
MM-ZX=?0DI2O48)V F)4?5KZ^Z!'E&\PGE/O_ #DO6.G=-.$JX0$Q91>1B8X?
MJBS=?O+Q6+JIY#'?5\YCOOJCO@_8$=\'[ COAYKHOJKTC7Z 8](?>WN4>5'W
MHF)MEV72VY9H%J-;D@;([_*_M*_XQW^5_:5_QCO\K^TK_C"VU<)!LG>/\WN5
MOIY/_B)Z+XE7!Y323ZNX7&D7JK&,,UVUW;R(N6#R&*N+2@?6,699M<RK:+D]
M,5FW*-_X+>'/ 2D!*1J$%"TA23J,%;57I$\)O6B,IY20^'D916AQ( I9H*4[
MC(_YG[IA+F:[#E#^6?%*\@UPES-=F38_+/BM.0:M[9<0E:=BA6"W*L-RS9-J
MRTBR*PW+93EOPK*.KL(GI-%%)KYZ/CW1/H]S/'ON.%M.)M(6*$15,ZM+7FE%
M3TPEAD42-N)WH$U-M2ZE<$.+H8L2T[+S"_-;=!.Y<(H=UQ]Y>;:;%I2M@C/R
M;N>;M62JA%_/N8;R[<X,<&.#ZXX,8;E#N. 8V3NN'59A?+]'U-PAUX7@FR@<
M6J&6/* JKEU]SL^>JD,2K-VAI&.^^J [+N6B-6%8F'*6;3D'=I^01_N.[V%)
MZ2E7*4/="&%S?8[>QN*S#R9AT:E*M>H1V/*RY*=24B@C0(8;&-,>N+3ZU/KX
M[A$NMIM+81H40*",V!VQTA"1"&TIJE"0FXQP3T=RJJ]S4F%NK,+0NY:%F[\X
MRA!LMC$QBJ+3*Z_5,:22#Q0%*-$)PK&B:J.%(I]&L>D/O;W*/*C[T.RBY9QQ
M3=-($:Q7XQ\S=_:$?,W?VA'S-W]H0Z\10N**J<N\?YO<K?$$5!U&#V.I*D(-
MC1U$:NY4A#B<1? %JPI6M=P$:;R7CQDKK%)3)P7QJ0$)@*F$IS&M$N*4@+;;
M2L;<8NW2=<*4X=!":J)V1+NS=TO/*4I&JQ?=W%HOLH>+2K:+::V3M[E*SU [
MD;O<TE*=-NN#G)"'&U!;:Q:2I.!'<D^CW/CBE(IN4W!N8;[)C#@M-.!E"D\1
M68DYO)I7+.*<I9MD\=1KC)<_,RYF'9E"+0"K-Y36L(R;+RBLPJT!-*7C05PI
M\8G))$JIDRM=,KK:OI#>0^Q5%2J=NM;4UPA,C,,**"UG"ZD\MU.;UQE9R8R<
M4,2[=2V7*YQ)KQ780],9-R8XTVMU3.;0X5%)*>'6!*.2LQ/9]](SUHG-UNA,
MFVPN?GC^1:U<\(DIZ0=R8\X:)SAJ*G"MPAE"FES,T]WMAO$QF'\AOM3)P:*[
MS_MAF9F4+SCPT&!PB8:3E3(\SDUEW@NKO]5!#,R6#,AU=@!*J:JP>QLGNS,L
M#9+Y58'-='X8M'L2Q;POV4Y:W1V2GY/S:LGU^<)-?A\=VL5.XIZ4(J<6S\(H
MMH-#SE*'PC-ITMJML+Y?H]3:3VQ_0')K_OC@.J':Y?3Y]7=&?2A:M>&Z^GCM
M#=##?"5B=@@)& BI@L2QT<%.;>2,ZW88*APG,8_',HN3"O\ ":@*S78C'UKU
M&,VTF@]\6Y912K9%B<8M'SDW&'&D/A-L4HY= "M,M@G<N61SQI46.,1I-4]&
M+EE,:+P,7+!YHU1>M YXO<M<21%&DV./7!=>581K4J 0FS+HX(VQ/#C2?5^<
M2SQ0A".$;X[[&D**&S7%X!Y1'!$5W:@T,7W*QCC[FD>/,>D/O;V=3,OH8*[%
MFV:5QB:>86'&E6:*&O1'<'^;W*W^5 44EG5AYM7&1I=P.Y6!%XK%P W<[+'-
MN:T^2J"VH9I\8MG=XD>^%R[][;P+936EJHPA$DVG-MMI"6_JTPA4N_=-,7*K
MK&WQ);3B0MM8LJ2K B&LDH*6G\SG$,)306!==J[DGT>XT[@.X9.;9<S3JT-)
M2YYIMF^&W\LY6=GPC\G?[R8D4I 2D/T 'HF,GH:;"$YA!H-I%\9;;5<HV[OU
MD,EM86 M*30Z[$9,:=2%MJ#04DZ](QE(##,*]T3_ "O?P")\:\\/=&5.R.^5
M>S==MK_C6,DI;^<T76F-*BS\8R,J3[;E)" <T>#PKOC$C/Y1E$2#,K0TK>JA
MK[XR384A&@BP7> %6SCQ80VQ.363"A*\X+-H&M/1XXR/+N*"W&E(;4H:R$4@
MH2VE*!*-JH!KN-8,BZHH2ZI8M#4;51ZX9:?S4YDLJHG9MH-8AI]' =0%BNP[
M@&^<Y?H]92:LMZ".N&TJ%'7--?=*^:H&./<5 <0=)-Q3KI 4DU!C:HX)VP5*
MO6K&"XZJRF,PPDALX)&*H"DA"%#6H@Q^-SJUCS$81VMH6O.-YW,*J,4M6!L3
MN86'$W&S#HEU65@*OYX[?+!T;:1I(<:/%>(T)E'V]&*@6A]4Q>DCFW;A%R#S
MQ5YY#?/%)=LON;3"5S:J5X+8@)$3ZN-(_.)?) /%N4WZ%TK2-&_<OC6(N4-S
M#=V1HX[8J-5\ CQUCTA][>S:IJT<W9"0E5,:QP'?WD<!W]Y' =_>1P'?WD/L
M@U#:RFO(=X_S>Y6_3,9K.-!Q(<-> DZXJ+P=>_PC",-^*Z+@X+B<1 ;G</)?
M&!Y=D5!J.**:]<2#:FUB3D&S,%13HJ<-R>C'<3.RJ+18';::QLA+S*JI/J\2
MR1/R(3V7)S%3:-*M'ACN2?1[J-X-S'?2F4S,J:5+V.UV:ULJKN,RZI@R^;<M
MV@FNJ&)<*M!I"45VT$+GI:>7(J<-I:4HK?KI>*1)3LO,.#L<7H4*YQ5]]>?U
M1*Y7,R4*8L]JLXT.V)F5*[ >046AJA4EG>R$J65$J33&$3,OE-UN72X%YBS>
M:&M+5?A G6IA<C.:W&Q6O'RPF>G9QW*4R@U27!0 [<3$M*SI$G+(0 J8UD8_
MTB35\G\KOS<PLWH2NUR88\D-(FZLS"!5+C?DG7RB P_\HYQV4%V8%0*?M$>J
M&)94P9<-+M!03:U4@Y*+I2G,I:SE-FOU0K(IFG"DJM9Y(H0;5H0U^$LN364)
M=LU#*J^\J,!"192D4 '<'.7Z.64FCKF@CKA%H59:TU]7=76_.3="DG5?NK4H
M"T!6U':[21RTBTO2<UJC123';7+#PX%+^F.$"Z<5G&*-H4X>(1<R&Q]<P3G&
MS]419P<V;8HK&+M,<6XOT8<79K2H4*Q><V?K1>$.<>,<&SR&*H=4GEC0FCSJ
M,=\"NB/Z(B]T#HCMDT:>D8TUJ7ZHT4BWL&,%UWA' ;!!6K@H%HP75<)Y97^<
M1&V*;+MPE)I'!Y]Y>:10&/JQ77M$7*"O2C30H<8OBY8Y[MS6(QC&,8JHT]*-
M#]H[BAXZQZ0^]O7.PWLUG*6M$&O3'SW_ .DCJCY[_P#21U1\]_\ I(ZH^>__
M $D=4%2C51-2=X_S>Y6_=8<%6W$E)AF6"U.!I-D*7CXB4J 4#J,6I)W-?^)5
MZ##K\^PILH%UF\+.H PR]8+><2%6#BGB@J. OA-KAJTE<L&=DTVF#WY@>\0E
MYI5I"O$9I]L!3C32EI"L"0(D9U20A;[25J2G '7W%/H]VIO])8!BB%@GNX$W
M+-3%,+::TC.2TBPTYYX3?T[^I-!QQ1"TJY#NWG>.<OT<JR:L-:"/B83:%'G=
M-?P'=@L7-NFO7%@W*&Y8_)B\F"B6E5S5G%0C0R60>,?TBY+<N-L(:4^7GEX@
M0*H"U:RJ*)  XMUQFMD5)^,69E&>:U.#$15A><^KY0C30#RP5)K?$Z$WT,7H
M(BH-#Q1<Z>>^/)/*(O;3'>?]T=Y_W1WG_=%S0Z8HDT]"+;FDJ*#&!)-'75Y8
MU<4!*11(N'YQG8OW[EF* *539%S1YX*;A39%Y)C@B#=>+XJH5&T15)Z(O%=R
M^ABX4Y(N=5SQWP?LQWP?LQ>ZKFNBM*G:=RVJY(@DXJO\=8](?>[L_P WN5W"
M7RK)!3C\IPV1^4;/"'+"' E2;0M46*$<OB4BZ^XI3,LO.=C^0M6HGD@KE7#+
M*V"])YH4B;8I_P"1N])@+;4%H.!&X9ED%4BX>VMCR#M$)<;5:0H5!\0=9)H'
M$E)(XXEI%I2EML)LA2\3W%/H^)XQ<=)5PC'<OX2<=]C&V,-V\1:4JB8I:IR]
MP)-P$&^C0X*8"D**5#6(JKOJ+E=>YAO'.7Z-+:#1]_1'$-9A*E"K+.FKX#NY
M;5S'88[$FNU3"+D+\X10D4VUCL&5-WY5V VV*)&XI:KDI%3#LTO5AO!(Y-(1
M:Q>5\(76\I0*GF&Y;9.97Q12::SZ//U], MK(/FKC*5V%CW;FDD*Y1'>Q'!]
M<>5TQY?3&*^F."3RF+FQSW[EHZ*/.5A&;E/M/GX0 G$XJV_G)0Q1VX^<,#%E
ML\JHH(*_-N'+'&<=TP..*C15M$7IM\8C$ [%1=7<U1@(P&Y>8_Q%<457JP3L
M\>8](?>[L_S>Y7<99UUBUDY1LO/IQ:.HTV0E:"%(4*A0U^(-9,D4*:1,@Y^=
MU-(U@?6,,RS-0TTD(34UW2Y)N&6<V#@'F@-3Z.QW-3GD*A2BI*V:7ZQ#@OLI
M>4 #J%T!!JZ^<&D8Q5.;DD=*HM)RE:5L4BZ'9>80&YIK$# C;W2:6DV5):40
M1R1DU]]Q3KRVJJ6LU)[BGT?%&W!@DT.ZZX<%&@[HVGR:1C#2R<1&$:]W7N/(
M3BI! @@W$;DRZ>"H@#F_[WR^7Z,4XLV4)%23!< -";#:.+5"&?RATG#Q^(67
M46N/6(L]F/YOS:Q8;30>_=2PGA.8\D(1KQ/+N540!QP[FU@E5$W'5#4R+RA5
M>7;#TT@U0Y2R>*D5)H-W@V3M3&4$RSM"DCGCM\JESC ZHTF7$<BH_+#F$=]4
M.5$?./\ 88^<#]E4?.1^PJ._$\B([6V\Z>B.U2Z&1M7>8MS+JGCLU10"@V"$
M_G,%IX0U;8HC'W10<!&\)5LN&\O%8NJGD,=\7'?3T1WW_;'??]L7NGHC2)5R
MF+KO'V/2'WN[/\WN5W%;3B0MM8HI*L"(1H+;DF:(T 5V:G&$NLK2XVL52M)J
M#W&\@1@:;S\%Y%2E<R@CLB9<%6V!LXSOK*DA0V&+38+"]K9I%EJ>F&P36B%4
MA3S<Q;6K'.HK7GCMS=D>>C2$5%XABSY;>ET]T6'*9NFE:PI#29,-B5 [7F>#
M3B[B/1\44A8M)5<08)EGDV?-<U1^,/)L[&]<)2A-E(P'<,=Y8<J-84,1 +LP
MIQ'FA-("4B@%P'<%/L+#3QX0/!,#LE] ;_\ '4DPAEI-AM H!OE?1GX/95<.
M^D>Z.SW4Z*;F@=NWQ&BGT\U\4#Z>>Z+MRIPA;Y[VC#X;@88O=UGS8O)6KSC"
MVE7!6N%-N)LF'$JX"5Z,%M3@1D]@]M63<XKS8#C5Z#A=3<6ZNY*!4PMQRX3)
M(/$2;MR\5B]I'[,=Y1T1WI,=Z3'>DQ<T@?9WJ?SGL)X:HINVE<PB@^BV/2'W
MN[/_ &?<KN12H!23<0=<3)E%.(8>->Q[6@@Z[,/RK+WXRPHI6RO15=KILW]X
MKRQ<D#DW7)J:<#3",5&%.B1,MDNSVMQ^YQP[0G9"BE(25&IH,>YW70O_ ,3/
M5U]TFP!4EI5 .2,EMNH4VXEJ]*Q0CN(]'Q>THV4B.T)LI\XQ?,'FBN?5&F X
M(\U6P[^FY3NN&ZKZ+H@UF7. -G'%BIL<)USBA#;:;*$B@ [N5*-$B\F"VUH2
MX_N^--Q3AXHT7%H/'%M*LZQZHJI>;.Q0@H8<"U+N--0A-"%*5>:0IPXZAQP7
M%WN.7G=2H\-*KC#4C)A1<5PU)%]^H0%&3:)'!,R;D\T'LDM6M6:!IZ]Q$JDW
MKTE<G]^Z!#+OGH"NZ)_.:RD6E1:5>H[MI7_477)BX5[JGQYCTA][NS_-[E1L
M.T1?VQ&V*I-1W%"YALI?1P'VC8<3SQG9:27/J! +;:@#3;?C"V&P\Q-H%I<O
M,-E*TC?K2AQ*U(X02:TAV4R;D],NA)H9Z;.C]E(QAMJ9*9A=D!:K- H[:=RK
MS'>92?U5"!W1QU7!0DJ-(8G6+69>3:3;%#W&HX8\6TC?LBTYHMC!.]K@8S3W
M3W'#NIW%_11>=O."4:U&*]\?=-PV0&47K-ZU^<?$$,IX3I@-UHE/"(\HQ\W4
M>5<!&DPLX5O$%!%1K28K84CT3&+@BVP]?T&$]DG11O&Y-G2*>%3;"6F:)5];
M$Q8<N4-9W#;7;<_PTXPMYRY2M6P0GEB5KYG<Z0Z-5:C\Y+XN:)$<9OW:G&+
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M;*1WEDZN/NK[P%2V@J /$(DIYU*4./HM%*,!W.[@'#Q)2]@K!6KA*[BE8PK
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MYSD1\VMCZB@8L&4?!.K-F^/F,S^Z5'S&9_=*CYE,<[9CYD]^S'S-?/2/FO\
MO3UQWI">58C2=83]H]4:4V@<B:QISJCR-T^,:2WG.50ZH^:A7I*)C0E&4_JQ
M% *#Z)2AKOKEPC./JSB]F\(2;+0N4L:^(0$(%E(C,I[VCA<9A+#*P'"+"S7
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M8I&@I#GHJB]!WER#T159#8XS'#,POS419IV*QYHX1BR@4$5XXF6/\-TTY/\
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M5@,-S,MFB!PC%$QF$$V/+4GW0$2LK80+@50.RIDV?,1'D6QMTE19E)=2U;3
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M_*%+6JVE7$!2X\?'_P"L=(W?_P"E/__$ "\0 0 " 0,"! 8# 0$! 0$!  $
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MV0KOX]!%DVH>=^&3*@H%A"Q*'&B4P42BIJ1FNJ@X8)YM,QBR%?9C!+'^2ZH
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M- 5W/(OI'<[3[T)]7K/&+2!N>1[H'@"$310V8C75KDC;R<?W*=Q"4V%-AJL
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M+V09S4G)]AF3^G_X]O\ EW)K5L;9P=?IXWL#J+W_ &^(AWWJ1=:_HQ (ECM
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M-G3 /.+.@(-=<V\I[8SHH^D4LS?A6FGX2JMR-2(70Z"*8J <6KL-AC _1N5
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MB8D9F>@U'9\!'TT!N3W K>A/0C?D56]$Z\_27T>D;P-RN0IV%,O#?$1/\\-
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M'@\_A5+6J9X@P".$8#,>@4'P;H0HT?"4PH%9X%5,&OE%+&+7"V[.+U=WL?\
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M]WJ_TS:EM0:W^KA.1V"03"%H@HK-K F% T V_P#N5R22RU,V(N"UOH)I]*'
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M3E% &@Z#0=^L9,T?BBWJZP M@@X&C'?U1YFDU(K2*W=;@],2@[UIM?.7K_\
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MPL_J^/\ \X6?U?'_ (.SG%6%"\%ZN-)2/H**PP =33_[]0G6G6@'_E_J^/\
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M8O$N8IUP_BDYJ;XM^XGZQ1]\QAJE\W/M<P]2GUH]@FHXFWY1-=<!08/=V_\
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M]' E(CUES$0ED#31N=XI]B-Y_MQ^(Q/A[)\G9^([DW@"G]:F 0;HPULH>>/
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M^'G#UO924B!UY?@'=X'KB>;B[R0H6TW?5CM]\([YWSNG=.Z%T:]6G"O$[H3
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MK4>M7YGL1[C]I<;S/M1VT4>TN7%BQ8Q8MHE 9N.":^='MB$-7$ ;0 \??0Y
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M>45AMJ#TS*K8!Q9KHB>LRY>4YL/ELX_NUGL,?BUN#L3!\@4S4@\C L]B<-!
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M 0/1/V.G::X"%ECW"R+@P9[-/E!OQ?ZNLU>3X/7>\R[)95FL%JM<EJLM;2R
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M(4G*)N^WK%5#"=#>DT@P6T&"-"9HO2;\,!5W>.<?$B^!CX.-Q2G"SM=^4&
MJO,?-ME9F7F&L6EU&N?O"72*E$+ET5D 9>:E:U^54;78Z(^-NH&\T2?,N#ZO
M:&N3(Y?PS9<56STWSIZ37XM-1XY]8G2+^*]KAREZ/\G04C'M_,52K:[QB2V=
M![N(>#& H)T2?HQ]I^[6,TH]')L1>+6V$^V+;<O/XNA7M8^TSW*^WV\3LAI4
M299?*?F)FN@..L DM9$^"QL/1?[E_P"5</+\2T9#.U[D]U /XAD29$;'XR^F
MDY74](OH."'FX@2@D5V!;[>TQUOE<W&QF-XKQ1N/^S0-C73T^_,NS\(XTUZ
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M-=33XN+*0^@?>:_=_$!4F=F.=A""ZNCG$04M*+Z/4=S^HZ0AS2Y']FAO1$,
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M5KEB7 .J!:9P,7,]P9/&H/64U"&PAYRV!>W/HTS0VY3'S  6-&9D,$P]?>=
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MT%.YCWEP2X_D+&+E_;$I+=M:\XXXY3I87Z/LRU&K1U8?99I@:G9-<=]C[_\
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M:&KMM[>%W:^-J)LC[ I?=[OD_P#B_J^/G32NH4;R;,?O>*VO+^XI^/\ N+_
M_F(V/-"=OS0K8\T)VO-"WY\_ZN?]7/\ JY_U<_ZN?]7/^KG_ %<_ZN?]7/\
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MX\*:<^%32G[$17VE_&O7_P 4_5\?^ LAW[F"O3%Z&\K7\RI[-$BU'5ZSNO\
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M-61=R?QF"P$X)7T\-I(;/U'Q'(%J4$>KHT1^C\S*512U^455 ($T+<1D#'V
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M^D'VG[4M/M-#_B7 % Z%:P.<)_CS_P >?^//_'G_ (\_\>?^//\ QY_X\_\
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M?OOWG[[]XZ"BRRN<> 0"6% <S]]^\_??O$ 982O&OB@#*"1XUG[[]Y^^_>!
M)86)SX&DHHLKG,_??O/WW[QD#-AB^,>!)&:#%\9G[[]Y^^_>.@HLLKG'@$ E
MA0',_??O/WW[Q &6$KQKXH R@D>-9^^_>?OOW@0"6%B<^!I**+*YS/WW[S]]
M^\9 S88OC'@21F@Q?&9^^_>?OOWCH*++*YQX! )84!S/WW[S]]^\0!EA*\:^
M* ,H)'C6?OOWG[[]X$ EA8G/@:2BBRN<S]]^\_??O&0,V&+XQX$D9H,7QF?O
MOWG[[]XZ"BRRN<> 0"6% <S]]^\_??O$ 982O&OB@#*"1XUG[[]Y^^_>! )8
M6)SX&DHHLKG,_??O/WW[QD#-AB^,>!)&:#%\9G[[]Y^^_>.@HLLKG'@$ EA0
M',_??O/WW[Q &6$KQKXH R@D>-9^^_>?OOW@0"6%B<^!I**+*YS/WW[S]]^\
M9 S88OC'@21F@Q?&9^^_>?OOWCH*++*YQX! )84!S/WW[S]]^\0!EA*\:^*
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M0&P.JX>-VZ/BQ;=+3*.]ATCJ0$ITM<"^=L:4J"#^%K*_S/K1:$.:CMTE7%'
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M]:FMY45TNW/*^ &@#A@!04<'CU/8R\?H 9@V:41@;^Q+M-H:TFWZ_"10O1<
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M-G3Q\DW=,@Y9I$F-UB[-GRH'19V6:C?X$W>)CV/J^!,N;&O2.J]9TWUG3?6
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M/1$&@FC_ #/W/'_?J&@EAIPS<O/C:ST?)(RA7;>'(&7P[#S_ .+F_@ZG_!<
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MZ<O+\1BXT *O.4QGU)[)*<I=47IYB.UZ4_?_ '/W_P!P&_Z^<W*[5.;^JX9
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M^W=,7)8>DI4VU>-D:L^MCXXQ3F8,$J>4M<%*Z(<T+V/Q-<"6H?OF LP:Z]H
MW[T4-GH\6\1%1;!@)U!89. X_N,YJDMP7M*MI1[XW T>AAM%<F)0?<)HH>3$
M M-\#\HL;9P/,0-5:O@M.D+X.GT8!;EL?\@9HE4P><',>@GU04@FB?+->=E0
M',1]L)?+IP?IJ:5Z/X>J%S:EH#X;WT5OG7VE2ZLM*,7ZS0>RG( [U$KBTO\
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M\2SWKR^.JJU:U59PTOK! 9?/;(8PZ^EF*2]VNX]Y7-M!\ 4O\@_@F8H &KG
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MTR+YU!9]XW^J7JQDE17K)8-+K6'[[KOFPD:O27T7K-!@SU4KT)C*@"4G&_@
M85: X9E.Q++7>KBB";:0JJSYQ6L84TY-QJ7C+ADIE;Z$(X>HB_9''\)9V,=H
M@ 3(6W41E7:S["Z.@T0@L+L.$$%A=AP@UVFWK)HD=/X$R^GU@_I%J5NH[!!3
M9HMM1]6"%IA.A7PYGC.7@.JXC052MM@="4\Z%\]^0I+'EC^OK*.CQ8TA7MND
MRM"Q6\]B@ED1Y5:$]MB73].G,PT]O0=;5<SD%7*X-@G15Z3$"-(R>T2+-Y]P
M^\36N%M_,QEX:FB=R:<,!P-J\A.I;(HJ%=_^]Y[.1]LQ4'3VDT>/$0KOS=/
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MP3O9,(JZX0,S2:0C+W^1M [,LW[8/*-E?8Y:?%H8^)<QR&H+Q+4\9J:2R*.
M_P!D+YCM+$?U(-EF3PMZ8TK]9]M8LEW Z'!T\1/<=;*+C :FDCEE5T>5B9T
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M0=&OW6+&HH<LH/$4:!4U+UTL&M'CY"*@MX)B<WE=6->%95W>()% 5M>?JO\
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M&G1_T00M,N8#EK']9B#:5":D-HE[3IN7\7;:SU09N.D>YA$EW+%*E\I7]?\
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M.&!N@BBD*?$(C];-P'AQ \#_ +B$3,6*PREU:ER[Q_I7C"@[O!U\%FE56O\
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M-[]!$'$7=>1^9N$0S)Y:$17?[HNV?H.]?_))^YX_[]2IOC):@CZH3Y"W1_\
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M2222222222222222222222222222222222222222221?_P DDDD@$@ D@$
MD $ @D$@@D@ DD@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD/_P#P9)))))))
M!))()))))))))))))!))))))))))))))))))))))))))))))))"O_P":2222
M222222222222222222222222222222222222222222222222229__P DDDDD
M$ $@@@$D$D$ D$ D $$DD$ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDC]O\
MY)))))))))))))))))))))))))))))))))))))))))))))))))))))))))*B
MN>I)(!)())))(!)))))())!)))))))))))) ))))))))))))))))))))(P/_
M "2222222222222222222222222222222222222222222222222222222222
M22R3_P"D@$ DDDDDDDDDDDDDDD$DDDD@DDDDDD@D@DDDDDDDDDDDDDDDDDDD
MDDDDD@DG]DD@$$@D$$    @  @@$@DDD$ DDD$D    @@DDDDDDDDDDDDDDD
MDDD@D_\ ))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))!^I) !())!! ! ))))) !!!!)!) !) !  !)() (!!))))))))
M))))))))))))/>I)()(!)! (! )! ((( !!!)! ((!( (( (  !)))))))))
M))))))))))/_ "2220222222222220222220220 2022220222222"220222
M0"2222222222222*]F22 "22"""0" ""0 020"0" 2 "2   2 2020"0"222
M2222222222222222/??F222" 222 22 2"0""2"""222"002202"20 02222
M2222222222222223_P DDDD@D$D@D @$D$@$$ $$$DD$D $$@D$ D@$ $$ D
M@$D @ $DDDDDDDDDDDDDDXTDD  @DD@$ DD $$ $D @ DD$$@D@@ @$DD$DD
M  DDDDDDDDDDDDDDDDDDDA__  ))))))))))))))))))))!!)))))())))))
M))))))))))))))))))))))/_ "222022000"2"" 00"02022202220 0"""2
M00""" 020""2""2222222222223/^222""""0"02"22022022""022 22""2
M 0" 00 "2"2222222222222222221J;J2222222222222222222222222222
M2222222222222222222222222223_P DDDD@ DD $D$ @@@@@D@D$@@@$ $$
M $$@ DD D@$$$$ D @ DDDDDDDDDDDDD/(DDDDD@$DDDD@DDDDD@DDD$DDDD
MDD$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDA_,DDDDDDDDDDDDDDDDDD@$D$
MDD@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD_\ ))))))))))))))))))))))))
M)))))))))))))(()))))))))))))))))))))#._)))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))/))/\ 2220 " 00200 "
M0 """" "00"2 0222222222222222222222222"S]4222222222222222222
M222222222222222222222222222222222222222222?HDV22222222222222
M2022022222" 22202222222222222222222222222222QC?I22  022220""
M"2"000"20"0"22" 20222222222222222222222222'_ /\ _)))()))()))
M))))))))))))))))))))))))))))))))))))))))))))))))-_\ _N22
M00 0"0"0"22000""0222"222""2"2"0 "" " 00"222222222220_P#_ *Y)
M(((((  !  )( !)!) )(!!(! ) !!))))))))))))))))))))))))$DDC)))
M!  !)())))))))))))))))))))))))))))))))))))))))))))))))))-))(
MY)( )( ((!( !(! !)())((())!  ! ))((!)(!))(   )))))))))))))(Y
M'W))))())!))()!)!())( )!)()))())))))))))))))))))))))))))))))
M)))))(((!())))))))))))))))))))))))))))))))))))))))))))))))))
M)))))!   )()( )!!!) !) !! ()!( (!)))) ) (((( !! (())))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))(( )() ))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))()))(!))))))))))))))!!)))))))
M)))))))))))))!))!))))))())))))))))))))))))))))))))))))))))))
M))))))))))))))()))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))(!( ((!((! !())  ()) !(()  !()!(! !)))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))())))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))) !))(()!)!()!((()))) ((!)!)(!!!)))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))) )! ( !!))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))!)!(! () (  (((!!! ( !))!  ()!(!!))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))())! )!!))))))))))))))))))))))))))
M))))))))))))))))))))))))))))) !!) ()! ()((()!)!)! !(!( !(!!)
M !))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))()!)! (()))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))!)))))))))))())))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))!))))! !)))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))!!)))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))) )))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))))! ) !!!))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))())))!!)))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))(()!!(()
M))))))))))))))))))))))))))))))))))))))))))!)))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))!))!))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))!)))))))))))
M)))))))))))))))))))))))))))))))))))!))!)))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))-MMMMMMM))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))-MMMMMMM))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))-MMMMMMM))
M)))))))))))))))))))))))())))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))(%(A))))))))))))))))))))-MMMMM
MMM)))))))))))))))))))))))))!))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))#Y))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))(!?D!P7A)))))))))))))))))))-M
MMMMMMM)))))))))))))))))))))))) )))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))-Y))))))))))))))))))))
M))))))))))))))))))))))))))))))))))"V8/M/XL89))))))))))))))))
M))-MMMMMMM))))))))))))))))))))))))!)))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))(        &    )))))))))))))
M)))))))))))))))))))))))))))))))))))))$NJ+>VR.U)3))))))))))))
M))))))-MMMMMMM))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))))))))))))))))))))))))))-F( )))))))))))))
M)))))))))))))))))))))))))))))))))))))) K9._.W,S)6QSWXY(A))))
M))))))))))-MMMMMMM))))))))))))))))))))))))!)))))))))))))(PO)
M)%$XI)))))))))))))))))))))))))))))))))))))))))!X/3%Y))))))))
M)))))))))))))))))))))))))))))))))))))))))%0@N<0DDYJ<.'^XNI=/
M!)))))))))))))-MMMMMMM)))))))))))))))))))))))(!)))))))))))))
M))+X'S(@64HO)))))))))))))))))))))))))))))))))))))(.#A]LZ9)))
M))))))))))))))))))))))))))))))))))))))))))))&;[.+%=TEL:J-PW7
MPN8F^9))))))))))))-MMMMMMM)(#K_$G)))))))))))))))))))))))))))
M)))))###S%!3Z&;G)))))))))))))))))))))))))))))))))))))*"P@[08
MU)))))))))))))))))))))))))))))))))))))))))))))))I87/$V8KX63]
M+&\E19*/SU))))))))))))-MMMMMMM(TN8Y__%))))))))))))))))))))))
M)))))))))'$KDC(>>S1-))))))))))))))))))))))))))))))))))))+&=K
M9(C87))))))))))))_[)))))))))))))))))))))))))))))))()IQ!TD0RC
M):/2(!I<)I@FSR]-9)))))))))-MMMMMMM.B^8Y__P#^B222222222222222
M22222222222222223F222222222222222222222222222222222222222222
M21?@=B]AC5(22222222221QL22222222222222222222222222222220$;#3
MWN)?^-!/D9))9=:"E #$<KB222222223;;;;;;8R<OF.?_\ _P"U))))))))
M)))))())))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))!Z)4JT#TA)'))))))))))HZ+)))))))))))))))))))))))))))))
M))#:A0S/6LJ\20Q';&E%$DMSP%)JD+))))))))-MMMMMMEIR^8Y__P#_ /[<
M\DDDDDDDDDDD@DDDDDDDELDDDDDDDDDDDDDDDDCO))))))).HDDDDDDDDDDD
MDDDDDDDDDDDDD@7DBPS$J8%5DDDDDDDDDDEK<$DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDD@[E"LU2?]M2A#"29$Y&*=22MLBL3T@DDDDDDDDVVVVVVV6G+YCG__
M /\ _P#_ +)))))))))))())+_E@E7H9))))'XO870M:[BF>DDDDDDDDDDJ5
M==\_IX3)))))))))))))))(9))./D>?')'))))))))))))))))))))))))))
M))))))))))))))))-'# NW;<89_BLFPDDDB+_I98/(G8S,))))))))-MMMMM
MMEIR^8Y__P#_ /\ _P R22222222222221%!2BP]*22220CG^_:+M!3I3$@'
M$VVLDXT;;^^FLY4)\KVF2222222222222221"*QRW05&2222222222222222
M22222222222222222222222200_\7 8^IX!0I2E_)))))#8PV=:?<SSXB222
M2223;;;;;;9:<OF.?_\ _P#_ /\ DDDDDDDDDDDDDDDW4_++-BDDDDD>DDDD
MADDDDDDDDDDDDDDDDDDDDDDD3+Y?B^7FDDDDDDDDDDDDD#BX]G*_6DDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD^\3^^^=X_Y=I<6W\22 9:2K^+;
MTZ=,L9\DDDDDDVVVVVVV6G+YCG__ /\ _P#\$DDDDDDDDDDDDDDDDDDDDDDD
MDDD^DDDDADDDDDDDDDDDDDDDDDDDDDDDDDDDA%!"O\DDDDDDDDDDDC* PYOF
M?DDDDKDDDD$#B!D$\DDDDDDDDDDDDDDDDDDDDDDDDC,@.VC@/_"HA*RVZDL(
MF)7N"W9U6'L4=N>DDDDDDVVVVVVV6G+YCG__ /\ _J=R2222222222222222
M226R222220F22226222222222222222222222222222220S.E.2222222220
M5RG@I%I22223A?X@8LZ67+UYBR22222222222222222222221(!7,4T%K?".
M\9I)%M7,2S!*K[E)[ UY)9222223;;;;;;9:<OF.?_HYMX[222222222222"
M21;/HL\*R22220&2222622222222222222222222222222222221,JF22222
M222%J9I7(6I62220^#V7,8R:I?YT.22222222222222222222222UR"^3I#R
M[' X?A%#8QG)PE@@Q+A+2+YWQ0"22223;;;;;;9:<OF.?_DDDDD222222222
M222"21;IBXJPR22220:2222&22222222222222222222222222222222259^
M2222222"O*4D+$;"22228%X1);:<X\N+*22222222222222222222220?(2.
M2QJ1NL'P&#Q'3@K5/L^N$I)U*/?JR?R22223;;;;;;9:<OF.?]$DDDDR2222
M2222222"226I2WTDR22222*2220622222222222222222222222222222222
M2202R222220T#7O3_I/J2222222222222222222222222222222222222221
M3%*ORBL23UF(R IZ!ZICIH\_"E+X.B,S(XGR2223;;;;;;9:<OF.?^DDDDD2
M22222222222222222222222220Z222062222222222222222222222222222
M2222220SV222223%M+CZ7;+E222222302222222222222222222222222222
M2222K9>AEC"7PIV]*DEJ)>ZB((^I(4)*E")3"&3R2223;;;;;;9:<OF.?XDD
MDDER22222222222222&>22222#9HI#G2220* AQ=1#22222[9R]"22222222
M22222222222!=R22222 F\.MVB4O2222222;HO!]+V222222222222222222
M222222204HZLV(B?DF!)(S'H.*;_ .,A9;VR21=RQRAS(DDDDVVVVVVV6G+Y
MCG\)))))LDDDDDDDDDDDDDDD>8_LGL-P/1CRU4&)BA>F8F)6L0[2_>ZA0LDD
MDDDDDDDDDDDDDDDDD94DDDDBNI#@08<@:<DDD@DD-^Q\49_$DDDDDDDDDDDD
MDDDDDDDDDDDDB,FG9 2]+Q=22"PZXT^[;&?88*4Q229[.W/SIDDDDVVVVVVV
M6G+YCGY)))).4DDDDDDDDDDDDDDG< 4>$W=9@ ;\2R8.HGSF@T.X<@5;DA7J
MS4DDDDDDDDDDDDDDDDDDDAZDDDDGK2 ^1XI_!$DDD@DD.D3VXQX<DDDDDDDD
MDDDDDDDDDDDDDDDDG<UV2% 1?%T"6A4[V4%;;*;J%U,!2_.FS#;CZDDDDVVV
MVVVV6G+YCGV))))/LDDDDDDDDDDD@DDE 4GF%3/D+YZGP?BL,X^1"XOM)!BA
M6SI0 TDDDDDDDDDDDDDDDDDDDDODDDDBY7<S?2UL*,DDD$DDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDD&DDXEWP0J[7B1%KR"WJ#;=;:E?\ [6F:C\B^6FI)
M))-MMMMMMEIR^8YV222225)))))))))))())(XRAF"W]_8?(5]1P".Y*JL1$
MADHV_'X2=UO)))))))))))))))))))))7))))S917XRO*FG)))()))))))))
M)))))))))))))))))))))))))"9)/[X7ZS'-.HDN\OQ\FVW0VXC:7+B128R$
MGLI)))-MMMMMMEIR^8Y\222221)))))))))))()))%S\%#()072:1J6#$.2)
M%9.:/_*G,EGO,R%)))))))))))))))))))))Y)))(R;!<E0YZDA))())))))
M))))))))))))))))))))))))))))) ))!F19M/KV56$O%CTW0VV0VYML)Q)6
M5R,EOTI)))-MMMMMMEIR^4>2222228I)))))))))))))):9OM* 5J=87AN(]
M"AC048CG(4?TC:CPB"K)))))))))))))))))))))K9)))H)P\EDCC E)))))
M))))))))))))))))))))))))))))))))))PH&]&Q/?#W3F5^3ZRVM6VTVWJ/
MT@TE7J@6I^+)))-MMMMMMEIR^+!B22222;Y)))))))))))))(DU6+?@W^AWI
M F%I723-]Z3+MI=/DN:&8P%)))))))))))))))))))))#I)))/Q#H?\ D L
M220"22222222222222222222222222222222222=2"3#WK7XL+^I.];X-LQM
M^--M-?\ B92AR#,+_(DDDVVVVVVV6G+XCA))))))*DDDDDDDDDDDDDDB9A&=
ME39&2C1/4^<6'&YH=@$=MP31DGE$Y<DDDDDDDDDDDDDDDDDDDDDQDDDDGFWM
M7\YMK,DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD\D_]B"0>.+R2C*9
MG;;D+>[;;%9[LZ27Y6!_^HDDDVVTN(.V6G+_ )\R222222O)))))))))))))
M)V)5;,=\<PF.8:<Q/J%E'4'EG+WHL@<^%O?)))))))))))))))))))))!3))
M).Y_?=1_X_9)(!)))))))))))))))))))))))))))))))))))(')!\CXM?@-
M$4F])<VVW>VVV&\E_8XDF0*\(3K)))-MML7MMEIRRY!R2222221)))))))))
M)()))YM3!TP)Q8@[R&6A ^$GJ8<],S1A\!+_ !@B22222222222222222222
M22!2221 !AX*9=%*2222222222222222222222222222222222222226PNHI
M$"AH[SI3 D2.-MEAMLYL/M0HM2"_*G^Q2223;;:\4[9:<M.0$DDDDDD22222
M2222222"22#,W8QQQ4A\S"6*$<D2A!$?:A4-SHO49,3XR222222222222222
M222222*>220]S457$ ^*222222222222222222222222222222222222222(
MY1'.-9!HO05<+0X^MMLMU<EMLBO)7I#NX7K#R223;;0DG[9:<MN0$DDDDDER
M22!IR222222"22<N.1C#_P!MBX?UGP_^PWS%".<OTK0H:"MXO,DDDDDDDDDD
MDDDDDDDDDDDDKDDDC"F,1<(T7D@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDB^257_"0?M4C"2/ZUL;;WZ[NS <R:7:TU/ R=DDDDVVW3IVV G+;D!))
M))/N\DD@_P"!))))))))(SI4A]))))!1BL+Q+7Y) 6?RI.8PV))+^*S)))))
M)))))))))))))))))([)))QU@J0%\Q9())))))))))))))))))))))))))))
M))))))))))6&!".)\/Z5H#TA:CS^0WN2V17EZ@EV0DSP5@))))-MMV0YMM S
MRY 22223O8))/_\ _P DDDDDDDDDDDDDDDDDDDADD$DD$DDDD@A[9$DDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDFLDDD-2:@)^XQDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDD@2E R8CQO%[F)26>92M;:A;?88@V22E./#Y?(DDDDVVT
MU-VVTEWSD!)))))BCXD'_P#X&))))))))))))))))))(1))))'))))))))))
M))))))))))))))))))))))))))))))K9)))!K9JN!CY ))))))))))))))))
M))))))))))))))))))))))/ 8)TPU0\6X)4D*:3]%WNU'<P9GXD98$5W?VI)
M))-MM*V=MM),BY 222227)&//_\ _P#\DDDDDDDDDDDDDDDDDDCDDDDD<DDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD\DDDD&GHY6SXDDDDDDDDDDD
MDDDDDDDDDDDD    DDDDDDDDDDDDD2$_&R0RCX.@*R1HWVY]WZ0Y\B7;:5ZB
MI:CG]DDDDVVVS[VVTDD2D!-!)))$D@__ /\ _P#[DDDD@DDDDDDDDDDDDDCL
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD_9DDDDBG)9]ODDD
MDDDDDDDDDDDDDDDDD$$ @D$$ D $DDDDDDDDD!GD@H!ZO<KX-'2X6$Y]H;1<
MY3><20M_)1.TTDDDDVVSVYVVTDDAL!)?)))<DC__ /\ _P#\DDDD@DDDDDDD
MDDDDDDE$DDDA$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDE:DDDDA
MGDB#$$DDDDDDDDDDDDDDDDD  D@ @$$@ $  @DDDDDDDDE?L@GK^(^IPBQ2Q
MSK4[^29\53@[6WO7IDOG$DDDDVVU;)&VTDDE\!)+1? DDD?_ /\ _P#@DDDD
M@DDDDDDDDDDDDDG4DDDGLDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MD@ 4DDDEL$M!]TDDDDDDDDDDDDDDDD$@$$ D$@ @@  D$D$DDDDDD@!;G">B
M0[$?*OHJ6.MN5JBU9^"-2ZS]'F1%DDDDDVVVVFVVTDDB\!)C_#DDDD[_ /\
M_P#XDDDDDDDDDDDDDDDDDDD\DDDF\DDDDDDDADDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDGADDDD)-PDY\4DDDDDDDDDDDDDD@@ D@$$ $D DD @@DD$@DDDD
MDDZF=0,+1K_N82E*2KA8P2HQ5<72SH"9=QQTDDDDDVVTM&VVTDDD$!)CDDDD
MDDC_ /\ _P#<DDDDDDDDDDDDDDDDDDF<DDDFLDDDDDDDFA/L),(BDDDDDDDD
MDDDDDDDDDDDDDDDDDDLDDDD;/[X\7LDDDDDDDDDDDDD@   $D$@DDDDDD@@D
M$$D$ DDDDDB]$!B\FG^L,[:*27!C@0BVA)22/LW+Q:;,DDDDDVVV$>VVTDD@
MB@(DDDDDDD@G_P#_ -R222222222222222222"2222J222222229%)1JIX22
M22222222222222222222222203XR2,[R+0O(22222222222222""02022222
M2222220"00 02222225)[4#2C^\@I^X);@_>_>];)))./B3$Z8222223;;5H
M?;;2206:I;<22222221L#B22222"2222222222222.R#>1XU*222222?P.+B
M\_J222222222222222222222222203-"233MWEW82222222222220" 00 22
M22222222222200 ""2222223V"'N%M+G"I6!;Y7,I/:I)(V1Z5\A6*222223
M;;%[?[;2(=-/"@HT#R222222222222222222222222222*W2ASWS?OR22222
M22222222222222222222222222222222"0962-N48SWDR222222222200 02
M"2222222222222222 ""00222222?C/7BLXG,!)14]]Y=%]))":].1.0*622
M2223;;$9S[9X&##((@$DZ*Z222222222222"2222222222222;$'T2?0E(.^
M2222256!>22222222222222222222222222021)$2*O98HME22222222222
M 0  222222222222222222"0" "222222'_/I0<4MP1)6 9)7I))B##^EZR/
MX&222223;;"2_;;O&#>V7A<DDFAT22222222222"222222222220Q\1"22?2
MRN"S7R222<"_"22222222222222222222222222022:]2%\3?30J22222222
M2222"0222222222222222222222022"222222#+T+1%BGYP))>)(-*998"IT
MF?">8"222223;;=^/;;O&!6AO^$DDDD@2222222"220222222222222+7_$Z
M22?R3QR1QGR22'PC"2222222222222222222222222202226#ZCVRDOZ2222
M2222222 02222222222222222222222000022222220 21EL6H."0*LQTBTX
M0,X__N>+LB222223;;#['[;O&"B/U&-P(3^!" 0 0"2"222222222222223V
MR>O^21[23^R23*>22+13N222222222222/N2&222?R22 V2022 0Y[GH$GE&
M222222222 "0 22222222222222222222222200 "222222222)A5>J$.1'5
M8P>P%[SCX-5&Y2222223;;+':;;O&!2L[6X0DDDDH222222 202222220"22
M22!B(&)&23>20"&22/J220GR22222222222225$[:8G,=C"W)MBF22222M*Q
M*8@B222222220"""22 22222222"22222222"222200 02222222220U)Z.5
MAD2?8">->V3O[M>.L2222223;;(2G;;O$V+^HIMZ$DDDE>2222 222222220
M2 2222?HT+A>2 H20JSR20Y22>BK"2222222222213#='C_"+,O/L46B22"2
M2$ENC-6Z22222222"02022202"   00 "0" 0  022222200""2222222227
M("RF<D>I8M)4(#E'',QK>2222223;;;;;;;O)W10Y 7_ )))))(DDDDDDDDD
M@DDDD D$DAJ:;$YRE.W,,A0TLDAWXGD._)DDDDDDDDDDDD +]ZW2DHZP!P J
M&DD@DDD)O[7\8DDDDDDDD@$D@DD$    @D$@$@$@DD$@$ DDDDD@ @ DDDDD
MDDDDDD! E0NU!8/4Z:TEY'AS:8$DDDDDDVVVVVVV[]=QSDO6_*))))*LDDDD
MDDDD@DDDD@$DB.=J&D1>9IM54CD\\DZENEV99O,DDDDDDDDDDDDDDDDDDDDD
M@,DDDDDDDDD!%UZ\'DDDDDDDD@  DDD @D$@@$@ D @@$@ DD DDDDDD@$@D
MDDDDDDDDDDDDGFC+>))#"94$1/Q0 <DDDDDDDVVVVVVV[$=V_1U?_P#R2222
M5)))))))))!))))))"#YP9!*)',WB,A))))/Y(!TW?=7))))))))))))))))
M)))))))))))))))) 3Q3,[)))))))(( )))) ()! ( )!!!!!)) !(!)))))
M)))(())))))))))))(U)D8)>27\8LJ%/JM?9))))))-MMMMMMNM'=EV/_P#_
M +A))))\DDDDDDDD@DDDD<DW'D@/DDBDG=DFYTDDDDDDD90B&F7DDDDDDDDD
MDDDDDDDDDDDDDDDDDDD$DDD@(;7RVDDDDDDD$D$DDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDD$D$DDDDDDDDDDDDG34[1+LH%ZID>!O^N4DDDDDDDVVVVVVV^<=V
M1P/_ /\ ]$DDDEB222222222222* W)R3K""%221#?MG'S]M_B" KEI<WG^2
M2222222222222222222222222222228R%I1V222222"""2222222202222"2
M2222222222222222   "222222222229.<\8$Y5$BV4Q:@G"22222223;;;;
M;;;=QW9(J?\ _P#^B222>))))))))))))) <UP =( '$H(,CMELZPLML! /-
M_?@X$!))))))))))(Y)))?))(I)),))())))(R\'AUI)))))((!!)())))))
M! ()( (! (( !))))))))))( ()))))))))))(LQ@G, J4K<78O^^5))))))
M))-MMMMMMOW'=D8?_P#_ /\ R222=9)))))))())))MT<%1B888?A /6-EEV
M.MMDJ!)+83$HTK))))))))))(Y60,YFYLHR"'.BI))))(::CP;))))))(!))
M)!))))))!!((!!)!((!(!))))))))))(!()))))))))))(?P1K>DQ-?.-%Y2
M#9))))))))-MMMMMMOW'=EH5_P#_ /[))))(DDDDDDDD@DDDFWD!5,X$'2=J
MCVL\Z^"^JT2H#A7NZ7@6LDDDDDDDDDDF7Z2#YD!/1(7;4DDDDDDDJ)HKHDDD
MDD@$$DD!,$DDDDD   DDDD$ $$DDDDDDDDDDDDD   DDDDDDDDDDB&3LAL\B
M&:N9#TXDDDDDDDDDDVVVVVVV_<=V2!7_ /\ _P A)))*DDDDDDDDDDDDB.V*
M\;Y-E10H!G5* )>.&E6L$0 7Q_GNLDDDDDDDDDDGGW*_'\CX_P#O>V/Y))))
M)-PHJ/Y))))()))(#>8)))))) ) ((( !)(()))))))))))) ())))))))))
M)) .:T,R+)))))))))))))))))-MMMMMMOW'=D@3_P#_ /\ @3222)))))))
M)))))(AX'!6 E@XE'")<D1>H$,1>K!,N3:]M*K))))))))))))))))))))))
M)))))))))(4X[B!)))) (!) "N/,Q)))))))))))))))))))))))))))) )!
M)))))))))))K:*IDE)))))))))))))))))-MMMMMMOW'=DP1_P#_ /XA+)))
M$DDDDDDD@DDDFOXNU("6%@$'DE21M*<UK5VH&/010YQ*LDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDD9X1$V4DDDDDD$@)3BLJ2DDDDDDDDDDDDDDDDDDDDDDDD
MDDDDD DDDDDDDDDDDE)<ZJLTDDDDDDDDDDDDDDDDDVVVVVVV_<=V0!__ /\
M_P ]))),4DDDDDDDDDDBI0_*5 FW!@E_XH\G]B<R>$0* C E BN6LDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDCL[SM4DDD@$DDI%>G=]PV(DDDDDDDDDDDDDD
MDDDDDDDDDDDDDD DDDDDDDDDDDB)Z>NTDDDDDDDDDDDDDDDDDVVVVVVV_<=V
MZ!E?_P#^1KP23=))))))))))(0)MUM9)O(9),0!(5CTG,H&,I('X*MD^DK))
M)))))))(3)))!9+I)))))))))))))(6,8W3))))  )+?RG-J'AKE;YEGCJ7!
M))))))&?)))))))))( ))))))))))))(@N7-S)))))))))))))))))-MMMMM
MMDG'=U0:M_\ _G/TDDGR2222222"22<7Y);W0 "6 223&/9;9Q+2'$6 00QY
M9+*R2222222218H&'T%ST/B R3=J2222222,Q54OR220"02#U;Z%$FTN=W7C
M@E=!(_R222-9S4M2(R222222  222222222220./=;222222222222222223
M;;;;;;9-QW0@$0O_ /\ .UT223)))))))()))(L%H_\ &02*@2 1UG;;40)9
M+$>"2!-K))%2222222221&9^J<.PR92W[6\F2222222-5#9&2222 2220"VD
M?=#S[B,MFHM #1*222.41-O]]#R22222" 222222222223]%T>2222222222
M22222223;;;;;;;]QUX$$*/_ /F["Q)) DDDDDDDDDDDDJ-SP)3).D1NO8AO
MM6DQN<,D:S-$&-Q5$DDDDDDDDD@3*(F:L?N=K83X<DDDDDDDD:Y$$$DDD$ D
MDDD 6MF$"N:3#"H]7V)K<DD@@)H=S*H\DDDDD$@$DDDDDDDDDDD*DX2$DDDD
MDDDDDDDDDDDDDVVVVVVV^,8#L!,P?ZJ[E))),DDDDDDDDDDD@8X-DC4\>@;.
M=DC0G: S+&$DIB?DU;G$DDDDDDDDDDDDDD!DDDDDDDDG$DDDDDDDX+'*RX@D
M@@@DDDDDRKO[7(9=J-]G^(!D4D'D4+DDDDDDDDDDD@@ DDDDDDDDDDE,79OT
MDDDDDDDDDDDDDDDDDVVVVVVVZ!?+D!)) Y7[\4))FDDDDDDD@DDDG"J7\E][
M?AA4O\B!!)]1OJLCZVL<4^3JDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@RE:0
MND@D@$DDDDDD=4S74V<\QS&8(#9+I)GDDDDDDDDDDDDDD@D@DDDDDDDDDD@S
M!V&LDDDDDDDDDDDDDDDDDVVVVVVV^NHSD!))),7[M%)),DDDDDDDDDDDG;#,
M\GFCBCOF\\GAE=D*P,4CE<Z\K8^"DDDDDDDDDDDDGJN''F7$UP4DDDDDDDD(
MK72B]X  $$@DDDDDEX>(%WEU7"8$G8,?DDDC$DDDFDDDDDDDDD@@DDDDDDDD
MDDC02U0LDDDDDDDDDDDDDDDDDVVVVVVVKQ@SD!)))-H7+B))/DDDDDDDDDDD
MDCDTDFGFDD$DDD@DD$DDDD$DFDTD@TD DDDDDDDDDDDDD\3PQ#C-./TDDDA7
M=-!LF[DA>X  $ @DDDDD@Y#ZPW.SD0EUM-VYDDDANZP*V.'KDDDDDDDD$DDD
MDDDDDD@_1TN$DDDDDDDDDDDDDDDDDVVVVVVV;Q@SD!))))*4XF))*DDDDDDD
M@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD4NB/<3:9'LD
MDDE\EYIDF;DEZX  DD$DDDDDG!D\YC_3U.B.JQE0DDDGHJ?U,!T]DDDDDD@
M$DDDDDDDDDD-()2\DDDDDDDDDDDDDDDDDVVVVVVV[Q@SD!))))))TC))/DDD
MDDDD@DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDE^=E#@30
M56,DDDF $DDDB?@%ZX  $D$DDDDDC_FK9JZ9A+8!UC7DDDDGQ\:D#P=^DDDD
MDDD@$DDDDDDDDDG(&"2DDDDDDDDDDDDDDDDDDVVVVVVV[Q@SD!))))))DFA)
M/4DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDE@$DDDB_@%ZX  D $DDDDDCO'!64;>YL9QC'0DDDDDDDDDDDDD
MDDDDDD$$$DDDDDDDDDC,>Z'DDDDDDDDDDDDDDDDDDVVVVVVV[Q@SD!))))))
M$C))*4DDDDDDDDDDDDDDDDDDDDD$D$D<DP<DDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDA DDDD+_DAZX  D$$DDDDDB1;-QG*S%&3*?CDDDDDDDDDD
MDDDDDDDDDDD$$DDDDDDDDDD)EDJDDDDDDDDDDDDDDDDDDVVVVVVV+B]'(3;;
M;;;;LDK;;$DDDDDDD$DDDDDDDDDDDDD2]GZLZ%,=*$DDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDE@ @--BZ E>8D@ @DDDDDD&885'NZ_\DDC50DFDDDD
MDDDDDDDDDDDDDD@D@DDDDDDDDDDY+1%DDDDDDDDDDDDDDDDDDVVVVVVVTDDD
MDDDDDDDDDDDDDDDDDDDD@DDDDDDDDDDDDDD"&=ANGH%U%TDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDPD)$DF_9%Z<DDD$DDDDD@+M1K\S2 ;<@;#DGV
M$DDDDDD@U9($DDDDDD@ @DDDDDDDDDDY4QVDDDDDDDDDDDDDDDDDDVVVVVVV
MTDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD^ N&9:;U13,DDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDD"HD DB[  C5---,DDDDDDWF.83!CT4\DA
M$DF;LDDDDD%OD7I@DDDDDDDDDDDDDDDDDDDW09@$DDDDDDDDDDDDDDDDDVVV
MVVVVTDDDDDDDDDDDDDDDDDDDDDDDD$DDDDDDDDDDDDDD\DDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@D B;  ^<   @DDDDD:JJX3DD]<
ME$DDA#D1\?LDD&#=9FV-DDDDDDD $DDDDDDDDDDB=]>4DDDDDDDDDDDDDDDD
MDVVVVVVVTDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD'<$DDF[  ZX $@ DDDDD4/4FL
MH_CLDDNDKIDDD8,D"O@25&17DDDDDD@$$DDDDDDDDDDAM/5$DDDDDDDDDDDD
MDDDDDVVVVVVVTDDDDDDDDDDDDDDDDDDDDDDDDD  DDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD0FM$DF_ETZX  $ DDDDDW
M3FHH;!T\DB?DA.DDDLTG]G)"[MH(DDDDDD@ $DDDDDDDDDD@R+8DDDDDDDDD
MDDDDDDDDDVVVVVVVTDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDGD DDDFWFXZX  $$DD
MDDD&?@);A+.$DA;LDD=LD2HP4VAL0A&\DDDDDDD$ DDDDDDDDDDD-&0TDDDD
MDDDDDDDDDDDDD$DDDDDD\DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDE@@DDDB^GD:X
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M?^3_ (B_\_Z@_P#)_P 1?^?]0?\ D_XB_P#/^H/_ "?\1?\ G_4'_D_XB_\
M/^H/_)_Q$EYU@)!() FC>&G"1 *))))))))))))%1() )/I))QPCBW.0 FZJ
M?)))))))(!))))))(UW('\S-@)(!))))))))))))))(F[)6U(VHFY$W9*VI&
MU$W(F[)6U(VHFY$W9*VI&U$W(F[)6U(VHFY$W9*VI&U$W(F[)6U(VHFY$W9*
MVI&U$W(F[)6U),HME!(( !OZ +_N\]F))))))))))))))( () 9)(8Q BT%V
M:8>^#))))))))())))))($'! +;8    ))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M)))))))))))))))))))) !    GP"HUDLDH)))))))))))))))!!))))(GPY
M-X9P:*W]W))))))( ()))))))I(  (     !Y)))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))!  (GP'&F ) (!))))))))))))))))))$I
M*:RIT+0D8U%N"I)))))! ))))))))@  (9)     9)))))))))))))#_ /\
M_P#_ /\ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@@ $&? \ZX   @DDDDDDDDDD
MDDDDDDDDF'_,YCIKWKG^&#@D$DDDDD D$DDDDDDELA)H*\$ $@@DDDDDDDDD
MDDDDD'__ /\ _P#_ '))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))(  )OP&TN  ()!
M))))))))))))))))))T(#^K%;VZ-T1R)CO))))))!))))))))'A(  &EG(&E
M))))))))))))))!__P#_ /\ _P!R22222222222222222222222222222222
M22222222222222222222222222222222222222222222222222222200 "(K
M\ #K@    222222222222222222=P<<>,VB;?$5:*X1RP2222""222222202
M"00  0M> "22222222222220?_\ _P#_ /\ <DDDDDDDDDDDDDDDDDDDDDDD
MD@ DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDE#DDDAARDDDDDDD
MDDD5$  X:[DDBX  $$$DDDDDDDDDDDDDDDDDDA+UO"F=J.,JH!;=_C>(DD$
M$DDDDDDDN4@DD     $DDDDDDDDDDDDDD'__ /\ _P#_ '))))))))))))))
M))))))))))!)))))))))))))))))))))))))))))))))))))))))))! 3)+@
M)TN:C)))))))_P  2LR+]4 +P "0422222221_R222<R2223<;3\[+VT7OIL
MSI5< D2200"2222222*#LB D     222222222222220?_\ _P#_ /\ <DDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDY'B=*GT<?(TDDDDDDF,$$1DB_IM^X @F4@DDDDDC4,V2*G_ '))(]@;
M>'_1-R*ZMW*NNNZ-)))!))))))))(1)))+[)) ("9)))))))))))))!__P#_
M /\ _P!R2222222222222222222222222222222222222222222222222222
M22222222222222222>R 622"22220"22"("0220;QG7-=OI2""222223..WU
M@,M227&2YUS3.72/#!P.O I'2 22 022222222"02"2=M+@1)J2222222222
M2220?_\ _P#_ /\ <DDDDDDDDDDDDDDDDDDDDDDD@DDDDA))))))))))))))
M))))TDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ E@   D#]!Q"X   @H$
MDDDDF..EG<D\TDND@2,=P7ZCZDO$Q8E\%A-$D$D@DDDDDDDD$@$@.6\:R)=D
MDDDDDDDDDDDDD'__ /\ _P#_ ')))))))))))))))))))))))())))(VVVVV
MVVVVVVVVVVVVVV)))))))))))))))))))))(ZD9)+9)))))))))(0(!!!!F-
MG[8   !.)))))))7I))))))))))D/ML">QSO'9:<'O\ AR22"22222222202
M  "2^0S4"R22222222222220?_\ _P#_ /\ <DDDDDDDDDDDDDDDDDDDDDDD
MDDDDDC6__P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ Z\DDDDDDDDDDDDDDDDDD
MDG /!>\APAWLDDDDDDED @D '>^'54 $$AXDDDDDDDDDDTDDDDDDDS1^9N1!
MG,S ;N4]0'DD@DD$DDDDDDDDDD $  @+7  DDDDDDDDDDDDDD'__ /\ _P#_
M '))))))))))))))))))))))))))))(WK_\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ 222222222222222222227R,$H/(P/)2222222122220/Q>I*@2"0
ML "2220BXLX%SJOR222 L(+MZ*7<222222 ""22" 22222222220  "
M "22222222222220?_\ _P#_ /\ <DDDDDDDDDDDDDDDDDDDDDDDDDDDDC;^
MVVVVVVVVVVVVVVVVVVDDDDDDDDDDDDDDDDDDDDSC\CD#4D@\DDDDDDD!LDDD
M&DGSUU--;D  DDDDV24S7L@2<DDDD=S:(!IDDDDDDDDDDDDD@ DDDDDDDDDD
MD$$ED     $DDDDDDDDDDDDDD'__ /\ _P#_ '))))))))))))))))))))))
M))))))(VWY))))))))))))))))(Y))))))))))))))))))))))))))))))))
M)))) )))!(TNV$> )(!!)!)))(PE2G#-#)))))))D9Q)))))))))))))) !!
M)))))))))!X!:I9(    Y)))))))))))))!__P#_ /\ _P!R222222222222
M22222222222"2222-MI)))))))))))))))))+B2222222222222222 F2222
M22?>2*2222222 ]P" 29+MC%@   2" 22222222222222222222222222222
M222222 02222222222/03H(%[00";&22222222222220?_\ _P#_ /\ <DDD
MDDDDDDDDDDDDDDDDDDDD@DDDDC;;M_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /XDDDDDDDDDDDDDDDDC;J%%F;$:OZ#&%LDDDDAHBMDDF2[8Q8   $$$ DDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$DDDDDDDDDC$@DE$ *63O DDDDD
MDDDDDDDDD'__ /\ _P#_ ')))))))))))))))))))))))()))))HVVB22222
M2222222222227)))))))))))))))("FPYG!/,][7@B9))))(P!)!))TNV$6
M  !( )!))))))))))))))))))))))(!))) ))))) (()))))))))((( (!)!
M)))(9)))))))))))))!__P#_ /\ _P!R2222222222222222222222222222
M*-MN_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#MDDDDDDDDDDDDDDD@6K64
M3X0C</[64DDDDDE@$DDDD2[81\  DDD@D$DDDDDDDDDDDDDDDD$$$$@D@DDD
M$$@@DDDD$DDDDDDDDDDD$#JS. @ @ DDDDDDDDDDDDDDD'__ /\ _P#_ '))
M)))))))))))))))))))))))))))M6V\222222222222222223G))))))))))
M))))))))))))))))))))))))((!)))$NV$>()!'- !(!)))))))))))))) !
M( ! )!)(((() )) ! !)))))))))) ;)))%T ( E9)))))))))))))!__P#_
M /\ _P!R2222222222222222222222222222:W-M_)))))))))))))))))(R
M2222222222222222222222222222222220 2"22!+MA&?OI<="02 2222222
M222222220 "0 20"220 00"20 0222222222222. 0022?/_ ,DDDDDDDDDD
MDDDDD'__ /\ _P#_ '))))))))))))))))))))))))))))(Q.FVRVVVVVVVV
MVVVVVVVVVWY))))))))))))))))('U)))))))))))))(()   )$NXT6( !$G
M)(())))))))))))))))()!!! () )) !))))!)))))))))))(-K))))))))(
M))))))))))))))!__P#_ /\ _P!R22222222222222222222222"2222<\]M
MMT                 2R2222222222222222'J=949GKR22222220 ""22=
M+N]%K_/?<2222222222222222222222222222222222200022222222222:A
M^0"R    ""22222222222220?_\ _P#_ /\ <DDDDDDDDDDDDDDDDDDDDDDD
M@DDDDEMA;;9'_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _'DDDDDDDDDDDDDD
MDDAT4\HF;#TDDDDDDDD$D@DD!2[(1\!63@DD@@$DDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDD$@ DDDDDDDDDDDA@@  N$$D   DDDDDDDDDDDDDD'__ /\ _P#_
M &)!)))))))))))))))))))))())))(64.VVPO\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ H2222222222222222,0VX 5ZCR222222220 22-9GNM+@"
M"22000"2222222222222222  2222222222 00222222222222"0"  #'<2
MZJ22222222222220?_\ _P#_ /\ 8D$DDDDDDDDDDDDDDDDDDDDDDDDDD@?I
M-3;8))))))))))))))))))4DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD8$DD8
M#G['3 $ $A4DD@ $ DDDDDDDDDDDDDDD@ D  @$  DDD DDDDDDDDDDDDDD@
M @DDO;,VV0;DDDDDDDDDDDDDD'__ /\ _P#_ &)!))))))))))))))))))))
M))))))):3@.FV^VVVVVVVVVVVVVVVVVQ9)))))))))))))))))))))))))))
M)))(B2V;O['N%C0    ))))  (!))))))))))))))(  (!!(( ))!)!)))))
M)))))))))"(!2 'R.DM<9)))))))))))))!__P#_ /\ _P!B022222222222
M2222222222222222(9FLW-LT                 8R22222222222222222
M2222222222222/B!+R7-T1"     #:222"2  22222222222222" " 002""
M2""0"2222222222222;2-^2"0?;9@*22222222222220?_\ _P#_ /\ >3$D
MDDDDDDDDDDDDDDDDDDDDDDDDDG_;Q/[;8\DDDDDDDDDDDDDDDDD?DDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDD@$  EUV="     $6DDDD @$DDDDDDDDDDDDDD
MDDDDDDDDD@D  $DDDDDDDDDDDDDB$@  @ DDDDF$DDDDDDDDDDDDD'__ /\
M_P#_ //:@+6Q)))))))))))))))))())))(79X%JFVS_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /R222222222222222222222222222222*2"  CMZ7D
M    0V2222"0  "22222222222222222222"2 ""22222222222222:0  "2
M02220,22222222222220?_\ _P#_ /\ \HZG9\0"8?DDDDDDDDDDDDDD@DDD
MDBA0A0 K;?222222222222222225TDDDDDDDDDDDDDDDDDDDDDDDDDDDDDB@
M  '3!,DX@    DGDDDDDD$ @$DDDDDDDDDDDDDDDDDD@$D DDDDDDDDDDDDD
MDDDF$$22S$$$@@DDDDDDDDDDDDDDD'__ /\ _P#_ /*.IWK;;02/))))))))
M)))))())))(WX"Q]RFVVVVVVVVVVVVVVVVVVVY))))))))))))))))))))))
M))))(!)(]!'F7 #T(!()(!(S)))))))!(!))))))))))))))))))))))))))
M)))))))))))))-"P  %_))!=9)))))))))))))!__P#_ /\ _P#RCJ=ZVVVV
MVOR222222222222222220KJA^?\ ;;;;;;;;;;;;;;;;;;;;DDDDDDDDDDDD
MDDDDDDDADDDD$D $DDDMEH  6<YUD$D  WLDDDDDD@@$@$DDDDDDDDDDDDDD
MD@ DD@ DDDDDDDDDDDDDDDDD&$D@  /[[Y DDDDDDDDDDDDDD'__ /\ _P#_
M /*.IWK;;;;7:"3)))))))))))))))(QP%*/.0&VVVVVVVVVVVVVVVVVVY))
M)))))))))))(COW3TY)!)!!)))))&>IY!'0 *GONDD@)))))))))    ()))
M)))))))))() ) !))))))))))))))))))%K!( ))))))))))))))))))))!_
M_P#_ /\ _P#RC@%ZVJVVT2VT.9R22222222222227@ L9B_)MMMMMMMMMMMM
MMMMMMMN22222222222222]K:^H"22"22222(KG>2 21VH# 2    "2222222
M222002 2"222222202 "2022222222222222222222>QN02 222202222222
M22222220?_\ _P#_ /\ \HZE>M*M&RK+MMMR\DDDDDDDDDDDDDUR]'@XW;;;
M;;;;;;;;;;;;;;;;DDDDDDDDDDDDDD0P9#F3DDDDDDDDXLR0#D$D"K!&
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M[:JBN+SJO W@5:G[7Y1/2-_A<])))))))))))!3-<KGG: KKY)NI)))(%I!
M "ZAL !!   )))))))))))))))))))))))))))))))))))))))))))))))))
M(X( )9!#VR\HI)))))))))))))!_^V_Q_P#RAN;'@T_^9'XTNJZ222222222
M2222:]$<G/88*1S)^0LA(?V+6%=:QK&R222222222299=X=4X/><K*24R222
M2222  :W@3,     "2222222222222222222222222222222222222222222
M222222>26D2V"2223F22222222222220?_@'[_\ \H:<?V$?9#%M@T2IDDD
M$DDD$DDDDDK+M2";DN(&,'*_R^?THZR! XJV4DDDDDDDDDDC?1F/,_NC *,D
M*LDDDDF;8 $@.#O)      $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDE5$@ D=, $/LDDDDDDDDDDDDDD'_Z7G__ /*&T]'P--;;;:9;
MX((!!!))!))))))#?R:>,>%$K^U89)/$VK,T:>K)!3))))))))))(I^T5^>1
MS#ZK)*))))))*G(( &_"=P     )))))))))))))))))))))))))))))))))
M))))))))))))))))))()((! 6:9)))))))))))))))!__2VY_P#RCD-#K_!9
M^K2]8J2220222 "222222"4]M685MM  =_K^'B*? =S V0.R222222222222
M2222222222,F22222<20 0:/=[$     %R22222222222222222222222222
M222222222222222222220 %H020222220  2222222222220?_VR0?\ \H_<
M_*?IA8F]7,5DDDDDDDDD@DDDDAQ.E4_@OY6T_P"R#IL=R)VZ^'E_E5))))))
M))))))))))))))))(C)))))(Q(! _B41?()())*I))))))))))))))))))))
M))))))))))))))))))))))))))))(8*8!#(   !)))))))))))))))!__P _
M_P#_ /*/@9;G.\^7YCJ2E))))))))))))))3%L'%08FPGB;876"^ *?K!F=T
M*#)))))))))))))))))))))))1)))))!!!),Y*! +"3P)FU)))))))))))))
M))))))))))))))))))))))))))))))))))))(9)))'0()( +))))))))))))
M))!__9(/_P#RCH,"QPO]%4C[95J22222222"2222"3J7?*?HA&_JG&1O].WU
MEVM@-+722222222222222222222223N2222220"00ZTN0122(TN2/2222222
M222222222222222222222222222222222222222222222 3&TV !UF222222
M22222220?_N21?\ \HZ/,J=P+Z  >IR/LDDDDDDDDDDDDGDB0KYJ7V2P9)K5
M4KOJ$V)JB7-X4DDDDDDDDDDDDDDDDDDDDDD$DDDDDD@DAO=H$U \ DD DDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@@@ D*6,-K#4D
MDDDDDDDDDDDDD'__ /\ _P#_ /*.IF;:LB%!*[:';QY)))))))))))(B2<4N
MN6 ;3,I]A[32F%.8#8Z=H=))))))))))))))))))))))9))))))(('H(!,I+
MC (!!(N9))))))))))))))))))))))))))))))))))))))))))))))))(!)!
M)!#5O_FK))))))))))))))!__P#_ /\ _P#RCJ?:00R2VE6V&VR.,N222222
M2222<DDJBXK\2_!NB[_1BPBEF#Z':1#2222222222222222222221!222222
M22I2 "(_P!7K)?)$"2222222222222222222222222222222222222222222
M2222222"22"207M^"222222222222220?_\ _P#_ /\ \HZG< LEL,G-K-MJ
M9-HDDDDD@DDDDG__ /S:.KU"@@6B!<;G1JS(9SA*_P#22222222222222222
M22220V2222222 "0 258,"@2    "2222222222222222222222222222222
M222222222222222222200"2      222222222222220?_\ _P#_ /\ KHZG
M>L_3X(UN_MMMMMSDDDDD@DDDDES;;:C5"->?;3WM#P[9SZ7J7#A'<DDDDDDD
MDDDDDDDDDDDDDB)DDDDDDDF%0$DDDM'H      DDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@$ $     $DDDDDDDDDDDDDD'__ /\
M_P#_ &*NIWK0&3;;B;;;;;K:9))))()))))1_P#_ /FTDA,,VV-1T)B%$))5
M&K%%4DDDDDDDDDDDDDDDDDDDD/,DDDDDDD$ VU$D6DC9     DDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDF\DGX@$@  $HDDDDDDDDD
MDDDDD'__ /\ _P#_ & 2IWK5:*EZAK;;;;[4Y)))))))))))_P#_ /\ _P#_
M + %X$6MNA"'% EXI46!,DDDDDDDDDDDDDDDDDDDF*DDDDDDDDU $DD@J;9P
M     $DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDF(EQ
M#M@DDCMDDDDDDDDDDDDDD'__ /\ _P#_ &())WK4+;;;;?&+;:K;))))))))
M)))._P#_ /\ _P#_ (MH?D6)U<%7QD"[<N"Y,DDDDDDDDDDDDDDDDDDD/LDD
MDDDDDD, DDDB0()B$$@$ -$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDED$ %D I)I<GDDDDDDDDDDDDDD'__ /\ _P#_ &))/WK:K;;;
M;5B;[7NI)))))))))))(U_\ _P#_ /\ M].#^E(G=+4R;SQ'E#RR22222222
M2222222222$N222222222 ""2.UWCJ<220 ?>R2222222222222222222222
M2222222222222222222222222262  """2220622222222222220?_\ _P#_
M /\ 8D$R>MM[?MMMMN:-YLDDDDDDDDDDDDD__P#_ /\ _P#N2X(WLZD6T%^>
M_P#>8;.222222222222222222&R22222222220" ("J=O@ZTNDPRCR222222
M222222222222222222222222222222222222222222$"026@ 022 F222222
M22222220?_\ _P#_ /\ 8D$$NMMMM5MMMMM5M\DDDDDD@DDDDDDD_P#_ /\
M_P#K;>A+T>OI,VB#?G)?M_)))))))))))))))))B2I)))))))))( (./0 EG
M S)!)*K)))))))))))))))))))))))))))))))))))))))))))))))))(;!
M !+1!)(;))))))))))))))!__P#_ /\ _P!B02#"VVVUUVVVVU6V2222222"
M2222221?_P#_ /\ FG#.FU"V"C47DF:Z?_W2222222222222222:&2222222
M22222 8ZN " #OOMM_LN"222222222222222222222222222222222222222
M22222222222"" 2 2VTTR222222222222220?_\ _P#_ /\ <DDDF3MMMM15
MMMMMH<DDDDDD@DDDDDDDC_\ _P#_ .7(!WH(I+]GSZ3'<A!X\DDDDDDDDDDD
MDDDF=ADDDDDDDDDDDD@:%D %QL#=$DDD,@DDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDD@Y$ $      DDDDDDDDDDDDDDD'__ /\ _P#_
M '))))##0C+;3+;;;7Y))))))))))))))(?_ /\ _P#/^C=%M3D^>M__ +IA
M4^TR222222222222<Y1Z2222222222222<:"  1B@&      "22222222222
M222222222222222222222222222222222222226 P2222222020222222222
M2220?_\ _P#_ /\ <DDDDBNEO)MKPMMG,DDDDDDDDDDDDDDDD7__ /\ O](7
MA"R['L"Y/1K9Y!H22222222222#B2C222222222222222222 " 7Z2P
M"22222222222222222222222222222222222222222222222202222"P"222
M"222222222222220?_\ _P#_ /\ <DDDDDGQU35MK=N!DDDDDDDDDDDDDDDD
MDD__ /\ HDH222222220</I_O5AQASSWFA?L8APUN222222222222222220
M 0 S0.D     222222222222222222222222222222222222222222222222
M2202"00@0P 06F22222222222220?_\ _P#_ /\ <DDDDDD@R&X]M2=\DDDD
MDDDDDDDDDDDDDB7_ /\ S9;W>[;??;;;;;-VM;:PTC  'S"3-]R222222222
M2222222222 0  ;51W     "222222222222222222222222222222222222
M22222222222222   " 4D0DF R22222222222220?_\ _P#_ /\ <DDDDDDD
MDNHO?DDDDDDDDDDD@DDDDDDDDD-__P#;14=G[KB3;;;;;;;;;?))))))))))
M)))))))))))))))))))($X!!!*+C*!   ))I))))))))))))))))))))))))
M))))))))))))))))))))))))((())!!:2333))))))))))))))!__P#_ /\
M_P!R22222222222222222222222"222222222,__ /\ YM#9[M8'_P#_ /\
M_P#_ /\ _P#R22222222222222222222222222220'R2*X%&&3 0022:+222
M22222222222222222222222222222222222222222222222""222 4VDR222
M222222222220?_\ _P#_ /\ <DDDDDDDDDDDDDDDDDDDDDDD@DDDDDDDDDD_
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ \DDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDF $#\?L@@4-4$0X!$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD'__ /\ _P#_ '))))))
M)))))))))))))))))))))))))))) _\ _P#_ /[?[7__ /\ _P#_ /\ _P#_
M /\ \DDDDDDDDDDDDDDDDDDDDDDDDDDDDD# $E7 O$"0 :IP@$$DDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDD'__ /\ _P#_ ')))))))))))))))))))))))))))))))))))S__ /\
M_P!)#O\ _P#_ /\ _P#_ /\ _P#_ /)))))))))))))))))))))))))))))!
M)#Y  !H())))))!1))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))))))))))!__P#_ /\ _P!R2222222222222222
M2222222222222222222W_P#_ /Z 3O\ _P#_ /\ _P#_ /\ _P#_ /))))))
M)))))))))))))))))))))))!T) )GC7IA)   )(M))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))!__P#_
M /\ _P!R22222222222222222222222222222222222'_P#_ /Y2(A__ /\
M_P#_ /\ _P#_ /\ \DDDDDDDDDDDDDDDDDDDDDDDDDDDDDE@'W_ _E=8$D@
MDY$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDD'__ /\ _P#_ ')))))))))))))))))))))))())))))
M))))))/_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ \DDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDD,1D$DOL@? @  *4DDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD'__ /\ _P#_ '))
M)))))))))))))))))))))()))))))))))))$DDDDDDDDDDDDDDDDDM))))))
M)))))))))))))))))))))))))C( !.#N,]LMEO()))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))))))!__P#_
M /\ _P!R22222222222222222222222"2222222222222222222222222222
M222222222222222222222222222222222022020)C5      222222222222
M222222222222222222222222222222222222222222222222222222222222
M2220?_\ _P#_ /\ <DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDBZ4 $KV& P     $DD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDD'__ /\ _P#_ ')))))))))))))))))))))))())))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))) I"C5#Q3(
M-))))) )))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))))))!__P#_ /\ _P!R222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M3B021$2;P"R22222"2222222222222222222222222222222222222222222
M22222222222222222222222222222220?_\ _P#_ /\ <DDDDDDDDDDDDDDD
MDDDDDDDDD DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDH @   &-N0$  @ I$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD'__ /\ _P#_ '))))))
M)))))))))))))))))) ))))))))))))) H//&54YO'@%''))))))))))))))
M)))))))))))))))))))   !)) 4!?S   #HK))))))))))))))))))))))))
M))))))))))))))))))))))))))))))))))))))))))))))))))!__P#_ /\
M_P!R2222222222222222222222222"222222222223&SZ8UX-7R*IUJ.2222
M22222222222222222222222222222"0"20"$I60MO_:A\222222222222222
M222222222222222222222222222222222222222222222222222222222220
M?_\ _P#_ /\ <DDDDDDDDDDDDDDDDDDDDDDDDD  DDDDDDDDDDDTOC(^&'=C
MI( %\DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD@ $DDD@AJ2=$DE27DDDDDD
MDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD
MDDDDDDDDD'__ /\ _P#_ '))))))))))))))))))))))))))))))))))))))
M'RVWT,6G#$]-WU))))))))))))))))))))))))))))))))))  )))((!?[2(
M)$B)))))))))))))))))))))))))))))))))))))))))))))))))))))))))
M))))))))))))))))))!__P#_ /\ _P!R2222222222222222222222222222
M2222222222222222222222222222222222222222222222222222222220""
M222"2  M6W>2222222222222222222222222222222222222222222222222
M2222222222222222222222222223MMMMMMOR222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222 22222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M2222222222222222222222222222222222222222222222222222223_Q  O
M$0$  @ #!0<% 0$! 0$    ! !$A,4$046%QL2"!D:'!T? P0%#A\6!P@,"P
M_]H " $# 0$_$/\ XLD0Y-"$$UNI?:->!\/W$6%W.)?1_P!T&)5T,6'@!NS?
M;S[H/@7Q:Z5, ) 4@Y*>L$L#NQ'B8GG&M1Z\M_\ MSAVNA*0 \7'P+\Z@LUY
M%>K&C#RO:9[ND]3VF(X>\Q/'WK_85W-G-Y'JX<Y@0;W5YNWYG!_NJNY^/"Z#
MROM*^Y=1^9PJ*2G_ &N><@\9F3:NKW^F79<'8Z,,?:'=[?K_ %QJ\5H<BM>=
M[,P5M^9P?[HJ''JBR6K0]7+J\(IA'&UZG2=P<6/5AI['R=SQVD9TGO,.E?[4
MENY%H U9GS[W ]WRBU@.[]PR<'4TYF/EX0069;#1T+.9C^O]=C%S6\;]99<P
MT=^O=XR\[E&ACH;?F<'^Z4('F'8)H*'T]?+:RK@]?]JA)20<FF_V[&\F3N,O
M;8@9RMT_UP5#AL^&WFWYG!_OGI<L ZOIM!SI#U]?]R8.UR(N:#/FXOML"ZT7
M?GY?[#X;>;?F<'^]#C:X! =F9\5S^;MFEYYNA'BM6WO_ -LK5+KN"<#\<X%W
MX/JOTCF*WG%]CNV8"!YO(UF6P8#<>[K_ +#X;>;?F<'^]4A8N3<;^_3ASV93
M&CU7?[?O_;L!>]V "O:(H7$]6/G,*2\G1Y/Q_P!A\-O-OS.#_>60,.1OXO#K
MRSV5BG-Z/7PW_P"XHX#)G >#VF>(\SVJ"%#C['W@"\LG8 5CY<3C,V1>)H]Y
M_K_AMYM^9P?[M2+#YO;?X<@!1ELQK\;NX''ISRS_ -X]G$6<$]SIM(?17@_O
M_7_#;S;\S@_W62G.XNX]88.@R-AA;B>CGTYQ5;?]P"X'9H+@>;\=MF[)\7]?
MZU.P#6-Y]Q/@/M': '71Y;1NBF=W@!NX3X#[1*A,B>?^X K)YZO>[!1WHNM=
M\WO.)\7O.)\7O.)\7O&8 *8KEC6._P#VK%S,'>QU?$8/$R>O&*V0XV/J><;J
MI\.,6$3PQ?;S@0Z/-=[L1)02E<G+D8'O_K:X&][=>/;Z?[A&;$L[^V&5!='_
M &JIJ#1SL3U[3YZ#5@E?C=_ X=>6?^M/DC>.C.$\6<)XLX3Q9PGBSA/%G">+
M!( R!QS_ -Q;R#3/K.,\#VG&>![3C/ ]IQG@>TXSP/:<9X'M%C59F'H?[8HI
MFF+]GC,MX3Z/O$Y+N/>%S?<>\<(!Q6_(KK&,1-V1X'_R/7E?3_S@CROI_P"<
M$>5]/_(2+,X$X$4?B_*^G_2$*$$<O]I3*8T:B=YTY$ 254!L7S@^Q2Y#@H.7
M)K2EB?B?*^G_ $A"IBN_]?5['$9JV!'%1&1*=Z>;[$IKUJ?;A'2HS6'[@[ >
M5V\<.[:@YQ66$R>(B8S&*-&*J?P_E?3_ *0A5"N_]:BH3&U4T:WQV*UJ&LP'
M252S818 &/M[QR]#''29<1D;^+Z;IPJ'A>,J5M2\XT8P-WX7+P,^LP;\-Y7T
M_P"A(R$@3.5,B)$E&"B+/_4"9D*B-N;PK<IG?I#;#R/GAYSQ='S&&4<=\<PU
MRF3$K;4JD,OFQDSF4M"-+I7>W1R+CY@:,RG"\/B7##.8-B<<O$]N^9!P<G1[
M]KH0]9,^[7PQERLJ&]#N03+&9Z;#@11]_P"5]/\ .H4"V +5P"U4&\3M4-JO
M9B"J<!XP$V+"*8O^5<HM@X\;*(D2)$E3">4 P\(N+_2$5!,3P$WJ@PCX$L@$
M$ :7$%[X(ET_N)I/BO1)>V]Q?JLPF@8M^!EKS[5/-0>LI>,<G%Y&[B\.OG&S
M.*UOX''H=TQ/$WX/++RAGM@J]N-\5F.7ZF<G4:FRCAG,?Y""RM):D"#U@2-<
MYI#'/ S=2+FKC=)][Y7T_P Z@5>L5+\WQ/PEP0>Z-"BX5>J(-*,.!QR(T*+F
M?O\ ILR]_P!(H'&(FV3KA"6R*ZQ=$0WRWV$,]0;YJF0 &=><KHKA'0*K_&TP
MR,V49V@(D2)$BKE1WW$"6_Z$!<":&'G#*.RCG V@384S08R=YH[,!;&(<^?+
M3KG,.^L]YCB'8=[DCU/: /IG-O>'CNCY%:K-X;SY'@(2H/GCL4"V9>.\OPF5
MKD'UHA<YX'K+F4<RP]&,U Z?Q'9QWC[0J2' ?5Z0+AG.Q/2H,][##NSN,U;9
MN) :LXDSD.13 <F#T8^ZQ<WW?E?3[1&2D3FS41JKAN_.+[XK,(3,/E_@T,+I
M?7!G")_"#8"RB) .4N-B=TP#4#8"RB) .4]7TV9>_P"D0JSYWSI.L(GDPZPC
M:W'3?F$RV(RSSWA#3%]XEQ[E\I2?XRHP_,P$=!,/679$6QQC*1E3#RIC[F8)
M4]>_S]8$!LQ=^P* BE28]I[J,W[P>G'#5A>4"&JLT^"W@P+BE:WG$\DF!;30
MUU,;UCMJ/#I4?4/#I-)R>*5$[4&:PY-+!U/+<<<^4K>4ZOL>;YPN Y S.XQC
M%&FGS&-^3&:9R'O<,:%Q(>=$QGOA7R/6&Q\,]5](9;OD#I<T!\6!YOQ9D".]
M];CM">Y])FC6CD[_ &3%UWE/F>L]=1.HC.3:#^/G!R[Q>C[S ,3@KSR\Y=$3
MAC,X;C+N*="U\\(E35YQZ/NO*^GV* 7 C.,9:0AL$.SODF/*SSB.A3^?JF-)
M+.UK+0E)#[L9=+7&-1O[XAMH0^[&/A-5L8T:J!0$2]RKR;@@W"JE1BA+(@%,
M,3SR4]KJ7#0,= VO^*I'?:2J]$F?YS!S [0*&)$F#E3$/"! E3)LG[@TA:N<
M5Y1%%"Z#5Y0P(#K_ ()W(BH%$M3%;P_>RTKPE*.C'G1V4#UG>T9T^#-]B4*:
M<..+'T9L\'#K45S5?B?K88*UF(EH&;O>!I;UF/5:1EW[WX5.XXO =V:\Z]98
M WH/IB]\,LC>V^!?FDQ%7YT>'[B@D',H+[XP11N[9%D8O".IKTV@41Q!ZS$1
MKB]&SRA\;^ KS+Z3F2"]O68PAXF/B5YW*@1^)Y8^4*C\CUE+(T+BY&OA*2^&
MMYG,AJB.B)E!<P](B?:^5]/L$)!Y(0A#8(=L>C<UE//_  66+CV8_P OB+,/
M$V[CU8[5 C_6(]L!A&5C$F'EQ6?"!L5+_5]MGL#3#%3QW2R9@PPR6IP(%F N
MM'JQ298^><KDI-'T_P "Z_NB= /*7#UJU/+<<<^4 4$(OGU)G9R'O4)?/-KT
M8""9,WU(O*G=^YPG@]IG >9[5,\W*SWA)!SWE]V/E K#DS\,]C^;<AP4!:*-
M[@>,$69+I<FKQRYQ&6:7%86+BL'@9OA*=#XM/#/SEDCYA"4@&@)G/%7'- 1V
MUC,U/UVU1;@\78E8/9SB*LCO,>Y,3N8J<-5C7K7>]\3RC58^&#Y2T&#3-XY^
M,9+Q 8X..#F=-T,IS-$W0P^M3<[F)XPXD0'3,?A*D^T\KZ?6"X (0A"$-@A]
M'$S",J8;_P#B[HL*8;[OVF#,3 ?)W<Y<^^ARV(UB)=.SM@HAC#RV8^3ZP)4J
M5,5,G[4B^EUXT>4X$IY%]9SC1\[I<-]OSPA@2K#$E(:./=7JZ?X!](1V-U:$
ML'TJ)_7X; --6RCL>0'6X:6+U7ORJ&,=T*OQNYD#^'M0Y!X!T)ET\PG2L5TJ
M8\[\3W\XY74US>&?A<9R)IF\<_&XL14Q&F=CDF'!X2YBBC"@#5QU=#PEWW<#
MOU>]>%0J\9E<M]6^+==U01@LYU[1VVG-/=8+G3O_ %$3"W?^H587DGK4<4'6
MY?1@$,X+Z(EY(GK7E,R3DCUJ;^.(GGEYPVF."/3;X'?!_>Q!N//]]>T=R8CR
MR3A#/X7S"5P<QCW.9%&4&.-Y_JMA'+U-$^9.D /@^([G9BF!C<JYB(ZT(E?9
M>5]/K,^V!"$(;!#Z>:>"+S(:T.F8?B05HC]M<1.OX-:SG&B.:3A/&<)XSA/&
M<#XDX'Q)P/B3@?$G ^).!\2<#XDX'Q)P/B3@?$G">,X3Q@N0G&_)D"[A\)GK
MS]GOX;XJMO8I;+4C V#V0QD"A$GA3Z16/#U(&TJ7<+[6TJ+BH%M9BI$,%02A
M:Y4 '#\]2QT'B@(51NQZ3,0[H;39QF;0[\'EEY2B:^\\K/&I1Z(OG_90H98'
M/6&U9&&W+LYH1!I\) +O=W4?I-0.2OQ:B)7OH/<+=V428)=J\ZTNL+V=[>7_
M #Q2'+>9P\O=A=%R!L;]WO,SCL("DGIX!\3&:MY'WN%Q)YE>9?2,8NM5_'RB
MU-P%]$P(.3!]?25Q-\,3?RN!V/(C&X?.&"Z \SUC6'#1T>R8C1F]#)Z>W*)3
M3%:8KP KQ7*8/04Q?8)D;WV]5@%". '3:!3-(DH:;&97V7E?3ZS/M@0A"&P0
M^M0'7T^^4#:D;\0#?6-O*M9;:*FK8:E',<Q3$VV5@66PS="M8N%$BV&(TA:7
M3AA<8P6K51W*@OA<1(/1ZFB<26MY%X!XJ$%(OE>3R2Q\8F66=:<W([Y94&:4
M#G9KOB*JB"-87!OR7AQBEU U&S@.H7C4:*S'61BS6@[V TME>3R2Q[GZ:T6Q
M+&#QG QT3. \XZ8\_>?(?><GP_<>'X3BGA%M3PBOZ$^</:?+4XV+ZHIJ\66:
MO%G$^+%<UXR[5XSC15S^V$9,JU@.2\8'D_%@&KQE>N _J>T"_0@.8>'[AJ#S
MAK>;]34OC!LQ/#W@V=.YAD#,F?$@CB?@1457GQ[=9TL3U[/W(05#!<P][Z1V
M/QB0-HF,I7#_ "RM&8PK9DY&%7'?PB&G@?>;L^#[P!D.Y]X#37EA !2,8:FA
MCTPEI;BCF:/43 >X%?-])8QW)71-7^9.J%P!=Z>EQ^7Y6]"7.*F[UM.LM!NB
ME>.)X7$*RXY&;T.D/%B:KC"6*.3HP,D,\P>9G>F!*TSXKJI06..!\'#S)3 7
MN<'P<^[9@.%NS/"+!/$,OU\QC=BS>9=L&BR8^8[S#I'8N<$OS*Z1K+-5CX8/
ME&L@T'\?.7K(X8^SUE&ZYZO!Q/"!#V_*!>\>$NQOBOPB;71!LAX-^7\F1&F>
MF$(+??CC!2XSB8]H*-96!8/E!Z*BQ/L?*^GUF?; A"$-@A];)W_3[[$;<D<D
M<Q\GF$25TUP!O#,-S"&74O>8(^"2I$&&"D<+=;UX>-TI8+ M*F-Z49>.E.V2
M"^'MMC2:W+!J@%]^.^,I3HN=XQYZ<=<V9;<=XL1W8#C%>X[5FTG$;R8PNEFB
MRYX1"U*CD4PKD83"PUD!7&@QO#KRCA<9^(OF'TT6<O&#F 9P'G.!G S@9OO+
M/D/W/D/W/E7[GR'[E8I>4QEU.*\I\@]H!J^/Z@>_QAN'QGR+/G7WE7]^\ TP
M'1.&\(!H\"?P"!Y'P)P/@0#(>$X3PG">$X3PG"G"G"B^9.$\)PGA.$\(IF/"
M<#X$7S/@3^ 131X171%-,5_=]XK^S[Q31\8IJ^)[1T5Y1TO+%Z>3]QT1YQ'*
MGO\ U$<K=Y$M<S)\&*S&P7$,S-\6?P,!F#W1_;9E!)EOCPF2SW_@>:_7#M M
MHH;0U [YSJ0=@FQ4</\ *)NW698P)ITLS0.^$LD(1J[C%\-.^H@A&]Q?;K+5
M0\<#NNCPCP"%H*[W .ZX19?$'D5YS<'%1U_< ,#8K&0XK1YQ&C<+8=PS?*4/
M? 8!ST[V5=<W9O'+PN%[7 =;>+CABRT'#+S>QZ1&7)U'>0>./ >SY,*BM@CF
M.HGS?+_F0]+KREN3Y&#AX/=,3!6B^N/@RL0]^9[GAWRFP;QN;ZOR_4U[>7TJ
MHQQ+ETM?B>#CYRE.'&\WAGX7$B;X?7!OG?*!4\1OQ>X<XC@(Y.G=6$H:D? X
M"+8W)]_>*UED[@(-K/H82()4N\/**CPF8_8>5]/K,^V!"$(;!#ZQTF1A]]0_
M("&*'/#$OAX1N(*"L Z% <5MKS9:AR"U=488X!4;5D[4Y7G6<&8)F28B[^</
M77$P2KP9\F:_YP<Z+1# UDF%>)$VV:LLNW/%5S:"L W+"<] 7!;IK&QQ$'RQ
M.5JJ.&ZU,!=T%NKNQ$HJ&+BC=:XA?PB^@<$ 7:@&*XX7K$:4#8F-KK%&N$4E
M6+')Q?IYO,@KD_2 EZ7^/SF3+W$S(165.]B,P\)^DS)J>^9AZYG$=VS.,[YO
MES(7+>6'O,H),@>G69_><X@]G,):3!B2JOC"+&<74@AL!C*AHN+_ )/<DBAB
M+0F6W!JO37PWQ%]:>W=XRE6[?GX>\!'BF)]CNA;^,M;QU9B:'/\ 4PAI='*4
M;[A>FKR,9G=]>A[^$"XDZN ].X\)7#2Z,!ZOER@ 0:!6RI?#J<_# \8M+BQ>
M;[9=T=<P:.-87*UUEWKSU.\A8P,MYQ.)H^C#+$=V$J<'XQ:+N /IA+6Y;L_-
MB>+RF)TXK#YS)1TN\P?9\HQ-E,!P?#AGA<1\X[6:#W,3S?@Q%4[4Q&!U..>>
M6\Q.YA#AFG)O]SOA5X^==1E/>;S+PS/.)P$WF,(A+5,&*]/FG*(JGMF.,K]@
MAAD=6PG$IB642L_K>5]/K,^V!"$(;!#ZK3-Z?EWYR"N5]+%W_7\QEV]TW:Y+
M&YQY^T-E/E,RORQZ1%0J9C$S,<WZF'(><RY>OA]SPB#ILH,V .6R;+)C.\R8
M><QK7B]((&QCBIYA^E7I#$?4%V,L9PHOL@N<G\FQG6$]*> ;0O ENE^6CBXM
MWBBYK:KD?-VLK0<5Z&G7CM'5L7=\QFE73E^Y<U!JQ\>\/0]_"#;/$X!P]@PV
M.OEAX>]]TI"56II.- P'%Z])IJK]CO<("Q@;<<?5AZA\OW 38-%]^DQMW4TL
MRN#=S^91R&-I'-;_ ')34(Q72+:;,1:-XP?9[X]94W8#N]EEE,&9F\<_&Y3#
M@7T<GKPC5(S$ZO-]IF!?-]JF1QR-J#@S+WNPZ0\_%]SVF\/+']S)TIX'[B/G
M,3$(Z.,OTX7Q9YG"%%C;O7H]3A'L^\'OT[_&$\PA#RJ)W]E&A;,62G&&(?N/
MU[D?XPZ;!S1Q#O@^\,'T[F<)Q%3]7ROI]9GVP(0A#8(?47=$,\F,RT_#@K1'
M[:XB=?K97,Z,%<@Z?2Q/SZ_G1:%S<3EA^IJ>/[_J9W8X8Q$P9@F!QQF&4<3Y
M[PR[/M4$+M/#7RE9<@9;+5:BM"R"6[E$-?2'&XO2>4=HZ7MQ<[Z6 53'L,SD
M(/C1S9,6N.;(['*-,.<4XH(WT<68$JY[,H[,%YD(X-&KQ<!PF-0Q$@FRQ&J8
MS'\?GN-##. *-@,K8:H/GF.7?T:[H]=QVK-=:O7>P=6&VJWH8,&%?.Z' X^A
M[]WC+%CQ9#T.K*/T5W:]_A$-D?R&?TA<]YX>\Q<OC,VCSE,:JS6C 'FV]T<U
MO&^C ]7PB7>+GR_<="ZO3^[$JS."I[XW-YQ/,E,N/)W.[D^3V;E:%=^IWS))
MWL*='R>$K=J+Q.3F=]G"':7>,^YR?&^$T8<\?:9PN["9LKWQ;.9JKO9D%^>,
M)DOC[PO:8^PSC ??'C_90BG8M FC+W'-[/N=>3CSE"4<*<SE[/E+.=%.\1R3
M3:C1-$OX'N^43*0\"9S/?V!68P!F6"TQW1@5H1%4_4\KZ?69]L"$(0V"'86M
MBR62R4[+ VOWQ!ZE268&HX,R1:A@,C5&28M(!=^ &G>T=\OV@ !LMQ#+.,FT
MX*SK?>>&4&:X=U6%W6:;F7Z;HW;W0.+"J][8G?9KOEY83-P#Q:/.)O;5=(X,
MDL>YGG/5!RUXBH7RL7W1<@]$KX<?J/"X^C#1\#I]+&_S/_ ET#,6JYXS&L#>
M8Q&RF8(T\X+:[M?LC!VN 3,\\W=P/5B B&XJQ@V&*%,#U80XOQ@Q.).D$AL7
MJ,MMR;WZ(N<K*:*Y3!N,W<I#"9@%%AFDR.[9U<TB'B[ TH.7<;P)E)E\H\=E
M @+PP(WH!O?R"8RL3/DV4C":L1<<W./M\M'?1Q=5N]V!PH,B&W+V$P,VMQ\-
M\I[>X#%>;KR,.><9KP7J^AXPZ #0@7L6\]K 97;3D87ZPMJ "M P/F<O1Z&5
M)4AL0LQA$PSO8UBPT;G?R==W+*B/@S;S=S//GGL67,".&AZ^TO!^XWP6LJS.
M_/TX2]LW&CW[O"/8OE._7O\ &8IW#4YDX$K<E;DX$X$*,B7$;0Y3O[&I"I&S
M1WFVG&Y'KO\ F,')@Z.@]>69+YXAOXF_J>>S=AKQ?UIX]GU4>UP:\7*/<,0K
MQ_D*RN4(53$3EQ= ?J>5]/K,^V!"$(;!#L9OI4FX_??(;IB\X0[@=XGA#*PK
M9J*ER3P",HM8%]Y'FYDDIV897A;@.-EY^$?R$6U4QP45HMS6+G$[O4CBD'>N
MNZZF <M*%XV6ZY31?!XF8[S" #E3N6W%++-"\,'C+=,"8X49TM%Y7O:U^HL/
MC,)\#I]+&G^$QIH[R8S@<,_""NQICTQC?[PPMC]A@-B^ W]^G#G%K85#&NX8
M88:@MN#HQUWW1CXV3.'>Q@O+Z)=:3)2(%,X4 "B*MU "B*MU, $4;&, 4P!1
M,6ZF)@QV()3.! P!L4%%$R5 RJ@"B*MU,E2C Q_'B@@45"69@<WVB[+R.+VW
MNO5X^&:]#TW=T .AD;"$1<DW<7VS?.4-6ZK(?,@_<"'5/-WUN.!WV[ OL9XP
M7]SWB=PU0\7 ]X0K ^;ATN XS6?+?^YE2T4&=!C?$QWRC^(XP4;( &I*A+,O
M']$*9APXMWLP;'?<3?[Q8L8%DQ?G&/,(1,Z:<#YG!BX!1Q3/OWPHV!D/7=WX
M<Y2X?@//=TY0L62Y<N7!@P9:R]K&T?.Z6O4Y)GS>_2&D5IT//CUYY]E4RC56
M3CB>.D&M8[HAOT-N",R5?.TBJ/T_*^GUF?; A"$-@AV'/Z7*K[ZHX072YF&!
M&:K2Y4M P/"XBMMD)ED8YYKW$$CKI37,RRF'3932B9C"T1Q&O"H(V86*K=OH
M-]&XQ98Q)BLM2@U;^\1EED@@%VYAR *QN[SN,5  MY$440P;*>_! V(8WBWL
M6J= W9LL2I'$3$L9U!1*IH<LZL!+NLG'NC2@7B,<JJPXW@T^HL/BS!RCZ6=<
MO\-N-O>\>H8;])8'AJ2XO,W?6(V3GR,_F^ PH#R):N4<,V5"EO27O"--0SO3
M-#9SG$CKG>D44#"5*EY69C_D39<=@GFH7A:5A>1F9\LXW-#%]#YCU&ASP&X^
M8L#]^[W?V"'$?QW[CO>-FVSBZKP]72! H/-^?N(?@0+F6P0TN&$=<L//.(6K
MF40IHMB]V!U?"4>REOAD'E??,,<PBC!$?+."--LB*IC.<4>O[@VV)B\WV(+-
MYD!IEBMYQZ)!&"ZFY^90%49P0UL7G^IC;@>;^NL%)<N7 "%C+S#?C#=RZ2IJ
MG,<SE[901<.G.7+ERX,&#!AM0")8Q[G>K<XG#AIRR2CWHW.#PXZ<LA!9E*PV
MP2T#O@-X6\QVJL[0<'77^^LP0S9>T-@3U(1Y;$IKZ7E?3ZS/M@0A"&P0^L>4
MORSP'/T@H'T<"GI^O^'<'8RXQ/,0ZV,UL:F[ZM6L8.KZ>$I UE;3;*G,8 ,Q
M\YA8AC,.444N&S8W$ZQUSR*7+W2I6P82J<M/K(-+LHM7_@/,$;$R9^TTJ,UN
MM_4M==WTY<(F 7@\&[OSB](P?,/$FA73QERKR.'%]-[$2M7%U7=[L$4HK#@3
M=HR-@H[>,-@'SFL+*@#P(E2O<^92\?HOU%U@UN^F[=L470Q8\?W"J6!._2.L
MYBQ;F:.Y^9Q*'+ ;SYB,(#:^'NRYS'WTC?[3BRY<N7+ERU.&E]]Y!W-\AZ]3
MA!=9&88I^N,6HIS@P8,&#!@]D2\4&O$X\->>:@G _&72&5BXCC>7=6,LA0Y'
M]CX!9O/::Q'P?:(D,386/)-8[Y;SX^^RD!EMPF/LS&6!]+ROI]9GVP(0A#8(
M;7+Z=1O/WX"[>972YDE7!F>!S/J9S,I.6'C-$G>>\ZW%])0U.7[G[H_<+F/'
MVF2 ]Y,T7ECTB.#//NB.8RQI]#!RIE[FU6D8+:]^'6:$[WM-#'(OVF;#P/>(
M,!WGM+_I?N?I$S(=ZNLS5\(K,?2"\H#;NYF6KO*FE>9]K@#!O'VF7A[R:W[L
M819NYB&9^*QH8:F[]=(&_K V2_4M#.K>;CZR_P"&$J2I1BLI9S$7J7490A2U
ML6=ST1TO!UBE!=\J5*B83I7SS^L%03'&DS.^9[!6H9M@&D5I$%'2!:HM49H@
M,&)M0!9^4,GB[@WL95]VD8*M ]7UV) [UKR-'EQN'5P-V!S><IZDP4S1UW!\
MJ,-1;N'#H2D%9/=]97:G0V"WMJ!;"IZO@OLAOZ'[EFNR7SF&(C<?D$79Z_+C
M4*8L*.CP^'AN>;  X3XG+3Q:8O6M8L6++[ W(S!RK>QPG00"G>;GNYQ.PF1K
MP?488J&3,YFM=V&7%M6#O]1_)A#9HF4&#!@P8/9*Y\9OXG'KSS%,I<-Z]MYI
MF<1[JUEJ(M.9GPXP =_Z.T5F$2;+;4#$W/7^;*-ZX2T^EY7T^LS[8$(0AL$/
MK.53YT^_,&PA*<HU8WPPF56=_P"H_'QR&W7D_<IQ3M5H7,W?"HAA!Q?:&%U>
M!\[YE<=UOBRBQ%A@H\#WA%*>;%RNM]X?C5S@*G%U.9M.5?411SCFAX$R9\*Z
M5,E'D?>XW/.ZX'E>&?A$5)%*7DF5#F?:&#Q%!N%UJ8!D@8N[A,M)D6[B(%1B
M;=/&,EU\BX,Q'>>THX>)^H9B.#AYQ.-)V!6BDR,3DQN<=US*%\H+:5O,>DR@
MG(F:;W3%G7Q9C2?(?.^97'=CXN.S;,N$.L',^T'+ZGM-'=[WB-+L<5![IFGA
M'M VH*P.1^(2\&;Z'EPG\2'?]-!-0>+%+="*VV72E4)O6*"V8\91W*(9PPRA
M\(K/$ZS!,!W2I4J,O7=3]8^>Z#$,IB??'>,N((M2YD3.E*& 9$!%8 TF5$%$
MS/R:("">\UN-WIX[+N%-7H4!B]T!8TQ=QP#5>/.HUF1H;C<0 *-G(AYNOAEX
MPTL_O*H[LN=NLN'H?/64XRP?._8%$>UP)72"SJ>*ATOL;G<G/]0%-BY^T W4
M\XVP9<G8.)O)KETX.Y^<8B8&YJ^W67,Z &7.LH3V7CC!\:^.^5"8F;>;N[3A
MRBR^R#&J1L@)\O[L?G8PVO-O^:D4:#F?,QC8<6FCRFN2R?3G!@QVW(M',<G?
M"'9 GJ.YX<'F<3%@7%D[WMT@B60@OB5T_4133L&GP'S/?8DL;X33K'Z/E?3Z
MS/M@0A"&P0VN?TU?=/O\FTQ3-%Y$QYHXM3&2Y$J-J1S2-[Z;X4*7WL"H#D5V
M5;,!C ,5/&"9,KOCC%C\04KAM^1?F>S65VY]FM^4R!LT-><"H -#8JYB8'^<
M#L<L,!GQXQ.^(WQ&^#8XMTU@.T"W069:CGAU@<0#AC%%"_-TP@#D=I^&QOWW
MK<IOE=\KOC7$.,9%9L-N[[OH_$L,EC',)@FX>WTC.[CX8RP1Q3$F(O(@ABF#
MC-9A"<B4+X5%0PSF.WI4J5'*"^3]8Q%83+LX:Z0T5V4)7K&52*;(8BL(*5+"
M5<*\HB!1 K"%2S\FPRR^_3U>Z:I6S(514VE=<!S<O#/NC';2WG\QEJ,L$([\
MK^QF6L%NQ[5QWT>*3&Y3KM$9S%AM#Q8+/#LK!DX^, 2R'F2YN*S]^9$[6#C$
M\QPR\8K(HZ+>'A,'[%ZK;KX:<.4)FP29+O'<[L:<)@*='D]EB&D)E+W+]-K4
M<'RXDPMF> ^>#%+KJ,?#@/)W\F(L!(,(T^U.\^93PY.\AM&Q%X1$P882DES2
M65OWG//]YV1.%W<'ATY91-P=(*<E[=@WS$Q*R(ENI+. =)F^CY7T^LS[8$(0
MAL$/K&K[S[^FM.>'6-Q(<,6 ,;.+_(9(\"6X&?ID_=Q&+?.QMNCO_4:C0XD=
M&\GWF1#P?:+>J>T:;[XKK&:HF'8PSC3'V!1OG'!N4S$F>#O7TF(H\L(,C[\>
ML.X3E,0U;HE@:UR8Y9'G')4KDXH:QQZ7RAF!V!DR\9QLS1;0;@3-7PF+".&+
M[32E<6+*WGUC"G7(F3YW1W1/-@/'7!CF,YD4SG?[P60>21NE-HQ;IF 7<-8B
M^53",+L!VW+H?BK1I8,J5DX/TO$75%2V;%" 8L78XNCLAA@G&!=-BXH$KXJ5
M*F%3RK_CZSS\K+T>R;+I88WF^QU8=?@7XY'0\8C9C'Q"_-J9PD15^.QCFF):
MQTB&H;*J[QZSY9IMK\GWB6.#K\P@5@0LDT^>TP1Y>T43I* DNWDZUXGG&+,L
M!\N,Q;F9\2"[;HXGN/*!^..9RWGGOW]E?*:QZ8=BZ<!D\?9C@ZM0]>[S(#!O
M!\<GYI"(L.H^$(081N)N&[T\)2D94;]0JTMWOS",T^&V&,!Y_N8DT[M(V*F8
MH,-'J>OCOEM)S/1]/#="*PS]&)[;*<]E7#UY,M6]]&PT/!TF;Z/E?3ZS/M@0
MA"&P0^LZ;]^81F;,T9CMG(T[Y4H3D$ 8$P8GF0Q>('ME,\$[0!F3+6*#-<\S
MT;FG<\)GCX7ZR[+R?N&++X3./P'O,DV[YDP&YOSOE"\$Y$5 TC><IG67A BF
MW-?>.37Q?>'VR\2)\PV*PW^A+24V])9FOF#,[7+#I#J^YCFH=\4I^;'VF(OD
M/>9"W)-0.;^IHOQ7UF*@/**C5Y@<IAEGYF&IY?W/V9^X$TGAGX,L@I.P=*YD
MI%,JV0' '<C-^?'VCIMWP?6+@7'7 FK'>'HQ^RW-?2H" #+ RR?BD>4QAF$K
MES,'Z/SN*=38<<+#FRP>".IOB:Q,\)8;VQ<0'2*43*V9\=GA_CB:7>Z]D0$R
M#&99-SDQ?(J&/W'ZA'Q#'R_<!A:R>LQE[6;N2MXP738&LQRW&,\@Z,\UZ&S2
M)S?2:IF7 ^9;:XXGP1GS3+92#F82N>6#OT]N^5%E=G)QCLPHW7$W>W[F*NXX
M/[Z]H6R#YGZN(OH]C!?><3?W=.4;,X^SU.^;RBGT?.$(1-#R>3&(?W_<ISGF
MOS0BB&CY\XC!)6B_#2!4QT?1BH\2,AXLS>]NGA*I\&3N>YYG?+9:/,^,X#L!
M#1AS,2(C3+)<_5^H+3<OKL+><H['Z/E?3ZS/M@0A"&P0V+?U.2L?OS!M"*M[
MD;G9!83AZH^,1O:]H&:+W1;9'Q9O,YQS2#2ZO]1 81*]9Q8OFQ3K.4GT.W%8
M=:P):CQS$& ,5L79SL8#O>J=X'KL,TSW3=OGA,<,Y2_T)RMF&W<\845@)9U[
M!K',&NOI!-964WRK6)F<S>GAV/7;EL"'@J<<(E8S.8;9;U[/NWY='XNM-<'G
M\Z3'&75]'Q%U3J;#C=1 QZS2+C6,@ACDF.R^DX0+'8X.FQ8]R5*F"+DWI[_X
M^@<RSE\OQ[6#\^IGY7"*:/&Q7=AXRU<=EQ9#'YX07TL"7Y,L.TS&=P]3UEWS
M+/U%S"W-7VE>\&FASCJUKMJX>O&,W8RT6OI+1LC RO$WF_YQX1VX?;S@_O/Q
MF(ND\=S\U[.:$-P$91/IV,X:PUCP<.[I-%"Q-S5]<80A"8T54G.I2!SQ>4JQ
MI!Z1.6$2LF(<G/YO@[YGZC@['.&[[N#N=WM#M32T>/+>9Q2PUX,,#0Q(-C1\
MG"828L7UA#DSX3A!?EC&*F:0Z&9G,(^AY7T^LS[8$(0A#86^+]4QP9P)^^R@
M7Q)GN\*ZPBU/+'I%."/A+[MIBF>;W3)_ B%%>>$S '+&$8JYU$6#UZRXJ-3$
MQJ>$Q(? B&S*6Z1;)BM&:-.1NA[ N93C1ML(Z%LSC[\.L:(Q)1CHO2-NJ<SA
MF/2>T%]8$I4<"$4KQA9R[X%1/,_<P)'*HYEG)]XYX.9<6ZZR#WR!@>@FTSR(
M!"T80CV DH7-P.;76%F#EBS]<29-$TYY3+W>64>5#.(Y,S1.>,U0F]?)& _2
M5AW/Q=6YYG,CEG$++#]"W\!XX0WW768('@2A@0RAL6M7"X[E$,X8)PLZC+#S
M\EBE%-^W(GFO_'C4EBZ6?Q\Y1$%)V ZZ$;C+U3'F=GQR\@A.,"2OKK3NP8DS
M -(]I@:84?!)A9PL=5>41>$>?ZBDS3GL!6B'K*Q]?0C,,\IP)9=XD%-22G-9
MIN&9ZFW*@9P,P>)\Q(+>QQ.S>^=)X-'9=&>CN9D]6G=C@]SY7!9N0A"6)W1R
M>7A^X53L!BP13//CSB;@Z:0GQL'=^V[=LOKDK=^'6HJS68,+R\XK):QWGRR(
MJG8D#+4EN?0\KZ?69]L"$(0EW"'U[:/)^^,,K,S"$UBYQ!4.4"4.Y3VA%DX4
M3(H[B5X",$ZS/V9HR[#5*]#U871]^/6"5"=Q"J\ 1L'2[XT:['<2_!*/,@!2
M7Q]X>0AOR2+<4[B:]>\]HC.[S%EYS;]68UR BLHNFE\/<C?&8H%"UA!0X&/G
M 9J[_P!3)D=_ZCRZ^?O*D,'),GLA?*(J1$:5%J0XYQOJYW'O+<AX?N.M>1.I
MA#I<=%\6&4$*J.P#/&OI \9>! S+XOO"J*\E]Y74CN?>-F$D,LS5IG@-='XR
MB,LSOEF_X?H<00^##0X0CCEW68&,MWRK8AJ FJ*A9",]\.,J6Y?>*6*5*F4G
M)!^_\>-8D8YBM2W&1AX;<!,'FRQ-A#PM\UAY> >!"$;]&_#&.;W:[\?5AL-?
MH5K?AY3#M(<,M(CU \,?>:T@!1MPWP,N?ZF488 0FP'%]V&.PQ,33]1-D,M1
M:8)RW/*LXBHI)B[>)S,.CY=A,V>^K?R'7QTEL^)B<M3L K1$$LSCS6T[KK8#
MD[%">#@\]'TF.NF\31](0A'=F[UCO,U>NQ!QUD.JQ"L*VHS,(QCHZ2V7$8/$
MR]>,:PUX9^'LLK$"C7!&)R91\:8,SX/Y+J'@\)7>/7&9#QGF3K 3Z'E?3ZS/
MM@0A"7"!,!=(+7$^N#K6(E9GWH);X3+AS,Q83E^XN*[\_:6<#@3';=LU/694
M[; QLA 8'REFF.=6;Z1-A'GV A3/=%6Y?++VHW'OB^D W=RPCT1>.+*,M>!G
M[0+@-^;%Z]B7<8])5>'JROK<*N5-\IOB6*Q-CWKN[1Z2S1N8.SQC!M$0G$<!
M<N[6*F?:_798C8*E')B=\QBB IC?*.FQ=HK;ET/QEP-,&6QR<'O^B&Y#S)2-
M,#-.5(%!L%'O0W!##.8ZZ$L'<NAL8 VZ)Q-?\A=_"YN!Z[2.OY$!8"X'J_-9
MA=%O==]-CU&XLVY/GAZQX#0)0]G78=Y8^?#G* ]QI!.V<QOB7L"?\"#L((%_
M$]HA;6-])=TJF"BPQ#QX\_2 HX,^)[G9QA+-31',>"3D27>LK\UQ&9/(O;C&
M%WZG+=SSXQ;Q=E;NQ-%,N6GEM/;A\<+YCB1+KGB'S$B )E"$0)PF</)RD^"W
M=FG7Z$_3-("BJ_F<K@ZNYS);=62]TS+WO69L5MX>I.AZ$R'&5?C?AC 5]#RO
MIV6%@WO;L9W?*!K F'!KRG=\IP;;7*^QGVP(0A-82U;8J$M>7ZAZX^OA_7[T
M?3W1;/>^<>\6&B.Z#*)V(VS(N;E@-(US)P(TSV"V4+J#X3.-W,%L!Q?3.8]X
M1ZL)LUWXI3@L.&$?C]T3.@OBQ!=O"96PJM'G[P!20B,"NZ#/KR6+94[Q]I5Q
M>\]F6HYPP/T3#L!9+QG'^,<XO:C<H_3O=-"CBG]F+=R%S.Q<8AHB8.U<,)KQ
MYK S(\Y6)0WD<ZCDQT5S/:XKG'O.DS@.Z+,^P!&3.-,4+Y$,@H]B/-TF,L]Q
M@>\NTHP[GXP7-8BD<R6KGD\_H5W5)ZGDDKV_'QA#<<6$4UA-_M,O*]8Y7'N3
M-$W&=_CU/2<J)YW[3/#0E2I?\#_D1;5Y1^S:-74P76#2Z::MRW$22+E2-;MT
M7*@.BXI6DJAIR&;SNHY+'+^=)2 BFD5_#2"@=HH.&3BRQ7B\B%S['PM=#YS&
M!D0#XFW$<[%X<([T.OZ@L1*LB(W01-?27I&N,<G$_4KF\'?^^S8#B7S?H<>!
M<N%98GJ>OCVVW@#P_NU4W!UF./5'QP?3PF/&CW:>W="$=)P?6$JC1N7,FG\[
M XM'G^HDO\6%:W,8]&DV&_<PF >=![QTXXK@$N9OV)I7D/-_5RX^AY7T[;SC
MUGPF][6?; A"$(0A#26'UT;Y][F!L!$\[+PF'@<BH\<-K$0\0,<,GN^A^S14
M=:1S!_90D=T#$8<@B2L.2)S<7UN9ZQ;F["J06\>_WAU$#A.>#41@2\2/:)F
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ME/5F>T$.S(-[[$SQB(%PB4PNO]0&BROT-H\H'J^GC$?'ZOE?3LF-8#%Y;N^
M0*/N(E6/N]D$%5TR?.I0T&+7QCQUR^G"M$  :0A Z\[](69=(1V2'2$&H@N(
MF5J^O6VME?B5@\(?,Z[0+53+6^6R6<PJXNQ M()6-3/6^<;EKZ\ !.)!3<H
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MJP.6XA0URB=CQB2_!F5HYXLQX,-[,TW,O5'@.<.73$1IV-5"SA,*(_4?Y$C
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M4:Q\N#QE#D!*@M(X[W;D_P #Q1!@PAE_#*#;.N;/.S,^UO8W5RXNR]EU!&<
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M"5&EI1+$$PR F'#9VN2S!CLOR)FQ/1A&F8^)^&NW)]"5\;9&V0LOB5=^:SG
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M.)\&*T:V*T;G$^#.)\'ZG4]79XI0RM\.F,X4)!+V,T^!Q=E2C[\U93+F/#A
M+(^B 5KL$#<>S,]FP3/9<N7LN7",@0($"! E.KONJ)MW[^R3/A^!4%L--1Y^
M&DNLX6:=M3#-RE2H$0S8K/PHAPA@JV #OS>M=TPWY.KZ0@MQU^@8??&4:"UP
M1G\^'\^%]N@6&HFU?;@-!H!'\^'\^&4:B7Q5V)0*G -P:ING\^'\^ $( ,:W
MKHN_8!"BC"MXZING\^'\^ 4"!Q#<FB[]F4:"UP1G\^'\^%]N@6&HFU?;@-!H
M!'\^'\^&4:B7Q5V)0*G -P:ING\^'\^ $( ,:WKHN_8!"BC"MXZING\^'\^
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M($"! @0($"! V&PVFPV!V#"4<2$)4J5^$UF-P1^F/WN3S^MK_P"&I>< %!M
M;#8!@#M@R'V9]3J>KLE#:4-B8\_8@NEOS_<S_P"ZT[M^X[WB6W5EH&O-NL?[
M'5OI,K0IGR.+,9C,9C*91]BJ-PL"&N#$M=A,^H97.8&U >&H-+,IB'>F$-T>
M @E4=E0SEY$$VJ(SZ#X0($"! @0($"! @=@VG8#M4R9@<9AD0_#)<P9RAE;I
M;NE-98]A!+7*!4N[?>Y//ZVO\W:DYSCOE[3COE[3COE[3COE[3COE[3COE[3
MCOE[3COE[3COE[3COE[3COE[3COE[3COE[3COE[3COE[3COE[3COE[3COE[3
MCOE[3COE[3COE[3COE[3COE[3COE[3COE[3COE[3COE[3COE[3COE[3COE[3
MCOE[3COE[3COE[3COE[3COE[3COE[2W9D_YG/";ZL(5 JW%9:=8Y8#D'$X^Y
M$=J,%C0ZXXCP;.<=KF%%>5F'FNKE0O"5& YG#>O@194DPN\3#<:5-6)."GO@
MQ16YU?I/U<I3#P2LC.4.'@\C8LW4 43!82\&<*4#<@"B5;R :[+2R$-;V>5C
M]P(%Y2EI @0($"! @=L[ =@VA^)SF,J+3,@'90RDI*2@BAG%[D&OWN3S^MK_
M #>=S]I8?A$65%/XR$.=@>\6Q8F6Y\)DMD-DAQBXP;P[Z.R;B0%<;Q-/-VTD
MXW#?CY?9Z_4LEK>%-3%CTXV>![S,0<*>ESUI/>(V6PNK61!F+;S]"O.$@ =2
MBM<;\,,>$WT?I0YN]W[X.\#S_?W-%W$'.9?:^(P)QC&2%>9!04-U" 3-A1EV
M<I1-(AJH)F[6K)E6K*M98E6<%,U#5@^L$<MALS_#(,Q,H\3:8[YCOEQ9O@;B
M&]]]D\_K:_S>=S]H--P;+_"%7J91%4_B;<]P^:P/EH\VI<FX.ZVI9-8KMCG*
M*\[CW'56AA<.._'?PEDH+\(%3>0,>D#)>>'ELI/9GRPIN-4*&9$<HLW<7@$2
M\0?:XEVU;EAAUE7+3D&"_-\&#MGWDP /-^>$2T)5^OEK]=^H$'B7U9H#S]Y3
MF?.$FPY)GW/HX1CW;O-\S'5Y:G>82H%3 O!K^Q6!N E:#U/HOVXC1Q[23?\
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MO)R]>WSB?ET;'D_VP@5'SE2P$L8[T$4VK BT7&Q99LF!"@! X"!I-TJ1C+"
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M'Z; K;59?0S]SU[?/PN#8\G_ -:/T$LKLH,II*=_8%G-@!EL-E?>Y//ZVO\
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M<KERU\(1.AE-#!F;^/,_#Y7+W^\-7IC'Y$]7TE0YK<0_"POG_;@X"PSUOG,
M=5'C?HPEB6/+=!?0^=R0>]#=CKWU,:JQ7@<(1C0Z6OI'NZM?/'[++%F"7;P^
M5'8 <\9G/APZ1S#\6"%)/+SF90\_GC,6OT0JFCMB](BU=<(I[HWNZ"ZL7EP.
M6U+.5GM_L6&&ROR&3S^MG80A"$(JF(OLFFW(ME[5Q&9@CD[!28N$1,^T*906
MKNL6K;X:Q$:?N_/="*D+FF"HP[I+\.$134V5*&)HB R7 >/'G,P2U;B8^\Q1
M4QE1EM6O/#RC.8\^#[/S3\-E<O?[S,T2HF,'E[,7TX>><354' @-WZA%'PKU
ME]:"CTB;".OSVF8<3&^,P#!D;]W=#%7\O2"LW%?L;,<CWB./#=I#;JG'VF<%
M>'SQF4/SG#(%1IA+W)8S((Y=MX.# PT7\<H(& 9877&M\I2P\#WP[MELU<#O
MV,SGEX?[G6:_B<GG];.PA"$(0B3$@&(SE:;#C#L<J72<XI;*X80!>)$[Q(51
MN,6:EL9TA&+;';8.YP@Z.4:8F7;&L2%AK8/W8L>+T0PB.$I%<8:5WQUF7+$
MHF-"(<EOOJH6-D7>(/E$P(2,M\H[CP(N(L$WP37>,/H\38B[X[OW W$E5PQY
M_7IE?609P+LRN7O^64%KA&%:-^K&L.&^&V%[S\P["HN"MKBLV,>R;FD :'6
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M^P"LPPYG9\X?=^>="8L3/L@69S U*13#PLY@=F8WP:M26(3 =R8Q2M60@9J
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M<SNP*91%OZJ$>0?3#-+9<K=L'MG .WP)?#N.!IL4"V:H/+]QM<SOV3L_,_\
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M:<:$%H,&;J9\;Q]-A&OKRO#RAF"8Y6_&L&\6B%(U&*C3+@;,=A4):QC3N_&
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MAI6+H2L59=6(0&3CC@DQ;5FMQ8(L1AATAM%_Q!XMSFM/M7G$V<NF?A?E%9S
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M#5](0I$SG=D-POQ9FK9>P1N^82Q>DY,_Y)D\_K:_^6KH2G?*=\O1[5^+S9C
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ML2 P@9&AP='P0%!@X?%P@,"P_]H " $" 0$_$/\ XLEN -\>"IONOF&HO/\
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M:#GO>&7.7-6HZ?)]#7=%ZG,N3XN'K+X'=#JP#U()8KO?%'G'"M< O4^<L3P
M#U;])DO-]@'698'D+[Q>0\B7Y#R?$S(/@]JA.(\SWAMP0U/9\I@P\"ST5])K
M(X ?0,S VJ_T](V?A#W/B8SA<5^F?I$S!W.&S0BW&*UKA,65+_*R^??>QM4,
M6481G*.<8QRCV=VDP(4^D!M6?OW=BQCE2@E1N**57ZI41BTA$$&M5!:%D4JO
MU0L:U[!5K745EAXFN\>941+#=R^PE]\9F"W\8KC&%S3"4"5?Q4 5Z:P6I09?
MPHJW,"P$RV9YC+ERY<N*#+F+FP5S6+LN5^/Y" @74X;R86^+5KH<XX04T_@0
MX#.(K93T:AWZ^7'947\!V7M<ZK*$:C+MJL,^&!Z1@\B^9B>EPR]0\G^]@"V8
M+!S61\O Z2QBWFL_#<</.Y8\;K%>.0Y7QW2OPK5'K@> 14 -Q1YOL,PX!Y6^
M;\$/M+BKZ0( M]M$#-PAF-J]M<%.DPP3P>Y3ZQ."'%7Z-=9R1 5]<I@*O@X>
M3?I4M$!Y/KAZRS;F.F^68(XASR^/.5ZQT3)Y3=$#NBYD#^-E\^^]C8$/GC&.
M<8QRCVT+=315]/X%HQ <GY=/XN1;1$<,/&"H8K#$&7+ERY>RXL9>$&8N80TW
M'VB[+F+?C9(%MO' 'RT8FPQ8XYA<J35#SF,.EOL>\,AI?<.4L5M:GO\ P'*Y
MH?-5H9LKQO1H.>]X9<X@O!$/3HLR$YGXN,H9R+ZI'CJ[J/9@BFWC\$XSS?,R
MH.2][GJ24_$;>C7UP]8Y3<QAYY;!< \3)NKMW&<J0=+6]APSY0R+(!@2TY-B
M\W(\[X11I>!;SR](R5[T66/-E\33+F5!=M12C'?H]O&'%]#MIDAELFYP\1P?
M$A0'$87U/0F=@T.'GB>;*MXM5AY8GE!DIO<X8F&)G6L>ER=1WGW&)\5HZ)O/
MN$ YDK*CB38 G#\3+Y]\Z\D1C&,8YQC'*/<X^Q^LIG3'=_Q<PIBQZVYCCAO?
M$JCLQ4P8%K:+ERX\8N$&8N83!SO:++ERYAN[\5U>;5^5OK./;>K72<MV_?&5
MK@/?WF)E>.#_ )+V6\/&_8U_@%"C. 0+:N1SJV4"KG8? W'#SV.*70M3)(YJ
M]*EL'!H'O<5;'DITJ9Q+BOF9,O-F63DLZCF^MRG!?)]ST@5MW3)YY>=0G-NN
M3RR\JAP #0=:JDS''B<8% =MS570Y&KYRM\:CX:'@'&Y@1D8;KKR4OQN.<(>
M+Y@U6<E\! Y6\/[@K33P_N,4LYKVN&'5R!T153'%75 _7!.E^LRB>8G2YC>%
MP1],_2(65Q$Z[3YKI_6Q=673M6+AX6>D34"6I<CAXF3XPS1:M45887YWEL:8
M+HZC]S-8]&D\DWG#[GL0S@XH1PA87\/+Y]]D\$8QC&.<8QRCW>2^;&!R(Z$&
M&4_JL05_HP5HG%0P@O*<3Y,XGR9Q/DS_ !F?XS/\9G^,S_&9_C,_QF?XS/\
M&9_C,XGR9Q/DQQR_)G%?LSCF^97E?,"L#L'5K+*GL"XXT@S%SSW@K[,F++ER
MY57?^+4V-0&BFDP9F.'M99M7W?+EEX_OK@0O.6K^,,DR\-.\E&4MV+US]8Q8
M#?B/)I]6&EK-<M/26@=907FX[<Q'D+ ;/-'6**IXH>D:$.8]KE0'NM'B-/'.
M$DQJ765ZU>-;/"7*_M\AB:OD,?6^A$;;F5V(S3,5]@56-,]V2GDV3/\ S2NE
M16"G%7Z-=8/A[T'^GK +;BZZIC[\U)[/6!6 \'V:]+BEI<1(45'%8S=\?':=
M=UW3#C)^LN 9 5BKXX!G$D8AH?*S.WPHZ!'[:XJ]=HLD0%F<M5F<'\(R^??9
M/!&,8QCG&,<H]]</3W_.O^9:B9;<=>M^T$TLK>,3#/@H=.6O27RLB54,"NZ&
MX F,B^76("?TQB(+9GECZRBUC[3%B.[!5$85. ,HZ;\B&HO2?4/B%6/G'Q/]
MXCC>8^( _+^IP7S@6:?%@>=O%^8%_?Y3@_-^9PD!P/(AE/((!B>0^)_E'Q#
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MRMHH]98&J77.=/\ =AM90]UE\^^R>",8QC'.,8Y1VC&^[YQ?O7\^I4"FR9/
M>=;%9SA +5[5#.9D9EV,0R!,\)53<HPXT!SAX-94J'GO2 3*49,SQ@LZ8&"5
M8&".4!NJ9$W"SD!ZQ:*P]XYAQSR\XBYQ&:.X3@[/<H%EDJ5L/VZF94P>1&9$
MF [!0SF3DP$7,L!,\I4:S1&<*"Q&1E0R# \EYL0%;CU_4"C9"NMYQ-_SQYS
M[WS4^/[[NS>A"USB1K6(P+RF$-9O(KVECX]1G$Q=)D@K:O94>/?/UXQ8#G,
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MIB(S.22>34/7ZP+PAPO'8+-/22P]QE\^^R>",8QC'.#6,8<4-8];![\9FD
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MRG!IY9>D)AJ:\:/2;YU]:/*:=@QYK$4=XM>!?K$Z:+MWKI[^$"S@.GM->KY
M?8E8KICXW[8S"H#'P,GC7A#>86M,\ZE^:M7[]WQ$K-E<'/#WE_O(WS@@H$.F
M,3A8<'P/=QA<SH^%X'S&UYES6CTQC%_0OWB<SKQ\:/*75;G-_KWBWD][7VGW
M'.UB!1B7T+]Y=C;BKX0 =/K@?,#EX+#D?-2RW >_OWF<X6*0)4<%KRRE>">
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M9G]M\#24KPX'>BQ>&X\7@.SB?->LQ:ZZ/P^\T=E:1B5QWUTWLJ.1R/=X](W
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M4,-^DU$>GE\QPPBQ8L6+%BQ8NPQ5K'?ZAZ3AG*FMH:7>^FP R/TF7S[[V/\
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MK\1WO-AO>3BGK\3BGK\2TUUW?1=-@V5'J'R8(EDX>J>L>SG<_B5*E2I4P_4
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MAN5,YBMEJN&>:B"6!BK%';0UN.*%0.A*9B&X(O9!6B.UL+%2X8PQ2+.V;%0
MHEDK']G%OF9>1\O0E2N&?G_1U>[!5$QDJWX/[])G*;C ^>DQ;76]V7A5Q<_
M^?*)FM=7L@UR]##JRK,ZLYF/];$@I0Y;:@W/4ERTOA+-TL[ LW3@BK_,<.[?
MS<SEV<B!LW[;.HZ'L9?%[1C&,8QU3H1!,8IP60G0=D%G/VX!RLO[4N(YF&U
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MRMVVP^?IWN6'\PKM7^AS.7?9?%[1C&,8QC+R7K!37;KNV(,XUQ=10H2\-FS
M.UF;N/WENAAK'\K+Y>[V1J7+EPFLN#C+C+F;*<)2#<B(\<I4J)P-E*V5$C%I
M-Q#>E968,F,L$$6$!.S<N&5W1^K@/NL!VI-2/9N3\^,TA0JHF;]A,,]=YZ'O
MX2T31/=^[_P@BWVL\"/#NM'OO>&6^,1,MM[XUI,G]8]W4NLOYEC^FS.7?9?%
M[1C&,8QC!*#P<8E-/X&*T<B(RUVHVT^GE!NFV_2+*HQ<S07VF+L=PFEAYLIQ
M/3%N5#U_&R^7N]H=I'82X[,5($VYTVF01<(KVY(1 C#M)MV!'*3)EQ>Y+48W
MD4743TBAI)>,W)KTOYAL+V+4"6?K#1VN!"S<L5QU\")R4<O[S_!PE]O="M\0
MP^9D*)_GK#RI&F J@Q["+Y^M,O?,)A,)1OE&^4;YA,)<S_FMRY<O]#F<N^R^
M+VC&,8QC&6C9 X]B*I[E!FPMV-,.AJ]I!P8YIA"J8.#!@67?+&38VAJ?C9?+
MW>W;+@Q9<N7VX4;(&B &"%FV+>$("G9EA"A+.;!36VYPM,"9[%=AV9V^F(.+
M#A F&$N7+BP6MF7P?K*5?UK\3$O%]&AXZ\.?Y68"?4\2 'L^Y\9FD.+H?>$(
M(2P:C5;G=N\XJRV>-]-F=6JFO CS I^?^29G+OLOUNEW&,8QC&,RQ@IJ-8>(
MP>VAF+@61MUT0"L7HEKW85E++@?'XV3R]WN;F,QV6S&7L"%$K>UQ@T-L"M6P
M/(QS!F]Z8JE[QLN4VBYO;!>$147L+1!A*B1"4E<97&:TS!/:]_U=RXSCP^Z2
MES'(?=")5M<7\ +E$HB5W#D.(;\,F V Y%PPR7K6^7P#?7%\1[QL5IR7Z&RC
M&& YN?D=9F7.(Y/)_FYQ>'ZS,Y=][WM C'7$ECE&,8QCMP)81&E4$MQ-_;1,
M6'+' BXW@[H;[!\'/QMR[UX1O)[R^P7+2]BQ?#AOTE:QNK+ERY<N\&#@\-TR
MER]BPJ$(--QE9<O8MM;%Q8]AS-CV/?\ 5'/&=Q*ED7WQ8[PS0W'W/\%PPVC4
MPF':P6[,.7]L3<@:'+:J-6\Y?WX3&+#7>ZQ4Y0JW_P PKM9056?K,SEWWO>V
MW@[67>)&,8QVWC6VK8)QA*Q4-_HG()@#7%N@B]NXASB9BYASAW.9VXYK&',<
M7\>IJY_/X@?VF $%$=ER]I3@S&3+L9NPEQ>SB;A+BQQEH[1/;]_U(4,?0-[*
MH<#%77C,H0RX\7V_!,^[L7$/L?<("^=?@R)F+6]P/-E+DTQ?O@P\Z'P_HF:-
M;C .;\LSP16$RUOG&M=?YKA^NS.7?>][=AWI2Q+(QC':EE,Q-3KW:49'T88;
ME?(J8@NUDO?L(N  <CW_ "$$ICWYF7Q^$.3JU %E$=M]@EMP@IK9H12Y<N.[
M0S7+PWQ<%F\T\(!$L=E64RSAA!X6L -6(:A5G,OHRY@7CB#2^?R2XRYBQ@S)
MX??]127FZ$4X&JNO.,. /7^MQY\/RZI@.;]UB5THI"[\S5YW,D([W/W?6+7O
M(?&/K,I3JKC]YU#/P;LOCU90%P,_CR(MO#$O-'/UZPE\@OCIZQ;Q?^!W^@S.
M7?>][=C/!C_6)8XD8Q[ &F#'5Z_=W=(.<5Q"N4T#?.!UE\GC#+8?)E+R'<[7
M14$8+@ZXGB_?**WYC^4CR6./P6IC[XQC'L$)5B2Q(Q<N7L/F>NN$M+1&Z*'+
M!]Y=00#@V+K<\3>14Q7%,T;S?Q::[YQA'DC*=,/6_HDI:_4#Q?097;@:<C#U
MS\9>Q:AA+BL\/O\ IT/&-_+YRF"J'U^5B'@F_B_'YC1S35Y?,)5G?D''B^>]
M@<!WO]:Z1S5YW6CT95J^9_7I$[7F=E[YF_#_ + ,..+QW2NZK?L/^+YG+OO>
M]NTR\00 LC'LH"F:A9Q^90W/N_*"8A[I 4Q^UAN<H]S$+.) -C4^XB\5D!JQ
M$N:O1_,/ R9?$1*S.\R2V7+G %CCB1E+E :PW4KNE8URA,TIL=A*V"N4Q3$P
MWQ2A#<%N7+@V#G?KP\MTQM!S3KQXN'EN5*,4>0Q]:F5A6>& 'A9XW+ERYFR]
MF7P^_P"E"%:Z$J<=\GCOY9<Y7LV@^X'TE]\-#0^[_P LP=KH0:9OUC\3"^Z#
M0Y^Q#*4Y4=,8Y;;QVY3.5/5$6%]8LMES"42N,J5*-\PE[MIG4?\ BV9R[[WO
M;MHD\-2 -D>X<T0&8GWCW=^)G -#GV*HW/O3\VK5B9_/>9>SQ%@C KL/8/!'
M:YPP[&&T4;(=E@^3?S-?/E4JRQ\FSU(E;0.K[;6+V"YD\/O^C!6B4GOSX:>/
ME%J0:KGXLMOS7L>[Y1P]KJ_EU)\=S\#_  BM-;UGYZ$$M>?P^?+?$2EKV %1
M-%YOANPERMVS&?$ZP_1O97=5.!'# _XOF<N^][V[A&AAJ0#9W*#AT2YF3-7=
M4/8P%D.OYV%.+T>[R[:C,09=42'8=N1, B[3?L)C%[+14EC"V",!N?AT^29,
M=!Q33Q%B,Z3!'396TGL^_P"A,#:[I0^[>7SY2M.)JS\]/"I8GQM/[\/.8I7#
M0Y'Y565=QC*O!\<7R^4E3Q X^6A+T/"/=TZ\(U2K<,O[[)X+6(;O[Z<\L9X8
M&G/GMO?!1-SK,0^L68RY<PF$PF$PES%E;Y>[_C&9R[[WO;N51X:GQ!L@*TX/
M<XIDSB)O@@L[O)8ERF#YF+^<H.QEHY:=UEER]A;@E3,AF<]94M-I>P(Y8R*7
M+B[1EDN7+ER[P@PABF2;S=\;F,W?TIXFLQBXVG-\]<(X>'VS><3:PGM^_P"?
MFPF_(\V">@^3\2R .]S\W%EI8;W ^7TCEWF[3R_*H+%N+>6DQ>SXM'I\QH%\
MD],V8 CWY'SZ2U*]PP/E\>UE&J7RO96QR ^WM'1=!:N0?<C7:YC<]&X:X9ZR
MTOA+-TLW=@6;I>XEO^-9G+OO>]NZ4LZ#$V$Z09MA4R)>Z><OHH M=E2R.D!<
MA[DL)BND7?/I^@M'/2(CQ.YR=EV5"<Z84Y,J5*-69FPJE;+,MM[;E]FX2Y<U
M-,UU-SQ\YE9U+ >&O,N4*#U.3F>$7>*F#X.3XU+I=PE;+GL^_P"6"J#&8D@<
M<.N/I$S\+Y/Q *%FKCUR\)@F-NQ>N7K,' ^;\>DMF7'\RAL/"^LP-?.NE1;Q
M>YL<F>9OY[_. ]M"O/'RJHX!FZEX&XXLR2!QS>.RKVX<W/TZS"^]\-?GP_Y)
MF<N^][V[L6BR*;;>DW>;S* +':*Y#!*L''3LFU%Y^)ZP!9V<XNC7T36[?^/T
M6%.#U.YR=EV+B)EK -@G69^Q5S_"1B4D*/6#W>=RE"OCB>9CYA"M'PW^)9*O
MS/)Q]26S4X-/DUZ+&QEN8F_7+\?/;D%F8U<4_M](O$3D7ZM=)CR+B_%3@'P)
M@C7P/=KWF!F/-^/2*V_1Y9?JG9R#ZX?>4=+IB^U^Q,Y@X'S<O!7&!SM<B !G
MKS<X++)P\RO^29G+OO>]N]02F,;K;M(S@N.D$%FQ!*9G,9NF$Z]G%R68N2[5
M!;//2[I2_P =_P"DNU8.?SW!V+_$O;>RY<N7+A1T34E&*-WR8^LPKEB]4$)0
MYV"8\F_2:RZ^+V89=CDWUN*]P_LA\]YGM,N+R3W29BNO29IYCXAUL.(SBH-@
M+RG$^3+]?DPP1YSX@V)Y#!M4_LI\S, /'XN/RWF^Q/ZH_N9MO(]IO9S7YJ [
M]">LRA>6/2YA?DA]\I@A<UOQ,S3EATJ*JUM_6$Y$4'-_H66U9>C_ (>KL,#;
MPE,G'S\OF%*]^^?@J*P6:><5I_Y'F<N^][V[\&BR*66])HLWGQ-2EZP5'?!!
M,XWD%M=AX M9$ ,[TCD%><;N@W'WYE<J/TH CE'P,V7QVS:=-]&=;,9CGLQ8
M6Y=G'9C^+[7OL:MCEA,S/''K<ZB#X2"]A_IF13R?>;F<Q^*@-*CB3_,?,_S'
MS'/>0B)?J1S!]?B)?U^$2R3X,#F/ ^8/-?$/F)R#QOV)EP>#[LSZO(#VF?[Q
M8JMO[%FQ! U4'37/#C$@ATMR/"_6HYIW&3[XD<)QOS?O.Y_N7^2I3=7CY_%R
M\MAKR@;P/-P/^29G+OO>]OPL;!F-=>K"*HV,9C>?$T&O#/RB3!!Y3*KS<IJ,
M]?C]4XBCS3N<KPZQIN!;7)@&Z(4"4P_N ?D7#!:+B\65]7B8=-BW<%?738/$
MH+:Y,-25[^Y 8O<XQR,?W?#RX/XGM>_[ZF57; ;Q<Z]M[X'"X(' PQ^#E4S*
M!QP/8E$YSOX/67D'R#V]XNBW >_P$LT7>XQ+#>.9IXG25H=1Y&1YX^'>U_Q?
M,Y=][WM_!1OR,OB(C3W%(7CAUE0O''K+B=WO&&-T?:7*]\S%A2(&G0ZLJ%W^
MT9Q$S]YB3!1XV+*A>./6(6=WO$$HU0#?B6_?6&@U''?Q_$]KW_>Y8]PU1K.&
M_GN.LM3#)+'=J>4KAOC3F'%Q?"8"!X'NVRS!>+>R]\P8//\ 9COD'3NPN90C
M_P 6S.7?>][?P:I5S^?U7M>_[U[06TND%PT8UH?+Z'K%P\60?'=RQ>4!5XNG
M)Q^NZ/4M<WM&_'Z,P+ET)9*)4I[%,M,"-MK_ ,6S.7?>][?P?>.].'=TC &;
M+WP##I=Q7,QKRV%)NH05AEYP!-'\CVO?]Z]FC\;S>1\^LOA0U7-^>1*A$;LE
MSU?))A"W>#[TX;<68'-]CCTE'50KX.>JXWV#?B]4Z7H[%RV6EI;VG_BV9R[[
MWO;^#HSP8R\+NE;FH]:EMW NP:;]?&#V,R:KV(SVGS/LYL]0_D>U[_OZLJ\)
MCI7S?+Y8918U9_!X2^]J/GP\YB=/H<CLZ)777UB;D1\L/8[!Q>#T9TO1WS_Q
M;,Y=][WM_"+@S,HX"D[EB]./D_$R2*W_ -?W ,$%I]X,TU\OB)0\)]G-GJ'\
MCVO?]Z;85.)5LQ^_,X>E3% =QGY&,P.YO<#YZ1W3W&!]Y]BI4PA@>?/6#O;]
M'#XF'%ZSN(TD4;$6@>K*FWATKV[TWQ_XMF<N^][V_A. >#U.YRRB:SKFP4;(
M/93FS%743M)^3[7O^]>5EP^W,*=\?8VULPER[VZS&9]UE/@C%]#GKY0>GI8.
M9U6"]!;J4>4J8TSQ/MZ02\QIY.7WCWF?_&,SEWWO>W\*P P<^'Z;VO?^ 98]
MQ=F6;R,XA'3?J\?N,QEWF[!(T/7@2YRDOR;E=U4O_C&9R[[WO;^% P6,OKE:
M7_DX;U^)PWK\3AO7XG#>OQ.&]?B<-Z_$X;U^)PWK\3AO7XG#>OQ.&]?B<-Z_
M$X;U^)PWK\3AO7XG#>OQ.&]?B<-Z_$X;U^)PWK\3AO7XG#>OQ.&]?B<-Z_$X
M;U^)PWK\3AO7XG#>OQ.&]?B<-Z_$X;U^)PWK\3AO7XG#>OQ.&]?B<-Z_$Q%,
M:RX7^_ON3YQX;GCKLQ3 WN']S%:'3^LO-E Y)Q:^\/&7/.4N7+V83"8;+E_\
M:S.7?>][?\W(HX#U8IL+,/J])E,?>_;]2._^@_OUA=8.'R_$7KKO^XL(34@-
MX#[X?\DS.7?>][?\M"62R5N[5*#R/=EI(^/K]8:A;@^^\O >#7SF"C3A%;;=
MCK;'H?[C)<C'Q?\ DF9R[[WO;_EKV+VF M92XO1_<-0#5UCC&?#[[R@(^L4K
M5O8=>%COP.G_ "3,Y=][WM_RP[A\V.MYS%WZ:S%5?;Z;,WP_Y)F<N^][V_YZ
MY;IX16W;_P DS.7?>][?PX#BEE"$*V4FRG8B9P6U--""DF<I=E7E*K93*V!;
M4TVRDV4_]ZS.7?>][?P^ M8E<8<0SB< AID%4$J4$:R18$?),Z:Y4:$.)%2B
M*E,Q%9GBL2>5FG'R040DT( K$,,HMM_Q.NS>W"8;+_XWF<N^][V_B$-F")<.
MQO)F3<9[(X2F29TUSWQTC*HDJJRRR7N*#5H',Q,D5TV*5-=DI:OXI<PV5W%;
M,_\ C&9R[[WO;^'"F45<66JK@IE.-!3*+>+!3*8EW,YI7!&4%,I>L5<X(RBG
M.93C0+:BHK9I7!K*<:6C<6U_B]=S7_&LSEWWO>W_ $&Y?8N7_P ;R9<^U_U/
MM?\ 4^U_U/M?]3[7_4^U_P!3[7_4^U_U/M?]3[7_ %/M?]3[7_4^U_U,!A5?
M_D ?_\0 +Q !  $# P(%! (# 0$! 0   1$ (3%!46%Q@1"1H;'!(##1\$!0
M8.'Q<("@L/_:  @! 0 !/Q#_ /.E^L5^J&3$V,/^<&FFFFFFFFFFFFFFFFFF
MFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF
MFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFF_F2NY2+<1F4VCZ<]!%0"
MS1 DEV0/\W--------------------------------------------------
M------------------------------------------------------------
M---------]/!M(%DBD683ZM5@A(M="B!<,EG,T J$U0(0V49/\=---------
M------------------------------------------------------------
M-----------------------_6*_5#8F+F3_\NQFXY;:9FXY;:9FXY;:9FXY;
M:\X0NJ@)80YM;_YM,S<<MMM5/_\ HC@C6=9HF^'A-4P(!?F&+9H>_3%1:B$N
MG8=_ \,R$@LK@S#Z/EX R $JX*-L:42)N>!6Z*,P1&)DI>"-6E0IC31)D90U
M!2P\=HE!T)<4F*P6J*),!N\>$52HPR8DTGP3M6+LEF[EIC*$T^D8"PJ)@WL+
MV_\ 7C,W$II K0KCD++N*Y6\J>$!RM&JA%BYJKK$YAVH%C.=%+2J!<'/$2&_
M$U$! 8M.?JOF)%(CCV%L3+ +4([A4\8#1<,06K95"X0=Y:B:1<-Q(_B' @)2
M^;:;8#,,QJ/SB 3(R$D1P^##>L:?4P,B2REM1R]CM2(*1N(;/!1:J&1IL02#
MG,#:F<!F651NJW5^HO#1W@E)&%;!"DIN=@>I61@;Y'2C"KP!:B066':/%/C.
M07,BS&$Q-J-)N0#LL8'(O'UAL=,*$4!1N3]AOX]2\R4),)9@&THAW>!I9RS
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MHKJ_X";CH-$L(*35P.#E^I<V4HURYV=&NKBD!-^=S^ @QQ&L ("A;I"5"@#
M+R1);0-BEB+_ %C6R^<4*!L)3:I9O/G9&4M##:8B'^2#PCI;9($@2V*=.959
M 0@(NP,V6_\ @3EMJ?C@80C!RQ%.Y&3$#2-W+=W^DI@FR3")<:,0&G;0LT1@
MT2CK!_EIFBU (2;BD,9G:LT$-H3, E6- O/W<3!:)#S"!A%7$M4P?,P ,$'%
MK1)A]<AD(8;,-0<;CBL 1=3,Z5(T6&*P)5Q&-:(DA]N^^,"6F*8];KC:A#F)
M9J'M,E,;F@)D&C)X+I0.Q:") 76'"):D(J*P@,V#1.9YJ=)ME,,2T%@FX@34
M 'K,:EPDI$TIU=[U,;NJ0>+R24-#-K6# [*4L+$2U"AZQ&Y<+4JVFH /68U+
MA)2)I2J+,.I,2<XUJPDWL/KA-Q6T^":O>,^,2AA-D#$@T1SQN8A!@,,B;@(0
M)/HK2QM6M,Z4$6U1!NSP;P#7%;Y:YA8&&&S#1E];P+&"-;.E03T/TUO&U02%
M8B65LX%$8V4L,T"4I#;2=-!&KF9-O"7UR.$30R7J4; *8U 9N,XH]$(C$HAO
MT:A0]8C<N%J5;32'S!R!LB:E1.$AG*A)KH0"P%H!9# 6)#/1$ 4 (!4+R2]Q
M@A(C9&G]1/B;H4"< P8B(B!^1(0 L@! (E6)5J%#UB-RX6I5M-'S"< O4"0[
M1M4CUP!E> #L@M%,J%<K=GLJMY-S4DB2=Y8'38'CI2!)*!&NA( $2,U'#P6&
M\JL!!BYNS9Q4+(,U#,O7DGC_  $W"X8MW%:#$<@H.^5ZL#O1'=:V]I/6HD67
M)3R /<>U9C7%2S#:C^1N/B@$Y;I!_P U#EMH*RD8V)/H4[=H33FVG-(,1-OI
MOL**&LB$([D H^&(F= A#L)?<I_#4"$3(G@PX.3#>ST@]CZMZ92/C)4S5=(O
M4V4;Q9AL4XIPI6VE)C:-_H(<Z;(W:621-V?VA8STZB7*H$<UA YLQF M([_<
M"9'1RD61A.YZ:1!@2Y@U>?ID&3D.X8@E@LG[*V,0=HR0Q*)^=64B R6@+O\
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M!80*9+$V;-"2"& %\4$0(I-.L\?:D"NLW &E4Q4Q%@O@0#%IN5>-7*$X"I
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M]X"3:HJ 1'"8R(DWI&MMKL0R0A@T44+3'S[98D N&IA"($?FPFPHI%($!"
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M>1A,'H 54CF4&&K#>=1LIE0X5'!^N4"1)& PCA&DP.115XUE@Z-$ "$>:$L
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M9" 7"@R]Z+3@$PT&Y*(:\,Q"V(%!D!04DE.TC 1*JX UH5[K C4B^DNB^<M
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M0)+!=$V:L5VL/))*F>:;@Y^0V(*1X994>A\0*1T%@FK9%"1IFDKXG4WI[@V
MP4+<H(D19I>KN74D$83:XQ?+P\^G7S0!(Y*ED=7*$.%$HM6)F\'DYK"48Q%0
MLEE)&+ AF1(00);:#6"<1 ?2%-@A&5XA<+B B2QA'46Z0-SK<N&C2(U#6)R
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MP\QR4!$KMJ&W(-B(R96-9HL2')ES&@)8F2"XWSE8EI)83!N8E?/NR8 S("H
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M$_+"E,%#J;]F4SJ$"%&1W4<)4:G)L=T'MA3(<R%,C8*)@(W**R&;]!\A&22
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M1BND42&5;$13$D(-^"!3-(622N]4!(<XB1F!@ ;IH[:&GX7"1"OF!B9$KCR
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M(HU19'%#V',P@(2B:=7A2,@!2C!2)ED;FAE&%CA?3\6M1X6U)(9D8(XB-/\
MQPW!@C4 R>4@868#>0W; I=019QS*:NQ]98)H&VRR,3(%,"SJ:>!Y(I !8
M _FP"[43G/.C "J G"54N39,#+26LIZJ2Z]J7A( B>$"28']0Y;:%E;IJ4+
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ML6J'6OIBQT 7I5RWK%J3DJ!!)%+YP;P0Q,,+!AV:.4HX-*$  56Q1) )36
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MM/G*54XUB1;-C#F<$A0A:Q&.9<\O:8+ !<9B01<Y*0*#L9(-J"NI9=A"@CM
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M:::::::::;^L5^J&Q$W,'U0#!%V2DR'4?O=============7;#SB!6Z# _\
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M^%[Q2UFB1AOF72D\<"()ZK#UJ?7EO51)Y4?@"[<OWJT'#AH%^[*>50?-A_%
MMU.)/F@+<L0?)"E^N8<N[TZ400#(7ZC2@KB4W"[:=2CSQEQ<_)194S_7?J@9
M "ZNE!H+YGICO4L/&H#[T>>.^)I)8V[3U6D6-M#]2MG>/FLE0869DWS:#%;J
M@=6SZ5J)N(Z0+_1LLDQD3P:DA1ZPJ(PL8+'\[*B_R9ND_)67PS<D>'U[SHK
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M4MI8A)0AP.QH'%K?W\ATDEX;7L:O1HF;1 >X0FO73I85+N<;>!+&%$@6)[4
M)\PG605[* N@LB[$*!%H1K.T&]O]T=DR\H$[A"B8/T'UF.U"05$1[T5*2SEF
M^=!KGPH?9BAX\YK;UG$NZA1%7 @R&I0]./&,!"$D-GBHP9J.!B7=:*N;;^1U
M[J0")%TA>]_:EC' +=+![*+JW =D+#M3T2RE'K"?2CF$.CW\E4[$W,^HJ0KV
M9]04<1@>4R;TS;TF6G.9!Y&:)&T/6PD*0#=1GE3'([876'NK4&<0\T^)3F#S
M9?!*5'16T>6^CQ@9/H0UHEY-S4I% 'BZCO\ -6S+"Y&)ZZ-1L @2>AD=FH\]
M*4YF28N75OX6G44C9/.SIYU@.=>H#1*0D0N)DK1B$VSU^7G2X32V6U$_37>@
M 0>4>6SSK4D:2$;([/- )/Z'\CGXF#6%:ZUUK^YQADLUA@#0MBY.R4--W>@-
M+?MH897""#&OI4IFGPF'DQ_)P"#C8#E4*..$022QK<^^$!5" #*M6E#I(F%3
M#_1H!C*P'>OV3YK3E<.\UK]J^:_:OFDB4S]-?MO'CQX\>/'CQX,2.?IK7[5\
MU9/LR:.S7[)\T(DES^R=A 0)50MZ5 7/*]_VYVHP ! ! 'T 4%=1^)U*0JL[
M1/#*ITU(6H?4_%3=*?"!^K>[UN):Z*LE!\-^M3K;,1R7_/\ %::+2@8S$])?
M.I)#ZA1-^8*,9(J0(@]87SHYOQ(%@"I12E2ZH0+RT2"68!7=C+R_WLTAEH()
MA@ :NA<J_JX8-@V# 5$0'O0K:T(G4:X8/;TN]%,1"]PG 9EV"BX:RFPRUO-&
MQ18VAL/W:E@X>)TG!Y!XIHX9(/35IG"=$/*=.0R+('H!!W:=>7?R+%+,)D6Z
M"7:FU,Q!B)6F+3X$'YB1)Z6/,*=%!":<A&W5:@Y9$L.J$M<='3M QZ3'>I4>
M,AJ=3Z+>$D)'M29/F2I.[!:GU30B>A>M&[ KCU2B7W0('0D]-04VTN?%JG:H
M%_9ZDHP?2G;824&8+(<2QFK ]E8GJ#;O0QY,NB8:]>E39I77L\OEVIJ[!9?)
M](F]ET:CLEP-=/0CUHP2XW$UJ)VVA*8DV @[4+"A(R4G0;^E:-F[W36?*P1[
M >(!T NVMD^:@8#"XE'[#_NARHD/>-RBBR!D:&3^@_(Y^)@UA6NM=:_X'F@!
MX26/,=_Y+,VK@58.[% ,>5"J0BRVT^@VSL&4&(ED$\M*?@&"I,-,DL@#"&*D
M./6 D$T BQ;:H]EIV 5!0XV1UH?55&MA)2DLB1-*8UPR ,@PA)8#".I2H:8
MUA1 Z27K*3E Z(0G12&K)0I84HI2+P#4H@Q7=F;XEO23LH*1;##S-\:U)Z[
M4( $"%EB2AF$,G)XK'K!B3>A!+69K@0ET@3]LD:CT "5:6;>'=A07;2T$9C@
M?+0R8U9/R2O^/2D=AO>8/;PRKJP<%9X.[X>;*_0OF@"6$20^1HZMF9!Z793D
M0"& ^9,\/JY2K-@/**C.,1:?(@H<#A?\.4??H4!/"\M2V)-YM+(1E >TU^R?
M-*E?*E>[_&#0INBR\J4KT@2>M6[;$FCM04$97+RJ(:-V_-5H46 "!=Y+]Z7J
M*19?)*QAB&/+O8O6/(0QIY8*TD6X=)BK$RG(-HF#3>HK2IM>^?TVHP(*K.2P
M)/TI$SJ2[O4@[[&.3I4B#O6O<%'V/!@]S^AG^2!*HB39A?K."9636+O(3L?2
M+L0 6PV?1HDAPU)W(T&N)>3^5)+6F_7KXB=24Z"AZ+'^+&R%/EB+]\<U@CD,
MO,8=+]:FLB_$ >E26)H.)Y;5#HEU%Z$M!@,NJ6#N%<!<@7;%& !JWW4' N5
M'+I4/@1=;N24'JE6:L@P&"Q9CK4]H"$]X/2D<ZVBQ\JN\S>>L6_O4%, A.-Z
M;5^U.Z%&"TL;JBX[U"@2,T:2H#I+BEI:QV1D$O:@DDBW6P'6:*T@)0M3A-3\
MTQ@+V4"0'10\QJRA\B]]?6I_$A3OK87HT/UX.]L?('A8$'X"%8"6; <.OKTJ
M-0NRWK:_6=3H&0Y&N4 LG>(CW&I=S($/I/)HLP*4!Z6>4H3*,*1ZV3ZM85!
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M8RB-T O256PI7"TDR+</>BT)(D'H.[/%%)K!@'M/PRBD!OSY$JQ,V("/(H4
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MBE>ZTGVW.M==6:U?C,'S2JNNJ% @S )'K4_&-[/Y3** ?7)YHH$-R]R#3J%
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MI2QB"_I6W4>=/*I=9&F9U Q'S*: Z)#$EYYI:9IJ:C"E[5" 9J 5#LVD+EQ
M4,4&RB?2GF.S\I%,\;YU\U--R-LH:S_H4^5,-F:ERD([UKU$!*)8H<Z:M>X#
MIM3>5:6?4:FFR&5(*/R!EZ40._\ JN.WB :<L_U0+RE"<K<ZDW6I<3=Q@.0^
MET!WK/V9$9'G'4SV3TCYHT+']QJ!(?<Z^!]=@#A[UF60PM8JBCP+"S97D/#7
M^^]0U:26QUTJ8\2Q\E&?T;_85T -V*Z T9]PI8Z:TBMNE_P5Q1@MMG*4^2>7
MT:*TU@4ME#P&0](-748YN&0/1'6C-A@&P4"T&/!!^]*!5@,K48(VJ @AURUB
MIT 2N HL1'1ZR(J 074GH*T42NQ?PJ4*FB?E2P)"6:O9_L'Q00I(2Z!\0,E
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MJZ4L8\CROVJ>+!Y8SY3WH4*"!)D+Y>5UY2:J%9#:S6#@Q[-VDDAQ],I8"#)
M/K2 *^AHQ<[,_0&G$]S]8^?0K'$$63/O#LV*8%B*.T>V>M"C#1I0DA-L+GX[
MU P-TY(]H3RJ!*M?,3MNT1@,P3T_E1DO4-&6'0UN4D8"X?-26%_4_6I0BAR(
MTBH2S97)LW&S;$5>@B/N9A=2>9?(U I>YT?]Q6Z2)ZZTH;-W2K[Z5WJC+-/R
MH1--:+ W]!]*!<R?R/R.?B8-85KK76OQZ  JV UHC073GIVL=ON T[6)5AYG
M\DS-JX%6#NQ0#'E0JD(LMM/I[D>-)C!PC)MA\U#=)I/V5$GKL>C11$.IH]:S
MU(W#B6QZT-6(>A754-ZZB@[U&F/'$UG@XB!4][N6/O3RFEB9':4VG:E!/,\O
MW:DT+6,<*@U*&0L12-Z3O2M"RE\(L:EM*5"N5C3L/E41N26A1:VAXR\XJ:6/
MD3=6GE5T/](^:NEA>[YI_9H0N3O2EDK835QL=J@*,+)]+<8(J01=-T"?*E#[
MEZ=V@MJ.*@:-0WJ&]$J<+E%T&M2@(9$AH&]0WJ "5<!39'60%Y8T&WE4:0H"
MD-ZAO4*0"6!S4,9%H+?M3KS 'M*&QJ\5-/F.CERM+UHU-2:7UF3^K]A^(EH)
M;S9K@X06P"G<ZS]D<YD/*>G#Y7Q1M4DE+K.0*"T#B(HCNA(G$T7*C#/@02([
MV4?V6U2,Y\K14<L^C/PJTU%):!ZG_:GP7]*IHC\)'S]8G@K(*6G:\6J*4$$0
M9,!FXLLW%#A_@V%6A92?MB/)^C35T4\G8?L;*8:D'=;'IYFH@ @T"EBL/3)-
M71[2O:D!414D!N_MU"@(WZ7L;"8SQ 6LL&?X-B[W6C,4)BM-#%'%8JMKZ#0N
M':-Z!1)\%%_SM.=3HCC\TW\\01XQ*S<>@^KX(()0>X>C':I?8QW/9?*@H "$
M21*D))+]T=-O)WH>+,#"2#*]"\<G"HHHY#A>O"/([GTF7*#N15FEALP^Z_0#
M (0B2)6/-<HQ1RXCAY5-CVI&!Z*1PE&&A1M0S2FH9RW!Z58B66[_  >]0I&N
MY_U2%H]A35P-DJ'1+]BD!:*PW-N3BDA6 N.'A_&]*P,3*"$34BIFDZ0+S=R)
M'4-QJ( \(L6;H;Y3BUPW2\K 8 T-"B5$BQ$:W>57"<EJT*B&TOS2/@BB@)N2
M7)HJ!!EWY,W!PD;4P2"5>H^.U 8S)_'_ ".?B8-85KK72JU@]S@I>8+N'N7?
M2I2\&4#9-^M*>A!+:78SUC[MSX^4 _32+B0$T-CV#_(!FS<C!4V)I2!E4B9#
M<+Z_2CGDML^S2D -22INVYE5(S)U^BHH&X5HVWRH9PT^2-.6#H4R8.6FQ=YE
M2 PL1D>10("C _DH5*0%$YO>EC5E3+1=^TOYJ:5?,JY$[2&A9/15#FK66_6D
M)^5/.GE7&0"2DW]3RH(B V+>"9M#('0I,JR7H_-%9B*4T1L^*Q\U WN_P!1-
M<,"OS3J*0NH?.:$3R2(FMJ*EM423Z5)%V'X:]':%?'\T"H0VE7$!F*NT>=0Z
MU/+S,7S%ZQ"_>RM'7O9_ZJ< '%X=V6I;UUM9?E0DM+T*B[INM1L6=1#UHP]8
M*]*N&]!!4<%Z#^%)%218^J+2IBE$F>Q34D&B5BCH8K'5H&0=2N1OZLL!#(2X
M Y@]RN)U>LGF%(E:N98"KD9'D^PP>GDWX5$M@]5,+<#5:P3@*FE*\T(=1/!E
M8.M:3F^[I3!=U%'& ]/ PU:Z _H574EZ%^ *%FI^&)^/FIJ:O?\ 5ZF:8%ZL
MOL?7CQSB77@=W69%G_"$JK4,Z"4S^)L3_@TBD2$T?!7I1%2$V@]VA*$CN,Q0
M+%?\*@I(.6;J,>7NH+TI%E$#N]@=*3%/&AL&P%BM-#%94)BM-#2K8IO<C>66
MVZ#2B2-8$(,NURD8N7]'X4<6"%ESV*@@C%.7P-  E70I$D+LX&3S$JT5$#,_
M)?T/DIA9LP:ZCRF@42B1-2BW A-39-DI]U^\MZUD>3QD.XQEY#E G)3L3VZ$
M9.I'($ZTW8Y[&D?)^D<@BZNOK]-M(QV(NZ-QX6@H)VF<GF3VFA'9#D<D^'"L
MJ,+"O-?YHI8N7*K>D5F*?3QQ4&+N:GYJ4IPHLR9ZC?SH2,VAH+/K4#LSWEW.
M0,-W$-2"POG#![G:@?O>6EI_3>LYM0THB.*"*.2D("+LBB!0&27YESU"K_2Q
M_'_(Y^)@UA6NEFV@,K4*@O8_0X*PHGQE!(CI06ST8/NC<:1J.2FRL[ZE$/)4
M?R#+),9$\&I(4>L*B,+&"Q])',KT)&*65E_MFGA/UP7RJ,$!$]@DN=[4&WY$
M#O2!J1#U@9\Z38;I+1?CH>;UI2L<5C@I#,@%Y:NQ]0RGAKUI4F-(IY17)\B?
M>B>YQ^:IL>@"!</YH#&R24\J1O2=Z8 (W$D;4#':P]JOXX[?K3=UZB3TH$(0
ML@WHR6V$%/QM[/D*U+C1_FA\O;A[)I&5. Q1JR4EF'\5,%IDK4;9I*Q1T@L1
MG4,^<5!FF+U.]%K"V7\T4U0>CL_FK&7FV[6W)757775757#&B3UJ9DS^B*]4
M0^9H)F%M_-#E'!0I1'S]2;QV=*M*'>]ZA5HW@5&.-YGFUZ9H4\J>=/.C@$N_
MJ:4F.G4N[^*E!P_P:EIG<#T"@NRPA+E+-%:#-J)(T,S=JE)%!A!(G]8XG&0@
MQ@X30O224ZZP=#/I^Q%I+$[R'S72@>=OFC0S6:HLK3%%Q,8-7KO160%QHU&8
MJ/8Y+&C"F[6OG3YUBQ6FE%HT?*KR>G34L=JYI?M4U^HJY>"KH+]@+?#]0Y"#
M7>C"[*3%P+2G^< RW<["$+2A'^$#*--G-1,VL=V"IH8+'@KTUFIN(3[#'FJT
MZ9M@'Q2Q2:P#U;?-$32MG!#[-&TB]UC">9'33616%::TU@5IIQE"P0'@U:=&
M2%R=DX"8M[4C1%5JP];>93-F)J*G 6Z^)C8,H\GO[4<-0Q;0 UMZS2IGN@>U
M%,D*RK7?2:)QRP3V: 9(\6+$.D7/*BJ&$)$W*D#[S.!Y(\WT#.5J),KW9AN5
MXLB^@N9EZ2P-G9] ,@!*N"F(1,X-WD+T3P)$@I)W6#U^B6.R8L!=Z$N=RC&1
MB<Q=^Q+F6M8UJK.@(*D6_(:1M L= /"+9CX+J&;]6BVK ![!XC\61J.::.6R
MNXM[3WI+R*HFM\CEB>:O01;.<MOV6F,2Y0)DD<5[2HU/S5O6J\+(RRPOQ2L\
M5#>9\[U*R9CN@E$'RGT4QUT*,?QOR.?B8-85KJ8<P1T7/I'GX9(U.8*9Q1IC
MX2>@[\??8LEU1T[CW"B$C#A"1\G^."01.$Z!T86CY@: 5;F6[](VI78HLF>"
M@A.895/B-3\JB6C*(>]1&>+C AEQ*O<FFP\:-'BG:A,L=:3O2-Z3O2-_6E*D
M$3BF Y48&U[-.>3,/,I9L04 IW0X=LT%98#!=V;M/.FVC4DS"MT6&W+3$):4
M!QIV-)]R76%!(282QJ#L&A4)1#&<0(YO4=Z!O4=Z.5:I1?-?BKC:/D*<W<.Q
M#1XI"/, 2]$M3%ALU'>@+Q8%6K;MXYB+FAK?BH;U#>H;U#>@[U'>@Y$.6H=+
MV6J!HI9ZNM2YVA*Y0P+6LM]*N!;F:3O2=Z1O2-Z31.](WH3F X)9@9[TR%M$
M*=A\J(*^H:3.Y*LAL&G>CABS: 0%-3;3GT_K!=)80O=1X .M!OX"L @"X%N%
M]E"R'IH<>D4"X D:4031.4/24M<J%&1A-2KR%(S!0EIBL=8*Q5.P@2[B^HU.
M3*\X/EC0J:=7T4M_!?+]9JU<)#UB_K]2B7>R1ALFY'4_PJD71S>_'F\OBA"@
M"&E#>7G&UY%8* ;D*"DP,@G+Y!314FQZM'F9A&T!^HO>M-::PK"M-84P6.VB
M\?N:M*0?!-C]O4N32EG\TS3%)X1]/H7T8M/?2*FPG("9= /2HV);CW[O@\ZZ
M=E4]8S441*-D<J$:3 3.2\DHJU$62Q;D81CBIO,1&?X?1OO03V^@NBJ23+1H
M2>H+$[<ZB2MR:OJB>997(R/(^,3K-./?/28XH   "P&GA>23C8Q9[46(C[#8
M>8^,A0CN-A.1#VJ+)';)@:VAW@WH69'I DB.U:JSIM:0>A0@C8IY(>6S&:N(
M 5,;RGZ81(&O*Q["LFALHI!;3O&*0#0@C=(7.S3P('F$H$\2%>LH@._4)6#N
MU/:>Q1BK<7:95LE,MY,TZ'8HQ]S\=^>]C6B8F.K3PX=4L%O,*>M$*"C4@S;K
M-0/],SK2R/I1S\3!K"M=1U(%[V/2/#:0 T*R6:+?^JF#0B=&C^?O0!SINCH]
MF'M3T7Z61J^1#T#^.P\PX041T:4R21.9+KU^DX@29>^P58"#"/F2]J21/J^Q
M% $C:GRF@9Z0M+W:>= KP]:*CJ-U24&_;-)),Z67G3H8.J)4R>ZNG+R=2GPD
MSW4\F@-D[4W!R\5BQU(H9#['YK-'NV7:HA= *5DZ5&((P(?*]'@GC5[TFA3
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MZ@!-BDA)*DI@V^V$M! R@G[('D0DA+&T#-&#<)G&$@03.G\N]4(/,G[+4?\
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M!1/3I(! &]Q&]&#YT:4-+T.JB7WA8:M$"1--K\41>D!8:AJ5EK*0Y-0X\RA
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ML.U"?P,"&&%)[_VZ)R+0 NJ[5 #:=CK3>T/8MXGY%"D#D2I*:E+*+Q&5KR5
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M30N98=<K *V*0)P -;W 3E)RM0,^!Y<:X*185!K31#"H((IO20H4$T*5B@9
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M<1J\0<M3=&-)M2LTO,6"8)&%"68BG1M"]R,KY#3[,C%@C 8C"7$21%^PH%6
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MAH] XDP>?X$@2@P93"0J$4J-W][IRUW745<OT*KO."%&J&)]M%2F*-@JA3>
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MRFZI555?I $4.!NK8IJ6LMT]2>55-X;".N!(X2B=U:],L1!<XS0AVI78M!6
M57%),9B!>LA$81-<R4!5'K?V*3-Q"\11)*AC'"Z*&1RQ0J*87LH2N5:N9#UI
M8]8J^K<.1!9YU@R9<RL7U\WNS-O PJ10_:9"T!I"F"[6(P U+4=!5B>NEFC
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M:'@3E_QR.")4[^*EP<>6B0",,+ABGR]Q8<-H3LMNEI6-? VLM,7A:L\GD0
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M- XQU4%G&L$%T **(%O6\#\.ODH69TQ(#20AK3R,BC86 GF'R:O^E)87,@S
M@,4A23%<<(43JBVFE"F>;UB%QD="+,4G]4TT6F)*0KQD1YXF<9)&A($@P!)0
M,B&2SX7XS]PSS&A@%U!K03HI<7822,S)(PH3=>RP%!#&"92+ W=/@^!\,;-I
M./#NXD^L6;O@*8/87B&X ';[J3_%$B$1LB:46LLUA@E*$+%R9@!*1*6V(H:E
M#&B"V""ZD6$.&P))PB)(T(H +U*?R\"!^0%[Q4CM-3L&CH=:3B3Z4*"!A-%1
M22 ],/O/:DIND&2H'F DV&9PO-O:I8 -WWU[/G3[=B$3Z!1D8:P8=U1XI1E7
M5-(B1Z5@@=]:%"CCZH*TO##0J)'&@=.:VT^M(+"E3 %%$5@DTZ]V7O1!(@_G
M?LM50@N;TUUB^'76NI;CF>X8UV^4.SN)6YJU%G+.4EL0;K*S8+D"I0!6S*&\
MTC$C=OND2=[A0VN+.9C &&UPQ>%(29UJN+$<$+Q1^1 H 8 T/IM1:K33YX\O
MM3+B+<2&IRS&?,6XE/\ #.WTA: $3.XK/,+2#7E^ZL2?$G8*_ %,N$V =YN>
M8TLIPAJ!<KNKM6@I"0^#L=)]%%QN%,GNLKE5\&8 A C:[+B!UTS2[FL-+8.L
M:NK>I3BQ(,!JYBXZD1L%1.&$7,8\!6W83;,8?@V\+SQ8MX5%G)C"W>)*Q610
M"W26.D;1#YD-!&$1PU@M]'&IN>G@$1^]0"6@X8K IL]=URO+6#.L0^".PE/L
MZJ1X+ ZBJ2*!%VB9_$'B@<#/-( EWDJ:"'8[(4SO@47:A (R.$^TM!2]@X:@
M^+KNKNN5W? WIRRA0])>?A@*@3=FSUH\"!FOI%[L4  ("U!!:IXM4H6J3"H1
MM4$VH(;4:4@CTJ^%0:8I[D>5")A)_N8V#"<0%R*7+^Q&4C#]BP\4=MF3K3IX
MJZ*%*3PIYR'F5&=$'JI]%/T_@0% UZ*@0*IMTT+40!JM'AJN!X$&*L"V\-J)
M6<(08T22#!%),)!X'DBD %@  #ZW-V(GV59*+*@'DF$"S=\_!^T,KF[P)2%8
M(6WLFA<W 0YNA&I"97D+L !0 H!^001"%EUH:[0 ^P$>]%Y1'$,3*4X/(\((
MAP>C$.;=:*-4%FX"Q1\,%O+# DT?X1<; !8*1899A!PO"PNA+I3V0Y(B) 6"
MPX))I$S#Y!LB.2I:X+7<@":!<Z'(.1')0Q!BBVL3!>@7.AR#D1R4,!T 02PY
MY[T    L!6:"!_O4=JP<:71! 0@L04\XX-B1(Q$6BI:X+7<@"?""(<'HQ#FW
M6BC5!9N L4?#!;RPP)-'^$7&P 6"ID'$W6826#+I08Q[  J@($E"^2@W@D5$
M *V19"41A_@0YZHBP:@@DNI'!#4-EH# T0*4WF D4*'0"%ZF/Y3;'R(?FK53
M3:@$B3<<NNU7Z"P5BF 2RZ-9&TNU2.W<7#9_>:"2#KW'H>IQ0:&,76]3L]2H
M-,TH'1P^E*MUFGS^@4,4+T*%#%"]"CBA] !I":% RB;\45X];O4%"'0?U>77
MCK4-6&U1 ?SOV0J8"E59:UUB^'76NL6E*S$]DGR=J"5@PI@CL.QG6DK? )@=
M*#]5LB *QJ+!T^MR%$B9&K#8VS09\\]_M71GEM D[S_#)YIY@%)J0-J%"F2
M00"%G(?86A^H]<!3O0&GTT2KG<\508JT,GN(5= 72D4R*Z3[:8W<N6:12Z*R
MS3DT&>"4M- %%\OH(.K?Z,H*3D$G(+]QHR9[DR>I/F-*,@@V $ &@'TGDS^A
ME^MZAZ7>X!ZQ]!+=$H+D:D<D,L#P2=0F1$PC3"(@('8&P&=@,1] -C("1-FK
ME(H$[27F.]0ALM*32&=&2)L+3:H8SQ[73W@W&E41@%VEHZ$-@_?!YC3I))[*
M"@10J$Q02<6F?DM2>?4GD- )$1PFM!>BHSN4V;++WI6)'3V_N$>$(LHA,L(@
MT&B.7!&\WV=&\%#IC.PQV\)MP*>*=/%.E'6IT/WPDI6>C[_?4% UZ&HD_)6
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M!H #@*!B7!Q%'?9YBE2)[LBR0WA.]<]3:T^NG[B'I2W41TL?$O1;V]<DX:>
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M=5IX<539R&Y84,_+L3LZ)D>*7D;-S:P.)&6.6U0"]"< 4JP!3)0M!1I;PF7
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M ?M.U,9 7"1 =G4:06]!F3. "@#&_A:7MV@@+)),Q/-*M55(H996 +MZ-J4
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M2K($('B6QP;5^AK]#2LW0WZ*?%"L44!; A#I)6BHY4Q4<05@M76E#T2I?O\
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MM7^]L;S$LW".DE(P,$K< %7#.T,XH&BF;@03K=<:M.VE9OAL!9 G%&U2#!R
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M,I:TXXU%AAO!HVH*$"C5&:PU&+JXUQC;,J+Q&(V2BDH1+6#QI$IFC!4)BL6
M#>(R%ZQ14:*'=HQ/%#:_;+*)[ZFH!1LE8"UF&8YG>*(8A4.<9H* A*M*(%V4
M;:0S;,]J%95EI2\$R&'J<F:*$C(EP1#2=&@J^S L:'-I U4!K!+I1,3(T#(C
MN&-E'OOF$CR\ K )YP069+UAN>]7!1=8LH@%A))0)B %U./ R$5A0%K#%(W
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M0M4 Y2561VM%H$P<ZAT-3P=C-A"'(2+,%QO4,+E@<!2=':GJI6S5U)0<6
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M/R*F2LJRM_%7 0C=&&-]*NXD)J'2E:AG9+*:O@LT( $RR/9J,.@LB49J&(D
M0D$NL'C%(DK5;H6GIXKLRB%&'1W[^#\BIDK*LK?QG=Z ,N8=)\$RLJ"!7+X9
MK$X4@Z!](5F"M289,<GC/A@@JW-O"!TJ0XI8R\^*PSI"4N,ESP!DR$RJ#0T,
MZ>*NA-39").NOTQ%,\[(<A"IOXGA*&MAN8GFA=E@F)'- W@&K!U;O\O"M%#A
MTJ4 H,EKC#2::4$@9!#2R(%(N$_#0@A0!G 3#$D$7O!@K RZ1(,6+RB2(+0/
M71WMPLQ"W@E J#(#++"R388<++#.@L(5);0E)D[(,>3^$JF+W7IB:YY6<74
M:<(HS&0G:%(B DA0L9(=^P%&&&$DC!,+,*V-W ,2**10)NU.2"A+L 3%I6U6
MGN'J%!$(54)9.4TF14VH@T"R,\D8,^>GE)3H).U/BI)3'(3D (+Q2M54U'NR
M6T2,D$LTM'*PI4RFT,BOG3[%]DP&5H4RS2[W@?-08 [L?2A;M'+_ +Z)A.-F
M#=:]*) YT1'VH\#7=@\VB;3A)*,/K'7@YJ%4!^JR^/Z7"M%8'T3<G=12X2HZ
M/.G2E:@STP-OK)2LXH?<O%Y&B#"WAIFI;"2D+$!"0O>V-06A0.@!]P&-2G-6
M2WU(#!6?/2)AE(KLM3>H/!(["+4F%G:FC-'?Y0'F+(CV\3@\#D\<CF\5+B6R
M3Y%!DMBQ/G6F9U?_ "L1FV7I^:0SN!:/7*[WHQ!8VI9>T!E= I@BH;E@T"H^
MD!]B:K9DW$,)%72=J<ZE:Z XLTZ%\Q6(B+(I)A"$PV4(4@#[J(R8!(5IN&S-
MJ+Y90%,AH1.U%B!FN8ILR)V()D59I3K5#*T NC#NOD.- O\ $F<"V RQ:=AT
MW4A4&2$2+T$@@VFV=IF$2V:N/3+,RHE\N=J9G[#83KF0 37#@)1FRD Y@E+P
M1(>"O4K,+-B7N  BFR0H0&"!$R"LQ Q+;#AD:^'%G2;BS.$IGQ:1D<.('LV^
M[-M >*?+&)L7IA$7099, 2HQK63U.*,?Q6TTG<_*5,K?T']:=%BL5/%1V WI
M/(!P%.["()R./2J2:^X?Q5E(63O?Y_LOU]2U>+C6KPY>'"G/VXCEI8'1HXD)
M3YH"" 0!H5(W E($,!!X6'@!N 8?IGZM$V<R_I<?P"6!:@=A:Q,Q2V](L$P:
MQG$O^083.NM)6QO !R*5 PYEY"= YEJXU='8()&"9NQ(T7;"#Y=%!Y+WIVC8
MW3.(0M+:.E V2,'":0@+<BI#E,MJ4,M:9T5Q?O4-K1XP'<B-!OKFDP=,QY91
ML EFIZYZBK9(IUD4)&X3QY(F3%2 EJV&K%,W&3) )V)).Z;E%7],=1!B)YL6
MFP_Q22! >'75K"A=#<I9!896#*8"XKALH$JARB]Z_4[*U*R%V$8 N18+Z4SM
MIG(K<#;763=?922(%'+'H#YTU3&1,1[5$FSL>Q-6S3N#LF'K2 ],(232!F"Z
MBHJ.KF]RIXCEZVC08CDLGX*QX_I<*+B%.04;U7@Z!_NE=G05F>C92659>:10
M01EHDU=_K085,5E-.20I Z-A)P8PO0<>:$"944((F++?=,]*E"V?O3XAD\%E
M3+Y+%"D$# ,*;TO3I@5"$FL)<#8J&XYN2J0R2BZ+"6IG*+@@J(,'2[,S+4_+
M.^++ $H692XEJP\1 2$6(7$40"N SJ S#$E E%&/ Y:BD.9"3VJTBN)H]H]:
MS5,D%^?>KSQQMZS6#YB/IB@. MB/ Y_$($P7:4>5\P;]:'P!M00?8CT0C(;>
MD[L40'$QYT0[$5']YP@O0W6A,S>KDI)A$DD(93 68D&C6O+D+&F$0$=%IKY9
M[.7H-!,K[=++#F&5OP4(EIB$N^=[*E1NRD)PZEW*%9"''R-(=9MJ*->;^!#.
M4$!ON5PB5SM^OF<4#=^@.?!IZD:WHETM-L9=H*6T)EB!R[S]ZDT^Y5Q^Z"%8
M\$(P1-&86K<V8B$[ 5@2-#:C;]0-*3^+C2UYYJ)@8\HIV593N!+8WJ/807]U
M \IH #R80+LP6.0>$J8<S-$0'D^F]2; @WG'J*8TO [_ /:,3 @_L_V6KQ<:
MU>'+PX4Y^]-V#'I\^*&HOYJ, _;-#))CZ0;4Y&?TFE;@")J??#.EH"XALW"U
M-YLZL)  P6#_ !\J.FSY,04DEOS4/+S0V  =* @Q"(!!J@6F:1,[)68B8$PO
MG1:20<]QV11MC0A(FS5\-ZH;(L><T@B)(Z43F>4@OT7FA#(4.7849T"D/CKL
M*J%H8HB (0AR ]U->.&0R@1.&AXTC)&;@-P;.*E05'LXFRQ@QL4;'&!]S )3
MK6ANFPD!0>:&Q\>20 L :%"HN#)L,D.)IHS2KVY$)Y^S$KO'9M$7*YNN?!D
MHILFM$'A$^P-A*M.RAJR^W@"6"[346686]!J/2A;"=VLWV(@5J@JU6D&YZT-
M\6:W2AFVW@H&2)$SJ"/NKLJYV;Z^(O@7Q)%XB!?@,1.BSYP6)D6=0PU 5@ $
MN  T*GR3G20GD?#Y*6&I(N=/IA(ZY:Y/!31BC.B2GJ\U;T -*.(M]E*:^V*Y
M%TF,.I%Y($!T.4D"XJ@F<6E?49F<FPLL$ "0!F)2:IG,JL"22\&-<T54,8,;
MEB8&W-,)#X!$0ODG>B5-[*$0;Q+G0I6"V2.R+=@[4FQ5?;HA8L<M4Z:X;(B0
MQGW*0X?@B!R\B@4'61 %CFZE4$,LA*4K+[TZ.L$Y!"!F0@D,C0SRIQ*2$%4J
MP*#!>7/4-0K%UWR*!0=9$ 6.;ONN4-Y&%)L-26;%U 7#VVB$,,"+P.5O4Q?X
M:4G\62)*Z\,^\>$&]FW)00@R!(-)RF P3*3*[#/HSUXCBT X3\,8H380NHZG
M8=CO2!S(L<'PHFS)(/0_U_:?LM7BXUJ\.7APIS]Z9[PX.E\^-I2Z$@]REX)"
M7 A]1^F+A(#V%])JY$B-P]P?OMG#5)8)+EEO1>;G5JPHKENO^=\)\T_D*D?'
M@@ ;,_9]3[5:*3AH<C3!"_HFE:BZ)Z>O@XK-]B(% ^ !8 )57%/!2!0D9QW9
M4*]LH^'60$3(_=&2A%'73P9*AIE3#P8:AJ3Z&,Z&@AWK75M1<Y;%?^72\)%[
M+FF7/OY:6IP$3@!]6K^BW)/M0'KF>DTR0#<?J, ),V65T4N@G,-BH%(!I0 !
M'].$:.,2\K2FG94EH<#I+-DPM:W]24*0_BH'8_N2?4'@ZL)-8@ -:+TATIM%
MR$FH$)RH&01$>3Y4B*)":44G*OU;_7^T_9:O%QK5X<O#A3G[VM*,>C>*(6_F
MR'S0PRD\@W]WZ1YL2>1*8F)"R#'O\C[ZF$0&$:T]SH(UES_,;!D##E$V1LFC
M7&C!&@3=X\<6H?2*. %HR8A-R4H!(Z&U]/!'"N))0 &%EH3F,,HT!3+A?H K
M6HT%, +-:PC+7#Z6;EVAJ*,KFR@("(B7_P 1;5'7>Y[>M$*-HDZ/@5 F5PE2
MO-90/>*FX3G1\44YL;NE8K&!V&7TI2'>O2'*HMB+*$)0)K,VR>(784+$WBC
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MB=9ODJ"#F!C:7R4I?A_DWZH,]'#&^6*4E#P@A6350D)A &;;EUEJ K*'-#J
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MI2)>WX9IE$Z*?[/2GP=:R#SMZ4)?=%;RQ41 .*QL!],BBO8/+UI9&Q(C[;-
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M=A1X-S#=W]7QA]#.IH87GD=ZP*]4_%#DXE42MXS2:&0+$N5W>6E(\&Y?NT9
M"P&GU KA"B:5JX]%@>S_ .L@P"$(EFI$BE*YQJ4S!@62F%O_ -J-<.\\T#(
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MFJ9"HZ+-"C, )]U)H@:5G+:W^7"2,A:RQ2$8+:  ! 6+L%+G)@# HNX);MA
M&2@YZ]IDD0"Z)EAH%&;BR"X0$<D;Q6S2I+M@(@I0G.:/*'9"N7+$FL I-CQ$
M6TP1 RG9(,7*0TH:!D2!'"(DXW0+ZRYUI0!0/$12S;D:EVF)DQ [J98,N5"1
M*(9DWO.WUVX-B,Z;#RQQ-6^Y!ZDM(;[D-!S'#S>T'$#BN*>8!+Z%9XN93I=@
M!V\.7QWA\'#6'Z&HO$)OJ *2A](!<[X43ISI(JL/*8<2V"8I#DD\&"!26)7:
ML<&5"F44;!N$-09YOH1*<$@P;!BF2,*;@>("R!9A:=6J2F-FW$$ZA?J+"]$!
M;N)B0S@&(H?1[44$(4G5BG!0PXK%*B/X&.SR0#/MZ46PD# 18HFD&AK2MRY1
M]1MF;R)/Q1Y1&,KPBE[=J'#%IQ\!AHZ+'&?6BJ/W..H(>]9T&$GJ*5S (6LL
M_F]J]59TFPD]*9CHBJW!&%DZZ%;41TW<;@Q0P!.(,I-8+CQL/\=7#M(WQ4Z
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M3W4$EBT;8)HZQLE34QPS-!G=LEAKQIEMFM&)/J85A6>-G88@(O+,68E*"21
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M>3711S1)B(22%Q EE>)%TWO3%^26!B>6HL@86H:T1YB]/8DUH0B8&4":VPW
MB[&$^&N!<OH--T[<0I-PV;90LK)A*6<A%L@0OLLME?OP"3#LL?CO1"2Y%[?O
M% 2,C1HJ"K8V4<QL5!@N]B?6O3)3^:FZ.6)[Z^E<")L=HI25[DWIBN) $"O8
MJ7J:HPCDFHA.\7Q2Y8O,OBE(9X;9S+')>HLDW+R5^=:S,H/<79![40<B)O3E
MU)&BZZDRMY*-L#76BPDA-!8BGYH_UI>%T1HAN3T/S7_%?FG0;J'YH(UMZE+R
M4(?STK*M<N6LD@DI@;U@F2*9=7]XVH"$)56 J =3^H)86E-"&*G^=^B &@F$
MT1-/X=__ &'($NED$&1$Q/U(@V*B @"BB%F23]D2Z>PSIVEZ^KPT]"DLMOP\
ME+ 2U0>B/O1I); ?BIS-VDGQ7J!GP*P_Z_6:Q NZ#R+5AJ,\!E%\Q#S'TI%@
MD4ZIE?(J;@)=0[C/2*WR/X>;:CY1-RA&'Q04"[5@1Y5P5P5-I2NCRK*'RK/M
MVK->14G/E5^$ZP7D5%!#"6J'#6B#RFA&.3;?6*@O)E"30@'TA,7"91(U8& N
MMJE:KP4HW"2!82R*"&X*#*"Y8EC:6L6J*H0?PP,JCA"$JX30D@W!@0.2W+-$
M$^"N5T85EM <M'QC.977[H'C,9:TC^8M#3/0/YWZ#%=5,KQXH(B2-(J;R4G5
MA-:AT$;>8M&($;L]DH.=UHG_ "JG!IBQHC ^W\B^M&BQ<D!X91V\/V6Q_CBX
M=$DB,AT!JP-'S T1J7,-G[/I'N^%Z,,?TL+<%S1V[_U"C2BC22)HT*$*&QD7
M 'T9J;91;<("<!O%IL<#6/9H1?,\)R[32I6BZ,#'?:@4F0'+&3;T%3!<NV5+
MST6Z82&X ZJ*NNY$P+3$1&R1>K+32UBVP"J6VH&^/JDDLOG:I+>VBPA%)"=*
M*HS=>&&L"B='B2D)1X1,EEAFY,*VI$+FBXF1>#!UEV:"&4 -RG%&36Y*$JXO
MV>'F2>U*]$!O@Q C(DN3UH2(3S6!=98EOM_ 68T/9R_/6L@2@9*AL;2*+4;<
MS06Z_O2C(@( @/"7D>4:OE[U!"//W3R\?8ITJ90RE2;[?%0S?H2/.G8@"'42
MIW@$M@V=N.SJT;&:'N&.^*-YQ,25;M)]%7%74B'4H+C8*A-1(+6+_%*X'L-<
MW]=:YOZZT/*=(_-!]B'Q5]$=_P EJP!@,%>J<OH:U.D4IIT;.2 TJ%I49SLX
M.I# 5YE)WHMZ^Q58F:8 ++D/V0FW05>$H27^<6J..<TP,U#<M!*WI$<*8*)
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MRQ');-S0TUIRQDR->M4<OL4REF:%? . D.(^[^RV/\<7#DL$SA3PZ$I1ZPJ
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M!0!D0/EF.K!428;"4<A!YT#242'*8A\AK!+N4='9X;_2B55??'P.#NZ4"80
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M78D/6#O4=)(\@_@R5?\ &SPMI;^<<48=Q:3H 3K!2P,V5UN>JL=!W'R1$]:
M=T(?;1#?RRG_ !RA;I>/EHG!%U9ZA>]6ZN]T]"5\@I/XL.^<PZ>K0_%-RM7H
MR1T?ZPN'V\=?ZTE@F<*>'0E*/6%0"EC)<^SG8$ZT3@2#"9':C"]0RLC),KZ*
MC5J;FZL=5_O)4;%62]Q#YQ4DZAV,Y[YH9@C(59,LT#:8L2%Q$PU"I>)+-B(]
M6&-;VD/H'&0BM..X[F]34U-34U-34U-34U-34U-34U-34U-34U-34U-34U-3
M4U-34TD.XL#4:063QJM1_ORD<EP2>;6!X(F"20@RA",$3K3?'%Q\_P :&8U3
M.&QNULI:^\4$?2L-F)I1@W,P]THOV/(Q/K22J[OJSY XJ%8I4?/%Z2[5+V44
M+06J<]":"RZ^ZP9"03N6H4ZUR@LB'$%]ZN6P&RQB2[WHFY08DO??!G,XI,'X
M".@K=XHB=VZJ5RG8.:TS9=1* 2#&%77P(X@+ HW>U*PP'ZWJ&_BU^T;6K]JO
MB@4.9#V@[U(Z09P(0[,GV)*$LE&E H+LEP0D,X?EW9E"5Y 2\7& F++#DY0#
M2/4D);FLI!128<G\UOF+<XQ8H>@PE+P75II?#:BD>M,D,J#L'!"TI(3:8%9$
M'!!,F0.9FX3)4':63%,+IQ)DLYB.E$".(3H3)22"S0&.X@"YA12&)B8-WLDP
MA,"RC&08%,A%') V8$@1KP4/#1?E=8I2$&XEXH(@G;((Y@9P0D7@4RA-P !#
M0!5,7:B*\QS"D *E:7@@ K'\V_WA:DS<MF#!PRA!4I&X8R4OP]:FK,$OE#Q1
MF)':A*H!;#4COLV8I?P5:P"L4.*+*HC)@4DTD5FQ12W'N1F]K7A;&Q!4 "U$
M<5!_,>\.UB;#HW%%"T1;EE;G,P1!UFKR',X$V014-+[E'06#033.JFQ[8U)*
M)A8:S 4E'8AY2_K1[8#DAPJ"0VQUSXM6D![)D[^RM6FBD?!2>OTJ.$C2AY0T
MENB1G#W8.P4U!K$1Y?A1[3K?N-+" [4'_!T74=VJ*WBS"/DAZ5=\TS(>1 ]Y
MHM!<"@#I3'F$FKS]SM_5KL*8B)*;^1ZE_*NBN1ZXKC-H'I6O]:C-FX&"+LQ2
MD#*I40FZ6U^T!"B$@6^KHV7FI 0X1S- ,Q";&%[":)"]%B/T&X5*62=D_.U$
MQ0O(8L/K[T9=RTVU6_W1-RQD7+MFR6XLY*A*.\1(DF?H0"UQ_%.00,(Z?TDH
M%6-QH*<@!(F$_OG[&#'RC38-G&ZI^8[>&%H*ZP78YT.4IODKR%X5[ -,V8X@
MR1O6ABNS+=T\H[ZF1L>R<(VUWOJ2#DUW&!]N1-$Q4AZ$@[BM$[NHHF)Z$GK,
M:T4)6(LC-T#I/6I$2RPTY8L=;5;"PI>EQ?I!H&*9#J51YB<=31.U8!P")[CQ
M1Y #-4$Y7!F,R%**3$/37TJ5H-&XN./N.%G[5=A*HW$*E4RA^(/VC[*30'%"
M-J+XBKVC4(T1KAH$:8>S&H! X9HP60E%""DB)AA;V000NI2R0(V%T02W0;V!
M+^MF)Y42DE<)(Y6@& ^!'@:N-5+$482@(FS(V0*9>20601O(HA=.6NFJ[!@"
M@:"2U" B@C^:RK&#A+X*-T7:Y>Z=6E.1QU-QT3>@H!8M3DVJ*BHJ*BIP2ERA
M#T/WBHI&5:_[BK-S(8$<5> Y7/V6X]3)HECYA0 &1)'^L7&X,'&DULH=@^M.
M8AI?6EH#D )\WQ6-T;PD:N%3 \-V0#=DT'0NTMO5XS$2V/,J N1/XYI4140@
M>@I7%$4?,?Z4F;5R*M#<F@&/*A%9!8;Z?9V5( 2@XZ5=6Y#8#G;W>PS&A9D2
M$39JXQ+!2<-(;J42K#O &>=Z$NPQ0OJ@0"&<O",]2C<$091U$F@*$X M=IG(
MN  957JDY'<^F?.U::F]34U-34U-34U-34U-34U-34U-34U-34U-34U-34U-
M34U-34U-2K"YWZZ>6W]\0@L4@"PO:U GTE(TEZ-*)HA T1*6]LNN:$8P7;H!
M$6E>[FDK-F<M3:M].I-$X'D], /4K]&:22KOL^[!K#U$2 .,0$3"Q\T/>#3)
MV1Z:TG+"'NV.DT1&,FTW+#V*.4G*VP7 ?^C:[P"-Q'(N4<+26@29A(DYVI_-
MMC)OD CO>GB;>C+#V7L'W B!!.YZ@NZ*)I*K8*+SS-[Q^D?:2:%HPVH"TL0J
MT$0+)"I:C962 6$TUW.^87C:,@Z"6@7".HVEI,4Q$&:!*AQE0IFP'41-OZK(
M6O"4QI3%B5H5#;T1'37!*\Q%YBHL=Y$(!<Q9)#=H^@\[#70E"EA%%DU:E4#\
M%&%J$H(_G :SFX _.C&X>5!QAE86,Q-0.C3./4D[T74<))X,)O'@*DANL4A(
M!PC1=DZB=!M;FMBAK,=-J*Z2%09(KQ"=J,B!(&1/L&G%. :K@/6#6@!*!!K8
M'=H  0! ?UJXVS\.'T*&$W F>LU)WHAP'<J=NG[+*5(@;%AO41ZEN%A" \JE
MF+T>'<#YT,=.?)@$*0(\U'>A]*(WVE>Z%]*T2A$G5(]:_P"[V 3_ #L@@XV
MY$&GCA$,$L:V/LF:$E/7V*A-01>D8@+;6P[T]M:UK*#UBGX"1#</.HI(LRU(
M2%S63%9DR XG4SW.&DP#(DR4/=3X8:9(A@R!:>IKY_3>@!(D/E7_ &'XK_L/
MQ7_8?BO^P_%?]A^*_P"P_%?]A^*_[#\5_P!A^*_[#\5_V'XK_L/Q7_8?BO\
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M$)0'ZEO.I95=2#RQ4B,2+FF3EN:,/,FD5#(GI00/XBG9DHV.2B]Q4-WQ]XT
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MA*A ,\(D\\43@1FCVWTV2?W>G;H':[0Q*IF^3RHS8Z"DQ0UV8BEYT^ I"2-
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MR((BH1(%++,Z36%DE(PD.:9G$:C3YH2$32T4$%.EAJ;E$M'PSCK41\9G>?\
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M9*RX0"'K \)O[/?4%>G20H[0H)"4;!@E(4$@"[A']5L\=LV,K)DASQ#'-$D
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M%"/6)X?W>KN),),N^^'&BBR4JI\N4%YL0R:?9]$ITH2Z'KM^&%KI0ED/7?\
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M TG+2>H4>#(=5BC]$3$,+ >8C_(A,X5[D5:!,MKU%(%!DG,'M4Y5810.M12
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M":FCL[>'#Z%EXH!TJ0V(:,VD$J WJ-]$1[KB@$9302F,S.&@(L@+)XJ-1J%
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M] O_ - Q54MM0&C67V.2?QZLU+!I_ IAVBC&_P!I92=4D1R'1)IDO4Y1FZX
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ML-W0I627*[U%,%-* *$?<R]/[9<.6B5$PCD$87<$=1;TC*NXJ)/D3S&*R:*
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MO_M3XAUC\T6!!T:U\T&Z]J;&(9-;S^'^.KATG_T2$ +JNE8TV]'0A7"?PX$
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M41TBB0&5%XO_ #]P  +X-QUEUP<LZ4IQ41W8I]_#\$^/_55P\,+F)"DFT@T
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MOZ$)HH)L*D?K :! 2JP%3!B(%*?+I;FEW,F)3;LH4R>&#V[S7-"J.'T=T_\
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MU^_\M8YNB?>O3SRI<'F:3 FTHSLQ;N:?V22G&Y/W&M&A!!P%W_JRX=)_]$A
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M-=1*QPO;>81=RB-PMS7+4B. T^F@$QEBHY5PFN]"7L K"VPL<K]N44E,F2.
M#2UN[T-*HZZ!L]R'O4+]&<6@]5(*@J"H*@J"H*@J"H*@J"O?^[_ZLN'5TK*B
M[AT)2ER9 4I<!2YH?YTA=RC5:!RL'>EXWX:&W\^]1R'7/G-1I_(CRB:,2M+H
M^V'$>=.S(AAG8EO.G"9 S.:$;L=IH%Y))O<W;.V="C%P)C<:]GO0@$7YTV.W
MYHY<4ZCNON^5(F</+L-=ZP9Z%&VQES.+-UM@K+*P.9K!@7B.L5-,X,H/1 G6
M:PML"78M4-*^"J!AV>\/-3=3$_3*WZ%0U#4-0U#4-0U#4-0U#4-$ *V#1F8]
M?_5EPZ" CADA:>)I[HF@M@)<!NZ_YTQ&0]H/5Z**ZCH-Q>[_ +HKT->:-/*M
M@E+JX)T"G8S1J%+KFD NJ4,D#E[5%RZ9>[OZM&WBZ0MB9TXH9;;?LCAKKM0T
M$VJ_=NO1$=:,8B!]!*2<,7%@Z-O(XIN_!9Q9;I4:0Q84L=?920"EDH9!N/@&
M82H/7\U#<?E_< !:)@)V RU%[B&TS_K_ -77#F7VAL1(3!)E5;P?YR UP(<B
M_B@&GH.)MWR"H*STD!0+A05EC$]H\_HZB$&3 W7<U7M4I/[7P ^^7TKAZ CT
M\<LMP1O'YHF#DDY-]M>]"R :EO2B7.L7*<FHZWJ5(4@G6H%C(,\GYJ"H*@J"
MH*@J"H*@J"@,HTI8I@/LID=)7:*_@\S_ -77#@I_$)()V  @<5#))<_SF+Q
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=I8=E'2/_ # %*WPY*##.H*/50  (# ?_ ,4[_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>distributionfunctia.jpg
<TEXT>
begin 644 distributionfunctia.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P@ 1" &M XD# 1$  A$! Q$!_\0
M'  !  ,!  ,!              4&!P0! @,(_\0 &@$!  ,! 0$
M      ,$!0(& ?_:  P# 0 "$ ,0   !_5(
M
M
M
M                        !&&6%</N;&3X
M                     .;OG@EX   ZH^NZ/L   0YBA\SV-J)LBRK%]
M                                       (.S#4K];X<2>OS[5K,<WY
MCT   'WH7=9V<       "J%K
M  !QR<>#-MFAVQ=@"-GCNWC?3QE2[=-O     \_?GOU\       JA:P
M                                "%LPY[K4K!4FG:LT_5G  I6%OW7=
MP            !5"U@    &:E*+R3A\"LDT>"_
M      &:[.?S=\W3-MS]6?FBE^?'8$54N5W-U):Y2MVSB            "J%
MK *WEZL?6M  2]VC.Z&=CI\BG$:3I%DH58_5Y]P
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MRW*UY)JO,   *9A[UQV\+V^_           ,W(\Z33P98<A:"[ JA:P
M  0Y,    ]"@&A                  QKT65.59A.UIK90L@   "-JVZ3@^
M@TCT_E'T          !R%%+(6$   JA:P
M ")GBI6E4]_GT?;G[H63>      I^+N=]BO8=++            _/AIA=P
M"J%K                             ,5])DZYY_3[H^P      !G_ )ST
MU]]#YKWZ^            ?ELU@TP   JA:P
M  "IWJT%:A]C1\>^       !2L+?NN[@            #\R&J&C@  %4+6
M                         "IWJU6O5M5P](       #X\=YWYKU%SW,&7
MN4@           !@!K!9P  "J%K                           *!JTJO
M=K[+YW4]GT     #AKV(ZM: JN1LW3=P)6W3             _+)I1K@/B<1
M\R7!5"U@                         C9H\_U:73QU[_&BY%_R     5[-
MTXNI<$12O7;>\^!].N)*U5             'YV-++\#"C/BZGZ!(LJ9H
M                     (2S#%3QT#5I:[@:<E#(     ..">GXNY\^>M ]'
MYH                #\S$B?H@%5(H^9H8*H6L
M  &8[6?=LVWWQ=]/'0   'ISUF_F/52URD/GSU:M?'[[%8
M   ?GXT8O8  !5"U@                      Y.^>*7C--G/FJTWWY^Z%D
MW@    (JI<A*&A<-K#                   'Y,-J-)   *H6L
M             C)H\CW\R_Y5V9K2R\$H    YHI8#.TA7<W4T'T?F>F6(
M               "EF.FSEO   *H6L                      Q'TN1L/G
MM3MC[     %<S-3[=\2%BM]Y(OM)P                   (4RLT4M(  !5
M"U@                     SO6H_0T#)O      9KY?UE_]%YGKFA
M               R8NY8@<Q!G 70%4+6                    #T^_,]UJ
M/1QU?<NZ     !GGF_3V74R9[0S@                    !^8C:"Z@Q<Q<
MULW4%4+6                    <W?.+>CR=&R+]LH60     !2L+?NN[@
M                     ?F UHT4 KQ'EQ(LJ9H                    !
M7;<'-WS:Z-D     "+J7*[FZGRX[O?H/.                     "K&4EX
M-'   *H6L                   A;,.4[N=:*-B]Y=SMC[     %'P?0<%:
MUH7I?+_7KD                     #E/Q^?H$TD   JA:P
M      #,]G/T/)O=/'0     %(P?02-FK9M7)
MXS 30C2   "J%K                !6[D%+T:DA%V![?&C9%\     ?'CN&
MHWZ]FZ>@>C\T                       (8_.IJAIX  !5"U@
M      'S^_,<]#EZAB:$O!*     !QPS0>?HB)IW9:Y2FKU#NL5P
M               ,*+F:$"L%//8U4%4+6                9#OYE^R[E@J
M3@     4C!]!&U;=XW_/?3KE\=D]?S]                        #\E&Z
M&@@RPR<LI^A@50M8               *G?K5RW!I^+H     0=#0@L_1^G7/
M7-!:M?'                           PDT\LX  !5"U@
M  S78H:5CWP    !3\7<LNID]<T(                           'Y>+V
M;,  "+*F:                #-MBAI./?  Y(9H>E>  YXI8*AHZ-Z7RWMU
M\                           %/.DAR_@  %4+6             >#X]<
MC*]S.DH9/CU\T_%T !3<3=@,[3OGH?-_3[R !VV*_P!.N0
M             .(P\UDL@  !5"U@            \&)^DR+/2L>_S[9J5B=K
M3  "E86_==W                                      JA:P
M   "*GBH6I3ZN.O7ZE8)+KFVQ$4KU7RM?JEA  E+=.PZ68
M                    !6"B&Q JA:P          "M7*XLM.P!R0S<D,]%\
M_P"BT?T_E>F6(                                     #/BCF\@JA:
MP          9UKT8R:.^Y=SVR-7@KV!6\S6MNQB2=JIV3P
M                          "J%K         *=H5:?H5>;&V&?>NV7=\'
M#!8NVY@#WZYZIH0                                        !5"U@
M  KF9JQM6T   *EZ'&\31 1G2]>8W4,M\]#YP
M                     19ET\?RT:@  ^'$GW[C   $I7EM6?: CR1!X/ /
M(/     !'D@         1Y('D'@\@\'D'@\@\'D'@\@CB0         /);
M     "*)4         BB5        !%$J         19*         BB5
M      . [P      5<[3C.(N@       *H1I]"\@       &7$T2A8P
M  9X?0FRR        $(?(L        !7CE.$O(     *D9R=9E)I)NH
M !QD*98?4W0       $.?G@ERR&R       $08^=AY-J        ,7/8V8
M      J!FA]C=      "D'T.TY"X@       @SK((MP       !$'W.H^P
M     *^?8DCH        (($Z        54CSL+<
M    <)W   '"=P  /0XB0    .8YB2 (4F@ 0Q,@
M           &+E&-/,[+@<))E?)0$23I535"CE++*4T_4I^>CR7<C2NER*Z2
MAVE6+(<1P%N(PS(OY[G64\D3C+23A7SL*>6TKY[&X$B
M              #'B!)PK1I!EA5"W%S)DCR++"?<XBJ'2=QI)E1+D,<AV&7E
MN+F6DACYD"3))'U*H54M1QG82!%GH74IQ;2HDP>Y03]"':
M                    ")) ^P       (DD#[        '&=@ .,[
M
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M#81DMN"]]WVKL[)P*ITP"#2J1<A@4$)8 +\E[@W*6?Q5B/CM_CC[:4-C-&,
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M!1,4%2%14V"!D3 QH3(T06%QT1 6(#-4(D"QX5!C)9"@_]H " $" 0$_ ?\
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M0:R<X)XZ!]UR:XV6:,J&-#CW"&AQ[A#0X]P@F,R@[24%RRU&=?VMD- DW?\
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MQT&FL\$L=!)E%(2E))I3_P"%C__$ %00  $# @(#!P\("0($!@,   $" P0
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M:X,U[-!2([:5#80GOV=N/"L(5'@O&.',0;SK41M_/CI:9$5N'(B/*C.-,BR
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MVVC;+Q6H1])I3F*LUK=>?:CQ-*&E92;UH502@7O<4D%AN]OL"NT->P*[0U[
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M6O8"NV*]DUVQ7LFH*4?2(S64"+5P<>LT4LH" >3]DV_,E>^.])+:)2=TI2H
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MISU$CQC=9\"DPZ@; $P<,\*D-831&@T-Y'2HE!(7$%A+6<3<HR0&N!+CPO\
MI\!+9ADGLBX_5*I-QOA HC18T>IF"L,I#&4N!&[M7\1Y%NK7T6?!$+B;\M*(
MSVMX:V+3-VL^"+BIM4VA),$_%9=L$0HB07@)>!BCIN<^^&G&Z]]#7B,15"#-
M6E%8:$)L-UUJ=%,=$M\GJK !E$V)H<O FGV@ C$Q27PVK0H)XTY1I&*NRK;N
M(J%BQ:QX)&NB<4PVS202@<.\!J!:X(]@,>!@CA:8()4FQ4AS5$Y9(P,K^:'P
M\$/L"QX(:*72G= ]#2^6F5;B%>KX(L?CNVBG#-")AQ"6JA)7(J_6E.V%4+%C
M8V\TE.+(L[IR%R_'N%<() 3++*6?Q]:(&+P!E6I E(SLE-[G="[F0M#=6*B-
MD%F3#-D:GT1"'1TR 56S],,O&2O$!$N,?81X25G_ $ ZTSE1F7#81 S.%/:K
M"B%AADL.M 3"K5V+R49B'2C62Q:I=Y("!UO%V3]646($C,,H;U,:^-.,QXO^
MQF=K%430"3(Q;)1]!1G*E-T'_NFKQEZ4Z8+IG]KB*@U%F%P962;,,Z4<R+8#
M.4ON"S>:0I\[2WDK%S6EA<+<4_S\53 30[H?N6YJOB#M*0<TZ:;^#4R@,A#"
M+C&K&V'TPCU$O/&K>%W$*"X9_0Y6BTNAH!3!)0."[$49(6CV35 "9T-&A&F_
M05F+QP=:F( @B'% W5>;%HH=PPU.,Q]N69VL51- ),C%LE'T%&<J4W0?^Z+Z
MDC6PEEILF=U"W"<Z">S633CK49X*I"B9J%]G1&QXO)/BP8(XZG$(2X#WETM&
MZ QK)3%I?T(US9>VMNR%EM)899 ;Z@8B\3=-SV2+L!(S#>-ZTE-^K"&S?B4)
M <;W!B\ AT+,VEA@M9D)N/<%HD49+:)RSE-W%1!@2B'% W5>;%HJTZ<9$A$2
M7+.F'0H[P8E*<VO^$++W'"[\/]4J<F96,J9S  B;U=PC!'D%QA,W-IBMUC:8
MF47#()=*A >#@I*DA)8<IKC\IEPNO12@H1G)?7[!9GKA SO':4NU(P:4S@9)
M03>5%D--K!9*Y.C:H>\B>3FX3=+KS:4HB]-S"(B[5IG4O"6$)!-PO%^% J4$
M$"2J*XZ#L4I2S\S,)5D3*S,LS%9[>&22".?/<I""W!,TD%>_"M/H<.N;S3&L
MVFO-&>9'X 1:5QEX!7"A OU:3 7@+89"]MJ/&XX062C(\4$DZT&MP%BMY4-2
MGN^E@3G$FF5-_"72$#<BPYM,C1LD62)EIN)A(/G<TSL6U6;MIDE&1")?12$)
M<"A!A XM/7#?8*U[2LG6\IC66H(,NY9E?-V*&DV 0"2J*_@[%*4L_,S"59$R
MLS+,Q6>WADD@CGSW**<,L"0E$QLJ %EM(/$RS%,\&]3*2VDG^7(N0SX0=:)A
MQB;'-<^ 6L[N768IYN&J7JED7ZM0'N3B1R/U4@:R0HCE!CC;41-SYUA 03<+
MQ>-*?W@,J33,.O\ 35F&_;3"ET%8X021>+SU-365/?);3-)Z$S&AQB93E6 ,
M:J&5\W8HXL+2.)Q<+=$XQJMUK2:743R7C-((C1+'$^%WI6*LOA5*1$7:M)A3
MR(0*^;\45L1</9:TG5.5-V30_5HQQ0*DXE8,0' &,M'CP>@>GV/\)2+!BA7W
M 3[ 8\#\)2+!BA7W 3[ 8\%;$ZU-AC5]/&,1<AN7+_P__]H # ,!  (  P
M !"222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M222222222222222222222222222222222222222222222222222222222222
M22222222222222222222222222222222222222222222222222222" 22222
M222222222222222222222222222222222222222220   #22222 " 222222
M2222222222222222222222222222222222223(0$DDG22222220222222222
M222222222222222222222222222220'S;8>-MMMOR2222220222222222222
M222222222222222222222222220A^22>2222222222220222222  0"22222
M22222222222222222222222$N%);2222222222222021I)(R" ""22222222
M22222222222222222222Z0!MLR2222222222220222222222222222222222
M2222222222222222$2>22222222222222220222220  2 " 0"2222222222
M2222222223_))'R:222222222220 222"20I)(P00""2"222222222222222
M2222224#R2228R22222222220"2 "02222222222220"2222222222222222
M20)"22220)R22222222222"2220222222222222222222222222222221M(R
M222220B222222222222 2220222222222222222222222222222220*22222
M223>2222222222222222022222222222222222222222222223*R22222222
MR222222222222022202222222222222222222222222222)R22222222V222
M2222222222"22202222222222222222222222222223)R222223$G"222222
M222222202020222222222222222222222222227)Z22222<ER3R222222222
M22220202"22222222222222222222222225:R222229^2222222222222222
M222 202222222222222222222222222(62222;D\222222222222222222"2
M220222222222222222222222228-&222220R2222222222222222222 2220
M22222222222222222222221%>22222_TR222222222222222222222220222
M22222222222222222222*222222Q.22222222222222222222 2220222222
M22222222222222228R222220622222222222222222222222 20222222222
M222222222222%^2222222R222222222222222222222"2220222222222222
M222222220<2222222>2222222222222222222222"22""222222222222222
M222223.222222 22222222222222222222222"2220222222222222222222
M20A>222222JR22222222222222222222202222022222222222222222221B
M222222?222222222222222222222220 2220222222222222222223)+R222
M220^2222222222222222222222222222022222222222222222Y2222222_]
MN222222222222222222222222"222022222222222222221&222222; )R22
M2222222222222222222222"2"202222222222222222#222223=^22222222
M2222222222222222222222202222222222222222:222223&222222222222
M2222222222222222 222"2222222222222222*226VV\N222222222222222
M22222222222200222022222222222221>]:22"-MN2222222222222222222
M2222222220"222022222222222223M>221R2222222222222222222222222
M222222222220222222222220Y02*,DOR2222222222222222222222222222
M2222220"0222222222223^24+22222222222222222222222222222222222
M22202022222222222!4?RN22222222222222222222222222222222222222
M2202222222221(U:):222222222222222222222222222222222222222220
M222 DDDF "+R22222222222222222222222222222222222222222222 I))
M3;;;820 "0"22222"222222222" 0" 0" 0 222222222022222222222222
M22222222222222222222222"222222222222222222022222220222222222
M 2222222220222222220"222222220222222222022222222"22222222 "2
M2222222"222222220 2222222222222222222"222222" 22222222222222
M2222 2222222220222222222"22222222022222222222222222222222222
M"222"22022222 2022"222222222222222222222222222222220"   " ""
M"22 "0 2"22""22 22222222222222222222222222222222"2   ""02002
M0""002000"00222222222222222222222222222222222222022222222022
M222222022"22222222222222222222222222222222222222222222222222
M222222222222222222223__$ "T1 0 "  ,'! (# 0$! 0    $ $2'1\#%!
M46!AD?$P<8&QH<$0(.% 4)"@_]H " $# 0$_$/\ X7%61[SR!/($\@3R!/($
M\@3R!&:)]F^9J07NGOP,1/9RG@W*!86#$:Q3:U@&]W>@@@@@@@A1S<+%> QZ
MWL+Y?Z3O.@[RAZHZ;7Q.FU\3IM?$Z;7Q*=*UTF$9N-?Z5 [N^QRG4=YU'>=1
MWG4=YU'>=1WG4=YU'>=1W@U)>7OQ'ZA\MO7K.B]Y;4V_V_"_3S019A_G7K+,
ME.&[.;=$S_BB8X@I/.,IYQE/.,HDL<QM5\V0G&*KT0"X::_[RZ!:XC>/LD\'
M#P</!P\'#P<![!7@/[7D( =Z;-%,OY'H!MQ#[2</A=CUZDZ;LRG3=F4Z;LRG
M3=F4=FTMYG5!;! @;^.[-@*_BWP(7CPTP"%VQ2.XZ-RLPG9:M=^9;PT3IN\8
MF PKXZDU#G-0YS4.<U#G"+:=;SA$=W\_G_N-I_XP)7#AXFH,IJ#*:@RFH,IJ
M#*(E<>/C_P!E9I1K#Q,=9CUR)3+Q_,1P#Z/Y_P"XVW,2Q,IJ=3^<YU/YSCC$
M/I@!%G[B5\%*4;Q!XUOX1;;>7C5+J K%7SE-0Y34.4;V+=_K4?PCCL6.R[_<
M^A].7[1#%7[X2V=P';_A%F5P%-[PCY[7:N+RZY85E^. .*M_XOQ_V\NHU=W"
MX /^)U%1P%^HCB[2E-[?> 24* ^7]\N,8M[((MMN !1ZR"V-NS]SJ>^:=3WS
M3J>^:;63-AQ"Z](*+S8P#;[<M5H71 QT=<9T>OF8"WJG=-7%\DUI&M(,3,"D
M&P:WN-N$\@SR#/(,?H+:6X\LN!5?O^IKCE &07LQ3[(9#=>J*#5@OWBD ;2%
MQDV([=G Y@)RRLYX A5('3T@%;V!W@!O#KQ'A-$1HB X!-B5E/B8;=U;<.7<
M=(]VIY AO<!P]L<IUOYSF ">I?\ +;::VS9>S[>8$.R)3;U>/LU^IKKG+\JO
MTPQO8??U.F[,YTW9G-Q$VJ<XDZ@Y@&'<54_#N);.X#MZR!>0;YQ=9YQG&16G
M%7[Y@5"IKA'(:Q_1ZQ6W ;S'%A\PUJ$3Y5Y@4%L!4ME_>4)BG_6?K)U%&PO:
M[U<*F$ M -_HPP**Y@5[(EV%W XXGK_DN87X4)?6[UB^Q%OH1!I_' ,+W"==
MUO'E^CO5QS5P8?CC-090SL#U5J(65LW-;'9<QE+28CO]H(G>O,! NR_V39</
M;UK=\IM]JWAOB= )C\5O=E<NJ;3* 5G7.:ASFH<YJ'.%8V7CY?5 .U@$ZKOF
MF%<#\7P<NK168N--J<!ZP^XO8^YTW9G.F[,X/TLO$X)#X@@!<,92.<%:Y=4X
M!-JK]:Y+%F'0?Q9,7-24RC@5WLYY!G/.,XB4M>76 E8TZ!X^H\#M.'28[$4W
M[IKQEB5"8_ ?6/-\7*%.*/":)Q>:M^+H/NC^R""""&#&$7@7[Q 2@;N)'#6N
M+R_LG6G6E+@#K=.GU\0]SIT_K0= TKO^(L2L,'V=_M$MHZ-\T)^YH3]S0G[F
MA/W-"?N*5)M5M[\P8O+N#!=]_P#)U7O_ )&&\_OH?;F1R#80,X/\F,JSC=_R
M6EIQ/A98H4F[=-.IIU-.IIU-.I@!FL>9/Q9^+_2^LIMHNIXAB@RVMB(%[EOC
MC,!U2]^:1!VO\Z]8L#3KC-L^$1V;5M#'YG3=F<Z;LSA>X%C8[!G5]C*%WHPY
MG/6%?>&[B[XYS>M2MYE1&<E;M=G\VVJ08ZT#MX"L\XSGG&<LE'!5.7'F2QA[
MGO-&QHV-&QHV-&QHV-&QHV-Z<"A?Q;#A?:>"SX+/@LA%LP*7#M# H=&&LG$.
M1RXRN'?-0YS4.<U#G-0YS4.<U#G%%6<,%,/B-0YS4.<U#G-0YS4.<U#G-0YS
M4.<6Q3KB_P#X6/_$ "T1 0 "  ,'! (#  ,!      $ $2$Q\$%18&&1T?$P
M<;'!@:$0($!0D.&@_]H " $" 0$_$/\ HN?MKD+\3SCM/..T\X[3SCM/..T\
MX[3SCM"Q2V\3YXFMP&%X_P !&B?<[SR!WBC*)*2[!R+Q5R-KZ 888888=YB2
MI!O&!NK-KA^_;Z,Y_HR_4//N36/>:Q[S6/>:Q[QZ<U6K>4Q*]PO_ ,;CX#7,
M[SE.DY3I.4Z3E.DY3I.4Z3E.DY3I.4Z0Q@KAX7J,2,J4K9R&<TZ2D,W**S_M
M^W]\4'T63#W>3NF+L5F>S\3/157X _BE0[E">(=YXAWGB'>!4,&%"_QC% *+
MC*!67_OI(-5@E8>XSR\/+P\O#R\/+P=L16*?0<!-!RSN97[1^_Y8%YRP7X&;
MQY,SLSG.KO.<ZN\YSJ[SG.KO AH*.)TCH;RSP(XLQ*1S+R:&?.9U7W_BFZEU
MAKE!8Z8(+-KS*EG5;.@/CB4FY;B>(@F540%[:S'8&$UQ&N(UQ&N(LD-X@PR&
M:KU_G];\1D?\,-0CCC?TD\<QXYCQS'CF/',#4 8X7]K_ ,R)NH:0^Q<V%1*P
M/M+JVO8[0Q7&.SZ]'];\1D<1$(;6O#[&<E^NTY+]=HZ*QK73TVK6/T,N#&[!
M*P4W7LWP*P.'G&:Q8^Q?U$P2>T:XC7$ XTI8WMY>M9G0&&:JSJI\SY</Y/#=
MF.93MJ"859>K?^%();,'8;X8.@V'#H:(WI31WB136Q_B_8_!PZ9L*+A$2+O;
M^A_B/$[;T/F7HF1;#=%:&VU>GUPX;@61Q=E^TJ2H#9CB>\52OK'*9RS^IRG1
M[3E.CVG*='M*"K!F,%'+G%U4YL5R]^&A2:M44&#..;A^?G'51;Q?4,Q;KX9H
MV-&P@08EBE*7L,*,9X(G@B>"(= 3;1PR0V0YA\I-5[HRU2[P$<LZ>L1\JUUZ
MK&ET7I#S2R8#87L?_7B!.D1S,&/..\NV6];^?2:B1:,8E8]S?-0]YJ'O%ST<
MS'O,VV]EMOAUE%IN%^)YQVCI'$+SL"[LWOXG)?KM,J;;?JN7J4JJ967,[W?!
MQ G-.]R+@UA1A6Q+K#W9JG9'AP66 ? >F\5#/XG-]'M.;Z/:;<PF9VA+B#"R
MFEB-YV;1SV03"K+U;]76<D5279&XY3QCM#T.VX#XX@$[JLOR1@! 9-[7UF\B
M#LR<,?Q,PP#H5Q CHMBJ85?'*\V.(H4Q_ ?'K$= )2UD;!-]S&";:U7VXXMM
M\09D2T1Q"K&#S'=RB%2VXW>O^D<0OUD$5[?H]9M:QJO>"EG[8:-.T'EMHW</
MHBRL\0SA8,=-X[W8G*>.8SH%?JD'"IW[3>9U,/(7>"?<,YL#B!'%)](HK&M[
M?K4J;;+WY+L@%T#A^?;?PZ<EBY?AEGBR7A&N(UQ&N(:7KI1/@%^JB=#%9RG1
M[3%R _6]PZA#;-K>J<,Q(IMBJZ^LQH=7Q.;Z/:<WT>T>.JJP=XQ8A0JG*7:F
M\"^'0X]LVWGN9RJ56?K5FJIQYI^Z9@]%C<M(@W.T\8[3QCM   4'#H>(WH$"
MK9>I45D,><P>*7LVS3A*H;!P_*_/$6K[>J'!;-IOGZ[X.*I^W@^L9K=B:W8F
MMV)K=B:W8F-[1K>5[0.FR[=S#!8&'#X*T3G.DY[I+7P7@O<FL8-2=_R_U:@M
M5E;/S!HS8XGN;/>$ W^SM-.?4TY]33GU-.?4TY]0(0#88'$&#.J=OMR@4!T/
M><KH>\'U895_?1^_$@/J%$APSGPC(;?Z&0ER@;3?W_EC*!@_D(9Z@'K-*YI7
M-*YI7-*YB)F^)/V)^Q_2A2ME;5SRQ"I!DS$MK:%;IEG .G%*W]B8>[R=S$C*
MKQA*K3A"E6EY+.;Z/:<WT>T5G$IP3-)RG5[Q15./$Z];I>65^]Y1D%JL<-U[
MIL.,"NZXG[+V\_O_ "JJ==AJ"G[">(=IXAVE*AW@'#@7#0Q]GVFA(U)&A(T)
M&I(T)&A(U)"!''3;]UQWUE_2^^^OBF*)F4;_ 'C%)=JD'G-U.[PX2(2\'+X?
MB:XC7$:XC7$:XC7$$  ;Q?,ZXC7$:XC7$:XC7$:XC7$&'-LF_HK_ .%C_\0
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MW-+$0]9;C44LOT\-08 D3H:HZN01"+8@YT!! ('F)%5QG;0J^YK8-V,S<?9
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M>_H8C_4;V!D8HF3B:[-DD%V-^L/I\B! @$$)%4,#RTAD/%S(T=!]O@G&Z;H
M,F \G]^HOF8@!#,- OOI"(&@>&0B*EE=/(9YTHJD1A+L/ );*]';N^]GT)'2
M[N(%A_6L+Q*0GU@N <&^D7-<%$U3D<>,DYI#:G  +KVE^M>TOUH>CY93>)#
MZ;?70H57KK*.6+#N6>I JDB*0(HA6%'+,KSSZ3EP04W900/@@V%RW4@FV5[$
M75Q.4D$ 68Q(;(6&N&\\,ZCFH(%+\.F7+[/?\=/0K@2&T7%&PW>W2S4!3L8*
M< '/C%[PD$ O2XM#5"K+2XRSG2L*ZI@%XTL1EH9]4/R(' &P'!ZG9V)?'E38
M1"$8:NV,JE%Y2%IE8QGX#J6(DR0)PT7""E?)7GMH&8T,\CH1MG(_C&Z$H6,,
M^!;[8/=_+,?2]_04^;L% <VJW!TU$D<$5LT!0WG;Q#&V H LYQ=-,*8+ 2_;
M4Z]802C$A3C8N!V?6,B$^\ E2T*&M[2=QDZH^42F QX!+97H[=WWL^@N/_2=
M_BEO- "9X&ZO)E]:S(WK&\ 7:2=-%AD=;%?,D!KP?G'"!$9Q!Q>ZM4VF5$%W
M*E.Z.)Q]_0,>+_U][_;K\HL3&LUL %?L?-IIIIH@H:C%L,N.9IGI%>$#$T4<
M$> @?UZRDAQP@3-\A4)NUFS4M!<KWMQ[G4L/YV7B(X _-^<YX9&N[T?W]3SA
M(PJX!W=0]A^>SJK,GLY[.G>,DQ!*KADK]-!3WK_G2_"--FL *O5Y?I\N<0N\
MA3=&8NC LB*,($5JZ'*(&5LS?F5*E2I4QLP(^F&#UIU#5)> 3*C09$$B:6,P
M)B0Y@*9;=HWGMU]< 5 @  !MX!+97H[=WWL^;/" KHK@2"(+'+=4333_ )#&
M%)]VO[;4"D.FJ$ @ &>.?GR?NO\ ?\,],N7V>_XZ>8IM8;:!AF5X36.NE\Y+
M"FSN?"D-DI3ETL4^E=A$M;A>/CM3G(J6)<6+HU>PI L6:[G1W.CN]'<Z N?N
M[:G>QJ!!JWE5_A% *(<$*&Z&%9IUVL1O-@!L%H%GP+?;![OY9CZ7OYC\YH=Y
ML/D!AK2?'++O*7ZFA=(RC4(\ @ A (8U*5_,!*S^'' &*HI@$ LK!05T=O\
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M(RJ_5TAJ2]:,@BKC^-NG!"."V_8A<S)6E%PWLR6-XC+BH^8T:-&C1J  2/K
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M"@L0QU'0.7]8C*]<%"-$)=PA;4A#6.-L&P7W3HU(HUZ+5(U;&"1K$F"/"!-
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MP[0IIPW)AT+V_:?(5<08ZNFLX%T9T-8=H$Y"-+Q&ZH8M2I*#": Y^6PL+IJ
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6PE +&2'9E/E9[A(>4I4AE#@_^'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image001a07new002.jpg
<TEXT>
begin 644 image001a07new002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $-*+D-U;6UI
M;F=S   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,R-P  DI(
M @    ,R-P  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( TP$+ ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M?4U#(NUR!5NJTW^M--,3+-%%%24**,4"B@!**6B@!**6B@!,4N*** "C%%%
M"44M% "44N** $HHHH **** "BBB@ HHHH **** "BBEQ0 E%+BC% "44N*,
M4 )12T4 )1BEHH ,48HHH ,4F*6B@!**6B@!**7%)B@ HHHH **** "BBB@
MHHHH **** "BBB@ HHQ1B@ HI<48H 2BEQ1B@!**7%&* $HI<48H 2BEQ28H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BEQ1B@!**7%)B@ HHQ1B@ HHQ1B@ HHQ1
MB@ HHQ2XH 2BEQ1B@!**7%% "44M% "44M&* $HI<48H 2BEQ1B@!**7%&*
M$HI<48H 2BEQ1B@!**** "JTW^M-6:K3?ZTU4=Q,LT445(Q112"EH **** "
MBBB@ HHHH **** "BBB@ HHHS0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 8I,4M% "8
MHI:* $HI:* $HI:,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N
M*,4 )12T4 )1BEHH ,4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+24
M%5IO]::LU6F_UIJH[B99HHHJ1@*6D%+0 4444 %%%% !1110 5%<W4%G;O<7
M<J0PQC+.YP *DKR_XLB75-;\/Z"\[PV=W/F<(?OCT- '>:5XET;7)'32-3M[
MQH_O+$^2*U:\8\3>&M,\ ^-/#M[X:MVM?-F$<T4;'$@/&37LN<J#ZC- #JIZ
MKJEIHVF3ZAJ$HBMX5W,Q_E]:?>WL&GV<ES=2!(T&22?TKP/XG^,Y]?F6RB)C
MM <^5G]36;J+VD:?5_EW-8TY.#J=%_5CW71-9L]?TF'4=-E\R"89'J#Z'WK0
MKYS^&?B^Y\.WC68S);R')BSU]2*][L]<TZ\M4GANX]K#."V"/8TE47M'2>Z"
M5-\BJ+X6:-%4_P"U+ =;R#_OL4?VKI__ #^P?]_!6AD7**J?VKI__/[!_P!_
M!1_:NG_\_L'_ '\%,"W153^U=/\ ^?V#_OX*/[5T_P#Y_8/^_@H MT54_M73
M_P#G]@_[^"C^U=/_ .?V#_OX* +=%5/[5T__ )_8/^_@H_M73_\ G]@_[^"@
M"W153^U=/_Y_8/\ OX*/[5T__G]@_P"_@H MT54_M73_ /G]@_[^"C^U=/\
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MM73_ /G]@_[^"@"W153^U=/_ .?V#_OX*/[5T_\ Y_8/^_@H MT54_M73_\
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M]JZ?_P _L'_?P4?VKI__ #^P?]_!0!;HJI_:NG_\_L'_ '\%']JZ?_S^P?\
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MP4 6Z*J?VK8?\_D'_?P4IU.Q S]KAQ_OB@"U153^U=/_ .?V#_OX*/[5T_\
MY_8/^_@H MT54_M73_\ G]@_[^"C^U=/_P"?V#_OX* +=%5/[5T__G]@_P"_
M@H_M73_^?V#_ +^"@"W153^U=/\ ^?V#_OX*/[5T_P#Y_8/^_@H MT54_M73
M_P#G]@_[^"C^U=/_ .?V#_OX* +=%5/[5T__ )_8/^_@H_M73_\ G]@_[^"@
M"W153^U=/_Y_8/\ OX*/[5T__G]@_P"_@H MT54_M73_ /G]@_[^"C^U=/\
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MPVO_ #[Q?]\"IZ* (/L-K_S[Q?\ ? H^PVO_ #[Q?]\"IZ* (/L-K_S[Q?\
M? H^PVO_ #[Q?]\"IZ* (/L-K_S[Q?\ ? H^PVO_ #[Q?]\"IZ* (/L-K_S[
MQ?\ ? H^PVO_ #[Q?]\"IZ* (/L-K_S[Q?\ ? H^PVO_ #[Q?]\"IZ* (/L-
MK_S[Q?\ ? H^PVO_ #[Q?]\"IZ* (/L-K_S[Q?\ ? H^PVO_ #[Q?]\"IZ*
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M>P"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ -)2FDH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TE !5:;_6FK-5IO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4>3>_P#/TO\ W[%6Z* *GDWO_/TO_?L4>3>_\_2_]^Q5NB@"IY-[_P _2_\
M?L4>3>_\_2_]^Q5NB@"IY-[_ ,_2_P#?L4>3>_\ /TO_ '[%6Z* *GDWO_/T
MO_?L4>3>_P#/TO\ W[%6Z* *GDWO_/TO_?L4>3>_\_2_]^Q5NB@"IY-[_P _
M2_\ ?L4>3>_\_2_]^Q5NB@"IY-[_ ,_2_P#?L4>3>_\ /TO_ '[%6Z* *GDW
MO_/TO_?L4>3>_P#/TO\ W[%6Z* *GDWO_/TO_?L4>3>_\_2_]^Q5NB@"IY-[
M_P _2_\ ?L4>3>_\_2_]^Q5NB@"IY-[_ ,_2_P#?L4>3>_\ /TO_ '[%6Z*
M*GDWO_/TO_?L4>3>_P#/TO\ W[%6Z* *GDWO_/TO_?L4>3>_\_2_]^Q5NB@"
MIY-[_P _2_\ ?L4>3>_\_2_]^Q5NB@"IY-[_ ,_2_P#?L4>3>_\ /TO_ '[%
M6Z* *GDWO_/TO_?L4>3>_P#/TO\ W[%6Z* *GDWO_/TO_?L4>3>_\_2_]^Q5
MNB@"IY-[_P _2_\ ?L4>3>_\_2_]^Q5NB@"IY-[_ ,_2_P#?L4>3>_\ /TO_
M '[%6Z* *GDWO_/TO_?L4>3>_P#/TO\ W[%6Z* *GDWO_/TO_?L4>3>_\_2_
M]^Q5NB@"IY-[_P _2_\ ?L4>3>_\_2_]^Q5NB@"IY-[_ ,_2_P#?L4>3>_\
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MV=8_E6+W;GD5T_PQ^*/B;5/%VK^&?'5C##?V$+3Y@7& !DJ1W^M 'K/DWO\
MS\K_ -^Q1Y-[_P _2_\ ?L5\]7_QG^(>HZ;JOB'P_::5;:'92L@6=E,P .,X
M)R3^%>M_"CQ!KWBCP%:ZOXGBBCN;@EH_*7:&3L<4 =5Y-[_S]+_W[%'DWO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4444 %%%% !4%[_QXS_\ 7-OY5/4%[_QXS_\ 7-OY4 1:3_R![3_KDO\
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M .N;?RH BTG_ ) ]I_UR7^57*IZ3_P @>T_ZY+_*KE !1110 4444 %!HHH
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MRM(B_/<E>3G\J /H"E%<1\)?$NH>*/ -O>:P0]W&[1.X_CVGK]:[>@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** $HHHH **** "JTW^M-6:K3?ZTU4=Q,LT"BE%2,***1C
MM4MZ#- '&_%1;1_ MRM[#)+EAY8C7)#]C7'^'/B\VG:';6>IZ/=-- @3=&AP
M0.E=/_PLS3)M(U&[NK"8Q6-QY+(4SN/K6/\ \+A\-%<_V5+_ -^/_K4 =/X-
M\>0>,)KF.*QN+4P ']ZN-U=;7(^"_&NE^*Y[E-,LGMFA +%H]N<UUU !112$
MA5)8@ #))[4 +17+K\0O#TOBF/0+>[\^\<=8AN0'TS6QK6N:?X?TU[[5KA88
M4'4]6/H!W- &A17(^&/B9X;\6WS6>EW3BX'*QS(4+_3/6NNH *@O?^/&?_KF
MW\JGJ"]_X\9_^N;?RH BTG_D#VG_ %R7^57*IZ3_ ,@>T_ZY+_*KE !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV*V_Y]X_^^: '_:(?^>J?]]4?:(?^>J?]]4S[%;?\^\?_?-'V*V_Y]X_^^:
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M +1#_P ]4_[ZH^T0_P#/5/\ OJF?8K;_ )]X_P#OFC[%;?\ /O'_ -\T /\
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M?\^\?_?- #_M$/\ SU3_ +ZH^T0_\]4_[ZIGV*V_Y]X_^^:/L5M_S[Q_]\T
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MS0 _[1#_ ,]4_P"^J/M$/_/5/^^J9]BMO^?>/_OFC[%;?\^\?_?- #_M$/\
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M$/\ SU3_ +ZH^T0_\]4_[ZIGV*V_Y]X_^^:/L5M_S[Q_]\T /^T0_P#/5/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$'1JZ9?O:?/U6_\ F91]V5CT:BFTM<QJ+10** "BBB@ HHHH **** "BBB@
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MM_+\S.C_ !$=%0:0]:*W,C'\4>)K+PEH4NJZFDSV\7WA"FYORK!\)?$/P_\
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MG<!GWKNOB=K#Z+X&NYHH!.9<0[2,XW=Z\\T+X>^-Y=#MY;/Q%)902+O2W5^
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MNBJGEW__ #VA_P"^#1Y=_P#\]H?^^#0!;HJIY=__ ,]H?^^#1Y=__P ]H?\
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M]\&@"W153R[_ /Y[0_\ ?!H\N_\ ^>T/_?!H MT54\N__P">T/\ WP:/+O\
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M]_X\9_\ KFW\JGJ"]_X\9_\ KFW\J (M)_Y ]I_UR7^57*IZ3_R![3_KDO\
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MQE]@\S&['./6GYI**Z-D8BT4"B@ HHHH **** "BBB@ HHHH **** "BBB@
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M[3_KDO\ *KE4])_Y ]I_UR7^57* "BBB@ HHHH **** "BBB@ HHHH ****
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M9W&/)NX9/]UP:SKKPCHEYGS["/G^[Q65-\.=,7_D'2S6A_V7-'-BX]$_G_P
MY<))?$T_1?YG7]>]%<,OA3Q)I^38:VTP[+-VI6OO'-B,W5I:W*+_ ,\^IH^M
M2B[2@_DKC6%4E>,X_-V.XI17#P_$">%]FI:-<PXZN%R*TK?Q_P"'YV"-=F-^
MZNA&*M8NA]J27KH9_5*_2+?IJ=-15*VUC3[M08+R%_\ @8JXK!AE2"/45TQG
M&2O%W,)1<79H6BBBJ)"BBB@ HHHS0 449HH ***,T %%&:* "BBB@!***6@
MKGM#_P"1JU__ *ZQ_P#H KH:Y[0_^1JU_P#ZZQ_^@"L*N\?7]&:P^&7I^J.A
MI*6DK<R%%% HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "@T4&@!**** "JTW^M-6:K3?ZTU4=Q,LT445(Q:I:QJ2:/H]UJ$J,
MZ6\9<JO4XJ[4-U;17EK+;7"[HI5*LI[B@#S[6O%N@>(?AS'J>M0-]FFE ^SK
M(-X.<5%;_#3P'>V<-RC;5E0,!]H /-8?BOX+K;64EQX:EGFF:3/V=V^4 GG%
M6[7X%VDME"]QJ=W%.4!=%D.%/H* .U\)^$?#_AN>XDT!]S2@"3]Z'KJ*X[P1
M\/+;P5<74MM>37!N  1(Q.,5V- !1110 4444 %%%% !4%[_ ,>,_P#US;^5
M3U!>_P#'C/\ ]<V_E0!%I/\ R![3_KDO\JN53TG_ ) ]I_UR7^57* "BBB@
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M<5O<?ZJ1I/OUL6-_:ZE91W=A.EQ;RC*21G(84 6**** "BBB@ HHHH ****
M"BBB@ HHHH **** $HHHH *K3?ZTU9JM-_K351W$RS1114C%HHHH BN+B&TM
MWGN9%BBC&69C@ 5S.E?$;0=:UI],L)9))54ONV_*0/2J/Q=2Z?P!/]CW8$BF
M7;_<SS7 >%[S0-.^)5E=VMQ%!9+I^'8GC?CD4 >TZ5K>GZU%(^FW*S"-MK@'
ME3[U?KRGX42I<^+_ !-<Z?G^SY9@8CV)S7JU !1110 4444 %%%% !4%[_QX
MS_\ 7-OY5/4%[_QXS_\ 7-OY4 1:3_R![3_KDO\ *KE4])_Y ]I_UR7^57*
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M)H M455_M*U_OG_ODT?VE:_WS_WR: +5%5?[2M?[Y_[Y-']I6O\ ?/\ WR:
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M_P#?)H M455_M*U_OG_ODT?VE:_WS_WR: +5%5?[2M?[Y_[Y-']I6O\ ?/\
MWR: +5%5?[2M?[Y_[Y-']I6O]\_]\F@"U157^TK7^^?^^31_:5K_ 'S_ -\F
M@"U157^TK7^^?^^31_:5K_?/_?)H M&D%5?[2M?[Y_[Y-']I6O\ ?/\ WR:
M+5&*J_VE:_\ /0_]\FC^TK7_ )Z'_ODT 6L455_M*U_YZ'_ODT?VE:X^^?\
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MK0GGO6\(PZAJ,_+75Q(-X]A74>*-#\3^(]!T?7H;-+77]/?>]IGAO8&O3J*
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M,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]***
M# ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]
M*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#TI-HI:* $P/
M2EP/2BB@!-H]!1@>E+10 FT>@_*N?T0?\53KP_Z:Q_\ H KH:Y[1/^1JU_\
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M]:UZ6PPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M] &K\.?%MEKQN;/3M!DTF*W ;#)M#$UW=<_X;\5:#XAEG30I4D:+E]J8KH*
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M -&"KIWYT3+8[(B@4II*@H6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK=HUMJEI'<Q,,8=<X^GI7FM[\,]<\)W3:A\.-4DC4'<VFW#9C:M7[*KM[K_
MA<\=]4>L4M>9:#\7H5NQIGC:PET6_!V>9(O[N0^Q[5Z1!<0W4*RVTJ2QL,JZ
M-D&LITY0W-(R4MB6BBBLR@HHHH **,T4 %%%% !1110 4444 %%%% !1110
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MKMS'JUDCR8PLZC#I]#7GS>'?'/PX<S>&;IM=TA3DV,YRZCV-:<M.I\&C[?\
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MS_\ 7-OY5/4%[_QXS_\ 7-OY4 1:3_R![3_KDO\ *KE4])_Y ]I_UR7^57*
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ME0!%I/\ R![3_KDO\JN53TG_ ) ]I_UR7^57* "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\A_C1]N?_GTG_(?XU;HH J?;G_Y])_R'^-'VY_\ GTG_ "'^-6Z* *GVY_\
MGTG_ "'^-'VY_P#GTG_(?XU;HH J?;G_ .?2?\A_C1]N?_GTG_(?XU;HH J?
M;G_Y])_R'^-'VY_^?2?\A_C5NB@"I]N?_GTG_(?XT?;G_P"?2?\ (?XU;HH
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M/^0_QH^W/_SZ3_D/\:MT4 5/MS_\^D_Y#_&C[<__ #Z3_D/\:MT4 5/MS_\
M/I/^0_QH^W/_ ,^D_P"0_P :MT4 5/MS_P#/I/\ D/\ &C[<_P#SZ3_D/\:M
MT4 5/MS_ //I/^0_QH^W/_SZ3_D/\:MT4 5/MS_\^D_Y#_&C[<__ #Z3_D/\
M:MT4 5/MS_\ /I/^0_QH^W/_ ,^D_P"0_P :MT4 5/MS_P#/I/\ D/\ &C[<
M_P#SZ3_D/\:MT4 5/MS_ //I/^0_QH^W/_SZ3_D/\:MT4 5/MS_\^D_Y#_&C
M[<__ #Z3_D/\:MT4 5/MS_\ /I/^0_QH^W/_ ,^D_P"0_P :MT4 5/MS_P#/
MI/\ D/\ &C[<_P#SZ3_D/\:MT4 5/MS_ //I/^0_QH^W/_SZ3_D/\:MT4 5/
MMS_\^D_Y#_&C[<__ #Z3_D/\:MT4 5/MS_\ /I/^0_QH^W/_ ,^D_P"0_P :
MMT4 5!>N?^72;\0*M*VY02"/8TM)0 M%%% !1110 E%%% !5:;_6FK-5IO\
M6FJCN)EFBBBI&**#R,&@4&@#G)? 7AN>9Y9=,B9W;<Q(ZFF?\*\\+_\ 0*A_
M*M#Q+X@MO#.A3ZE=@LD8PJ#JS'H*X+PI\1=>USQH-,OK..VBEA,L497YL=N:
M .^TCPUI.A22/I5HENT@PY7O6K7*>#O&1\27>HV-S;?9[JPEV.N>"/6NKH *
M*** "BBB@ HHHH *@O?^/&?_ *YM_*IZ@O?^/&?_ *YM_*@"+2?^0/:?]<E_
ME5RJ>D_\@>T_ZY+_ "JYF@ HHHH ***,T %%&:* "BC-&: "BBB@ HHS10 4
M449H **,T4 %%%% !111F@ HHHS0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4E+10 4E&*6D E9NM>']+\0V36FL645S$PQ\Z\CZ&M+'%&*:;3NA6ON
M>1W?P[\3>"[IK_X=ZFTEN.6TZY.5QZ+6IX>^+]E<7:Z9XMM)-#U+.TK."$8^
MH/:O2,5C>(/">B^)[1H-9LHYMPQYF,./H>M=/ME/2JOF9\CC\!K12QSQ++!(
MLD;#*LIR#3J\AD\(^,_A[(USX-OVU73 <M87)R47T6N@\+_%K2-:N%L-7BDT
M;4\X-O=#;N/L:4J$K<T/>7X_-![1)VEHSOQ2TU"K*&5@P/0@Y!IV:YS4****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBB@ JM-_K3
M5FJTW^M-5'<3+-%%%2,444"B@#E/B-X?N/$G@^>TLQF>-A*B_P!XCM7D%IXT
MNM+\:PZQ>:+<^9:VWV4Q",\D#&:];^)>NWOAWPBU_IK[)EE49/I7/^'?B0FH
MZK867B#1UMI+Q1Y5RZ##M0 [X3Z?J$]]J_B34K=K;^TI,I&PP<?2O3:\?\2?
M$W7-/\4746C6<<FFZ>X6<XZ#N:]5TN_CU32K:]A^Y/&''XT 6Z*** "BBB@
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M\$;2KM=E!9?0XY%53JQJ?"98W+ZN":55J[[-.WK;8DHHHK8\\**** "BBB@
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M/>XC&%ZXX% '3\48H[]*4BD E'!HQS1B@!12=Z,44 !Z&D!_.B1UCC:20X5
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MT3Q+XCU#39OL4P,L< VX0#M@#)KK[/X;:M!\?+KQC));G2YH"BJ'/F;B!VH
MYKQ]XE\:>&[#POX$T[6!/XEU,XGU(#'? QD<?_6KB?B)HGCG0]:\)6_CC7+?
M6(3?J8)4!WJ=PR#P,UZ]\6_A7=>-?[/U7PW=K9:WIS9BD=B PSGKV-</J/P9
M^)/B&[TG4/$WB*VOY[*Y5O(9CM1 020<<GB@#WO5=2CTC0[K4)<%;:!I"/7
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MN3A<D\_G0!Z;;!TM8DGD#RJ@#L/XFQR:FJI_9UL?X#_WT:/[-MO[C?\ ?1H
MMT54_LVV_N-_WT:/[-MO[C?]]&@"W153^S;;^XW_ 'T:/[-MO[C?]]&@"W15
M3^S;;^XW_?1H_LVV_N-_WT: +=%5/[-MO[C?]]&C^S;;^XW_ 'T: +=%5/[-
MMO[C?]]&C^S;;^XW_?1H MT54_LVV_N-_P!]&C^S;;^XW_?1H MT54_LVV_N
M-_WT:/[-MO[C?]]&@"W153^S;;^XW_?1H_LVV_N-_P!]&@"W153^S;;^XW_?
M1H_LVV_N-_WT: +=%5/[-MO[C?\ ?1H_LVV_N-_WT: +=%5/[-MO[C?]]&C^
MS;;^XW_?1H MT54_LVV_N-_WT:/[-MO[C?\ ?1H MT54_LVV_N-_WT:/[-MO
M[C?]]&@"W153^S;;^XW_ 'T:/[-MO[C?]]&@"W153^S;;^XW_?1H_LVV_N-_
MWT: +=%5/[-MO[C?]]&C^S;;^XW_ 'T: +=%5/[-MO[C?]]&C^S;;^XW_?1H
M MT54_LVV_N-_P!]&C^S;;^XW_?1H MTF*J_V;;?W&_[Z-']FVW]QO\ OHT
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MTGY=5]%KV'%'2MZ=:4%R[KL1*";OU/.]*^,FB7NFW+7Z2Z?J%M&6>TF7!SZ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPL:@PS(.#7;T44 %%%% !1110 4444 %07O_ !XS_P#7-OY5/4%[_P >,_\
MUS;^5 $6D_\ ('M/^N2_RJY5/2?^0/:?]<E_E5R@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KC/"7_(]^,O^ON'_P!$K79UQGA+_D?/&/\
MU]P_^B5JX[,E[H[&C&32T5!1GZCHMAJLEL]_ )3:R>9%SC:WK5X*H& *?104
MY-I1;T0E%+102%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%%  :2E-)0 56F_UIJS5:;_6FJCN)EFBBBI&%+2"EH **** "BBB@ HHH
MH **** "BBB@ J"]_P"/&?\ ZYM_*IZ@O?\ CQG_ .N;?RH BTG_ ) ]I_UR
M7^57*IZ3_P @>T_ZY+_*KE !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %)2T4 %<9X2_Y'OQE_U]0_^B5KKY9HH%W3RI&OJ[ "N)\)WUFOCCQ:QO+?
M$ES$5_>#G$8']*N.S)>Z.YI>])G(!!R#WI>]9E!1113 **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6DH *K3?ZTU9JM-
M_K351W$RS1114C%%%%% !1110 4444 %%97B34;_ $K0I[O2=/.HW48^2W!Q
MOKA4^(GB;_A&-2OM;\,2:0\2$0L6+9- ">./BI>:#KK6&A64-Y';E5NIG)PC
M'^'CO6]XI\?1^&O#MC<O;F?4+]%^SVZ="Q'?VKQJ?Q1X?D^'ITRTCN6U:XN!
M<7<\L9&XYR?FKJ]6URRUW5?!=[;AHX(W$)\]<#<* .@\/?$C7%\2VND>--$&
MFM??\>TD9)'XYKTRO+/BG(DGBSPS;PR@7/V@-M7[P&:]27[@SUQ0 M07IQ8S
M_P#7-OY5/4-U&9K26)>&="H- $.D_P#('M/^N2_RJY6=:)?VUG%#Y<3>6H7.
MZIO,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0!;HJIYE__ ,\(O^^Z/,O_ /GA%_WW0!;HJIYE_P#\\(O^
M^Z/,O_\ GA%_WW0 S5=&L-;M/LVJ6ZW$.=VQB1S^%8R_#CPFK!ET:%6!SD%L
MG]:W/,O_ /GA%_WW1YE__P \(O\ ONGS-"LBS'&L<:H@PJ@ #T%.JIYE_P#\
M\(O^^Z/,O_\ GA%_WW2&6Z*J>9?_ //"+_ONCS+_ /YX1?\ ?= %NBJGF7__
M #PB_P"^Z/,O_P#GA%_WW0!;HJIYE_\ \\(O^^Z/,O\ _GA%_P!]T 6Z*J>9
M?_\ /"+_ +[H\R__ .>$7_?= %NBJGF7_P#SPB_[[H\R_P#^>$7_ 'W0!;HJ
MIYE__P \(O\ ONCS+_\ YX1?]]T 6Z*J>9?_ //"+_ONCS+_ /YX1?\ ?= %
MNBJGF7__ #PB_P"^Z/,O_P#GA%_WW0!;HJIYE_\ \\(O^^Z/,O\ _GA%_P!]
MT 6Z,U4\R^SS#%_WW5E=VT;QAN^* '4444 %%%% !24M)0 56F_UIJS5:;_6
MFJCN)EFBBBI&+1110 4444 %%%% !3)88YXS',BR(>JL,@T^B@#E?%W@2P\3
M:*+"$1V)\P/YL40SQVIOB#X?Z;X@\,VNE3,8'LU'D3Q#!1@.M=910!Y_X4^%
M5KH&K+JFJ:E<:Q>Q<02W!_U=>@4F*6@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFW"7$$@^61#D&K5>;?!72+W3?"]S/=[U@NIS);1M_"G;BO2: "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** *][?6NG6;W5].D$$8RSN<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% #73S(V0\!@1Q7@WQ)^'=CX5L8M2LM1OW>[NQ&Z/,=H#'M7
MO=>:_&Q#)X9T]0"?].3H,]Z (],\.:)\*K$^(I+O4;L3QJCK(^_;GG(%;_A_
MXD:/XDU&YMK*.YC2WB\UYY8]J8^M9OQ10O\ #2- "<^5P![5J/I7G_#$VNFP
MK'++9  (N"QQTH R9OC1X<AU V_D7[PAMOVI8,Q?7=71:_XUTOP_H4&JS>=<
MP7&/*%NF]GR.PKQW3=0TRR\('0M>O[^U*DB6WCM=V/QKL];U+_A%_!6A)H\<
MDVGMC-S+'N>)?7'K0!N>&?BCHGB?4_L%O#=VEPRY1+J+87]A7%:Q\6I+/X@"
M1!>_V9;9CFM!'\SMG&X"JMK>)JWQ0T*_MKBXNH5;:998/+P<=*VO&=[:^'/B
MC9:MJ-FSV?DX)2+=N;UH Z[5OB'I&B0Z9/?I<)%J2;XVV?='^T*R[+XR>&+N
M]GMY#=6HB!(DGBVB3Z5C?$AH-3U_P=,L;&WFG#;2G8^HI?'FG6<GQ*\.QFT0
MQG[RA.#]: .A\-?%30O$^MMI=JEU;W'/E_:(]HD^E.\2_%'0O#6H&QE2ZO;E
M.)([.+>8_K7/^)+:"W^-OA\PPB(F,@E%P*YFZNO^$/\ B-K<VMW-U91W3$Q3
M16_F>:#0!ZQI'C;2M;\.SZQ8&1HK=298F7$B$=B*YNX^-OAJ&"*18;Z8R'#"
M.'/E_4YK+\&+H<GA+Q-J&@7=Y<F9&\XW,>S#8/04_P  V=H?@W?2M;(9'28N
MS)\QXXH W/%GQ"LK/P*FJZ6TTGVY2D$D2Y\MO?TQ5+X7_$'_ (2&W72;X74V
MH0)NDN73Y'_&LKP);FZ^!-U$D/FOB7:C+DCGM5_X0^)],O-)30X+:2._M%/G
M,T6 >?6@"3XU6,S>';+5+8R*]C=*[;&(RN><U6^*-_-JG@?2K#3&8W&H[755
M."0%KN_%FF_VOX2U*QQS- P''0XKR7X;WC^(?%FF6MS'(R:);/'EU."V<4 =
M3X"U_P CX47,MS(?.TU9(Y,G)4CI6?X%UBP\'> FUW7I9/M&J7#R(F2SR<\
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M:3- "T4E% "T4F:7- !11FC- !11FC- !11FC- !11FC- !11FC- !11FC-
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E1110 4444 %%%% !1110 4444 %5IO\ 6FK-5IO]::J.XF?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pipelineimage.jpg
<TEXT>
begin 644 pipelineimage.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'H W@# 2(  A$! Q$!_\0
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M?_X[7A?Q@M=WQ:\:''_,;O?_ $>]<A]C]J^ZIY;AY13<4?#SS"NI-<Q]2?\
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MJ/L?M1_9F&_E0?VAB/YSZD_X>/>//^A=\/?]^Y__ ([1_P /'O'G_0N^'O\
MOW/_ /':^6_L?M1]C]J/[,P_\J#^T,1_.?4G_#Q[QY_T+OA[_OW/_P#':/\
MAX]X\_Z%WP]_W[G_ /CM?+?V/VH^Q^U']F8?^5!_:&(_G/J3_AX]X\_Z%WP]
M_P!^Y_\ X[1_P\>\>?\ 0N^'O^_<_P#\=KY;^Q^U'V/VH_LS#_RH/[0Q'\Y]
M2?\ #Q[Q[_T+WA__ +]S_P#QVC_AX]X]_P"A>\/_ /?N?_X[7RW]C]J/L?M1
M_9F&_E0?VAB/YSZD_P"'CWCS_H7?#W_?N?\ ^.T?\/'O'G_0N^'O^_<__P =
MKY;^Q^U'V/VH_LS#_P J#^T,1_.?4G_#Q[QY_P!"[X>_[]S_ /QVC_AX]X\_
MZ%WP]_W[G_\ CM?+?V/VH^Q^U']F8?\ E0?VAB/YSZD_X>/>//\ H7?#W_?N
M?_X[1_P\>\>?]"[X>_[]S_\ QVOEO['[4?8_:C^S,/\ RH/[0Q'\Y]2?\/'O
M'G_0N^'O^_<__P =H_X>/>//^A=\/?\ ?N?_ ..U\M_8_:C['[4?V9A_Y4']
MH8C^<^I/^'CWCS_H7?#W_?N?_P".T?\ #Q[QY_T+OA[_ +]S_P#QVOEO['[4
M?8_:C^S,/_*@_M#$?SGU$W_!1SQZ5.WP_P"'@V."8IR,_3S:J_\ #QGXD_\
M0%\+_P#@+<?_ "17S/\ 8_:C['[4UEN&7V1/'U_YSZ9_X>-?$G_H"^%__ 6X
M_P#DBC_AXU\2?^@+X7_\!;C_ .2*^9OL?M1]C]J?]FX;^1$_7Z_\[/IG_AXU
M\2?^@+X7_P# 6X_^2*/^'C7Q)_Z OA?_ ,!;C_Y(KYF^Q^U'V/VH_LW#?R(/
MK]?^=GTS_P /&OB3_P! 7PO_ . MQ_\ )%'_  \:^)/_ $!?"_\ X"W'_P D
M5\S?8_:C['[4?V;AOY$'U^O_ #L^F?\ AXU\2?\ H"^&/_ 2X_\ DBC_ (>-
M?$G_ * OAC_P$N/_ )(KYF^Q^U'V/VH_LW#?R(7U[$?SL^F?^'C7Q)_Z OAC
M_P !+C_Y(H_X>-?$G_H"^&/_  $N/_DBOF;['[4?8_:C^S<-_(@^O8C^=GTS
M_P /&OB3_P! 7PQ_X"7'_P D4G_#QKXD_P#0%\,?^ EQ_P#)%?,_V/VH^Q^U
M']FX;^1#^OU_YV?3/_#QKXD_] 7PO_X"W'_R11_P\:^)/_0%\,?^ EQ_\D5\
MS?8_:C['[4?V;AOY$'U^O_.SZ9_X>-?$G_H"^%__  %N/_DBD_X>-?$G_H"^
M&/\ P$N/_DBOF?['[4?8_:C^S<-_(@^OU_YV?3/_  \:^)/_ $!?"_\ X"W'
M_P D4?\ #QKXD_\ 0%\+_P#@+<?_ "17S-]C]J/L?M1_9N&_D0?7Z_\ .SZ9
M_P"'C7Q)_P"@+X7_ / 6X_\ DBC_ (>-?$G_ * OA?\ \!;C_P"2*^9OL?M1
M]C]J/[-PW\B#Z_7_ )V?3D/_  4:^(:L?-T+PVZXZ);W"G/U\\U8_P"'CWCS
M_H7O#_\ W[G_ /CM?+?V/VH^Q^U+^S,-_(BEF&(_G/J3_AX]X\_Z%WP]_P!^
MY_\ X[1_P\>\>?\ 0N^'O^_<_P#\=KY;^Q^U'V/VI?V9A_Y4/^T,1_.?4G_#
MQ[QY_P!"[X>_[]S_ /QVC_AX]X\_Z%WP]_W[G_\ CM?+?V/VH^Q^U']F8?\
ME0?VAB/YSZD_X>/>//\ H7?#W_?N?_X[1_P\>\>?]"[X>_[]S_\ QVOEO['[
M4?8_:C^S,/\ RH/[0Q'\Y]2?\/'O'G_0N^'O^_<__P =H_X>/>//^A=\/?\
M?N?_ ..U\M_8_:C['[4?V9A_Y4']H8C^<^I/^'CWCS_H7?#W_?N?_P".T?\
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M4T]4W;2WY]CUJ;P!JWBSX[>"SXVDTC7=.6PGN+/4;&#RTO\ 9AE$J9(R-P;
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M ,17UOGWH_&G_K!C_P"=?<A?V%@^S^\^2/\ AC_Q)_T%=,_[ZD_^(H_X8_\
M$G_05TS_ +ZD_P#B*^M_QH_&C_6#'_SK[D']A8/L_O/DC_AC_P 2?]!73/\
MOJ3_ .(H_P"&/_$G_05TS_OJ3_XBOK?\:/QH_P!8,?\ SK[D']A8/L_O/DC_
M (8_\2?]!73/^^I/_B*/^&/_ !)_T%=,_P"^I/\ XBOK?\:/QH_U@Q_\Z^Y!
M_86#[/[SY(_X8_\ $G_05TS_ +ZD_P#B*/\ AC_Q)_T%=,_[ZD_^(KZW_&C\
M:/\ 6#'_ ,Z^Y!_86#[/[SY(_P"&/_$G_05TS_OJ3_XBC_AC_P 2?]!73/\
MOJ3_ .(KZW_&C\:/]8,?_.ON0?V%@^S^\^2/^&/_ !)_T%=,_P"^I/\ XBC_
M (8_\2?]!73/^^I/_B*^M_QH_&C_ %@Q_P#.ON0?V%@^S^\^2/\ AC_Q)_T%
M=,_[ZD_^(H_X8_\ $G_05TS_ +ZD_P#B*^M_QH_&C_6#'_SK[D']A8/L_O/D
MC_AC_P 2?]!73/\ OJ3_ .(H_P"&/_$G_05TS_OJ3_XBOK?\:/QH_P!8,?\
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MN_\ 07L/^^G_ /B*^LZ*/[>Q_P#/^"#^P\'_ "O[SY,_X8]UW_H+V'_?3_\
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M?V]C_P"?\$']AX/^5_>?)G_#'NN_]!>P_P"^G_\ B*/^&/==_P"@O8?]]/\
M_$5]9T4?V]C_ .?\$']AX/\ E?WGR9_PQ[KO_07L/^^G_P#B*/\ ACW7?^@O
M8?\ ?3__ !%?6=%']O8_^?\ !!_8>#_E?WGR9_PQ[KO_ $%[#_OI_P#XBC_A
MCW7?^@O8?]]/_P#$5]9T4?V]C_Y_P0?V'@_Y7]Y\F?\ #'NN_P#07L/^^G_^
M(H_X8]UW_H+V'_?3_P#Q%?6=%']O8_\ G_!!_8>#_E?WGR9_PQ[KO_07L/\
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M?\K^\^3/^&/==_Z"]A_WT_\ \11_PQ[KO_07L/\ OI__ (BOK.BC^WL?_/\
M@@_L/!_RO[SY,_X8]UW_ *"]A_WT_P#\11_PQ[KO_07L/^^G_P#B*^LZ*/[>
MQ_\ /^"#^P\'_*_O/DS_ (8]UW_H+V'_ 'T__P 11_PQ[KO_ $%[#_OI_P#X
MBOK.BC^WL?\ S_@@_L/!_P K^\^3/^&/==_Z"]A_WT__ ,11_P ,>Z[_ -!>
MP_[Z?_XBOK.BC^WL?_/^"#^P\'_*_O/DS_ACW7?^@O8?]]/_ /$4?\,>Z[_T
M%[#_ +Z?_P"(KZSHH_M['_S_ ((/[#P?\K^\^3/^&/==_P"@O8?]]/\ _$4?
M\,>Z[_T%[#_OI_\ XBOK.BC^WL?_ #_@@_L/!_RO[SY,_P"&/==_Z"]A_P!]
M/_\ $4G_  Q[KO\ T%M/_P"^I/\ XBOK2BC^WL?_ #_@@_L/!_RO[SQ'X$_#
M/4_A7KVL6-Z/M45Y#%(MU"K>4I0O\N2!DG?^E%>OC6+-M5.GBX4WP3S##SG;
MQSZ=Q^=%>+7K5,14=6;U9Z^'HT\-35."T1HT445B=!^3'P?_ .%YW'[3'[4&
MG_!:T\,-)?:V8-2OO$4KK)9@R3B-X0#@GE\[E8<+Q5W]IW]F(_LE_P#!->7P
MG/JD>JZS<^*K74]0O+966+SW!0+'GG:J1H,G!)!.!TK]$/AU\ ?!GPI\:>,?
M%7AK39;+6O%MRMWJ\SW4DJS2!G8%58D(,NW"@=:L_&KX(>$?V@O!+^$O&UA+
MJ.AM<1W)AAN)(&\Q"=IW(0>Y[T ?!W[8WP%\%_!G_@G=<S^$="2PO]8?0[C5
MM0W-)/>R!MWF3.2<G=*YSQ][Z5;_ &Q?&OA[Q!??L<V6G:S8ZA=G7=.O/)MY
MED<0D6RB0@'@%ACGN#Z5]\^)OAGX9\:?#^X\$:YI$.H^&+BT6RDL+C+*8E "
MC.<@C:"&!R" <YKQ/PK_ ,$ZO@+X-_LB72_!?V>\TK5(=8MKXW\[W GB.8PT
MA?+1@\[#\I[B@#YGU#X/>%/C9_P5D^(NA^,M-&M:';^'[2_.FRR,L$\JV=JB
M&15(WA1(Q /?!KH%\(Z--_P5:G\+2:;;R>'V^'?]FMIS+F(VWD"/RB#U79\O
MTK['TOX ^"='^-FL?%BVTR1/&^K62:?=7QN9"C0JL:@",G8#B)!D#/'O2K\
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M25V&;:-^WTSUQ15-=!A7Q VK^=-YQB\GRM_[O''./7BB@#3HKY,_X:F\7_\
M/MI?_?B7_P".4?\ #4WB_P#Y]M+_ ._$O_QRODO]9\O_ )G]Q]=_JKF?\B^\
M^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F
M?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\
MQRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__
M )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)
M?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%
M_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\
M^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F
M?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\
MQRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__
M )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)
M?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%
M_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\
M^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F
M?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\
MQRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__
M )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)
M?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%
M_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\
M^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F
M?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\
MQRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__
M )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)
M?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%
M_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\
M^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F
M?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\
MQRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__
M )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)
M?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\^LZ*^3/^&IO%
M_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F?W!_JKF?\B^\
M^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\ QRC_ %GR_P#F
M?W!_JKF?\B^\^LZ*^3/^&IO%_P#S[:7_ -^)?_CE'_#4WB__ )]M+_[\2_\
MQRC_ %GR_P#F?W!_JKF?\B^\^G]<BU29+8:7-% RS S><,[H\'('!YSBM3;Z
MU\J6/[3GBJY:1731H J%@9()<,1V_P!9U-5_^&I/%_\ SZ:7_P!^)/\ XY5R
MXCP$8J3D[/R(CPQF,I.*@KKS/K.BODS_ (:F\7_\^VE_]^)?_CE'_#4WB_\
MY]M+_P"_$O\ \<J/]9\O_F?W%_ZJYG_(OO/K.BODS_AJ;Q?_ ,^VE_\ ?B7_
M ..4?\-3>+_^?;2_^_$O_P <H_UGR_\ F?W!_JKF?\B^\^LZ*^3/^&IO%_\
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M4WB__GVTO_OQ+_\ '*/]9\O_ )G]P?ZJYG_(OO/K.EKY+_X:F\7_ //MI?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH FM;.>]9U@C:5E4NP7LHZFH:='*\62CLA(P=IQQZ4VM)<
MO*K7OU[>5C*/-S/FM;IW^84445F:A1110 4444 %%%% !1110 4444 %%%%
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MJ:1OB<Z;G"%%6]Z-[VVDKGBU%?4WA[X9:?J2Q6E[X'L=,LY(#^^EN]]V#CN
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MQGCGKD&O7_>OVW#8B&*I1K4W>+/PC$X:IA*LJ-56DAU%%%=9S!1110 4444
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M,FT;\>F>N**I+X?@7Q VK^9-]H,7D[-_[O''./7BB@#R7_AE'PS_ -!35O\
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M_P ^D']M9A_S^E]YXC_PRCX9_P"@IJW_ '\B_P#C5'_#*/AG_H*:M_W\B_\
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M_,_8_P#4O!?\_)?A_D?9G_#17@'_ *#3?^ <_P#\11_PT5X!_P"@TW_@'/\
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MW_@'/_\ $5\9T4?ZW8S^2/W/_,/]2\%_S\E^'^1]F?\ #17@'_H--_X!S_\
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M_P 17QG11_K?C/Y(_<_\P_U+P7_/R7X?Y'V9_P -%> ?^@TW_@'/_P#$4?\
M#17@'_H--_X!S_\ Q%?&=%'^M^,_DC]S_P P_P!2\%_S\E^'^1]F?\-%> ?^
M@TW_ (!S_P#Q%'_#17@'_H--_P" <_\ \17QG11_K?C/Y(_<_P#,/]2\%_S\
ME^'^1]F?\-%> ?\ H--_X!S_ /Q%'_#17@'_ *#3?^ <_P#\17QG11_K?C/Y
M(_<_\P_U+P7_ #\E^'^1]F?\-%> ?^@TW_@'/_\ $4?\-%> ?^@TW_@'/_\
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M/_\ $4?\-%> ?^@TW_@'/_\ $5\9T4?ZWXS^2/W/_,/]2\%_S\E^'^1]F?\
M#17@'_H--_X!S_\ Q%'_  T5X!_Z#3?^ <__ ,17QG11_K?C/Y(_<_\ ,/\
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MS7:6Z5FDVTO31&]<? '1-/U:PLKWQ5]GEU!5^RP>5F1W(R<C. .@![FH[?\
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M?777_AC"#7/)<U]M--/^'"BBBL#<**** "BBB@ HHHH **** "BBB@ HHHH
M**** +%K;Q307#O<+"\:[D1@<R'/057J>WL9[J&>6*,O' N^1A_",XR?QJ"M
MYIJ$7RV\^^N_R,*;O.2YK^6FFFP4445@;A1110 4444 %%%% !1110 4444
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M>?\ \"H/_CE']EX[_GU+[F']M9?_ ,_X_>O\SSZBO0?^% ^/O^A>?_P*@_\
MCE'_  H'Q]_T+S_^!4'_ ,<H_LO'?\^I?<P_MK+_ /G_ !^]?YGGU%>@_P#"
M@?'W_0O/_P"!4'_QRC_A0/C[_H7G_P# J#_XY1_9>._Y]2^YA_;67_\ /^/W
MK_,\^HKT'_A0/C[_ *%Y_P#P*@_^.4?\*!\??]"\_P#X%0?_ !RC^R\=_P ^
MI?<P_MK+_P#G_'[U_F>?45Z#_P *!\??]"\__@5!_P#'*/\ A0/C[_H7G_\
M J#_ ..4?V7CO^?4ON8?VUE__/\ C]Z_S//J*]!_X4#X^_Z%Y_\ P*@_^.4?
M\*!\??\ 0O/_ .!4'_QRC^R\=_SZE]S#^VLO_P"?\?O7^9Y]17H/_"@?'W_0
MO/\ ^!4'_P <H_X4#X^_Z%Y__ J#_P".4?V7CO\ GU+[F']M9?\ \_X_>O\
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M !RC_A0/C[_H7G_\"H/_ (Y1_9>._P"?4ON8?VUE_P#S_C]Z_P SSZBO0?\
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M!_X4#X^_Z%Y__ J#_P".4?\ "@?'W_0O/_X%0?\ QRC^R\=_SZE]S#^VLO\
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M_P"^J.>/<+,DXHXJ/[1'_P ]%_[ZH^T1_P#/1?\ OJCGCW"S).*.*C^T1_\
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MM$?_ #T7_OJC[1'_ ,]%_P"^J.>/<+,DXHXJ/[1'_P ]%_[ZH^T1_P#/1?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-'V6+_GFO_?-?F?^IJ_Y_?A_P3]0_P!=Y?\ /C_R;_@'YVT5^B7V6+_GFO\
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M )_?A_P0_P!=Y?\ /C_R;_@'YVT5^B7V6+_GFO\ WS1]EB_YYK_WS1_J:O\
MG]^'_!#_ %WE_P ^/_)O^ ?G;17Z)?98O^>:_P#?-'V6+_GFO_?-'^IJ_P"?
MWX?\$/\ 7>7_ #X_\F_X!^=M%?HE]EB_YYK_ -\T?98O^>:_]\T?ZFK_ )_?
MA_P0_P!=Y?\ /C_R;_@'YVT5^B7V6+_GFO\ WS1]EB_YYK_WS1_J:O\ G]^'
M_!#_ %WE_P ^/_)O^ ?G;17Z)?98O^>:_P#?-'V6+_GFO_?-'^IJ_P"?WX?\
M$/\ 7>7_ #X_\F_X!^=M%?HE]EB_YYK_ -\T?98O^>:_]\T?ZFK_ )_?A_P0
M_P!=Y?\ /C_R;_@'YVT5^B7V6+_GFO\ WS1]EB_YYK_WS1_J:O\ G]^'_!#_
M %WE_P ^/_)O^ ?G;17Z)?98O^>:_P#?-'V6+_GFO_?-'^IJ_P"?WX?\$/\
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M )_?A_P0_P!=Y?\ /C_R;_@'YVT5^B7V6+_GFO\ WS1]EB_YYK_WS1_J:O\
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M$U:_UFSFU&;4FN=1""3?(J*5^0 8 C'YFO9J* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R->U"\T^.V-CI[7[23+
M'(H;;Y:'.6_SZUKUEZUK]EX?CMWO)#&)Y1#'M0MECT''TK4H **** "BBB@
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M(WV]8O.,>PXV^N>G>B@#Y8_X>6?#C_H >*O_  %MO_DBC_AY9\./^@!XJ_\
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M_P#DBC_AY=\.?^@!XI_\!;;_ .2*_-OBCBCZU/L'^M&.[K[C](_^'EOPX_Z
M'BK_ ,!;;_Y(H_X>6_#C_H >*O\ P%MO_DBOS<XHXH^M3[!_K1CO+[C])/\
MAY=\.?\ H >*?_ 6V_\ DBC_ (>7?#G_ * 'BG_P%MO_ )(K\V^*.*/K4^P?
MZT8[NON/TC_X>6_#C_H >*O_  %MO_DBC_AY9\./^@!XJ_\  6V_^2*_-SBC
MBCZU/L'^M&.\ON/TC_X>6?#C_H >*O\ P%MO_DBC_AY9\./^@!XJ_P# 6V_^
M2*_-SBCBCZU/L'^M&.\ON/TC_P"'EGPX_P"@!XJ_\!;;_P"2*/\ AY9\./\
MH >*O_ 6V_\ DBOS<XHXH^M3[!_K1CO+[C](_P#AY9\./^@!XJ_\!;;_ .2*
M/^'EGPX_Z 'BK_P%MO\ Y(K\W.*.*/K4^P?ZT8[R^X_2/_AY9\./^@!XJ_\
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M^'EGPX_Z 'BK_P !;;_Y(K\W.*.*/K4^P?ZT8[R^X_2/_AY9\./^@!XJ_P#
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M_DBOS;XHXH^M3[!_K1CNZ^X_23_AX_\ #B\&#X:\53;/FQ]BMFQCO_Q\4?\
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MT:5[[IK6^O1H\=T7]F3P9\1/B3;^&_ OCBXU+3=/MY9]>U6Y@ C@\MU7]SP
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M4 9=QKUG:ZQ;:7(["\N$+QKM)! SW_ UJ57;R?.3/E^=CY<XW8]JL4 %%%%
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M **** "BBB@ HHHH **** "BBB@#:T/Q=J7AW2]6L+*5$MM4B$%TK1ABR@Y
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M*']B8_\ Y]L^4/PH_"OJ_P#X=M_%#_H+^%O_  +N?_D>C_AVW\4/^@OX6_\
M NY_^1Z/85/Y0_L3'_\ /MGRA^%'X5]7_P##MOXH?]!?PM_X%W/_ ,CT?\.V
M_BA_T%_"W_@7<_\ R/1["I_*']B8_P#Y]L^4/PH_"OJ__AVW\4/^@OX6_P#
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M/^@OX6_\"[G_ .1Z/85/Y0_L3'_\^V?*'X4<U]7_ /#MOXH?]!?PM_X%W/\
M\CT?\.V_BA_T%_"W_@7<_P#R/1["I_*']BX__GVSY0_"C\*^K_\ AVW\4/\
MH+^%O_ NY_\ D>C_ (=M_%#_ *"_A;_P+N?_ )'H]A4_E%_8F/\ ^?;/E#\*
M/PKZO_X=M_%#_H+^%O\ P+N?_D>C_AVW\4/^@OX6_P# NY_^1Z/85/Y1_P!B
M8_\ Y]L^4/PH_"OJ_P#X=M_%#_H+^%O_  +N?_D>C_AVW\4/^@OX6_\  NY_
M^1Z/85/Y0_L3'_\ /MGRA^%'X5]7_P##MOXH?]!?PM_X%W/_ ,CT?\.V_BA_
MT%_"W_@7<_\ R/1["I_*']B8_P#Y]L^4/PH_"OJ__AVW\4/^@OX6_P# NY_^
M1Z/^';?Q0_Z"_A;_ ,"[G_Y'H]A4_E#^Q,?_ ,^V?*'X4?A7U?\ \.V_BA_T
M%_"W_@7<_P#R/1_P[;^*'_07\+?^!=S_ /(]'L*G\H?V)C_^?;/E#\*/PKZO
M_P"';?Q0_P"@OX6_\"[G_P"1Z/\ AVW\4/\ H+^%O_ NY_\ D>CV%3^4/[$Q
M_P#S[9\H?A1^%?5__#MOXH?]!?PM_P"!=S_\CT?\.V_BA_T%_"W_ (%W/_R/
M1["I_*']B8__ )]L^4/PH_"OJ_\ X=M_%#_H+^%O_ NY_P#D>C_AVW\4/^@O
MX6_\"[G_ .1Z/85/Y0_L3'_\^V?*'X4?A7U?_P .V_BA_P!!?PM_X%W/_P C
MT?\ #MOXH?\ 07\+?^!=S_\ (]'L*G\H?V)C_P#GVSY0_"C\*^K_ /AVW\4/
M^@OX6_\  NY_^1Z/^';?Q0_Z"_A;_P "[G_Y'H]A4_E#^Q,?_P ^V?*'X4?A
M7U?_ ,.V_BA_T%_"W_@7<_\ R/2?\.V_BA_T%_"W_@7<_P#R/1["I_*']B8_
M_GVSYO\ "NDZ1JUQ>KJNK?V3'%;/+"_EE_-D'W4XZ9]:P?PKZ>U3_@GS\0M#
MCA>\UKPM$L\HA3_2;ILL<XZ6WM6A_P .V_BA_P!!?PM_X&7/_P CT>QJ6^$M
MY/CFE%47IU[GRC^%'X5]7_\ #MOXH?\ 07\+?^!=S_\ (]'_  [;^*'_ $%_
M"W_@7<__ "/1["I_*9_V+C_^?;/E#\*/PKZO_P"';?Q0_P"@OX6_\"[G_P"1
MZ/\ AVW\4/\ H+^%O_ NY_\ D>CV%3^4?]B8_P#Y]L^4/PH_"OJ__AVW\4/^
M@OX6_P# NY_^1Z/^';?Q0_Z"_A;_ ,"[G_Y'H]A4_E#^Q,?_ ,^V?*'X4?A7
MU?\ \.V_BA_T%_"W_@7<_P#R/1_P[;^*'_07\+?^!=S_ /(]'L*G\H?V)C_^
M?;/E#\*/PKZO_P"';?Q0_P"@OX6_\"[G_P"1Z/\ AVW\4/\ H+^%O_ NY_\
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M_P#%T44 ']B_%C_J)_\ @2/_ (NC^Q?BQ_U$_P#P)'_Q=%% !_8OQ8_ZB?\
MX$C_ .+H_L7XL?\ 43_\"1_\7110 ?V+\6/^HG_X$C_XNC^Q?BQ_U$__  )'
M_P 7110 ?V+\6/\ J)_^!(_^+H_L7XL?]1/_ ,"1_P#%T44 ']B_%C_J)_\
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M_P#%T44 ']B_%C_J)_\ @2/_ (NC^Q?BQ_U$_P#P)'_Q=%% !_8OQ8_ZB?\
MX$C_ .+H_L7XL?\ 43_\"1_\7110 ?V+\6/^HG_X$C_XNC^Q?BQ_U$__  )'
M_P 7110 ?V+\6/\ J)_^!(_^+H_L7XL?]1/_ ,"1_P#%T44 ']B_%C_J)_\
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M?_@2/_BZ/[%^+'_43_\  D?_ !=%% !_8OQ8_P"HG_X$C_XNC^Q?BQ_U$_\
MP)'_ ,7110 ?V+\6/^HG_P"!(_\ BZ/[%^+'_43_ / D?_%T44 ']B_%C_J)
M_P#@2/\ XNC^Q?BQ_P!1/_P)'_Q=%% #6T+XK,REEU%BO()N%./I\]._L7XL
M?]1/_P "1_\ %T44 ']B_%C_ *B?_@2/_BZ/[%^+'_43_P# D?\ Q=%% !_8
MOQ8_ZB?_ ($C_P"+H_L7XL?]1/\ \"1_\7110 ?V+\6/^HG_ .!(_P#BZ/[%
M^+'_ %$__ D?_%T44 ']B_%C_J)_^!(_^+H_L7XL?]1/_P "1_\ %T44 ']B
M_%C_ *B?_@2/_BZ/[%^+'_43_P# D?\ Q=%% !_8OQ8_ZB?_ ($C_P"+H_L7
MXL?]1/\ \"1_\7110 ?V+\6/^HG_ .!(_P#BZ/[%^+'_ %$__ D?_%T44 ']
MB_%C_J)_^!(_^+H_L7XL?]1/_P "1_\ %T44 -.@_%5G#E=1+CHWVA<C_P ?
MIW]B_%C_ *B?_@2/_BZ** #^Q?BQ_P!1/_P)'_Q=']B_%C_J)_\ @2/_ (NB
MB@ _L7XL?]1/_P "1_\ %T?V+\6/^HG_ .!(_P#BZ** #^Q?BQ_U$_\ P)'_
M ,71_8OQ8_ZB?_@2/_BZ** #^Q?BQ_U$_P#P)'_Q=']B_%C_ *B?_@2/_BZ*
M* #^Q?BQ_P!1/_P)'_Q=']B_%C_J)_\ @2/_ (NBB@ _L7XL?]1/_P "1_\
M%T?V+\6/^HG_ .!(_P#BZ** #^Q?BQ_U$_\ P)'_ ,71_8OQ8_ZB?_@2/_BZ
M** #^Q?BQ_U$_P#P)'_Q=']B_%C_ *B?_@2/_BZ** .Q^%6E^-;7Q))+XC6Z
3^R?9V4-<2AQNRN.Y]Z*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tcp101vaschange.jpg
<TEXT>
begin 644 tcp101vaschange.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?M_\*] HH \__P"%B>._^B<_^5^W_P */^%B>._^B<_^5^W_ ,*] HH \_\
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MK]O_ (4?\+$\=_\ 1.?_ "OV_P#A7H%% 'G_ /PL3QW_ -$Y_P#*_;_X4?\
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M\*] HH \_P#^%B>._P#HG/\ Y7[?_"C_ (6)X[_Z)S_Y7[?_  KT"B@#S_\
MX6)X[_Z)S_Y7[?\ PH_X6)X[_P"B<_\ E?M_\*] HH \_P#^%B>._P#HG/\
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MK]O_ (4?\+$\=_\ 1.?_ "OV_P#A7H%% 'G_ /PL3QW_ -$Y_P#*_;_X4?\
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M."0#CZ@4 <Q_PL3QW_T3G_ROV_\ A1_PL3QW_P!$Y_\ *_;_ .%>@44 >?\
M_"Q/'?\ T3G_ ,K]O_A1_P +$\=_]$Y_\K]O_A7H%% 'G_\ PL3QW_T3G_RO
MV_\ A1_PL3QW_P!$Y_\ *_;_ .%>@44 >?\ _"Q/'?\ T3G_ ,K]O_A1_P +
M$\=_]$Y_\K]O_A7H%% 'G_\ PL3QW_T3G_ROV_\ A1_PL3QW_P!$Y_\ *_;_
M .%>@44 >?\ _"Q/'?\ T3G_ ,K]O_A1_P +$\=_]$Y_\K]O_A7H%% 'G_\
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M )!UO_US7^0KY3+O^1_C?\%'_P!R'UV9?\D[@?\ '6_]QDU%%%?5GR(4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G/[17[3WA_\ 9ETK
M3;O7K36;M-4E>*%=/MUD*E "=Q=T4=1@9R><#@X]&HKEQE.O4HRAAIJ$WM)K
MF2^5U?3S.K U*%.O&>*@YP6\5+E;T_FL[:^3['S#_P /7_AW_P! 7QI_X"6W
M_P D5Q/Q[_X*E6>O^!)M/\!Z?K6FZK>9CDOM0BBC-I&1R8@DCY<] 3C;UY.,
M?:E8/Q-^&>B_%[P9>:#KUFEYI]XN&4\/$W\+HW\+KU!'\LBOD\PR;B&KAITJ
M>.C=II6I<K_\"YVUZI-K='V.79YPW1Q5.K4R^5DTW>KS+_P%P2E;LVD]F?FA
M^R_^UAKG[./CA[Q9)M2T;4I-VJ6,DF?M&>LJD])1Z]^A]1]7_P##U_X=_P#0
M%\:?^ EM_P#)%:G[+W_!/S1_@+XSO->U2[C\0:A#.PTEFBVI9Q=I"IZS'ID<
M+VY.1]%5X'!_#?$6#P/LJF)5+5M0<%4M\^96OO9777=L^AXTXHX:QV/]K3PK
MJZ).:FZ=_ER.]EI=V?39(^8U_P""KWP[9@/[&\:#)Z_8[;C_ ,F*\G_X+WZY
M#XF_X)Z:#J5NLRV^H>)-/N8A*ACD"O;7+#<IY!P>0>AK[TKY3_X+%_LT^-?V
MJ_V3;7PSX#T<:YKD/B"UOVMC=P6O[E(IU9M\SHG!=>,YYK[[+,+F%%R^NUU5
M3VM#DM_Y-*Y^>9IB\MK**P.'E2:O>]3GOV^S&UOF?FG\:?'/P_\ VS?A-\+_
M (>_!/X+W]I\2-+2S@UG6;72+>T:]9+8QRAOL[-YBO*1*9IMK 1]MS5]4_M#
M:#=^%O\ @M9^S/I=_<"\OM-\&6%K<3ABPGD1M35GR>3E@3D\\U]__L]>%+[P
M%\ ? ^AZI"+?4]%\/V%A=Q!U<1316T:.NY20<,I&02#VKY@_:6_9)^('Q!_X
M*V_"'XH:1H:W?@?PSHL=GJ>H_;K>,VLJR7[$>4SB5N)XN45A\WL<>N>,>7?M
M>_'S]J#P3\5/'%Q;_%WX+_"[P_H=U<R:)HFJZGIO]IZO9(6:%ECEBF?S98PK
M;6:/EL #BND^%O\ P5E\11_\$J]6^,'B+3=/O_&6DZJ_AVW6.,Q6U_='RS',
MZK]T!)"S*I 8QD#;N&/#]<_X)J?M#>#_ (S_ !)M['X<_"_XA6/C_49Y$\8>
M)A;7UQIT<LCMYT2S2B2*7#Y8B*0@CY2< UZ?\"O^"7/CSQ%_P2F\5?"/Q99V
M_A7QI<>)9-<TE9;V&X@9D2 1^8\#. KA)4ZY7(8CC! .G_9)U7]M;Q;XB^'O
MCCQ1KO@_6OA[XNEM[N_T98+2WN]-T^90XF.V%&W!&#!5FD;) 9>N/)_B/_P4
MP^,?[2'Q\\;:;\-?B=\*?@]X3\%W3V=JWBN_L;2?7"CR*'4W4<I9F*$X145
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MI&'.UBTY=0SY4(A)&2,<GJ/[6_[4?[ OQ]^'NG_'37/"OC;P?X]OELC/IUK
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MT]'%KK[LDX_@F]KK=?DG\1OB3K?Q9\6W6N>(+^74-2NL;I'P JCHJJ.%4=@
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M4PV)G0JP<'%OW9;KLGHKZ=;6>Z"BBBNPXPHHHH **** "BBB@ HHHH ****
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M_P"%<R?]##XA_P# H?X4?\*YD_Z&'Q#_ .!0_P *Z:B@#F?^%<R?]##XA_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK=WJPW$<EWN0QN<9NI2.0,=#7LW_  MOP[_T$E_[]2?_ !->;PK_ ,B;"?\
M7J'_ *2CT^+O^1YC/^OM3_TIG245S?\ PMOP[_T$E_[]2?\ Q-'_  MOP[_T
M$E_[]2?_ !->\?/'245S?_"V_#O_ $$E_P"_4G_Q-'_"V_#O_027_OU)_P#$
MT =)17-_\+;\._\ 027_ +]2?_$T?\+;\._]!)?^_4G_ ,30!TE%<W_PMOP[
M_P!!)?\ OU)_\31_PMOP[_T$E_[]2?\ Q- '245S?_"V_#O_ $$E_P"_4G_Q
M-'_"V_#O_027_OU)_P#$T =)17-_\+;\._\ 027_ +]2?_$T?\+;\._]!)?^
M_4G_ ,30!TE%<W_PMOP[_P!!)?\ OU)_\31_PMOP[_T$E_[]2?\ Q- '245S
M?_"V_#O_ $$E_P"_4G_Q-'_"V_#O_027_OU)_P#$T =)17-_\+;\._\ 027_
M +]2?_$T?\+;\._]!)?^_4G_ ,30!TE%<W_PMOP[_P!!)?\ OU)_\31_PMOP
M[_T$E_[]2?\ Q- '245S?_"V_#O_ $$E_P"_4G_Q-'_"V_#O_027_OU)_P#$
MT =)17-_\+;\._\ 027_ +]2?_$T?\+;\._]!)?^_4G_ ,30!TE%<W_PMOP[
M_P!!)?\ OU)_\31_PMOP[_T$E_[]2?\ Q- '245S?_"V_#O_ $$E_P"_4G_Q
M-'_"V_#O_027_OU)_P#$T =)17-_\+;\._\ 027_ +]2?_$T?\+;\._]!)?^
M_4G_ ,30!TE%<W_PMOP[_P!!)?\ OU)_\31_PMOP[_T$E_[]2?\ Q- '245S
M?_"V_#O_ $$E_P"_4G_Q-'_"V_#O_027_OU)_P#$T =)17-_\+;\._\ 027_
M +]2?_$T?\+;\._]!)?^_4G_ ,30!TE%<W_PMOP[_P!!)?\ OU)_\31_PMOP
M[_T$E_[]2?\ Q- '245S?_"V_#O_ $$E_P"_4G_Q-'_"V_#O_027_OU)_P#$
MT =)17-_\+;\._\ 027_ +]2?_$T?\+;\._]!)?^_4G_ ,30!TE%<W_PMOP[
M_P!!)?\ OU)_\31_PMOP[_T$E_[]2?\ Q- '245S?_"V_#O_ $$E_P"_4G_Q
M-'_"V_#O_027_OU)_P#$T =)17-_\+;\._\ 027_ +]2?_$T?\+;\._]!)?^
M_4G_ ,30!TE%<W_PMOP[_P!!)?\ OU)_\31_PMOP[_T$E_[]2?\ Q- '245S
M?_"V_#O_ $$E_P"_4G_Q-'_"V_#O_027_OU)_P#$T =)17-_\+;\._\ 027_
M +]2?_$T?\+;\._]!)?^_4G_ ,30!TE%<W_PMOP[_P!!)?\ OU)_\31_PMOP
M[_T$E_[]2?\ Q- '245S?_"V_#O_ $$E_P"_4G_Q-'_"V_#O_027_OU)_P#$
MT =)17-_\+;\._\ 027_ +]2?_$T?\+;\._]!)?^_4G_ ,30!TE%<W_PMOP[
M_P!!)?\ OU)_\31_PMOP[_T$E_[]2?\ Q- '245S?_"V_#O_ $$E_P"_4G_Q
M-'_"V_#O_027_OU)_P#$T =)17-_\+;\._\ 027_ +]2?_$T?\+;\._]!)?^
M_4G_ ,30!TE%<W_PMOP[_P!!)?\ OU)_\31_PMOP[_T$E_[]2?\ Q- '245S
M?_"V_#O_ $$E_P"_4G_Q-'_"V_#O_027_OU)_P#$T =)17-_\+;\._\ 027_
M +]2?_$T?\+;\._]!)?^_4G_ ,30!TE%<W_PMOP[_P!!)?\ OU)_\310!TE>
M)?M[?LP^)?VJO@U8Z+X/\;7W@'Q'HNKPZU8ZE;-*GF21Q31B)VC9713YN[<-
MV"@^4U[;10!^8NHZS_P4*_9J0Z?]GT[XE:;;L8X+V*"UU!G .,Y'E7+9SG,B
MY_+%17?[;7[>OQ 9+73?@S9:!-DIYL?AR>#<3C!+7=PR<8// YY[8_3^B@#\
M^/@/^Q+^U1\9?C/X6\;?'#XI2:3I/AK6+76%\-Z?<JZW3V\BR+&\5MLME5L;
M2^9&P6XYR?T'HHH \F_:3_8;^%G[7FH:3=?$3PLOB&XT..2*R?\ M&[M#"LA
M4N/W$J;LE5^]G';&37&?%O4(_P#@FA^S-H]C\'/@[KWCJQ76/LJ^']'NKN>>
MU299YI+EG,=S*RAT5>1@&51D8 /T910!^2/_  2J\;_%[]ES]H#Q+:ZI^S[\
M2)--^+WB#38[O4;K3;VR@\.1"XN \SEK4K(B+=EB2T8 B///'3-X2^,__!,+
M]NCXH>*/!_PAUSXH>#?B---=V@TB*:80>9,TZ!FABE:,Q,[H5=!N&"&Z&OU(
MHH ^'_\ @D!^RCXZ^'6O?$SXL?$W26T+Q9\4-2:Y33I%"36T;32SRNZ#_5^9
M+*,(<$"($CD5]P444 %>?_$9=WQU^'0(R/\ B9]?^O=:] KS_P"(G_)=OAS_
M -Q/_P!)UH [[R$_N+^5'D)_<7\J=10 WR$_N+^5'D)_<7\J=10 WR$_N+^5
M'D)_<7\J=10 WR$_N+^5'D)_<7\J=10 WR$_N+^5'D)_<7\J=10 WR$_N+^5
M'D)_<7\J=10!^>/_  5Z_P""?>J?VNO[0'PEMFM_&WAU1/X@T^V0_P#$YMD&
M#.JK]Z1$&'4<N@R,,@W>S_\ !,G]O[1_VR_A5:PW4T4?BC3X_+N(I&'F3[0,
MY]7'4_WAAO[P7ZG/-?DW_P %'_V9=4_X)E?M!V'QX^&.ZR\%>(M22+6M)MR$
M73;QMSAHEZ"-\.RC&$;<GW'"U[6"K0Q%/ZG7_P"W7V?^7?R\TCSL13E1G[>G
M\UW_ *_KJ?3G_!=>-4_X)^:QM51_Q-K+H/\ ::OK;PI"G_"+Z;\B_P#'K%V_
MV!7X:_MS_P#!:'Q1^V)\,;SP+)X9T&Q\.S7,5Q]K5)5O96C.5./,9$!R<C#?
M45[1\"_^#B/Q1J<UKH_BKPWX/T=51(8;Z""Y>#@8'F*9LKV^8$CUP.:J64UI
M\M--::;Z;L4<?35Y._W>2/UR\A/[B_E7,^-_A'I/C4&5XOL=\.5N8!M;/;<.
MC?CS[BNFBE6:-71E=' 964Y# ]Q3J\>G4E!\T'9GH2A&2M(\O3Q'XB^$KB+6
M[;^VM(4X6]B&9(Q_M'^C?]]5W?ACQ1I?C"Q^T:?-#.O\2@8>,^C+U%:CHLJ,
MK*&5A@@C((KA/$_P4C^W?VEX=N6T74EY"H2(9#Z8'W?PR/:NGGI5OC]V7=;/
MU73Y&/+.G\.J[=?DSNO(3^XOY4>0G]Q?RKSW1_C#>>&+Y=.\763V4W1+R-<Q
M2^Y _FN?H*[^ROH=2M4GMY8YH9!E'1@RL/8BL*V'G3^+;OT?S-*=6,]A_D)_
M<7\J/(3^XOY4ZBL30;Y"?W%_*D-O&1_JT_[YI]% 'S3\<_V.]4\'^+&\?_"&
M9=$\20DR7>DIA;74EZL%4_*">Z'Y3P1M89/7?LR?M=Z/\==^BZI:KX=\;6&8
M[S2;A2AD9?O-%NY.,'*'YEYSD#<?:*\;_:;_ &/M*^/ CUC3;@^'?&EAA[/5
MK?*,[+]U9=O) XPP^9>,9 VGY#%9/B<OJRQN3)6;O.D](R[N'2$__)9=>Y]I
MA<ZPV948X'.V[Q5H5DKRAV4UO.'_ )-'H[:'L7D)_<7\JY'X_P *#X#^-OE7
M_D WW;_IWDKQGX(?M@:MX%\6I\/_ (PV_P#8GB*'"6FKR86UU)>BEF'R@GLX
M^4\@[6&#ZY^TE';#X%>++NXFDA6ST:\EC(N&CC9O(?:'4$+("<#8X(.<8.:[
MZ.<83,,!5J4VURQDI)JTH.SNI1;5FO6SZ.QYU;)<7EV84:55)\THN,D[QFKJ
MSC)7NG]ZZJYP_P#P3IB5OV1?#)*J?WEYU'_3U+7N'D)_<7\J\+_8#U+1?$WP
M1M;K3;HM/9W=W#+:PW#QQ6RM.[1@VX(C4F,J<[<G).2<FO=JZ.'H4H97AX49
M\\8PBKK9V25]WV[F'$TJD\WQ,ZL.24JDW9[J\F[;+OV&^0G]Q?RH\A/[B_E3
MJ*]@\,;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+
M^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+
M^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+
M^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+
M^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+
M^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+
M^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+
M^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+
M^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+
M^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+
M^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+
M^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*CR$_N+^5.HH ;Y"?W%_*BG44 %
M%%% 'Q#_ ,%G?CEXW\+VWPG^%_@76IO#.H?%[7'TN?5()3#+#&LEM$(Q(I!1
M6>[4L5P2(\9 )!^:?V/=%\3?#KX(?MR>&!\0/$BZE\-UBCL=<AU">SN/.L)=
M3(>,B0M$9OLJ(55SD,%)8=?O#_@HG^PA:_MT?"W3;"WUB3PYXI\,W9O]#U15
M9E@E( 9&VD,%;:AW+\RE%(SC!^$=!_X(F_M(ZGXE\5Z;JWQ*\.Z?H/CB\CO/
M$U[;:I=S'77$CRAY(O*0RLKRR-MD*KN).3P: /O3_@EO\6M9^.'[!'PZ\2>(
M+ZZU+6+JTN+:YN[F0R37)M[N>V#NQY9BL0)8\DDDY)KWZN-_9Y^".D_LW_!/
MPUX&T1I)--\-V2VD<LGWYVY9Y6[!G=F<@< MQQ794 %%%% !1110 4444 %>
M?_$3_DNWPY_[B?\ Z3K7H%>?_$3_ )+M\.?^XG_Z3K0!Z!1110 4444 %%%%
M !1110 4444 %%%% !7Y'_\ !RC\<=6;QWX!^&\4TD.AQZ>WB.YB4_+=3O++
M;Q%O^N:QRX_Z[-[5^N%?FG_P</\ ['&K?$GP+X?^+6@VTM[)X.@?3=<@C7<Z
M63OOCN /[L<C.'P"<3!N%1B.[+I15>/,<N,3=)V/QWHHHKZH\$_>[_@A7\=]
M8^.?[!&FKK=Q)>7G@W5)_#D=Q(VZ26"*.&6$$_[$<ZQCVC'?-?8U?'__  0V
M\*>&?"'[ 'A^+P]KEEKEYJ-W/J6M&W8_Z)>R[08&4\JR1I$IS]XJ2.#7V!7R
M&,5J\DE;4^BP[O2CZ!1117,;%76-%M/$%BUK>V\5S _5'7(^H]#[CFO/[WX8
MZU\/;I[SPG>-);D[I-/G.Y6^F>#^A]S7I5%;T<1.GHMNSV,ZE&,]7OWZG%^#
MOC18Z[<_8=2C;1]44[&AG^56;V)Z?0X/UKM*Q/&/P]TOQS;;+ZW!D482=/EE
MC^A_H<BN,\KQ5\'?N%O$&A1_PG/G0+^I&/Q7Z5M[*E5_A:/L_P!'_F9\\Z?Q
MZKNOU1Z=16#X,^(^E>.K?=8W'[X#+V\GRRI^'<>XR*WJY)PE!\LE9FT9*2O$
M****DHX#]I#X3^#OBK\-;V/QFMO;Z?I\3SKJ+,(Y=.XYD1STZ#(.0W (/%?F
MK\0/CCXBUSPFO@M?$VI:QX1TFZ<V GC\IIXP<1EQDMM &51F(7/'08_5WQ#X
M>L?%FAW6FZE:PWVGWT9AG@F7<DJ'J"*_-_\ ;._8QOOV==<;5M)6:^\'WTF(
M9C\SV#GI%*?3^Z_?H>>OXWXJ97C/9K'8.-HV<:CC=2:TLI6T<5;K>S\C]L\(
M\VP7M)9?C9WE=2I1E9Q3UNXWU4W?I:Z\SSWX"?'O7OV>?'<.M:+-E3A+NT<G
MR;V+/*./Y-U4\^H/Z=_ KXZZ%^T%X$@US0YLJ<)=6SD>=92XYC<?R/0CD5^5
M_P /?A1XD^+%W>6_AS1[[6)K" W,ZVZ;C&@_F3V4<L>@-?>O[ /Q3^'0\!P>
M%-!A?0?$L'S:C8Z@0+N\G P[A\#S,8/R@ J!]T#D^'X59IBZ.(^J5IJ-":;B
MI75Y+^1[-_S*_P KGT'BYE.#KX;ZY1@Y5X-*3C9VB^M1;I?RNWSL?1U%%%?T
M ?SF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%<+\<OV?=&^/\ IUA:ZQ=:M:QZ=(TD?V*=8]Q8 '<&5@>G
M!QD<\\FM:,82FE5ERKJ[7_"Z(J2DHW@KOML=U7PW^V'\6_%7AC]HWQ%8Z;XF
M\0:?90?9O+M[;49H8H\VL+'"JP R22<#J2:]B_X=N>!O^@KXL_\  FW_ /C-
M?+?[1?PVL?A%\9-8\.Z;-=SV6G^1Y;W+*TK;X(Y#DJJCJYQ@#C'UK[/AG"X/
MZU+V<^=\KT<;=5KNSP,VK5_8KFCRZ[IWZ/R15_X7SXY_Z'/Q9_X-[C_XNOT*
M^"M_/JOP<\)75U--<W5SHUG+--*Y>25V@0LS,>22222>237YDU]??#3]@#P;
MXS^''A_6+K4O$T=UJVFVUY,L5Q (U>2)78*#"3C).,DG'<UZ/$^%PGLH>T?)
MJ]HWOIZHY<GK5N>7*N;3J[?YGT]7G_[3&F?$G6_AA)8_"O4O#NB^*KRX2+^T
M=9B:6"P@^8R2H@5@\HP H92I)Y&.1YZO_!-WP.K C5O%G'/_ !]6_P#\9KT/
MXP_'+P3^R#\);;6O&FM2Z-X<T\P:<MY+!/>2%R-J!A$CNS':<MM^M?!8JCAX
M)>PJ.7>\;6_%GTM&=67\2/+\[_HCX?\ ^"0GQ+^(VI?MP?&_P;XY^('B;QN/
M!YN+!6O[^:2U,T%^T#2Q0.Q2+=M/"@8!Q7Z/U^0?_!./]M3X9_#'_@HS\<O%
M&N>)OL.A_$/6+S_A'[K^S[J3[?Y^IO+%\J1%H]R,I_>!<9P<'BOU\KC-SX=O
MO^#@7X$V?A.WU);/QY<7-Q<20'38M,M_M<2)MQ,V;@1!'R0H$A?Y3E0,$WO%
M_P#P7N^ GA?2-&NK>7Q=KDFK0^=+;:?IB>=IOS%=L_FRQJ&^4G",_!!Z$$_.
M_P#P1:\":+K/[!OQ_OKS2=/NKVY@NK&6>:W5Y'@6P,@B)(SL#G=CIG!Z@5/_
M ,$Y/AQH&J?\$5OCQJ5QH^G3:C<6FO&6Z>!3,_V;34E@RV,XCD)91T!)/<T
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M;P1+9QE9]3^UR7/V@W(^9?)C\ID^S\KEN6QD8Y\Y^./_  6!\4?#[]J'Q?\
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M_P EV^'/_<3_ /2=:] KS7XN&\7XR_#W^SUMVN_^)CY8G)\O_4)G..>F?QH
M]*HKF?-\8?\ /'P]_P!]2T>;XP_YX^'O^^I: .FHKF?-\8?\\?#W_?4M'F^,
M/^>/A[_OJ6@#IJ*YGS?&'_/'P]_WU+1YOC#_ )X^'O\ OJ6@#IJ*YGS?&'_/
M'P]_WU+1YOC#_GCX>_[ZEH Z:BN9\WQA_P \?#W_ 'U+1YOC#_GCX>_[ZEH
MZ:BN9\WQA_SQ\/?]]2T>;XP_YX^'O^^I: .FHKF?-\8?\\?#W_?4M'F^,/\
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M^NSUU/)K4YX:7M:7P]5V\_3\C]!@<T5^4_[.G[>GQ+_X)S2Z#X+^*MU'XO\
MA/JCBV\.>-/+EF.GJ /]'FVY?]V,;H6S)&!E#)'LK](_"_B[7O&_ARQUC1[K
MPGJFE:E"MQ:7=K<230W$;#*NCKD,".XKP\3A9T)<L_Z_X/D>A1KQJ*\3M:*Y
MGS?&'_/'P]_WU+1YOC#_ )X^'O\ OJ6N<V.FHKF?-\8?\\?#W_?4M'F^,/\
MGCX>_P"^I: .FK/\2>%-/\76'V?4+6.XC_A)'S(?53U!^E9/F^,/^>/A[_OJ
M6CS?&'_/'P]_WU+51DXNZW$TFK,YB7P;XD^%$C3:!<-JVE [FL9N70?[([_5
M<'V-<I\?/VA+?7?A-<Z#IL,D?B+Q.W]D):3+_JED!65R>FT(2,\$%@<5ZEYW
MC#_GCX>_[ZEKY\T;59OC#\8M6\774=G]ETG.E::UNI$<Q4GS)@3RV<X#'J#C
MM7MY?RXB;J5XWY-;]WT376_Y)GG8KFI)1I2MS?AW:[6_,Z/]D[4V^$OC>^^'
M]U.\MC?1?VGH\LG5V  GB^O&\ = &/>OH:OF'XL:3>?V3:ZYI/RZYX9G&H69
MQG?M^_&?4,H(([X KUSX=?$77OB?X/L=:TO_ (1V6UO8P^W?+NB;NC#LRG(/
MTJ<XHN;6*7VM)?XEU^:U];E8&I:]%]-O3_@?E8]"HKF?-\8?\\?#W_?4M'F^
M,/\ GCX>_P"^I:\0] X_]HC]D#PK^T-;&YNHFTGQ%$!]GU>T4+.A'W0XX$BC
MC@\CLRUY)HG[07Q#_8YU:WT/XJ6=QXD\*NXAL_$EH#)(@["0G[Q]5?#]2"X
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M?\\?#W_?4M '345S/F^,/^>/A[_OJ6CS?&'_ #Q\/?\ ?4M '345S/F^,/\
MGCX>_P"^I:/-\8?\\?#W_?4M '345S/F^,/^>/A[_OJ6CS?&'_/'P]_WU+0!
MTU%<SYOC#_GCX>_[ZEH\WQA_SQ\/?]]2T =-17,^;XP_YX^'O^^I:/-\8?\
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MQL_X)O\ [-/['WQFTO0_B5\;O$CFZ\NXDTFRT7=<00$X!GFC\P1JW)X0.5Y
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MXU"876IZG=D>??S 8!(7A44<*@Z G))))]EHHH *\_\ B)_R7;X<_P#<3_\
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M -:NI:9;:UI\UI>6\-U:W"&.6&9!)'*IZAE/!!]#7S1\0_V+M>^$'B:7Q?\
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M5^#-.\::?]GU"W651]QQQ)&?56[?R-=D<2IKDKJ_GU7^?S.=T7%\U+3RZ?\
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M.:Z2OF?XH?L1:EX!\32>,/@SJC>&=<7+3:27Q9WHZE%W95<_W'!3.,;,5K?
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MRJ<>>+ZI)M.2[-7NN^[^HJ*\R^''[8WPW^*/EIIOBK3X;J3@6U\QM)L^@$F
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MXL?M&_'[XT1V-U8>'?&.M3IIGG#_ %IGNY;J1<XP3&K0@D<9?\OT>H *\_\
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MFHKF?^%0Z#_SZR_^!$G_ ,51_P *AT'_ )]9?_ B3_XJ@#IJ*YG_ (5#H/\
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M5#H/_/K+_P"!$G_Q5'_"H=!_Y]9?_ B3_P"*H Z:BN9_X5#H/_/K+_X$2?\
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MM$H\TOF5792X*/L:, V/#G@'0O![LVDZ+I.EM(,,;.SC@+#WV@5]C>&_V-_
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M !?_ &#/A[\6)'NX]-;PYJS'>M[I.(#NZY:/&QN>2<!CZUY[_P (K\?_ -F
M;M)U"W^*7AN#_EVN03?1H/0$^9GH %>0#^[7U517S6+X5P52H\1AKT*O\U-\
MM_\ $OAE\TSZC!\78ZG26&Q5J])?9J+FM_AE\4?+E:]#P'X7_P#!1'P7XNO_
M .R_$D=[X'UR-O+EMM44K"C^GFX&W_MHJ5[Q8:A;ZK91W-K-#<V\RAXY8G#I
M(IZ$$<$>XKF?BC\#/"7QGL/L_B70;'5-J[4F=-MQ$/\ 8E7#K] <5X/?_L/^
M,O@E>R:A\(?'5]8QEO,;1M4??;R^V<%&/8;D!']_O7-]9SS ?QX+$P_FA:-3
MYP;Y9?\ ;K7H=7U7(<Q_W>H\+4?V9WG3OY32YH_]O1?J?4E%?+VD?MX^(_A'
MJ,.E_%_P/J&@RLWEKJFGQ^9:S'U"Y*GU)1V_W17OGPV^,7A?XOZ7]L\-:YI^
MK1* 76&3][%_OQG#I]& KT\MXBP&.E[*C.U1;PDG&:]8NS^ZZ\SR\TX;S# 1
M]K6IWIO:<6I0?I*-U\G9^1TM%%%>V>"%?-'_  55_P"3;]/_ .P_;_\ HBXK
MZ7KYH_X*J_\ )M^G_P#8?M__ $1<5\MQM_R(L5_@9]9P)_R4&$_QH^D=-_Y!
MUO\ ]<U_D*FJ'3?^0=;_ /7-?Y"IJ^GA\*/E9_$PHHHJB0HHHH **** "BBB
M@ HHHH **** "BO#_P!L7XT_$CX'Z9'K7A/0=!U+P[9VQEU2[OR2ULYD"J%5
M9HV(.X=%;\*I?LO?&/XQ?%?6--U#Q1X5\-Z=X-U2R-U#?V3@2OE08_E-P[ '
MW3/TKY^?$F'CF']F^SJ.IIM"3C9_:OMRWTOM=-'T<.&<3++O[4]I35/71SBI
M76O+R[\UM>7>S3ZGOM%%%?0'S@4444 %%%% !1110 4444 %%%% !1110 5X
M_P#M\_M#:S^RI^R/XP\?>']/L=4UCP_%;-;6]XCO;L9;J& LZHRL559"QPP^
M[U%>P5F^,O!VE_$+PIJ&AZYI]KJFCZM ]K>6EP@>*XC8896!]: /S2^._P#P
M5!^$?QST3]GU/&7AOX=^/[G7)%7QD][:3Q+X):4VBW!B1]S;<M*>68,+53SD
M$>E_\)5_P3\_YY?"?_P72?\ Q%0_'#_@@3\-?&7Q'\):AX+;_A$_#]G?F?Q'
MILEQ<W9U2WWPD0P.\A,)VK,-V3S*#_"!7;?\.)OV=O\ H7M>_P#!Y<?_ !5
M'T5^S5>^ =0^"6AS?"\:./ C+,-+&EQ^7:8$T@EV+@8_?"3/&=VZNZKC_@)\
M"_#O[-7PFTGP3X3M9K/P_H@E%K%+.TSKYLSS/EVY.7D<\^N*["@#R;]I/]N7
MX6?LAZAI-K\1/%*^'KC7(Y);)/[.N[LS+&5#G]Q$^W!9?O8SVS@UE&S^"/\
MP4-^&&A^-KJUTGQSX3T.XN+BPN=2MY[>U@D3Y)FDAF" J-G/FH5P,CCFO0OB
M5\!O WQGFLY/&'@OPGXLDT]66U;6=(M[YK8-C<$,J-M!VKG&,X'I7RE_P52_
M9=^)_B_]GCPW\.?V??"NG:=X7O+JY?Q!I>C26.CPF+Y&C3#O$NQY&D9U3[Q
MW<=0#YF_9I^%'AW]I3_@LK/XL^"NCVNB_#'P%=1WEY>6$ MK%V2 QL(8UPJK
M/+N"JH *!GP!D5T'[2G[(WQR\&_MV?%;XD>&?@;X%^*OAO7&1;9?$]M::E;[
M?)MV,D%LUQ'+YH*E,A3_ !@9ZUZ%^Q'I/[7'[.C>"_ \?P%^&/ACX?Q:E:Q:
MY?6M["]\;=I46YNW8:DYDG\O<V=C<J %P M=G\>/$W[<?@WXH>*]-\">'? ?
MBSPGJE]+)HFJS26L5UI%LS$QH5DG@#.BD EXI<E>K=P#H/\ @C]^UWX;_:;^
M$/B33]'^'_ASX;:QX5OXSJVEZ#9I::?<-.C!+A8U52KMY#HRMN(\I?F.<+]>
MU\G?\$GOV"-<_8G^'/B6^\8:A:W_ (T\=7<5WJ:VSF2*U6+S/+CWG&]]TTK,
MP&,M@9 W'ZQH *\U^+FJ#1OC+\/;EH;BX$?]H_NX$WR-F!!P/QS]*]*KS_XB
M?\EV^'/_ '$__2=: -K_ (6;'_T!O$/_ (!'_&C_ (6;'_T!O$/_ (!'_&NF
MHH YG_A9L?\ T!O$/_@$?\:/^%FQ_P#0&\0_^ 1_QKIJ* .9_P"%FQ_] ;Q#
M_P" 1_QH_P"%FQ_] ;Q#_P" 1_QKIJ* .9_X6;'_ - ;Q#_X!'_&C_A9L?\
MT!O$/_@$?\:Z:B@#F?\ A9L?_0&\0_\ @$?\:/\ A9L?_0&\0_\ @$?\:Z:B
M@#F?^%FQ_P#0&\0_^ 1_QH_X6;'_ - ;Q#_X!'_&NFHH YG_ (6;'_T!O$/_
M (!'_&C_ (6;'_T!O$/_ (!'_&NFHH YG_A9L?\ T!O$/_@$?\:/^%FQ_P#0
M&\0_^ 1_QKIJ* .9_P"%FQ_] ;Q#_P" 1_QH_P"%FQ_] ;Q#_P" 1_QKIJ*
M.9_X6;'_ - ;Q#_X!'_&C_A9L?\ T!O$/_@$?\:Z:B@#F?\ A9L?_0&\0_\
M@$?\:/\ A9L?_0&\0_\ @$?\:Z:B@#F?^%FQ_P#0&\0_^ 1_QH_X6;'_ - ;
MQ#_X!'_&NFHH YG_ (6;'_T!O$/_ (!'_&C_ (6;'_T!O$/_ (!'_&NFHH Y
MG_A9L?\ T!O$/_@$?\:/^%FQ_P#0&\0_^ 1_QKIJ* .9_P"%FQ_] ;Q#_P"
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MS_PLV/\ Z WB'_P"/^-'_"S8_P#H#>(?_ (_XUTU% ',_P#"S8_^@-XA_P#
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MFQ_] ;Q#_P" 1_QKIJ*^D/ESF?\ A9L?_0&\0_\ @$?\:/\ A9L?_0&\0_\
M@$?\:Z:B@#F?^%FQ_P#0&\0_^ 1_QH_X6;'_ - ;Q#_X!'_&NFHH YG_ (6;
M'_T!O$/_ (!'_&C_ (6;'_T!O$/_ (!'_&NFHH YG_A9L?\ T!O$/_@$?\:/
M^%FQ_P#0&\0_^ 1_QKIJ* .9_P"%FQ_] ;Q#_P" 1_QH_P"%FQ_] ;Q#_P"
M1_QKIJ* /!OVV/'L>K?LN>+K==+UJ R6\0\R:UV1K^_C/)SQ6O\ LO?$&/3_
M -G7P5 =*UR8PZ/;KOBM-R-A!R#GD5-^W;_R:9XS_P"O:+_T?%6U^R=_R;/X
M%_[ MM_Z+%?*1_Y*67_7A?\ IR1]?+_DEH_]A$O_ $W$W/\ A9L?_0&\0_\
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M)^#=4\!?\$[/ACI^LPSV]\UE<7GES AUBN+R>>'(/(_=2QD#TQ7T90 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQJMYH%PW'E:G:L@!_P!]-R#\6%>[5R?COX#^#/B:'_M[PQHNI22=9I+51/\
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MQ/\ ])UKT"O/_B)_R7;X<_\ <3_])UH ] HHHH **** "BBB@ HHHH ****
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M[1##"SR$^FT#-?05*-2G+EFM3QXU(R5TSU__ ()O_P!H?\-\?!_^S/-^T_\
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M_P!#)%_X+T_QKIJ* .9_X1SQ+_T,D7_@O3_&C_A'/$O_ $,D7_@O3_&NFHH
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MA\/2H4U1H148K9)))>B6@L3BJV(J.MB)N<GNY-MOU;U9S/\ PCGB7_H9(O\
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M&'_@CM\%?%WQ#\-ZOX;B\.M\/]-L=3M=4\/PVOVW^VI;T9\\WOG;XFB*QE,
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M3@@X.S'4=:ZNLWQGX2L?'W@_5M"U*,S:;K5G-87<8.-\4J%'&?=6(H ^7_\
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M0?#:S^*W@-7$$'CS1H%>\A0\+YDH";CVVR^5(QR=[]_H;X(?#7X1?M3>'O\
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MM+<\C!5'^CJ.2: /1**S_P#A+M)_Z"FG_P#@2G^-'_"7:3_T%-/_ / E/\:
M-"BL_P#X2[2?^@II_P#X$I_C1_PEVD_]!33_ /P)3_&@#0HK/_X2[2?^@II_
M_@2G^-'_  EVD_\ 04T__P "4_QH T**S_\ A+M)_P"@II__ ($I_C1_PEVD
M_P#04T__ ,"4_P : -"BL_\ X2[2?^@II_\ X$I_C1_PEVD_]!33_P#P)3_&
M@#0HK/\ ^$NTG_H*:?\ ^!*?XT?\)=I/_04T_P#\"4_QH T**S_^$NTG_H*:
M?_X$I_C1_P )=I/_ $%-/_\  E/\: -"BL__ (2[2?\ H*:?_P"!*?XT?\)=
MI/\ T%-/_P# E/\ &@#0HK/_ .$NTG_H*:?_ .!*?XT?\)=I/_04T_\ \"4_
MQH T**S_ /A+M)_Z"FG_ /@2G^-'_"7:3_T%-/\ _ E/\: -"BL__A+M)_Z"
MFG_^!*?XT?\ "7:3_P!!33__  )3_&@#0HK/_P"$NTG_ *"FG_\ @2G^-'_"
M7:3_ -!33_\ P)3_ !H T**S_P#A+M)_Z"FG_P#@2G^-'_"7:3_T%-/_ / E
M/\: -"BL_P#X2[2?^@II_P#X$I_C1_PEVD_]!33_ /P)3_&@#0HK/_X2[2?^
M@II__@2G^-'_  EVD_\ 04T__P "4_QH T**S_\ A+M)_P"@II__ ($I_C1_
MPEVD_P#04T__ ,"4_P : -"BL_\ X2[2?^@II_\ X$I_C1_PEVD_]!33_P#P
M)3_&@#0HK/\ ^$NTG_H*:?\ ^!*?XT?\)=I/_04T_P#\"4_QH T**S_^$NTG
M_H*:?_X$I_C1_P )=I/_ $%-/_\  E/\: -"BL__ (2[2?\ H*:?_P"!*?XT
M?\)=I/\ T%-/_P# E/\ &@#0HK/_ .$NTG_H*:?_ .!*?XT?\)=I/_04T_\
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M33__  )3_&@#0HK/_P"$NTG_ *"FG_\ @2G^-'_"7:3_ -!33_\ P)3_ !H
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M,5L/F;S2-6$_W-M5=?W>EM[W:WTO[RO8_:\MSK@>' M7 XK#WS-R7+/DD_\
MG[9\WM$K*+BI:Q7,X-T*CIN;]X_X031?^@3I_P#X#K_A7QO_ ,%L?#6GZ-\
M?AO+:6-K;2-\2=)4M%$%)'DW9QD?05]O5\7_ /!</_DWKX;_ /92M)_]$W=?
M4X7^-'U7YGXI6^!^A];6/@71390_\2G3_N+_ ,L%]/I4G_"":+_T"=/_ / =
M?\*T+#_CQA_ZYK_*IJQEN:&3_P ()HO_ $"=/_\  =?\*/\ A!-%_P"@3I__
M (#K_A6M12 R?^$$T7_H$Z?_ . Z_P"%'_"":+_T"=/_ / =?\*UJ* ,G_A!
M-%_Z!.G_ /@.O^%'_"":+_T"=/\ _ =?\*UJ* ,G_A!-%_Z!.G_^ Z_X4?\
M"":+_P! G3__  '7_"M:B@#)_P"$$T7_ *!.G_\ @.O^%'_"":+_ - G3_\
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M *\_^(G_ "7;X<_]Q/\ ])UKT"O/_B)_R7;X<_\ <3_])UH ] HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBJ^KZ;'K6DW5G*SK'=Q/"Y0_, P(./?FFM
M]0/C'XN?\IT?AK_V3B7_ -*KVOM:OSWU+]B3PK%_P50TWPB-0\0?V;+\,9=5
M,GGP^>)1J8CQGRMNW;VVYSW[5]X?#[P1:_#?P7IVA6,EQ-::9$(8GG8-(PR3
M\Q4 9Y[ 5W8I4.1*E-R:TVMIO?=^EOQ.:C[3F?/&U]=[Z]MOQ-BBBBN Z0HH
MHH **** "BBB@#QG]I/_ ()_?"3]J^"9O&'@W2;G5)AC^UK:(6VH+QC_ %R
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MHH *\_\ B)_R7;X<_P#<3_\ 2=:] KS_ .(G_)=OAS_W$_\ TG6@#T"BBB@
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M/H&MLMO</)T*POG9-SG 4[\#)1:^FJ\*I3E!\LU9GI1G&2O%A1114%!1110
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M[W\DNQ^:>S?UCGOTM^)]:4445YQU!1110 4444 %%%% !1110 4444 %%%%
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M%?\ !13]I[PYI,)LO#MCJ]W%%:19\F$0:G<1P+CI\L;.!GG&?>OTJH *\_\
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M/RND4N S'?BOU(\!?$WP[\4].O+SPWK>EZ]:Z?>2Z?<S6-RLZ07$1 DB8J2
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MMZ?I?QA^)^C^$=7U2 75MIPM+K4;YX2Q42F"UBEE6,LK .RA258 G!Q^;?\
MP=H_M&^#OVH?^"*?PN\=?#GQ18^*?!WB3XH6/V74M/E)ANE33=95T8$ ADDC
M(9' *LF" 10!^UU%?'/P1_X+=_LJ>*OB?X9^#]C\;/"M[\0;B"UTZ*SC6X:T
MGNRB(($OO+^R/*7.T(LQ8M\H&>*]H_; _;U^#W[ O@:W\1?%_P ?:'X(TV\=
MH[079>:ZOF4 L(+:)7FFV@C/EHV,C.,B@#UZBOGG]B__ (*O_L[_ /!0K4[S
M3_@_\4=#\7:MI\1N)],,-QI^H+$"%:46UU'%,T8+*"ZH5!9<GD9U/V5O^"DW
MP3_;7^$OBGQU\,_'5MXB\+>";B:VUR]DT^\T\Z:\4(FDWQW444FT1G=N"E3@
M@$D$  ]RHKP?]GS_ (*;? O]J?\ 9D\4_&3P+X_L]:^&O@DW@UW67L+NS73/
MLENMS<>9%<11S?)"ZOPAW!AC-=A^R=^US\/?VXO@EIWQ&^%VO-XF\&ZM-/!:
M:B=/NK$3O#(T4H$=S'')A75ER5P2#@F@#TBBOFG]L;_@L/\ LU?L!^.[/PO\
M6OBMHOA;Q)>1I,NF)9W>I74,;YV/+':0RM"K8)#2!01R.*^/?^"W/_!R-HG[
M"?P=^&M[\!]8^'_Q \8?$*.#Q!!;:M8W]U8R>'I1=1"\CD@>% YN;8Q;&EWJ
M5?,?&0 ?JQ17S%X _P""S'[,GQ,_98U;XUZ7\6=%C^&&AZTWAV[UO4+*\TU5
MU$0QS_94AN88YI)#%*C 1HVX$XSM;%3]DK_@MM^RS^W-\3X_!?PP^+VC^(/%
M5PKM;Z7<:??:7<7FQ2[B 7D$7G$*&8B/<0JL<8!( /JBBOFWXR?\%?OV:_V>
MOBWXX\"^./BSX?\ "_BKX<6-MJ&OV.HPW,)M8KB..6!8W,7EW$KI-&PA@:27
M#9V<''2?L4_\%'O@E_P43\-:IJWP9^(&E^-;;0Y$BU"**WN+.[LB^[89+>YC
MCF17V/M8H%;:V"<&@#VZBOS_ /V\/^"WO[+,?PW^,WPAM?C=X87XD+X2UO3H
MK2(7/V<7OV*=%MUOA']E\_S,((Q-OW_+C=Q7C?\ P;!_'3PC^SA_P06L_&GC
M[Q)I?A3PGH/B/5Y+[5-2N!#;VJM=*B@D]V=U55&2S,  20* /UDHKY"_9Y_X
M+U?LC?M4?&&R\ ^!_C3H>I^+-3N19V-E=:;?Z:M_.6VK%!+=0112NS<*J.Q8
MD8!R,]W^T1_P54_9]_9,^,5WX!^(_P 3-(\(^*K'P]_PE,]I?VURL::?YAB$
MGGK$82[2*56$.97.-J'(R ?05%?+^N_\%G_V8?#'[*&@_&[4?BUHMC\-/%%S
M/9Z1J<]E>)<:E- [1S1Q69A^UNR,A# 0\<$\$$_E[\8/VSOAS^W'_P '4'['
MOC;X3^-+#QIX1D\#M;BYLS)']FN/^*@,D4L,BK)#-L:(LDB*^UD)&"* /WBH
MHKX]^)W_  7Z_8]^#OQHF^'_ (@^.GA>U\36MT;*XC@M;R[L[28,4:.6\AA>
MVC96!#;Y1L(.[% 'V%17C?[0W_!03X-_LJZ!X!U;QYX\TO1=)^*&IV^D^%[Z
M.*:^M=6GN%#PE9;=)$6)E96\YRL0# EP"*\QTG_@N;^RGX@^$OQ&\=:?\7]+
MU+PC\)KRRL/%&I6FE:A<16$MY*\-KL"6Y:X262-PLEN)$.TG=@9H ^LJ*^>_
M@7_P59_9Z_:8^/VJ?"_P'\4-$\3>-M%TMM9O;&T@N#%;VJE [&X:,0;D,B!X
MQ(70DAE!!QY?XA_X.)OV+?"_Q2;P==_'SPQ_;"3_ &9I8+&_N--5\D<W\<#6
M@48^]YNT>M 'VI17C?[1'_!0/X-_LJ?#_P &>+/'7CS2])\,_$+4[72/#FIV
M\4VHVNJW%RAD@\M[9)!Y;HI;S6Q&!@E@"*I_LG?\%)?@?^W1XS\9>'_A+\0M
M+\<:EX!DBCUL6%O<+#;>:7$;1S/&L4Z,8W >%G7Y>O2@#W"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK\M_^"MG_!.GQY\7OC'?^.].T;2_[*OM8TO3+(>"] GFU^^BDV&YO-1*$AE@
M,9"L.#B(G9MY_4BBO+S;*:684/85KVO?3N?=>'GB!F'!^:K-LN2<K<K4EO%M
M-I=F[6O9Z-VULUX/_P $Z?V;_$7[*?[/C^#?$ECX#M;JQU6X>VG\+6+VD>I6
MY6-8[FY#<M=-M(8] BQKSMR=G]N;]D+1?VW/V==8\#ZLR6MU-B[TF_*;CIMZ
M@;RIL=U^9E8#DH[@8)!'K]%=V#HQPM.-.CM'1?(^9S[.,1G&/K9CC+>TK2<I
M65E=[V70_FF_:E_8=^)G['GBVXTOQKX:O+6WC;$&JVT;3:;>KSAHYP-ISUVM
MM<=U%)^R[^Q!\3/VP?%MOI?@GPS?7=O(V)]5N(VATVR7NTLY&T8'.U<N?X5)
MXK]\/^"C'_)COQ,_[ DO\UJ'_@FK_P F#_"7_L6[7_T&OHGFDU14[:MM?=;_
M #/E_J$?:6OH7OV%?V/]%_8A_9TT?P1I;1W5Y'F[U>_";3J5ZX'F2X[*-JHH
M/1$4')R3[%117BRDY/FEN>E&*BK(*\>_;:_;A\#_ + OP?7QGXY?4I+.XO([
M"TLM-BCFOKZ9@3MC1W13M569B6  '7) /SPW_!P/\&E_:,/PQ_X1CXH-KX\2
M?\(OYPTRR^RFZ^U?9MV?M?F>7OY^YNQ_#GBOEOXX_M!> _\ @H7^W5\0O$7C
MKQOX3\._#?X#Z-J.G>#M&UG6;>SD\1:P8Y%^TI!,ZNW[V,."J_\ +&V4\EA4
ME'Z!? ?_ (*>_#3X]?LA>(OC=;+XB\/^"?"\]Q;Z@=6LD%W&T*QLQ$<$DH8'
MS4"X;))Y KPWP9_P<C?LZ^+?']OHDT?C[0[6XF$(UC4=)A73TR0 S>7.\JKS
MG)CX .<5Q_\ P;A7_A'X@_L ^(O ^J3>&]<O#XEN[N_T"[>&YE^RO%:A)9;9
MLGRF=" S+M+*<<BO)?\ @JIJ&D_\%4?VPOA[\ ?@KI>GZA+X"FN$U[Q+:VP-
MAI$;&-7B#H,>3"$;=@[6D947Y@<@'[!VUS'>6\<T,B2PRJ'1T;<KJ>001P01
MWKY2_;Q_X+%_"_\ X)Y?%;2_!OC31?'.J:MJNDIK,;:)96TT,<#S30J&::XB
M.XM!)P 1C'/-?3G@CPK;^!/!>D:':M)):Z-90V,+2'YF2)%12??"BOA7_@HU
M_P $\?CU\;/V]?!OQK^"/BWP7X3U;P?X5&CV]UK3LTJ3&6_$FR(VL\;!H;PK
MEP,$DC! ( /5OV+/^"OGPO\ VY=.\<WGAO2_&>@V/P]TY-4U:XUVRMX8U@82
MG*&&>7) A<D'''3/.//?@'_P6EN?BW\3?AS:ZY\&_$/@_P  _%_4;C2_!WBF
M?68+HZE/$VS$MJJ!H07PN2[9)R-P!(\V_P"">O[:OQ<_:(^/OQ8_97_:';3[
M[Q!#H-];-J^GVT5O-@A(94/DA8F5XK@2(ZHA&T@YW +Y%\<?V;/BW_P3_P#!
M'P6L?&GBKP'XMTSX5^(+@_"WP]X>MKHZ]XKU6XEWP)=(ZK&L,4C*SF,L=I\O
M):1& !^B7Q2_;I3PU^V7X1^"/A'PO)XT\4:K$-2\2SI?BTMO".F<?Z1,WEOO
MD8<I#\A;*99=ZD^_5^1/[-W[:>H?\$])?BQ?WWPLU[XL>*-"U6VN?C-X_CUN
M"V_L^^N7VK9VL+(S3PP.7C&UD7<K'Y4*8_6+P3XPL?B%X,TC7]+D,VFZY90Z
MA:2$8+PRHLB''NK T :E%%% !7&_M%?$6\^#_P"S[XZ\6Z=!;W6H>%_#VH:O
M:PW 8PRRV]M)*BN%()4L@!P0<$X(KLJP_B?XXTSX9?#3Q%XDUH2-HWA_3+G4
MK\)'YC&WAB:23"_Q'8K<=^E 'XQ^!OCM\7?^"H'B.;2?%W[0GA'X=Z3(_E_V
M3<7ITE9QGA8X8U1;CKTDE+<>W'3>'?\ @F3X(^!__!53X1_";6[V;X@>&_$_
MAV?7-0:Y4VD=S*(-2*!!"^Y8PUK$V-[9.025.*^G+O\ 9[_8M_X*1(TGA>\\
M.Z3XFOL8_L2?^Q=3#E?^?.10DASU;RFR1][GGQ[Q;_P13^-'[,/Q(TGQQ\$?
MB#9Z_JGAI7&EQZBJ6M]:*RR*T2"7?;NI620$,44^8WR]30!^G_@#X?:'\*O!
MUAX?\-Z3I^AZ'I<9CM;&RA6&&!22QPJ\9+$L3U+,2<DDUL5Y?^QGX@^(?BC]
MFKPS??%;3UTOQ_(MPNJVZQI&%*W,J1-M0E!NA6-OE.,MVZ#U"@ KC/VA?CGH
MG[-?P7\1>./$,OEZ7X>M&N'0'Y[A_NQPI_MR2%4&>,L,X&37EO[;OPY_:,\=
M:MX>?X%^/O"7@RSMX9QJ\>L6R2M=2$IY10M:7'  <$#9U'WNWQA_P4(\&?M(
M7OA+X1^#_B%X=USXTVNFWD^N^)_^$-TR<6NJ,MP5@MI)8;0+'M@R.8 <R,?F
MP&H TO\ @GY_P4'^/?QF_;W\*>%_B!KD</AGQAIEUK<&BKI=I$(;9[:::VQ(
ML0FQA$92SDLI!.<U'^T'^VI\>->_;[^)7P_\*?&[X<_"OP_X69'LSXM%A9VC
MKY< ,:32VLKO*6D+[2>@;&  *\G\.?M:^,M2_P""NGAGQPWP/\3Z'KJZ?%I2
M>"R)UN[>W-JT'G@?9581I&QDQY04*A^8#YA]7?M&?";]B'XO?$KX@ZUXZU_P
M[8^-+>]>WUN2;Q#=:??6]Q"BPL(;4R*LI'E=4BD#$D\Y% 'T/^P?9_%"#X(R
M7'Q6\=>$_B)K6H:E)<:?J_AWRFL6L3'$J(&C@A5F$BS$D*>& W'&![37YM_\
M&Y]QJG_"#?%JVCGOI_!UOK%F=',X*J9BD_GD+G <QBT+ ?[/M7Z24 %>?_$3
M_DNWPY_[B?\ Z3K7H%>:_%S3CJWQE^'MNMQ<6ID_M'][ VV1<0(>#[XQ]#0!
MZ57S#_P6H_Y1(_M'?]D^U?\ ])7KWC_A7,G_ $,/B'_P*'^%<[\7?V8-"^//
MPM\0>"O%U]KFM>%_%5A-I>JV$EZT:W=M*A22,LFUERI(RI!'4$&@#^=O]E"7
M]A6/_@VR\:_\)A_PJG_AHYM*UH-]L6(^+O[8^UW']E?9-_\ I'D>5]CWFW_<
M[?,\SG?7>:/^T_X;_9M_X-VOV/\ 2?BY\(O#GQ8UCQ5XNU5_!T'CF_EL]#T*
M*.]NTCO;PI\TMN([H!8I/W9B??D+&@/ZC^(/^#;O]CWQ1)X<>^^$UC,_A6UB
MLK%A?W2-)%$,1K<%9!]J( "YN/,.T 9P *]G_:%_X)A_!_\ :K^!^F_#?Q_X
M;B\0^!]%$8TS27/V>+2O+C,4?V5H@CVY6,E 8F4A21TXH _ _P"#&K1O_P '
M$_[+IMU_9!M;A)XTF7]G-95\/ .MW\MTQ_=O=[6*L8B1LV \\5](_L2?L=_#
M+]KK_@Z(_:XC^)W@O0?'6G^$[>74M/T[6K5;RP6X>2RA\R2W<&.7$<C@"16
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MMLFE:M-JMS"T"V\[7$(:..18I0DKLP$B-UP<CBO?O^%<R?\ 0P^(?_ H?X4
M?@I_P6)^"O@/X2?\%+/C1\>O OQ2_9:\>>+=/M(8/&OPC^,]E:M.9(K"U8+I
MB787[1))#%"4:W>-U,CHLK9*#R3_ (+#^(/AO^TG_P &]'[,/QA\#?"'P_\
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M*YD_Z&'Q#_X%#_"@#IJ*YG_A7,G_ $,/B'_P*'^%'_"N9/\ H8?$/_@4/\*
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M#_X%#_"@#IJ*YG_A7,G_ $,/B'_P*'^%'_"N9/\ H8?$/_@4/\* .FHKF?\
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MBBBBLR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 <G\2OCUX&^#$UG'XP\:>$_"<F
MH*S6JZSJ]O8M<A<;B@E==P&Y<XSC(]:^(_\ @MEI%Q^U1^S7\.]1^&=C-\4-
M/3Q0^\^%LZLLH6WF# -;;S@;&!(^Z1S@XKZO_:3_ &&_A9^UYJ&DW7Q$\++X
MAN-#CDBLG_M&[M#"LA4N/W$J;LE5^]G';&37F'QPF\4?\$X?A+X1TOX"?!Q_
M&G@VUN[MM8T>TNKFXOK;>5D1HF9I96W,9<DI*!A1\HP" ?)W[ ?QB^ ?@/\
M;3\-Z)J'[.OB3X)_$265[71;K4/$&I:AY<T\3PA)8;GRRGF*[QJWEN-S#[OW
MA!^S#\"/"O\ P4X_X*/?'K5/B=#J6N:7X;N);/2K$WDML(8EN9((,M$X(\N.
M+.T':6<DY[]'X4^&7QH_X*0_\%!/A[\3O&7PNU#X3^$?AO-;7*1ZI')%<S?9
M[DW*1@RI')*[RX&1&J*H)ZGYJC>$OC/_ ,$POVZ/BAXH\'_"'7/BAX-^(TTU
MW:#2(IIA!YDS3H&:&*5HS$SNA5T&X8(;H: .B_X(C7=U\(/VH?V@O@_;WMQ?
M>'/"NKS&Q\X\H]M>36K.!G ,B",M[QK^/Z35\/\ _!(#]E'QU\.M>^)GQ8^)
MNDMH7BSXH:DURFG2*$FMHVFEGE=T'^K\R6480X($0)'(K[@H *\[^+%RNC?%
MCP'JEPLRZ?9-?K/.L3.D)>!0@8J#@L0<>N#Z&O1** .9_P"%P^'/^@C_ .2\
MO_Q-'_"X?#G_ $$?_)>7_P")KIJ* .9_X7#X<_Z"/_DO+_\ $T?\+A\.?]!'
M_P EY?\ XFNFHH YG_A</AS_ *"/_DO+_P#$T?\ "X?#G_01_P#)>7_XFNFH
MH YG_A</AS_H(_\ DO+_ /$T?\+A\.?]!'_R7E_^)KIJ* .9_P"%P^'/^@C_
M .2\O_Q-'_"X?#G_ $$?_)>7_P")KIJ* .9_X7#X<_Z"/_DO+_\ $T?\+A\.
M?]!'_P EY?\ XFNFHH YG_A</AS_ *"/_DO+_P#$T?\ "X?#G_01_P#)>7_X
MFNFHH YG_A</AS_H(_\ DO+_ /$T?\+A\.?]!'_R7E_^)KIJ* .9_P"%P^'/
M^@C_ .2\O_Q-'_"X?#G_ $$?_)>7_P")KIJ* .9_X7#X<_Z"/_DO+_\ $T?\
M+A\.?]!'_P EY?\ XFNFHH YG_A</AS_ *"/_DO+_P#$T?\ "X?#G_01_P#)
M>7_XFNFHH YG_A</AS_H(_\ DO+_ /$T?\+A\.?]!'_R7E_^)KIJ* .9_P"%
MP^'/^@C_ .2\O_Q-'_"X?#G_ $$?_)>7_P")KIJ* .9_X7#X<_Z"/_DO+_\
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M/_DO+_\ $T?\+A\.?]!'_P EY?\ XFNFHH YG_A</AS_ *"/_DO+_P#$T?\
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MG_A</AS_ *"/_DO+_P#$T?\ "X?#G_01_P#)>7_XFNFHH YG_A</AS_H(_\
MDO+_ /$T?\+A\.?]!'_R7E_^)KIJ* .9_P"%P^'/^@C_ .2\O_Q-'_"X?#G_
M $$?_)>7_P")KIJ* .9_X7#X<_Z"/_DO+_\ $T?\+A\.?]!'_P EY?\ XFNF
MHH YG_A</AS_ *"/_DO+_P#$T?\ "X?#G_01_P#)>7_XFNFHH YG_A</AS_H
M(_\ DO+_ /$T?\+A\.?]!'_R7E_^)KIJ* .9_P"%P^'/^@C_ .2\O_Q-%=-1
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!3\0Z[;
M^%_#]]J=XWEV>G6\EU.W]U$4LQ_(&OR?^$3?M&?\%,/!/Q(^,&C_ !F\0?#_
M $OPW>W$.C:!IEW-;VUP\4*7'V=O)E0*%C>(>9(LA9F.>]?JE\2O"TGCGX<^
M(-%BD6&36--N+%';[J&6)D!/!X&[T-?DK_P3A_;T\%_L/_LI_%KX9_$)=4T?
MQA#JM]=6EC]CED:]FDM(K8V^54K$RO!RTA"X?CI@@'VI_P $<_VN]>_:[_9.
M:^\67BZAXF\+ZG)H]W=E LE[&(XY(IG XW%9"A( R8R3R<GZPKX8_P"" 'P?
MU'X=?L8ZAK6I6]Q:MXRUR6_LUD&T26B111)(!C/S.LO/0J%(]3]ST %%%% !
M1110 4444 %%%% !1110 4444 ?"/_!8FY^//A+X3>+/&7AGQ_9^"?AWX5BL
M3#:Z,TL.MZM/-<0P.9+A<&*-6FR CC<$(9>0:]\_X)J>+]6\>_L*?#76-<U/
M4-9U:^TKS+F]OKA[BXN&\V0;GD<EF. !DDGBO ?^"W'[7OP[TW]ESQ]\(YO$
M6SXA:A#IEQ;Z3]@N3YB"_MIR?.$?DC]U&[8+@\8ZD ]?_P $;OVG_ WQ+_94
M\(^ =$US[;XN\':,&UBP^QW$?V0-,X'[QT$;_>'W&;K0!]@T444 %%%% !11
M10 4444 %%%% !1110 5\[_MO_LV_%_]H_7/#EA\/_BQ+\+?#-O#/_;$UBDA
MU"YE8IY10QE&VJH?_ELG)Z'J/HBOBW_@K_\ \%'[[]C+P9IWA7PK&8_&OC"W
MDD@U&5-T.CVX;8TP&#OE)R%&"!@L<X"L >'_ /!-_P"/'Q?^%_\ P4L\1? W
MQ5X^U;XE:#8B]AN[S4;B6\:W>"/S$GC>5FDC.[$;(7*YD(Y*J:_4*OSE_P""
M1?Q!_9U^#.M1Z+I7Q,_X3CXR_$23_B87TFBZC%YTF#*]O%+- H";@S%W8&1@
M"<?*H_1J@ HHHH **** "BBB@ HHHH **** "BBB@#RG]M7P]XS\3?L[:Y;^
M!?&FE?#W5DV3W/B#4)1%!IME&V^YD+E6"8B#'<=N.3N7J/S'N_BI\5/V<_VP
MOASHOP__ &E-3_:$F\17T/\ :&GVM_-J%E&IE0/"Z&>:+8R,YWHZL@0DA, U
M^EW[<GQW\!_ 3]G_ %"Z^)5GJU]X-\3.?#FI1V$32-Y5U%(C[RKHZH4#*60[
M@6&.:_(W]JSQ!\%O#GQ@\!7'[']YXNM/%UQ=;)EL9+Y8S(3&(8X_M7[YG+;M
MPR8R#SQ0!^Z5%5- :\;0K(Z@L:Z@8$-R(_NB7:-^/;=FK= !1110 4444 %%
M%% !1110 4444 %%%>9_MEZ#XR\5?LL^.M+^'R22>,=2TJ6TTQ8YHX7+R81M
MKR%41MA?#$C!P00<4 ?F5_P4O_;?^)?QI\?^,_$'PQ\8>)O"WPQ^%=U;^'FO
M=&U2>Q76]0F=@[;H7'F*-C[3D@)&K8!EK]2?V8]9O/$?[-GP]U#4+J>]OK_P
MUIMQ<W$[F26>5[6-G=F/+,S$DD\DFOQQ_:.^&7[1'[-?_!/VW^'GC3X7>%/"
MOPYM=:BO)M6M[^&YU*[O7+%3(8[V0'(^7B( *BCC'/ZG?\$T]=\=:_\ L:>"
MY/'VBZ;H>HPZ?!!IT5E('6XTU8(Q:S-B63$CQX+#((/\*]* />**** "BBB@
M HHHH **** "BBB@ HHHH *_&O\ :&^.VLZ]_P % OBYH/BK]IWXA?!GP[H^
MINFEBQ_M34+:0@JODI!:S((@%^;=C!.>YS7[*5^?O[0?[9'[%M_XG^).G^._
M!FDS>,],U*\TW4DG\)"34]3N;=S S07<:,%R8AM9I8S@@G!)H ^AO^";VC1:
M1^S;&UO\8[[XY07NHS7,?B*[>4S1@K&/LQ66:61-FW.UF!'F?=&>??*_._\
MX-VO &O>'?@/XZUV]M+NS\.^(M8A.CK/_P MO)C=9I$X&Y<M&F\#!,3#^$@?
MHA0 4444 %%%% !1110 4444 %%%% !1110!\"_\%2/VN/';?M)^#?@3\-_%
MEEX"NM<L_P"T]=\1W,XM5L(#YC &8_ZM5CAD=BI!8LB@CD'N/^";OPDU_P "
M?$#6KZ3]IZW^/WA^;2Q#):KJQOVTR\,J$.#]IGPNQ6&=RDEON]Z^5?\ @K%\
M.?"/@[_@JAX-\3?%G3]4NOA7XHTJ'[?+9F526B2:$INCP^4<02.J'<4?@Y.
M[_@G1HO@?5/^"OMY?? .WUB/X5:;HD_VV20W AVO %P3.?-*-<^6567YB4)Q
MA> #]:J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "N)\8?LU?#GXA>)5UK7_A_P""=<UA2"+_ %#0[6YN01C'
M[QT+<8'?M7;44 ,M[>.SMXX88TBBB4(B(NU44<  #H!Z4^BB@ HHHH ****
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MHH **** ,/Q]\,_#?Q6T3^S?%'A_0_$FF[Q)]EU6QBO(-PX#;)%9<\GG%)X
M^%WAGX3Z0VG^%?#NA>&M/=][6VE6$5G"S=,E(U49]\5NT4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:^+7@GQDV@Z#XH1QK?A$:5YEM>NX)9DF\Y?+_?8E'[L[274':^!]/4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826854880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEI Document - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_EntityAbstract', window );"><strong>Entity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Menlo Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001566044
<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,977,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_EntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_EntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827413808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,206<span></span>
</td>
<td class="nump">$ 4,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short&#8209;term investments</a></td>
<td class="nump">49,295<span></span>
</td>
<td class="nump">26,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">786<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,574<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">63,861<span></span>
</td>
<td class="nump">31,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long&#8209;term investments</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">10,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid and other long&#8209;term assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">66,867<span></span>
</td>
<td class="nump">42,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,462<span></span>
</td>
<td class="nump">1,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,559<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">1,796<span></span>
</td>
<td class="nump">1,796<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,817<span></span>
</td>
<td class="nump">3,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, long&#8209;term</a></td>
<td class="nump">6,735<span></span>
</td>
<td class="nump">8,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non&#8209;current liabilities</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,574<span></span>
</td>
<td class="nump">12,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 55,000,000 and 36,500,000 shares authorized at December 31, 2017 and 2016, respectively; 5,298,593 and 5,280,058 shares issued and outstanding at December 31, 2017 and 2016, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid&#8209;in capital</a></td>
<td class="nump">2,207<span></span>
</td>
<td class="nump">699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(59,191)<span></span>
</td>
<td class="num">(30,115)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(57,034)<span></span>
</td>
<td class="num">(29,441)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</a></td>
<td class="nump">66,867<span></span>
</td>
<td class="nump">42,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">14,183<span></span>
</td>
<td class="nump">14,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">44,820<span></span>
</td>
<td class="nump">44,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">$ 50,324<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827094720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value per share (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">28,322,761<span></span>
</td>
<td class="nump">14,120,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued (shares)</a></td>
<td class="nump">25,975,346<span></span>
</td>
<td class="nump">14,120,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">25,975,346<span></span>
</td>
<td class="nump">14,120,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Preferred stock, liquidation value</a></td>
<td class="nump">$ 109,800<span></span>
</td>
<td class="nump">$ 59,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (shares)</a></td>
<td class="nump">55,000,000<span></span>
</td>
<td class="nump">36,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (shares)</a></td>
<td class="nump">5,298,593<span></span>
</td>
<td class="nump">5,280,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (shares)</a></td>
<td class="nump">5,298,593<span></span>
</td>
<td class="nump">5,280,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value per share (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued (shares)</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Preferred stock, liquidation value</a></td>
<td class="nump">$ 14,300<span></span>
</td>
<td class="nump">$ 14,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value per share (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">14,106,583<span></span>
</td>
<td class="nump">14,106,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued (shares)</a></td>
<td class="nump">14,106,583<span></span>
</td>
<td class="nump">14,106,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">14,106,583<span></span>
</td>
<td class="nump">14,106,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Preferred stock, liquidation value</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value per share (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">14,201,878<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued (shares)</a></td>
<td class="nump">11,854,463<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">11,854,463<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Preferred stock, liquidation value</a></td>
<td class="nump">$ 50,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814693280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration and license revenue</a></td>
<td class="nump">$ 4,582<span></span>
</td>
<td class="nump">$ 674<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">29,007<span></span>
</td>
<td class="nump">11,255<span></span>
</td>
<td class="nump">2,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,168<span></span>
</td>
<td class="nump">3,751<span></span>
</td>
<td class="nump">1,687<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">34,175<span></span>
</td>
<td class="nump">15,006<span></span>
</td>
<td class="nump">4,608<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(29,593)<span></span>
</td>
<td class="num">(14,332)<span></span>
</td>
<td class="num">(4,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income and other expense, net</a></td>
<td class="nump">517<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(29,076)<span></span>
</td>
<td class="num">(14,068)<span></span>
</td>
<td class="num">(4,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available&#8209;for&#8209;sale securities</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (29,101)<span></span>
</td>
<td class="num">$ (14,094)<span></span>
</td>
<td class="num">$ (4,608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss attributable to common stockholder per share, basic and diluted (in USD per share)</a></td>
<td class="num">$ (5.69)<span></span>
</td>
<td class="num">$ (2.82)<span></span>
</td>
<td class="num">$ (0.97)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted&#8209;average number of common shares used to compute basic and diluted net loss per share (in shares)</a></td>
<td class="nump">5,108,121<span></span>
</td>
<td class="nump">4,987,133<span></span>
</td>
<td class="nump">4,735,148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828535536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Convertible Preferred Stock and Stockholders' Deficit Statement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Series C Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, beginning at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock, beginning at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,383<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning (shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,962,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2014</a></td>
<td class="num">$ (11,410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="num">$ (11,439)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">14,106,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 44,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of unvested stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available&#8209;for&#8209;sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, ending at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">14,106,583<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock, ending at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,183<span></span>
</td>
<td class="nump">$ 44,820<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending (shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,280,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Dec. 31, 2015</a></td>
<td class="num">$ (15,953)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="num">(16,047)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of unvested stock options (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available&#8209;for&#8209;sale securities</a></td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, ending at Dec. 31, 2016</a></td>
<td class="nump">14,120,883<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">14,106,583<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock, ending at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,183<span></span>
</td>
<td class="nump">$ 44,820<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending (shares) at Dec. 31, 2016</a></td>
<td class="nump">5,280,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,280,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Dec. 31, 2016</a></td>
<td class="num">$ (29,441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">699<span></span>
</td>
<td class="num">(30,115)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,854,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of unvested stock options (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock on exercise of stock options</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available&#8209;for&#8209;sale securities</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, ending at Dec. 31, 2017</a></td>
<td class="nump">25,975,346<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">14,106,583<span></span>
</td>
<td class="nump">11,854,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock, ending at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,183<span></span>
</td>
<td class="nump">$ 44,820<span></span>
</td>
<td class="nump">$ 50,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending (shares) at Dec. 31, 2017</a></td>
<td class="nump">5,298,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,298,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Dec. 31, 2017</a></td>
<td class="num">$ (57,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2,207<span></span>
</td>
<td class="num">$ (59,191)<span></span>
</td>
<td class="num">$ (51)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to Additional Paid-in Capital, Vesting of Early Exercised Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_AdjustmenttoAdditionalPaidinCapitalVestingofEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6657135616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Convertible Preferred Stock and Stockholders' Deficit (Parenthetical) - Preferred Stock - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_TemporaryEquityStockIssuedIssuanceCosts', window );">Preferred stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_TemporaryEquityStockIssuedIssuanceCosts', window );">Preferred stock issuance costs</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_TemporaryEquityStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_TemporaryEquityStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814998752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,076)<span></span>
</td>
<td class="num">$ (14,068)<span></span>
</td>
<td class="num">$ (4,608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums', window );">Depreciation and amortization</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on available&#8209;for&#8209;sale investments</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium on investment securities</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock&#8209;based compensation expense</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="nump">573<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of equipment</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(786)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,790)<span></span>
</td>
<td class="num">(555)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets', window );">Prepaid and other long&#8209;term assets</a></td>
<td class="nump">66<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">620<span></span>
</td>
<td class="nump">889<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,976<span></span>
</td>
<td class="nump">466<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,796)<span></span>
</td>
<td class="nump">10,327<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non&#8209;current liabilities</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(28,247)<span></span>
</td>
<td class="num">(2,291)<span></span>
</td>
<td class="num">(4,183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(64,148)<span></span>
</td>
<td class="num">(55,309)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities', window );">Proceeds from sales of investments</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="nump">43,110<span></span>
</td>
<td class="nump">14,250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(15,065)<span></span>
</td>
<td class="num">(37,490)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">50,324<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Deferred financing costs</a></td>
<td class="num">(867)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">49,491<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,718<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">6,179<span></span>
</td>
<td class="num">(39,781)<span></span>
</td>
<td class="nump">43,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">4,027<span></span>
</td>
<td class="nump">43,808<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">10,206<span></span>
</td>
<td class="nump">4,027<span></span>
</td>
<td class="nump">43,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash Investing and Financing Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred financing costs</a></td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Depletion and Amortization, Excluding Amortization of Discounts and Premiums</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_DepreciationDepletionandAmortizationExcludingAmortizationofDiscountsandPremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Expenses and Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_IncreaseDecreaseinPrepaidExpensesandOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Prepaid Expenses and Other Long-term Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_IncreaseDecreaseinPrepaidExpensesandOtherLongtermAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with maturities (principal being due), prepayments and calls (requests of early payments) on securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817873088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Formation and Business of the Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Formation and Business of the Company</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Formation and Business of the Company</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Menlo Therapeutics Inc., or the &#8220;Company&#8221;, is a late&#8209;stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The Company is concurrently evaluating the use of serlopitant for the treatment of refractory chronic cough, a cough that persists for at least eight weeks despite treatment of any identified underlying cause. The Company believes that its product candidate, serlopitant, a highly selective once&#8209;daily, oral small molecule inhibitor of the neurokinin 1 receptor, or NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R, has the potential to significantly alleviate itch and cough symptoms. Pruritus associated with atopic dermatitis, psoriasis and prurigo nodularis, as well as refractory chronic cough, each represents a significant patient need.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company was incorporated in Delaware in October 2011. Since commencing operations, the Company has devoted substantially all of its resources to developing its product candidate, including conducting clinical trials and providing general and administrative support for these operations.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Initial Public Offering</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In January 2018, the Company completed its initial public offering (&#8220;IPO&#8221;) of shares of its common stock, pursuant to which the Company issued </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,050,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares of common stock, which includes </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,050,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares issued pursuant to the over-allotment option granted to its underwriters, and received net proceeds of approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$125.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, after deducting underwriting discounts, commissions and offering expenses. In connection with the completion of the Company's IPO, all shares of convertible preferred stock converted into </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9,629,405</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares of common stock.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Since inception, the Company has incurred losses and negative cash flows from operations. For the year ended December 31, 2017, the Company incurred a net loss of $</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">29.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and used </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$28.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> of cash in operations. As of December&#160;31, 2017, the Company had cash, cash equivalents and investments of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$62.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and an accumulated deficit of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$59.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company&#8217;s research and development activities. Management plans to finance operations through equity or debt financing arrangements, and/or third&#8209;party collaboration funding. There can be no assurances that, in the event that the Company requires additional financing, such financing will be available on terms which are favorable to the Company, or at all. If the Company is unable to raise additional funding to meet its working capital needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company believes that its existing cash, cash equivalents and investments as of December&#160;31, 2017 together with funds available from the January 2018 IPO, will provide sufficient funds to enable it to meet its obligations for at least the next twelve months.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812723376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Reverse Stock Split</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On January 8, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2018, the Company effected a reverse split of shares of the Company&#8217;s common stock at a ratio of 1-for-</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2.6975</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> pursuant to an amendment to the amended and restated certificate of incorporation approved by the Company&#8217;s board of directors and stockholders. The par value and the authorized</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">shares of the common stock were not adjusted as a result of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse split for all periods presented, and the conversion ratio of the preferred stock was adjusted accordingly. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Segments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company operates in </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">one</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long&#8209;lived assets are maintained in the United States of America. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Preparation of financial statements in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, stock&#8209;based compensation expense, the resolution of uncertain tax positions and valuation allowance, recovery of long&#8209;lived assets and accruals for research and development costs. Management bases its estimates on historical experience on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Risk and Uncertainties</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company&#8217;s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s potential drug candidate, uncertainty of market acceptance of the Company&#8217;s product candidate, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company&#8217;s product candidate requires clearances from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the product candidate will receive the necessary clearances. If the Company was denied clearance, clearance was delayed or the Company was unable to maintain clearance, it could have a materially adverse impact on the Company. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to complete clinical studies and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. The Company limits its credit risk associated with cash and cash equivalents by placing its investments with an institution it believes is highly creditworthy and with highly rated money market funds. As of December&#160;31, 2017 and 2016, cash and cash equivalents consisted of bank deposits, cash and investments in money market funds. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Investment Securities </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company classifies its investment securities as available&#8209;for&#8209;sale. Those investments with maturities less than 12&#160;months at the date of purchase are considered short&#8209;term investments. Those investments with maturities greater than 12&#160;months at the date of purchase are considered long&#8209;term investments. The Company&#8217;s investment securities classified as available&#8209;for&#8209;sale are recorded at fair value based upon quoted market prices at period end. Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of comprehensive income or loss. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight&#8209;line interest method. Dividend and</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Property and Equipment, Net</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Property and equipment are stated at cost and depreciated using the straight&#8209;line method over the estimated useful lives of the assets, generally between </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">three</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">five</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> years. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The carrying amounts of the Company&#8217;s financial instruments, which include cash, accounts payable and accrued liabilities and other current liabilities, and deferred revenue approximate their fair values due to their short maturities. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and investments. As of December&#160;31, 2017 and 2016, the majority of our cash, cash equivalents and investments are held by </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">one</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> U.S. financial institution in excess of federally insured limits. We invest cash in excess of our current needs in United States Treasury and government agency securities, highly&#8209;rated short or medium&#8209;term debt securities and money market funds and, by policy, diversify our investments to limit the amount of credit exposure. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company has an investment policy which limits the Company to investing in highly rated corporate and government notes, and no individual investment may comprise more than </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5%</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> of the total portfolio.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">accounts for income taxes under the asset and liability method which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company&#8217;s assets and liabilities and their financial statement reported amounts. Management makes estimates, assumptions and judgments to determine the Company&#8217;s provision for income taxes and also for deferred tax assets and liabilities, and any valuation allowances recorded against the Company&#8217;s deferred tax assets. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and to the extent the Company believes that recovery is not more likely than not, the Company must establish a valuation allowance.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">has adopted ASC 740-10, Accounting for Uncertainty in Income Taxes, that prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&#8217;s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research and development costs are expensed as incurred. Substantially all of our research and development expenses consist of expenses incurred in connection with the development of serlopitant. These expenses include certain payroll and personnel expenses including stock&#8209;based compensation expense, consulting costs, contract manufacturing costs, and fees paid to clinical research organizations, or CROs, to conduct research and development. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as an expense as the goods are delivered or the related services are performed. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company estimates non&#8209;clinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage non&#8209;clinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Patent Costs</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company has no historical data to support a probable future economic benefit for the arising patent applications, filing and prosecution costs. Therefore, patent costs are expensed as incurred.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company recognizes rent expense on a straight&#8209;line basis over the non&#8209;cancellable term of the operating lease.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company measures and recognizes compensation expense for all stock&#8209;based awards made to employees, directors and non&#8209;employees, based on estimated fair values recognized using the straight&#8209;line method over the requisite service period.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The fair value of options to purchase common stock granted to employees is estimated on the grant date using the Black&#8209;Scholes option valuation model. The calculation of stock&#8209;based compensation expense requires that the Company make certain assumptions and judgments about a number of complex and subjective variables used in the Black&#8209;Scholes model, including the expected term, expected volatility of the underlying common stock, risk&#8209;free interest rate, as well as estimating future forfeitures of unvested stock options. To the extent actual forfeiture results differ from the estimates, the difference will be recorded as a cumulative adjustment in the period the estimates are revised. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company accounts for options issued to non&#8209;employees using the Black&#8209;Scholes option valuation model and is measured and recognized as the stock options are earned.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Convertible Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company recorded the convertible preferred stock at fair value on the dates of issuance, net of issuance costs. The convertible preferred stock is recorded outside of stockholders&#8217; equity because, in the event of certain deemed liquidation events considered not solely within the Company&#8217;s control, such as a merger, acquisition and sale of all or substantially all of the Company&#8217;s assets, the convertible preferred stock will become redeemable at the option of the holders. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">All outstanding convertible preferred stock converted into common stock in January 2018 upon the effectiveness of the IPO.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Comprehensive income (loss) is defined as the change in equity of the Company during a period from transactions and other events and circumstances excluding transactions resulting from investments and distributions to owners. Comprehensive loss consists of the net loss and changes in accumulated other comprehensive income, which are comprised of unrealized gains (losses) on available&#8209;for&#8209;sale investments.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">To date, the Company&#8217;s clinical drug candidates have not been approved for sale by the FDA and the Company has not generated any revenue from product sales. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On August 10, 2016, the Company entered into a license and collaboration agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd., together referred to as &#8220;JT Torii&#8221;, which is referred to as the &#8220;Collaboration Agreement&#8221;. Under the Collaboration Agreement, the Company granted to JT Torii the rights to develop and commercialize products containing serlopitant in Japan for the treatment of diseases and conditions other than nausea or vomiting. In exchange, JT Torii paid an upfront, non&#8209;refundable payment of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$11.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. In addition, the Company is entitled to receive aggregate payments of up to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$28.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> upon the achievement of specified development and regulatory milestones, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$15.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> upon the achievement of a commercial milestone, as well as tiered royalties from the mid-single digits up to the mid&#8209;teens on sales of licensed products in Japan. The Company&#8217;s performance obligations under the license agreement includes the transfer of intellectual property rights in the form of licenses, obligations to participate on certain development and/or commercialization committees with the collaboration partners and supply manufactured drug product for clinical trials. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company recognizes revenue pursuant to the Collaboration Agreement in connection with the clinical development and commercialization of products covered by the collaboration, including non-refundable upfront license fees, contingent consideration payments based on the achievement of defined collaboration objectives and royalties on sales of commercialized products. To date, the Company has not generated or recognized revenue from sales of its product candidates.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Revenue from the Collaboration Agreement is recognized when </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(i)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">persuasive evidence of an arrangement exists, </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(ii)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">transfer of technology has been completed, services have been performed or products have been delivered, </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(iii)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the fee is fixed and determinable, and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(iv)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">collection is reasonably assured. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company evaluates revenue agreements with multiple&#8209;elements in accordance with ASC 605-25 </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue Recognition - Multiple Element Arrangements</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting based on the achievement of certain criteria including whether the deliverable has stand&#8209;alone value. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Upfront payments for licenses are evaluated to determine if the licensee can obtain standalone value from the license separate from the value of the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">obligations to participate on certain development and/or commercialization committees with the collaboration partners and supply manufactured drug product for clinical trials</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> in the arrangement to be provided by the Company. The Company is reimbursed by JT Torii for the non-commercial supplies of serlopitant at the same rate as charged by the third party manufacturer, which does not include a significant and incremental discount to JT Torii. The assessment of multiple-element arrangements also requires judgment in order to determine the allocation of revenue to each deliverable and the appropriate period of time over which the revenue should be recognized. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under the Collaboration Agreement, the Company has determined that the license does not have standalone value separate from the research and development services because </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">JT Torii cannot resell such license on a standalone basis or use the license with its available resources to obtain any economic value without the Company&#8217;s participation. T</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">he license and the services are combined as one unit of accounting and upfront payments are recorded initially as deferred revenue in the balance sheet. Revenue is then recognized on a straight-line basis over an estimated performance period that is consistent with the term of performance obligations, unless the Company determines there is a discernible pattern of performance other than straight-line, in which case the Company uses a proportionate performance method to recognize the revenue over the estimated performance period. The Company is recognizing the upfront fee on a straight-line basis over the initial period of performance of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">six</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> years, which represents the estimated development period in the territories based on the initial development plan managed by the joint steering committee. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The term of the agreement is through the expiration of the patents associated with serlopitant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any changes in estimated periods of performance on a prospective basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">At the inception of each agreement that includes milestone payments, including the Collaboration Agreement, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non&#8209;refundable payments that are contingent upon achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved, assuming all other revenue recognition criteria are met. Other contingent payments in which a portion of the milestone consideration is refundable or adjusts based on future performance or non&#8209;performance (e.g., through a penalty or claw&#8209;back provision) are not considered to relate solely to past performance, and therefore, not considered substantive. Amounts that are not recognized as revenue due to the uncertainty as to whether they will be retained or because they are expected to be refunded are recorded as a liability. The Company recognizes non&#8209;substantive milestone payments over the remaining estimated period of performance once the milestone is achieved. Contingent payments associated with the achievement of specific objectives in certain contracts that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are recognized as revenue upon achievement of the objective, as long as there are no undelivered elements remaining and no continuing performance obligations by the Company, assuming all other revenue recognition criteria are met. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under the Collaboration Agreement, the Company is entitled to receive aggregate payments of up to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$28.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> upon the achievement of specified development and regulatory milestones, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$15.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> upon the achievement of a commercial milestone. Two of the milestones, which amount to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> each, relate to the preparation of an IND for submission to regulatory authorities in the territory are considered substantive given that they are triggered by the Company&#8217;s performance relative to the achievement of pre-specified, &#8220;at risk&#8221; milestone events, including the submission of all completed clinical trials data packages and the validation of the manufacturing process. All other milestones, which amount to an aggregate of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$24.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, are considered non-substantive because the milestone is dependent upon the performance of the collaboration partner rather than the Company. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#8217;s balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, current portion. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Expenses related to the collaboration agreement are recorded as a component of research and development in the statement of operations as incurred, and to date have been immaterial.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During the fourth quarter of 2017, the Company achieved a substantive milestone related to the validation of the manufacturing process under the Collaboration Agreement, and recognized revenues of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$2.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On September 1, 2017, the Company entered into a separate services agreement with JT Torii to provide research and development services, including regulatory, chemistry and manufacturing support and related materials that is distinct from the original Collaboration Agreement. The Company evaluated the new services agreement and determined that the research and materials delivered to JT Torii represents a separate earnings process that provides standalone value to JT Torii. The fees received under the services agreement will be recognized as and when such services are performed by the Company and JT Torii consumes the benefits of those services. The Company has no obligation to provide services unless requested by JT Torii and agreed to by us. The Company is eligible to receive reimbursement of estimated costs incurred and payment for research services performed directly by the Company at agreed upon rates. During the year ended December 31, 2017, the Company recognized revenue of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and recorded expenses of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> as research and development expense in the statement of operations related to the new services agreement. The services agreement terminates upon the termination of the Collaboration Agreement or by mutual agreement of the parties.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Net Loss per Share of Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted&#8209;average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted&#8209;average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock and common stock options are considered to be potentially dilutive securities. Because the Company has reported a net loss for the years ended December&#160;31, 2017, 2016 and 2015, diluted net loss per common share is the same as basic net loss per common share for those periods. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In November 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016&#8209;18,&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. The update requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016&#8209;18 is effective for public entities for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In March 2016, the FASB issued ASU 2016&#8209;09, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Improvements to Employee Share&#8209;Based Payment Accounting</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> as part of its simplification initiative, which involves several aspects of accounting for share&#8209;based payment transactions, including the income tax effects, statutory withholding requirements, forfeitures and classification on the statement of cash flows. The standard is effective for companies for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years with early adoption permitted. The Company adopted this standard as of January 1, 2017, and there was no impact to the Company&#8217;s financial statements as a result of the adoption. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In February 2016, the FASB issued ASU 2016&#8209;02, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Leases</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight&#8209;line basis over the term of the lease, respectively. A lessee is also required to record a right&#8209;of&#8209;use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASC 842 supersedes the previous leases standard, ASC 840 </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Leases</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In January 2016, the FASB issued ASU 2016&#8209;01, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. ASU 2016&#8209;01 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In November 2015, the FASB issued ASU 2015&#8209;17, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> to simplify the presentation of deferred income taxes. The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. We have elected to early adopt ASU 2015&#8209;17 as of the beginning of our fourth quarter ended December&#160;31, 2015 on a prospective basis. There was no impact to the balance sheet amounts as a result of early adoption.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In August 2014, the FASB issued ASU 2014&#8209;15 related to Presentation of Financial Statements &#8209; </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Going Concern (Subtopic 205&#8209;40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. This update provides guidance about management&#8217;s responsibilities in evaluating an entity&#8217;s going concern uncertainties, and about the timing and content of related footnote disclosures. Under this amended guidance, an entity&#8217;s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. This update is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company adopted this standard in 2016 and there was no impact on the financial position, results of operations or related financial statement disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In May 2014, the FASB issued ASU No. 2014&#8209;09, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, which supersedes the revenue recognition requirements in ASC 605, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue Recognition</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, FASB issued ASU No. 2015&#8209;14, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, which effectively delayed the adoption date by one year, to an effective date for public entities for annual and interim periods beginning after December 15, 2017. In March, April and May 2016, the FASB issued additional updates to the new revenue standard relating to reporting revenue on a gross versus net basis, identifying performance obligations and licensing arrangements, and narrow&#8209;scope improvements and practical expedients, respectively. The effective date of this additional update is the same as that of ASU 2014&#8209;09. The guidance permits the use of either a retrospective or cumulative effect transition method. The Company has not yet selected a transition method. The Company is still finalizing the analysis to quantify the adoption impact of the provisions of the new standard, but it does not currently expect to have a material impact on the financial position or results of operations. Based on the evaluation of its current collaboration agreement and associated revenue streams, most of the revenue will be recorded consistently under both the current and the new standard. The FASB has issued, and may issue in the future, interpretive guidance which may cause the Company&#8217;s evaluation to change. The Company believes it is following an appropriate timeline to allow for proper recognition, presentation and disclosure upon adoption effective the beginning of fiscal year 2018. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">There are no other recently issued accounting standards that apply to the Company or that are expected to have a material impact on results of operations, financial condition, or cash flows.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817873888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The fair value of our financial instruments reflects the amounts that we estimate we would receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose and recognize the fair value of our assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 1 &#8209; Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date;</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 2 &#8209; Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active;</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 3 &#8209; Inputs that are unobservable.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During the years presented, the Company has not changed the manner in which it values assets and liabilities that are measured at fair value using Level 3 inputs. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the years ended December 31, 2017 and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows (in thousands): </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Corporate notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">46,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">40,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Government notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,175</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,175</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">60,958</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">19,963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">40,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,808</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,808</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Corporate notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">26,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">7,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">18,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Government notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,193</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,193</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">41,109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">22,226</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">18,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company uses a market approach for determining the fair value of all its Level&#160;1 and Level&#160;2 money market funds and marketable securities. To value its money market funds, the Company values the funds at $1 stable net asset value, which is the market pricing convention for identical assets that the Company has the ability to access.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The investments are classified as available&#8209;for&#8209;sale securities. At December 31, 2017 and 2016, the balance in the Company&#8217;s accumulated other comprehensive income was comprised solely of activity related to the Company&#8217;s available&#8209;for&#8209;sale securities. There were no realized gains or losses recognized on the sale or maturity of available&#8209;for&#8209;sale securities for the years ended December 31, 2017 and 2016 and as a result, the Company did not reclassify any amounts out of accumulated other comprehensive income for the year. The Company has a limited number of available&#8209;for&#8209;sale securities in insignificant loss positions as of December 31, 2017 and 2016, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized cost for the investment at maturity. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table summarizes the available&#8209;for&#8209;sale securities (in thousands): </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Corporate notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">46,133</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">46,098</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Government notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">61,009</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">60,958</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,808</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,808</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Corporate notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">26,134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">26,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Government notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">41,135</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">41,109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812696400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheets Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheets Components</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Balance Sheets Components</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Accrued Expenses and Other Current Liabilities</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accrued personnel expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">273</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accrued clinical and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,559</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817936048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Commitments and Contingencies </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Legal Matters</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company&#8217;s industry is characterized by frequent claims and litigation, including claims regarding intellectual property. As a result, the Company may be subject to various legal proceedings from time to time. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Management is not aware of any pending or threatened litigation.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">License Agreement</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In December 2012, the Company entered into an exclusive worldwide royalty free license agreement with Merck Sharp &amp; Dohme Corp., or &#8220;Merck&#8221; for exclusive worldwide rights for the development and commercialization of serlopitant and two other NK</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">1</sub></font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8209;R antagonists in all human diseases, disorders or conditions, except for the treatment and prevention of nausea or vomiting. The Company paid Merck an upfront non&#8209;refundable, non&#8209;creditable licensing fee of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> dollars and issued to Merck shares of its common stock. In addition, the Company has agreed to make aggregate payments of up to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$25.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> dollars upon the achievement of specified development and regulatory milestones.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Future milestone payments are considered to be contingent consideration and will be accrued when the applicable milestone is achieved. Through December 31, 2017, no milestones have been achieved under the license agreement. </font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company conducts its operations using leased office facilities. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In September 2017, the Company entered into a lease agreement.&#160;The </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">30</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> month lease, beginning on October 1, 2017, provides approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> square feet of office space in Redwood City, California.&#160;Base annual rent is approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$55,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> per month, with annual increases.  The Company recognizes rent expense on a straight&#8209;line basis over the respective lease period.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Rent expense for the years ended December 31, 2017, 2016 and 2015 was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$400,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$208,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$7,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December&#160;31, 2017, total future minimum lease payments under our operating leases are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51020408163265%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">Year ending December 31:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">675</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total future minimum lease payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,504</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Indemnification</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As permitted under Delaware law and in accordance with the Company&#8217;s bylaws, the Company is required to indemnify its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of December 31, 2017.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">From time to time, we may have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812689824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Convertible Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December 31, 2017, the Company&#8217;s Certificate of Incorporation, as amended, authorized the Company to issue up to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">28,322,761</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares of convertible preferred stock, par value of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.001</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, of which </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> were designated Series A convertible preferred stock and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,106,583</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> are designated Series B convertible preferred stock, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,201,878</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares are designated Series C convertible preferred stock. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In July 2017, the Company issued </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,854,463</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares of Series C convertible preferred stock to investors at </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$4.26</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> per share with gross proceeds of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$50.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In January 2018, the Company completed its initial public offering (&#8220;IPO&#8221;) of shares of its common stock, pursuant to which the Company issued </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,050,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares of common stock, which includes </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,050,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares issued pursuant to the over-allotment option granted to its underwriters, and received net proceeds of approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$125.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, after deducting underwriting discounts, commissions and offering expenses. In connection with the completion of the Company's IPO, all shares of convertible preferred stock converted into </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9,629,405</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares of common stock.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company had outstanding convertible preferred stock as of the times set forth below as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares Issued and Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Aggregate Liquidation Preference</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,106,583</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,106,583</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">45,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,201,878</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,854,463</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">50,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">28,322,761</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">25,975,346</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">109,800</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares Issued and Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Aggregate Liquidation Preference</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,106,583</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,106,583</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">45,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,120,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,120,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">59,300</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Significant terms of the Series A, B and C convertible preferred stock as of December 31, 2017 (collectively, the &#8220;Preferred Stock&#8221;) are as follows:</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Liquidation Preference</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In the event of any liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, the holders of the then outstanding shares of Series A convertible stock and Series B convertible preferred stock and Series C convertible preferred stock are first entitled to receive the amount of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$3.19</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$4.26</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> per share, respectively plus all declared but unpaid dividends for such shares, prior and in preference to any distribution of any assets of the Company to the holders of the common stock. If, upon the occurrence of such event, the proceeds distributed among the holders of the Series A, B and C convertible preferred stock are insufficient to permit the full payment of the aforesaid preferential amounts to each holder the convertible preferred stock, then the entire proceeds legally available for distribution to the convertible preferred stock shall be distributed ratably among the holders of the Series A, B and C convertible preferred stock in proportion to the full preferential amount that each such holder of convertible preferred stock is otherwise entitled to receive.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Upon completion of the distributions required by the above&#8209;mentioned liquidation preferences, any remaining proceeds shall be distributed among the holders of Series B and C convertible preferred stock and common stock pro rata based on the number of shares of common stock held by each, assuming full conversion of the Series B and C convertible preferred stock to common stock at the then&#8209;effective conversion price for such shares.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Dividends</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The holders of shares of Series A, B and C convertible preferred stock are entitled to receive non&#8209;cumulative dividends, out of any assets legally available, prior and in preference to any declaration or payment of any dividend on the common stock, at the applicable dividend rate of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$80.00</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> per annum for each share of Series A convertible preferred stock, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.2552</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> per annum for each share of Series B convertible preferred </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">stock and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.3408</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> per share per annum for each share of Series C convertible preferred stock</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, all subject to adjustment from time to time for recapitalizations, payable when and if declared by the Company&#8217;s board of directors. The Company has never declared any dividends on its convertible preferred stock.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Voting</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The holder of each share of Series B and C convertible preferred stock are entitled to one vote for each share of common stock into which such preferred stock could then be converted and, with respect to such vote, such holder has full voting rights and powers equal to the voting rights and powers of the holders of common stock and is entitled to notice of any stockholders&#8217; meeting in accordance with the Company&#8217;s bylaws. The holders of shares of Series A convertible preferred stock do not have a right to vote, other than as required by Delaware law and for certain directors, as set forth below.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The holders of shares of Series A convertible preferred stock are entitled to elect </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">two</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> of the Company&#8217;s directors. The holders of Series B convertible preferred stock are entitled to elect </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">two</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> of the Company&#8217;s directors. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The holders of Series C convertible preferred stock are entitled to elect </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">one</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> of the Company&#8217;s directors. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The holders of outstanding common stock are entitled to elect </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">three</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> of the Company&#8217;s directors. The holders of convertible preferred stock and common stock, voting together as a single class, and not as separate series, and on an as converted basis, are entitled to elect any remaining directors of the Company, subject to the approval of the then serving members of the Company&#8217;s directors.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Conversion</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The holder of each share of convertible preferred stock has the option to convert each share of convertible preferred stock into such number of fully paid and nonassessable shares of common stock as is determined by dividing the applicable original issue price for such series by the applicable conversion price for such series in effect on the date the certificate is surrendered for conversion. Each share of convertible preferred stock shall automatically be converted into shares of common stock at the conversion rate at the time in effect for such series of convertible preferred stock immediately prior to the earlier of (i) sale of the Company&#8217;s common stock in a firm commitment underwritten public offering pursuant to a registration statement under the Securities Act of 1933, as amended, with gross proceeds of not less than </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$40.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> in the aggregate and an offering price to the public of no less than </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$17.21</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> per share, or (ii) upon the receipt by the Corporation of a written request or agreement of the holders of a majority of the outstanding Series A, B and C convertible preferred stock, voting together as a single class and on an as converted basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The conversion price of the convertible preferred stock was initially set at an amount equal to the issue price. The Series B and C convertible preferred stock conversion price is subject to adjustment for stock dividends, stock splits, re&#8209;capitalization and upon the occurrence of certain triggering events related to anti&#8209;dilution protection rights. In the event that a future preferred stock financing should occur at a price lower than the last preferred financing round, the conversion ratios of the existing preferred stock are changed to protect the ownership position of existing investors.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6609772624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December 31, 2017, the Company&#8217;s Certificate of Incorporation, as amended, authorizes the Company to issue </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">55,000,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.0001</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> par value common stock. Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when and if declared by the board of directors, subject to the prior rights of holders of all classes of preferred stock outstanding. The Company has never declared any dividends on common stock. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, there were&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">12,548,103</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;shares of common stock reserved&#160;available&#160;for issuance.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817872288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under the Company&#8217;s 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;), the Company may grant options to purchase common stock, restricted stock awards, or directly issue shares of common stock to employees, directors and consultants of the Company. During 2015, the Company&#8217;s board of directors and stockholders approved an increase to the shares available under the 2011 Plan to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,086,600</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During 2017, the Company&#8217;s board of directors and stockholders approved an increase to the shares available under the 2011 Plan to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,339,724</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">December&#160;31, 2017</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, there were&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;color:#000000;">411,772</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;shares of common stock available&#160;for issuance under the 2011 Plan. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Options may be granted at an exercise price per share of not less than </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">100%</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> of the fair market value at the date of grant. If an incentive stock option is granted to a stockholder holding </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10%</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> of the Company&#8217;s outstanding capitalization, then the purchase or exercise price per share must not be less than </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">110%</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> of the fair market value per share of common stock on the grant date. Options granted are exercisable over a maximum term of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10 years</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> from the date of grant and generally vest over a period of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">four years</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total stock&#8209;based compensation expense for employees and non&#8209;employees recognized in the statements of operations was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">660</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total stock&#8209;based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">1,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">573</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">At December 31, 2017, there was approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$7.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> of unamortized compensation expense, which was expected to be recognized over a weighted average period of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2.9</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> years.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">2011 Plan</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The table below summarizes stock option and restricted award activity under the 2011 Plan:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Number of Shares Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Weighted- Average Remaining Contractual Term (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Balances at January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">317,405</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">0.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:1px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Exercised </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(317,405</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">0.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Balances at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,485,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Balances at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,485,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.99</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9.32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,805</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,040,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:1px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Exercised </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(18,535</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Balances at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,506,926</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">8.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">24,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Includes early exercise of </font><font style="font-family:Trade Gothic;font-size:9.5pt;">317,405</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> options during the year ended </font><font style="font-family:Trade Gothic;font-size:9.5pt;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, of which </font><font style="font-family:Trade Gothic;font-size:9.5pt;">138,864</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic;font-size:9.5pt;">218,216</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> remain unvested as of December 31, 2017 and </font><font style="font-family:Trade Gothic;font-size:9.5pt;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Upon vesting of restricted shares and exercise of options, the Company issues common stock from its authorized shares. During the years ended December 31, 2017, 2016 and 2015, the Company received </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$34,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$98,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> upon the exercise of stock options, respectively. There were </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">139,636</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">222,077</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares of early exercised restricted shares which have not vested at December 31, 2017 and 2016, respectively. As of December 31, 2017 and 2016, the Company had recorded a liability of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$43,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$68,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively for the early exercise of stock options, recorded as other current liabilities and other non&#8209;current liabilities. When options are subject to the Company&#8217;s repurchase right, the Company may buy back any unvested shares at their original exercise price in the event of an employee&#8217;s termination prior to full vesting.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The aggregate grant date fair value of employee options vesting during the years ended December 31, 2017, 2016 and 2015 was approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$539,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$182,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively. The aggregate intrinsic value of shares exercised during the year ended December 31, 2017 and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$209,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">zero</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The weighted average grant date fair value of stock options granted was </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$5.56</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1.79</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.15</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> per share during the years ended December 31, 2017, 2016, and 2015, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">There were </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">no</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares exercised in the year ended </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Stock Awards Granted to Employees and Directors</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock&#8209;based compensation expense is based on the grant date fair value. The Company recognizes compensation expense for all stock&#8209;based options and restricted awards on a straight&#8209;line basis over the requisite service period of the awards, which is generally the option vesting term of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">four</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> years. Stock&#8209; based compensation expense related to awards granted to employees and directors for the years ended December 31, 2017, 2016 and 2015 was approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$791,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$314,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> an </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option valuation model. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. Industry peers consist of several public companies in the biotechnology industry with comparable characteristics, including clinical trials progress and therapeutic indications.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The expected term of the options is based on the average period the stock options are expected to remain outstanding. As the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior, the expected term is calculated as the midpoint between the weighted-average vesting term and the contractual expiration period also known as the simplified method. The risk-free rate is based on U.S. Treasury zero coupon issues with remaining terms consistent with the expected terms of the stock options, as determined at the time of grant. To date, the Company has not declared or paid any cash dividends and does not have any plans to do so in the future. Therefore, the Company used an expected divided yield of zero.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In addition to the assumptions used in the Black&#8209;Scholes valuation model, the Company must also estimate a forfeiture rate to calculate the stock&#8209;based compensation for its equity awards. The Company will continue to use judgment in evaluating the assumptions related to the Company&#8217;s stock&#8209;based compensation on a prospective basis. As the Company continues to accumulate additional data, it may have refinements to its estimates, which could materially impact the Company&#8217;s future stock&#8209;based compensation expense. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following assumptions were used to calculate the fair value of awards granted to employees and directors during the years indicated:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">6.0 - 6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4.6 - 6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">3.1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">75% - 100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">68% - 74%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">74%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Risk&#8209;free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">1.9% - 2.3%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.3% - 2.1%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.0%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Dividend yield</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Stock-Based Compensation for Non-employees</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock&#8209;based compensation expense related to stock awards granted to non&#8209;employees is recognized as the awards vest. The Company believes that the fair value of the stock&#8209;based awards granted is more reliably measurable than the fair value of the services received. The fair value of stock awards granted is calculated using the Black&#8209;Scholes option valuation model. Stock&#8209; based compensation expense related to awards granted to non&#8209;employees for the years ended December 31, 2017, 2016 and 2015 was approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$661,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$259,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$64,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The fair values of common stock awards granted to non&#8209;employees were calculated using the following assumptions for the periods presented:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">8.3 - 10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9.3 - 10.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.0 - 1.8</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">74% - 100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">84% - 86%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">62% - 74%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Risk&#8209;free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">2.1% - 2.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.6% - 2.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">0.5% - 0.7%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Dividend yield</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817928336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Net Loss per Share Attributable to Common Stockholders</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net loss attributable to common stockholders, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(29,076</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(14,068</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Weighted&#8209;average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,285,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,280,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,060,918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Less: weighted&#8209;average common shares subject to repurchase</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(177,421</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(292,925</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(325,770</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Weighted&#8209;average common shares used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,108,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4,987,133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4,735,148</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net loss per share attributable to common stockholders:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(5.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2.82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(0.97</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:60%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Convertible preferred stock issuable upon conversion to common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9,629,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,234,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,234,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Outstanding common stock subject to repurchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">139,636</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">222,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;">324,355</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,506,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,485,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock options available for issuance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">411,772</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">198,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,684,110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">12,687,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">7,140,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">7,243,265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817829248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company did not record a provision or benefit for income taxes during the years ended December 31, 2017, 2016 and 2015.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following is a reconciliation of the statutory federal income tax rate to the Company&#8217;s effective tax rate:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:624px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:244px;" rowspan="1" colspan="1"></td><td style="width:107px;" rowspan="1" colspan="1"></td><td style="width:15px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:107px;" rowspan="1" colspan="1"></td><td style="width:15px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:108px;" rowspan="1" colspan="1"></td><td style="width:15px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Statutory Rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">State Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Permanent Differences</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">General Business Credits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Change in Valuation Allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(36</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Tax Reform - Tax Rate Change</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Deferred Tax Assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">NOLs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10,458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Depreciation and Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">226</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">362</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock&#8209;Based Compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research &amp; Development Credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,063</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">586</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">233</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Deferred Revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Other Accruals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total Deferred Tax Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Valuation Allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(14,993</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(11,631</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(6,621</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net Deferred Tax Assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-top:0px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-top:0px;text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-top:0px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-top:0px;text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-top:0px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-top:0px;text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The net change in the total valuation allowance for the years ended December 31, 2017, 2016 and 2015 was an increase of approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$3.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$5.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1.9 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December 31, 2017 and 2016, the Company had net operating loss carryforwards for federal income tax purposes of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$44.3 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$28.2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively which expire beginning in the year 2031 and federal research and development tax credits of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$2.1 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively which expire beginning in the year 2031.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December 31, 2017 and 2016, the Company had net operating loss carryforwards for state income tax purposes of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$15.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$15.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively which expire beginning in the year 2031 and state research and development tax credits of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.9 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.4 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, respectively which do not expire. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Federal and state tax laws impose substantial restrictions on the utilization of the net operating loss and credit carryforwards in the event of an ownership change as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&#8217;s ability to utilize these carryforwards may be limited as a result of such ownership change. Such a limitation could result in the expiration of carryforwards before they are utilized.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company has adopted ASC 740-10, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Accounting for Uncertainty in Income Taxes</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, that prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&#8217;s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction of the provision for income taxes in the period that such determination is made. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December 31, 2017 the Company had  </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">no</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> accrued interest and penalties related to uncertain tax positions.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company filed US and California tax returns with varying statues of limitations. The federal and California tax years from 2011 to 2017 remain open to examination due to the carryover of unused net operating losses and tax credits. The Company does not expect any material changes to the estimated amount of liability associated with its uncertain tax positions within the next 12 months.</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Uncertain Tax Positions</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table summarizes the activity related to unrecognized tax benefits (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">For the year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Tax Benefits:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Unrecognized Benefit &#8209; beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Gross Increases(Decreases) &#8209; prior period tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Gross Increases(Decreases) &#8209; current period tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">515</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">136</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total Unrecognized Benefit &#8209; end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Tax Reform</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 34% to 21% (the &#8220;Rate Reduction&#8221;) effective for tax years beginning after December 31, 2017. The Company reduced deferred tax assets at December 31, 2017 for the effect of the Rate Reduction. The Rate Reduction did not impact the Company's provision for income taxes for 2017 due to the full valuation allowance on deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. The Company determined that </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$7.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> of the reduction in deferred tax assets resulting from Rate Reduction was both provisional and a reasonable estimate at December 31, 2017. Additionally, the Company is still in the process of analyzing certain provisions of the Act including the application of new executive compensation limitation provisions under Internal Revenue Section 162(m). These items are subject to revisions from further analysis of the Tax Act and interpretation of any additional guidance issued by the U.S. Treasury Department, IRS, FASB, and other standard-setting and regulatory bodies.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817750096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">From 2011 through 2016, the Company has operated with significant consulting and management services provided by Velocity Pharmaceutical Development, LLC (&#8220;VPD&#8221;). Development services fees paid to VPD under the Development Services Agreement were </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$1.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> for the years ended December 31, 2016 and 2015, respectively. The Company also reimbursed VPD for consulting, travel and other expenses incurred on our behalf. As of December 31, 2017 and 2016, the Company did not have any outstanding liabilities to VPD. Several managing directors of VPD have served as officers and directors of the Company. David Collier, M.D., a former member of the Company&#8217;s board of directors, is the Chief Executive Officer of VPD, and Xiaoming Zhang, Ph.D., our Senior Vice President, Non&#8209;Clinical and Pharmaceutical Development, is a Venture Partner of VPD.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817931088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On January 8, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2018, the Company effected a reverse split of shares of the Company&#8217;s common stock at a ratio of 1-for-</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2.6975</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> pursuant to an amendment to the amended and restated certificate of incorporation approved by the Company&#8217;s board of directors and stockholders. The par value and the authorized</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">shares of the common stock were not adjusted as a result of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse split for all periods presented, and the conversion ratio of the preferred stock was adjusted accordingly. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company adopted a 2018 Omnibus Incentive Plan, or 2018 Plan, effective on January 23, 2018. The 2018 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights and other stock and cash-based awards (including annual cash incentives and long-term cash incentives). The Company has reserved for issuance pursuant to awards under the 2018 Plan, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,000,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company adopted a 2018 Employee Stock Purchase Plan, or ESPP, effective on January 23, 2018. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The ESPP will enable eligible employees of the Company and designated affiliates to purchase shares of common stock at a discount following its effectiveness. The Company has reserved </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">325,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares of common stock for issuance under the ESPP.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In January 2018, the Company completed its initial public offering (&#8220;IPO&#8221;) of shares of its common stock, pursuant to which the Company issued </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,050,000</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares of common stock and received net proceeds of approximately </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$125.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, after deducting underwriting discounts, commissions and offering expenses. In connection with the completion of the Company's IPO, all shares of convertible preferred stock converted into </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9,629,405</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> shares of common stock.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6662037664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Unaudited Quarterly Financial Data<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Unaudited Quarterly Financial Data</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Selected Unaudited Quarterly Financial Data</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following tables show a summary of the Company&#8217;s unaudited quarterly financial data for each of the four quarters of 2017 and 2016 (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="30" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">June 30,</font></div><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#160;2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Collaboration and service revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">2,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">909</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">12,252</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">9,244</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">6,675</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">6,004</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(9,277</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(8,172</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(6,153</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(5,474</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Basic and diluted net loss per common share (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(1.59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(1.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="30" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">June 30,</font></div><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#160;2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Collaboration and service revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">5,374</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">3,699</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">3,636</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">2,297</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(4,836</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(3,398</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(3,562</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(2,272</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Basic and diluted net loss per common share (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(0.96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(0.68</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(0.72</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(0.43</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Basic and diluted net loss per common share are computed independently for each of the quarters presented. Therefore, the sum of quarterly basic and diluted per share information may not equal annual basic and diluted net loss per common share.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815440928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Reverse Stock Split</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On January 8, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2018, the Company effected a reverse split of shares of the Company&#8217;s common stock at a ratio of 1-for-</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2.6975</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> pursuant to an amendment to the amended and restated certificate of incorporation approved by the Company&#8217;s board of directors and stockholders. The par value and the authorized</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">shares of the common stock were not adjusted as a result of the reverse split. All issued and outstanding common stock share and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse split for all periods presented, and the conversion ratio of the preferred stock was adjusted accordingly. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Segments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company operates in </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">one</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long&#8209;lived assets are maintained in the United States of America. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Preparation of financial statements in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, stock&#8209;based compensation expense, the resolution of uncertain tax positions and valuation allowance, recovery of long&#8209;lived assets and accruals for research and development costs. Management bases its estimates on historical experience on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Cash and Cash Equivalents </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Cash and cash equivalents are stated at fair value. Cash equivalents include only securities having an original maturity of three months or less at the time of purchase. The Company limits its credit risk associated with cash and cash equivalents by placing its investments with an institution it believes is highly creditworthy and with highly rated money market funds. As of December&#160;31, 2017 and 2016, cash and cash equivalents consisted of bank deposits, cash and investments in money market funds.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investment Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Investment Securities </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company classifies its investment securities as available&#8209;for&#8209;sale. Those investments with maturities less than 12&#160;months at the date of purchase are considered short&#8209;term investments. Those investments with maturities greater than 12&#160;months at the date of purchase are considered long&#8209;term investments. The Company&#8217;s investment securities classified as available&#8209;for&#8209;sale are recorded at fair value based upon quoted market prices at period end. Unrealized gains and losses, deemed temporary in nature, are reported as a separate component of comprehensive income or loss. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the corresponding establishment of a new cost basis for the security. Premiums (discounts) are amortized (accreted) over the life of the related security as an adjustment to yield using the straight&#8209;line interest method. Dividend and</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Property and Equipment, Net</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Property and equipment are stated at cost and depreciated using the straight&#8209;line method over the estimated useful lives of the assets, generally between </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">three</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">five</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> years. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in operations in the period realized. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The carrying amounts of the Company&#8217;s financial instruments, which include cash, accounts payable and accrued liabilities and other current liabilities, and deferred revenue approximate their fair values due to their short maturities. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents and investments. As of December&#160;31, 2017 and 2016, the majority of our cash, cash equivalents and investments are held by </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">one</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> U.S. financial institution in excess of federally insured limits. We invest cash in excess of our current needs in United States Treasury and government agency securities, highly&#8209;rated short or medium&#8209;term debt securities and money market funds and, by policy, diversify our investments to limit the amount of credit exposure. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company has an investment policy which limits the Company to investing in highly rated corporate and government notes, and no individual investment may comprise more than </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5%</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> of the total portfolio</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">accounts for income taxes under the asset and liability method which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company&#8217;s assets and liabilities and their financial statement reported amounts. Management makes estimates, assumptions and judgments to determine the Company&#8217;s provision for income taxes and also for deferred tax assets and liabilities, and any valuation allowances recorded against the Company&#8217;s deferred tax assets. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and to the extent the Company believes that recovery is not more likely than not, the Company must establish a valuation allowance.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">has adopted ASC 740-10, Accounting for Uncertainty in Income Taxes, that prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in the Company&#8217;s income tax return, and also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research and development costs are expensed as incurred. Substantially all of our research and development expenses consist of expenses incurred in connection with the development of serlopitant. These expenses include certain payroll and personnel expenses including stock&#8209;based compensation expense, consulting costs, contract manufacturing costs, and fees paid to clinical research organizations, or CROs, to conduct research and development. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized and recognized as an expense as the goods are delivered or the related services are performed. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company estimates non&#8209;clinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage non&#8209;clinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Patent Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Patent Costs</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company has no historical data to support a probable future economic benefit for the arising patent applications, filing and prosecution costs. Therefore, patent costs are expensed as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company recognizes rent expense on a straight&#8209;line basis over the non&#8209;cancellable term of the operating lease.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company measures and recognizes compensation expense for all stock&#8209;based awards made to employees, directors and non&#8209;employees, based on estimated fair values recognized using the straight&#8209;line method over the requisite service period.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The fair value of options to purchase common stock granted to employees is estimated on the grant date using the Black&#8209;Scholes option valuation model. The calculation of stock&#8209;based compensation expense requires that the Company make certain assumptions and judgments about a number of complex and subjective variables used in the Black&#8209;Scholes model, including the expected term, expected volatility of the underlying common stock, risk&#8209;free interest rate, as well as estimating future forfeitures of unvested stock options. To the extent actual forfeiture results differ from the estimates, the difference will be recorded as a cumulative adjustment in the period the estimates are revised. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company accounts for options issued to non&#8209;employees using the Black&#8209;Scholes option valuation model and is measured and recognized as the stock options are earned.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Convertible Preferred Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Convertible Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company recorded the convertible preferred stock at fair value on the dates of issuance, net of issuance costs. The convertible preferred stock is recorded outside of stockholders&#8217; equity because, in the event of certain deemed liquidation events considered not solely within the Company&#8217;s control, such as a merger, acquisition and sale of all or substantially all of the Company&#8217;s assets, the convertible preferred stock will become redeemable at the option of the holders. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">All outstanding convertible preferred stock converted into common stock in January 2018 upon the effectiveness of the IPO.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Comprehensive income (loss) is defined as the change in equity of the Company during a period from transactions and other events and circumstances excluding transactions resulting from investments and distributions to owners. Comprehensive loss consists of the net loss and changes in accumulated other comprehensive income, which are comprised of unrealized gains (losses) on available&#8209;for&#8209;sale investments.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">To date, the Company&#8217;s clinical drug candidates have not been approved for sale by the FDA and the Company has not generated any revenue from product sales. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On August 10, 2016, the Company entered into a license and collaboration agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd., together referred to as &#8220;JT Torii&#8221;, which is referred to as the &#8220;Collaboration Agreement&#8221;. Under the Collaboration Agreement, the Company granted to JT Torii the rights to develop and commercialize products containing serlopitant in Japan for the treatment of diseases and conditions other than nausea or vomiting. In exchange, JT Torii paid an upfront, non&#8209;refundable payment of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$11.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. In addition, the Company is entitled to receive aggregate payments of up to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$28.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> upon the achievement of specified development and regulatory milestones, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$15.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> upon the achievement of a commercial milestone, as well as tiered royalties from the mid-single digits up to the mid&#8209;teens on sales of licensed products in Japan. The Company&#8217;s performance obligations under the license agreement includes the transfer of intellectual property rights in the form of licenses, obligations to participate on certain development and/or commercialization committees with the collaboration partners and supply manufactured drug product for clinical trials. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company recognizes revenue pursuant to the Collaboration Agreement in connection with the clinical development and commercialization of products covered by the collaboration, including non-refundable upfront license fees, contingent consideration payments based on the achievement of defined collaboration objectives and royalties on sales of commercialized products. To date, the Company has not generated or recognized revenue from sales of its product candidates.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Revenue from the Collaboration Agreement is recognized when </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(i)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">persuasive evidence of an arrangement exists, </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(ii)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">transfer of technology has been completed, services have been performed or products have been delivered, </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(iii)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">the fee is fixed and determinable, and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(iv)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">collection is reasonably assured. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company evaluates revenue agreements with multiple&#8209;elements in accordance with ASC 605-25 </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue Recognition - Multiple Element Arrangements</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. The Company identifies the deliverables included within the agreement and evaluates which deliverables represent separate units of accounting based on the achievement of certain criteria including whether the deliverable has stand&#8209;alone value. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Upfront payments for licenses are evaluated to determine if the licensee can obtain standalone value from the license separate from the value of the </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">obligations to participate on certain development and/or commercialization committees with the collaboration partners and supply manufactured drug product for clinical trials</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> in the arrangement to be provided by the Company. The Company is reimbursed by JT Torii for the non-commercial supplies of serlopitant at the same rate as charged by the third party manufacturer, which does not include a significant and incremental discount to JT Torii. The assessment of multiple-element arrangements also requires judgment in order to determine the allocation of revenue to each deliverable and the appropriate period of time over which the revenue should be recognized. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under the Collaboration Agreement, the Company has determined that the license does not have standalone value separate from the research and development services because </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">JT Torii cannot resell such license on a standalone basis or use the license with its available resources to obtain any economic value without the Company&#8217;s participation. T</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">he license and the services are combined as one unit of accounting and upfront payments are recorded initially as deferred revenue in the balance sheet. Revenue is then recognized on a straight-line basis over an estimated performance period that is consistent with the term of performance obligations, unless the Company determines there is a discernible pattern of performance other than straight-line, in which case the Company uses a proportionate performance method to recognize the revenue over the estimated performance period. The Company is recognizing the upfront fee on a straight-line basis over the initial period of performance of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">six</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> years, which represents the estimated development period in the territories based on the initial development plan managed by the joint steering committee. </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The term of the agreement is through the expiration of the patents associated with serlopitant.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any changes in estimated periods of performance on a prospective basis.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">At the inception of each agreement that includes milestone payments, including the Collaboration Agreement, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. Non&#8209;refundable payments that are contingent upon achievement of a substantive milestone are recognized in their entirety in the period in which the milestone is achieved, assuming all other revenue recognition criteria are met. Other contingent payments in which a portion of the milestone consideration is refundable or adjusts based on future performance or non&#8209;performance (e.g., through a penalty or claw&#8209;back provision) are not considered to relate solely to past performance, and therefore, not considered substantive. Amounts that are not recognized as revenue due to the uncertainty as to whether they will be retained or because they are expected to be refunded are recorded as a liability. The Company recognizes non&#8209;substantive milestone payments over the remaining estimated period of performance once the milestone is achieved. Contingent payments associated with the achievement of specific objectives in certain contracts that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are recognized as revenue upon achievement of the objective, as long as there are no undelivered elements remaining and no continuing performance obligations by the Company, assuming all other revenue recognition criteria are met. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Under the Collaboration Agreement, the Company is entitled to receive aggregate payments of up to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$28.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> upon the achievement of specified development and regulatory milestones, and </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$15.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> upon the achievement of a commercial milestone. Two of the milestones, which amount to </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$2 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> each, relate to the preparation of an IND for submission to regulatory authorities in the territory are considered substantive given that they are triggered by the Company&#8217;s performance relative to the achievement of pre-specified, &#8220;at risk&#8221; milestone events, including the submission of all completed clinical trials data packages and the validation of the manufacturing process. All other milestones, which amount to an aggregate of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$24.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, are considered non-substantive because the milestone is dependent upon the performance of the collaboration partner rather than the Company. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#8217;s balance sheets. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, current portion. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Expenses related to the collaboration agreement are recorded as a component of research and development in the statement of operations as incurred, and to date have been immaterial.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During the fourth quarter of 2017, the Company achieved a substantive milestone related to the validation of the manufacturing process under the Collaboration Agreement, and recognized revenues of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$2.0 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">On September 1, 2017, the Company entered into a separate services agreement with JT Torii to provide research and development services, including regulatory, chemistry and manufacturing support and related materials that is distinct from the original Collaboration Agreement. The Company evaluated the new services agreement and determined that the research and materials delivered to JT Torii represents a separate earnings process that provides standalone value to JT Torii. The fees received under the services agreement will be recognized as and when such services are performed by the Company and JT Torii consumes the benefits of those services. The Company has no obligation to provide services unless requested by JT Torii and agreed to by us. The Company is eligible to receive reimbursement of estimated costs incurred and payment for research services performed directly by the Company at agreed upon rates. During the year ended December 31, 2017, the Company recognized revenue of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.8 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and recorded expenses of </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$0.5 million</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> as research and development expense in the statement of operations related to the new services agreement. The services agreement terminates upon the termination of the Collaboration Agreement or by mutual agreement of the parties.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share of Common Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Net Loss per Share of Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted&#8209;average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted&#8209;average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock and common stock options are considered to be potentially dilutive securities. Because the Company has reported a net loss for the years ended December&#160;31, 2017, 2016 and 2015, diluted net loss per common share is the same as basic net loss per common share for those periods. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In November 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016&#8209;18,&#160;</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. The update requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016&#8209;18 is effective for public entities for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In March 2016, the FASB issued ASU 2016&#8209;09, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Improvements to Employee Share&#8209;Based Payment Accounting</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> as part of its simplification initiative, which involves several aspects of accounting for share&#8209;based payment transactions, including the income tax effects, statutory withholding requirements, forfeitures and classification on the statement of cash flows. The standard is effective for companies for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years with early adoption permitted. The Company adopted this standard as of January 1, 2017, and there was no impact to the Company&#8217;s financial statements as a result of the adoption. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In February 2016, the FASB issued ASU 2016&#8209;02, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Leases</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight&#8209;line basis over the term of the lease, respectively. A lessee is also required to record a right&#8209;of&#8209;use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. ASC 842 supersedes the previous leases standard, ASC 840 </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Leases</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In January 2016, the FASB issued ASU 2016&#8209;01, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, which addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. ASU 2016&#8209;01 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In November 2015, the FASB issued ASU 2015&#8209;17, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> to simplify the presentation of deferred income taxes. The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. We have elected to early adopt ASU 2015&#8209;17 as of the beginning of our fourth quarter ended December&#160;31, 2015 on a prospective basis. There was no impact to the balance sheet amounts as a result of early adoption.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In August 2014, the FASB issued ASU 2014&#8209;15 related to Presentation of Financial Statements &#8209; </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Going Concern (Subtopic 205&#8209;40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. This update provides guidance about management&#8217;s responsibilities in evaluating an entity&#8217;s going concern uncertainties, and about the timing and content of related footnote disclosures. Under this amended guidance, an entity&#8217;s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. This update is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company adopted this standard in 2016 and there was no impact on the financial position, results of operations or related financial statement disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">In May 2014, the FASB issued ASU No. 2014&#8209;09, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, which supersedes the revenue recognition requirements in ASC 605, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue Recognition</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, FASB issued ASU No. 2015&#8209;14, </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, which effectively delayed the adoption date by one year, to an effective date for public entities for annual and interim periods beginning after December 15, 2017. In March, April and May 2016, the FASB issued additional updates to the new revenue standard relating to reporting revenue on a gross versus net basis, identifying performance obligations and licensing arrangements, and narrow&#8209;scope improvements and practical expedients, respectively. The effective date of this additional update is the same as that of ASU 2014&#8209;09. The guidance permits the use of either a retrospective or cumulative effect transition method. The Company has not yet selected a transition method. The Company is still finalizing the analysis to quantify the adoption impact of the provisions of the new standard, but it does not currently expect to have a material impact on the financial position or results of operations. Based on the evaluation of its current collaboration agreement and associated revenue streams, most of the revenue will be recorded consistently under both the current and the new standard. The FASB has issued, and may issue in the future, interpretive guidance which may cause the Company&#8217;s evaluation to change. The Company believes it is following an appropriate timeline to allow for proper recognition, presentation and disclosure upon adoption effective the beginning of fiscal year 2018. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">There are no other recently issued accounting standards that apply to the Company or that are expected to have a material impact on results of operations, financial condition, or cash flows.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:5px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The fair value of our financial instruments reflects the amounts that we estimate we would receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). We disclose and recognize the fair value of our assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 1 &#8209; Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that we have the ability to access at the measurement date;</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 2 &#8209; Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active;</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Level 3 &#8209; Inputs that are unobservable.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">During the years presented, the Company has not changed the manner in which it values assets and liabilities that are measured at fair value using Level 3 inputs. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in debt and equity securities that have readily determinable fair values (marketable securities). At a minimum, the disclosure might address accounting policies for investments classified as trading, available for sale, or held to maturity and may include how the entity determines whether impairments of available for sale or held to maturity investments are other than temporary, how the fair values of the entity's securities are determined, and the entity's accounting treatment for transfers between investment categories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6381980&amp;loc=d3e87707-122711<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6403650&amp;loc=d3e20905-112640<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21459-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812577008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Assets and Liabilities Carried at Fair Value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows (in thousands): </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Corporate notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">46,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">40,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Government notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,175</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,175</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">60,958</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">19,963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">40,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Fair Value Measurements Using</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,808</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,808</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Corporate notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">26,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">7,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">18,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Government notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,193</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,193</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">41,109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">22,226</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">18,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Summary of Available-for-sale Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table summarizes the available&#8209;for&#8209;sale securities (in thousands): </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">8,685</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Corporate notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">46,133</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">46,098</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Government notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">61,009</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">60,958</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,808</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,808</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Corporate notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">26,134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">26,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Government notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">41,135</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">41,109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815582256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheets Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accrued personnel expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">273</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Accrued clinical and development expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">245</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,559</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812715456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">As of December&#160;31, 2017, total future minimum lease payments under our operating leases are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.51020408163265%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;text-decoration:underline;">Year ending December 31:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">675</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total future minimum lease payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,504</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817884368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Convertible Preferred Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The Company had outstanding convertible preferred stock as of the times set forth below as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares Issued and Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Aggregate Liquidation Preference</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,106,583</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,106,583</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">45,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series C</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,201,878</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,854,463</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">50,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">28,322,761</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">25,975,346</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">109,800</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Shares Issued and Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Aggregate Liquidation Preference</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Series B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,106,583</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,106,583</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">45,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,120,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,120,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">59,300</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828669872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Share-based Compensation, Allocation of Recognized Period Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total stock&#8209;based compensation expense for employees and non&#8209;employees recognized in the statements of operations was as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">660</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total stock&#8209;based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">1,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">573</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The table below summarizes stock option and restricted award activity under the 2011 Plan:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Number of Shares Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Weighted-Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Weighted- Average Remaining Contractual Term (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Balances at January 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">317,405</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">0.31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:1px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Exercised </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(317,405</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">0.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Balances at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,485,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Balances at December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,485,132</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.99</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9.32</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3,805</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,040,329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:1px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Exercised </font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(18,535</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Balances at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,506,926</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">3.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">8.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">24,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:0px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Includes early exercise of </font><font style="font-family:Trade Gothic;font-size:9.5pt;">317,405</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> options during the year ended </font><font style="font-family:Trade Gothic;font-size:9.5pt;">December&#160;31, 2015</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">, of which </font><font style="font-family:Trade Gothic;font-size:9.5pt;">138,864</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> and </font><font style="font-family:Trade Gothic;font-size:9.5pt;">218,216</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"> remain unvested as of December 31, 2017 and </font><font style="font-family:Trade Gothic;font-size:9.5pt;">December&#160;31, 2016</font><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">. </font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mnlo_EmployeesandDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following assumptions were used to calculate the fair value of awards granted to employees and directors during the years indicated:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">6.0 - 6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4.6 - 6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">3.1</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">75% - 100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">68% - 74%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">74%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Risk&#8209;free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">1.9% - 2.3%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.3% - 2.1%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.0%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Dividend yield</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mnlo_NonemployeeMember', window );">Non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The fair values of common stock awards granted to non&#8209;employees were calculated using the following assumptions for the periods presented:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Expected term (in years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">8.3 - 10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9.3 - 10.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.0 - 1.8</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">74% - 100%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">84% - 86%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">62% - 74%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Risk&#8209;free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">2.1% - 2.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1.6% - 2.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">0.5% - 0.7%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Dividend yield</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mnlo_EmployeesandDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mnlo_EmployeesandDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mnlo_NonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mnlo_NonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812620032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net loss attributable to common stockholders, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(29,076</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(14,068</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(4,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Weighted&#8209;average common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,285,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,280,058</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,060,918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Less: weighted&#8209;average common shares subject to repurchase</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(177,421</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(292,925</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(325,770</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Weighted&#8209;average common shares used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,108,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4,987,133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4,735,148</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net loss per share attributable to common stockholders:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(5.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(2.82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(0.97</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:60%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Convertible preferred stock issuable upon conversion to common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">9,629,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,234,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,234,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Outstanding common stock subject to repurchase</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">139,636</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">222,077</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;background-color:#ffffff;">324,355</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock options outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,506,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,485,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock options available for issuance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">411,772</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">198,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,684,110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">12,687,739</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">7,140,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">7,243,265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817862288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following is a reconciliation of the statutory federal income tax rate to the Company&#8217;s effective tax rate:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:624px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:244px;" rowspan="1" colspan="1"></td><td style="width:107px;" rowspan="1" colspan="1"></td><td style="width:15px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:107px;" rowspan="1" colspan="1"></td><td style="width:15px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:108px;" rowspan="1" colspan="1"></td><td style="width:15px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Statutory Rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">State Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Permanent Differences</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">General Business Credits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Change in Valuation Allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(36</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Tax Reform - Tax Rate Change</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred tax assets are as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Deferred Tax Assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">NOLs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">10,458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">5,992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Depreciation and Amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">226</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">362</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Stock&#8209;Based Compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Research &amp; Development Credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">2,063</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">586</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">233</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Deferred Revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">1,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Other Accruals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">98</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total Deferred Tax Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">14,993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">11,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">6,621</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Valuation Allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(14,993</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(11,631</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(6,621</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Net Deferred Tax Assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-top:0px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-top:0px;text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-top:0px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-top:0px;text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="padding-top:0px;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="padding-top:0px;text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following table summarizes the activity related to unrecognized tax benefits (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">For the year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;font-weight:bold;">Tax Benefits:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Unrecognized Benefit &#8209; beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Gross Increases(Decreases) &#8209; prior period tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Gross Increases(Decreases) &#8209; current period tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">515</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">136</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">20</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Total Unrecognized Benefit &#8209; end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6636109552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Unaudited Quarterly Financial Data (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summary of Unaudited Quarterly Financial Data</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">The following tables show a summary of the Company&#8217;s unaudited quarterly financial data for each of the four quarters of 2017 and 2016 (in thousands, except per share amounts):</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="30" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">June 30,</font></div><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#160;2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">March 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Collaboration and service revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">2,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">909</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">12,252</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">9,244</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">6,675</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">6,004</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(9,277</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(8,172</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(6,153</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(5,474</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Basic and diluted net loss per common share (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(1.80</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(1.59</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(1.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="30" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">September 30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="padding-top:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">June 30,</font></div><div style="padding-bottom:2px;text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">&#160;2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:8pt;font-weight:bold;">March 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Collaboration and service revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">450</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">5,374</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">3,699</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">3,636</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">2,297</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(4,836</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(3,398</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(3,562</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(2,272</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">Basic and diluted net loss per common share (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(0.96</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(0.68</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(0.72</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">(0.43</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-bottom:2px;padding-top:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:9.5pt;"><font style="font-family:Trade Gothic,sans-serif;font-size:9.5pt;">Basic and diluted net loss per common share are computed independently for each of the quarters presented. Therefore, the sum of quarterly basic and diluted per share information may not equal annual basic and diluted net loss per common share.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173487&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827562224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Formation and Business of the Company (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,277)<span></span>
</td>
<td class="num">$ (8,172)<span></span>
</td>
<td class="num">$ (6,153)<span></span>
</td>
<td class="num">$ (5,474)<span></span>
</td>
<td class="num">$ (4,836)<span></span>
</td>
<td class="num">$ (3,398)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
<td class="num">$ (2,272)<span></span>
</td>
<td class="num">$ (29,076)<span></span>
</td>
<td class="num">$ (14,068)<span></span>
</td>
<td class="num">$ (4,608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,247)<span></span>
</td>
<td class="num">(2,291)<span></span>
</td>
<td class="num">$ (4,183)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash, cash equivalents and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (59,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (30,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (59,191)<span></span>
</td>
<td class="num">$ (30,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (shares)</a></td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering, net</a></td>
<td class="nump">$ 125,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (shares)</a></td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember', window );">Convertible Stock Converted into Shares of Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Common shares issued upon conversion of convertible stock (shares)</a></td>
<td class="nump">9,629,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=mnlo_ConvertibleStockConvertedintoSharesofCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769150192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Reverse Stock Split (Details)<br></strong></div></th>
<th class="th"><div>Jan. 08, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Number of shares issued for every share converted in reverse stock split</a></td>
<td class="nump">0.3707<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6609104320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>segment </div>
<div>financial_institution</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>financial_institution</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits', window );">Number of financial institutions holding majority of Company cash and cash equivalents and investments in excess of federally insured limits | financial_institution</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum', window );">Individual investment limit as a percentage of the total investment portfolio (percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Individual Investment, Percent of Investment Portfolio, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_IndividualInvestmentPercentofInvestmentPortfolioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Financial Institutions Holding Majority of Company Cash and Investments in Excess of Federally Insured Limits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_NumberofFinancialInstitutionsHoldingMajorityofCompanyCashandInvestmentsinExcessofFederallyInsuredLimits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6661686160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of plant and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of plant and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827166560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Revenue Recognition (Details) - JT Torii - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mnlo_JTToriiMember', window );">Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodLineItems', window );"><strong>Revenue Recognition, Milestone Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CollaborativeAgreementUpfrontPaymentReceived', window );">Collaborative agreement, upfront payment received</a></td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod', window );">Collaborative arrangements, revenue recognition, initial performance period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mnlo_JTToriiMember', window );">Development and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodLineItems', window );"><strong>Revenue Recognition, Milestone Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds', window );">Collaborative arrangements, potential milestone proceeds</a></td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Amount of revenue recognized for each milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mnlo_JTToriiMember', window );">Commercial Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodLineItems', window );"><strong>Revenue Recognition, Milestone Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds', window );">Collaborative arrangements, potential milestone proceeds</a></td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mnlo_JTToriiMember', window );">Development and Regulatory Milestone, Preparation of Investigational New Drug Submission, Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodLineItems', window );"><strong>Revenue Recognition, Milestone Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds', window );">Collaborative arrangements, potential milestone proceeds</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mnlo_JTToriiMember', window );">Development and Regulatory Milestone, Preparation of Investigational New Drug Submission, Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodLineItems', window );"><strong>Revenue Recognition, Milestone Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds', window );">Collaborative arrangements, potential milestone proceeds</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mnlo_JTToriiMember', window );">Non-substantive Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodLineItems', window );"><strong>Revenue Recognition, Milestone Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds', window );">Collaborative arrangements, potential milestone proceeds</a></td>
<td class="nump">$ 24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_ResearchAndDevelopmentArrangementMember', window );">Research and Development Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodLineItems', window );"><strong>Revenue Recognition, Milestone Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development arrangement, contract to perform for others, compensation earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_CollaborativeAgreementUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_CollaborativeAgreementUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_CollaborativeArrangementsPotentialMilestoneProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements, Potential Milestone Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_CollaborativeArrangementsPotentialMilestoneProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements, Revenue Recognition, Initial Performance Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_CollaborativeArrangementsRevenueRecognitionInitialPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mnlo_JTToriiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mnlo_JTToriiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnlo_DevelopmentandRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnlo_DevelopmentandRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnlo_CommercialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnlo_CommercialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnlo_DevelopmentandRegulatoryMilestonePreparationofInvestigationalNewDrugSubmissionMilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnlo_NonsubstantiveMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnlo_NonsubstantiveMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828441264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 60,958<span></span>
</td>
<td class="nump">$ 41,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value Measurements | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">19,963<span></span>
</td>
<td class="nump">22,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value Measurements | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">40,995<span></span>
</td>
<td class="nump">18,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value Measurements | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Corporate notes | Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">46,098<span></span>
</td>
<td class="nump">26,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Corporate notes | Fair Value Measurements | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">5,103<span></span>
</td>
<td class="nump">7,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Corporate notes | Fair Value Measurements | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">40,995<span></span>
</td>
<td class="nump">18,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Corporate notes | Fair Value Measurements | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government notes | Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">6,175<span></span>
</td>
<td class="nump">11,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government notes | Fair Value Measurements | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">6,175<span></span>
</td>
<td class="nump">11,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government notes | Fair Value Measurements | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government notes | Fair Value Measurements | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">8,685<span></span>
</td>
<td class="nump">3,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">8,685<span></span>
</td>
<td class="nump">3,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value Measurements | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">8,685<span></span>
</td>
<td class="nump">3,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value Measurements | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Fair Value Measurements | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82895926&amp;loc=d3e24584-111560<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815541584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Available-for-Sale Securities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Money market funds, amortized cost</a></td>
<td class="nump">$ 10,206<span></span>
</td>
<td class="nump">$ 4,027<span></span>
</td>
<td class="nump">$ 43,808<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">61,009<span></span>
</td>
<td class="nump">41,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax', window );">Unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax', window );">Unrealized losses</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CashCashEquivalentsandAvailableforsaleSecurities', window );">Fair value</a></td>
<td class="nump">60,958<span></span>
</td>
<td class="nump">41,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateNoteSecuritiesMember', window );">Corporate notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">46,133<span></span>
</td>
<td class="nump">26,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, unrealized losses</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities, fair value</a></td>
<td class="nump">46,098<span></span>
</td>
<td class="nump">26,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">6,191<span></span>
</td>
<td class="nump">11,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, unrealized losses</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities, fair value</a></td>
<td class="nump">6,175<span></span>
</td>
<td class="nump">11,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Money market funds, amortized cost</a></td>
<td class="nump">8,685<span></span>
</td>
<td class="nump">3,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax', window );">Money market funds, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax', window );">Money market funds, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds, fair value</a></td>
<td class="nump">$ 8,685<span></span>
</td>
<td class="nump">$ 3,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_CashCashEquivalentsandAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents and Available-for-sale Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_CashCashEquivalentsandAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedGainbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents, Accumulated Gross Unrealized Loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_CashandCashEquivalentsAccumulatedGrossUnrealizedLossbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Available-for-sale Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_CashandCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateNoteSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateNoteSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826966080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued personnel expenses</a></td>
<td class="nump">$ 1,108<span></span>
</td>
<td class="nump">$ 273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_AccruedClinicalandDevelopmentExpenses', window );">Accrued clinical and development expenses</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 3,559<span></span>
</td>
<td class="nump">$ 581<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_AccruedClinicalandDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical and Development Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_AccruedClinicalandDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815546464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_OperatingLeaseMonthlyRentExpense', window );">Operating lease, monthly expense</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating lease, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 208,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mnlo_MerckMember', window );">Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">Licensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mnlo_DevelopmentandRegulatoryMilestonesMember', window );">Development and Regulatory Milestones | Merck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_CollaborativeArrangementsPotentialMilestonePayments', window );">Collaborative arrangements, potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=stpr_CA', window );">CALIFORNIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Leased office space, square footage | ft&#178;</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_CollaborativeArrangementsPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements, Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_CollaborativeArrangementsPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_OperatingLeaseMonthlyRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Rent Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_OperatingLeaseMonthlyRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredIndefiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mnlo_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mnlo_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mnlo_DevelopmentandRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mnlo_DevelopmentandRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767643984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Operating Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Year ending December 31:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2018</a></td>
<td class="nump">$ 656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">$ 1,504<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828273760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,322,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,120,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect', window );">Number of directors common shareholders are entitled to elect | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering', window );">Threshold proceeds of public stock offering of Company common shares that triggers automatic conversion of preferred convertible shares into common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering', window );">Threshold price per share in public stock offering of Company common shares that triggers automatic conversion of preferred convertible shares into common shares (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Preferred stock, liquiditiy preference per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_TemporaryEquityDividendRatePerDollarAmount', window );">Preferred stock, dividend per annum (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect', window );">Number of directors preferred shareholders are entitled to elect | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,106,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,106,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,106,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Preferred stock, liquiditiy preference per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_TemporaryEquityDividendRatePerDollarAmount', window );">Preferred stock, dividend per annum (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect', window );">Number of directors preferred shareholders are entitled to elect | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,201,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,854,463<span></span>
</td>
<td class="nump">11,854,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_TemporaryEquityIssuedPriceperShare', window );">Preferred shares issued, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Preferred stock, liquiditiy preference per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_TemporaryEquityDividendRatePerDollarAmount', window );">Preferred stock, dividend per annum (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect', window );">Number of directors preferred shareholders are entitled to elect | director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (shares) | shares</a></td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering, net | $</a></td>
<td class="nump">$ 125,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common shares issued upon conversion of convertible stock (shares) | shares</a></td>
<td class="nump">9,629,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (shares) | shares</a></td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Directors Common Shareholders are Entitled to Elect</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_NumberofDirectorsCommonShareholdersareEntitledtoElect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Directors Temporary Equity Holders are Entitled to Elect</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_NumberofDirectorsTemporaryEquityHoldersareEntitledtoElect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_TemporaryEquityDividendRatePerDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Dividend Rate, Per-Dollar-Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_TemporaryEquityDividendRatePerDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_TemporaryEquityIssuedPriceperShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Issued, Price per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_TemporaryEquityIssuedPriceperShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Terms of Conversion, Trigger, Minimum Pricer per Share in Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_TemporaryEquityTermsofConversionTriggerMinimumPricerperShareinPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Terms of Conversion, Trigger, Minimum Proceeds from Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_TemporaryEquityTermsofConversionTriggerMinimumProceedsfromPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreferencePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815191840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock - Convertible Preferred Stock Outstanding (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">25,975,346<span></span>
</td>
<td class="nump">14,120,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Preferred stock, liquidation value</a></td>
<td class="nump">$ 109,800<span></span>
</td>
<td class="nump">$ 59,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">28,322,761<span></span>
</td>
<td class="nump">14,120,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued (shares)</a></td>
<td class="nump">25,975,346<span></span>
</td>
<td class="nump">14,120,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Preferred stock, liquidation value</a></td>
<td class="nump">$ 14,300<span></span>
</td>
<td class="nump">$ 14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued (shares)</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">14,106,583<span></span>
</td>
<td class="nump">14,106,583<span></span>
</td>
<td class="nump">14,106,583<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Preferred stock, liquidation value</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">14,106,583<span></span>
</td>
<td class="nump">14,106,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued (shares)</a></td>
<td class="nump">14,106,583<span></span>
</td>
<td class="nump">14,106,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding (shares)</a></td>
<td class="nump">11,854,463<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Preferred stock, liquidation value</a></td>
<td class="nump">$ 50,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized (shares)</a></td>
<td class="nump">14,201,878<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock issued (shares)</a></td>
<td class="nump">11,854,463<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769069072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (shares)</a></td>
<td class="nump">55,000,000<span></span>
</td>
<td class="nump">36,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (shares)</a></td>
<td class="nump">12,548,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816277008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available under the Plan (shares)</a></td>
<td class="nump">12,548,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock&#8209;based compensation expense</a></td>
<td class="nump">$ 1,452<span></span>
</td>
<td class="nump">$ 573<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized compensation expense</a></td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unamortized compensation expense, recognition period</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Liability for early exercise of stock options</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate grant date fair value of options vested during the year</a></td>
<td class="nump">539<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate instrinsic value of shares exercised during the year</a></td>
<td class="nump">$ 209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in USD per share)</a></td>
<td class="nump">$ 5.56<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised during the year (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mnlo_EmployeesandDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock&#8209;based compensation expense</a></td>
<td class="nump">$ 791<span></span>
</td>
<td class="nump">$ 314<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mnlo_NonemployeeMember', window );">Non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock&#8209;based compensation expense</a></td>
<td class="nump">$ 661<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlo_A2011StockIncentivePlanMember', window );">2011 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available under the Plan (shares)</a></td>
<td class="nump">3,339,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,086,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuenace under the Plan (shares)</a></td>
<td class="nump">411,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised during the year (shares)</a></td>
<td class="nump">18,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlo_A2011StockIncentivePlanMember', window );">2011 Stock Incentive Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Option exercise price as a percent of fair value on grant date (percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Option vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlo_A2011StockIncentivePlanMember', window );">2011 Stock Incentive Plan | Incentive Stock Option Granted to Stockholder Holding 10% of the Company's Outstanding Capitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Option exercise price as a percent of fair value on grant date (percent)</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlo_A2011StockIncentivePlanMember', window );">2011 Stock Incentive Plan | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Early exercised restricted shares that had not vested</a></td>
<td class="nump">139,636<span></span>
</td>
<td class="nump">222,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock&#8209;based compensation expense</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock&#8209;based compensation expense</a></td>
<td class="nump">$ 660<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mnlo_EmployeesandDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mnlo_EmployeesandDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mnlo_NonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mnlo_NonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlo_A2011StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlo_A2011StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mnlo_IncentiveStockOptionGrantedtoStockholderHolding10oftheCompanysOutstandingCapitalizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827600848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option and Restricted Stock Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlo_A2011StockIncentivePlanMember', window );">2011 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balances, beginning (shares)</a></td>
<td class="nump">1,485,132<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">1,040,329<span></span>
</td>
<td class="nump">1,485,132<span></span>
</td>
<td class="nump">317,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares)</a></td>
<td class="num">(18,535)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(317,405)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balances, ending (shares)</a></td>
<td class="nump">2,506,926<span></span>
</td>
<td class="nump">1,485,132<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, exercise price per share (in USD per share)</a></td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, exercise price per share (in USD per share)</a></td>
<td class="nump">5.56<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, exercise price per share (in USD per share)</a></td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual term</a></td>
<td class="text">8 years 9 months 15 days<span></span>
</td>
<td class="text">9 years 3 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 24,033,000<span></span>
</td>
<td class="nump">$ 3,805,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mnlo_EarlyExercisedStockOptionsMember', window );">Early Exercised Stock Options | 2011 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(317,405)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested options included in early exercise (shares)</a></td>
<td class="nump">138,864<span></span>
</td>
<td class="nump">218,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlo_A2011StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlo_A2011StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mnlo_EarlyExercisedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mnlo_EarlyExercisedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828417424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Fair Value Assumptions for Director, Employee and Non-Employee Grants (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mnlo_EmployeesandDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum (percent)</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum (percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum (percent)</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum (percent)</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mnlo_EmployeesandDirectorsMember', window );">Employees and Directors | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mnlo_EmployeesandDirectorsMember', window );">Employees and Directors | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mnlo_NonemployeeMember', window );">Non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum (percent)</a></td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum (percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum (percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum (percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mnlo_NonemployeeMember', window );">Non-employees | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mnlo_NonemployeeMember', window );">Non-employees | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mnlo_EmployeesandDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mnlo_EmployeesandDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mnlo_NonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mnlo_NonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826784416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,076)<span></span>
</td>
<td class="num">$ (14,068)<span></span>
</td>
<td class="num">$ (4,608)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,076)<span></span>
</td>
<td class="num">$ (14,068)<span></span>
</td>
<td class="num">$ (4,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted&#8209;average common shares outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,285,542<span></span>
</td>
<td class="nump">5,280,058<span></span>
</td>
<td class="nump">5,060,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Less: weighted&#8209;average common shares subject to repurchase (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(177,421)<span></span>
</td>
<td class="num">(292,925)<span></span>
</td>
<td class="num">(325,770)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted&#8209;average number of common shares used to compute basic and diluted net loss per share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,108,121<span></span>
</td>
<td class="nump">4,987,133<span></span>
</td>
<td class="nump">4,735,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share attributable to common stockholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in USD per share)</a></td>
<td class="num">$ (1.80)<span></span>
</td>
<td class="num">$ (1.59)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (5.69)<span></span>
</td>
<td class="num">$ (2.82)<span></span>
</td>
<td class="num">$ (0.97)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816804624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders - Antidilutive Shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the calculation of EPS</a></td>
<td class="nump">12,687,739<span></span>
</td>
<td class="nump">7,140,987<span></span>
</td>
<td class="nump">7,243,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock issuable upon conversion to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the calculation of EPS</a></td>
<td class="nump">9,629,405<span></span>
</td>
<td class="nump">5,234,800<span></span>
</td>
<td class="nump">5,234,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnlo_OutstandingCommonStockSubjecttoRepurchaseMember', window );">Outstanding common stock subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the calculation of EPS</a></td>
<td class="nump">139,636<span></span>
</td>
<td class="nump">222,077<span></span>
</td>
<td class="nump">324,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnlo_OptionsOutstandingMember', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the calculation of EPS</a></td>
<td class="nump">2,506,926<span></span>
</td>
<td class="nump">1,485,132<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember', window );">Stock options available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from the calculation of EPS</a></td>
<td class="nump">411,772<span></span>
</td>
<td class="nump">198,978<span></span>
</td>
<td class="nump">1,684,110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnlo_OutstandingCommonStockSubjecttoRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnlo_OutstandingCommonStockSubjecttoRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnlo_OptionsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnlo_OptionsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mnlo_OptionsAvailableforFutureGrantunderStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816192128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State Tax</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent Differences</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">General Business Credits</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation Allowance</a></td>
<td class="num">(11.00%)<span></span>
</td>
<td class="num">(36.00%)<span></span>
</td>
<td class="num">(41.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax Reform - Tax Rate Change</a></td>
<td class="num">(24.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816948928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOLs</a></td>
<td class="nump">$ 10,404<span></span>
</td>
<td class="nump">$ 10,458<span></span>
</td>
<td class="nump">$ 5,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and Amortization</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock&#8209;Based Compensation</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research &amp; Development Credits</a></td>
<td class="nump">2,063<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred Revenue</a></td>
<td class="nump">1,791<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Other Accruals</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total Deferred Tax Assets</a></td>
<td class="nump">14,993<span></span>
</td>
<td class="nump">11,631<span></span>
</td>
<td class="nump">6,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">(14,993)<span></span>
</td>
<td class="num">(11,631)<span></span>
</td>
<td class="num">(6,621)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net Deferred Tax Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827207936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit', window );">Reduction in deferred tax assets resulting from the rate reduction</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">44,300,000<span></span>
</td>
<td class="nump">28,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Development Tax Credit | Federal Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Development Tax Credit | State Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Change in Deferred Tax Asset, Provisional Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mnlo_TaxCutsAndJobsActOf2017IncompleteAccountingChangeinDeferredTaxAssetProvisionalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mnlo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815044992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Uncertain Tax Positions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Benefit - beginning of period</a></td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross Increases(Decreases) &#8209; prior period tax positions</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross Increases(Decreases) &#8209; current period tax positions</a></td>
<td class="nump">515<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Benefit - end of period</a></td>
<td class="nump">$ 803<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814775680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=us-gaap_AffiliatedEntityMember', window );">Velocity Pharmaceutical Development, LLC | Development Services Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party expenses</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=us-gaap_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=us-gaap_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mnlo_DevelopmentServicesFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mnlo_DevelopmentServicesFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816883504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2018</div></th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 23, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,548,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Number of shares issued for every share converted in reverse stock split</a></td>
<td class="nump">0.3707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common shares issued upon conversion of convertible stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,629,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlo_A2018OmnibusIncentivePlanMember', window );">2018 Omnibus Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mnlo_A2018EmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlo_A2018OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlo_A2018OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mnlo_A2018EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mnlo_A2018EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812911600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Unaudited Quarterly Financial Data (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration and license revenue</a></td>
<td class="nump">$ 2,775<span></span>
</td>
<td class="nump">$ 909<span></span>
</td>
<td class="nump">$ 449<span></span>
</td>
<td class="nump">$ 449<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,582<span></span>
</td>
<td class="nump">$ 674<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">12,252<span></span>
</td>
<td class="nump">9,244<span></span>
</td>
<td class="nump">6,675<span></span>
</td>
<td class="nump">6,004<span></span>
</td>
<td class="nump">5,374<span></span>
</td>
<td class="nump">3,699<span></span>
</td>
<td class="nump">3,636<span></span>
</td>
<td class="nump">2,297<span></span>
</td>
<td class="nump">34,175<span></span>
</td>
<td class="nump">15,006<span></span>
</td>
<td class="nump">4,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Other income (expense), net</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,277)<span></span>
</td>
<td class="num">$ (8,172)<span></span>
</td>
<td class="num">$ (6,153)<span></span>
</td>
<td class="num">$ (5,474)<span></span>
</td>
<td class="num">$ (4,836)<span></span>
</td>
<td class="num">$ (3,398)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
<td class="num">$ (2,272)<span></span>
</td>
<td class="num">$ (29,076)<span></span>
</td>
<td class="num">$ (14,068)<span></span>
</td>
<td class="num">$ (4,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in USD per share)</a></td>
<td class="num">$ (1.80)<span></span>
</td>
<td class="num">$ (1.59)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
<td class="num">$ (0.96)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (5.69)<span></span>
</td>
<td class="num">$ (2.82)<span></span>
</td>
<td class="num">$ (0.97)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MA]]=V W&'NT_-KX)M@W\NHOV"U!+ P04    "  CA'Q,F5R<(Q &  "<)P
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MW;F^.?6ES^WHLOWUHG"';CB-^_/FLE]TN>CJT[07%EXWY-;_ U!+ P04
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M5$I+HY,MC,*S:?C'02F/NGM-S'O3=[W]0*O+T-$'X]^*]3]02P,$%     @
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M@'0!\AP@^@.4"U#G !7U!F@7H&\-,"[ W!H0NH#P:PRJ-R!R =$Y0/;W$+N
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MFED(&^P]1H-R/K,H--@1C &Y\VHS0-.<1.( XB:W ]#<;X7MQTC[T7R'L37
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M^3[8=EJSR?'8SR^(+<^X_ M02P,$%     @ (X1\3"W L$BT 0  T@,  !D
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MR\;^U\9X0"G)%8Y0BQ]L-B34/AQO\&S',1L-;[KI!['Y&Q>_ 5!+ P04
M"  CA'Q,"3'#>;0!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q]4V&/U" 0_2N$'W#LLCWOW+1-;L\83339G%$_L^VT)0=,!;H]_[U >[5J
MXQ=@AGEOW@Q#/J)]=AV )R]:&5?0SOO^R)BK.M#"W6 /)MPT:+7PP;0M<[T%
M42>05HSO=F^8%M+0,D^^LRUS'+R2!LZ6N$%K87^>0.%8T#U]=3S)MO/1P<J\
M%RU\ ?^U/]M@L86EEAJ,DVB(A::@#_OC*8OQ*>";A-&MSB16<D%\CL;'NJ"[
M* @45#XRB+!=X1&4BD1!QH^9DRXI(W!]?F5_GVH/M5R$@T=4WV7MNX+>4U)#
M(P;EGW#\ ',]MY3,Q7^"*Z@0'I6$'!4JEU92#<ZCGEF"%"U>IEV:M(_3#7\[
MP[8!? ;P!7"?\K I45+^3GA1YA9'8J?>]R(^\?[(0V^JZ$RM2'=!O O>:[F_
M.^3L&HGFF-,4P]<Q2P0+[$L*OI7BQ/^!\VWX85/A(<$/?RC,M@FR38(L$63_
M+7$KYO:O)&S54PVV3=/D2(6#29.\\BX#^\#3F_P.GZ;]L["M-(Y<T(>73?UO
M$#T$*;N;,$)=^&"+H:#Q\7@7SG8:L\GPV,\_B"W?N/P%4$L#!!0    ( ".$
M?$PA[2E'M $  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;'U3
M86_;(!#]*X@?4!+';:+(MM1TFC9IE:)6VSX3^VRC N<!CMM_7\"NYVW6O@!W
MW'OW[CBR <V+;0$<>552VYRVSG5'QFS9@N+V!CO0_J9&H[CSIFF8[0SP*H*4
M9,EF<\<4%YH66?2=39%A[Z30<#;$]DIQ\W8"B4-.M_3#\22:U@4'*[*.-_ ,
M[GMW-MYB,TLE%&@K4!,#=4[OM\=3&N)CP \!@UV<2:CD@O@2C*]53C=!$$@H
M76#@?KO" T@9B+R,7Q,GG5,&X/+\P?XYUNYKN7 +#RA_BLJU.3U04D'->^F>
M</@"4SVWE$S%?X,K2!\>E/@<)4H;5U+VUJ&:6+P4Q5_'7>BX#^/-;3K!U@')
M!$AFP"'F86.BJ/P3=[S(# [$C+WO>'CB[3'QO2F#,[8BWGGQUGNOQ79_E[%K
M()IB3F-,LHR9(YAGGU,D:RE.R3_P9!V^6U6XB_#='PKWZP3I*D$:"=+_EK@6
M<_@K"5OT5(%IXC194F*OXR0OO// WB?Q37Z'C]/^R$TCM"47=/YE8_]K1 =>
MRN;&CU#K/]AL2*A=..[]V8QC-AH.N^D'L?D;%^]02P,$%     @ (X1\3 @$
M91>_ @  ? L  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL=5;1CILP
M$/P5Q <<V) $3DFDRU55*[72Z:JVST[B).@ 4]M)KG]?8SB*[/%+L,WLS!I[
M)[N^"_FF+ISKZ+VI6[6)+UIWCTFB#A?>,/4@.MZ:-R<A&Z;-5)X3U4G.CC:H
MJ1.:ILND854;;]=V[45NU^*JZZKE+S)2UZ9A\N^.U^*^B4G\L?!:G2^Z7TBV
MZXZ=^0^N?W8OTLR2B>58-;Q5E6@CR4^;^(D\[FC6!UC$KXK?U6P<]5O9"_'6
M3[X>-W':9\1K?M ]!3./&W_F==TSF3S^C*3QI-D'SL<?[)_MYLUF]DSQ9U'_
MKH[ZLHF+.#KR$[O6^E7<O_!Q0XLX&G?_C=]X;>!])D;C(&IE?Z/#56G1C"PF
ME8:]#\^JM<_[\";/QC <0,< .@445B<9A&SFGYAFV[44]T@.'[]C_1F31VJ^
MS:%?M)_"OC/)*[-ZVY)5N4YN/=&(V0T8.L=,B,2P3Q(42>RH%TYQ> 8SS&QX
M-E?/5Y@@AP2Y)<CG!$7J;!%A IM<0)$%(*".",)D6&0)19: ('=$$&:!1590
M9 4(EHX(P@3.I( B!2 H'!&$*;%("45*GZ!T#QYA @=/4EQ!*:!PCQZ" F=/
M I5* (5[^A 4.'X"R_6)4$#A7@ ("MP @NN:9#[%<N7J %!9!'1P^1-0VZ5G
M<3[(_+,%=+ #$+^\:4I<'00*V"'!)D#\"J=IYNH@4![0P3Y _"*GZ<+50:!E
M0 =; 0%UOO#N@0^B:>B^83<@?JG3U/4<" J8#L5^0/U2I\2U'0@*_:MB/Z!^
MJ5/B^@X$!7R'8C^@?JE3XOH.! 5\AV(_H*#4<[=. 8@2][XEL^:GX?)LVSX5
M'<2UM3WG;'5J+9^H;9[^PX>^]#N3YZI5T5YHTX+91NDDA.8FE_3!U/+%M,+3
MI.8GW0]79BR'?G"8:-&-O6XR-=S;?U!+ P04    "  CA'Q,;1O;1<8!   W
M!   &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6QM5&&/G" 0_2N$'W H
MN]YM-VIR>TW3)FVRN:;M9U9')0=B =?KOR^@9^T>7X09WKPW,S#FD](OI@.P
MZ%6*WA2XLW8X$F*J#B0S=VJ WITT2DMFG:E;8@8-K Y!4A":)/=$,M[C,@^^
MLRYS-5K!>SAK9$8IF?YS J&F J?XS?',V\YZ!RGS@;7P'>R/X:R=15:6FDOH
M#5<]TM 4^#$]GC*/#X"?'":SV2-?R46I%V]\J0N<^(1 0&4] W/+%9Y "$_D
MTOB]<.)5T@=N]V_LGT+MKI8+,_"DQ"]>VZ[ !XQJ:-@H[+.:/L-23X;14OQ7
MN()P<)^)TZB4,.&+JM%8)1<6EXIDK_/*^[!.\TEVOX3% ^@20-> 0] ALU#(
M_".SK,RUFI">>S\P?\7ID;K>5-X96A'.7/+&>:\E31]R<O5$"^8T8^@&DZX(
MXMA7"1J3.-%WX30>OHMFN OANZUZEL0)]E&"?2#8_U?BX:;$&.9#7"2+BF3O
M"6AR(Q+#W':2;"Y.@F[#DS6H4F,?QF7C7:?BD8:+_P>?1^H;TRWO#;HHZYY/
MN.1&*0LNE>3.Y=*Y*5X- 8WUVP>WU_-;G@VKAF5,R?JO*/\"4$L#!!0    (
M ".$?$RL*C]YL0$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM
M;&U3VXZ;,!#]%<L?L$X<>E$$2)NMJE9JI6BKML\.#&"M[:&V"=N_KVT(I2DO
M>&8XY\S%XWQ$^^(Z $]>M3*NH)WW_9$Q5W6@A7O 'DSXTZ#5P@?7MLSU%D2=
M2%HQOMN]95I(0\L\Q<ZVS''P2AHX6^(&K87]?0*%8T'W]!9XEFWG8X"5>2]:
M^ ;^>W^VP6.+2BTU&"?1$ M-01_WQU,6\0GP0\+H5C:)G5P07Z+SN2[H+A8$
M"BH?%40XKO $2D6A4,:O69,N*2-Q;=_4/Z;>0R\7X> )U4]9^ZZ@[RFIH1&#
M\L\X?H*YGS>4S,U_@2NH (^5A!P5*I>^I!J<1SVKA%*T>)U.:=(YSOHWVC:!
MSP1^1V!3HE3Y!^%%F5L<B9UFWXMXQ?LC#[.I8C"-(OT+Q;L0O9:<\YQ=H]",
M.4T8OL+L%P0+ZDL*OI7BQ/^C\VWZ8;/"0Z(?UMFS;%L@VQ3(DD#V3XN'NQ:W
M,/=)V&JF&FR;MLF1"@>3-GD571;VD:<[^0N?MOVKL*TTCES0AYM-\V\0/812
M=@]AA;KPP!9'0>.C^2[8=EJSR?'8SR^(+<^X_ -02P,$%     @ (X1\3%J(
MQ/:W 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL;5/;;MP@
M$/T5Q >$77:=1"O;4C91U$J-M$K4]IFUQQ<%&!?P.OG[ '9<-_4+,,,Y9RX,
MZ8#FU38 CKPIJ6U&&^>Z V.V:$ )>X4=:']3H5'">=/4S'8&1!E)2C*^V5PS
M)5I-\S3Z3B9/L7>RU7 RQ/9*"?-^!(E#1K?TT_'<UHT+#I:GG:CA!=S/[F2\
MQ6:5LE6@;8N:&*@R>K<]'/<!'P&_6ACLXDQ")6?$UV!\+S.Z"0F!A,(%!>&W
M"]R#E$'(I_%GTJ1SR$!<GC_5'V/MOI:SL'"/\G=;NB:CMY244(E>NF<<OL%4
M3T+)5/P/N(#T\)")CU&@M'$E16\=JDG%IZ+$V[BW.N[#>)/PB;9.X!.!SX3;
M&(>-@6+F#\*)/#4X$#/VOA/AB;<'[GM3!&=L1;SSR5OOO>2<)RF[!*$)<QPQ
M?('9S@CFU><0?"W$D?]'Y^OTW6J&NTC?+:,GR;K ?E5@'P7V_Y1X_:7$-<S-
MER!LT5,%IH[39$F!O8Z3O/#. WL7'Y']A8_3_B1,W6I+SNC\R\;^5X@.?"J;
M*S]"C?]@LR&A<N%XX\]F'+/1<-A-/XC-WSC_ %!+ P04    "  CA'Q,UM(5
M#;<!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6QM4^V.G" 4
M?17" RP.X[;3B9KL;-.T29M,MNGV-Z-7)0M>"SANW[Z CK5;_P#W<LZY'URR
M$<V+;0$<>=6JLSEMG>N/C-FR!2WL'?;0^9L:C1;.FZ9AMC<@JDC2BO$D><>T
MD!TMLN@[FR+#P2G9P=D0.V@MS.\3*!QSNJ,WQY-L6A<<K,AZT<!W<#_ZL_$6
M6U0JJ:&S$CMBH,[IP^YX2@,^ IXEC'9U)J&2"^)+,+Y4.4U"0J"@=$%!^.T*
MCZ!4$/)I_)HUZ1(R$-?GF_JG6+NOY2(L/*+Z*2O7YO1 206U&)1[PO$SS/7<
M4S(7_Q6NH#P\9.)CE*AL7$DY6(=Z5O&I:/$Z[;*+^SC=I#?:-H'/!+X0#I'
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M&E2JH0OCLLHN4_%(P\7_@4\C]9WIAG<&G95USR=<<JV4!6=E<^>\M&Z*ET!
M;?WVWNWU]):GP*I^'E.R_%<4'U!+ P04    "  CA'Q,2MPL0],!  "<!
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MY0)'(,00:1M_%DY_E32%V_V5_;/M7?=RQA*.G/SN:]45_L[W:FCP2-0KG[[
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M-O #],_A+(U%5I:JX]"K3O1(0IWCN_!X2BW> 7YU,*G-'ME*+D(\6N-KE>/
M"@(&I;8,U"Q7N ?&+)&1\6?AQ&M*&[C=/[-_=K6;6BY4P;U@O[M*MSE.,:J@
MIB/3#V+Z DL]!XR6XK_!%9B!6R4F1RF8<E]4CDH+OK 8*9P^S6O7NW6:3^)D
M"?,'1$M M :$L:ME3N24?Z*:%ID4$Y)S[P=J?W%XC$QO2NMTK7!G1KPRWFL1
MI4E&KI9HP9QF3+3!A"N"&/8U1>1+<8K>A$?^\)U7X<Z%[U\H3/T$>R_!WA'L
M7A#<^@D.7H+#6P6WP:L>^3#O="GV)HD]!._T*?$2)!\O,_42I!\HTX?9O4I"
M-G>/@VS<U"E4BK%W$[_QKH-]%[F[^Q\^OPK?J6RZ7J&+T&8"W#VMA=!@I 0W
MIN6M>8A6@T&M[38Q>SF/XVQH,2PO#5F?N^(?4$L#!!0    ( ".$?$PQ9^6:
MG (  /L*   9    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;)568:^:,!3]
M*X0?\$H+*!HDF9IE2[;$O&5OGZM6)0\H:ZN\_?NUI3J%RX)?A)9SS[GWV@,W
M;;AXER?&E/=1%I5<^">EZCE"<G=B)94OO&:5?G+@HJ1*+\41R5HPNK=!98%(
M$$Q02?/*SU*[MQ%9RL^JR"NV$9X\ER45?Y:LX,W"Q_YUXS4_GI390%E:TR/[
MP=3/>B/T"MU8]GG)*IGSRA/LL/ _X?F:Q"; (MYRULB[>\^4LN7\W2R^[A=^
M8#)B!=LI0T'UY<)6K"@,D\[CMR/U;YHF\/[^RO[9%J^+V5+)5KSXE>_5:>$G
MOK=G!WHNU"MOOC!74.Q[KOIO[,(*#3>9:(T=+Z3]]79GJ7CI6'0J)?UHKWEE
MKXWCOX;! <0%D%L COX;$+J <&Q Y *B3@!J2[&]65-%LU3PQA/MWUM3<XKP
M/-+=WYE-VVS[3+='ZMU+1F91BBZ&R&&6+88\8.)'S K /"+6 &+R#X-TEK=4
M"9@JL0310QH3F" $"4)+$#X03&&"""2(@ R23K-:S,1B*HO!&-:(08T8T)AU
M-/J8, A@D0DH,@$(!K*<@@33\:U,0(($R*!S8I9)KY4D@35FH,8,T @[YW;6
MUX E< #[)P!$H@&* 0OB\<W$L#5PWQO]=CI0?'\TXP$9V$ X!&2&*& +X>B)
M8F&'8.CX]XJ->\4._;&P13#DD8'7#89-@I]P"89M@L?XQ('&U H;!4-.&4B4
MP#X@P?A:">P#@D?4ZD /AAVP&QGXC$!>&7BO$-@'Y(DO"8%]0/K?DC#HO.?7
M#H3Q7;7!RU"NL%L(X!8<=(5B2*CK;'0W5)BQ\#L5Q[R2WI8K/9_8*>+ N6*:
M40?[WDE/HK=%P0[*W$[UO6C'L7:A>.U&372;=[._4$L#!!0    ( ".$?$Q<
MWF?^X ,  #P5   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;)68[VZK
M1A#%7P7Q !=V9L$0V99Z4U6MU$K1K=I^)O8Z1A=8%TA\^_9=_L2RV;/8Y$,,
M^.QXYL2_G<FNS[K^WAR5:KT?95$U&__8MJ>G(&AV1U5FS1=]4I5YYZ#K,FO-
M;?T6-*=:9?M^45D$%(9Q4&9YY6_7_;.7>KO6[VV15^JE]IKWLLSJ_[ZJ0I\W
MOO _'WS+WXYM]R#8KD_9F_I3M7^=7FIS%URB[/-254VN*Z]6AXW_DWAZCJA;
MT"O^SM6YN;KVNE)>M?[>W?RVW_AAEY$JU*[M0F3FY4,]JZ+H(ID\_AV#^I?/
M[!9>7W]&_Z4OWA3SFC7J61?_Y/OVN/$3W]NK0_9>M-_T^5<U%A3YWEC][^I#
M%4;>96(^8Z>+IO_M[=Z;5I=C%)-*F?T87O.J?SV/\3^7X04T+J#+ B%G%_"X
M@"<+@B&SOM2?LS;;KFM]]NKAKW7*NB^%>&)CYJY[V'O7OV>J;<S3CRT+L0X^
MND"CYNN@H2L-W2J>;06'%TE@$KAD03 +ZM?+FRP(!V 8@/L ?!. <0 ) T@K
M QE.;!@D<2^I>DD<IE$RL<)622'"%.<2P5PBX(;$ 6(8('[<C14,L+KOQB")
MKNH4:1KSQ U;1>8GQKDD,)<$N!'A "D,D#[NA@@Q).%]/T;-=:DR3--H2HHM
M$TF2N/)Q0"N )PY3!29.T )7,'."'W"%K7+#J2-SDML\,+K"9I?%RA$"$R>B
M!6Y@YD0,LDBF=L3VE\1L(M,]!,@H%F'B2 @S+&R(63CV(8'1$\D"6S!\(GW$
MEM2J-Q+A="\!JA618RL@3#+9)#.Y6A6&C\3CII"CW:%^-S5E%-W;4(!L9D,A
MC#+9*#,)1PA,(<D%MF *"34^RY;H[HXR*[E-!+-,@&5RS".$Z:/5 CLP?80Z
MGV5'8M4:BY7U);%50HC4E0]&F0#*Y C!&#\.'W>%,7Z,>M_4E5%TQQ6@FG&%
M,<L,6";'M,:.X77!],J8/D8]T')%WD5G5G*;"&:8 <.N/9HQ?;Q@?&5,'Z/>
M9]EA#Z>6'7.2VT0PPPP8=HV_C+'C!?.KQ-A)U/7BB1W2GDR3.)DR U2<N"83
MB1&6 &%R#&P24R<7C*\24R=1S[-,L8=39(JMFC'%\0\H()A<(3![<L$4*S%[
M$G4^RQ1[/$6FV*H94S#'$G!,CAE68@+E@AE68@(E:GR6*?9T.MU-9B6WYP*8
MXPAP[#IHB3![T8+I-<+L1:CC3>T81?&,';.2(9'@ZABK.U?\(ZO?\JKQ7G7;
MZK(_MSIHW2H3+OQB?#VJ;'^Y*=2A[2Y7YKH>SO.&FU:?QK/*X')@NOT?4$L#
M!!0    ( ".$?$Q_'-[)4P,  !D/   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;)57V6[;,!#\%4'OC7CH#&P#M9*B!5H@2-'V6;%I6X@DNA)MIW]?
MZK K<E>.^Q*)\NQPEKN<D+.3K%^;G1#*>2N+JIF[.Z7V]Y[7K':BS)H[N1>5
M_F4CZS)3>EAOO69?BVS=!96%QP@)O3++*W<QZ[X]U8N9/*@BK\13[32'LLSJ
M/TM1R-/<I>[YPW.^W:GV@[>8[;.M^"[4C_U3K4?>A66=EZ)J<EDYM=C,W8_T
M_I$%;4"'^)F+4S-Z=]I47J1\;0=?UG.7M(I$(5:JI<CTXRA2410MD];Q>R!U
M+W.V@>/W,_NG+GF=S$O6B%06O_*UVLW=V'768I,="O4L3Y_%D%#@.D/V7\51
M%!K>*M%SK&31='^=U:%1LAQ8M)0R>^N?>=4]3P/_.0P/8$, NP10_VH 'P+X
MK0'^$.#?&A , 8$5X/6Y=XOYD*EL,:OER:G[?MAG;=O1^T"7:]5^[*K3_:;7
ML]%?CPO.Z<P[MD0#9MECV C#3$0*$9R8D <(B;@)>418^+^9/)W')1F&)L,Z
M FX0<)R HP2\(_ - M]:C1X3=IBJPU#"2&BM"$3YA$76FB @'I/86A:(8M%$
M5CZ:E8]D%5A9]9A@-$E("4FLK"#*IW3$98@)4#$!(L9:O&4 IK&Z*;V&,$2$
MJ(@0$6$59QF"*3X$ULY($0P+<2$1*B1"A%CU7T:P-"0)+%0*4;HTHP(:8F)4
M3(R(F2!(4(+D]OU'"6Y'!&KPB>U'!.8:4LYM4X(PIF'^A* )?Z2((&"0]-V&
MO0HQA>#>1ADBA-E"&&Q(>ZNG&&BJ:RGNDQ0Q2I_;8CA2)I+8C8O =)E&+F@*
MPBV.(A[G3U4:-R8:_$?WXK9"$5^!W0M-(Z2)[2P(BE*:3.G!W84B]@*;%SH'
M:-YK$%,([BP4L1;8O#'L2VK_7T5 4U)PCZ+)+:V;(#6*P$:"J"LU8KCC,<3Q
MIG8CPSV*T=L[ETV<G!!W 2<?!HTC#F-[51"4<:@QY>#^PC!_L8\L#!J'W;A7
M(:80W%<8YBOV<87!8Q$0<@UB"L'=B2'G)M\^L@R@\)T"0112(&]T@V@OC=^R
M>IM7C?,BE;Z,=%>&C91*:$9RIQEW^IYZ&11BH]K72+_7_66M'RBY'RZBWN4V
MO/@+4$L#!!0    ( ".$?$S8=JBI]0$  &P%   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;'U4[8Z<(!1]%<,#+'[A3B=JTK5IVJ1-)MMT^YO1ZV@6
MQ0(S;M^^@(YQE?:/P/6<<\]!)!VY>)4-@/+>.M;+##5*#4>,9=E 1^4#'Z#7
M;VHN.JKT4ERP' 30RI(ZAD/?3W!'VQ[EJ:V=1)[RJV)M#R?AR6O74?'G"1@?
M,Q2@>^&YO33*%'">#O0"/T#]'$Y"K_"B4K4=]++EO2>@SM#'X%@D!F\!+RV,
M<C7W3)(SYZ]F\;7*D&\, 8-2&06JAQL4P)@1TC9^SYIH:6F(Z_E=_;/-KK.<
MJ82"LU]MI9H,'9!704VO3#WS\0O,>0CRYO#?X 9,PXT3W:/D3-JG5UZEXMVL
MHJUT]&T:V]Z.XZQ_I[D)X4P(%T(0_Y<0S81H0\"3,QOU$U4T3P4?/3%]K(&:
M,Q$<([V9I2G:O;/O=%JIJ[<\B@\IOAFA&?,T8<(5)GR/*/:(R%\@6!M87(1.
M%Z'E1RM^$,=N@<@I$%F!^%V,#YL8$R:QF'YJ$OB;K,4>%#Y&;B>QTTF\=T+\
MC9,)0]9-PBVH<(!BXG9"G$Z(PTFP<4+V3?P-IMACDG_L2.+TD>Q\'+:?)MGM
M>D3(!E3L0>00;(S@U;DW]]!W*BYM+[TS5_H7L@>]YER!UO,?=*1&7WW+@D&M
MS/11S\5T 4P+Q8?Y;L/+!9O_!5!+ P04    "  CA'Q,-3TD5&("  "6"
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M\QG"1$/,&L+$/<;3>?O0/AC:MP+!0""!!0)0(+ "X4!@-IHU !,AV"0$34)
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M'YU:2@.6,'ZP!3?V;9@=#K5QYM;::KPAHV-D/UU^/+] Q5]02P,$%     @
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M,R &;1O=!EQ'O6]AN*<"8JKV#+$"URZ!I6D<V@?EXBBD%&)+4C :LBK>',P
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MH9Y9=@R]8-X)3ZD/75#4Q9(:X?2Z@Y5),/\:24PD9C@)!L?)VOC@,@D68X$
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MKJOND-[=2''H7T!XPUN0Q7]02P,$%     @ (X1\3/TQ"$T^ P  )0T  !D
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MXNK/4I3R/ ]1^#;Q5.P/QDU$BUG#]^*[,#^:1V5'4:^R+2I1ZT+6@1*[>?B
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M26F$C3.^LQ$>;+G5#TJQ,Z[+;%^U-4<[,++IZJFH+^H6?P%02P,$%     @
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M9F7D^@DFN\_,S*Y LRM (#3, DP0&68A9FV8A<:*8+,A:#8$!&+#+,081E*
M69B]S\S,1J#9:"'@KUS#[)()UL9Z3@%F8?8^,S,;@V9CP(AI%F+,_0DQQB&1
M 4QP8QFL0;-K8!!S@T&,N<$@QEC[&<3<,.LZ\+GI !+FJ@4A<]E"T&(I? #-
M'=\XZ=V%A+F%=@"S\))^!LH^@'K#:')+U82==07 K9Q>&J$.^TGO6&4\>>J6
M,_IWJOK0M]^[3%^Z_,#L7#;<.E A[U!]TYTH%41Z=![DT57(:FEL5.0DU&LD
MWUE?,O0-0=NA'$)C3;;]#U!+ P04    "  CA'Q,\K: QY,"  #!"0  &0
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MIO63DAZD'B9JS-M>I9U(UG1]F-<W@XO_4$L#!!0    ( ".$?$PP':ZS/ (
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M \A!3]A&QG^ 8LS1T936!C,V5[-ML+I.\1215$ID'3 T74!<D)R3" .WE?\
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M^"Z0EMJVMDM6_T63H34V4JRP%]"1MRMU%3OJ/%TPSVV%BT\X)GCZ,O .+A[
MN,<GYZ#Q[HGN95&[(\Z+D_1SO'#DR;!<?>2D]%K)@GGWYL;,AEAIW4J<CGR:
MQ+QX:G0FFN CJ5L?RN1F=X_J_(3QM2]:A@V),R'RS(#K.'DH@K6[KW-V0Y$9
M]\<,?@X;<(>2@,KNZ3=?0)<NDH]Q(?UM-4I^V"Y&::CVL<N&;VVT4O^/7W@
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M#%M<&\IH821)#=:D/+XR!UOS;X7TGCDE!X,0KC:Z\ 5WW6T; "AG[+,L>2B
M7D!,/VLF5$'9PG\5/;HH-SOM"F@W%M$("DP18@@\:F9-<XZ:6^$IAM'OBT<9
M$G'I\\9>]1P-WOCF.[O2.M%*'QYIP$/  )S^1_LH</(DV><4>^,P21TM^>0'
MJC^:^!UN3@,0:O5T[+2J.Z1@@17G#=(+ZW73D(DH.R<S.(MGT!+8!A].^X4
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MJR55&:SM)S51-*R0@!:16?\^<:2Z$CMF*J2$F"5[_(:UE8@;FPOV;/#M7O]
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MW'(:+,5V7M]Y).P70SD,S2KJ^19?$=BLB5PMN!XYM_/YB"UR3UP8A9["OVH
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MOW^_ J[Z^O,<3%.4@K*EAH&XKA;Y*J8:B]5IQQT\N,<*\XU(-$54^%"@KY8
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M]/7O/W[HZS7O@LGB5CE!U/%."O6>1Y/X.\VJ7]%W10!;DUL38!>%=EKE7)+
M9HURF>_XZG=79_UHOOLH\TG@G>GF^U^V(!TB?S\G[;%/2&4EX["-6BMDD#\V
MVVU_+8^=)F-X*U%\3J)#/=N5.A!,=3TOF'FW$@I..&I\FG@<COZT!A\LZ<O/
MQ@#4I^! .N*1WJ8[X6*J$;:H=]CW&<B;>9+UFF1D:\U\)F1$G*BD([Y[<V,V
M5*R5;R562UYC8I0\-3I%&(VL11R*\Q1O=O=HVTS&:4\Q?4Z25"X4(NK-V?3&
M8XMK4 +@ -JT?\PVV)@7#  00G@#1O2;+V L%.VB\MMJE/RP78S097&?TZG;
MQ<:W-HJ:\\<O/(#D\KLN<:WG<07RF[A2QF 19 C,0=%8PL"3\7XXS4]GP^HE
M5[2ZCEF\1>LUML0BFM2MMZ1NL:_5&<4L"K=-[:(MY@:IVPJN&QL@/'"Y$.>I
MRS\I4:IDR+L?P<[B].3W%#BC&Y:&*4N7)^""0!2XQJ ,.'>0N('P[:\F'D$B
MZLW4@6+!D.=VI3FK5/'H6E&:;PGOZP:?0534,+8Q9K#ZT<%N;CO.XLA;CJ08
M>P0&@4M<E1J#B+%!AX;.W$&%(2*]$<QXBD17S^*J-05O72Q>H]:$"#W%/6&>
M;=1I"]]9[#!GV$ZZ=Y1!RU=I$<A"S[\_<RMR;MRMBGOQ 85@F%U.NXJ%=C)F
M:@+>OF1-'A7D%>8JH!:[T3P3(6+-AJK8#)5AT;7H7HNV$7HW,!*]):TJ*"_1
M\?RNJJ-[H'B<:Z#0+?5C"36H_@)N&%!""CEVFPTVW3$7*9(!\DUE9P0R$KNU
M!E$8E1]ZE]P>!C#D5@X,O$6/W=5RP8%>_BBK/%JT-XVP,M_=1;FI=LCLD'.I
M\JH9ZN[)+8N;"L9TK[I&O/&5&G;B!S"2]]0;<;9 PP<:S06Y1 YC,Q$B"67O
MP+NDYQODX\C0E.P*#AY<Y"^@!+.3XI0<^;N,](F<\M/FDN_G?7/ -0ORP)\4
M\!-_=US_2%P726FK/4^#U\U5O)G3$Z,]2@CA>_-;T]OP=0]TP+B 9?%-3"I#
MR62HSA*!PQY/Z?"$-&F]DN=. =)=W?%R6]V!)=7H=FEN*NI\&].2\I5S5;:J
M]3 (>3&>O9[.DC[UYW7RHXR5O.51DAOO_(QGILEYPJUD3]BO8 E_SM )7([2
MXVQ= K7L?U[G4M$4TD0)G()./83W]ET596[SNJ!,>W=1@:Y$!$>S)N(@LT7;
MRZPP,T8RX;_*=8XB+<IIV3J6%2WBT'VQ]+P>G4-X8VEN#,P5WA(NB#(-6[Y]
M$W4K^X_%WU5.^4O+P0./Q>784(O>&@]4!4^:<J3J%W)@IQC0'*61K5?;Q'YM
MLK6TC<Q"(%<F$*(!T1KKU(#!I?;,"E.CO# I6>5 .@H<1>!P6JAT_*:D""5:
MO<JOY1+'L0?!ZA(OH>]!B;Z,NILQ@FD) 1-/^0>E-<<W+M16HO$"YAGI?:'/
M,U5HA" 1NV=YM.:!REKN?&KPBY7TA[@CJCE ]1JT^N"VKTWWE@S&,8W9:Y\B
M(R(X.*[L:5"#).>+OEZB _96"0K4U O4S]-0=$,;'RSAHGH@,KCYWA-?U]@*
M+P%_J35)'472KC5G*21>=92#BT)'< ?NU">!\T7>V6*=^+M=FZ5%H2K!8R&Y
MU,WLU.[,/N$V"'H&/BN],(\B+*_;L97,AP^\XNRAIXO^EKL:?1G0MU-8_DJ1
M0\T+$_7'KG.&1L-KFM<ENZJX(W)GX&"\18LAUZ#T3<V:*&&+2UHINB8]9^1V
MV: 2^F#KBS<LNF,]B=_=/>IAECR6.HCUN%%/V7\:^+3!\1@7: =K"P&[32US
M3X1VTYJKOW\RG'8E :(J,![9CL?KVZ.?(F(6Q\N-3_^96DH#0>2U!AE(B/%F
M^+A<YI5,A964:(9K*D!.>XI+-IT:LW8>BFTV+PHEW8J<-T7^%)=%+JQ$M;6/
MT:*M,3E;B,2DO:S4TE4+$=!.,9"OE+\XS]S!=U=#_86W<@2(W"#;PG.Q+>3K
MJ+:J&>#&2=H1HZ.$@-<(64&CMX;1BR:XN!\E45U2K5&-(+1:B=]7RIY<=J<S
MO;@L2;^P-PQIWBC],0:J'GEBN-2('05^ZOP9J7=,!$<NSE'B>I1%>,=WFO/A
M*E5=57+I>3C'!@F95C9$G-*MBL'BF &YA-&IP>&;V"KU!HKD-E#[LXK""Y'.
M3O'^+'2*[U7WL$:1BW$)U2!H/R.'9]EU:+GJ6W>*Y!WJ>(8\B;@%Q[5+/+6B
M)M=7G7/BI0O8&3./-P>GS.];2.HNR5*,>(@7M%/P'0P0PA9 *?E!_.2V$%NE
MO3;3]F0=&NT[(-LNC/!3#-*Q4XF:1C>_=NY#_\5)/KI'KZZPQTPR'9\34N:S
M)PMBSW\.Z<>G5A7M8ETDRZAUMT2\R#QIMGX>!E:A"2&M,=Q)CK !VBXB!&TM
M&(*6NOL.HGSG4FNSAO'@C.J?7417 !^H,2$KAEOM)-/*<>7MSA>=Q)XLI+0/
M>K+"MO>3:?"UAC2(M7B>VPR]R\_G^3"]8I2G2W!M$3?LQIU[-U,1C,N0&A>=
M3/\Q^LWM]K.@H3AG.:26]<UHY\5"T[[;CA+Z. 3;S;(4<AEC3:ZP=<&7*BN2
MP9J<:"Z5<!A28<&7>"<@%+WNWMBD_1O8Q@MMJO\\?GVX34]5AQ&:WBDE.#1_
M>P.J#JFR("&C38RU MKD^Y\8[1I(5& 8>:ML&8(U1#I%2V=][A26.SK'KI.E
MV;'\*-#V_;WW).\+&'A1V[-1L)37=@ZIALY$&Y)0F>,#'$AN:V5NU9)$$! Y
MVZX;2A8$3?/G[#Y4P*#MJND.>CQ13K3 ^DM2 -'ZOO-#AZZ1)\:PIN=QV\!X
MP]'=,\1<(A[8:N$H<MX;,X/>+G00A7)Q[YI2@600H=SL!1,J881F^1QP:@[<
M;B]$A@SM#GZ6-[R;,)N.L.ICB\XI&P ,'"IFV[#G?#C:_0AWH#W9-/2G8>TE
MS"OT*_J[S4VRA3I3M/((A]S3I0?GO>[(_0C"8-#U)*L*Q3>4N&@UQYVZZBT'
M9ES8H5@K;,PH>1. D!!E%&2W8!CBL*%#3T@M8S5@4$%N+?[(F^V"F8-"J95=
M)N>A72Y]C/I#Z7 U)VG/,EK9#>;X"^ZO5E:#A?RMQNBP;]#SR<BT>\C7F$+S
MK)G[;C\LB9H6RUNIA]68^PHS<&#L;7!4&EK.P/;UFZ3,?1%JHF?A/O3DG:G1
MNL/<@IKC4R2<,\=MLV$WZ/%+=9H4;W4<LQUW-U7&&,<,Q--[?B';TE>32%R0
ME,#^,I&6?*7?!#<OUO.L)69E)5E$X]3 4T;L%O*5E5/K/#W9),3/B(8X9Z3Z
M& 5Y*W!QS/[0*]CQV!D8N-/7+.2A+".8 9PX;\54W@"/@+QZBELXKQNA(5I;
MM=5)DJ2L.7[[)F[)/MPDV _5$RVNEG$;$^4,Q$FM'H*?"FC:@D6^K\SL$&]M
M,;?^B\/'T4.)VNL0CUCU!]__T#+\^H/::%-B]2BE;H11S=E('JM.!AOBB?R@
MP+%4-$ P!IPA2;FU1Q4%'AY&P'>' 7?1[2X)[4S35%2N!!$2 Z7@-!,"]LF<
MDARJU/:4H]LYMS@K^I"P",KGK=O[FRB;U.'_L16<6N@D=HS@#?!H#@3(2_T4
M# H X6YZ4'K#JA5E^.^P9KK,^Z<?[4L,73NBUHB^"S-^UXM)S*MU%0OI_M1L
M29>Q-%V?'Q[[?S"N>^@ ON_Q!W#S 2VB#[/])8W*TR, I:5+#X6#LT8PG(<?
MYVF@K!"_>K= ZU,^SULHSG555NB,ZL.$.?@\)N_]A! [U('14CX#CHG[Y6=I
M]M4DWQ/$[@EV SO5*H+>![]N2,\\N?G\]92&%QI%(.+/GJ,2&N [T,2;Y.1+
MM8%MFIZ-3[_#NF+M)$*/G&1$"L"9=T9\.(WD+6:RX\O?XW2:Y$N&<"Q5/<]/
M);EDQW/IUL)$K)T01I8T$9  JTS8O^1>=WB$F>X$;+$?@D61=0)ZTD)J[\5,
ML:72SUG.1G]R(X+]\_EKO*4DYZ.ND=+P@IPUE*A(K08)3UPC-X/M))'"F>P-
ML"O4N@=;JJ)(L1^RHWN(6;0R)=.J?;@988J)+.3 LB,A: ,3@(4KWB?=C>P6
MJ53M@V*EG%2&R7<TC62BQ!KOW?@Z3=Y[K"G@,:$S"]Y->9"+YJ3"TY-\QK%T
M355K"OAU0!?CF"-[!14IZ;%:H;^SD89C&852VFE(Y$%R[V?7N\5"7(9^VP/3
M[?F8<F=B\B_A\:$483N$+H1$UWP)%-<'>V@$*VKNOS*BY\CU[](C8^,J)2Z+
M!MU !]J:"AU>'$&'T8!DI,&GU7.@I@VJ5MMMISA*@#2(TFSVU-S-"D4F_C:P
M._>)57?M=UIY4=.#E^61@KMXX3I'(MUW^5VMY2E'4.\TU8+4$TS#NSJ?GJ96
M=+TE:2Y>2H/15XD7P6 XB(XT!KJ7&@\'S+SB%^(X47B4C&?#,3@I1ODH)4S-
M7 @*/U>UMF(B?5EWW%BS/H^#43)8EA#4$.40D?M5R/+9JF%I4X%PT:/&>T[!
MJ%;-;-,.B\N&X(HT?$,A+$D2HN:]GHQI+C+^(E2$BB;&\\:5%4W[YA#C"DE4
M^C9^A1D;49:JS15S6.PBM9 5:95'UAC[K 5Z<;M_XXTL@<([+B?,,DAJZA7@
M7E,MY<.N\1!,F2PL0#%IC;"< P/DVHP&H$_185LO5J$:JZA;^SI2TF\-&,90
M3&"U^H6]:AE- <9@5C,,8<&86"9LEGT4M*T6&6X5WS1TSR!\OF;6;S!) Y&H
MY6DE[E1^,-;Y[N.55=GB.]?I2_C9WT_FNK*Z(_@6K,WG""/=_!BC!#D]-*!+
MA3_^X*"SS.?/W9RQ5-W*FDVT_F)VUPM[V-'!QI.NS(N5HQ=K4^EA#>W_EL/W
M=L1L\/1GJJ^"+/U>W.V?R=U^VU(U$*%0+$1&A".(1%*LGO6N1;U8>M';)!EV
M+7U')-A6-"U[((GQWU!O:@.S"6[873L>4%:E>OX9XS=\&^E)W;8P!&U(>ZM]
MQA@86.]X=\]$*V$/H]*%(":UG/7]9NQL,#GKR[!2TP(_%3NFI<7$O(DH0LH)
MX;7G@_1PKFN;>5_:Q];1ACO_.:A1\LOD#]18@8 YZS(Y^;R[V[().=:-.T=;
M\DUTHP,T&ITO QR4R5NTE8+Z=B/2"Z;$20Z[G-<=OU-$OI!4%W*,AP\]'VQ\
M1GQN"B,T3*\+EQ8%?SPA;B(QE_?N_"($],P:$ @@CM0(;BV(Q)N\K*HM8CHZ
M1M>$3 "4_VNF(%U$VC,;W_V:L[4UCN"S8:RU5BA4K"UP[#P[5LTA@5KA3Z#6
M-+DO04\6%1RQ6VEK5EDXM'ET:/'F"=?%F +YGIF]DCN+466%-_:K\+6V3H_/
MOL/_:46>I>/%/&CG]%CJ?8*#-I<&&B5O^?ZY;O5%\S*+!S;#7%Q])D[5;CND
M?"PUR(O8.4XN#"&W'HC B/+(8G_>PRM^JD:>7Z#-'E5_W<9(6K? >4 (U.90
MNAA?G)J6T-+:^@+IWB[&K9$*I_!6K[L($> \BT$C0] A+9'=H_AA@07,4FZN
M*S'K@5P#LK;%4<Z_)3KP"PAY6C #(L]UU+24+XV$SAO%VM*\GB+4"CN_9&<R
M3%:X[+B$1 N"I4)%41'MQAIZ/TT\];S*)]:YVA*&@S/GG.)$T='K=H24,>\.
M\>4S#M(F1AN(OQ!1[PZ(WQ.'Q4+9!<'<K98$#V:3:(E H)P!DC;Q?OX+2/H[
MT9(RP^1X:_SG#7(D)7EOPR[@5CY+K-=4/^)? MJ,##&5Q)G S^B) X[%/C9U
MA JK#CNPD^#"\##"#WHL"4=>S'<;'X"S J+@6%B)$EPEH;>3Q0Y1(;JOT26/
MP,R[AESTTJ=)2A&?]^7A,>0M5LW0$EUAE> EPY\JS7!MYL @6\CVA&>&CCQM
M;+0H^->Q=?[E(6\?AJKKG0UIQQZ(-<#3+:UK?,W#FJ;" H-_N^.68N)505UO
MZ]1&].<%@*)<&GX9YJDU?NA&N[= 7I@3L=+F@P=^13(*[Q8*D54H.P'E8_6,
M#@XXUK]@];8:!D;2H82!.;'D%3OLD2=GH=_M$"W898T&.XJ8)+Z'M/7,DAP.
MBD9QXW>%XRCYWDN)/" IB0]9;8K!9"'F4YID&X@>-((U=AB3OA5>OG5PID+5
M$ZR2DR;(G4>R0R:@*7E^L_B Z$KBF?*U3"7_0QIA&WC CGD]<84-=FEX= 3'
MS(F0P]OQ.E/HW.:@\".N'9-(:*Q$V3 AJRLKH\I#K#<DSQC7&51/S,X(]2#V
M#NQS"'#RKQ)9N)(=L\QYI$.K]I )K#FZ<]Y_96[!_]]8)(U3H,D9&GN:&=%2
M\J-]'MPPI?;28^J(US1U@I!U_OT]72J<YZ;IP]';U?U.E%A?R7PN_E,H]<+/
M3V1@:/;* !*# 5=):Q JL\^>AQ[WFI;+LA>UBHI?<<=#H,5@WK6;D590$B-G
MY<9#77/\,_]62..C4[+YA9:T*XJOS.MNVP!6/..S9<E# 4<(DO-94Z8*2BO^
MJZBV1;G9L7KG+A'"%A282\0P?=C4D><<M6C#4PRCWQ>/,B0V#,@;>]5S-'CC
M.S_M2FL *DV@I/L3(0APGB#MHR#[D["=4SB,(Q=UM.23'ZA0:>)WN#D-\+'5
MT['3JNY0@Q6$=]X@O4->70PIB[)S,H.S> 8M&6I([K1?"$)(!58F==P1A^W-
ME&LUWR6Z3'5PO'=3U-ZMO_+6ZH4CKD$W,1C1V&FY&:3NW\MTI^WINH+6>(:V
MU>X4S%3NS.Y9%1#++*.>!/HOK^G+41:E+7VH<H2M'=XG7<!9[W[CCSV]C+PK
MVN]@P#R,, 9;^</=\K#(6!02MH(\6E&B29X]I.G>Y YFE'P0QA$0 (@[V@""
M<R+\:X<A$'G7OG$)]G[;A,GO:Q';LK5D\T/)HU;_:!V"LFM7Z]1*#XS:$;<3
M>^B$235@;@ S*JE7O8;<MPH<>Z@-Y\!),L-56F%:&RS'4L$2^H(<QP/D:VR4
M9KI;W(SV:"%\\H7*)SN(A)]WZW7&K5L=*?M8RBT8+ 6O/PQ^5%+@#;:]U]'=
M?6[O]3R\P>U$#Z[,-I)!AHAX5SURD-*X9G+"$91= ^]JP"P>VI:O=(Q?*&'G
M5KM>\7/_RFSJHS'2&V:D/PHW4?ESFGQV-Y&++C\$7B;L0YZ>QD]_];(G?O+L
MM*<G$Q_1=\F/W<9"KY*K].)JYOY+&O/T]^[3K?7SH08^R?E%.KZ^2F;I9'R6
MG(_3Z^N9/?N'5K>?Y"*=7,[D__4A_2]OH!SOJ^0"AII=P8?)=7I]<08?9/ P
ME?\4!W*Q_T#.TJOQE?OOX0.9PO;"HY?I=#I+)E?IU=79\(%,)NGD^DS_<^!(
MSN&I\35\F$YA\ L\&QX^3&8?:U"<D=<@FE^36OW"KJYD!(3R&MI?Y@ZFG![
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M.?E?&P5\M]V->)@P$F)C/,I:%K'OOFG1EBIN?6U#-TI;_V3W"DZH,7.DQ.9
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MJ[:NYV'?%_W1B.[MDGB.X2V8FU]02P,$%     @ (X1\3*][ K;S 0  YR
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MN\)9"3HLX>MM0&_CZVU ;^/K;4!OX^MM0&_CZVU ;^/K;4!OX^OM0&_GZ^U
M;^?K[4!OY^OM0&^_PEDW.NSFZ^U ;^?K[4!OY^OM0&_GZ^U ;^?K[4!OY^L=
M@=Z1KW<$>D>^WA'H'?EZ1Z!WY.L=@=[Q"K]53O3.33VD[4L9#NT^7[KDT_!O
M:R9PY_)^3)?/.$_]=O]$Z3)N2>'\>O'OTWGJ1T3X]+^&Q[]02P,$%     @
M(X1\3) #]W/4 0  K"   !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS=I=3\(P
M% ;@OT)V:UCIQ_ CP(UZJR3Z!^IV8 O;VK0%X=_;#371S$0C).\-8SO=.>]&
M\UPQ>SY8\J-]4[=^GI0AV!O&?%Y2HWUJ++6QLC*NT2&>NC6S.M_H-3$QF4Q9
M;MI ;1B'KD>RF-W12F_K,+H]7N]:SQ-M;5WE.E2F9;NV^-9T_-XP=53W:WQ9
M67\1%R2C^WWLXN.U>1*K/F&_F/#]QNX\WO>X(^>J@OX4S:Q654Z%R;=-O"7U
MUI$N?$D4FCKUI794/ 57M>OWO$OMPH-N8F.VK]F7!>GY<H1#3<,!^LHI)X>X
M+6AH5%\X?O)_#?S8#;EQ-+8N5EVH!AXO1EK&JF?=PE,^(G5;IZ#B5\-CZ_/]
ML*_&;?KO0R_\L^A9?_C?6S]=#@&20X+D4" Y,I <4Y <ER YKD!R7(/DX!.4
M("BB<A12.8JI' 55CJ(J1V&5H[C*46#E*+(*%%D%BJP"15:!(JM D56@R"I0
M9!4HL@H4606*K!)%5HDBJT215:+(*E%DE2BR2A19)8JL$D56B2*K0I%5H<BJ
M4&15*+(J%%D5BJP*15:%(JM"D56AR)JAR)JAR)JAR)JAR)J=4=;^F#:Z:G]*
M\F+,YF,^Z_^DL'@#4$L! A0#%     @ (X1\3!\CSP/     $P(   L
M         ( !     %]R96QS+RYR96QS4$L! A0#%     @ (X1\3&;S"V""
M    L0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"
M% ,4    "  CA'Q,3$,9/>X    K @  $0              @ &9 0  9&]C
M4')O<',O8V]R92YX;6Q02P$"% ,4    "  CA'Q,F5R<(Q &  "<)P  $P
M            @ &V @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M ".$?$S&>'!@EP(  )H)   8              "  ?<(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    "  CA'Q,IS;$._T#  "<$P  &
M            @ '$"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ (X1\3-$6Q:9R P  -!$  !@              ( !]P\  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ".$?$SX1IIU* ,  &(,
M   8              "  9\3  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    "  CA'Q,5+;Y*1\%  "/&P  &               @ ']%@
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ (X1\3'I)'+OH
M 0  X@0  !@              ( !4AP  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( ".$?$S7E-S*V@0  -@8   8              "
M 7 >  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  CA'Q,
M_FTJ); !  #2 P  &               @ & (P  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ (X1\3$X"2*6T 0  T@,  !@
M     ( !9B4  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M ".$?$R4HTOGM $  -(#   9              "  5 G  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ (X1\3![<UU*P 0  T@,  !D
M             ( !.RD  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    "  CA'Q,+<"P2+0!  #2 P  &0              @ $B*P  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ".$?$SL$O*^M0$
M -(#   9              "  0TM  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ (X1\3,@&YKBU 0  T ,  !D              ( !
M^2X  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  CA'Q,
M^XO+J;0!  #2 P  &0              @ 'E,   >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( ".$?$QH&7$RM $  -(#   9
M      "  = R  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ (X1\3(+=-%"U 0  T@,  !D              ( !NS0  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  CA'Q,[VRO3K0!  #2 P
M&0              @ &G-@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( ".$?$P),<-YM $  -(#   9              "  9(X  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ (X1\3"'M*4>T
M 0  T@,  !D              ( !?3H  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    "  CA'Q," 1E%[\"  !\"P  &0
M@ %H/   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ".$
M?$QM&]M%Q@$  #<$   9              "  5X_  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ (X1\3*PJ/WFQ 0  T@,  !D
M         ( !6T$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    "  CA'Q,6HC$]K<!  #2 P  &0              @ %#0P  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ".$?$S6TA4-MP$  -(#
M   9              "  3%%  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ (X1\3)XC1@,! @  "P8  !D              ( !'T<
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  CA'Q,[HN.
M8\$!   W!   &0              @ %720  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( ".$?$Q*W"Q#TP$  )P$   9
M  "  4]+  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M(X1\3*X)<?:W 0  T@,  !D              ( !64T  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    "  CA'Q,N:G4O'<#  #>#@  &0
M            @ %'3P  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( ".$?$S:9[O,J@$  )\#   9              "  ?52  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ (X1\3"AG^,?K 0
M$04  !D              ( !UE0  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    "  CA'Q,12F8'-X!  #Z!   &0              @ 'X
M5@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ".$?$PQ
M9^6:G (  /L*   9              "  0U9  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ (X1\3%S>9_[@ P  /!4  !D
M     ( !X%L  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ".$?$S9(_U60@0  .<4   9              "
M 4]J  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ (X1\
M3*%./74R P  90\  !D              ( !R&X  'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    "  CA'Q,*;2"8^8!  #1!   &0
M        @ $Q<@  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( ".$?$SU&#S$.00  +,4   9              "  4YT  !X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ (X1\3#^]61H9 P  7@P
M !D              ( !OG@  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    "  CA'Q,P+70QFH#   1$0  &0              @ $.?
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( ".$?$S],0A-
M/@,  "4-   9              "  :]_  !X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ (X1\3'<$XW.Z @  X D  !D
M ( !)(,  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  C
MA'Q,>_8J=(8"  "?"0  &0              @ $5A@  >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( ".$?$SRMH#'DP(  ,$)   9
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M970U,RYX;6Q02P$"% ,4    "  CA'Q,XVHAV;,#  !)$   &0
M    @ 'PE0  >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M ".$?$RYPFN'WH<  '@6 @ 4              "  =J9  !X;"]S:&%R9613
M=')I;F=S+GAM;%!+ 0(4 Q0    ( ".$?$RJU%PP7P(  &8-   -
M      "  >HA 0!X;"]S='EL97,N>&UL4$L! A0#%     @ (X1\3*4B\>8K
M!   =",   \              ( !="0! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( ".$?$RO>P*V\P$  .<@   :              "  <PH 0!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ".$?$R0 _=SU $
M *P@   3              "  ?<J 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     _ #\ *Q$  /PL 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>183</ContextCount>
  <ElementCount>248</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - DEI Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/DeiDocument</Role>
      <ShortName>DEI Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001001 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Statement of Convertible Preferred Stock and Stockholders' Deficit Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitStatement</Role>
      <ShortName>Statement of Convertible Preferred Stock and Stockholders' Deficit Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - Statement of Convertible Preferred Stock and Stockholders' Deficit (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/StatementOfConvertiblePreferredStockAndStockholdersDeficitParenthetical</Role>
      <ShortName>Statement of Convertible Preferred Stock and Stockholders' Deficit (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/StatementOfCashFlows</Role>
      <ShortName>Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Formation and Business of the Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompany</Role>
      <ShortName>Formation and Business of the Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Balance Sheets Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BalanceSheetsComponents</Role>
      <ShortName>Balance Sheets Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/ConvertiblePreferredStock</Role>
      <ShortName>Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Net Loss per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2131100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2134100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2135100 - Disclosure - Selected Unaudited Quarterly Financial Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialData</Role>
      <ShortName>Selected Unaudited Quarterly Financial Data</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Balance Sheets Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BalanceSheetsComponentsTables</Role>
      <ShortName>Balance Sheets Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/BalanceSheetsComponents</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/ConvertiblePreferredStockTables</Role>
      <ShortName>Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/ConvertiblePreferredStock</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2325301 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2328301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/IncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2335301 - Disclosure - Selected Unaudited Quarterly Financial Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataTables</Role>
      <ShortName>Selected Unaudited Quarterly Financial Data (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialData</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Formation and Business of the Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompanyDetails</Role>
      <ShortName>Formation and Business of the Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/FormationAndBusinessOfCompany</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Significant Accounting Policies - Reverse Stock Split (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesReverseStockSplitDetails</Role>
      <ShortName>Significant Accounting Policies - Reverse Stock Split (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2404405 - Disclosure - Significant Accounting Policies - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>Significant Accounting Policies - Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Fair Value Measurements (Available-for-Sale Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/FairValueMeasurementsAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements (Available-for-Sale Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Balance Sheets Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/BalanceSheetsComponentsDetails</Role>
      <ShortName>Balance Sheets Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/BalanceSheetsComponentsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Commitments and Contingencies - Future Minimum Operating Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumOperatingLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Operating Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/ConvertiblePreferredStockDetails</Role>
      <ShortName>Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/ConvertiblePreferredStockTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Convertible Preferred Stock - Convertible Preferred Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/ConvertiblePreferredStockConvertiblePreferredStockOutstandingDetails</Role>
      <ShortName>Convertible Preferred Stock - Convertible Preferred Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2419401 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/CommonStock</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/StockBasedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Stock-Based Compensation - Stock Option and Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/StockBasedCompensationStockOptionAndRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option and Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2422404 - Disclosure - Stock-Based Compensation - Fair Value Assumptions for Director, Employee and Non-Employee Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/StockBasedCompensationFairValueAssumptionsForDirectorEmployeeAndNonEmployeeGrantsDetails</Role>
      <ShortName>Stock-Based Compensation - Fair Value Assumptions for Director, Employee and Non-Employee Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2425402 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2425403 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Antidilutive Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/NetLossPerShareAttributableToCommonStockholdersAntidilutiveSharesDetails</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders - Antidilutive Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2428403 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2428404 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2428405 - Disclosure - Income Taxes - Uncertain Tax Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/IncomeTaxesUncertainTaxPositionsDetails</Role>
      <ShortName>Income Taxes - Uncertain Tax Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2431401 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2434401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/SubsequentEvents</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="mnlo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2435402 - Disclosure - Selected Unaudited Quarterly Financial Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataDetails</Role>
      <ShortName>Selected Unaudited Quarterly Financial Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.menlotherapeutics.com/role/SelectedUnauditedQuarterlyFinancialDataTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mnlo-20171231.xml</File>
    <File>mnlo-20171231.xsd</File>
    <File>mnlo-20171231_cal.xml</File>
    <File>mnlo-20171231_def.xml</File>
    <File>mnlo-20171231_lab.xml</File>
    <File>mnlo-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2011-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001628280-18-003726-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-18-003726-xbrl.zip
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M4V=4W+W]9M ?+KP=F-\?CK\49>=K,1GWKD;?7PUO*FPH>P!KT(%7FE&I7FI
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M==LS['YLQ.[53XC>CRWH_>6'QB=, ?JA!M'+$(??AH-B1K+G(P0UI%X&Z]_
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MQ3A/!MTS8_IJ!.?"P48,GP>#M]7TOWWXZ_!;40XJ._RY&%S!&_!S+T;I-R7
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M3&I6H.B5XC1IQ\")BQ0\\(JDP!AABAONTS**G,\AN!>0CT2!+8^"%@%X<P?
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M'5],3CXQ[L'94 [!1_8:B^H.F(7WP&KN7-DER6H&8B<XV^@<)*18ED%8C?4
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M^>5*DT__ QYK/'Q??)V 4^\TN?!YYD07HH$8)E,PWBY 2@,);V!8U">$LM3
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MGSFPQM3O 8'C$ZA-["%2D48XKR&L%5[:4"WK5,H92"E)KL_Q5VNRA;.D4&O
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M2\*\ -Q4/7!T+PQCPW1"#.IBFP4:;\]":(Y!TX=*-?51Y*3D'SK)T2H[B;U
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MP-PB7!F<2J Y$82.._-.^I5S2+7!^9[*WI3!BP@*HF5!7.DYX "!T^-$KA&
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MT;&0F-E:;/FF&1S-*KYB>A^JLI_&[#;$3Q9BMP5!J.FAKW$])F8W]-#S(XW
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M;=APC_E_&=D^@9%W-2T&_G7LV P=8&$>VB3;#*D3L7.1[>%-N1?H/  !C_4
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MXJ[1&O=[\NT/4F6^E>\.M=!C#-SF(/"=.':"0,,2:CV,@LBPG^N6O2@)#A0
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MPJ<'MFW%'H]]JX-AI&]#RAVZPN/NKH>;6[MC@6'88-&8ZQLA^*8QPU%YMA:
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M+AZQ3$6Z+G)PU[)/*=J::K' *$5ZLX!CA(> 06\+%FIVM!\=S3ZM3Q36@=]
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M(:B9D:[>Z%E+*JNJ,X37R8*V4=ZEJ?S^JK)ZR+RH7"LG8D*%.52E(Q1KZS9
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M;C+1L N+PJLPI4:[NL02^>EIDS$7[5FK9"%U0$/A;"4^E2VK<O2I6B5/0E;
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M-:7ZBKRN+5B.-M!O%6O,G_) ,5)+R2\T?VF7E:BI.PFR0:,;<VJK:25#"/!
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M+J-]NYJGRU6-D'JL?9YIT4N-3R=K5\)T(3K"X#^R>9?0$(H*[E<B;_0.57^
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M3!8%/ @"CA_P(A;;'H\BPW,B6Q^5C$I>&E$J8'^0OI>L9>*^&2?"/JM3EFM
M#D6ET."'!J9UIE*0!%A%3I*"72'KTD/WCSI5Y>L02"-<XC+Y9UZ!0*'_\K37
MD)ZX2Q<$>M(Y]*.0&X+L81X\^>WJP]76Q)H:7(J0'B2.R4TZEY-CX2.;@D!
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MS0E;1K?9,X:M_/8)GDUVZEU(XGY<6XBV/&NWY=EN=)N%DXC B,"H*H0[:EW
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MX-)1<AO'/II#>)2?^1;PI36_#-ER7Z>^XA%L\*17?,0=[EKX[NPBI.&5_KL
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MT=>(,Q+Q.M=A =H;^1TGG\6;1IWU_N5Z516+G(TBF $_)(WE ,<!W,(?@6V
MS^"O*.F^ ,;3D.VY67174(I(JIA-TU@&ZU [\Z:,S#?8QUBG!H'"@!B4YP^P
MM $1J_;(X7[RKFW/Q>%+F'LZ>%_\%<$GF#UW^;V^!A4M_R;8GY%]KZT?)%4B
M%_!D*_1\F,Q,6#B6Y(VI)9/*9*VYZ";R$4UPYD^" SUF0$;L^V0;ZL=K;PKV
MUA-@?:!Q!2#N7F@; (CM"EPP]@BOFL"2Z*4*-IE1J9!N8%)M9B52KA%.Z_MD
M&*G]%J3F9)":B?MI_OC/ L86?_3%#-M^PJMG0"C/WK[@^[F&:SV\M6[AQ_%=
M8JN_GYOJ^LX]7,);LW_=;5Y=M^]N>]?-NV:K>=>_ZP_OKN_,5OMZ2"YAQB6$
M]4YIS3+$KK. H_18W/>?E <3NWPQX\=2E:8+]M\%ZQU'(Y%P97[@ X.)@;:>
M?APX?<JP07F''_U(+,H]_JXM)"OR?03GS%\-]6=;@"@C(O@@Q"XJK-G,][YK
MAU2KJKE !\R&*S1@PV_!!,07T"B,?/7$!GNN &^3Q:SP_NIY]J-TG$O7?N^&
M@(@2IJ\5\O+WO06YU6RVN\V;NYXYO!W>F7>7G=O!7?]Z.+P<-GN7K=[9"_(G
M8 5X+'8]KKW$+JI=4& !&"O*)0,WBB/K!]$,M1;:3KXWTGY%%&)8 52DZTW!
MHAD)5XQ!*:?^AB^5@IUI0H*$ 6MJC]T N7<40KCHNGB!L"+EA%M(;:6#P9GT
M?&$D=ZL_*&4NOL^$B\8C1W=$2?C!*O1@@<I*XWO7\J;B*_^^)A*[A^#=M6_[
MW5Z[/;R[[0_:=\.K?M.\O;J^O>Q?][N=X57A@G=2J=+$8T"]'45=:B15MK25
M,8O6I&]K$7H V? P#+D@-E)3)T3J@-)9LI7!A@2V7VZAV=>--)4HP8=NK?T'
M%7U6L305E !$4%0%%0HJ7B%(XO.%H)\!Q)[86(#_I>R+A+9,%:&-';!U1HD8
MCX6.4R57%Q.X2XBZK0GN1KG>N1+9H;B>/^7.PHM-O"9]L-JF8I9PG/B:GR^:
M%^I[,.-6\OUP1)IR_UZZ>I <%B3Y06_SJ5\>I1U.WO940"?>6;1@B?DL$&^3
M#RN@-1]X-D,NW<$<KMT\W#_'3H^IU>GLL[^[=D=:/\%L]E_ZA.X+'_#2^VLQ
MA<&QIT#'UU^8@S X00Y"J9N5_P=L ':[8@(\(R>!&/(Y#+FS=DDIDF).RJ)H
MC1Y 6F(]8KT<62_W0L[$>L1Z^['>WA4^BBP#? Q&/>X)O2^I$_\9?/"\Q+NX
M(F/E.IJ77Y>4G12K2<G[.53^4$IFJYF2(2DE*24I)2DE*24IK5"(ZO@VL-HO
M/:5W6V+)-/.FR_G*7_E$K5K*L&:254!9/Y(QDC&2L<R#J/G@::W'$CE^QR7P
M)^%/N8N9E3=R/!:^<*V2=EDKL?2^*KZ=0\WD^C6%;$ZM0<]%.(_9Y*AF4DH1
M5A)7$M<ZBRN%6M<\Z".>&21'=;VI2W'6HBU:TH1G)5$47J7P*LD8R5CE9(P"
MK8<0^%?AJN.G5UAM!FN57?O"ECM*"I!_N/(@2L YO?8LD1!72ZV>BY"V2$A)
M2$E(RRVDN45R2$@IOGH(':]5,4<LX/BOM.KR)=9RP<*<Y,%NB+M2X)4"KQ04
MRE.DVI1U1R)%(I6G2'5(2[U4I"BL>E A0/Z=?<82H5/VAJDO>$Q*6YCD$![:
MU9R"JY3'6C45>B[2><S$N+ITT":A(Z$CH3NRT%',<YV=ZH7<R8V%%HJMM6??
MF>U%6+?Y)=76XH>JDM KY=O.3$3WI>]!5FP1!"[GKD?YA+UBVI7DF^2;Y)OD
MF^2;Y/NT60N;^];G,[CG^!H94E:U=PWVD]'=952C&C&=>3[WL4506H1!]PW%
M%GICSW_DOATWLL0FW<R7@>I<D^V)JKI)8AOLN/5-VML.7Y:TQO1%I@TU>Z4:
MLGH1#-D.7E-SFZ*;VYA-(%9>O6W,5B[-;7K='U[6$N5EMP]/^O;3WDYS/];;
M3QB3RLUL6+9Q$P >+&BL4S<*:.]H%'!LHE:-D*4B'G$D<62YB$<<>>X<69'M
MI=)%I.;#-:FE'K74*Q-'[L)#:BY%+?6(]4[(>M12CUBOEBWU:IQVM)ZB-\FF
M .;*7ZI-@?)Z,(<Z*2>7[9+Q6NGH0_Q#_$/\4Z; R)Z)W,U:J4;UH-\__I9;
M\:UGY>L4FP=>!,G^D1>]=G)=-4\+F$VCTRS^#%U=#@K0Z9P260H$1[6$H^Z
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MN36K)M8CUCN,]?9N&$9%L@Y)/UDA-6ZF7,7[ ]LW!)[+SD<D=15PH#3$JB^
M$L<1QQ''53A@4\,^L7]D-^5CA<N2O,7F\%TF\]\;QQE<I[2^CUG*9<^\$)W
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MXDY1>XK_,%O=1K?8Y#$CSAJU18+7*1'P2QI6,!3+ ''3??]4UN)X/M@+(+@
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M6(O!9QO/?:B84YPIL=F[2$/$H0J88.+^V,,,,EW6G"?QQ>#ML30D!M&$OT_
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M@PR!M*B1\BEXQXI&*_R03SC%7+L[G,NS%1T*&G:[80ZK-^I.H[5:D""?4<]
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M_ /E!,1GYHA$^)#"658(@!"@3)6P/VDV'8%UGQA7S>$[9&&X$"[(J-V,F ,
MH.SZ8LJEBPHR9<2U++26=5)5N8?@N?8"(N#K%%^R$0_@JA@9W$B9EH@*J;Y>
MN&TB'#5E9"@#\2B:XN 5]^GW!QF2'3! X*V%%_$PM2,R5!7CL<;=[,L 2"VQ
MC*^Y<6CIC-F;1*7460:_+G+ZJO6XO[Y99_B!WYGA*BN:1@Y7;)7J:P.MUR6]
MNZ(B=BMQ91)HV8?K,JI-JWC]LD3ZL@)@)!+ 9S,'7$><77J]CU4*BK-8!\U&
M818K6E'<!9Q1 JOU$B[N1L]@18,7-.EFH]7MMDXWZTT.3S$CFFN%PLC9[C17
MVY+G;(KO0]BM"%',  WE#P31Z$_05@H+[#^C(%2R/_:]*0OE5&&$^C^.'(")
MSV0(.N6_"BW0/^!/2NH?T6)5"#/.N!A/61<@P3*S_RY@(X_[-L[?!OO$"CT_
M:+"O&7=AP@/F@KWOSY^6!:, T4@"VFVA6GV5Z[^\4.ZH0%0;S8H\L@&*#M>L
M8.JR!R\4:^1PP:Z3+ES\" .-_9'EYUI>!!:F\M)&J:NE:T09[%&&D\3YQI>J
M)^!;C07G!CE<6:0/:C69BM ':E(S[Q%-"C#>P4.*7:>-5\56;,8.631142:#
M!2JX\"CM5:-(J<OBNS,BRJ9"J#>"R< MR_-MCB:#FMQ&H7YR^&,LR%OMHJV+
M9JL1 GW TN%ZPCAJ34'E\*&[Z&),..O?W AX.2XF_$_-&M?8@I> ZS)'&70'
M&-A)^%>8R4@XWF.M_<27K<6R  D,X1>DC<-'KR!-O!B*6F#9)?6SSF\E^FCZ
M%//R]50_#-:+I#JHC/I3/;L'LJ@]CLG?$U^<EM9?E_7H_J$J(U'0H7<OE(X"
M/<-9 #]A2R,'G'-#W82J3:F@&5<.<J 87O_-0Q,:_SJW*$8\D/C7M>NP&)M+
M)[*R-Y:Q\6-GW?<>P+3(;H/!.![P*5.U;[O\C T4JZV%?9T&[L[#-EBULK<Q
M/YJN:HMFE@3WXZL/>(8RL94]/ _GHCG\Q-26E!85%V-:0: \S VQ7A@*F+>V
MP)0%Z6I34'F),@Y%9T)3'AB3T@7&EUC2=24DJU5/$BJ?W[8EBJMO 0-3QWR3
M&)F-DJV"93A]3*J [S#,0.UH ;U%;)ZF3VZPV[U)IV/OV+9LRE4:$1!MP0W1
MM-U KS"S/:3FI& HB62CJS^?SO)$=ZWI="IL"8_#550QQQAQ!/<=J=?XE7S-
M NZ(;0"SY(L!CHZE/U4_2QV?B)"(C[X,0X"N632"I8('PF#4)D7D!Q'7^W;@
M0(A[W*+0X4W0<J&8/R&._UL1/$D9PY8*>YK#=ELY"GR*JY7X=/>^%P3S+1"X
M$,'< 0;5#DE1N\7-1I/!?<XZ-,I'/4K-MCPM+HOBQ]T,217?QZN9TAOF7_ST
MS7ZC91:_6P[,^DH";Z;[SRH*/POG02Q_YB5!<O"<6<)]Z(.*(,0'<""?R&X+
M9XP)SJ;\3P"@\"GY8];H.FC#8 ];8ZLY47M_=P6PTVR#S=CUB(K$E;@I#>B%
M$0(>*O+I#>J%6$Q&?6BC\8"0U,K8E%I8&X-%\-41D?E^3ZP!0#>% :9X9#>(
M%F*S:B@;DBF2J$@(^O!>"[A*K<" BL-#;6("@,K,TVVI\[ 0_T+<WD3-H8)1
M#;:0QZ6V\@&QHS#R5Z<_!OWK6CK72@71U,@4K6-Z.!C6THB"#P5N#C-/F=^O
MS@L9:Y29]%+K57P'Z-?XM>I!6O"*>SW7>$Z:5(\N/&LB9VSF!3*1]_1)$EX5
M[#9^D\\__1@%;^XYG[U-4QQ5AN-7$(HK!S[\\O>__32_Q -$"I\^.4#\2]>^
M_2N2,^2%3QX [E-Z#TX8I>JS&/]\<7>#^97_[/SGZ\T%DS;\P*WP3?]R<-6^
MZ=XV6W?=SG7SNMEN7][UA\VKJX%Y>]DT+WY9DO4%@=O>3G5=UG#E+/R$UDI.
M4D(;,.NPSO"X,&V13%O)@[*-;!1%RPM"=8$M0' LJ7Z/@L2B1FL*)YU!!R0%
MN([AQ .)?H@-*Y 3.8WO%6#;,T<^B%0V]7:UP>X%R%MLPX:/0A1E2!097BAN
MBW(,)"MHT$]@E0-X?P!- ':,BN[C/'P!#AC8+#%$^C%$BN\SX08J$UNZ2IG8
M.F@AIQA-4&9/?%.BAX3=8/]6^X(Z,P'_Z(M0!>Q!M\USMVP9 -;BK^,$T&,&
MY%:<]B RS*BTFWK6%%YLQYN5<-N(.VH:P42(^'X5(0DB1V'W/2H]>+.#=KQ$
M;3?&.(KRF!C*A=[53,QA^$%Z2)!D,@<C_GYPGE4!_XPX&&J^\W2G%1UWWKMC
M[)N-(SM$ 0RONJUA^ZHWO&S?7K<O>U>]SEVG>=NZ'0YZ=[>=JV,K@%T]QY4&
M.!TXKE<27T3,'W^X/+(E?DH7B*4KQ&YXR M5&N6AT^F.QY2,!FCVZR,I2BUB
MH BS(KU'],2BZ50=0=@<XHA2AOHK9:AQRE VYCRF>]3Q8\8>&,KQU4J+JG,U
MB'+8X(XM-%4Q *\M =[K/ DESD5^G=L!FEVKM-)79B-V[%S*[%!<1$-GX<4F
M7I,^.-1!.^$X\34_7S0OU/=@QJWD^^&H!TMZ+UT]2 R^)3_HHW7JE[AO>A.(
M%1_FPU-/?!:(M\F'%3Z>CSM[^']^:+"]]L#>_O4#])@ZU>YD_[+;AR=]>[/*
MI*OT[;3N9WK[:4E/"W^JV_NT[OO>7I&N#=4JW4;TR1BNS0**:A]>SN*DC2Z_
M8LR1?8"_30)VBUO)Q&GY<!K!%\%7H?#5.PIZ[5_@L&S0EE1XF5,Y*?52+F[,
MK81DZ5B5B$=R7KR<?Q&S,"[EU"3Y)OFN"/&J)-_+;SRIO/]OY H4]:VT7C/X
M#'E..OXYMQ!6$595@GA5PJJ3RO8'[EL35DX_H[H<6-\>:+FFD<;GPAR'CY)S
M )A[H<[-69B,]B#<:'NY3NJ><H3BU,42KKY:*'>,+']7CT,D/[^&,R7O)Y,_
MZ5I&O]\MG'REX:J"FV[MW^:@+$A8>?0C94R$JQ7AR(HA*X:LF,-(-VRN5IHG
M&X9LF(I@'ZEB(ERM"$<V#-DP9,,<1KI.AVP8LF$JBWVDBHEPM2(<V3!DPY -
M0S8,V3!DPYR[*J[(B:YC:HF/NB05EF?4U;>V=U.CG+>36B@UH\_>NN$YM#H@
MS;1XB\)L&:TU3=6>R3KG:!X4("Y5$!&"$*(/T8=44 [)!4:KTR$-1!J($(3H
M0_0I#7W.1P/UC%Y^2?JD@4@#$8(0?8@^I($.T$#-)OE I($(04Z]JU:B/<JC
M;K>I7GK2M;RI8*_B+;?7!G-WM(2BW5_:-J^$B9 K$4ME.[2:S<(Y[1Q-BF.*
M715$K33$JAI&$>&(<*05CYW8TFN35BP[QY!6/%^,(L(1X4@K'EDK]DDIEIYA
M2"F>+T01X8API!2/K!0')BG%LC,,*<4SA2@Z&KGRG-]%R!POH .1E$=1.BNA
M\L; JZ'1ZN?>7V/.!H?2HT2X\[HL#%-W8X  A^A#]"&%M9_"&AAF/[<3_*2P
M2&$1X!!]B#ZDL(I26#W#[.:V#TD*BQ06 0[1A^A#"JLHA=4U.OW<3F>2PB*%
M18!#9SF+$\HK'DA+-6BVI1.%PL93G&K'D,V$#P.=3CV7!1/N"_;*/$2$JT+M
M<O$N$:Y$H%B*%)VBRN6GHVZ?;3+7*[,QR.T\[&9;;8W$)12J'(>1!C@UD!'A
MB'"D.DEUGEQU=G/K+T.JDX",-  1KGZ$(]5)JG.-ZFSE=HJ(5"<!&6D (ES]
M"$>JDU3G&M79S*WX/JE. K*<MYM_#/G($6NOSWS.S,21KG@S$8H*9JOYPS*M
MS&5Z-N'[,OLL+$!Z@72!-/K[?)[#1C<?!EMZT,'GQ'.D@073%/Y&)LB\:2>A
MLD-Q/7_*G847FWA-^F"UULP2CA-?\_-%\T)]!]:UDN_KJ"NG(F"_BT?VV9OR
M%?:=<O]>NGJ0/ J]Y <M*^J71VF'$[@:B!6W! :!<?@L$&^3#RM<,A^WOU:I
MM-<B_?YI%7I,'?.'W:*\%G7B.57Y]N%)W]ZL,NDJ?3NM^YG>?EK2T\*?ZO8^
MK?N^MU>D)DNY7 JBSP'1D&8I4L2W.22#?'PN?(SZ]J@]E)'GV/JY7R>^$.P#
M_&T2L%OP9VSBM-R=>X(O8JK\X:MW%/2*HP0JB#'[S@+/D3;[GZ;ZI]S0=B,L
M,1T)?T[EMFFP5M/LE8L;]Z=PU5B5B$=R7KR<?Q&S4 DZ:S=)ODF^*T*\*LGW
M\AM/*N__&[D"17TKK=<,/D.>DXY_SBV$5815E2!>E;#JI++]@?O6A)73SZ@N
M!]*Q_/VS=JYQ%Q\$B(?2<]7Q?+CV05J"^>)!N)'(BRE+1-]R<>N)"5=?+72\
MI,_<:%C6C-"7,>@VDA9 N>*S0SO=XIM;EX:GSJ1SRXN,R&IA'ZEB(ERM"$<V
M#-DP9,,<1KI6*[?BD>7G*;)AR(8A54R$*S'AR(8A&X9LF,-(I]EQT#);Q4MY
M:7B+;!FR94@E$^%*3#BR9<B6(5N&;!FR9<B6(96<?*S$^:YC:HN/,X%Y1^X]
M$]]GP@U$<$I-7"=F(_KDIQN>0ZM2U3+K&NW\&H6=HW50@+1404((08@^1!_2
M0"_70&VC-\RMAP-I(-) A"!$'Z(/::!#-% [M_-UI(%( Q&"$'V(/J2!]L^W
M-EK#/FD@TD"$('32_R2[;2%0GDG7\J:"O8IWW%X;S!5A7NQ8(LJ6BT^)<$<P
M$>K;C6@P*)S1SM&B.*;454'22D.LJD$4$8X(1TKQR$JQGYLW34J1E")!%!&.
M"%=MPI%2?)=?HB<I15**!%%$.")<M0E'2O%=*[=.[J0422D21)U^"_?_M_>M
MS6T;2;N?=W_%E-\WYSA5L R =SM)%45)6]Y*8J^MS3DY7[9&P%!$ @(,+KJ\
MO_YTSP @0%$2*0'D@.Q4>5<D<9EYIN_3W7/8.[6_BH3Y84S5D)1%H9V5T'IC
MX&W7&-:7"OR0#+;%0R.Y\[TN!'/HQ@ )',*'\"&%M9G"ZAB=46T)0*2P2&&1
MP"%\"!]26,TIK%[?)H5%"HL$#N%#^+04GR-26+9A#TAAD<(B@=.N;4"--E5W
MR92G//8<>5:SZ_EI(ERLX90[AFPA(ACH?!X&+)[Q2+"WUC8LW!:T]:)= DXC
MH:A%BDY3/?.+47>.-IGKK7DRVL'V[1J.RQ%J'861!MBW("/@"#A2G:0Z]ZXZ
M^SO82";528*,-  !UU;@2'62ZERC.G>Q0T"JDP09:0 "KJW D>HDU;E&=78[
MI#I)=>HDR$K;S>\3?N6+M=>7_B[-Q/<"\6XF) J6;7ZWBI6UBJ<)GU?)I[(
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MRF8II]17$G\OJUM*I7QHN++8=<OW]3#>6=IJD#/W5""PO!_(5:)*S.>"24(
MZG=F/+I>#F"9GE)!+LJW2-U0J'!DGOC'*U4$B#O\$LDY8GC7BR7KEK<WU>1
M=8DXSEDWE\CO,CE<38;)4L+_2CT0$>R/U+W.8\N8[1)5640"[?NA4X2/<S4
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M)78E=CUD=J50ZYH'?4Z L<E176_J4IRU:8N6-.%1<12%5RF\2CQ&/-8Z'J-
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M91OV@!06*2P2..W:!M1H4W673'G*8\^19S6[GI\FPL4:3KECR!8B@H'.YV'
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M83#X$AR!C-""<P.J\M8#!(-'33;DN2CT42F"DI>>X%Q$UR("&\U101I\A?3
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M%=PW^.CW#Y[]T]]_>(_/\3[@__[T_P%02P,$%     @ (X1\3-,&-CI #P
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MA19JD S4CS0UMQ6@'_FXKJ,DTEX'@ W038=?C]#WXK:M(/6U^NV'BB$R<OF
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MC2H,")-NW!92YYING*W2#,<_)J=&:?6\'"H-%,?92^(3,<QI()GT#EG& $3
M4<N)]QA W^*6DA$D/M76XT6)3Y<A]AH3G^+E&R96';7!+'"8>"."S<>9ML0'
MAZ1YA.8($I^:<J8G\%+19\\<W#N3V(0MG#&4S[3,E')(:6X1% A;)<-G4]F0
M'#LXVJMQ>S60NP4M%4FN8T1+T,%J-_P#\>MGIYD+>LDH%C#>"F:#@XDUY<YZ
M7N'@@1IY58#.M/S\?HO>$4P^[3R-.YX$/99'/V\1UVF>(4RH!]1K8 QBS%*
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M&F=GO<I#CV>*,<@)%AYA"C7@D#CQ))ELOH?8F]_04D/?E=-N#<K+W#P.'C0
M"BB,-O7&C2!^MV9"3IL''O2]>=SQTM\2F)>R76@1\YQKRH25D&$5+^RMI-+(
MC+PZ; ?:.K]OV RBUT* <:_Q0^I]H-F^**?%4E^XQI]HE5G.($":(TVMLTH8
M@$CE5 -9+ZQN\#WDVLIZ/M]W!DQ: IA&!#C8*D-&.\*A8,9)#21VDE?8*:A%
MRB5_* )T 4SC/(B/1;!9R[Q\>#1A-R-XLURNBYOXWQ@[OPE,/J#=2YIGQ&J
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M^5XBEUO"/GJ#9/.?;1V41PEA'T;(@==D##(H++& >47##\YN+@K;(!G_VYC
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M1^]M/=:Z>C-?KLKU8PFH6!OIXY=\OI5\]_$][A?VX8I=.H9X@&>";K'D3@C
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M%$;];?>[]/;MK]CN=B??P!@"C"'+9PS]]L(75\^/Z;__ILP>'K>4GA]'X)<
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M.@9T1IZZ98C*"/SG>\%),2%_T_Z'HDKKGWYYW&95TP.\I 7:9[9V;*W,P+8
M M@!3H@=W\,^QAV,@',[1IMQS6)SN/;DM('E;;$S4HKTN?EY=WEV6G=(V[&_
M*=/V[NR2^37V,O^Q(>+3L5FC(R9S;S8"8&BO6NFK =/:JX=LU)CG[@HP3.B
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MN$OOZ2#L=^6926K_X^U-\NU3NLN*#?WY+DW*%*?-K_VR/R X\-T !9;E0BN
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MH'F!1XZGQ*-9H%N(3(-3!K)7Y8V,)D\:J&&57FJ,Q'3[X  [#'S^[2JJXH=
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M'1!&D! ZXB,T8O#)&9QV %X9VP/*IEF!V#1%#<E\DY#)^16;8KR^R>\(H7&
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M)VB1VQ%U1#B]S8Q7<YX[H#%^>$SI9_)*)L?-'52!9/<=Q7-Y6>_H<6'>SI
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M52*X5ZPG(IS[O[,'0TP8WZ+\"">52(;4F$THI?@<VFC5&I]E2*MF'U]NB$[
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M.<II;QP4IV:A&H4L&35H >IQJ>FA"0#=KNN'2G1\93NC[-W3PY$MG=7P-*7
M1KBZZ/O21N!UW\CNW0T:?P/VIN1.8*8FX@#<+&?!#]C9#JIR^N1J'U8CNNIU
M2<OVW^^V_>4''Y=/<C3LEW*_(+2(XIC'>4% 3'@8,D ZTQ&,@=;"0RL&72]?
MZ4Y3ZR_+T3[ QH*D:M2;7$T]YO7N!3_U#OY%+O0YWBK3.7DCUXQ,?K3-F\(-
M<,ZJ[GY0SFY(+X^\L:V7.>&:4_1."S9>V78FO#FNWBB*C*<TA5&*J&B-%G&*
M6.\5SO0V?;GVQ3$7R7=Y?<#%4KW33M#-R6G-97O.<V1*T_G28P6T[>&@9POL
M7MVVV^!WMA5W(T77@K2;=/K*;T?1OHEVERJ;4U\TZIKQS4_EJEP_RIJSR&&&
M,YSG&<$TRVC&.,EZTQSDL<',CQ6[$\WS=([)Y=F=9V.I;:*Q*9I=Z6J3OT>)
M/[TM\41P?2F;%D%'J.XK)L>$]"8+1^NEM!SXTNYZ^W%7/BS7M_VY]:+B-U3N
M3KYMF;Q(0QRGA$> $P(HHUPPN/>$)G&L-L3IT@/GXYV=E\>;1YJV4=4TFU:M
MIUT+5V,EJ*ML#)-R]C38!&>?%G:>EK8UVWG>M64]2(O&.EP/TF.VW-99FM06
MU9KI=FWMK.,L>+!$UG6$U73/M(LJ^+[:?MN7N_O>%81H@2%&(2]0F$9IV._/
M2:*TH+E&-\"I']-T"_IW^E0(-\+-;JF"]-9A0=1-C,V*Z"(9$Y5$Z?I?F]2X
M*XJZJ7%1%1VF:*JRJ)PJRX7QN72C*Z-A)GZDTF@:HE%M'*7G^#&Q;A)F03-.
M<Y31A&:P8!&B#)R*,@[YN+D.76ON9WG;P9F'UA];@U_*8HX=^7*AH]UAKX]O
M*#OQF%?GCM& EZ[8OH]V:<>C/-1EIM0HB%W<[[2(6)2P+&4Y+&B1L2Q)\YZ?
M(*'YR#E; X,3+5@9&,7:F!Z:;$?P$:QSJ;4MW%U>ON@!\2YDTX6>J>H><\\X
M)!7TC=/+G'[] <J?RL=R>R@7D'&:%!G$E,59G-$\1+RWFP%"QZ%/UYIC[AW/
M)-^U_HPEF[:8IEASJ:,5IAV5_?2&LA,![4(P+9J9BNTKRHSC>9-CXY0:N2+O
M%Z%'VUAYQE'($Y[D %*>YWD2QE$<]2X@!K6V@EDU[!AM[7#1MMIV(Z\.VG%C
M5#<%WT2"6V%@FX*3LSXU\*[KJ+\@;EPZ?*6DC=#4EKK9T,_^L=$+D& $2$XC
MDN.0Q83@XPP;(*)!JG,[MT6S6MS4OZ[[%Y5315V=&_VVYFK<G$EN/6H:G!/M
MZ^'0 \QTD H_B.DB,.-#H#6U&TG+]ER#UP_KI!$&"0ACD"'1[,48I.&QR9ND
MJ=84B /SCEN=1]=LPW*4Y*.@.97:5N%YRH,'9R+K"ZO/4QM9\IJK5@)4XZL]
M+54Y^W'YU)V9C%;_/*QWY;,]S&A[>]K&7.0Y0"DG*"$Y+T !LC#O'(  Y(G!
MG@N+UB=:8B6^_R[[F\WI6MW&?SEE8WC2@DWYU5@[M>1&C.V=E.?/=VX>SUFX
M:0]:N&EDG^FT!741!WCJ(!-^<-1%8)7SIW@D-\]/W,HCC!GB!!0DSPF*,,1A
M;S(5[+9!2AU[T[/1^,S5<;H:(M"ZEM:@-]N!@$,:Z3#-1%I/*684REO<,M='
MF52[:E66MS47$;;'U*#^O&1>[>0WGX\'@BXX8FF8Q@2E$2AX&"49[!N9,$^B
M3*</;=6PX]YS[VL@GX- 'AM=C\.85=$5L3:7WIJ8>R:U=$LJ?73UKW?5[J_-
MN=V?WSZGU@WZ-'0<0J&+='B"1B>A7:+2G7XFZ/QYN>^,-0O!6XR+AB99;C;U
MH&\A3S-.<%&$(<A)R#.2]+N&(8$)-&6J.X\FA>W],0QKQ'68*WT4^Y&F,8P^
M17 3G,70=,";*#P&N+'ZBF1WGUW_D#]!S .U8"K%[<]4+>(PA06$)&<9B',2
MH20^-O 927,+\_HF9J>>UU]/.%7UMN:VIZBLRNU\:LK7^2@K\U#*J?"#L2X"
M,YYWTM1N)"WY>KO<KEZ?^(I1PN*4L0QE)$V*+,F/Z_$A1#&S,*\_QKSCQO+1
M-=NP'"7Y*&A.I;95>)[RX.^\_H"P^CRUD26ON6HE0#6^VM/29.CB75T?A/GR
MP]VG\K8L[V7KF%0"^;O]6GP4S>AV[T!SL\E"-(LI3A /8UHD' ":'Z]N@ Q%
M6LNHW'DQZ1#%NG-=]G-7)Y?E_5K=7IM:.GT3; 5#Y"!&__.KJAXSCF$Y<?IC
M%_/E;,QXQ;NS=)W\#LX<#XZ>!XWK\XU/:"FL.";A)FM^L'R". ?&'EPJJ[OR
MX,/=L:H0B9E%%K,()SS.DA32K, )/A["'N=)"$>L.M"V-<V*@^-6Q[MCX\R$
MN,:"ZBTW<"/BN*4&@I"GABT9U,[I,H-+;126&!C+Z0G(1H=Q96G!2%WL=^07
M,4DQC#.<4$X!A 5&M-\A$"=".PO#GB9FIQKV?#CK3]Y-V)M_6W?;O7BKDCOO
MO?O:9;?255=.A1\T=!&8<==<4SM58DKKS3Q5_5VN3GU<;B2N/Y:[=75[N3]U
M412PR!E@+$L02;,"80Q[%P!+M)AIU? $U%P?-W7?GF_J;F JYYR;#^4I$CV
MVDV#&D)GRX >1$FO<//AS-.;H/4U>&6__;08U5%R *1.$N('2MV$5DWP0-O
M*1*0W^V>!,__OMP<R@4B19X"##$L0!PB7F#:+PR+0YK@Q4/C\^?]<K<?0U-=
MNSHO\:6+^N_S)3&#Y3[X6GY;;[>R223W,C4F?'B5+X34?H=-$^'SRVL<D]);
M.TXQNZ\K+"C"C&0)+5B6001Y"$ZHX/WKRK:*ES?;L:K_LO8.VGE52WDFY)_Y
M)55-P(_TDBK'9/22ZBFF/*@C!!!V3\M!MK?'_M&[?7E_FK6,<";*>D03#AF"
M&4G3Z @)G&.M1<WVK#J>%>P</5M()=_8T]A"XZS*H@#7XBL.[,RBN^:XCBW)
MW0SJJ"HX-*9C/0M^4-)!7)<C.HZ44Z4E+;_N^QG!9JC]77N:V"T][(0+G7L?
M=A]%PWV]W'1__K);;FLY^EMM%V%($(8@ @2'<4X+D,BMR:U?<BV(#D7=>^.8
MKG9F\R9(BAI=_<J''G6E[Z=E%(WW0>]^T/H?]&2N=D$7PO&KLR"FY?%HS0<X
M/5T^_>#WA/%6<[TY>KS_O/I>WA[D3D2R?%COEYOUOYI+AV0S??_TI;DZ@:<P
MXSS$% "0RZD#6&0)Y%CTIWE8<*W%RC;L.69V[Z+LGCYW\B9HW0Q^:QS5; M;
MD5J-TU.KK$=B"P([(:V":@,LM:FY'[2T&E'E[@G5'+1KUK;5PM:'NV9-&W[Z
M=;O^YZ&D9;W:K1^D%^B/=;W 4504*,T3S"B"&$AO>O-QAF(=[%DSZII]TK?@
MY&UPYI_HD0H/-:%G3VW%6<DYA-;$WPB-W8R'*FHV-"1J6W8_"&@_K,N!43>Z
M&;/PE^5]2:O[Y7J[0"E@-,8920H2%BE/$<U[B_*^A5'XT[#CF'AG[Z%HCGQN
M]SQ(]X+?6@?' D]'4D/&.5)3<Z&%N9#34.VDD@[(#+3UE%TFD;R%*V-UE*[0
M/MN&T%CK_ES>KK?[ZO/WI7P:[TAU?U]MF__^<WG_M=PM:,2)W*&0<H X##&(
M0MI[ M,X52&72_N3$*W=$W3>UM@WZT;W5=!ZWO2^&M_?V"\T75Z&\>=+2DRP
MJ)V-X+?6<\7JXS0M&I=G>Y >L[NSG:5)[>9L,]U>J6-39,&#>[-=1UA-]TS;
M'*]]O]Z6S2SA(DMQSDB>\BC,(68XC)*TM1Z'+(=:%R_:LNG!N*UTMIU?MSIX
MJZ&[C0%<-Y+;'\1547N&D=RC?,:CN?H)\*-/8#TJK5%=4]6,1S-:.,MIM_(V
M6A 6906+DHC# H4@@Y#1WB@!J=8UW"--.>\!-"V4NFVRK!NG@L.#^&KUK)-^
M?NY#<]I#\%/[=ZYO@' BO.&PASO-+8Q\=.W%UKN91SZ>":4S^&&FL!^LLQ7,
M6T,@8S1R<,\BBHHBQ[Q(:!0B!#DBQ=&!%"<V;@PS,>MZ%>NH>Q;_%/?]J6;
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M12@K.(F/J*)$::O%2!..:=)ZU;P?1[^,.F*F"JH190+Q],ABHINC*P1?4V:
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MJ_.^G[LXJFK>R0NC'@?O[/H3W&*L*KW/8TFCXC*^Q5A/N?&7+Z%^7%,NAEA
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MWKO6<K[!CYPSS*(,I461X)RA'#(B_(2 Q CRD':#'VRK^MY/[J'^T$<?C,'
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M,F=Z]^#:XUF7I;5=T[M/.+28DK.;8JIY<5G]ZQ<@F=259))Y82K=V[,EB4Z
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MG"8"6H-$/2K0T2Z):H)Z-O(<-+=WM @82.*0\DH92RG!! I2RL=)K7/XXQ,
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M+ALU"G$19<9>1>^84*Y1B0%A<F 7'#7.C)-SV8[#_6WGLA'#G :22>^090Q
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M(;K6&J0+1 A2A%&!HCM42J.Q'5B$:6.Z?7FS[.F@=K?OM5G U7+QM9A%-_O
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MN)GF_UP)LQGL?"O$919%2I&2$9UWTZCDZ*='.&;+;+QGDJW1:R#.4@:4Y0Y
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M*KZ-I9Q>Z#J;CCW<I^EV&6P.]S/SJ\(*N*==D)!"3@@T6EN I-:$ZE)6 OS
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MDNV"XPRK<TAX/$D'Y6+71_O,G//Y=#2]:LC%WM-9(.G"7^8<5]PP*CD5VU,
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MQX#.RD? OZ^/1R[.:U&D;3A)3?>3\M7;OW2S35&O)QWJ5,.91!-0^A>8"8J
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M,#$W,3(S,5]D968N>&UL4$L! A0#%     @ (X1\3%-.BTVMI@  "\L( !4
M             ( !@^L! &UN;&\M,C Q-S$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( ".$?$S5@#AY?7   (J@!0 5              "  6.2 @!M;FQO+3(P
D,3<Q,C,Q7W!R92YX;6Q02P4&      8 !@"* 0  $P,#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
